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1 Introduction 
 
 
Chapter 1 
Introduction 
 
 
1.1 Hyaluronic acid 
 
1.1.1 Structure and physicochemical properties 
 
Hyaluronic acid (HA, also termed hyaluronan or hyaluronate) was first isolated and 
purified from bovine vitreous humour by Meyer and Palmer in 19391. It took another 
20 years until its structure was solved2. It is a linear polysaccharide which consists of 
repeating disaccharides composed of β-1→3 connected N-acetylglucosamine 
(GlcNAc) and glucuronic acid (GlcUA) which are connected by a β-1→4 glycosidic 
bond (Figure 1.1). 
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Figure 1.1. Chemical structure of hyaluronic acid. 
 
The 20 to 25000 disaccharide units form a polysaccharide with molecular weights 
typically between 2×105 to 10×107 Da and an overall length of the molecule up to 2-
25 µm. The carboxyl groups of glucuronic acid which are deprotonated under 
physiological conditions (pka = 3-4)3 cause the highly negative charge of this 
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biopolymer. Hyaluronan is a member of the glucosaminoglycanes (GAG) which are 
generally composed of repeating disaccharides of an uronic acid and an amino 
sugar. But compared to other GAGs like chondroitin, chondroitin sulfate, keratin, 
dermatan sulfate, heparin and heparin sulfate, hyaluronan possesses a unique 
position in this group of macromolecules: HA, which is noticeably larger in size, is the 
only family member not covalently modified during synthesis, thus it lacks sulfation 
and it is not linked to a protein core. Additionally, hyaluronic acid differs in the 
location of its synthesis: whereas the other GAGs are synthesized by resident Golgi 
enzymes, hyaluronan is synthesized at the inner surface of the plasma membrane 
and is then extruded3-5. 
Until the end of the last century, it was assumed that hyaluronan forms random coils 
in solution. It was Scott who first found hints for a defined shape of hyaluronan by 
use of chemical, X-ray or NMR experiments6. Based on these findings, the model of 
a tape-like, two-fold helix was established (Figure 1.2): Every disaccharide unit is 
twisted by 180 degrees compared to the disaccharide behind and ahead of the chain. 
This conformation is stabilized by internal hydrogen-bond formation and interactions 
with the solvent7-9. 
 
Figure 1.2. Projections of the extended two-fold hyaluronan helix. Dotted lines represent hydrogen 
bonds. The models are shown at right angels to each other. Modified from Scott6. 
 
As a result of this specific arrangement, lipophilic patches occur in the secondary 
structures which are formed by the accumulation of axial hydrogens from 3 
carbohydrate units. These hydrophobic characteristics together with the hydrophilic 
nature of the carbohydrate hydroxyl and carboxyl residues lead to an amphiphilic 
nature of hyaluronan. 
The tertiary structure of hyaluronic acid in solution is based on hydrophobic 
interactions and hydrogen bonds on the one hand, and the electrostatic repulsion of 
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the carboxylate residues on the other hand. Although NMR and rotary shadowing 
electron microscopy data revealed a honeycomb like meshwork with neighboring HA 
chains arranged in an antiparallel fashion in very diluted solutions6, 10, a specific 
tertiary structure is not formed under physiological conditions. Hyaluronan in solution 
can best be described as porous, dynamic network of interpenetrating chains11. The 
tertiary structure resembles an expanded random coil with reversible formation and 
breakdown of interactions between the hyaluronan strains. This porous network is 
able to store huge amounts of water which is the basis for the highly viscoelastic and 
hydrating properties of hyaluronan. Thus, by binding water, the volume of HA 
increases by about 1000-fold compared to the non-hydrated state3. This hydrated 
network forms a diffusion barrier in vivo and therefore exhibits important functions in 
the transport of various substances like electrolytes or proteins through the 
intercellular space12. 
 
1.1.2 Hyaluronan in the organism  
 
1.1.2.1 Occurrence 
 
All vertebrates produce hyaluronan as major component of the extracellular matrix. It 
also occurs on the surface of certain pathogenic Streptococcus or Pasteurella 
bacteria. In mammals, highest levels can be found in umbilical cord (3 mg/ml), 
synovial fluid (3-4 mg/ml), skin (0.5 mg/ml) and the vitreous humour (0.2 mg/ml). 
Increased concentrations of HA are found within the matrix produced by the cumulus 
cells around the oocyte (0.5 mg/ml). Exceedingly high levels can also be found in 
rooster comb (7.5 mg/ml). For comparison, the concentration of hyaluronic acid in 
serum is 0.01-0.1 mg/ml. The overall amount of hyaluronic acid in men is 
approximately 15 g (for a 70 kg individual), with the largest portion (ca. 50 %) being 
found in the dermis and epidermis of the skin13. 
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1.1.2.2 Metabolism 
 
The biosynthesis of HA is regulated by the three different glycosyltransferases HAS1, 
HAS2 and HAS3. Possessing two different enzymatic components (glycosyl-
transferases), one which is responsible for the addition of glucuronic acid and the 
other one for addition of N-acetylglucosamine, these isoenzymes are unique14. The 
active site of these transmembrane enzymes protrudes from the inner face to the 
plasma membrane, and the HA is extruded during synthesis trough the cell 
membrane onto the cell surface or into the extracellular matrix (ECM)15. This form of 
synthesis clearly differs from that of the other GAGs which are synthesized in the 
Golgi body. 
The synthesized hyaluronan is finally released from the synthases e.g. by radical 
reaction or dissociation16, but stays (at least partly) in contact with the plasma 
membrane via interaction with cell surface receptors like CD44, RHAMM, LYVE-1, 
HARE, LEC-receptor, TLR-45, 17-22 or possibly the membrane-anchored 
hyaluronidase Hyal-2. A mechanism for the enzymatic degradation of hyaluronan 
was suggested by Csoka et al.23: In a first step, high molecular weight HA is 
degraded into fragments of ca 20 kDa by the membrane-bound Hyal-2. After 
internalization of the fragments, further degradation occurs in the acidified 
surrounding of the lysosomes via another hyaluronidase, Hyal-1, and two 
exoglycosidases, β-N-acetylglucosaminidase and β-glucuronidase. Finally, the 
monosaccharides (and perhaps oligosaccharides) are able to diffuse out of the 
lysosome and are used again, e.g., for the biosynthesis of hyaluronan. Hyaluronan is 
rapidly metabolized with one third of the whole hyaluronan present in the human 
body being turned-over every day24. In addition to enzymatic degradation of 
hyaluronan, the polymer is also cleaved under physiological conditions by radicals, 
especially reactive oxygen species like the hydroxyl radical25, 26. Thus, the 
depolymerization of hyaluronan in synovial fluids during the early onset of 
inflammatory arthritis is believed to be caused by reactive oxygen species rather than 
by the action of hyaluronidases27. 
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1.1.2.3 (Patho)physiological role of hyaluronan 
 
Several functions of hyaluronan are connected with its unique physicochemical 
properties: It functions as lubricant and shock absorber, regulates water homeostasis 
and it is an important structure-forming molecule especially in joint fluids, the vitreous 
eye or Wharton´s jelly. Besides these general functions, hyaluronan is known to 
interact with various different molecules, called hyaladherins28. This heterogeneous 
group of proteins can be divided into three classes: first, the extracellular 
hyaladherins, a group of HA-binding proteoglycanes like aggrecan, neurocan, or 
brevican constitute a gene family which is termed hyalectins14. HA stabilizes the ECM 
by interaction with proteoglycanes like aggrecan and the link protein and thus acts as 
a scaffold29. HA cell-surface receptors are termed cellular hyaladherins. The most 
prominent representatives are CD4430 and RHAMM31. Interactions with cellular 
hyaladherins mediate three important processes, namely signal transduction, the 
formation of pericellular coats and receptor-mediated internalization14. Recently, 
interactions of intracellular hyaluronic acid32 with the corresponding hyaladherins like 
the intracellular variant of RHAMM, P-32, Cdc37 or IHABP4 gain attention33. 
The biological activities of HA are diverse. It is known to be involved in embryological 
development and general processes like migration, proliferation, adhesion, and 
differentiation of cells21, 34, 35. Furthermore, it plays a role in the immune surveillance, 
inflammation and wound healing36-38 or in angiogenesis39 and tumor progression40, 41. 
The effects are strongly dependent on the size of the HA fragments: molecules of 
different size may even exhibit opposite effects. For instance, high molecular weight 
hyaluronan is anti-angiogenic and anti-inflammatory, whereas smaller hyaluronan 
fragments are angiogenic and inflammatory24, 36, 37, 42, respectively. 
 
1.2 Hyaluronidases 
 
The hyaluronidases were first discovered in the beginning of the last century by 
Duran-Reynals in extracts of mammalian testis und were identified as “spreading 
factors” due to their ability to facilitate the diffusion of antiviral vaccines, dyes and 
toxins43. With the isolation of hyaluronan by Meyer et al.1 and the identification of a 
bacterial enzyme that cleaves hyaluronan44 it became clear that the “spreading 
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factor” discovered in mammals is also an enzyme that degrades hyaluronan45. The 
term hyaluronidase was finally introduced by Meyer in 194046 but it is a kind of 
misnomer as this class of enzymes is also able to degrade other GAGs like 
chondroitin (sulfate). Meanwhile hyaluronidases, which are ubiquitously found in the 
animal kingdom, were identified and/or isolated from a large number of organs like 
liver, kidney, spleen, testis, uterus and placenta, or from the venom of lizards, fish, 
bees, wasps, scorpions and spiders. Additionally, hyaluronidases were found in 
bacteria or pathogenic fungi. The discovered enzymes differ in their molecular 
weight, substrate specificity or pH-optimum47-49. This group of neglected enzymes47 
was barely investigated since the discovery of the hyaluronidases in the last century 
due to their instability and other problems associated with isolation, purification and 
activity assays14. In the meantime much data is accumulating rapidly, in part due to 
the human genome project and the EST (expressed sequence tag) data bank26. 
 
1.2.1 Classification of hyaluronidases 
 
Based on biochemical experiments and the characterization of degradation products, 
Meyer first classified the hyaluronidases into three groups (Figure 1.3)50. 
The first group (EC 3.2.1.35), represented by the mammalian or testis type 
hyaluronidases are endo-β-N-acetylhexosaminidases and cleave the β-1→4 
glycosidic bonds of hyaluronan, chondroitin and certain chondroitin sulfates. The 
major products of these hyaluronidases are tetra- and hexasaccharides with N-
acetylglucosamine at the reducing end. Besides hydrolysis, these hyaluronidases 
also possess transglycosidase activity51, 52. 
The second group of hyaluronidases (EC 3.2.1.36) is commonly termed leech-
hyaluronidases and represents hyaluronate-3-glycanohydrolases that cleave the β-
1→3 linkages of the substrate hyaluronan. These enzymes from leeches and hook 
worms53, in contrast to the mammalian hyaluronidases, do not cleave other GAGs. 
The products of hyaluronan degradation are again tetra- and hexasaccharides but 
with glucuronic acid at the reducing end. 
Microbial hyaluronidases (EC 4.2.2.1) also termed β-eliminases or lyases, catabolize 
hyaluronan via β-elimination of the β-1→4 glycosidic bond. As a result Δ4-5 
unsaturated oligosaccharides are obtained. Thus, they are clearly separated from the 
other two groups which utilize a hydrolase mechanism. 
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Figure 1.3. Classification of hyaluronidases according to Meyer50. Adopted from Muckenschnabel et 
al.54 
 
Alternatively, based on their sequence homology it is possible to classify the 
hyaluronidases into two major groups: hyaluronidases from eukaryotes and 
prokaryotes23, 49. Additionally, a rough classification in acid- and neutral-active 
hyaluronidases is possible due to their different pH activity profiles14.  
 
1.2.2 Hyaluronidases from eukaryotes 
 
1.2.2.1 Mammalian hyaluronidases 
 
The human genome contains six hyaluronidase-like sequences: hyal1, hyal2, and 
hyal3, which are clustered on chromosome 3p21.3, and hyal4, hyalp1 (a pseudogene 
which is transcribed but not translated) and ph20 (spam1), which are clustered on 
chromosome 7q31.3. The six genes are known to share about 40 % of their identity 
with one another. They encode for Hyal-1, Hyal-2, Hyal-3, Hyal-4 and PH-20 and 
according to the carbohydrate active enzyme database (CAZY)55 they belong to the 
glycoside hydrolase family 56. In this chapter, the five human hyaluronidases as well 
as bovine testicular hyaluronidase are briefly introduced. 
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Hyal-1 
Hyal-1 is also termed LUCA-1 due to the location of the gene on a putative tumor 
suppressor site56. It was first isolated from human plasma where it is the predominant 
hyaluronidase found in concentrations of about 60 ng/ml 57. It degrades hyaluronan 
predominantly to tetrasaccharide fragments with the octasaccharide being the 
minimal substrate58. It also can be found in high levels in liver, kidney, spleen and 
heart. A second processed form can be found in urine23. Together with Hyal-2 it is the 
major hyaluronidase in somatic tissue. This acid active enzyme is localized in the 
lysosome and is thus responsible for the degradation of intracellular hyaluronan57. 
Recent studies provided evidence for the dependency of intracellular degradation of 
HA on expression of the surface receptor CD44 which is required to bind and 
internalize the substrate59. Mutation of the hyal1 gene leads to catalytically inactive 
enzyme which causes mucopolysaccharidosis IX, which manifests in periarticular soft 
tissue masses and a short stature together with somatic disorders60. Very recently 
Harada and Takahashi59 proposed an enzyme replacement therapy due to 
observations where catalytically active Hyal-1 was incorporated into cells and thus 
was able to restore intracellular degradation of hyaluronan. The role of Hyal-1 in 
tumor formation is still under investigation: on the one hand this enzyme is a 
candidate tumor suppressor gene, e.g. in tabacco related cancers61, on the other 
hand it was designated as a tumor marker, e.g. for bladder and prostate cancer62, 63. 
 
Hyal-2 
Hyal-2 can be found in virtually all human tissues except the adult brain64 and it was 
characterized to be lysosomal or GPI-anchored to the plasma membrane64-68. It is 
supposed to act in concert with Hyal-1 degrading hyaluronan. Despite being 
considerably less active compared to Hyal-1 and PH-20, the reported optima range 
from acidic to nearly neutral pH values64, 67, 69, 70. In several cases no activity was 
determinable at all68, 71. Hyal-2 seems to have a unique substrate specificity and was 
described to degrade high molecular weight HA to fragments of ca 20 kD (50-60 
disaccharide units)72. Meanwhile also a very slow degradation to smaller fragments 
has been reported69. Despite its catalytic function, Hyal-2 serves as a receptor for the 
Jaagsiekte sheep retrovirus (JSRV) and the enzootic nasal tumor virus (ENTV)68, 73. 
The function as a receptor for JSRV seems to be independent from its hyaluronidase 
activity70. Interactions with the cell surface receptor CD44 seem to play an important 
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role in the function of Hyal-259, 74. Like Hyal-1, Hyal-2 is involved in tumor formation 
and can act as an oncogene75, 76 as well as a tumor suppressor gene product77. 
 
Hyal-3 
There is only little data on Hyal-3. It is known to be widely expressed, e.g. in 
chondrocytes, testis and bone marrow as well as in breast cancer lines76, but until 
today, it has been impossible to determine enzymatic activity23, 24, 59.  
 
Hyal-4 
Hyal-4 was shown to be a GPI-anchored protein78, its expression is restricted to 
placenta and skeletal muscle23. Although no details about the enzymatic activity are 
known, Hyal-4 was reported to be specific for chondroitin and chondroitin sulfate, 
thus this enzyme would represent the first chondroitinase identified in vertebrates24, 
78, 79. 
 
PH-20 
PH-20, also termed SPAM1 (sperm adhesion molecule) was first described as a 
protein binding to the zona pellucida of the ovum80. It is GPI-anchored on the 
membrane of the sperm head81, 82 and facilitates the penetration of the egg via 
digestion of the HA-rich cumulus extracellular matrix83. It can be found in two different 
forms, on the one hand as GPI anchored enzyme, on the other hand as soluble 
protein which is released during the acrosome reaction84, 85. Thus, by its 
hyaluronidase activity on the one side and by its receptor activities on the other side, 
this protein possesses an important role during fertilization. Meanwhile PH-20 has 
been also identified in the epididymis, seminal vesicles, prostate, female genital tract, 
breast, placenta and fetal tissues and was also found in certain malignancies86-89. 
PH-20 is catalytically active under neutral as well as under acidic conditions82, 85, 90, 91 
and cleaves hyaluronan predominantly to small oligosaccharides with the 
octasaccharide being the minimal substrate58. In addition to its hydrolase activity, 
human PH-20 catalyzes transglycosylation reactions; this was also observed for 
bovine testicular hyaluronidase51, 91 which exhibits a sequence identity of 65 % 
compared to the human homolog. 
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Bovine testicular hyaluronidase (BTH) 
Extracts from bovine testis are known to possess hyaluronidase activity45 and 
preparations containing purified BTH like Hylase® “Dessau”, Neopermease® and 
Wydase® were therapeutically used for a long time34, 92. It has been shown that the 
major soluble hyaluronidase present in bull testis extracts is a fragment of membrane 
bound PH-2093. This well known representative of the mammalian hyaluronidases 
cleaves hyaluronan predominantly to tetra- and disaccharides52 and degrades to a 
minor extent the other GAGs chondroitin, chondroitin-4- and -6-sulfate. In contrast to 
human PH-20, the hyaluronan hexasaccharide is accepted as minimal substrate51, 58, 
94. Additionally, transglycosylation is catalyzed, depending on the pH value and the 
salt content of the incubation buffer58, 91, 95. 
 
1.2.2.2 Venom hyaluronidases 
 
Hyaluronidases are found as components of all types of animal venoms. Examples 
are the venoms from snakes96, 97, bees80, 98, wasps47, 99, scorpions100, spiders101, 102 or 
lizards103. In all these cases the hyaluronidase may contribute to local tissue damage 
and act as a spreading factor facilitating the diffusion of toxic components of the 
venom96, 104. Bee venom hyaluronidase (BVH) was the first eukaryotic hyaluronidase 
for which a crystal structure was determined. As a member of the family 56 of 
glycosyl hydrolases105, BVH has a sequence homology of about 30 % with that of 
mammalian hyaluronidases80. Compared to mammalian hyaluronidases BVH lacks a 
C-terminal domain of ca 120-150 amino acid residues. The analysis of the crystal 
structure revealed an unusual overall fold, a (β/α)7 barrel instead of a regular (β/α)8-
TIM-barrel. The HA binding grove is situated at the C-terminus of the enzyme. The 
active site is located in the middle of the hyaluronan binding site and is encompassed 
with highly conserved amino acids i.e. the catalytically active Glu113 and amino 
acids like Asp111, Tyr184, Tyr227 and Trp301, which are supposed to be involved in 
substrate positioning are also present in the mammalian hyaluronidases98, 106. 
Meanwhile the X-ray structure of a hyaluronidase from wasp venom with similar 
structural characteristics has been published (PDB code 2atm)99. 
Due to the co-crystallized hyaluronan tetramer within the BVH protein (PDB code 
1fcv98) it was possible to elucidate the catalytic mechanism for HA degradation. The 
unique double-displacement substrate-assisted mechanism is depicted in Figure 
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1.3107. In the first step, the hyaluronan substrate binds to the hyaluronidase and the 
carbonyl oxygen nucleophile of the N-acetyl group is positioned next to the glycosidic 
bond which will be cleaved. Thereby, the GlcNAc residue adapts an unusual 4C1 boat 
conformation (1). The carbonyl oxygen attacks the C1 carbon which leads to the 
cleavage of the glycosidic bond and the formation of the oxazolinium ion intermediate 
2 under inversion of the configuration at C1. At the same time the single catalytic 
amino acid Glu113 protonates the leaving part of the hyaluronan chain. In the next 
step, a water molecule attacks C1 which leads to the hydrolysis of the intermediate 2 
under inversion of the configuration and reprotonation of Glu113 (3). The remaining 
HA product is finally released from the active site. Thus, by the release of the 
hyaluronan fragments after cleavage and subsequent binding of a new fragment for 
the next cleavage, the enzyme follows an endolytic random bite mode of action78. 
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Figure 1.3. Double-displacement substrate-assisted mechanism of bee venom hyaluronidase. The 
saccharide in subsite108 -1* (1) binds in boat conformation, and catalysis is proposed to occur via a 
formation of a covalent oxazolinium ion intermediate 2 to the product 3. Adapted from Markovic-
Housley and Schirmer107. 
 
Due to the highly conserved amino acids which are involved in catalysis and 
substrate binding, the same mechanism for substrate degradation is assumed for the 
mammalian hyaluronidases106. The crystal structure of human Hyal-1, which was 
elucidated very recently (PDB code 2pe4)79, further supports this hypothesis due to 
the high structural similarity found for the active site of Hyal-1 compared to BVH. 
 
 
 
                                            
* By convention, the sugar residue subsites are labelled from –n to +n, with –n at the non-reducing end 
and +n at the reducing end of the substrate. Cleavage occurs between the -1 and +1 subsites. 
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1.2.3 Hyaluronidases from prokaryotes 
 
The hyaluronidases from prokaryotes cleave HA via an elimination reaction and must 
therefore clearly be separated from the mammalian hyaluronidases due to the 
different catalytic mechanism. The term hyaluronate lyases accommodates for this 
mechanism. The microbial lyases are important virulence factors involved in 
pathogeneses and in the disease progression caused by the pathogen. Thus by 
degradation of hyaluronan-rich tissues of the host, the bacterial hyaluronidases 
facilitate the invasion of the pathogen. Additionally, the hyaluronan oligomers created 
by the enzymes are potent inflammatory agents and promote a microbial-friendly 
environment109. Many gram-positive organisms like Streptococcus, Staphylococcus, 
Streptomyces as well as gram-negative bacteria like Aeromonas, Vibrio, Treponema 
pallidum produce hyaluronate lyases14. The hyaluronidase activity is associated with 
various disease conditions like meningitis, synovitis, hyperplasia, nephritis, 
mycoplasmosis, periodontal disease, mastitis, pneumonia, syphilis and toxic shock 
syndrome109-113. Among the bacterial lyases, the enzymes from S. pneumoniae and 
S. agalactiae are well characterized. The X-ray structures of these enzymes in 
complex with various hyaluronan oligosaccharides provided insight into the 
mechanism of substrate degradation110, 114-119. A longish, highly positively charged 
cleft was identified, which is capable of binding the anionic substrate polymers and is 
lined with lipophilic amino acids. Two important parts of the active site were 
identified. Firstly, His479, Tyr488 and Asn429 were identified as the catalytic amino 
acids (SagHyal3502 numbering) which are responsible for substrate degradation and, 
secondly, an aromatic patch consisting of Trp371, Trp372 and Phe423 was identified 
which is responsible for substrate positioning. Based on the X-ray data and site-
directed mutagenesis studies120, a proton acceptance and donation mechanism was 
suggested for the bacterial hyaluronate lyases (Figure 1.4). Firstly, hyaluronic acid 
binds to the positively charged enzymatic cleft where three disaccharide units can be 
accommodated (only two are shown in Figure 1.4). Secondly, HA1 and HA2 are 
precisely positioned by the aromatic patch providing the optimal position for 
degradation. Hydrogen formation of Asn429 and the carboxylate group of the HA1 
glucuronic moiety leads to acidification of the C5 hydrogen. In the third step His479 
withdraws a proton from the glucuronic acid C5 which leads to sp2 hybridization, and 
simultaneously Tyr488 protonates the glycosidic oxygen (O4) and thus breaks the 
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glycosidic bond between HA1 and HA2. HA1 glucuronic C4 is thus rehybridized from 
sp3 to sp2 similarly to the C5 carbon which results in the formation of the double 
bond. In the final step the catalytic residues are deprotonated (His479) or protonated 
(Tyr488) by a water molecule. A negative patch (Glu488, Asp478 and Thr480) is 
probably responsible for the repelling of the negatively charged product. 
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Figure 1.4. Mechanism of hyaluronan degradation by hyaluronate lyase from S. agalactiae 
(SagHyal3502) according to Li and Jedrzejas116. Schematic presentation of hyaluronic acid with HA1 
and HA2 as disaccharide units and the position of the sidechains of Tyr488, His479 and Asn429 
relative to the substrate. Modified from Li and Jedrzejas116. 
 
The hyaluronidases from S. pneumoniae and S. agalactiae, respectively, are 
supposed to degrade hyaluronan via a processive mode of action110, 116. Thus, the 
enzyme binds randomly to the hyaluronan molecule and cleaves it into two pieces 
(initial endolytic cleavage). The obtained unsaturated HA fragment then leaves the 
binding site, whereas the other fragment remains in the cleft where it is translocated 
by one disaccharide unit towards the reducing end. After cleavage and release of the 
unsaturated disaccharide, the remaining HA fragment is translocated again and the 
next disaccharide is removed from the hyaluronan chain (exolytic processive 
degradation). Based on the observation that at all stages of digestion a mixture of 
oligosaccharides of different size was present also a nonprocessive mode of action 
was proposed for SagHyal4755121. 
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1.3 Medical applications of hyaluronan and hyaluronidases 
 
The hydroscopic and viscoelastic nature and the high biocompatibility makes 
hyaluronan suitable for various medical applications. It is in use as vitreous humor 
supplement/replacement during eye surgery since the middle of last century122. In 
general, it can be used in surgical procedures to support regenerative processes of 
surgical wounds and it is used as anti-adhesion and anti-scar drug. Additionally, it 
appears that it promotes corneal, diabetic foot, tendon, bone, nasal mucosal, and 
venous leg ulcer wound healing14. The use of HA preparations for the treatment of 
osteoarthritis has been intensively studied123-126. Injected hyaluronan was found to 
suppress the cartilage degeneration, protects the surface of articular cartilage, 
normalizes the properties of the synovial fluid and even reduces pain perception. 
Increased HA levels are observed during periods of rapid cell turnover or in early 
wound healing4, 127. Furthermore, a change in the amounts of circulating HA is 
directly connected with events like blood loss, ischaemic stroke, septicaemia after a 
massive trauma, shock, major surgical procedures or extensive burns, and is 
indicative for liver cirrhosis, liver fibrosis, knee osteoarthritis and rejection following 
liver transplantation14, 38, 128, 129. Thus, hyaluronan can serve as a biomarker for 
various diseases. Hyaluronan also can be used in drug delivery where on the one 
hand it enhances the partitioning of drugs like diclofenac or ibuprofen into human 
skin and on the other hand enhances its retention in the epidermis14. Beneficial 
effects of direct conjugates of hyaluronan fragments and cytotoxic agents were 
reported130 as well as the use of implantable synthetic polymers to provide long-term 
delivery of antibiotic or anti-inflammatory drugs14. Furthermore, hydrogels based on 
crosslinked or otherwise chemically modified hyaluronan are potentially useful 
biomaterials for soft-tissue engineering applications14, 131. For a few years, 
hyaluronan can also be found in cosmetics as a “rejuvenation agent”132, 133. 
The clinical use of hyaluronidases which is based on the spreading effect was 
already described by Breu in 1952134. Thus, hyaluronidases can be used to increase 
the speed of absorption, to promote resorption of excess fluids and to increase the 
effectiveness of local anesthesia. Furthermore, the application of hyaluronidases 
leads to diminished tissue destruction after subcutaneous and intramuscular injection 
of fluids48, 135. It is a necessity for every derma-surgeon to treat side effects after 
injection of hyaluronic acid136, 137. Hyaluronidases can also be used to decrease 
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mycardinal infarction size138 and they are widely used in fields like orthopaedia, 
surgery, ophthalmology, internal medicine, oncology, dermatology and 
gynaecology34, 139-141. 
Hyaluronidase from bovine testis has been broadly used. However, there was a 
shortage in supply of BTH preparations due to the BSE risk. As a consequence, a 
number of cases of iatrogenic strabismus have been observed after cataract 
surgeries142. Thus, these bovine preparations should be displaced with bacterial or 
ovine hyaluronidases87, 143 or recombinant human enzymes20, 144, 145. As animal 
hyaluronidase preparations always contain a certain degree of impurities and 
treatment with BTH may cause adverse effects such as allergic reactions and skin 
irritation reactions146, 147, recombinant human enzymes should be advantageous. 
Hyaluronidase was also investigated as an additive to chemotherapeutic drugs for 
augmentation of anticancer activity and there is evidence that hyaluronidase itself 
may have intrinsic anticancer effects92, 148, 149. Furthermore, Zahalka et al. reported 
that they were able to block lymph node invasion by tumor cells in an animal model 
by treatment with hyaluronidase150. Nevertheless, the relevance of hyaluronidases in 
the development of cancer is discussed controversially: on the one hand human 
hyaluronidases are candidate tumor suppressor gene products, on the other hand 
there is evidence for an oncogenic potential of this class of enzymes.  
In general, the role of hyaluronan and the hyaluronidases in many 
(patho)physiological processes is far from being understood. For a long period of 
time the hyaluronidases have been a group of poorly characterized, neglected 
enzymes47. Additionally, potent and selective inhibitors are not known to date. The 
inhibitors encountered frequently are even more neglected than the hyaluronidases 
itself151. Such compounds are required as pharmacological tools for the better 
characterization and understanding of the hyaluronidases. Moreover, hyaluronidase 
inhibitors might be of therapeutic value, for example, as additives in the treatment of 
bacterial infections109, as anti-venom/toxin14 and anti-tumor agents152, to promote 
wound healing or as additives in the treatment of arthroses or gingivitis152. 
Additionally, it is conceivable that hyaluronidase inhibitors have a potential as 
contraceptives153 and for the development of new antiallergic drugs154. 
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Potent and selective inhibitors of hyaluronidases are not known to date. Such 
compounds are necessary as pharmacological tools for the characterization and the 
investigation of the (patho)physiological role of the hyaluronidases. Moreover, there 
is a therapeutic potential of hyaluronidase inhibitors in the treatment of various 
diseases1 (cf. chapter 1.3).  
The scope of this thesis was the design, synthesis and characterization of 
hyaluronidase inhibitors with focus on recombinantly expressed human enzymes. 
The project was mainly based on previous results and experience gained from the 
work of our research group on inhibitors for the bacterial hyaluronate lyase from S. 
agalactiae strain 4755 (SagHyal4755)2-4.  The de novo design of inhibitors of bacterial 
hyaluronan lyases, supported by x-ray structures in complex with inhibitors resulted 
in lead compounds with IC50 values in the low micromolar range. These compounds 
were inactive or only weakly active on the bovine testicular enzyme, a prototypal 
mammalian hyaluronidase, which was considered an appropriate model for the 
development of inhibitors for the corresponding human enzymes at the beginning. In 
the course of this work, in a complementary PhD project, the human enzymes Hyal-1 
and PH-20 were recombinantly expressed, purified and characterized with respect to 
biochemical and catalytic properties5-7. Therefore, it was possible to investigate the 
synthesized compounds for inhibition of three mammalian hyaluronidases. 
Additionally, inhibition of SagHyal4755 as reference enzyme for the class of bacterial 
hyaluronate lyases was investigated.  
The purification of the two recombinantly expressed human hyaluronidases is briefly 
described as the procedure was a prerequisite for this thesis. Additionally, the 
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investigation of reference hyaluronidase inhibitors under the assay conditions used in 
this work is reported with respect to the comparison of the inhibitory potencies of 
known inhibitors with those of the newly synthesized compounds. 
 
In a first synthetic approach glucurono-6,3-lactone, which is structurally related to the 
monosaccharide glucuronic acid, served as a scaffold for the synthesis of bacterial 
and mammalian hyaluronidase inhibitors.  
To identify new chemical entities for the development of inhibitors of human 
hyaluronidases, various compounds synthesized in our workgroup were investigated 
for inhibition. Based on those results, ascorbic acid was considered as lead structure. 
Thus, the synthesis of novel vitamin C derivatives and their inhibitory activity 
represent a major part of this work. 
When the chemical work of this thesis was finished, the first crystal structure of a 
human hyaluronidase was published8. The 3D-structure of Hyal-1 was used to 
perform docking experiments with selected potent ascorbic acid derivatives in order 
to gain insights into potential protein – inhibitor interactions and to suggest putative 
binding modes. 
Indoles were already identified as inhibitors of bacterial hyaluronidases in our 
workgroup3, 4, 9 and the indole based compound indomethacin is also known to inhibit 
hyaluronidases in vivo10. Therefore, the indole scaffold looks promising for the 
development of inhibitors. The synthesis of indole based compounds and the study of 
the SAR is the aim of another sub-project of this thesis. 
The synthesis and the investigation of the inhibitory activity of a diketopiperazine, a 
compound which was derived as potential inhibitor from previous molecular modeling 
studies2 and the preparation and investigation of nonsulfated glycosides as 
hyaluronidase inhibitors, inspired by promising results obtained for sulfated 
glycosides11, as well as the investigation of inhibitory activities of compounds which 
show structural characteristics related to the synthesized inhibitors are summarized 
in another chapter. 
In the last part, various bioanalytical investigations such as determination of plasma 
protein binding and hemolytic acitivity were carried out to characterize selected 
inhibitors in more detail with respect to further usage in vitro and in vivo. 
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3.1 Introduction 
 
Since the discovery of the hyaluronidases by Duran–Reynals1 in the beginning of the 
last century, various methods for the determination of hyaluronidase activity have 
been developed. An overview of the existing methods is given by Hynes and Ferretti2 
who have grouped the methods based on the type of assay performed. Methods 
based upon spectrophotometric, radiochemical, fluorogenic, enzymoimmunological, 
plate (solid media), chemical, physicochemical and zymographic analysis are known. 
Although many different assays are described, they appear to be rarely used today 
and discussed only briefly2. In many cases the early developed assays lack 
sensitivity or the procedures are rather cumbersome. The colorimetric assay 
developed by Reissig et al. or assays based on changes in viscosity or turbidity had 
been the most widely employed hyaluronidase assays3, 4. Recently, assays based on 
techniques like substrate gel analysis, ELISA or fluorescence were developed 5-8. 
In this thesis two assays were used to determine the activity of the recombinantly 
expressed human hyaluronidases Hyal-1 and PH-20, an enzyme preparation from 
bovine testis (formerly commercially available as Neopermease®) and a bacterial 
hyaluronate lyase from Streptococcus agalactiae strain 4755 (SagHyal4755). The 
principles of both assays are briefly explained. 
 
Chapter 3 Determination of hyaluronidase activity 
30 
3.2 Morgan-Elson assay 
 
The Morgan-Elson assay is a colorimetric or, according to the classification given by 
Hynes and Ferretti2, a chemical assay which is based on the reaction between 
reducing N-acetyl-D-glucosamine residues of the substrate with Ehrlich´s reagent (p-
dimethylaminobenzaldehyde) described by Gacessa9 and Reissig10. The reaction, 
which forms a red colored product that can be detected photometrically at 586 nm 
was investigated and described in detail by Muckenschnabel et al.11 Thus, 
hyaluronidase activity is determined by quantitation of the N-acetyl-D-glucosamine 
residues at the reducing end of hyaluronic acid fragments produced by enzymatic 
degradation. 
The suggested mechanism of this reaction according to Muckenschnabel et al.11 is 
depicted in Scheme 3.1. Hyaluronic acid is cleaved by the hyaluronidases during 
incubation. Then the reducing N-acetyl-D-glucosamine residues are cleaved under 
the basic assay conditions (pH 9, 100 °C) resulting in an anomeric mixture of 
chromogen I (α-configuration) and chromogen II (β-configuration) that are 
transformed under acid catalysis  (HOAc and HCl) to chromogen III via elimination of 
water. The final red colored product (λmax = 545 nm and 586nm) is subsequently 
obtained after reaction with p-dimethylaminobenzaldehyde.  
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Scheme 3.1.  Mechanism of the Morgan-Elson reaction. Modified from Muckenschnabel et al.11 
 
3.3 Turbidimetric assay 
 
According to Hynes and Ferretti2 the turbidimetric assay is a representative member 
of the physicochemical assays. It is based on the method of Di Ferrante12 who 
utilized the formation of insoluble complexes between cetyltrimethylammonium 
bromide (CTAB) and the residual high molecular weight substrate (mw > 8 kDa) after 
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incubation with enzyme to determine hyaluronidase activity by quantification of the 
resulting turbidity using photometric detection at 600 nm (Scheme 3.2). 
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Scheme 3.2. Principle of the turbidimetric assay based on the method of Di Ferrante12. Scheme 
modified from Braun13. 
 
Due to the fact that this assay is highly reproducible, fast and can be easily 
performed using microtiter plates, this protocol was chosen as standard method for 
the investigation of hyaluronidase inhibitory activities of the synthesized compounds. 
 
3.4 Influence of the pH value on enzymatic activity 
 
The activities of the four hyaluronidases from different sources are dependent on the 
pH value. The pH dependent activities of the investigated enzymes are shown in 
Figure 3.1. It is not possible to select a pH where all investigated enzymes show 
sufficiently high activity. Highest activity for the bacterial hyaluronate lyase was found 
at pH 5.0. To obtain comparable results concerning the IC50 values of the 
investigated inhibitors which also depend on pH, the human and bovine PH-20 
enzymes were tested at pH 5.0 where both enzymes show considerably high activity 
in the turbidimetric assay which is routinely used in this work. Thus, the obtained IC50 
values are comparable to results from previous investigations performed by Salmen 
and Braun in our workgroup13-19. 
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Figure 3.1. pH dependent activity of the investigated hyaluronidases as determined in the 
turbidimetric assay (black circles) and the Morgan Elson Assay (open squares); a) bovine testicular 
hyaluronidase (BTH), b) recombinantly expressed human PH-20, c) recombinantly expressed human 
Hyal-1, d) bacterial hyaluronate lyase from S. agalactiae strain 4755 (SagHyal4755); *modified from 
Hoechstetter20; **modified from Hofinger21. 
 
Since human Hyal-1 is only very weakly active at pH 5.0, the turbidimetric assay was 
performed at pH 3.5 where enzymatic activity is nearly maximal. Thus, it is possible 
to compare the IC50 values of the new inhibitors investigated in this project with data 
at acidic pH previously determined in our workgroup13, 14. 
 
3.5 Experimental procedures 
 
3.5.1 Materials and methods 
 
Hyaluronan (hyaluronic acid) from Streptococcus zooepidemicus was purchased 
from Aqua Biochem (Dessau, Germany). Bovine serum albumin (BSA) was obtained 
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from Serva (Heidelberg, Germany). The investigated hyaluronidases were enzyme 
preparations from different sources. Stabilized hyaluronate lyase, i.e. 200,000 units 
(according to the supplier, 0.572 mg from S. agalactiae strain 4755 plus 2.2 mg of 
BSA and 37 mg of Tris-HCl per vial) of lyophilized hyaluronate lyase, was kindly 
provided by id-Pharma (Jena, Germany). Lyophilized hyaluronidase from bovine 
testis (Neopermease®) (200,000 units, according to the supplier; 4 mg plus 25 mg of 
gelatine per vial) was a gift from Sanabo (Vienna, Austria). Enzyme solutions 
containing recombinantly expressed human Hyal-1 and PH-20 were prepared as 
previously described (see chapter 4)21-23. All other chemicals were of analytical grade 
and were received from Merck or Sigma. 
 
3.5.2 Morgan-Elson assay 
 
The test compounds, dissolved in DMSO (18 µl), were incubated at 37 °C in an 
incubation mixture containing 200 µl of  buffer (if not otherwise indicated: McIlvaine’s 
buffer: solution A: 0.2 M Na2HPO4, 0.1 M NaCl, solution B: 0.1 M citric acid, 0.1 M 
NaCl; solution A and B were mixed in appropriate portions to adjust the required pH), 
50 µl of BSA solution (0.2 mg/ml in water), 50 µl of HA solution (5 mg/ml in water), 82 
µl of water and 50 µl of an enzyme solution. The final DMSO concentration was 3.9 
% (v/v). After incubation at 37 °C, the enzyme reaction was stopped by addition of 
110 µl of alkaline borate solution and subsequent heating for 4.5 min at 100 °C. The 
alkaline borate solution was prepared immediately before use from a borate solution 
(17.3 g H3BO4 and 7.8 g KOH in 100 ml water) and a potassium carbonate solution 
(8.0 g K2CO3 in 10 ml water). After cooling on ice for 2 min 1250 µl of N,N-
dimethylaminobenzaldehyde (20.0 g N,N-dimethylaminobenzaldehyde dissolved in 
25 ml of concentrated HCl and 75 ml of glacial acetic acid; the solution was diluted 
with 4 volumes of glacial acetic acid immediately before use) was added and the 
mixture was incubated at 37 °C for 20 min. The samples were transferred into acryl 
cuvettes and the absorbance of the colored product was measured photometrically at 
a wavelength of 586 nm using an Uvikon 930 UV spectrophotometer (Kontron, 
Eching, Germany). As reference for 100 % enzyme activity the formation of the red 
colored product of a sample without inhibitor (18 µl of DMSO was used instead) was 
quantified. In absence of both enzyme and inhibitor (50 µl of BSA solution and 18 µl 
of DMSO, respectively, was used instead) a reference for 0 % enzyme activity could 
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be measured. In the cases where only quantification of the enzyme activity without 
inhibitor was necessary, the inhibitor solution was replaced by water (18 µl). 
The enzyme activity was calculated from the formation of the red colored product 
measured at 586 nm. The effect of the test compounds on the enzymatic activity was 
calculated according to the equation: 
  (Asample – Aenzyme) 
relative activity [in %] = –––––––––––––––––––––  · 100 % 
  (Ainhibitor – Aboth) 
where Aenzyme is the absorbance of the reference sample without enzyme (50 µl of 
BSA (0.2 mg/ml) solution was used instead), Ainhibitor is the absorbance of the 
reference sample without inhibitor (7 µl of DMSO was used instead) and Aboth is the 
absorbance without both, enzyme and inhibitor. 
 
3.5.3 Turbidimetric assay 
 
The turbidimetric hyaluronidase activity assay described by Di Ferrante12 was 
modified to allow for the performance in 96-well plates as recently described22: 
Incubation mixtures contained the following compounds: 31 µL incubation buffer, 8 
µL BSA (0.2 mg/mL), 8 µL HA (2 mg/ml), 13 µl H2O. For the investigation of the test 
compounds 3 µl of the inhibitor solution in dimethylsulfoxide (DMSO) were added to 
the incubation mixture. The final concentration of DMSO in the incubation mixture 
was 4 % which is well tolerated by BTH and SagHyal4755 as demonstrated 
previously13, 14, 24. The decrease in enzymatic activity by DMSO was also found to be 
acceptable when the recombinant human enzymes were investigated. If not indicated 
otherwise McIlvaine’s buffer was used as incubation buffer (see above). The 
enzymatic reaction was started by addition of 10 µL enzyme solution (see Table 3.1 
for prepared enzyme solutions). After incubation at 37 °C (incubation times see Table 
3.1) the enzymatic reaction was stopped by addition of 200 µl of alkaline 
cetyltrimethylammonium bromide (CTAB) solution (2.5 % (w/v) CTAB in 0.5 M 
NaOH), and the plates were incubated for 20 min at room temperature. The turbidity 
was quantified by measurement of the optical density (OD) at 580 nm in a microplate 
reader (Tecan Deutschland GmbH, Crailsheim, Germany). The plate was shaken in 
the reader for 10 s, then the OD was measured after 2 s of settling time by 5 flashes 
at the centre of each well. 
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For the investigation of potential inhibitors, samples without inhibitor and without both 
inhibitor and enzyme were taken as references. The activities were plotted against 
the logarithm of the inhibitor concentration, and IC50 ± SEM values were calculated 
by curve fitting of the experimental data with Sigma Plot 8.0 (SPSS Inc., Chicago, 
USA). 
IC50 values for BTH (Neopermease®) and SagHyal4755 generally were determined 
using the turbidimetric assay performed in acryl cuvettes as described previously19. 
As poor solubility of the compounds could lead to false positive results in the 
turbidimetric assay, the terminal solubility was determined prior to the investigation of 
hyaluronidase inhibition. To determine the solubility of the test compounds, a sample 
containing 600 µl of citrate-phosphate buffer, 396 µl of water, 300 µl of BSA solution 
(0.2 mg/ml in water) and 54 µl of a solution of the respective test compound 
(dissolved in DMSO) at various concentrations was measured at 600 nm. A cuvette 
filled with water served as reference. Compounds were tested for inhibitory activity at 
concentrations, where no turbidity was measured. 
In Table 3.1 the enzymatic activities, pH values and incubation times employed in the 
turbidimetric assay are summarized. The incubation periods were adjusted to obtain 
comparable substrate degradation. 
 
Table 3.1. Enzymatic activities, pH and incubation times employed in the turbidimetric assay. 
 
Enzyme 
Enzyme 
solution 
prepared 
[mU/ml]a 
Enzyme solution 
added to incubation 
mixture 
[µl] 
Final enzymatic 
activity in the 
incubation mixture 
[mU]a 
pH 
Incubation 
time 
[h] 
Hyal-1b 20 10 0.2 3.5 0.3 
PH-20b 1.0 10 0.01 5.0 4.5 
BTHc 9.0 30 0.27 5.0 0.5 
SagHyal4755c 97 30 2.9 5.0 0.5 
aAccording to the definition of the International Union of Biochemistry 1 unit (U) of hyaluronidase 
catalyzes the liberation of 1 µmol N-acetyl-D-glucosamine (NAG) at the reducing ends of sugars per 
minute under specific conditions. Enzymatic activity was calculated from the formation of the red-
colored product per unit time, using standards with known NAG concentration11; btested using the 
turbidimetric assay performed in microtiter plates; ctested using the turbidimetric assay using cuvettes 
as described previously19. 
 
BTH and SagHyal4755 were used at equiactive concentrations as described by Braun 
and Salmen13, 14. The enzymatic activity of Hyal-1 used in the turbidimetric assay was 
in the same range as that of BTH. As small modifications in the enzyme 
concentration only result in negligible changes of the IC50 values, the obtained IC50 
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values for Hyal-1, BTH and SagHyal4755 are comparable and conclusions about 
selectivity can be made. Due to economic reasons, the recombinantly expressed 
human PH-20 had to be used at significantly lower concentrations possibly leading to 
lower IC50 values. Thus, for selectivity considerations, representative compounds 
were re-investigated at equiactive concentrations (chapter 10.3.5). 
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The purification of recombinant Hyal-1 and PH-20 which were used in this thesis was 
done under the supervision of Dr. E. Hofinger according to methods previously 
described by our workgroup1-3. Thus, the purification is only briefly described here. 
More detailed information and experimental protocols for the construction of 
expression vectors as well as the expression and purification of the recombinant 
enzymes are included in a doctoral thesis and articles by Hofinger et al.1-3. 
 
4.1 Recombinant human Hyal-1 
 
The expression of Hyal-1 in Drosophila Schneider-2 (DS-2) cells transfected with the 
vector pMT/Hygro/hyal1 was induced by addition of CuSO4 to the suspension culture. 
10 d after induction the cells were harvested by centrifugation, and the medium was 
used for isolation of Hyal-1. To reduce sample volume, Hyal-1 was concentrated by 
ammoniumsulfate precipitation. Triton X-100 was added to the buffers to avoid 
adhesion of Hyal-/DS-2 to column materials as well as to centrifugal devices. 
Purification of the enzyme was achieved by cation exchange chromatography and 
subsequent Ni-IMAC. Cu2+ ions from the cell culture medium were chelated using 
EDTA prior to the chromatography steps as they complex the His-tag from binding to 
the Ni-IMAC. The identity and activitiy of the purified protein with a molecular mass of 
52 kDa was confirmed by western blot analysis and the Morgan-Elson activity assay. 
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4.2 Recombinant human PH-20 
 
Human PH-20 was also expressed as a soluble protein in hygromycin resistant DS-2 
cells with the C-terminal GPI-anchoring signal peptide missing after induction with 
CuSO4. After 10 days PH-20 was partially purified in the presence of Triton X-100 by 
chelating IMAC utilizing the Cu2+ ions present in the culture medium. The identity and 
activitiy of the purified protein with a molecular mass of 56 kDa was confirmed by 
western blot analysis and the Morgan-Elson activity assay. 
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5.1 Hyaluronidase inhibitors reported in the literature 
 
First inhibitors of hyaluronidases were described in the middle of the last century. 
Since that time inhibitors were identified in various classes of compounds. For 
instance, the inhibitory activity of diverse metal ions was described, among them iron, 
cadmium, copper or zinc salts1-3. The existence of a highly potent endogenous 
inhibitor, characterized as a thermolabile, magnesium dependent glycoprotein, in 
human serum and tissues was reported early4, 5. Meanwhile, newer technologies 
allowed to identify a hyaluronidase inhibitor, probably a protein belonging to the inter-
alpha-inhibitor family, in murine and human serum6. 
On the basis of substrate similarity, several polysaccharides were identified as 
hyaluronidase inhibitors. Heparin and heparan sulfate as well as sulfated, nitrated or 
acetylated hyaluronic acid were characterized as (non competitive) inhibitors1, 7-9, 
whereas dextran sulfate and sulfated hyaluronic acid oligosaccharides are supposed 
to act, at least partly, in a competitive manner10, 11. Chitosan was also characterized 
as an inhibitor, with direct correlation between molecular weight and inhibitory 
potency of the polysaccharide12. Synthetic polymers like poly mandelic acid13 or 
sodium-polystyrene-4-sulfonate are reported to be (irreversible) inhibitors14, 15. 
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Among the described nonpolymeric inhibitors are compounds from different classes 
of natural compounds, for instance, flavones and flavone-analogs like silybin, 
apigenin, luteolin and kaempferol16-21, saponins and sapogenins like glycyrrhizin and 
glycyrrhetinic acid22, 23 or polyphenols such as tannic acid20, aristolochic acid, the 
alkaloid reserpine24 as well as plant extracts22, 25-30. Other substances known to 
(weakly) inhibit hyaluronidase activity are antioxidants like ascorbic acid31 or propyl-
gallate24, various fatty acids32, L-arginine derivatives or guanidine hydrochloride33, 
representative anti-inflammatory agents such as indomethacin, which is regarded as 
an inhibitor in vivo, phenylbutazone, oxyphenbutazone and salicylates12, 24, 28, 34, 35. 
Finally antiallergic drugs like disodium cromoglycate (DSCG), aurothiomalate, 
tranilast or traxanox17, 36, 37 are claimed to possess hyaluronidase inhibitory activities. 
However, the inhibitory potency was in most cases low, that is in the high micromolar 
and millimolar range, in the case of low molecular weight substances. Thus, no 
potent and selective inhibitors are known to date.  
 
5.2 Inhibitory activities of selected reference compounds as 
determined in the turbidimetric assay 
 
In the case of hyaluronidases the exact determination of Ki values of inhibitors is 
extremely difficult. On the one hand, the substrate hyaluronan is difficult to quantify 
as the used preparations are not homogeneous but consist of a mixture of different 
HA molecules with different molar weights. Additionally, HA is cleaved by the action 
of hyaluronidases and the resulting hyaluronan fragments are again substrates for 
another catalytic reaction which affects the substrate concentration. On the other 
hand, the competing transglycosylation reaction also influences the substrate 
concentration, a necessary parameter for the calculation of Ki values. Therefore, the 
determination of IC50 values is a viable approach to collect comparable inhibitor data 
for libraries of compounds with respect to the elucidation of structure-activity 
relationships. As IC50 values are strongly dependent on the method and the assay 
conditions (e.g. incubation conditions, enzymes, enzyme concentrations, substrate 
concentrations, pH value), huge discrepancies can occur, so that a direct comparison 
of data from different laboratories is impossible in most cases, For example, DSCG is 
designated as one of the most potent inhibitors of bovine testicular hyaluronidase 
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with an IC50 value of 29 µM17. When this compound was investigated upon BTH 
inhibition under the assay conditions applied in this work, the compound proved to be 
much less potent: no inhibition of the enzyme was detectable at concentrations below 
2 mM at pH 5.0 in the turbidimetric assay, and an IC50 value as high as 1.24 mM was 
determined in the colorimetric Morgan Elson assay38 by Salmen39. 
Therefore, several reference compounds described in the literature were investigated 
for inhibition of the hyaluronidases under standardized conditions in the turbidimetric 
activity assay based on the method of Di Ferrante40 (see chapter 3) to gain reliable 
and comparable data with respect to the classification of the synthesized inhibitors in 
terms of potency. The structures of the tested reference compounds are depicted in 
Figure 5.1, the obtained IC50 values are summarized in Table 5.1. 
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Figure 5.1. Structures of investigated small molecule hyaluronidase inhibitors.  
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Table 5.1. Inhibitory activities of reference compounds on four investigated hyaluronidases, 
Hyal-1 PH-20 BTH SagHyal4755Compound IC50 [µM]a 
Glycyrrhizic acid 26 ± 1 17 ± 1 737 ± 30 46 ± 2 
Glycyrrhetinic acid > 100 6.9 ± 0.7 > 100 54 ± 3 
Carbenoxolone > 130 3.2 ± 0.5 134 ± 7 20 ± 1 
Indomethacin 390 ± 30 82 ± 9 540b 350c 
Diclofenac > 500 68 ± 7 > 1000 161 ± 11 
DSCG 474 ± 75 > 900 > 2000 1208 ± 81 
Phloretin 358 ± 49 200 ± 12 > 1400 213 ± 8 
Kaempferol > 1000 288 ± 23 > 1000 237 ± 15 
Sylibinin > 1000 111 ± 10 > 1000b 296 ± 18 
Lauryl gallate > 100 20 ± 3 > 100 13 ± 1 
L-Ascorbic acid > 60000 7564 ± 883 > 100000d 6100 ± 100d 
1,3-Diacetylbenzimidazole-2-thione > 1000 > 1000 > 1000b 160c 
3-Phenyl-1-(2-thioxobenzo[d] 
oxazol-3(2H)-yl)propan-1-one 
> 100 > 100 > 100d 15 ± 1d 
Tetradecane sulfonic acid 21 ± 1 7.6 ± 0.3 93 ± 5 12 ± 1 
Lauric acid > 100 25 ± 2 > 150 > 150 
Tannic acid 3.6 ± 0.5 1.1 ± 0.1 > 160 8.9 ± 0.6 
a inhibition of enzyme expressed as IC50 (µM), mean values ± SEM; IC50 values determined at pH 5.0 
(PH-20, BTH, SagHyal4755) or 3.5 (Hyal-1) in the turbidimetric assay; bas determined by Salmen39 at 
pH 3.6; cas determined by Salmen39; das determined by Braun41. 
 
It is obvious that broadly accepted inhibitors like kaemferol, DSCG or indomethacin 
only weakly inhibit the investigated mammalian hyaluronidases and the bacterial 
hyaluronate lyase from Streptococcus agalactiae strain 4755. Among the 
investigated inhibitors, strongest inhibition of Hyal-1 was found for the detergent 
tetradecane sulfonic acid and for glycyrrhizic acid with IC50 values of 21 µM and 26 
µM, respectively. The related compound carbenoxolone together with tetradecane 
sulfonic acid were found to be the most potent inhibitors of recombinantly expressed 
PH-20. The weak inhibitor DSCG was found to be outstanding due to the fact that 
certain selectivity for Hyal-1 versus human PH-20 was obtained, whereas the 
opposite was found for all other reference compounds. The substances were only 
very weakly active or inactive on BTH, whereas the bacterial enzyme was inhibited 
by most compounds in the (sub)millimolar range. The most potent inhibitors of the 
bacterial enzyme were the antioxidant lauryl gallate and the detergent tetradecane 
sulfonic acid with IC50 values of 13 µM and 12 µM, respectively. 1,3-
Diacetylbenzimidazole-2-thione and 3-phenyl-1-(2-thioxobenzo[d]oxazol-3(2H)-
yl)propan-1-one, which were recently identified as potent inhibitors of the bacterial 
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hyaluronate lyase in our workgroup39, 41 proved to be inactive when tested on the 
mammalian enzymes. 
Tannic acid, which is commonly used for the immobilization of enzymes42, is 
composed of gallic acid moieties attached to a glucose core und must therefore be 
clearly separated from the other nonpolymeric low molecular weight inhibitors which 
are subject of this work. Other sulfated polymers like sodium-polystyrene-4-sulfonate 
(PSS) also possess inhibitory potency in the (sub)micromolar range as reported by 
Isoyama et al.15, but it should be stressed that the molecular weight of those 
derivatives is extremely high (e.g. 519,000 g/mol for PSS990000). Thus, IC50 values 
in the same range as those of low molecular weight inhibitors are obtained when 
calculated on a weight concentration basis. Although the mentioned polymers or 
detergents like tetradecane sulfonic acid are rather potent hyaluronidase inhibitors, 
these compounds are far from being druglike and their utility as pharmacological 
tools for in vivo investigations is limited. Thus, the search for more potent and 
selective low molecular weight inhibitors is necessary. 
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Chapter 6 
Derivatives of the glucurono-6,3-
lactone as hyaluronidase inhibitors 
 
 
6.1 Introduction 
 
In the synthesis of a hyaluronan disaccharide fragment (see chapter 9) as potential 
inhibitor of hyaluronidases, monosaccharides were prepared as intermediates. D-
glucurono-6,3-lactone (Figure 6.1) is often used as a precursor for the synthesis of 
uronic acid derivatives1, 2. On the one hand this lactone shares structural similarities 
with ascorbic acid, which is a known hyaluronidase inhibitor3, on the other hand the 
carbohydrate-like structure is related to D-glucuronic acid which is part of hyaluronan. 
This prompted us to synthesize various D-glucurono-6,3-lactones and related 
compounds as potential inhibitors of hyaluronidase. 
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Figure 6.1. Structures of D-Glucurono-6,3-lactone, D-glucuronic acid and L-ascorbic acid. 
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6.2 Chemistry 
 
The synthesis of 1-O-alkyl-β-D-glucofuranosidurono-6,3-lactones 6.1-6.6 was 
possible without any protection groups according to the method of Bertho et al.4 
using D-glucurono-6,3-lactone and alcohols in presence of BF3Et2O (Scheme 6.1). 
The β-anomers were formed in high excess and were easily separated from the 
corresponding α-anomeric side products by flash chromatography. Saponification of 
the lactone4 yielded the corresponding 1-O-alkyl-β-D-glucofuranosidic acids 6.7-6.10. 
Aminolysis of 6.6 using NH3/MeOH or alkyl amines5, 6 in alcohol yielded the pertinent 
amides 6.11-6.22. To obtain the carboxylic acids 6.23-6.25, the methyl alkylamino-
carboxylates 6.20a-6.22a were synthesized according to known procedures7-10. In 
those cases the esters of 6.20-6.22 had to be cleaved after aminolysis of the lactone 
using aqueous LiOH to obtain 6.23-6.25. 1-O-Hexadecyl-β-D-glucuronic acid (6.26) 
was synthesized using the same conditions as employed for the synthesis of 6.1-6.6 
(Scheme 6.2). 
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Scheme 6.1. Synthesis of 6.1-6.25. Reagents and conditions: (i) R1OH (1-2 eq), BF3Et2O (2 eq), THF, 
60-70 °C, 1 h; (ii) NaOH, acetone, 0 °C to RT, 2 h; (iii) NH3/MeOH, 0 °C, 2 h; (iv) NHR2 (1-3 eq), 
MeOH, RT overnight; (v) 0.5 N LiOH (2 eq), THF, RT overnight. 
 
O
OH
O(CH2)15CH3
OH
OH
CO2H
O
OH
OH
OH
OH
CO2H
i
6.26  
Scheme 6.2. Synthesis of 6.26. Reagents and conditions: (i) Hexadecan-1-ol (2 eq), BF3Et2O (2 eq), 
THF, 60-70 °C, 1 h. 
 
Regioselective reactions were needed for the modification of the 3-OH or 5-OH of the 
lactone scaffold. Acylation predominantly takes place at position O-5 of the 1-O-
alkylated lactone as already described11, 12 if one equivalent of acid chloride or 
otherwise activated carboxylic acid is used (Scheme 6.3). The reaction of 6.6 with 
equimolar amounts of sulfonic acid chloride or anhydride also leads to the formation 
of 5-OH-monosulfonylated derivatives as major product13, 14. Monocarbamoylation 
using isocyanates was unsuccessful. Whereas 6.6 did not react with ethyl isocyanate 
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at room temperature, the addition of copper(I)-chloride15 resulted nearly exclusively in 
the dicarbamoylated product 6.31. Alkylation using alkyl halides and base is not 
possible in the presence of the sensitive lactone ring. Therefore, reactions avoiding 
strong nucleophiles are needed to leave the lactone ring intact. The monobenzylation 
of 6.6 was successful using benzyl bromide in presence of Ag2O16. However, this 
synthetic pathway was unsuccessful with other alkyl halides. Due to the large variety 
of commercially available carboxylic acids and acid chlorides, acylation was chosen 
as the method of choice for the modification of the lactone core. 
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Scheme 6.3. Synthesis of the 1-O-alkyl-β-D-glucofuranosidurono-6,3-lactone derivatives 6.27-6.32. 
Reagents and conditions: (i) RCOCl (1 eq), pyridine/THF, 0 °C, 1 h; (ii) Tf2O (1 eq), CH2Cl2/pyridine, 
-30 °C, 30 min; (iii) EtNCO (1 eq), Cu(I)Cl (1 eq), DMF, RT, 1 h; (iv) BnBr (1 eq), Ag2O (1.5 eq), 
EtOAc, 40-50 °C, 48 h. 
 
Compounds 6.5 or 6.6 were acylated as depicted in Scheme 6.4. After selective Cbz-
protection of O-5 the 2-OH was acylated using carboxylic acids together with DCC 
and DMAP as coupling reagents. Monobenzyl malonate (6.33) and monobenzyl 
succinate (6.34) which were needed for the introduction of a carboxylic acid residue 
in the amide sidechain were synthesized according to literature conditions17, 18. After 
acylation the protecting groups (Cbz and benzyl esters) were cleaved to obtain the 2-
O-acylated 1-O-alkyl-β-D-glucofuranosidurono-6,3-lactones 6.39-6.42. The 5-O-
acylated derivatives 6.45 and 6.46 were synthesized by treating 6.6 with nearly 
equimolar amounts of acid chloride or carboxylic acid and DCC followed by 
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hydrogenolytic cleavage of the benzyl ester. Finally diacylation of 6.6 was performed 
under similar conditions using an excess of carboxylic acid and activating reagents to 
obtain 6.51 and 6.52 after removal of the protecting groups. 
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Scheme 6.4. Synthesis of the acylated 1-O-alkyl glucurono-6,3-lactones 6.41-6.44, 6.47, 6.48, 6.51 
and 6.52. Reagents and conditions: (i) Cbz-Cl (1 eq), pyridine, -20 °C, 20 min; (ii) R3CO2H (1.1 eq), 
DCC (1.1 eq), DMAP (0.1 eq), EtOAc, RT overnight; (iii) 10 % Pd/C (cat.),  H2 (1 atm), EtOAc, RT 
overnight; (iv) R2CO2H (1 eq), DCC (1.1 eq), DMAP (0.1 eq), EtOAc, RT overnight, or: R2COCl (1.1 
eq), THF/pyridine, -20 °C, 10 min; (v) 10 % Pd/C (cat.),  H2 (1 atm), EtOAc, RT overnight; (vi) R2CO2H 
(2.4 eq), DCC (2.4 eq), DMAP (0.2 eq), EtOAc, RT overnight; (vii) 10 % Pd/C (cat.),  H2 (1 atm), 
EtOAc, RT overnight. 
 
Sulfation of 6.6 or the monoprotected derivative 6.36 using an SO3-pyridine 
complex19 and, if present, removal of the Cbz group yielded the mono- or di-sulfates 
6.54 and 6.55 (Scheme 6.5).  
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Scheme 6.5. Synthesis of sulfates 6.53 - 6.55. Reagents and conditions: (i) SO3-pyridine complex (3 
eq), pyridine, RT overnight; (ii) 10 % Pd/C (cat.), H2 (1 atm), EtOAc, RT overnight; (iii) SO3-pyridine 
complex (4 eq), pyridine, RT, overnight. 
 
6.3 Inhibition of hyaluronidases: results and discussion 
 
6.3.1 Inhibition of hyaluronidases by 1-O-alkyl-glucurono-6,3-lactones 
 
The hyaluronidase inhibitory activities of the synthesized 1-O-alkyl glucurono-6,3-
lactones are summarized in Table 6.2 (for substitution patterns see Table 6.1). 
 
Table 6.1. Substitution patterns for glucurono-6,3-lactones 6.1-6.6, 6.27, 6.28, 6.41-6.48 and 6.51-
6.55. 
OR1
O
OR2
OR
3O
O
6.1-6.6, 6.27, 6.28,
6.41-6.48, 6.51-6.55  
Compound R1 R2 R3 
D-Glucurono-6,3-lactone H H H 
6.1 CH2Ph H H 
6.2 (CH2)3Ph H H 
6.3 (CH2)7CH3 H H 
6.4 (CH2)8OH H H 
6.5 (CH2)11CH3 H H 
6.6 (CH2)15CH3 H H 
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Table 6.1 (continued) 
6.27 (CH2)15CH3 H COC(CH3)3 
6.28 (CH2)15CH3 H COCH2CH3 
6.41 (CH2)12CH3 COCH2CO2H H 
6.42 (CH2)15CH3 COCH2CO2H H 
6.43 (CH2)15CH3 CO(CH2)2CO2H H 
6.44 (CH2)15CH3 COCH2N(CH3)2 H 
6.47 (CH2)15CH3 H COCH2CO2H 
6.48 (CH2)15CH3 H CO(CH2)2CO2H 
6.51 (CH2)15CH3 COCH2CO2H COCH2CO2H 
6.52 (CH2)15CH3 CO(CH2)2CO2H CO(CH2)2CO2H 
6.54 (CH2)15CH3 SO3H H 
6.55 (CH2)15CH3 SO3H SO3H 
 
 
Table 6.2. Inhibitory activity of investigated glucurono-6,3-lactones. 
Hyal-1 PH-20 BTH SagHyal4755 Compound IC50 [µM]a 
D-Glucurono-6,3-lactone > 60000 > 50000 > 20000 > 20000 
6.1 > 4000 > 4000 > 4000 > 4000 
6.2 > 1400 478 ± 31 >1400 920 ± 103 
6.3 > 1000 1114 ± 137 > 1000 171 ± 10 
6.4 > 1400 > 1400 > 1400 683 ± 62 
6.5 > 400 69 ± 13 > 400 29 ± 2 
6.6 > 30 > 30 > 30 9.5 ± 0.7 
6.27 > 30 16 ± 2 > 30 > 30 
6.28 > 30 > 30 > 30 > 30 
6.41 99 ± 4 6.1 ± 0.5 373 ± 20 22 ± 2 
6.42 47 ± 4 1.8 ± 0.1 78 ± 1 2.9 ± 0.1 
6.43 > 100 6.4 ± 0.3 142 ± 6 3.7 ± 0.1 
6.44 > 30 > 30 > 30 16 ± 2 
6.47 57 ± 4 3.1 ± 0.2 107 ± 3 3.9 ± 0.1 
6.48 > 100 6.0 ± 0.2 118 ± 2 2.3 ± 0.2 
6.51 33 ± 1 2.3 ± 0.1 49 ± 1 2.3 ± 0.1 
6.52 > 100 5.7 ± 0.6 53 ± 1 2.6 ± 0.1 
6.54 21 ± 3 1.7 ± 0.1 53 ± 1 3.5 ± 0.2 
6.55 14 ± 2 1.4 ± 0.1 31 ± 1 3.1 ± 0.1 
a inhibition of enzyme expressed as IC50 (µM), mean values ± SEM (N = 2, experiments performed in 
duplicate), maximal concentrations of the test compounds were selected with respect to individual 
terminal solubilities in the incubation mixture; IC50 values determined at pH 5.0 (PH-20, BTH, 
SagHyal4755) or 3.5 (Hyal-1) in the turbidimetric assay. 
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Whereas D-glucurono-6,3-lactone and the 1-O-benzylated compound 6.1 were 
inactive on all of the investigated hyaluronidases, the compounds 6.2, 6.3 and 6.5, 
which are more hydrophobic than the unsubstituted lactone, significantly inhibited the 
human PH-20 and the bacterial SagHyal4755 in a dose dependent manner (Figure 
6.2). The determination of an IC50-value of 6.3 for PH-20 was impossible due to the 
poor solubility of this compound (maximum concentration: about 1 mM). However, 
this derivative causes 50 % inhibition at 1 mM. In general, the elongation of the chain 
leads to an increase in inhibition on those two enzymes. A considerable further 
increase in inhibition is observed comparing 6.5 with 6.3: Lenghtening of the chain by 
4 methylene groups leads to a 6- to 16-fold inhibition of the two enzymes. 1-O-
Hexadecyl-β-D-glucurono-6,3-lactone (6.6) was inactive on PH-20 at the 
concentrations used, whereas the bacterial lyase was inhibited with an IC50 value of 
9.5 µM.  
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Figure 6.2. Enzymatic activity of human PH-20 (black symbols) and bacterial hyaluronidase from S. 
agalactiae strain 4755 (open symbols) in the presence of compounds 6.2, 6.3, 6.5 and 6.6. The 
different shape of the inhibition curve in the presence of high concentrations of 6.6 most probably 
results from the limited water solubility of this compound. 
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The inhibitory activity decreased significantly when an additional hydroxyl group was 
introduced at the terminal position of the hydrophobic chain (compound 6.4). The 
human Hyal-1 and the BTH were not inhibited by the 1-O-alkylated derivatives 6.1-
6.6. The compounds 6.27 and 6.28 bear additional hydrophobic substituents at 
position 2 of the lactone moiety and possess very limited water solubility. These 
compounds did not show inhibition of Hyal-1, BTH and the bacterial hyaluronate 
lyase. The results were different for both compounds on human PH-20. Whereas the 
compound 6.27 with the bulky pivaloyl residue was more potent (IC50 18 µM) than 1-
O-hexadecyl glucurono-6,3-lactone (6.6), no inhibition was observed for the 
propanoyl substituted lactone 6.28 at highest investigated concentrations. This may 
be interpreted as a hint to a binding site of PH-20 where a more bulky hydrophobic 
residue is favourable to increase the affinity of the inhibitor. To increase the water 
solubility, carboxy residues with different spacer lengths were introduced at different 
positions of the glucuronolactone moiety (6.41-6.43, 6.47, 6.48 and 6.51, 6.52). The 
carboxyethanoyl substituted derivatives 6.41, 6.42, 6.47 and 6.51 showed distinctly 
increased inhibitory potencies on all four investigated enzymes compared to the 
corresponding unsubstituted derivatives (6.5 and 6.6). Figure 6.3 illustrates the 
inhibitory activity of 1-O-hecadecyl glucurono-6,3-lactones bearing additional 
carboxylic acid residues in position O-2 and/or O-3. 
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Figure 6.3. Inhibitory activity of 1-O-hecadecyl glucurono-6,3-lactones bearing additional carboxylic 
acid residues in position O-2 and / or O-3. Compounds marked with * did not show inhibitory activity of 
the investigated enzyme; therefore the length of the bar was arbitrarily chosen for illustrative reasons. 
 
Comparing compounds 6.42 and 6.47 it is obvious that the IC50 values are in the 
same range regardless of the different positions of substitution. Disubstitution 
(compound 6.51) is tolerated but results only in a weak increase in inhibition of Hyal-
1 and the bovine testicular hyaluronidase. The potencies on PH-20 and the bacterial 
enzyme remain rather unaffected by the different structural modifications of the 
inhibitors. The concentration-dependent inhibition of the investigated hyaluronidases 
by 6.51 is shown in Figure 6.4. 
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Figure 6.4. Enzymatic activity of the investigated hyaluronidases in the presence of 6.51. 
 
When 6.41, bearing a 1-O-dodecyl residue, is compared with the hexadecyl 
derivative 6.42, the lower homologue is superior by a factor of 2-3 with regard to the 
two human enzymes, whereas the elongation of the chain by four carbon atoms 
leads to an 8-fold increase in inhibition of BTH and SagHyal4755. Although, generally, 
the hydrophobicity of the substituents appear to be the key to high affinity of the 
inhibitors, it becomes clear that the structure-activity relationships are different for the 
four investigated hyaluronidases. Obviously, the four terminal carbon atoms of the 
hexadecyl chain confer additional affinity in the case of BTH and SagHyal4755 but do 
not in case of the human enzymes. When the carboxypropanoyl substituted 1-O-
hexadecyl-β-D-glucurono-6,3-lactones 6.43, 6.48 and 6.52 are compared with the 
corresponding derivatives bearing the shorter alkyl spacer between carboxyl moiety 
and the glucuronolactone core (6.42, 6.47 and 6.51), a minor decrease in inhibitory 
potency becomes obvious for PH-20, BTH and SagHyal4755, whereas the inhibition of 
Hyal-1 is completely lost. The solubility decreases when the carboxyl group in 
position O-2 is replaced by a N,N-dimethylamino residue (compare 6.42 and 6.44); 
therefore, the determination of IC50 values was impossible for Hyal-1 and BTH where 
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those values are generally higher than for PH-20 and the bacterial enzyme. However, 
it is obvious that the potency is significantly reduced by the basic functional group as 
the IC50 value of 6.44 drops to 16 µM for SagHyal4755 compared to 2.9 µM for the 
carboxylic acid 6.42. Inhibition of human PH-20 is also decreased by at least a factor 
of 16.  
Previous studies revealed that sulfated carbohydrates are potent inhibitors of BTH, 
BVH and SagHyal4755 with IC50 values in the (lower) micromolar range20. Hence, the 
lactone moiety was sulfated to investigate if this increase in acidity of 1-O-alkyl-
glucurono-6,3-lactones also correlates with an increase in inhibition of the human 
enzymes. The mono- and di-sulfated derivatives 6.54 and 6.55 show a clearly 
enhanced inhibitory activity compared to the nonsulfated parent molecule 6.6, with 
the disulfated compound 6.55 being slightly more potent than the monosulfated 
analogue 6.54 on all the four investigated hyaluronidases. The disulfated derivative 
6.55 thus represents the most potent inhibitor of the investigated mammalian 
hyaluronidases in this series with IC50 values of 14 µM, 1.4 µM and 31 µM 
determined for Hyal-1, PH-20 and BTH respectively. 
 
6.3.2 1-O-Alkyl-glucuronic acids and 1-O-alkyl-glucuronic acid amides 
 
Due to the fact that on one hand long hydrophobic alkyl chains are needed to obtain 
hyaluronidase inhibitors with reasonable affinity and on the other hand a polar acidic 
group seems to be essential to gain potency, the lactone group was saponified to 
obtain the corresponding free carboxylic acids, which are combining both structural 
features. As shown in Table 6.3, the potency of compounds 6.7-6.10 is more or less 
in the same range compared to the corresponding lactone derivatives discussed 
above. Inhibition of PH-20 and the bacterial hyaluronat lyase increases with the 
length of the aliphatic chain. Again the lengthening of the dodecyl chain to 16 carbon 
atoms results in a more drastic increase in potency of the compound for SagHyal4755 
than for PH-20. 1-Dodecyl-β-D-glucofuranosiduronic acid (6.9) also inhibits Hyal-1 
and BTH in a concentration-dependent manner (Figure 6.5) but for Hyal-1 the 
inhibition at terminal solubility was only 40-50 %, therefore, in this case the 
determination of exact IC50 values was impossible. 
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Table 6.3. Inhibitory activities of synthesized glucuronic acid derivatives 6.7-6.19 and 6.23-6.26. 
OR1
O
OH
OHHO
R2O
6.7-6.19, 6.23-6.25
O
OH
OR1
OH
OH
CO2H
6.26  
Hyal-1 PH-20 BTH SagHyal4755 No R1 R2 IC50 [µM]a 
6.7 (CH2)7CH3 OH > 1200 304 ± 78 > 1200 > 1200 
6.8 (CH2)8OH OH > 1600 > 1600 > 1600 1170 ± 70 
6.9 (CH2)11CH3 OH ≥ 500 12 ± 2 259 ± 5 36 ± 5 
6.10 (CH2)15CH3 OH > 50 3.0 ± 0.3 > 50 4.7 ± 0.1 
6.11 (CH2)11CH3 NH2 > 200 > 200 > 100 82 ± 4 
6.12 (CH2)15CH3 NH2 > 50 > 50 > 50 > 50 
6.13 (CH2)15CH3 NHCH2Ph > 50 > 50 > 50 > 50 
6.14 (CH2)15CH3 NH(CH2)2Ph > 40 > 40 > 40 > 40 
6.15 (CH2)15CH3 NH(CH2)3CH3 > 40 > 40 > 40 > 40 
6.16 (CH2)15CH3 NH(CH2)9CH3 > 20 > 20 > 20 > 20 
6.17 (CH2)15CH3 NH(CH2)2OH > 50 > 50 > 50 > 50 
6.18 (CH2)15CH3 NH(CH2)4NH2 > 50 > 50 > 50 60 ± 5 
6.19 (CH2)15CH3 NH(CH2)12NH2 > 20 14 ± 7 > 20 > 20 
6.23 (CH2)15CH3 NH(CH2)2CO2H > 90 2.9 ± 0.2 > 90 2.1 ± 0.1 
6.24 (CH2)15CH3 NH(CH2)3CO2H > 70 7.1 ± 1.6 > 70 4.2 ± 0.1 
6.25 (CH2)15CH3 NHCH2cyCO2H > 50 9.1 ± 0.8 > 50 > 50 
6.26 (CH2)15CH3 - > 60 > 60 > 60 > 60 
a inhibition of enzyme expressed as IC50 (µM), mean values ± SEM (N = 2, experiments performed in 
duplicate), maximal concentrations of the test compounds were selected with respect to individual 
terminal solubilities in the incubation mixture; IC50 values determined at pH 5.0 (PH-20, BTH, 
SagHyal4755) or 3.5 (Hyal-1) in the turbidimetric assay. 
 
Interestingly, the shapes of the curves are different: whereas steep curves were 
received for BTH and the bacterial enzyme, the curves of the two human enzymes 
are clearly flattened. Therefore, it may be speculated about different binding modes 
or modes of action depending on the considered enzymes. 
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Figure 6.5. Enzymatic activity of the investigated hyaluronidases in presence of compound 6.9. 
 
The inhibitory activity towards the mammalian hyaluronidases is completely lost 
when the carboxyl moiety of 6.9 and 6.10 is replaced by an amide group (compounds 
6.11 and 6.12) indicating the importance of the carboxylic acid moiety for inhibition of 
the hyaluronidases. An IC50 value of 82 µM was calculated for the inhibition of the 
bacterial lyase by the amide derivative 6.11 corresponding to a drop in potency by a 
factor of about two compared to the carboxylate 6.9 (IC50 36 µM). In this case 
solubility problems impairing the determination of IC50 values can be excluded; the 
solubility of the amides and the carboxylic acid derivatives lies in a comparable 
range. However, the elaboration of SAR was impossible for the amides bearing 
additional hydrophobic substituents (6.13-6.16) due to poor solubility of the 
compounds in the test system. No inhibition of the enzymes was found up to the 
terminal solubility of the compounds. Both 6.18 and 6.19 bearing a terminal amino 
residue at the hydrophobic sidechain are inhibitors of SagHyal4755. The solubility of 
6.19 was too low for the determination of the IC50 value; at a concentration of 20 µM 
the activity of the enzyme was inhibited by 40 % (data not shown). Interestingly, 6.18 
bearing the shorter spacer between terminal amino group and the amide group was 
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inactive towards PH-20 at the highest achievable concentrations, whereas an IC50 of 
14 µM was determined for the analogue with the longer chain, compound 6.19. It is 
conceivable that another hydrophobic area located in a certain distance from the 
binding site of the lactone moiety is addressed or that there is an energetically 
favored interaction of the terminal amino residue or both. The inhibition of PH-20 and 
SagHyal4755 is again increased when a short alkanoic acid moiety instead of an alkyl 
residue is attached to the amide group (compare 6.15 with 6.23 and 6.24). On both 
enzymes the inhibitory potency of these compounds is in the lower micromolar range 
and comparable to that of the nonsubstituted carboxylic acid 6.10. The carboxyethyl 
derivative 6.23 is more potent than the higher homologue 6.24. Surprisingly, unlike 
the alkanoic acid moieties in compounds 6.23 and 6.24 the cyclohexanecarboxylic 
acid in 6.25 caused enzyme selectivity. The bulkier cyclohexylene spacer is tolerated 
by PH-20, resulting in an IC50 of 9.1 µM which is comparable to the value for 6.24, 
but the inhibitory activity towards SagHyal4755 is completely lost within the range of 
solubility. Although human PH-20 and SagHyal4755 belong to different classes of 
hyaluronidases and share only very low structural similarity, the investigation of the 
synthesized compounds usually revealed similar orders of potency on these 
enzymes, whereas there were pronounced differences in SARs between PH-20 and 
the related other mammalian hyaluronidases. 6.25 is unique as this compound is 
capable of discriminating between PH-20 and the bacterial enzyme. This reflects 
structural differences between these enzymes: obviously, in contrast to PH-20, the 
binding site of bacterial hyaluronidases is too narrow to allow binding of the 
cyclohexylene spacer. Hyal-1 as well as BTH were not inhibited by the amide 
derivatives 6.11-6.19 and 6.23-6.25 in the investigated concentration ranges. The 
discrepancy between the results obtained for the three mammalian enzymes is 
extremely suprising, in particular, when human PH-20 and BTH are compared, as the 
latter has been considered a suitable model for the human homologue, PH-20.  
The potencies of representative glucofuranosides are illustrated by bars in Figure 
6.6. 
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Figure 6.6. Inhibition of human PH-20 and SagHyal4755 by various 1-O-hexadecyl-glucofuranosides. 
Compounds marked with * did not show inhibitory activity of the investigated enzyme at the highest 
tested concentrations (solubility limited); therefore the length of the bar was arbitrarily chosen for 
illustrative reasons. 
 
Interestingly, the 1-O-alkylated glucuronic acid 6.26 does neither inhibit the bacterial 
hyaluronate lyase nor the mammalian hyaluronidases. This suggests that the five 
membered heterocyclic system is superior because inhibitory potency resides in the 
glucofuranosides presented in this chapter, as well as in the ascorbic acid derivatives 
presented in chapter 7. Thus, although hydrophobic interactions of the alkyl 
substituents play a major role in increasing the affinity of the inhibitors, distinct 
interactions of the lactone-scaffold with the active site of the hyaluronidases exist. 
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6.4 Summary 
 
Generally, the presented derivatives of glucurono-6,3-lactone proved to be more 
potent when investigated upon inhibition of human PH-20 and the bacterial 
hyaluronate lyase from Streptococcus agalactiae compared to Hyal-1 and BTH. 
Especially the selectivity for human PH-20 versus the bovine homologue, which was 
proven by testing at equiactive enzyme concentrations (see chapter 10.3.5), is 
surprising. Whereas the parent compound, D-glucurono-6,3-lactone, does not inhibit 
human PH-20 and the bacterial hyaluronidase in the investigated concentration 
range, the inhibition of both enzymes is strongly increased by hydrophobic 
substituents in position O-1 (6.1-6.6). No inhibition of Hyal-1 and hyaluronidase from 
bovine testis was detectable for the 1-O-alkyl-glucurono-6,3-lactones 6.1-6.6. 
Nevertheless those two enzymes are inhibited as soon as acidic moieties like 
carboxyl or sulfate groups are added to the glucuronolactone scaffold. Variation of 
the place of the substitution (O-2, O-5 or disubstitution; 6.42, 6.47 and 6.51) causes 
only minor changes in biological activity. By contrast, the inhibitory potency is 
decreased (PH-20, BTH and SagHyal4755) or even lost (Hyal-1) when the spacer 
connecting carboxyl group and lactone core is elongated (6.43, 6.48 and 6.52). The 
disulfated 1-O-hexadecyl-glucurono-6,3-lactone (6.55) is the most potent inhibitor of 
the investigated mammalian enzymes in this series with IC50 values of 14 µM, 1.4 µM 
and 31 µM determined for Hyal-1, PH-20 and BTH respectively. Interestingly, the 
introduction of another hydrophobic residue in position O-5 of the glucuronolactone 
(6.27 and 6.28) does not result in increased inhibitory potency except for 6.27 
(bearing a bulky pivaloyl substituent) when tested upon inhibition of human PH-20. 
Saponification of the lactone moiety led to glucuronates (6.7-6.10) which possess 
significantly increased inhibitory activity especially for human PH-20. A distinct loss in 
potency is observed when the carboxyl group is replaced with an amide function 
(6.11 and 6.12) indicating the importance of this structural motive. The increase in 
hydrophobicity as in 6.13-6.16 is not paralleled by a rise in inhibitory potency. 
However, those compounds are barely soluble in the aqueous incubation mixture, 
thus, the determination of IC50 above 20-50 µM is considerable impaired or 
impossible. Whereas the amino-substituted compounds 6.18 and 6.19 clearly 
emphasize the different nature of the bacterial hyaluronate lyase and the human 
hyaluronidase PH-20, the SARs are similar for 6.23 and 6.24 bearing carboxyl 
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residues introduced via aminolysis of the lactone scaffold: both the inhibition of PH-
20 and SagHyal4755 increases when the spacer connecting carboxyl and amide group 
is reduced in lenghth. 1-O-Hexadecyl-N-(3-carboxypropyl)-β-D-glucofuranosiduron-
amide (6.24) with an IC50 value of 2.1 µM is the most potent inhibitor of the bacterial 
enzyme described in this chapter. Taken together, derivatives of D-glucurono-6,3-
lactone are potent inhibitors of recombinantly expressed human hyaluronidases, 
hyaluronidase from bovine testis and the bacterial hyaluronate lyase SagHyal4755. 
The IC50 values are lower than those determined for reference compounds (see 
chapter 5). Thus, the D-glucurono-6,3-lactones are among the most potent inhibitors 
of mammalian and bacterial hyaluronidases known to date. The results suggest that 
the lactone scaffold is mimicking a substructure of the substrate hyaluronan and 
binding to the active site. Hydrophobic substituents are conferring additional affinity 
by addressing hydrophobic areas of the hyaluronidases. This structural feature was 
found to be essential for inhibition of the enzymes. The hydrophobic alkyl chains 
might mimic the hydrophobic patches of hyaluronic acid21 as it was found in the 
crystal structure of a bacterial hyaluronate lyase in complex with ascorbic acid 6-
palmitate22. The structural requirements are very similar for the mammalian-type 
hyaluronidases. However, additional acidic functional groups are the key to potent 
inhibitors, especially in the case of Hyal-1 and BTH. It is conceivable that those 
negatively charged groups mimic the carboxylates of glucuronic acid moieties in 
hyaluronan and interact with polar amino acids which are present in the active site of 
the mammalian and bacterial hyaluronidases. 
 
6.5 Experimental Section 
 
6.5.1 General conditions 
 
Chemicals were purchased from the following suppliers: Acros Organics (Geel, 
Belgium), IRIS Biotech GmbH (Marktredwitz, Germany), Alfa Aesar GmbH & Co. KG 
(Karlsruhe, Germany), Merck KGaA (Darmstadt, Germany), and Sigma-Aldrich 
Chemie GmbH (Munich, Germany). Deuterated solvents for NMR spectroscopy were 
from Deutero GmbH (Kastellaun, Germany). All solvents were of analytical grade or 
distilled prior to use. If moisture-free conditions were required, reactions were 
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performed in dried glassware under inert atmosphere (argon or nitrogen); DMF (H2O 
< 0.01 %) was purchased from Sigma-Aldrich Chemie GmbH. Nuclear Magnetic 
Resonance (1H-NMR and 13C-NMR) spectra were recorded on an Avance-300 NMR 
spectrometer from Bruker BioSpin GmbH (Rheinstetten, Germany). Tetramethyl-
silane was added as internal standard (chemical shift δ = 0 ppm) to all samples. 
Multiplicities are specified with the following abbreviations: s (singlet), d (doublet), t 
(triplet), q (quartet), m (multiplet), bs (for broad singulet), as well as combinations 
thereof. The multiplicity of carbon atoms (13C-NMR) were determined by DEPT 135 
and DEPT 90 (distortionless enhancement by polarization transfer): “+” primary and 
tertiary carbon atom (positive DEPT 135 signal), “-“ secondary carbon atom (negative 
DEPT 135 signal), “quat” quaternary carbon atom. Mass spectrometry analysis (MS) 
was performed on a Finnigan MAT 95 (PI-EIMS 70 eV, HR-MS), Finnigan SSQ 710A 
(CI-MS (NH3)) and on a Finnigan ThermoQuest TSQ 7000 (ESI-MS) spectrometer. 
The peak-intensity in % relative to the strongest signal is indicated in parenthesis. 
Melting points (mp) were measured on a BÜCHI 530 using open capillaries and are 
uncorrected. Merck Silica Gel 60 (particle size 0.040–0.063 mm) was used for flash 
column chromatography. Reactions were routinely monitored by thin layer 
chromatography (TLC) on Merck silica gel 60 F254 aluminum sheets and spots were 
visualized with UV light at 254 nm, and/or iodine vapor or ammonium 
molybdate/cerium(IV) sulfate solution. 
 
6.5.2 Chemistry 
 
6.5.2.1 General method for the synthesis of 1-O-Alkyl-β-D-glucofuranosid-
urono-6,3-lactones 6.1-6.6 
A suspension of D-glucuronic acid or D-glucurono-6,3-lactone (1 eq), the pertinent 
alkanol (1-2 eq) and BF3Et2O (2 eq) in anhydrous THF was stirred at 60-70 °C under 
an atmosphere of argon for 1 h. After removal of volatiles the raw product was 
subjected to flash chromatograpy. 
1-O-Benzyl-β-D-glucofuranosidurono-6,3-lactone (6.1): The title compound was 
prepared from D-glucurono-6,3-lactone (5 mmol, 0.88 g), benzyl alcohol (10 mmol, 
1.0 ml) and BF3Et2O (10 mmol, 1.3 ml) in anhydrous THF (20 ml) according to 
general procedure 6.5.2.1 and was obtained after flash chromatography (PE/EtOAc 
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40/60 v/v) as colorless semisolid substance (0.52 g, 39 %). 1H-NMR (DMSO-d6) δ 
4.11 (s, 1H, CH2Ph), 4.32 (d, 1H, 2J = 11.4 Hz, CH2Ph), 4.50 (dd, 1H, 3J = 4.8 Hz, 3J 
= 4.8 Hz, H-5), 4.74 (d, 1H, 3J = 2.4 Hz, H-2), 4.76 (d, 1H, 3J = 4.4 Hz, H-3), 4.84 (dd, 
1H, 3J = 4.6 Hz, 3J = 6.4 Hz, H-4), 5.01 (s, 1H, H-1), 5.73 (d, 1H, 3J = 3.5 Hz, 2-OH), 
6.00 (d, 1H, 3J = 5.0 Hz, 5-OH), 7.30 (m, 5H). 13C-NMR (DMSO-d6) δ 68.40 (-, 
CH2Ph), 68.63 (+, C-5), 76.92 (+,C-2), 78.20 (+,C-4), 82.58 (+,C-3), 107.78 (+, C-1), 
127.32 (+, Ph-C), 127.95 (+, Ph-C), 128.09 (+, Ph-C), 137.40 (quat, Ph-C), 174.95 
(quat, lactone CO). EI-MS (70eV) m/z (%): 266 (66) [M+·]. C13H14O6 (266.25). 
1-O-(3-Phenylpropyl)-β-D-glucofuranosidurono-6,3-lactone (6.2): The title 
compound was prepared from D-glucurono-6,3-lactone (5 mmol, 0.88 g), 3-
phenylpropan-1-ol (10 mmol, 1.3 ml) and BF3Et2O (10 mmol, 1.3 ml) in anhydrous 
THF (20 ml) according to general procedure 6.5.2.1 and was obtained after flash 
chromatography (PE/EtOAc 30/70 v/v) as a colorless oil (1.10 g, 75 %). 1H-NMR 
(DMSO-d6) δ 1.70 (m, 2H, CH2CH2Ph), 2.54 (t, 2H, 3J = 7.8 Hz, CH2Ph), 3.24 (td, 1H, 
3J = 6.6 Hz, 2J = 9.2 Hz, OCH2), 3.72 (td, 1H, 3J = 6.3 Hz, 2J = 9.2 Hz, OCH2), 4.09 
(s, 1H, H-2), 4.46 (d, 1H, 3J = 6.3 Hz, H-5), 4.72 (d, 1H, 3J = 4.6 Hz, H-3), 4.77 (dd, 
1H, 3J = 4.6 Hz, 3J = 6.2 Hz, H-4), 4.92 (s, 1H, H-2), 5.69 (bs, 2H, 2-OH, 5-OH), 7.22 
(m, 5H, Ph-C). 13C-NMR (DMSO-d6) δ 30.44 (-, CH2), 31.56 (-, CH2), 66.31 (-, OCH2), 
68.63 (+, C-5), 76.81 (+, C-2), 77.88 (+, C-4), 82.52 (+, C-3), 108.49 (+, C-1), 125.50 
(+, Ph-C), 128.11 (+, Ph-C), 128.18 (+, Ph-C), 141.84 (quat, Ph-C), 174.95 (quat, 
lactone CO). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 312 (100) [M+NH4]+. Anal. 
(C15H18O6·0.8H2O) C, H. C15H18O6 (294.30). 
1-O-(Octan-1-yl)-β-D-glucofuranosidurono-6,3-lactone4 (6.3): The title compound 
was prepared from D-glucurono-6,3-lactone (5 mmol, 0.88 g), 1-octanol (10 mmol, 
1.6 ml) and BF3Et2O (10 mmol, 1.3 ml) in anhydrous THF (20 ml) according to 
general procedure 6.5.2.1 and was obtained after flash chromatography (PE/EtOAc 
30/70 v/v) as a white solid (1.03 g, 77 %). mp: 65 °C (ref.23: 72-73 °C); 1H-NMR 
(DMSO-d6) δ 0.86 (t, 3H, 3J = 6.7 Hz, CH3), 1.15 – 1.59 (m, 12H, (CH2)6CH3), 3.18 
(td, 1H, 3J = 6.8 Hz, 2J = 9.1 Hz, OCH2), 3.67 (td, 1H, 3J = 6.6 Hz, 2J = 9.3 Hz, 
OCH2), 4.04 (s, 1H, H-2), 4.42 (d, 1H, 3J = 6.3 Hz, H-5), 4.69 (d, 1H, 3J = 4.6 Hz, H-
3), 4.75 (dd, 1H, 3J = 4.6 Hz, 3J = 6.2 Hz, H-4), 4.89 (s, 1H, H-1). 13C-NMR (DMSO-
d6) δ 13.86 (+, CH3), 21.99 (-, CH2), 25.42 (-, CH2), 28.54 (-, CH2), 28.57 (-, CH2), 
28.76 (-, CH2), 31.16 (-, CH2), 66.77 (-, OCH2), 68.61 (+, C-5), 76.82 (+, C-2), 77.79 
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(+, C-4), 82.50 (+, C-3), 108.38 (+, C-1), 174.80 (quat, lactone CO). CI-MS (NH3) m/z 
(%): 306 (100) [M+NH4]+. Anal. (C14H24O6) C, H. C14H24O6 (288.34). 
1-O-(8-Hydroxyoctan-1-yl)-β-D-glucofuranosidurono-6,3-lactone (6.4): The title 
compound was prepared from D-glucurono-6,3-lactone (10 mmol, 0.88 g), octan-1,8-
diol (20 mmol, 2.9 ml) and BF3Et2O (20 mmol, 2.5 ml) in anhydrous THF (30 ml) 
according to general procedure 6.5.2.1 and was obtained after flash chromatography 
(PE/EtOAc 30/70 v/v) as a white solid (1.77 g, 58 %). 1H-NMR (DMSO-d6) δ 1.28 (m, 
12H, OCH2(CH2)6), 3.18 (m, 2H, OCH2, CH2OH), 3.37 (t, 2H, 3J = 6.5 Hz, CH2OH), 
3.67 (td, 1H, 3J = 6.6 Hz, 2J = 9.2 Hz, OCH2), 4.04 (s, 1H, H-2), 4.42 (d, 1H, 3J = 6.3 
Hz, H-5), 4.69 (d, 1H, 3J = 4.5 Hz, H-3), 4.75 (dd, 1H, 3J = 4.6 Hz, 3J = 6.2 Hz, H-4), 
4.89 (s, 1H, H-1). 13C-NMR (DMSO-d6) δ 25.37 (-, CH2), 28.53 (-, CH2), 28.82 (-, 
CH2), 28.85 (-, CH2), 32.43 (-, CH2), 60.61 (-, CH2OH), 66.77 (-, OCH2), 68.61 (+, 
CH), 76.81 (+, CH), 77.79 (+, CH), 82.50 (+, CH), 108.37 (+, C-1), 174.81 (quat, 
lactone CO). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 322 (100) [M+NH4]+. 
C14H24O7 (304.34). 
1-O-(Dodecan-1-yl)-β-D-glucofuranosidurono-6,3-lactone23 (6.5): The title 
compound was prepared from D-glucurono-6,3-lactone (20 mmol, 3.52 g), dodecan-
1-ol (20 mmol, 3,73 g) and BF3Et2O (40 mmol, 5.1 ml) in anhydrous THF (40 ml) 
according to general procedure 6.5.2.1 and was obtained after flash chromatography 
(Et2O) as a white solid (3.64 g, 53 %). mp: 78-80 °C (ref.23: 98-99 °C);  1H-NMR 
(CDCl3) δ 0.87 (t, 3H, 3J = 6.7 Hz, CH3), 1.25 (m, 18H, (CH2)9CH3), 1.52 (m, 2H, 
OCH2CH2), 3.41 (td, 1H, 3J = 6.9 Hz, 2J = 9.3 Hz, OCH2), 3.67 (td, 1H, 3J = 6.8 Hz, 2J 
= 9.3 Hz, OCH2), 4.38 (d, 1H, 3J = 6.9 Hz, H-5), 4.43 (s, 1H, H-2), 4.88 (d, 1H, 3J = 
4.9 Hz, H-3), 5.02 (dd, 1H, 3J = 4.9 Hz, 3J = 6.8 Hz, H-4), 5.10 (s, 1H, H-1). 13C-NMR 
(CDCl3) δ 14.13 (+, CH3), 22.70 (-, CH2), 25.89 (-, CH2), 29.17 (-, CH2), 29.37 (-, 
CH2), 29.56 (-, CH2), 29.65 (-, CH2), 29.68 (-, CH2), 31.93 (-, CH2), 69.07 (+, C-5), 
69.32 (-, OCH2), 76.98 (+, C-2), 77.53 (+, C-4), 83.17 (+, C-3), 109.09 (+, C-1), 
174.55 (quat, lactone CO). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 362 (100) 
[M+NH4]+. C18H32O6 (344.44). 
1-O-(Hexydecan-1-yl)-β-D-glucofuranosidurono-6,3-lactone (6.6): The title 
compound was prepared from D-glucurono-6,3-lactone (25 mmol, 4.4 g), hexadecan-
1-ol (50 mmol, 12.1 g) and BF3Et2O (50 mmol, 6.3 ml) in anhydrous THF (50 ml) 
according to general procedure 6.5.2.1 and was obtained after flash chromatography 
(PE/Et2O 20/80 v/v) as a white solid (6.60 g, 66 %). mp: 87-88 °C;  1H-NMR (DMSO-
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d6) δ 0.85 (t, 3H, 3J = 6.7 Hz, CH3), 1.24 (m, 26H, (CH2)13CH3), 1.38 (m, 2H, 
OCH2CH2), 3.18 (td, 1H, 3J = 6.7 Hz, 2J = 9.1 Hz, OCH2), 3.67 (td, 1H, 3J = 6.6 Hz, 2J 
= 9.1 Hz, OCH2), 4.03 (d, 1H, 3J = 4.0 Hz, H-2), 4.42 (dd, 1H, 3J = 6.4 Hz, 3J = 6.4 
Hz, H-5), 4.69 (d, 1H, 3J = 4.6 Hz, H-3), 4.75 (dd, 1H, 3J = 4.6 Hz, 3J = 6.2 Hz, H-4), 
4.89 (s, 1H, H-1), 5.66 (d, 1H, 3J = 4.1 Hz, 2-OH), 5.80 (d, 1H, 3J = 6.4 Hz, 5-OH). 
13C-NMR (DMSO-d6) δ 13.85 (+, CH3), 22.00 (-, CH2), 25.43 (-, CH2), 28.55 (-, CH2), 
28.61 (-, CH2), 28.83 (-, CH2), 28.96 (+, CH2), 31.20 (-, CH2), 66.76 (-, OCH2), 68.61 
(+, C-5), 76.82 (+, C-2), 77.79 (+, C-4), 82.49 (+, C-3), 108.37 (+, C-1), 174.79 (quat, 
lactone CO). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 418 (100) [M+NH4]+. Anal. 
(C22H40O6) C, H. C22H40O6 (400.55). 
6.5.2.2 General method for the synthesis of 1-O-alkyl-β-D-glucofuranosid-
uronic acids 6.7-6.10 via saponification of 1-O-alkyl-D-glucurono-6,3-
lactones 
To a solution of the pertinent D-glucurono-6,3-lactone (1 eq) in acetone was added 
0.5 M NaOH (1 eq) dropwise at 0 °C. After stirring for 2 h at room temperature, ether 
was added and the mixture was washed twice with water. After adding EtOAc, the 
volatiles were removed under reduced pressure and the remaining raw product was 
subjected to flash chromatography. 
1-O-(Octan-1-yl)-β-D-glucofuranosiduronic acid sodium salt23 (6.7): The title 
compound was prepared from 6.3 (3.0 mmol, 0.87 g), 0.5 M (3 mmol, 6.0 ml) in 
acetone (40 ml) according to general procedure 6.5.2.2 and was obtained after flash 
chromatography (CHCl3/MeOH 80/20 v/v) as a yellow solid (0.46 g, 47 %). mp: 30 
°C;  1H-NMR (CD3OD) δ 0.90 (t, 3H, 3J = 6.7 Hz, CH3), 1.32 (m, 10H, (CH2)3CH3), 
1.61 (m, 2H, OCH2CH2), 3.46 (td, 1H, 3J = 7.0 Hz, 2J = 9.5 Hz, OCH2), 3.81 (td, 1H, 
3J = 6.7 Hz, 2J = 9.6 Hz, OCH2), 4.10 (s, 1H, H-2), 4.19 (m, 1H, H-3), 4.38 (d, 1H, 3J 
= 2.1 Hz, H-5), 4.56 (dd, 1H, 3J = 2.4 Hz, 3J = 5.3 Hz, H-4), 4.86 (d, 1H, 3J = 1.9 Hz, 
H-1). 13C-NMR (CD3OD) δ 14.52 (+, CH3), 23.80 (-, CH2), 27.25 (-, CH2), 30.53 (-, 
CH2), 30.68 (-, CH2), 30.70 (-, CH2), 33.11 (-, CH2), 70.17 (-, OCH2), 74.20 (+, C-5), 
77.79 (+, C-3), 81.92 (+, C-2), 83.45 (+, C-4), 109.52 (+, C-1), 178.62 (quat, CO2H). 
ES-MS (MeOH + NH4OAc) m/z (%): 324 (100) [M+NH4]+. Anal. (C14H25NaO7·0.6H2O) 
C, H. C14H25NaO7 (328.33). 
1-O-(8-Hydroxyoctan-1-yl)-β-D-glucofuranosiduronic acid sodium salt (6.8): The 
title compound was prepared from 6.4 (3.0 mmol, 0.91 g), 0.5 M (3 mmol, 6.0 ml) in 
acetone (40 ml) according to general procedure 6.5.2.2 and was obtained after flash 
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chromatography (CHCl3/MeOH 80/20 v/v) as a white solid (0.40 g, 41 %). mp: 123-
125 °C;  1H-NMR (CD3OD) δ 1.29 – 1.64 (m, 8H, OCH2(CH2)6), 3.41 (td, 1H, 3J = 6.8 
Hz, 2J = 8.3 Hz, OCH2), 3.53 (t, 2H, 3J = 6.6 Hz, CH2OH), 3.79 (td, 1H, 3J = 6.6 Hz, 2J 
= 9.5 Hz, OCH2), 4.05 (s, 1H, H-2), 4.13 (dd, 1H, 3J = 2.7 Hz, 3J = 5.5 Hz, H-3), 4.34 
(d, 1H, 3J = 2.5 Hz, H-5), 4.53 (dd, 1H, 3J = 2.7 Hz, 3J = 5.6 Hz, H-4), 4.84 (d, 1H, 3J 
= 1.6 Hz, H-1). 13C-NMR (DMSO-d6) δ 25.36 (-, CH2), 25.51 (-, CH2), 28.84 (-, CH2), 
28.90 (-, CH2), 28.96 (-, CH2), 32.43 (-, CH2), 60.59 (-, CH2OH), 66.89 (-, OCH2), 
71.08 (+, C-5), 75.81 (+, C-3), 80.93 (+, C-2), 83.07 (+, C-4), 107.54 (+, C-1), 173.50 
(quat, CO2H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 321 (100) [M-H]-. 
C14H25NaO8 (344.33). 
1-O-(Dodecan-1-yl)-β-D-glucofuranosiduronic acid sodium salt23 (6.9): The title 
compound was prepared from 6.5 (3.0 mmol, 0.87 g), 0.5 M (3 mmol, 6.0 ml) in 
acetone (40 ml) according to general procedure 6.5.2.2 and was obtained after flash 
chromatography (CHCl3/MeOH 85/15 v/v) as a white solid (0.44 g, 40 %). mp: 83-85 
°C;  1H-NMR (DMSO-d6) δ 0.85 (t, 3H, 3J = 6.6 Hz, CH3), 1.24 (s, 18H, (CH2)9CH3), 
1.44 (m, 2H, OCH2CH2), 3.20 (td, 1H, 3J = 6.9 Hz, 2J = 9.4 Hz, OCH2), 3.55 (td, 1H, 
3J = 6.5 Hz, 2J = 9.2 Hz, OCH2), 3.71 (s, 1H, H-2), 3.77 (d, 1H, 3J = 2.9 Hz, H-3), 3.92 
(s, 1H, H-5), 4.23 (d, 1H, 3J = 3.8 Hz, H-4), 4.60 (d, 1H, 3J = 1.6 Hz, H-1), 5.18 (d, 
1H, 3J = 3.9 Hz, 2-OH). 13C-NMR (DMSO-d6) δ 13.92 (+, CH3), 22.05 (-, CH2), 25.63 
(-, CH2), 28.68 (-, CH2), 28.96 (-, CH2), 28.99 (-, CH2), 29.05 (-, CH2), 31.26 (-, CH2), 
66.93 (-, OCH2), 71.03 (+, C-5), 75.90 (+, C-3), 81.09 (+, C-2), 83.20 (+, C-4), 107.65 
(+, C-1), 173.29 (quat, CO2H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 380 (100) 
[M+NH4]+. Anal. (C18H33NaO7·0.6H2O) C, H. C18H33NaO7 (384.44). 
1-O-(Hexadecan-1-yl)-β-D-glucofuranosiduronic acid (6.10): The title compound 
was prepared from 6.6 (1.0 mmol, 0.87 g), 0.5 M (3 mmol, 6.0 ml) in acetone (40 ml) 
according to general procedure 6.5.2.2 and was obtained after acidification using an 
acidic ion exchanger (Amberlite® CG-120, protonated prior to use) and 
recrystallisation from EtOH as a yellow solid (0.25 g, 59 %). mp: 90-91 °C;  1H-NMR 
(CD3OD) δ 0.90 (t, 3H, 3J = 6.7 Hz, CH3), 1.28 (s, 26H, (CH2)13CH3), 1.54 (m, 2H, 
OCH2CH2), 3.36 (td, 1H, 3J = 5.8 Hz, 3J = 9.4 Hz, OCH2), 3.78 (td, 1H, 3J = 5.8 Hz, 3J 
= 9.4 Hz, OCH2), 4.03 (s, 1H, CHOH), 4.13 (m, 1H, CHOH), 4.40 (m, 2H, CHOH), 
4.85 (m, 1H under solvent peak, CHOH). 13C-NMR (DMSO-d6) δ 13.84 (+, CH3), 
21.99 (-, CH2), 25.56 (-, CH2), 28.61 (-, CH2), 28.79 (-, CH2), 28.96 (-, CH2), 31.20 (-, 
CH2), 66.96 (-, OCH2), 69.11 (+, C-5), 74.87 (+, C-3), 80.10 (+, C-2), 81.82 (+, C-4), 
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108.41 (+, C-1), 173.90 (quat, CO2H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 417 
(100) [M-H]-. C22H42O7 (418.56). 
6.5.2.3 General procedure for the synthesis of 1-O-Alkyl-β-D-glucofuranosid-
uronamides 6.11 and 6.12 
A solution of the pertinent 1-O-Alkyl-β-D-glucofuranosidurono-6,3-lactone (1 eq) in 7 
N NH3 in methanol was stirred at 0 °C for 2 h. The product was obtained after 
removal of the solvent. 
1-O-(Dodecan-1-yl)-β-D-glucofuranosiduronamide (6.11): The title compound was 
prepared according to general procedure 6.5.2.3 using 6.5 (1 mmol, 0.34 g) in 7 N 
NH3 in methanol (10 ml) and was obtained as a white solid (0.36 g, quantitative). mp: 
80-82 °C; 1H-NMR (DMSO-d6) δ 0.85 (t, 3H, 3J = 6.7 Hz, CH3), 1.24 (m, 18H, 
(CH2)9CH3), 1.46 (m, 2H, OCH2CH2), 3.25 (td, 1H, 3J = 6.7 Hz, 3J = 9.5 Hz, OCH2), 
3.62 (td, 1H, 3J = 6.6 Hz, 3J = 9.4 Hz, OCH2), 3.79 (s, 1H, H-2), 3.88 (dd, 1H, 3J = 4.0 
Hz, 3J = 4.0 Hz, H-3), 4.15 (m, 2H, H-5, H-4), 4.70 (s, 1H, H-1), 5.25 (m, 3H, OH), 
7.25 (d, 2H, 3J = 17.7 Hz, NH2). 13C-NMR (DMSO-d6) δ 13.83 (+, CH3), 21.98 (-, 
CH2), 25.55 (-, CH2), 28.61 (-, CH2), 28.83 (-, CH2), 28.96 (-, CH2), 31.19 (-, CH2), 
67.11 (-, OCH2), 70.21 (+, C-5), 75.58 (+, C-3), 80.25 (+, CH, C-2), 82.14 (+, C-4), 
108.29 (+, C-1), 174.39 (quat, CONH2). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 
362 (100) [M+H]+. Anal. (C18H35NO6) C, H, N. C18H35NO6 (361.47). 
1-O-(Hexadecan-1-yl)-β-D-glucofuranosiduronamide (6.12): The title compound 
was prepared according to general procedure 6.5.2.3 using 6.6 (1 mmol, 0.40 g) in 7 
N NH3 in methanol (10 ml) and was obtained as a white solid (0.42 g, quantitative). 
mp: 77-78 °C;  1H-NMR (DMSO-d6) δ 0.85 (t, 3H, 3J = 6.7 Hz), 1.24 (m, 24H, 
(CH2)13CH3), 1.46 (m, 2H, OCH2CH2), 3.25 (td, 1H, 3J = 6.7 Hz, 3J = 9.4 Hz, OCH2), 
3.62 (td, 1H, 3J = 6.6 Hz, 3J = 9.4 Hz, OCH2), 3.79 (s, 1H, H-2), 3.88 (t, 1H, 3J = 4.6 
Hz, H-3), 4.12 (dd, 1H, 3J = 5.6 Hz, 3J = 5.6 Hz, H-5), 4.18 (m, 1H, H-4), 4.70 (s, 1H, 
H-1), 5.18 (d, 1H, 3J = 6.0 Hz, 2-OH), 5.30 (dd, 2H, 3J = 4.6 Hz, 3J = 11.7 Hz, OH), 
7.26 (d, 2H, 3J = 18.1 Hz, NH2). 13C-NMR (DMSO-d6) δ 13.84 (+, CH3), 21.99 (-, 
CH2), 25.56 (-, CH2), 28.60 (-, CH2), 28.84 (-, CH2), 28.95 (-, CH2), 31.19 (-, CH2), 
67.10 (-, OCH2), 70.20 (+, C-5), 75.56 (+, C-3), 80.25 (+, C-2), 82.15 (+, C-4), 108.29 
(+, C-1), 174.39 (quat, CONH2). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 418 (100) 
[M+H]+. C22H43NO6 (417.58). 
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6.5.2.4 General procedure for the synthesis of 1-O-alkyl-N-alkyl-β-D-gluco-
furanosiduronamides 6.13-6.22 
A solution of 6.6 (1 eq) and the pertinent amine (1-3 eq) in methanol were stirred at 
room temperature overnight. The solvent was evaporated and the remaining residue 
was subjected to flash chromatography. 
1-O-(Hexadecan-1-yl)-N-benzyl-β-D-glucofuranosiduronamide (6.13): The title 
compound was prepared from 6.6 (0.7 mmol, 0.28 g) and benzylamine (1.05 mmol, 
0.12 ml) in MeOH (5 ml) according to general procedure 6.5.2.4 and was obtained 
after flash chromatography (PE/EtOAc 70/30 v/v) as a white solid (0.18 g, 51 %). mp: 
68 °C;  1H-NMR (CD3OD) δ 0.89 (t, 3H, 3J = 6.1 Hz, CH3), 1.28 (m, 26H, (CH2)13CH3), 
1.54 (m, 2H, OCH2CH2), 3.34 (s, 1H, H-2), 3.71 (td, 1H, 3J = 6.7 Hz, 2J = 9.4 Hz, 
OCH2), 4.01 (s, 1H, H-3), 4.09 (td, 1H, 3J = 7.2 Hz, 2J = 8.6 Hz, OCH2), 4.44 (m, 4H, 
CH2Ph, H-4, H-5), 4.86 (s, 1H, H-1), 7.27 (m, 5H, Ph-H). 13C-NMR (CD3OD) δ 14.52 
(+, CH3), 23.05 (-, CH2), 23.81 (-, CH2), 27.26 (-, CH2), 30.55 (-, CH2), 30.62 (-, CH2), 
30.67 (-, CH2), 30.86 (-, CH2), 33.14 (-, CH2), 43.76 (-, CH2Ph), 69.55 (-, OCH2), 
72.38 (+, C-5), 77.62 (+, C-3), 81.87 (+, C-2), 84.06 (+, C-4), 109.99 (+, C-1), 128.17 
(+, Ph-C), 128.45 (+, Ph-C), 129.51 (+, Ph-C), 139.87 (quat, Ph-C), 174.74 (quat, 
CONH). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 508 (100) [M+NH4]+. Anal. 
(C29H49NO6) C, H, N. C29H49NO6 (507.70). 
1-O-(Hexadecan-1-yl)-N-(2-phenylethyl)-β-D-glucofuranosiduronamide (6.14): 
The title compound was prepared from 6.6 (0.7 mmol, 0.28 g) and 2-phenylethan-
amine (1.05 mmol, 0.13 ml) in MeOH (5 ml) according to general procedure 6.5.2.4 
and was obtained after flash chromatography (PE/EtOAc 70/30 v/v) as a white solid 
(0.17 g, 47 %). mp: 45 °C; 1H-NMR (CD3OD) δ 0.90 (t, 3H, 3J = 6.7 Hz, CH3), 1.28 
(m, 26H, (CH2)13CH3), 1.56 (m, 2H, OCH2CH2), 2.82 (t, 2H, 3J = 7.5 Hz, CH2Ph), 3.34 
(m, 1H, OCH2), 3.46 (t, 2H, 3J = 7.3 Hz, NHCH2), 3.72 (td, 1H, 3J = 6.7 Hz, 2J = 9.4 
Hz, OCH2), 4.00 (s, 1H, H-2), 4.07 (m, 1H, H-3), 4.33 (d, 1H, 3J = 5.2 Hz, H-5), 4.43 
(dd, 1H, 3J = 5.0 Hz, 3J = 5.0 Hz, H-4), 4.84 (s, 1H, H-1), 7.23 (m, 5H, Ph-H). 13C-
NMR (CD3OD) δ 14.51 (+, CH3), 23.80 (-, CH2), 27.32 (-, CH2), 30.55 (-, CH2), 30.68 
(-, CH2), 30.69 (-, CH2), 30.85 (-, CH2), 33.14 (-, CH2), 36.66 (-, CH2Ph), 41.87 (-, 
NHCH2), 69.51 (-, OCH2), 72.34 (+, C-5), 77.72 (+, C-3), 81.84 (+, C-2), 84.12 (+, C-
4), 109.95 (+, C-1), 127.44 (+, Ph-C), 129.58 (+, Ph-C), 129.88 (+, Ph-C), 140.47 
(quat, Ph-C), 174.65 (quat, lactone CO). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 
522 (100) [M+NH4]+. Anal. (C30H51NO6) C, H, N. C30H51NO6 (521.73). 
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1-O-(Hexadecan-1-yl)-N-butyl-β-D-glucofuranosiduronamide (6.15): The title 
compound was prepared from 6.6 (1.0 mmol, 0.40 g) and butan-1-amine (2 mmol, 
0.20 ml) in MeOH (5 ml) according to general procedure 6.5.2.4 and was obtained 
after flash chromatography (PE/EtOAc 90/10 v/v) as a white solid (0.36 g, 76 %). mp: 
50 °C; 1H-NMR (CD3OD) δ 0.92 (m, 6H, CH3), 1.27 – 1.63 (m, 32H, 
NHCH2(CH2)2CH3, (CH2)13CH3), 3.24 (m, 2H, NHCH2), 3.36 (td, 1H, 3J = 6.8 Hz, 2J = 
9.5 Hz, OCH2), 3.75 (td, 1H, 3J = 6.7 Hz, 2J = 9.4 Hz, OCH2), 3.99 (s, 1H, H-2), 4.07 
(dd, 1H, 3J = 1.7 Hz, 3J = 4.8 Hz, H-3), 4.34 (d, 1H, 3J = 5.2 Hz, H-5), 4.42 (dd, 1H, 3J 
= 5.0 Hz, 3J = 5.0 Hz, H-4), 4.85 (s, 1H, H-1). 13C-NMR (CD3OD) δ 14.19 (+, CH3), 
14.49 (+, CH3), 21.10 (-, CH2), 23.78 (-, CH2), 27.30 (-, CH2), 30.52 (-, CH2), 30.67 (-, 
CH2), 30.84 (-, CH2), 32.62 (-, CH2), 33.12 (-, CH2), 39.95 (-, NHCH2), 69.54 (-, 
OCH2), 72.38 (+, CH), 77.71 (+, CH), 81.89 (+, CH), 84.05 (+, CH), 109.96 (+, C-1), 
174.52 (quat, lactone CO). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 475 (100) 
[M+H]+. Anal. (C30H51NO6) C, H, N. C26H51NO6 (473.69). 
1-O-(Hexadecan-1-yl)-N-(decan-1-yl)-β-D-glucofuranosiduronamide (6.16): The 
title compound was prepared from 6.6 (0.7 mmol, 0.28 g) and decan-1-amine (1.05 
mmol, 0.21 ml) in MeOH (5 ml) according to general procedure 6.5.2.4 and was 
obtained after flash chromatography (PE/EtOAc 70/30 v/v) as a pale yellow solid 
(0.12 g, 31 %). mp: 45 °C;  1H-NMR (CD3OD) δ 0.87 (t, 6H, 3J = 6.6 Hz, CH3), 1.25 
(m, 40H, (CH2)13CH3, (CH2)7CH3), 1.54 (m, 4H, OCH2CH2, NHCH2CH2), 3.28 (m, 2H, 
NHCH2), 3.45 (td, 1H, 3J = 6.7 Hz, 2J = 9.4 Hz, OCH2), 3.72 (td, 1H, 3J = 6.8 Hz, 3J = 
9.3 Hz, OCH2), 4.19 (s, 1H, H-2), 4.24 (d, 1H, 3J = 3.8 Hz, H-3), 4.32 (d, 1H, 3J = 6.7 
Hz, H-5), 4.46 (dd, 1H, 3J = 5.0 Hz, 3J = 6.2 Hz, H-4), 4.98 (s, 1H, H-1), 6.89 (t, 1H, 3J 
= 5.7 Hz, CONH). 13C-NMR (CD3OD) δ 14.12 (+, CH3), 22.70 (-, CH2), 26.10 (-, CH2), 
26.92 (-, CH2), 29.34 (-, CH2), 29.38 (-, CH2), 29.45 (-, CH2), 29.54 (-, CH2), 29.59 (-, 
CH2), 29.72 (-, CH2), 31.94 (-, CH2), 39.55 (-, NHCH2), 68.99 (-, OCH2), 70.31 (+, C-
5), 77.10 (+, C-3), 80.16 (+, C-2), 82.38 (+, C-4), 108.44 (+, C-1), 171.99 (quat, 
CONH). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 557 (100) [M-H]-. Anal. 
(C32H63NO6) C, H, N. C32H63NO6 (557.85). 
1-O-(Hexadecan-1-yl)-N-(2-hydroxyethyl)-β-D-glucofuranosiduronamide (6.17): 
The title compound was prepared from 6.6 (0.7 mmol, 0.28 g) and 2-aminoethanol 
(1.05 mmol, 63 µl) in MeOH (5 ml) according to general procedure 6.5.2.4 and was 
obtained after flash chromatography (CHCl3/MeOH 95/5 v/v) as a pale yellow solid 
(0.23 g, 71 %). mp: 65-66 °C;  1H-NMR (CD3OD) δ 0.90 (t, 3H, 3J = 6.7 Hz, CH3), 
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1.29 (m, 26H, (CH2)13CH3), 1.58 (m, 2H, OCH2CH2), 3.37 (m, 3H, OCH2, NHCH2), 
3.62 (dd, 2H, 3J = 5.8 Hz, 3J = 5.8 Hz, CH2OH), 3.77 (td, 1H, 3J = 6.6 Hz, 2J = 9.4 Hz, 
OCH2), 4.00 (s, 1H, H-2), 4.08 (dd, 1H, 4J = 1.8 Hz, 3J = 4.9 Hz, H-3), 4.37 (d, 1H, 3J 
= 5.1 Hz, H-5), 4.46 (dd, 1H, 3J = 5.0 Hz, 3J = 5.0 Hz, H-4), 4.86 (s, 1H, H-1). 13C-
NMR (CD3OD) δ 14.51 (+, CH3), 23.81 (-, CH2), 27.31 (-, CH2), 30.55 (-, CH2), 30.66 
(-, CH2), 30.70 (-, CH2), 30.84 (-, CH2), 30.86 (-, CH2), 33.14 (-, CH2), 42.59 (-, 
NHCH2), 61.56 (-, CH2OH), 69.51 (-, OCH2), 72.46 (+, C-5), 77.79 (+, C-3), 81.81 (+, 
C-2), 84.01 (+, C-4), 109.90 (+, C-1), 174.99 (quat, CONH). ES-MS (MeOH + 
NH4OAc) m/z (%): 462 (100) [M+H]+. Anal. (C24H47NO7) C, H, N. C24H47NO7 (461.63). 
1-O-(Hexadecan-1-yl)-N-(4-aminobutyl)-β-D-glucofuranosiduronamide (6.18): 
The title compound was prepared from 6.6 (0.7 mmol, 0.28 g) and butan-1,4-diamine 
(1.05 mmol, 92 mg) in MeOH (5 ml) according to general procedure 6.5.2.4 and was 
obtained after flash chromatography (MeOH/aqueous NH3 90/10 v/v) as a yellow 
solid (0.20 g, 58 %). mp: 140-142 °C;  1H-NMR (CD3OD) δ 0.90 (t, 3H, 3J = 6.0 Hz, 
CH3), 1.29 (m, 26H, (CH2)13CH3), 1.55 (m, 6H, OCH2CH2, NHCH2(CH2)2), 2.67 (t, 2H, 
3J = 6.8 Hz, CH2NH2), 3.26 (t, 2H, 3J = 6.6 Hz, CONHCH2), 3.37 (td, 1H, 3J = 6.7 Hz, 
2J = 9.4 Hz, OCH2) 3.76 (td, 1H, 3J = 6.7 Hz, 2J = 9.5 Hz, OCH2), 3.99 (s, 1H, H-2), 
4.09 (m, 1H, H-3), 4.34 (d, 1H, 3J = 5.1 Hz, H-5), 4.45 (t, 1H, 3J = 5.0 Hz, H-4), 4.85 
(s, 1H, H-1). 13C-NMR (CD3OD) δ 14.51 (+, CH3), 27.33 (-, CH2), 27.81 (-, CH2), 
30.54 (-, CH2), 23.80 (-, CH2), 30.68 (-, CH2), 30.86 (-, CH2), 33.14 (-, CH2), 39.82 (-, 
NCH2), 42.04 (-, NCH2), 69.50 (-, OCH2), 72.53 (+, C-5), 77.77 (+, C-3), 81.88 (+, C-
2), 83.91 (+, C-4), 109.93 (+, C-1), 174.67 (quat, CONH). ES-MS (DCM/MeOH + 
NH4OAc) m/z (%): 489 (100) [M+NH4]+. C26H52N2O6 (488.70). 
1-O-(Hexadecan-1-yl)-N-(12-aminododecan-1-yl)-β-D-glucofuranosiduronamide 
(6.19): The title compound was prepared from 6.6 (0.7 mmol, 0.28 g) and dodecan-
1,12-diamine (1.05 mmol, 0.21 g) in MeOH (8 ml) according to general procedure 
6.5.2.4 and was obtained after flash chromatography (MeOH/aqueous NH3 95/5 v/v) 
as a yellow solid (0.16 g, 38 %). mp: 66 °C; 1H-NMR (CDCl3) δ 0.87 (t, 3H, 3J = 6.6 
Hz, CH3), 1.17 – 1.61 (m, 48H, (CH2)14CH3, NHCH2(CH2)10), 2.69 (t, 2H, 3J = 6.6 Hz, 
CH2NH2), 3.29 (m, 2H, CONHCH2), 3.45 (td, 1H, 3J = 6.7 Hz, 2J = 9.1 Hz, OCH2), 
3.72 (td, 1H, 3J = 6.8 Hz, 2J = 9.2 Hz, OCH2), 4.17 (s, 1H, H-2), 4.23 (d, 1H, 3J = 3.6 
Hz, H-3), 4.31 (d, 1H, 3J = 6.6 Hz, H-5), 4.44 (dd, 1H, 3J = 4.9 Hz, 3J = 6.1 Hz, H-4), 
4.96 (s, 1H, H-1), 6.90 (t, 1H, 3J = 5.6 Hz, CONH). 13C-NMR (CDCl3) δ 14.14 (+, 
CH3), 22.71 (-, CH2), 26.12, (-, CH2) 26.55 (-, CH2), 26.61 (-, CH2), 28.89 (-, CH2), 
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29.03 (-, CH2), 29.07 (-, CH2), 29.10 (-, CH2), 29.12 (-, CH2), 29.24 (-, CH2), 29.38 (-, 
CH2), 29.45 (-, CH2), 29.57 (-, CH2), 29.61 (-, CH2), 29.69 (-, CH2), 29.72 (-, CH2), 
31.94 (-, CH2), 32.66 (-, CH2), 39.36, (-, NCH2), 41.74 (-, NCH2), 68.92 (-, OCH2), 
70.26 (+, C-5), 77.23 (+, C-3), 79.96 (+, C-2), 82.52 (+, C-4), 108.67 (+, C-1), 172.09 
(quat, CONH). ES-MS (MeOH + NH4OAc) m/z (%): 602 (100) [M+H]+. C34H68N2O6 
(600.91). 
6.5.2.5 General procedure for the synthesis of methyl esters 6.20a-6.22a 
To a solution of carboxylic acid (1eq) in anhydrous methanol under nitrogen 
atmosphere was added chlorotrimethylsilane (2.2 eq) at 0 °C. The mixture was 
stirred at reflux overnight, cooled, and evaporated under reduced pressure.  
Methyl 3-aminopropanoate hydrochloride10 (6.20a): The title compound was 
prepared from β-alanine (40 mmol, 3.56 g) and TMSCl (88 mmol, 11.1 ml) in 
anhydrous MeOH (50 ml) according to general procedure 6.5.2.5 and was obtained 
as a white solid (5.58 g, quantitative). mp: 65 °C; 1H-NMR (D2O) δ 2.76 (t, 2H, 3J = 
6.5 Hz, CH2CO2CH3), 3.23 (t, 2H, 3J = 6.4 Hz, CH2NH2), 3.68 (s, 3H, CO2CH3). ES-
MS (DCM/MeOH + NH4OAc) m/z (%): 104 (100) [M+H]+. C4H10ClNO2 (139.58).  
1-O-(Hexadecan-1-yl)-N-(2-methoxycarbonylethyl)-β-D-glucofuranosiduron-
amide (6.20): The title compound was prepared from 6.6 (1 mmol, 0.40 g), 6.20a (3 
mmol, 0.42 g) and NEt3 (3 mmol, 0.42 ml) in MeOH (10 ml) according to general 
procedure 6.5.2.4 and was obtained after flash chromatography (EtOAc) as yellow 
semisolid substance (0.33 g, 66 %). 1H-NMR (CDCl3) δ 0.87 (t, 3H, 3J = 6.7 Hz, CH3), 
1.25 (m, 26H, (CH2)13CH3), 1.58 (m, 2H, OCH2CH2), 2.57 (t, 2H, 3J = 6.0 Hz, 
CH2CO2CH3), 3.43 – 3.67 (m, 3H, OCH2, NHCH2), 3.69 (s, 3H, OCH3), 3.76 (td, 1H, 
3J = 6.8 Hz, 2J = 9.5 Hz, OCH2), 4.21 (d, 1H, 3J = 1.5 Hz, H-2), 4.25 (dd, 1H, 3J = 1.8 
Hz, 3J = 4.8 Hz, H-3), 4.32 (d, 1H, 3J = 6.7 Hz, H-5), 4.48 (dd, 1H, 3J = 4.9 Hz, 3J = 
6.6 Hz, H-4), 4.99 (s, 1H, H-1), 7.34 (t, 1H, 3J = 6.1 Hz, CONH). ES-MS (DCM/MeOH 
+ NH4OAc) m/z (%): 505 (100) [M+H]+. Anal. (C26H49NO8) C, H, N. C26H49NO8 
(503.67). 
Methyl 4-aminobutanoate hydrochloride9 (6.21a): The title compound was 
prepared from 4-aminobutyric acid (40 mmol, 4.13 g) and TMSCl (88 mmol, 11.1 ml) 
in anhydrous MeOH (50 ml) according to general procedure 6.5.2.5 and was 
obtained as a white solid (6.14 g, quantitative). mp: 94 °C; 1H-NMR (D2O) δ 1.85 (m, 
2H, COCH2CH2), 2.42 (t, 2H, 3J = 7.3 Hz, COCH2), 2.94 (t, 2H, 3J = 7.7 Hz, CH2NH2), 
3.60 (s, 3H, CO2CH3). CI-MS (NH3) m/z (%): 118 (100) [M+H]+. C5H12ClNO2 (153.61).  
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1-O-(Hexadecan-1-yl)-N-(3-methoxycarbonylpropyl)-β-D-glucofuranosiduron-
amide (6.21): The title compound was prepared from 6.6 (1 mmol, 0.40 g), 6.21a (3 
mmol, 0.47 g) and NEt3 (3 mmol, 0.42 ml) in MeOH (10 ml) according to general 
procedure 6.5.2.4 and was obtained after flash chromatography (EtOAc) as yellow 
semisolid (0.31 g, 60 %). 1H-NMR (DMSO-d6) δ 0.90 (t, 3H, 3J = 6.7 Hz, CH3), 1.29 
(s, 26H, (CH2)13CH3), 1.58 (m, 2H, OCH2CH2), 1.82 (m, 2H, NHCH2CH2), 2.39 (t, 2H, 
3J = 7.5 Hz, CH2CO2CH3), 3.27 (m, 2H, NHCH2), 3.36 (td, 1H, 3J = 6.7 Hz, 2J = 9.5 
Hz, OCH2), 3.66 (s, 3H, OCH3), 3.76 (td, 1H, 3J = 6.7 Hz, 2J = 9.4 Hz, OCH2), 3.99 (s, 
1H, H-2), 4.07 (d, 1H, 3J = 5.0 Hz, H-3), 4.34 (d, 1H, 3J = 5.4 Hz, H-5), 4.42 (t, 1H, 3J 
= 5.1 Hz, H-4), 4.85 (s, 1H, H-1). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 519 (100) 
[M+H]+. Anal. (C27H51NO8) C, H, N. C27H51NO8 (517.70). 
Methyl trans-4-(aminomethyl)cyclohexanecarboxylate8 (6.22a): The title 
compound was prepared from trans-4-(aminomethyl)cyclohexanecarboxylic acid (10 
mmol, 1.57 g) and TMSCl (22 mmol, 2.8 ml) in anhydrous MeOH (10 ml) according to 
general procedure 6.5.2.5 and was obtained as a white solid (2.1 g, quantitative). mp: 
164 °C; 1H-NMR (D2O) δ 0.99 (m, 2H, cy-H), 1.32 (m, 2H, cy-H), 1.57 (m, 1H, cy-H), 
1.77 (m, 2H, cy-H), 1.92 (m, 2H, cy-H), 2.30 (m, 1H, cy-H), 2.78 (d, 2H, 3J = 7.0 Hz, 
CH2NH2), 3.59 (s, 3H, CO2CH3). EI-MS (70eV) m/z (%): 171 (10) [M+·].  
1-O-(Hexadecan-1-yl)-N-(trans-4-methoxycarbonylcyclohexylmethyl)-β-D-gluco-
furanosiduronamide (6.22): The title compound was prepared from 6.6 (1 mmol, 
0.40 g), 6.22a (3 mmol, 0.62 g) and NEt3 (3 mmol, 0.42 ml) in  MeOH (10 ml) 
according to general procedure 6.5.2.4 and was obtained after flash chromatography 
(EtOAc) as a white solid (0.38 g, 66 %). mp: 66 °C; 1H-NMR (CD3OD) δ 0.90 (t, 3H, 
3J = 6.7 Hz, CH3), 1.01 (m, 2H, cy-H), 1.41 (m, 10 H, (CH2)13CH3, cy-H, OCH2CH2), 
1.86 (m, 2H, cy-H), 1.97 (m, 2H, cy-H), 2.27 (m, 1H, cy-H), 3.10 (m, 2H, CH2NH), 
3.36 (td, 1H, 3J = 6.8 Hz, 2J = 9.5 Hz, OCH2), 3.64 (s, 3H, CO2CH3), 3.75 (td, 1H, 3J = 
6.7 Hz, 2J = 9.4 Hz, OCH2), 3.99 (s, 1H, H-2), 4.07 (dd, 1H, 3J = 1.7 Hz, 3J = 4.7 Hz, 
H-3), 4.34 (d, 1H, 3J = 5.5 Hz, H-5), 4.41 (dd, 3J = 5.1 Hz , 3J = 5.1 Hz, 1H, H-4), 4.85 
(s, 1H, H-1). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 573 (100) [M+H]+. Anal. 
(C31H57NO8) C, H, N. C31H57NO8 (571.79). 
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6.5.2.6 General procedure for the synthesis of carboxylic acids 6.23-6.25 by 
hydrolysis of the pertinent methyl esters 
To a solution of methyl ester (1 eq) in THF was added 0.5 N LiOH (2 eq) and the 
mixture was stirred overnight at room temperature. After diluting with water, 
acidification with 1 N HCl to pH <2 and extraction three times with EtOAc, the 
combined organic phases were washed with brine, dried over MgSO4, filtered and the 
solvent was removed under reduced pressure. The raw product was purified using 
flash chromatography. 
1-O-(Hexadecan-1-yl)-N-(2-carboxyethyl)-β-D-glucofuranosiduronamide (6.23): 
The title compound was prepared from 6.20 (0.48 mmol, 0.25 g) and 0.5 N LiOH 
(0.96 mmol, 1.9 ml) in THF (10 ml) according to general procedure 6.5.2.6 and was 
obtained after flash chromatography as a white solid (0.1 g, 53 %). mp: 97 °C; 1H-
NMR (CD3OD) δ 0.90 (t, 3H, 3J = 6.7 Hz, CH3), 1.28 (m, 26H, (CH2)13CH3), 1.58 (m, 
2H, OCH2CH2), 2.52 (t, 2H, 3J = 6.7 Hz, CH2CO2H), 3.37 (td, 1H, 3J = 6.7 Hz, 2J = 9.4 
Hz, OCH2), 3.49 (t, 2H, 3J = 6.7 Hz, NHCH2), 3.76 (td, 1H, 3J = 6.6 Hz, 2J = 9.4 Hz, 
OCH2), 3.99 (s, 1H, H-2), 4.08 (dd, 1H, 3J = 1.8 Hz, 3J = 4.9 Hz, H-3), 4.34 (d, 1H, 3J 
= 5.2 Hz, H-5), 4.43 (dd, 1H, 3J = 5.0 Hz, 3J = 5.0 Hz , H-4), 4.85 (s, 1H, H-1). 13C-
NMR (CD3OD) δ 14.50 (+, CH3), 23.79 (-, CH2), 27.31 (-, CH2), 30.53 (-, CH2), 30.66 
(-, CH2), 30.69 (-, CH2), 30.85 (-, CH2), 33.13 (-, CH2), 36.12 (-, CH2), 69.53 (-, 
OCH2), 72.38 (+, C-5), 77.77 (+, C-3), 81.82 (+, C-2), 83.99 (+, C-4), 109.89 (+, C-1), 
174.71 (quat, CONH). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 491 (100) [M+H]+. 
Anal. (C25H47NO8·0.2H2O) C, H, N. C25H47NO8 (489.64). 
1-O-(Hexadecan-1-yl)-N-(3-carboxypropyl)-β-D-glucofuranosiduronamide (6.24): 
The title compound was prepared from 6.21 (0.42 mmol, 0.22 g) and 0.5 N LiOH 
(0.84 mmol, 1.7 ml) in THF (15 ml) according to general procedure 6.5.2.6 and was 
obtained after flash chromatography as a white solid (0.1 g, 48 %). 1H-NMR (DMSO-
d6) δ 0.85 (t, 3H, 3J = 6.6 Hz, CH3), 1.24 (m, 26H, (CH2)13CH3), 1.46 (m, 2H, 
OCH2CH2), 1.64 (m, 2H, NHCH2CH2), 2.14 (t, 2H, 3J = 7.4 Hz, CH2CO2H), 3.09 (m, 
2H, NHCH2), 3.23 (td, 1H, 3J = 6.6 Hz, 3J = 9.4 Hz, OCH2), 3.58 (td, 1H, 3J = 6.6 Hz, 
3J = 9.4 Hz, OCH2), 3.79 (s, 1H, H-2), 3.88 (dd, 1H, 3J = 0.8 Hz, 3J = 3.9 Hz, H-3), 
4.17 (m, 2H, H-5, H-4), 4.68 (s, 1H, H-1), 7.93 (t, 1H, 3J = 5.7 Hz, CH2NH). 13C-NMR 
(DMSO-d6) δ 13.85 (+, CH3), 21.98 (-, CH2), 24.79 (-, CH2), 25.53 (-, CH2), 28.59 (-, 
CH2), 28.84 (-, CH2), 28.95 (-, CH2), 31.18 (-, CH2), 37.89 (-, NHCH2), 67.12 (-, 
OCH2), 70.37 (+, C-5), 75.43 (+, C-3), 80.32 (+, C-2), 82.26 (+, C-4), 108.32 (+, C-1), 
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171.87 (quat, CO). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 504 (100) [M+H]+. 
C26H49NO8 (503.67). 
1-O-(Hexadecan-1-yl)-N-(trans-4-carboxycyclohexylmethy)-β-D-glucofuranosid-
uronamide (6.25): The title compound was prepared from 6.22 (0.32 mmol, 0.18 g) 
and 0.5 N LiOH (0.64 mmol, 1.3 ml) in THF (10 ml) according to general procedure 
6.5.2.6 and was obtained after flash chromatography as a white solid (0.12 g, 67 %). 
mp: 105-107 °C; 1H-NMR (DMSO-d6) δ 0.88 (m, 5H, CH3, cy-H), 1.17 – 1.48 (m, 29H, 
(CH2)13CH3, cy-H), 1.74 (m, 2H, cy-H), 1.87 (m, 2H, cy-H), 2.09 (m, 1H, cy-H), 2.86 
(ddd, 1H, 3J = 6.7 Hz, 3J = 6.7 Hz, 2J = 13.2 Hz, CH2NH), 3.02 (ddd, 1H, 3J = 6.7 Hz, 
3J = 6.7 Hz, 2J = 13.2 Hz, CH2NH), 3.23 (td, 1H, 3J = 6.9 Hz, 2J = 9.3 Hz, OCH2), 3.57 
(td, 1H, 3J = 6.7 Hz, 2J = 9.3 Hz, OCH2), 3.78 (s, 1H, H-2), 3.86 (s, 1H, H-3), 4.15 (m, 
2H, H-5, H-4), 4.68 (s, 1H, H-1), 5.20 (s, 1H, OH), 5.28 (s, 1H, OH), 5.38 (s, 1H, OH), 
7.87 (t, 1H, 3J = 5.9 Hz, CH2NH), 11.97 (s, 1H, CO2H). 13C-NMR (CD3OD) δ 13.84 (+, 
CH3), 21.98 (-, CH2), 25.51 (-, CH2), 28.24 (-, CH2), 28.59 (-, CH2), 28.82 (-, CH2), 
28.94 (-, CH2), 29.21 (-, CH2), 31.18 (-, CH2), 36.86 (+, CHCH2NH), 42.47 (+, 
CHCO2H), 44.23 (-, CH2NH), 67.21 (-, OCH2), 70.09 (+, C-5), 75.34 (+, C-3), 80.35 
(+, C-2), 82.37 (+, C-4), 108.39 (+, C-1), 171.84 (quat, CO), 176.64 (quat, CO). ES-
MS (DCM/MeOH + NH4OAc) m/z (%): 559 (100) [M+H]+. Anal. (C30H55NO8·0.8H2O) 
C, H, N. C30H55NO8 (557.76). 
1-O-(Hexadecan-1-yl)-β-D-glucuronic acid24 (6.26): The title compound was 
prepared from D-glucuronic acid (10 mmol, 1.91 g), hexadecan-1-ol (20 mmol, 4.85 
g) and BF3Et2O (20 mmol, 2.5 ml) in anhydrous THF (40 ml) by analogy with general 
procedure 6.5.2.1 and was obtained after flash chromatography (PE/EtOAc 50/50 
v/v) as a white solid (1.10 g, 75 %). mp: 49-50 °C; 1H-NMR (CD3OD+D2O) δ 0.89 (t, 
3H, 3J = 6.7 Hz, CH3), 1.28 (s, 26H, (CH2)13CH3), 1.49 (m, 2H, OCH2CH2), 3.30 (td, 
1H, 3J = 6.6 Hz, 3J = 9.2 Hz, OCH2), 3.79 (td, 1H, 3J = 6.6 Hz, 3J = 9.2 Hz, OCH2), 
4.21 (s, 1H, CH), 4.50 (d, 1H, 3J = 6.5 Hz, CH), 4.83 (d, 1H, 3J = 4.6 Hz, CH), 4.92 
(m, 1H, under solvent peak, CH), 5.02 (s, 1H, CH). 13C-NMR (DMSO-d6) δ 13.88 (+, 
CH3), 22.04 (-, CH2), 25.47 (-, CH2), 28.58 (-, CH2), 28.65 (-, CH2), 28.87 (-, CH2), 
29.00 (-, CH2), 31.24 (-, CH2), 66.79 (-, OCH2), 68.64 (+, CH), 76.85 (+, CH), 77.82 
(+, CH), 82.52 (+, CH), 108.40 (+, C-1), 174.80 (quat, CO2H). C22H42O7 (418.56). 
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6.5.2.7 General procedure for the synthesis of 2-O-acyl-1-O-alkyl-β-D-gluco-
furanosidurono-6,3-lactones 6.27-6.29 
To a solution of the pertinent glucuronolactone (1 eq) and pyridine (3 eq) in 
anhydrous THF was added the acid chloride (1 eq) dropwise at 0 °C under an 
atmosphere of nitrogen. After stirring for 30 min, the solution was poured on icewater 
and the mixture was extracted three times with EtOAc. The combined organic layers 
were washed with brine, dried over MgSO4, filtered and the solvent was removed 
under reduced pressure. The remaining residue was then subjected to flash 
chromatography. 
1-O-(Hexadecan-1-yl)-5-O-(2,2-dimethylpropanoyl)-β-D-glucofuranosidurono-
6,3-lactone (6.27): The title compound was prepared from 6.6 (0.7 mmol, 0.28 g), 
pyridine (2.1 mmol, 0.17 ml) and pivaloyl chloride (0.7 mmol, 86 µl) in THF (5 ml) 
according to general procedure 6.5.2.7 and was obtained after flash chromatography 
as a white solid (0.16 g, 47 %). mp: 40-41 °C; 1H-NMR (CDCl3) δ 0.88 (t, 3H, 3J = 6.7 
Hz, CH3), 1.25 (m, 26H, (CH2)13CH3), 1.31 (s, 9H, C(CH3)3), 1.53 (m, 2H, OCH2CH2), 
3.33 (td, 1H, 3J = 7.1 Hz, 2J = 9.0 Hz, OCH2), 3.80 (td, 1H, 3J = 6.8 Hz, 2J = 9.0 Hz, 
OCH2), 4.44 (s, 1H, CHO), 4.90 (d, 1H, 3J = 4.8Hz, CHO), 5.05 (s, 1H, CHO), 5.13 
(dd, 1H, 3J = 4.9 Hz, 3J = 6.7 Hz, CHO), 5.29 (d, 1H, 3J = 6.8 Hz, CHO). 13C-NMR 
(CDCl3) δ 14.15 (+, CH3), 22.72 (-, CH2), 25.97 (-, CH2), 26.97 (-, CH2), 27.14 (+, 
C(CH3)3), 28.91 (-, CH2), 29.39 (-, CH2), 29.46 (-, CH2), 29.61 (-, CH2), 29.65 (-, CH2), 
29.69 (-, CH2), 29.73 (-, CH2), 31.95 (-, CH2), 38.91 (quat, C(CH3)3), 68.54 (-, OCH2), 
69.10 (+, CH), 75.59 (+, CH), 83.34 (+, CH), 108.53 (+, C-1), 170.32 (quat, lactone 
CO), 177.38 (quat, CO2C(CH3)3). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 502 
(100) [M+NH4]+. Anal. (C27H48O7) C, H. C27H48O7 (484.67). 
1-O-(Hexadecan-1-yl)-5-O-propanoyl-β-D-glucofuranosidurono-6,3-lactone 
(6.28): The title compound was prepared from 6.6 (0.35 mmol, 0.14 g), pyridine (1.05 
mmol, 84 µl) and propanoyl chloride (0.35 mmol, 31 µl) in THF (5 ml) according to 
general procedure 6.5.2.7 and was obtained after flash chromatography as a white 
solid (90 mg, 56 %). mp: 30 °C; 1H-NMR (CDCl3) δ 0.88 (t, 3H, 3J = 6.7 Hz, CH3), 
1.20 – 1.30 (m, 29H, (CH2)13CH3, CH2CH3), 1.54 (m, 2H, OCH2CH2), 2.52 (m, 2H, 
CH2CH3), 3.32 (td, 1H, 3J = 7.1 Hz, 2J = 9.0 Hz, OCH2), 3.76 (td, 1H, 3J = 6.8 Hz, 2J = 
9.0 Hz, OCH2), 4.43 (s, 1H, CHO), 4.92 (d, 1H, 3J = 5.0 Hz, H-3), 5.05 (s, 1H, CHO), 
5.17 (dd, 1H, 3J = 5.0 Hz, 3J = 7.0 Hz, H-2), 5.27 (d, 1H, 3J = 7.0 Hz, H-1). 13C-NMR 
(CDCl3) δ 8.89 (+, COCH2CH3), 14.15 (+, CH3), 22.72 (-, CH2), 26.01 (-, CH2), 26.95 
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(-, CH2), 28.85 (-, CH2), 29.39 (-, CH2), 29.46 (-, CH2), 29.62 (-, CH2), 29.68 (-, CH2), 
29.73 (-, CH2), 31.95 (-, CH2), 68.74 (-, OCH2), 69.01 (+, CH), 75.25 (+, CH), 83.71 
(+, CH), 108.47 (+, C-1), 170.55 (quat, lactone CO), 173.16 (quat, CO2). ES-MS 
(DCM/MeOH + NH4OAc) m/z (%): 474 (100) [M+NH4]+. C24H44O7 (444.60). 
1-O-(Hexadecan-1-yl)-5-O-cyanomethylcarbonyl-β-D-glucofuranosidurono-6,3-
lactone (6.29): The title compound was prepared from 6.6 (3 mmol, 1.20 g), pyridine 
(3 mmol, 0.24 ml) and cyanoacetic acid chloride which was prepared according to 
known procedures25 (3 mmol, 0.31 g) in THF (10 ml) according to general procedure 
6.5.2.7 and was obtained after flash chromatography as a pale yellow solid (0.50 g, 
36 %). 1H-NMR (CDCl3) δ 0.88 (t, 3H, 3J = 6.7 Hz, CH3), 1.25 (m, 26H, (CH2)13CH3), 
1.53 (m, 2H, OCH2CH2), 3.35 (td, 1H, 3J = 6.9 Hz, 2J = 9.2 Hz), 3.60 – 3.79 (m, 3H, 
OCH2, CH2CN), 4.44 (s, 1H, CHO), 4.95 (d, 1H, 3J = 4.9 Hz, CHO),  5.08 (s, 1H, 
CHO), 5.18 (dd, 1H, 3J = 4.9 Hz, 3J = 6.8 Hz, CHO), 5.35 (d, 1H, 3J = 6.9 Hz, CHO). 
ES-MS (DCM/MeOH + NH4OAc) m/z (%): 485 (100) [M+NH4]+. Anal. (C25H41NO7) C, 
H, N. C25H41NO7 (467.60). 
1-O-(Hexadecan-1-yl)-5-O-trifluormethansulfonyl-β-D-glucofuranosidurono-6,3-
lactone (6.30): To a solution of 6.6 (1 mmol, 0.40 g) in anhydrous CH2Cl2 (9 ml) and 
anhydrous pyridine (1 ml) was added trifluorsulfonic acid anhydride (1 mmol, 0.17 ml) 
in anhydrous CH2Cl2 (2 ml) dropwise at -30 °C under an atmosphere of argon. After 
stirring for 30 min, the mixture was washed with saturated NaHCO3, dried over 
MgSO4, filtered and evaporated to dryness. The raw product was purified by flash 
chromatography (PE/Et2O 20/80 v/v) to obtain the title compound as a brown solid 
(0.30 g, 56 %). mp: 45-47 °C; 1H-NMR (CDCl3) δ 0.88 (t, 3H, 3J = 6.7 Hz, CH3), 1.25 
(m, 26H, (CH2)13CH3), 1.50 (m, 2H, OCH2CH2), 3.36 (td, 1H, 3J = 7.0 Hz, 2J = 9.1 Hz, 
OCH2), 3.77 (td, 1H, 3J = 6.8 Hz, 3J = 9.1 Hz, OCH2), 4.45 (s, 1H, CHO), 4.97 (d, 1H, 
3J = 5.0 Hz, CHO), 5.12 (s, 1H, CHO), 5.13 (dd, 1H, 3J = 5.0 Hz, 3J = 7.2 Hz, CHO), 
5.23 (d, 1H, 3J = 7.2 Hz, CHO). CI-MS (NH3) m/z (%): 550 (100) [M+NH4]+. Anal. 
(C25H41NO7) C, H. C23H39F3O8S (532.61). 
1-O-(Hexadecan-1-yl)-2,5-di-O-ethylcarbamoyl-β-D-glucofuranosidurono-6,3-
lactone (6.31): To a mixture of 6.6 (0.35 mmol, 0.14 g) and Cu(I)Cl (0.35 mmol, 35 
mg) in anhydrous DMF (2 ml) was added ethylisocyanate (0.35 mmol, 27 µl) and the 
suspension was stirred for 1 h at room temperature. After dilution with diethylether, 
the mixture was washed with water and brine. The organic layer then was dried over 
MgSO4, filtered and evaporated. The title compound was obtained after flash 
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chromatography (PE/EtOAc 80/20 to 40/60 v/v) as colorless oil (70 mg, 37 %). 1H-
NMR (CDCl3) δ 0.88 (t, 3H, 3J = 6.7 Hz, CH3), 1.14 – 1.30 (m, 32H, (CH2)13CH3, 
CH2CH3), 1.54 (m, 2H, OCH2CH2), 3.29 (m, 5H, CH2CH3, OCH2), 3.73 (td, 1H, 3J = 
6.8 Hz, 2J = 8.8 Hz, OCH2), 4.70 – 5.24 (m, 7H, NH, CHO). 13C-NMR (CDCl3) δ 14.16 
(+, CH3), 15.05 (+, CH3), 15.11 (+, CH3), 22.72 (-, CH2), 26.03 (-, CH2), 28.90 (-, 
CH2), 29.39 (-, CH2), 29.50 (-, CH2), 29.62 (-, CH2), 29.72 (-, CH2), 31.95 (-, CH2), 
36.12 (-, NHCH2), 36.34 (-, NHCH2), 68.74 (-, OCH2), 69.57 (+, CH), 76.11 (+, CH), 
78.53 (+, CH), 81.69 (+, CH), 106.68 (+, C-1), 154.14 (quat, CONH), 154.40 (quat, 
CONH), 170.50 (quat, lactone CO). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 560 
(100) [M+NH4]+. C28H50N2O8 (542.71). 
1-O-(Hexadecan-1-yl)-5-O-benzyl-β-D-glucofuranosidurono-6,3-lactone (6.32): 
To a solution of 6.6 (2.0 mmol, 0.80 g) and Ag2O (3.0 mmol, 0.70 g) in EtOAc (15 ml) 
was added benzyl bromide (2.0 mmol, 0.24 ml) dropwise and the suspension was 
stirred for 48 h at 40-50 °C. After removal of solids by filtration the solvent was 
evaporated and the remaining raw product was subjected to flash chromatography 
(PE/EtOAc 80/20 to 40/60 v/v) to obtain the title compound as a white solid (0.20 g, 
20 %). mp: 60 °C; 1H-NMR (CDCl3) δ 0.88 (t, 3H, 3J = 6.7 Hz, CH3), 1.25 (m, 26H, 
(CH2)13CH3), 1.51 (m, 2H, OCH2CH2), 2.69 (d, 1H, 3J = 8.9 Hz, OH), 3.37 (td, 1H, 3J 
= 6.9 Hz, 3J = 9.3 Hz, OCH2), 3.64 (td, 1H, 3J = 6.8 Hz, 3J = 9.3 Hz, OCH2), 4.16 (s, 
1H, CHO), 4.35 (dd, 1H, 3J = 6.9 Hz, 3J = 8.6 Hz, CHO), 4.65 (s, 2H, CH2Ph), 4.90 
(d, 1H, 3J = 4.9 Hz, CHO), 4.97 (dd, 1H, 3J = 5.0 Hz, 3J = 6.7 Hz, CHO), 5.14 (s, 1H, 
CHO), 7.36 (m, 5H, Ph-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 508 (100) 
[M+NH4]+. Anal. (C25H41NO7) C, H. C29H46O6 (490.67) 
Monobenzyl malonate (6.33)26: To a solution of malonic acid (50 mmol, 5.2 g) and 
benzyl alcohol (50 mmol, 2.6 ml) in anhydrous EtOAc (50 ml) was added a solution of 
DCC (25 mmol, 5.2 g) in anhydrous EtOAc (10 ml) at 0 °C under an atmosphere of 
argon. The mixture was stirred overnight at room temperature and filtered. After 
washing with water, the organic layer was extracted with a soloution of 2.1 g NaHCO3 
in water (40 ml). The aqueous layer was washed with EtOAc, acidified with 2 N HCl 
to pH<2 and extracted with EtOAc. After washing with water, the organic layer was 
dried over MgSO4, filtered and evaporated to dryness to obtain the title compound as 
a white solid (2.4 g, 25 %). mp: 30 °C;  1H-NMR (CDCl3) δ 3.49 (s, 2H, CH2CO2H), 
5.22 (s, 2H, CH2Ph), 7.37 (m, 5H, Ph-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 
212 (100) [M+NH4]+. C10H10O4 (194.18). 
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Monobenzyl succinate (6.34)17: A solution of succinic anhydride (50 mmol, 5.0 g) 
and benzyl alcohol (0.25 mol, 25.9 ml) in anhydrous toluene (100 ml) was stirred at 
reflux overnight under an atmosphere of argon. After evaporation of the solvent the 
remaining residue was taken up in EtOAc and water and the pH was adjusted to 8 
using 6 N NaOH. The organic phase was discarded and the aqueous layer was 
washed twice with ether. After acidification of the aqueous layer to pH <2 with 2 N 
HCl and extraction with ether, the organic layer was dried over MgSO4, filtered and 
evaporated to yield the title compound as a white solid (4.3 g, 41 %). mp: 50 °C; 1H-
NMR (DMSO-d6) δ 2.54 (m, 4H, CO(CH2)2), 5.10 (s, 2H, CH2Ph), 7.36 (m, 5H, Ph-H), 
12.25 (s, 1H, CO2H). EI-MS (70eV) m/z (%): 208 (5) [M+·]. C11H12O4 (208.21).  
6.5.2.8 General procedure for the synthesis of 5-O-Cbz-protected 1-O-alkyl 
glucurono-6,3-lactones 6.35 and 6.36 
To a solution of 1-O-alkyl glucuronolactone (1 eq) in anhydrous pyridine was added 
Cbz-chloride (1 eq) at -20 °C over a period of 20 min under an atmosphere of argon. 
The reaction was quenched by adding water and the mixture was extracted three 
times with CHCl3. After washing the combined organic layers with saturated 
NaHCO3, saturated KHSO4 and water, the organic phase was dried over MgSO4, 
filtered and evaporated to dryness. Flash chromatography of the crude material 
yielded the title 5-O-protected derivatives. 
1-O-(Dodecan-1-yl)-5-O-benzyloxycarbonyl-β-D-glucofuranosidurono-6,3-
lactone (6.35): The title compound was prepared from 6.5 (5 mmol, 1.7 g), Cbz-
chloride (5 mmol, 0.71 ml) in anhydrous pyridine (10 ml) according to general 
procedure 6.5.2.8 and was obtained after flash chromatography (Et2O) as a white 
solid (1.55 g, 65 %). 1H-NMR (CDCl3) δ 0.88 (t, 3H, 3J = 6.7 Hz, CH3), 1.23 (m, 18H, 
(CH2)9CH3), 1.50 (m, 2H, OCH2CH2), 3.27 (td, 1H, 3J = 7.1 Hz, 2J = 9.0 Hz, OCH2), 
3.78 (td, 1H, 3J = 6.9 Hz, 2J = 9.0 Hz, OCH2), 4.41 (s, 1H, CHO), 4.92 (d, 1H, 3J = 4.6 
Hz, H-3), 5.06 (s, 1H, CHO), 5.16 (m, 2H, CHO), 5.24 (s, 2H, CH2Ph), 7.37 (m, 5H, 
Ph-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 496 (100) [M+NH4]+. C26H38O8 
(478.58). 
1-O-(Hexadecan-1-yl)-5-O-benzyloxycarbonyl-β-D-glucofuranosidurono-6,3-
lactone (6.36): The title compound was prepared from 6.6 (4 mmol, 1.6 g), Cbz-
chloride (4 mmol, 0.57 ml) in anhydrous pyridine (10 ml) according to general 
procedure 6.5.2.8 and was obtained after flash chromatography (Et2O) as a white 
solid (1.4 g, 65 %). mp: 55 °C; 1H-NMR (CDCl3) δ 0.88 (t, 3H, 3J = 6.7 Hz, CH3), 1.23 
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(m, 26H, (CH2)13CH3), 1.50 (m, 2H, OCH2CH2), 3.27 (td, 1H, 3J = 7.1 Hz, 2J = 9.0 Hz, 
OCH2), 3.79 (td, 1H, 3J = 6.8 Hz, 2J = 9.0 Hz, OCH2), 4.41 (s, 1H, CHO), 4.92 (d, 1H, 
3J = 4.8 Hz, H-3), 5.05 (s, 1H, CHO), 5.15 (d, 1H, 3J = 7.1 Hz, H-1), 5.19 (dd, 1H, 3J = 
4.8 Hz, 3J = 7.1 Hz, H-2), 5.25 (s, 2H, CH2Ph), 7.37 (m, 5H). EI-MS (70eV) m/z (%): 
534 (20) [M+·]. Anal. (C30H46O8) C, H. C30H46O8 (534.68).  
6.5.2.9 General procedure for the DCC mediated synthesis of mono- or di-
acylated glucuronolactones 6.37-6.39, 6.45, 6.49 and 6.50 
To a solution of glucuronolactone derivative (1 eq), the pertinent carboxylic acid (1-
2.4 eq) and DMAP (0.1-0.2 eq) in anhydrous EtOAc was added a solution of DCC 
(1.1-2.4 eq) in anhydrous EtOAc dropwise at 0 °C under an atmosphere of argon. 
After stirring overnight at room temperature solids were removed by filtration and the 
organic layer was washed with saturated NaHCO3 and water. Drying over MgSO4, 
filtration and evaporation of the solvent gave the crude product which was subjected 
to flash chromatography. 
1-O-(Dodecan-1-yl)-5-O-benzyloxycarbonyl-2-O-(2-benzyloxycarbonylethanoyl)-
β-D-glucofuranosidurono-6,3-lactone (6.37): The title compound was prepared 
from 6.35 (0.8 mmol, 0.38 g), 6.33 (0.88 mmol, 0.17 g), DMAP (0.08 mmol, 10 mg) 
and  DCC (0.88 mmol, 0.18 g) in anhydrous EtOAc (10 ml) according to general 
procedure 6.5.2.9 and was obtained after flash chromatography (PE/Et2O 40/60 v/v) 
as colorless oil (0.40 g, 76 %). 1H-NMR (CDCl3) δ 0.88 (t, 3H, 3J = 6.7 Hz, CH3), 1.23 
(m, 18H, (CH2)9CH3), 1.50 (m, 2H, OCH2CH2), 3.25 (td, 1H, 3J = 7.1 Hz, 3J = 8.9 Hz, 
OCH2), 3.47 (s, 2H, COCH2CO2), 3.75 (td, 1H, 3J = 6.8 Hz, 3J = 8.9 Hz, OCH2), 4.82 
(d, 1H, 3J = 5.2 Hz, CHO), 4.95 (dd, 1H, 3J = 5.3 Hz, 3J = 7.0 Hz, CHO), 5.06 (m, 2H, 
CHO), 5.14 (d, 1H, 2J = 12.0 Hz, CH2Ph), 5.21 (d, 1H, 2J = 12.1 Hz, CH2Ph), 5.25 (s, 
3H, CH2Ph, CHO), 7.37 (m, 10H, Ph-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 
673 (100) [M+NH4]+. C36H46O11 (654.74). 
1-O-(Hexadecan-1-yl)-5-O-benzyloxycarbonyl-2-O-(2-benzyloxycarbonyl-
ethanoyl)-β-D-glucofuranosidurono-6,3-lactone (6.38): The title compound was 
prepared from 6.36 (0.8 mmol, 0.43 g), 6.33 (0.88 mmol, 0.17 g), DMAP (0.08 mmol, 
10 mg) and  DCC (0.88 mmol, 0.18 g) in anhydrous EtOAc (10 ml) according to 
general procedure 6.5.2.9 and was obtained after flash chromatography (PE/Et2O 
30/70 v/v) as colorless oil (0.42 g, 74 %). 1H-NMR (CDCl3) δ 0.88 (t, 3H, 3J = 6.7 Hz, 
CH3), 1.23 (m, 26H, (CH2)13CH3), 1.50 (m, 2H, OCH2CH2), 3.25 (td, 1H, 3J = 7.1 Hz, 
2J = 8.9 Hz, OCH2), 3.47 (s, 2H, COCH2CO2), 3.75 (td, 1H, 3J = 6.8 Hz, 2J = 8.9 Hz, 
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OCH2), 4.82 (d, 1H, 3J = 5.2 Hz, CHO), 4.95 (dd, 1H, 3J = 5.3 Hz, 3J = 7.0 Hz, CHO), 
5.18 (m, 7H, CHO, CH2Ph), 7.37 (m, 10H, Ph-H). ES-MS (DCM/MeOH + NH4OAc) 
m/z (%): 729 (100) [M+NH4]+. C40H54O11 (710.85). 
1-O-(Hexadecan-1-yl)-5-O-benzyloxycarbonyl-2-O-(3-benzyloxycarbonyl-
propanoyl)-β-D-glucofuranosidurono-6,3-lactone (6.39): The title compound was 
prepared from 6.36 (0.8 mmol, 0.43 g), 6.34 (0.88 mmol, 0.18 g), DMAP (0.08 mmol, 
10 mg) and DCC (0.88 mmol, 0.18 g) in anhydrous EtOAc (10 ml) according to 
general procedure 6.5.2.9 and was obtained after flash chromatography (PE/EtOAc 
50/50 v/v) as colorless oil (0.31 g, 53 %). 1H-NMR (CDCl3) δ 0.88 (t, 3H, 3J = 6.7 Hz, 
CH3), 1.24 (m, 26H, (CH2)13CH3), 1.50 (m, 2H, OCH2CH2), 2.68 (m, 4H, CO(CH2)2), 
3.27 (td, 1H, 3J = 7.1 Hz, 2J = 8.9 Hz, OCH2), 3.77 (td, 1H, 3J = 6.9 Hz, 2J = 8.9 Hz, 
OCH2), 4.85 (d, 1H, 3J = 4.9 Hz, CHO), 5.14 (m, 8H, CHO, CH2Ph), 7.36 (m, 10H, 
Ph-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 743 (100) [M+NH4]+. C41H56O11 
(724.88). 
1-O-(Dodecan-1-yl)-5-O-benzyloxycarbonyl-2-O-(2-dimethylaminoethanoyl)-β-D-
glucofuranosidurono-6,3-lactone (6.40): To a solution of 6.36 (0.8 mmol, 0.43 g), 
N,N-dimethylglycine (1.2 mmol, 0.12 g), DMAP (1.2 mmol, 0.15 g) in anhydrous DMF 
(10 ml) was added EDAC (1.2 mmol, 0.23 g) under an atmosphere of argon and the 
mixture was stirred overnight at room temperature. After dilution with water and 
extraction three times with EtOAc, the combined organic layers were washed with 1 
N HCl and water, dried over MgSO4, filtered and evaporated to dryness. The crude 
residue was subjected to flash chromatography (CHCl3/MeOH 95/5 v/v) to obtain the 
title compound as pale yellow oil (0.32 g, 64 %). 1H-NMR (CDCl3) δ 0.87 (t, 3H, 3J = 
6.7 Hz, CH3), 1.23 (m, 26H, (CH2)13CH3), 1.51 (m, 2H, OCH2CH2), 2.37 (s, 6H, 
N(CH3)2), 3.24 (s, 2H, COCH2N), 3.29 (td, 1H, 3J = 7.1 Hz, 2J = 8.9 Hz, OCH2), 3.78 
(td, 1H, 3J = 7.1 Hz, 2J = 9.3 Hz, OCH2), 5.00 (d, 1H, 3J = 4.7 Hz, CHO), 5.09 (s, 1H, 
CHO), 5.15 (m, 2H, CHO), 5.24 (s, 2H, CH2Ph), 5.26 (s, 1H, CHO), 7.37 (m, 5H, Ph-
H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 620 (100) [M+H]+. C34H53NO9 (619.79). 
6.5.2.10 General procedure for the synthesis of carboxylic acids and alcohols 
6.41-6.44, 6.47, 6.48, 6.51, 6.52 and 6.54 by hydrogenolytic 
deprotection 
The pertinent benzyl-protected compound was dissolved EtOAc and a catalytic 
amount of palladium on activated charcoal (10 % Pd) was added. After 
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hydrogenolysis (1 atm) overnight, insoluble material was filtered off, and the solvent 
was evaporated to yield the target compound. 
1-O-(Dodecan-1-yl)-2-O-(2-carboxyethanoyl)-β-D-glucofuranosidurono-6,3-
lactone (6.41): The title compound was prepared according to general procedure 
6.5.2.10 using 6.37 (0.46 mmol, 0.30 g) and 10 % Pd/C (0.30 g) in EtOAc (10 ml) and 
was obtained as a white solid (0.19 g, 96 %). mp: 57 °C; 1H-NMR (DMSO-d6) δ 0.85 
(t, 3H, 3J = 6.7 Hz, CH3), 1.24 (m, 18H, (CH2)9CH3), 1.40 (m, 2H, OCH2CH2), 3.25 
(td, 1H, 3J = 6.8 Hz, 2J = 9.0 Hz, OCH2), 3.72 (td, 1H, 3J = 6.6 Hz, 2J = 8.9 Hz, 
OCH2), 4.49 (dd, 1H, 3J = 6.0 Hz, 3J = 6.0 Hz, H-5), 4.79 (dd, 1H, 3J = 4.9 Hz, 3J = 
6.5 Hz, H-4), 4.92 (d, 1H, 3J = 4.8 Hz, H-3), 4.99 (s, 1H, CH), 5.07 (s, 1H, CHO), 5.99 
(d, 1H, 3J = 6.1 Hz, 5-OH), 12.95 (bs, 1H, CO2H). 13C-NMR (DMSO-d6) δ 13.85 (+, 
CH3), 21.99 (-, CH2), 25.31 (-, CH2), 28.38 (-, CH2), 28.61 (-, CH2), 28.77 (-, CH2), 
28.92 (-, CH2), 31.20 (-, CH2), 41.11 (-, COCH2), 67.11 (-, OCH2), 68.11 (+, CH), 
77.85 (+, CH), 78.60 (+, CH), 79.85 (+, CH), 105.25 (+, C-1), 165.80 (quat, 
COCH2CO2H), 167.59 (quat, CO2H, 174.41 (quat, lactone CO). ES-MS (MeOH + 
NH4OAc) m/z (%): 448 (100) [M+NH4]+. Anal (C21H34O9·0.3H2O) C, H. C21H34O9 
(430.49). 
1-O-(Hexadecan-1-yl)-2-O-(2-carboxyethanoyl)-β-D-glucofuranosidurono-6,3-
lactone (6.42): The title compound was prepared according to general procedure 
6.5.2.10 using 6.38 (0.52 mmol, 0.37 g) and 10 % Pd/C (0.37 g) in EtOAc (10 ml) and 
was obtained as a white foam (0.22 g, 87 %). mp: 58-60 °C; 1H-NMR (DMSO-d6) δ 
0.85 (t, 3H, 3J = 6.7 Hz, CH3), 1.23 (m, 26H, (CH2)13CH3), 1.40 (m, 2H, OCH2CH2), 
3.24 (td, 1H, 3J = 6.8 Hz, 2J = 9.0 Hz, OCH2), 3.47 (s, 2H, COCH2CO2), 3.72 (td, 1H, 
3J = 6.6 Hz, 2J = 8.9 Hz, OCH2), 4.49 (m, 1H, H-5), 4.79 (dd, 1H, 3J = 4.9 Hz, 3J = 6.6 
Hz, H-4), 4.92 (d, 1H, 3J = 4.8 Hz, H-3), 4.99 (s, 1H, CHO), 5.07 (s, 1H, CHO), 5.99 
(s, 1H, 5-OH), 12.97 (s, 1H, CO2H). 13C-NMR (DMSO-d6) δ 13.85 (+, CH3), 22.00 (-, 
CH2), 25.32 (-, CH2), 28.39 (-, CH2), 28.61 (-, CH2), 28.79 (-, CH2), 28.96 (-, CH2), 
31.19 (-, CH2), 41.12 (-, COCH2CO2H), 67.10 (-, OCH2), 68.10 (+, CH), 77.84 (+, 
CH), 78.58 (+, CH), 79.84 (+, CH), 105.23 (+, C-1), 165.79 (quat, COCH2CO2H), 
167.60 (quat, CO2H), 174.42 (quat, lactone CO). ES-MS (DCM/MeOH + NH4OAc) 
m/z (%): 504 (100) [M+NH4]+. Anal (C25H42O9) C, H. C25H42O9 (486.60). 
1-O-(Hexadecan-1-yl)-2-O-(3-carboxypropanoyl)-β-D-glucofuranosidurono-6,3-
lactone (6.43): The title compound was prepared according to general procedure 
6.5.2.10 using 6.39 (0.36 mmol, 0.26 g) and 10 % Pd/C (0.26 g) in EtOAc (10 ml) and 
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was obtained as a pale yellow solid (0.15 g, 83 %). mp: 94 °C; 1H-NMR (DMSO-d6) δ 
0.85 (t, 3H, 3J = 6.7 Hz, CH3), 1.24 (s, 26H, (CH2)13CH3), 1.40 (m, 2H, OCH2CH2), 
2.56 (m, 4H, CO(CH2)2CO2H), 3.23 (td, 1H, 3J = 6.8 Hz, 2J = 9.0 Hz, OCH2), 3.71 (td, 
1H, 3J = 6.6 Hz, 2J = 8.9 Hz, OCH2), 4.48 (dd, 1H, 3J = 6.4 Hz, 3J = 6.4 Hz, H-5), 4.80 
(dd, 1H, 3J = 4.9 Hz, 3J = 6.5 Hz, H-4), 4.90 (d, 1H, 3J = 4.8 Hz, H-3), 4.96 (s, 1H, 
CHO), 5.05 (s, 1H, CHO), 5.97 (d, 1H, 3J = 6.4 Hz, 5-OH), 12.28 (bs, 1H, CO2H). 13C-
NMR (DMSO-d6) δ 13.85 (+, CH3), 21.99 (-, CH2), 25.32 (-, CH2), 28.40 (-, CH2), 
28.48 (-, CH2), 28.61 (-, CH2), 28.78 (-, CH2), 28.95 (-, CH2), 31.19 (-, CH2), 67.06 (-, 
OCH2), 68.17 (+, CH), 77.84 (+, CH), 78.16 (+, CH), 79.96 (+, CH), 105.40 (+, C-1), 
171.08 (quat, CO2), 173.20 (quat, CO2H), 174.44 (quat, lactone CO). ES-MS 
(DCM/MeOH + NH4OAc) m/z (%): 518 (100) [M+NH4]+. Anal. (C26H44O9) C, H. 
C26H44O9 (500.62). 
1-O-(Hexadecan-1-yl)-2-O-(2-dimethylaminoethanoyl)-β-D-glucofuranosidurono-
6,3-lactone (6.44): The title compound was prepared according to general procedure 
6.5.2.10 using 6.40 (0.32 mmol, 0.20 g) and 10 % Pd/C (0.20 g) in EtOAc (10 ml) and 
was obtained as a colorless solid (0.15 g, 96 %). 1H-NMR (CD3OD) δ 0.90 (t, 3H, 3J = 
6.7 Hz, CH3), 1.28 (m, 26H, (CH2)13CH3), 1.51 (m, 2H, OCH2CH2), 2.36 (s, 6H, 
N(CH3)2), 3.34 (m, 3H, COCH2N, OCH2), 3.84 (td, 1H, 3J = 6.5 Hz, 2J = 9.1 Hz, 
OCH2), 4.50 (d, 1H, 3J = 6.7 Hz, CHO), 4.91 (dd, 1H, 3J = 4.8 Hz, 3J = 6.6 Hz, CHO), 
5.00 (d, 1H, 3J = 4.7 Hz, CHO), 5.13 (s, 1H, CHO), 5.16 (s, 1H, CHO). 13C-NMR 
(CD3OD) δ 14.49 (+, CH3), 23.79 (-, CH2), 27.19 (-, CH2), 30.32 (-, CH2), 30.53 (-, 
CH2), 30.62 (-, CH2), 30.66 (-, CH2), 30.79 (-, CH2), 30.85 (-, CH2), 33.13 (-, CH2), 
45.30 (+, N(CH3)2), 69.29 (-, CH2), 69.57 (-, CH2), 70.55 (+, CH), 78.62 (+, CH), 
79.37 (+, CH), 84.81 (+, CH), 110.51 (+, C-1), 177.20 (quat, lactone CO). CI-MS 
(NH3) m/z (%): 486 (100) [M+H]+. C26H47NO7 (485.65). 
1-O-(Hexadecan-1-yl)-5-O-(2-benzyloxycarbonylethanoyl)-β-D-glucofuranosid-
urono-6,3-lactone (6.45): The title compound was prepared from 6.6 (1 mmol, 0.40 
g), 6.33 (1 mmol, 0.19 g), DMAP (0.1 mmol, 12 mg) and  DCC (1.1 mmol, 0.23 g) in 
anhydrous EtOAc (10 ml) according to general procedure 6.5.2.9 and was obtained 
after flash chromatography (PE/EtOAc 60/40 v/v) as a colorless oil (0.24 g, 42 %). 
1H-NMR (CDCl3) δ 0.88 (t, 3H, 3J = 6.7 Hz, CH3), 1.25 (m, 26H, (CH2)13CH3), 1.49 
(m, 2H, OCH2CH2), 2.33 (d, 1H, 3J = 5.4 Hz, OH), 3.26 (td, 1H, 3J = 7.0 Hz, 2J = 9.1 
Hz, OCH2), 3.65 (m, 3H, OCH2, COCH2CO2), 4.41 (d, 1H, 3J = 4.8 Hz, CHO), 4.92 (d, 
1H, 3J = 4.9 Hz, CHO), 5.02 (s, 1H, CHO), 5.16 – 5.27 (m, 4H, CHO, CH2Ph), 7.37 
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(m, 5H, Ph-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 595 (100) [M+NH4]+. 
C32H48O9 (576.72). 
1-O-(Hexadecan-1-yl)-5-O-(3-benzyloxycarbonylpropanoyl)-β-D-glucofuranosid-
urono-6,3-lactone (6.46): To a solution of 6.34 (1.1 mmol, 0.23 g) in anhydrous 
CH2Cl2 (20 ml) was added oxalylchloride (5.6 mmol, 0.94 ml) and a drop of DMF at 0 
°C. After stirring for 30 min the solvent was evaporated and traces of HCl or 
oxalylchloride were co-evaporated with toluene. The remaining crude acid chloride 
was taken up in anhydrous THF (20 ml) and added dropwise to a solution of 6.6 (1 
mmol, 0.40 g) in anhydrous pyridine (7 ml) at -20 °C under an atmosphere of argon. 
After stirring for 10 min the reaction was quenched by adding saturated NaHCO3 and 
the mixture was extracted three times with CHCl3. After washing the combined 
organic layers with saturated NaHCO3, saturated KHSO4 and water, the organic 
phase was dried over MgSO4, filtered and evaporated to dryness. Flash 
chromatography (PE/Et2O 20/80 v/v) of the crude product yielded the title compound 
as colorless oil (0.39 g, 66 %). 1H-NMR (CDCl3) δ 0.88 (t, 3H, 3J = 6.7 Hz, CH3), 1.25 
(m, 26H, (CH2)13CH3), 1.53 (m, 2H, OCH2CH2), 2.23 (d, 1H, 3J = 5.6 Hz, OH), 2.68 – 
2.91 (m, 4H, CO(CH2)2), 3.31 (td, 1H, 3J = 7.0 Hz, 2J = 9.1 Hz, OCH2), 3.74 (td, 1H, 
3J = 6.7 Hz, 3J = 9.1 Hz, OCH2), 4.41 (d, 1H, 3J = 5.1 Hz, H-4), 4.90 (d, 1H, 3J = 5.0 
Hz, H-3), 5.03 (s, 1H, H-5), 5.14 (dd, 1H, 3J = 4.9 Hz, 3J = 6.9 Hz, H-2), 5.16 (s, 2H, 
CH2Ph), 5.25 (d, 1H, 3J = 7.0 Hz, H-1), 7.36 (m, 5H, Ph-H). ES-MS (DCM/MeOH + 
NH4OAc) m/z (%): 609 (100) [M+NH4]+. C33H50O9 (590.74). 
1-O-(Hexadecan-1-yl)-5-O-(2-carboxyethanoyl)-β-D-glucofuranosidurono-6,3-
lactone (6.47): The title compound was prepared according to general procedure 
6.5.2.10 using 6.45 (0.35 mmol, 0.20 g) and 10 % Pd/C (0.20 g) in EtOAc (10 ml) and 
was obtained as a colorless semisolid substance (0.15 g, 88 %). mp: 59-60 °C; 1H-
NMR (DMSO-d6) δ 0.85 (t, 3H, 3J = 6.6 Hz, CH3), 1.23 (m, 26H, (CH2)13CH3), 1.39 
(m, 2H, OCH2CH2), 3.24 (td, 1H, 3J = 6.4 Hz, 3J = 9.2 Hz, OCH2), 3.49 (s, 2H, 
CH2CO2H), 3.60 (td, 1H, 3J = 6.5 Hz, 3J = 9.0 Hz, OCH2), 4.08 (d, 1H, 3J = 3.0 Hz, 
CHO), 4.84 – 5.00 (m, 3H, CH), 5.49 (d, 1H, 3J = 6.9 Hz, H-1), 5.75 (d, 1H, 3J = 3.8 
Hz, OH), 12.93 (s, 1H, CO2H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 504(100) 
[M+NH4]+. Anal. (C25H42O9) C, H. C25H42O9 (486.60). 
1-O-(Hexadecan-1-yl)-5-O-(3-carboxypropanoyl)-β-D-glucofuranosidurono-6,3-
lactone (6.48): The title compound was prepared according to general procedure 
6.5.2.10 using 6.46 (0.49 mmol, 0.29 g) and 10 % Pd/C (0.29 g) in EtOAc (10 ml) and 
Chapter 6 Derivatives of the glucurono-6,3-lactone as hyaluronidase inhibitors 
90 
was obtained as a colorless solid (0.22 g, 90 %). mp: 75-76 °C; 1H-NMR (DMSO-d6) 
δ 0.85 (t, 3H, 3J = 6.7 Hz, CH3), 1.23 (s, 26H, (CH2)13CH3), 1.41 (m, 2H, OCH2CH2), 
2.38 (t, 2H, 3J = 6.8 Hz, CH2CO2), 2.59 (m, 2H, CH2CO2), 3.25 (td, 1H, 3J = 6.7 Hz, 2J 
= 8.9 Hz, OCH2), 3.62 (td, 1H, 3J = 6.7 Hz, 2J = 8.8 Hz, OCH2), 4.08 (s, 1H, CHO), 
4.84 (d, 1H, 3J = 5.0 Hz, H-3), 4.91 (s, 1H, CHO), 4.95 (dd, 1H, 3J = 5.1 Hz, 3J = 6.8 
Hz, H-2), 5.43 (d, 1H, 3J = 6.9 Hz, H-1). 13H-NMR (DMSO-d6) δ 13.85 (+, CH3), 21.99 
(-, CH2), 25.40 (-, CH2), 28.51 (-, CH2), 28.61 (-, CH2), 28.81 (-, CH2), 28.91 (-, CH2), 
28.96 (-, CH2), 30.02 (-, CH2), 31.19 (-, CH2), 67.07 (-, OCH2), 69.16 (+, CH), 75.52 
(+, CH), 76.57 (+, CH), 83.94 (+, CH), 108.33 (+, C-1), 170.72 (quat, CO2), 170.91 
(quat, CO2), 172.91 (quat, CO2). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 518 (100) 
[M+NH4]+. Anal. (C26H44O9) C, H. C26H44O9 (500.62). 
1-O-(Hexadecan-1-yl)-2,5-di-O-(2-benzyloxycarbonylethanoyl)-β-D-gluco-
furanosidurono-6,3-lactone (6.49): The title compound was prepared from 6.6 (1 
mmol, 0.40 g), 6.33 (2.4 mmol, 0.47 g), DMAP (0.2 mmol, 24 mg) and  DCC (2.4 
mmol, 0.50 g) in anhydrous EtOAc (15 ml) according to general procedure 6.5.2.9 
and was obtained after flash chromatography (PE/Et2O 30/70 v/v) as pale yellow oil 
(0.44 g, 58 %). 1H-NMR (CDCl3) δ 0.88 (t, 3H, 3J = 6.7 Hz, CH3), 1.24 (m, 26H, 
(CH2)13CH3), 1.47 (m, 2H, OCH2CH2), 3.23 (td, 1H, 3J = 7.0 Hz, 2J = 9.0 Hz, OCH2), 
3.47 (s, 2H, COCH2CO2), 3.58 – 3.68 (m, 3H, OCH2, COCH2CO2), 4.80 (d, 1H, 3J = 
5.1 Hz, CHO), 4.92 (dd, 1H, 3J = 5.2 Hz, 3J = 6.9 Hz, CHO), 5.02 (s, 1H, CHO), 5.19 
(m, 6H, CHO, CH2Ph), 7.37 (m, 10H, Ph-H). ES-MS (DCM/MeOH + NH4OAc) m/z 
(%): 770 (100) [M+NH4]+. C42H56O12 (752.89). 
1-O-(Hexadecan-1-yl)-2,5-di-O-(3-benzyloxycarbonylpropanoyl)-β-D-gluco-
furanosidurono-6,3-lactone (6.50): The title compound was prepared from 6.6 (1 
mmol, 0.40 g), 6.34 (2.4 mmol, 0.50 g), DMAP (0.2 mmol, 24 mg) and  DCC (2.2 
mmol, 0.46 g) in anhydrous EtOAc (15 ml) according to general procedure 6.5.2.9 
and was obtained after flash chromatography (PE/Et2O 30/70 v/v) as colorless oil 
(0.70 g, 90 %). 1H-NMR (CDCl3) δ 0.88 (t, 3H, 3J = 6.7 Hz, CH3), 1.25 (s, 26H, 
(CH2)13CH3), 1.53 (m, 2H, OCH2CH2), 2.75 (m, 8H, CO(CH2)2), 3.30 (td, 1H, 3J = 7.0 
Hz, 2J = 8.9 Hz, OCH2), 3.73 (td, 1H, 3J = 6.7 Hz, 2J = 8.9 Hz, OCH2), 4.84 (d, 1H, 3J 
= 5.2 Hz, CHO), 5.03 (m, 2H, CHO), 5.13 (d, 2H, 2J = 2.2 Hz, CH2Ph), 5.15 (s, 2H, 
CH2Ph), 5.20 (d, 1H, 3J = 7.1 Hz, CHO), 5.22 (s, 1H, H-1), 7.35 (m, 10H, PhH). ES-
MS (MeOH + NH4OAc) m/z (%): 799 (100) [M+NH4]+. C44H60O12 (780.94). 
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1-O-(Hexadecan-1-yl)-2,5-di-O-(2-carboxyethanoyl)-β-D-glucofuranosidurono-
6,3-lactone (6.51): The title compound was prepared according to general procedure 
6.5.2.10 using 6.49 (0.34 mmol, 0.16 g) and 10 % Pd/C (0.16 g) in EtOAc (10 ml) and 
was obtained as a pale yellow semisolid substance (0.11 g, 90 %). mp: 68 °C; 1H-
NMR (DMSO-d6) δ 0.85 (t, 3H, 3J = 6.7 Hz, CH3), 1.23 (m, 26H, (CH2)13CH3), 1.42 
(m, 2H, OCH2CH2), 3.48 (s, 2H, COCH2CO2H), 3.30 (td, 1H, 3J = 6.6 Hz, 2J = 8.9 Hz, 
OCH2), 3.51 (s, 2H, COCH2CO2H), 3.64 (td, 1H, 3J = 6.6 Hz, 2J = 8.9 Hz, OCH2), 
5.02 (dd, 1H, 3J = 5.2 Hz, 3J = 6.6 Hz, H-2), 5.03 (s, 1H, CHO), 5.07 (d, 1H, 3J = 5.2 
Hz, H-3), 5.10 (s, 1H, CHO), 5.55 (d, 1H, 3J = 6.8 Hz, H-1), 12.94 (s, 2H, CO2H). 13C-
NMR (DMSO-d6) δ 13.85 (+, CH3), 21.99 (-, CH2), 25.26 (-, CH2), 28.36 (-, CH2), 
28.60 (-, CH2), 28.78 (-, CH2), 28.90 (-, CH2), 28.95 (-, CH2), 31.19 (-, CH2), 40.71 (-, 
CH2CO2H), 41.09 (-, CH2CO2H), 67.57 (-, OCH2), 69.33 (+, CH), 75.48 (+, CH), 78.18 
(+, CH), 81.29 (+, CH), 105.34 (+, C-1), 165.55 (quat, CO2), 165.76 (quat, CO2), 
167.02 (quat, CO2), 167.56 (quat, CO2), 170.03 (quat, CO2). ES-MS (DCM/MeOH + 
NH4OAc) m/z (%): 590 (100) [M+NH4]+. Anal. (C28H44O12·1.8H2O) C, H. C28H44O12 
(572.64). 
1-O-(Hexadecan-1-yl)-2,5-di-O-(3-carboxypropanoyl)-β-D-glucofuranosidurono-
6,3-lactone (6.52): The title compound was prepared according to general procedure 
6.5.2.10 using 6.50 (0.71 mmol, 0.56 g) and 10 % Pd/C (0.56 g) in EtOAc (15 ml) and 
was obtained after flash chromatography (CHCl3/MeOH 95/5 v/v) as a colorless 
semisolid substance (0.29 g, 67 %). 1H-NMR (CD3OD) δ 0.90 (t, 3H, 3J = 6.7 Hz, 
CH3), 1.29 (m, 26H, (CH2)13CH3), 1.54 (m, 2H, OCH2CH2), 2.61 – 2.79 (m, 8H, 
CO(CH2)2), 3.36 (td, 1H, 3J = 6.8 Hz, 2J = 9.0 Hz, OCH2), 3.79 (td, 1H, 3J = 6.6 Hz, 2J 
= 9.0 Hz, OCH2), 5.09 (m, 3H, CHO), 5.14 (s, 1H, CHO), 5.46 (d, 1H, 3J = 6.5 Hz, 
CHO). 1H-NMR (CD3OD) δ 14.48 (+, CH3), 23.78 (-, CH2), 27.16 (-, CH2), 29.61 (-, 
CH2), 29.68 (-, CH2), 29.89 (-, CH2), 30.19 (-, CH2), 30.52 (-, CH2), 30.64 (-, CH2), 
30.74 (-, CH2), 30.80 (-, CH2), 30.81 (-, CH2), 30.85 (-, CH2), 33.12 (-, CH2), 69.72 (-, 
OCH2), 70.67 (+, CH), 77.42 (+, CH), 79.93 (+, CH), 83.42 (+, CH), 107.71 (+, C-1), 
172.59 (quat, CO2), 172.66 (quat, CO2), 172.80 (quat, CO2), 175.52 (quat, CO2), 
175.89 (quat, CO2). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 618 (100) [M+NH4]+. 
Anal. (C30H48O12·H2O) C, H. C30H48O12 (600.69). 
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6.5.2.11 General procedure for the synthesis of the sulfates 6.53 and 6.55 
using SO3-pyridine complex 
To a solution of the pertinent glucuronolactone (1 eq) in anhydrous pyridine was 
added SO3-pyridine complex (3-4 eq) and the mixture was stirred at room 
temperature overnight. The reaction was quenched by adding MeOH, the solvent 
was evaporated and the remaining residue was subjected to flash chromatography. 
1-O-(Hexadecan-1-yl)-5-O-benzyloxycarbonyl-β-D-glucofuranosidurono-6,3-
lactone-2-sulfate (6.53): The title compound was prepared according to general 
procedure 6.5.2.11 using 6.36 (0.8 mmol, 0.43 g) and SO3-pyridine complex (2.4 
mmol, 0.38 g) in anhydrous pyridine (5 ml) and was obtained after flash 
chromatography (CHCl3/MeOH 90/10 v/v) as yellow solid (0.3 g, 61 %). 1H-NMR 
(DMSO-d6) δ 0.85 (t, 3H, 3J = 6.7 Hz, CH3), 1.20 (m, 26H, (CH2)13CH3), 1.37 (m, 2H, 
OCH2CH2), 3.22 (td, 1H, 3J = 6.9 Hz, 2J = 8.9 Hz, OCH2), 3.59 (td, 1H, 3J = 6.8 Hz, 2J 
= 9.0 Hz, OCH2), 4.48 (s, 1H, CHO), 5.00 (dd, 1H, 3J = 5.1 Hz, 3J = 6.9 Hz, CHO), 
5.10 (s, 1H, CHO), 5.17 (d, 1H, 3J = 5.0 Hz, CHO), 5.24 (s, 2H, CH2Ph), 5.46 (d, 1H, 
3J = 6.9 Hz, CHO), 7.40 (m, 5H, Ph-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 
614 (100) [M-H]-. C30H46O11S (614.74).  
1-O-(Hexadecan-1-yl)-β-D-glucofuranosidurono-6,3-lactone-2-sulfate (6.54): The 
title compound was prepared according to general procedure 6.5.2.10 groups using 
6.53 (0.41 mmol, 0.25 g) and 10 % Pd/C (0.25 g) in EtOAc (10 ml) and was obtained 
as a white solid (0.18 g, 91 %). mp: 140-141 °C; 1H-NMR (DMSO-d6) δ 0.85 (t, 3H, 3J 
= 6.7 Hz, CH3), 1.24 (m, 26H, (CH2)13CH3), 1.39 (m, 2H, OCH2CH2), 3.19 (td, 1H, 3J 
= 6.8 Hz, 2J = 8.9 Hz, OCH2), 3.67 (td, 1H, 3J = 6.8 Hz, 2J = 8.9 Hz, OCH2), 4.45 (m, 
2H, CH), 4.72 (dd, 1H, 3J = 4.7 Hz, 3J = 6.4 Hz, H-5), 4.99 (d, 1H, 3J = 4.6 Hz, H-4), 
5.07 (s, 1H, CH), 5.86 (d, 1H, 3J = 6.4 Hz, 5-OH). 13C-NMR (DMSO-d6) δ 13.86 (+, 
CH3), 22.00 (-, CH2), 25.40 (-, CH2), 28.52 (-, CH2), 28.61 (-, CH2), 28.85 (-, CH2), 
28.96 (-, CH2), 31.19 (-, CH2), 66.83 (-, OCH2), 68.47 (+, C-5), 77.84 (+, CH), 80.44 
(+, CH), 80.81 (+, CH), 106.43 (+, C-1), 174.71 (quat, lactone CO). ES-MS 
(DCM/MeOH + NH4OAc) m/z (%): 479 (100) [M-H]-. C22H40O9S (480.61). 
1-O-(Hexadecan-1-yl)-β-D-glucofuranosidurono-6,3-lactone-2,5-disulfate (6.55): 
The title compound was prepared according to general procedure 6.5.2.11 using 6.6 
(1 mmol, 0.4 g) and SO3-pyridine complex (4.0 mmol, 0.64 g) in anhydrous pyridine 
(10 ml) and was obtained after flash chromatography (CHCl3/MeOH 80/20 v/v) as a 
yellow solid (0.48 g, 86 %). mp: 171-73 °C; 1H-NMR (DMSO-d6) δ 0.85 (t, 3H, 3J = 
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6.6 Hz), 1.23 (m, 26H), 1.37 (m, 2H), 3.18 (td, 1H, 3J = 6.8 Hz, 2J = 9.0 Hz, OCH2), 
3.63 (td, 1H, 3J = 6.8 Hz, 2J = 9.0 Hz, OCH2), 4.44 (s, 1H, CHO), 4.79 (dd, 1H, 3J = 
4.7 Hz, 3J = 6.2 Hz, CHO), 4.91 – 5.04 (m, 3H, CHO). 1H-NMR (DMSO-d6) δ 13.85 
(+, CH3), 21.99 (-, CH2), 25.45 (-, CH2), 28.55 (-, CH2), 28.60 (-, CH2), 28.90 (-, CH2), 
28.96 (-, CH2), 31.18 (-, CH2), 66.81(-, OCH2), 71.65 (+, CH), 76.95 (+, CH), 80.38 (+, 
CH), 81.28 (+, CH), 106.33 (+, C-1), 171.63 (quat, lactone CO). ES-MS (MeOH + 
NH4OAc) m/z (%): 581 (100) [M-2H+Na]-. C22H40O12S2 (560.68). 
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7.1 Introduction 
 
Ascorbic acid (vitamin C) is a six-carbon lactone which is synthesized from glucose in 
the liver of most mammalian species except primates, guinea pigs, Indian fruit bats 
and some insects. In those exceptions the biosynthesis is not possible due to the 
lack of the enzyme gulonolactone oxidase which is essential for the synthesis of an 
ascorbic acid precursor1, 2. Therefore, humans must ingest ascorbic acid with the diet 
where vitamin C is present usually in quantities of 10-100 mg / 100 g 3. An ascorbic 
acid deficiency is manifested in scurvey which may lead to death if untreated, 
indicating the enormous importance of this vitamin for survival. In economy this fine 
chemical is one of the most important specialty chemical manufactured with 
worldwide consumption of over 50000 tons4. The 3-OH of ascorbic acid is remarkably 
acidic (pKa = 4.2), thus it is completely dissociated at neutral pH. Among the most 
important biological functions of vitamin C are the antioxidant5, free radical 
scavenger6, neuroprotectant and neuromodulator7 properties. The basis of all these 
physiological and biochemical actions is the electron donor capability of ascorbic 
acid. It is implicated in host defense mechanisms8 and probably involved in the 
prevention of various diseases9, thus it may play a role in the prevention and 
treatment of cancer or viral infections10, 11. Eight different enzymes need ascorbic 
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acid as an electron donor in humans1, three of them participate in collagen 
hydroxylation12-14 and two of them are involved in carnitine synthesis15, 16. Until now 
only little information is available about the detailed interactions of vitamin C with 
proteins or enzymes at the molecular level. The first published crystal structure of a 
protein in complex with ascorbic acid was that of D-xylose isomerase (PDB code 
1xid)17. 
Recently, the crystal structure of a bacterial hyaluronidase from Streptococcus 
pneumoniae (SpnHyal) in complex with ascorbic acid, which was described to inhibit 
bovine testicular hyaluronidase18, was elucidated (PDB code 1f9g)2. X-ray analysis 
verified that ascorbic acid binds to the active site and suggested that additional 
interactions with a hydrophobic patch might increase the potency. Therefore, L-
ascorbic acid-6-O-hexadecanoate (vitamin C palmitate, Vcpal) was investigated in 
our workgroup for the inhibition of bacterial hyaluronan lyases, enzymes from S. 
pneumoniae (SpnHyal) and S. agalactiae strain 4755 (SagHyal4755), and bovine 
testicular hyaluronidase (BTH). Furthermore, SpnHyal was crystallized in complex 
with Vcpal and the x-ray structure was determined19.  
 
Figure 7.1. Binding mode of Vcpal (C atoms cyan) in the active site of SpnHyal (PDB code 1w3y). The 
inhibitor was found to bind in a ring opened form. Missing electron density did not permit modeling of 
the last three carbon atoms of the palmitoyl chain; The hyaluronic acid fragment (C atoms brown) is 
taken from the complex PDB code 11oh, for clearity only the tetrasaccharide is shown. 
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Compared to vitamin C, Vcpal is up to 1500 times more potent as an inhibitor of 
bacterial and bovine hyaluronidases. As shown in Figure 7.1, Vcpal binds in the 
same region of the catalytic cleft of SpnHyal as a hexasaccharide substrate20. In 
addition to hydrogen bonds of the carboxylate group of the inhibitor (the ring opened 
form of ascorbic acid was found in the crystal structure) with Tyr408 and Arg462 and 
of the hydroxy groups at C-4 and C-5 with Asn290, extensive interactions with a 
hydrophobic patch (Trp291, Trp292, Phe343) are evident. The hydrophobic face of 
the vitamin C moiety stacks with the indole ring of Trp292, and the palmitoyl group 
interacts with Trp291 and Phe343, but also with His399 and Thr400.  
These results prompted us to synthesize various ascorbic acid derivatives with 
increased lipophilicity and to investigate these compounds for inhibition of the 
bacterial hyaluronate lyase from S. agalactiae strain 4755 (SagHyal4755), the 
hyaluronidase from bovine testis (BTH) and the recombinantly expressed human 
enzymes Hyal-1 and PH-2021, 22. 
 
7.2 Chemistry 
 
 
6-O-Acylation of ascorbic acid was achieved using two different synthetic strategies 
as depicted in Scheme 7.1. 
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Scheme 7.1. Strategies for the 6-O-acylation of ascorbic acid (for details see below). 
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Method A uses standard coupling reagents for the 6-O-acylation of 2,3-di-O-
protected ascorbic acid. This method is compatible with all kind of modification at O-2 
and O-3 and there are no limitations concerning the carboxylic acid used. As a broad 
range of carboxylic acid activating reagents is commercially available, this synthetic 
procedure represents the method with the broadest range of applications. A 
disadvantage of this approach is the longer synthetic pathway because the 
preparation of the 2,3-di-O-protected building block. After the acylation at O-6, the 
removal of the protecting groups (PG) is required. Moreover, although O-6 is more 
reactive than O-5, 5,6-di-O-acylated compounds are obtained as byproducts which 
have to be separated by chromatography. Method B utilizes L-ascorbic acid together 
with methyl esters in presence of lipase from Candida antarctica immobilized on 
acrylic resin (Novozyme 435®) to achieve the 6-O-acylation23, 24. This enzymatic 
transesterification is highly regioselective - the protection of free hydroxyl groups is 
unnecessary – and the required methyl esters are easily accessible. This very short 
synthetic pathway comes to its limitations when the ascorbic acid moiety was 
modified prior to the acylation or when methyl esters other than linear fatty acid 
esters, e. g. branched or aryl substituted alkanoates, are used. Probably such 
compounds are not accepted as substrate by the enzyme. In these cases the 
“classical” pathway according to method A was applied in this work.  
The 6-O-acylated ascorbic acid derivatives 7.2a-f were synthesized from ascorbic 
acid and methyl alkanoates using Novozyme 435® in tert-amyl alcohol at 70 °C under 
reduced pressure23, 24. The required methyl esters 7.1a-f were prepared from the 
pertinent commercially available carboxylic acids using TMSCl in MeOH25 (Scheme 
7.2). 
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Scheme 7.2. Synthesis of 6-O-acylated ascorbic acid derivatives 7.2a-f. Reagents and conditions: (i) 
TMSCl (2.2 eq), MeOH, reflux overnight; (ii) Ascorbic acid (1 eq), RCO2Me (1.5 – 4 eq), Novozyme 
435® (50 mg/mmol), tert-amyl alcohol, 60 °C, 200 mbar, 16-24 h. 
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Etherification was chosen as the method of choice to introduce various residues at 
the end of the linear alkyl chain of carboxylic acids or esters which were then used in 
the aforementioned acylation reactions. In a first attempt ε-caprolactone was 
halogenated followed by esterification to yield methyl 6-bromohexanoate26 (7.3) 
which was then used to alkylate phenols27 or thiols28, 29 (Scheme 7.3). 
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Scheme 7.3. Synthesis of ether and thioether building blocks 7.4-7.9. Reagents and conditions: (i) 
HBr/HOAc, reflux 6 h; (ii) Addition of MeOH, RT overnight; (iii) R = aryl: RSH (1.1 eq), DIEA (1.1 eq), 
THF, RT overnight or  R = alkyl: RSH (1 eq), K2CO3 (2 eq), THF, reflux overnight; (iv) ROH (1.5 eq), 
K2CO3 (3 eq), acetone, reflux overnight. 
 
The building blocks 7.12-7.15 were synthesized via alkylation of the corresponding 
lactone using alkyl halides in presence of potassium hydroxide30 (Scheme 7.4) to 
yield the carboxylic acids 7.10-7.13 which were either transformed to the 
corresponding methyl esters employed in the enzymatic transesterification procedure 
(compounds 7.14 and 7.15) or used as free carboxylic acids (compounds 7.12 and 
7.13) to acylate 2,3-di-O-protected ascorbic acids according to standard coupling 
protocols as described below. 
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Scheme 7.4. Synthesis of the intermediates 7.10-7.15. Reagents and conditions: (i) RHal (2 eq), KOH 
(3 eq), toluene, reflux overnight; (ii) 1 N HCl; (iii) TMSCl (2.2 eq), MeOH, reflux overnight. 
 
The biaryl derivatives 7.17-7.26 were synthesized from 7.16 according to Scheme 
7.5 employing Suzuki cross coupling for the C-C-bond formation31, 32. The necessary 
boronic acids were commercially available or synthesized according to known 
procedures33, 34. Because the enzymatic acylation approach using 7.19, 7.22, 7.27 
and 7.28 did not yield the desired target compounds, these esters had to be 
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transformed into the corresponding carboxylic acids 7.29-7.32 to be used in the 
acylation procedure using standard coupling reagents. The aromatic carboxyl 
residues of 7.25 and 7.26 were protected using TBTA35 to form tert-butyl esters prior 
to the saponification step. 
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Scheme 7.5. Synthesis of biaryl building blocks. Reagents and conditions: (i) p-Bromophenol (1.5 eq), 
K2CO3 (3 eq), acetone, reflux overnight; (ii) RB(OH)2 (1.5 eq), Pd(PPh3)4 (1.5mol %), 2 N Na2CO3 (1-2 
eq), H2O / MeOH / toluene, 80 °C 48 h; (iii) TBTA (2 eq), BF3Et2O (cat), THF, RT overnight; (iv) LiOH 
(1.5 eq), H2O / MeOH / THF, RT overnight; (v) 1 N HCl. 
 
The alkylation of 11-bromoundecanoic acid using phenols in presence of KOH 
yielded building blocks with increased spacer length36. As the purification of the 
carboxylic acids proved to be difficult, the crude carboxylic acids were first esterified 
to obtain the building blocks 7.33 and 7.34, which were easily purified using flash 
chromatography. 7.34a was then obtained by cleavage of the methyl ester (Scheme 
7.6). 
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Scheme 7.6. Synthesis of building blocks 7.33, 7.34 and 7.34a. Reagents and conditions: (i) ROH (1.1 
eq), KOH (2.2 eq), toluene, reflux overnight; (ii) 1 N HCl; (iii) TMSCl (2.2 eq), MeOH, reflux overnight; 
(iii) LiOH (1.5 eq), H2O / MeOH / THF, RT overnight. 
 
With respect to the preparation of vitamin C esters bearing a side chain carboxylic 
group dodecanedioic acid was monoprotected using an equivalent of tBuOH in 
presence of DCC and DMAP according to known procedures to obtain dodecanoic 
acid mono tert-butyl ester37 (7.35). 
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To introduce aromatic residues next to the ascorbic acid moiety, the carboxylic acids 
7.39-7.41 were prepared from the pertinent methyl hydroxybenzoates and 1-
bromodecane according to Scheme 7.7. 
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i ii,iii
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p-O(CH2)9CH3
 
Scheme 7.7. Synthesis of building blocks 7.39-7.41. Reagents and conditions: (i) 1-Bromodecane (1.5 
eq), K2CO3 (3 eq), acetone, reflux overnight; (ii) LiOH (1.5 eq), H2O / MeOH / THF, RT overnight; (iii) 1 
N HCl. 
 
The α-branched alkanoic acids 7.42-7-47 were synthesized according to standard 
malonic ester synthesis38 from diethyl malonate and alkyl halides using NaH as base. 
These carboxylic acids were obtained in racemic form after hydrolysis of the ethyl 
ester and decarboxylation (Scheme 7.8). 
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Scheme 7.8. Synthesis of α-branched carboxylic acids 7.42-7.47. Reagents and conditions: (i) NaH (1 
eq), R1Hal, THF, RT then reflux overnight; (ii) NaH (1 eq), R2Hal, RT then reflux overnight; (iii) KOH 
(10 eq), EtOH / H2O, reflux overnight; (iv) 2 N HCl; (v) 170 – 200 °C, 5 h. 
 
As explained above, the obtained methyl ester building blocks were used for the 
synthesis of 7.48-7.63 applying the enzymatic approach (Scheme 7.9). In several 
cases the enzymatic acylation was not successful. An example is the reaction of 
methyl 6-[4-(naphthalen-1-yl)phenoxy]hexanoate (7.22) or methyl 6-[4-(4-
methoxyphenyl)phenoxy]hexanoate (7.18) with vitamin C in the presence of 
Novozyme 435®. TLC analysis revealed that only traces of the 6-O-acyl ascorbic acid 
were formed whereas the mixture contained mainly starting material and, due to 
enzymatic cleavage of the methyl ester, the corresponding carboxylic acids. In the 
case of methyl 6-[4-(2-methoxyphenyl)phenoxy]hexanoate (7.19) the acylated 
ascorbic acid 7.57 was isolated by preparative HPLC with a yield as low as 4 %. 
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7.48-7.63
i
         R
7.48  (CH2)5SPh    
7.49  (CH2)5SCH2Ph
7.50  (CH2)5OPh 
7.51  (CH2)5O-p-C6H4-C2H5
7.52  (CH2)5O-p-C6H4-Ph
7.53  (CH2)5O-p-C6H4-OCH2Ph
7.54  (CH2)5OCH2Ph
7.55  (CH2)5OCH2-p-C6H4-Ph
7.56  (CH2)5O-p-C6H4-2-thienyl
7.57  (CH2)5O-p-C6H4-(o-OMe-C6H4)
7.58  (CH2)5O-p-C6H4-(p-Me-C6H4)
7.59  (CH2)5O-p-C6H4-(o-Me-C6H4)
7.60  (CH2)5O-p-C6H4-(p-OH-C6H4)
7.61  (CH2)5O-p-C6H4-(m-OH-C6H4)
7.62  (CH2)10OPh 
7.63  (CH2)10O-p-C6H4-Ph  
Scheme 7.9. Synthesis of 6-O-acylated ascorbic acid derivatives 7.48-7.63 using Novozyme 435®. 
Reagents and conditions: (i) RCO2Me (1.5 – 4 eq), Novozyme 435® (50mg/mmol), tert-amyl alcohol, 
60 °C, 200 mbar, 16-24 h. 
 
Due to this shortcoming the 6-O-acylated ascorbic acid derivatives 7.87–7.103 were 
synthesized from the obtained carboxylic acid building blocks using standard 
reagents for the activation and esterification. However, the enediol system of vitamin 
C had to be protected to make the use of standard coupling reagents possible in the 
acylation step. Benzyl ethers were chosen as protecting groups, because they can 
be cleaved easily by mild hydrogenolysis which leaves the sensitive ester bond and 
the lactone ring of the ascorbic acid moiety intact. The double bond of ascorbic acid 
was not affected under these conditions. Additionally the benzyl protecting group is 
orthogonal to the tert-butyl esters which were used for the protection of side chain 
functionalities. Therefore 2,3-di-O-benzyl-L-ascorbic acid (7.66) was synthesized 
according to known procedures39, 40 and acylated followed by removal of the 
protecting groups present (Scheme 7.10). Compound 7.89 was synthesized from 
commercially available 2-hexyldecanoic acid. In some cases the 5,6-di-O-acylated 
byproducts from the acylation reaction (7.77a, 7.78a, 7.80a-7.83a) were isolated and 
deprotected to yield the 5,6-di-O-acylated ascorbic acids 7.96a-7.100a and 7.103a. 
The substitution pattern for Scheme 7.10 is given in Table 7.1. 
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7.64 7.65
7.66
O
HO
OH
OR2
OR1
O
7.67   R1=CO(CH2)10CO2tBu, R2=H
7.79   R1=CO(CH2)5O-p-C6H4-(p-CO2tBu-C6H4), R2=H
7.80   R1=CO(CH2)5O-p-C6H4-(m-CO2tBu-C6H4), R2=H
7.80a R1=R2=CO(CH2)5O-p-C6H4-(m-CO2tBu-C6H4)
7.84   R1=CO(CH2)10CO2H
7.85   R1=CO(CH2)5O-p-C6H4-(p-CO2H-C6H4), R2=H
7.86   R1=CO(CH2)5O-p-C6H4-(m-CO2H-C6H4), R2=H
7.86a R1=R2=CO(CH2)5O-p-C6H4-(m-CO2H-C6H4)
7.87-7.103, 7.96a-7.100a
7.103a
i ii iii
iv vi
v
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BnO
OBn
OR2
OR1
O
7.67-7.86, 7.77a, 7.78a
7.80a-7.86a
 
Scheme 7.10. Synthesis of 6-O-acylated ascorbic acid derivatives 7.87-7.103, 7.96a-7.100a and 
7.103a. Reagents and conditions: (i) abs. acetone, AcCl (cat); (ii) K2CO3 (1.1 eq), BnBr (2.2 eq), DMF, 
40-60 °C; (iii) 50 % HOAc, MeOH, 80 °C; (iv) RCO2H (1 eq), EDAC (1.1 eq) DMAP (1.2 eq), DMF, RT 
overnight; (v) TFA / CH2Cl2, RT 6h; (vi) 10 % Pd/C (cat.), H2, 4 bar, EtOH / EtOAc. 
 
Table 7.1. Substitution patterns for Scheme 7.10. 
No R1 R2 
7.67 CO(CH2)10CO2tBu H 
7.68, 7.87 CO-o-C6H4O(CH2)9CH3 H 
7.69, 7.88 CO-m-C6H4O(CH2)9CH3 H 
7.70, 7.89 COCH((CH2)5CH3)(CH2)7CH3 H 
7.71, 7.90 COCH((CH2)2CH3)(CH2)9CH3 H 
7.72, 7.91 COCH((CH2)5CH3)(CH2)9CH3 H 
7.73, 7.92 COCH((CH2)9CH3)(CH2)9CH3 H 
7.74, 7.93 COCH((CH2)2Ph)(CH2)9CH3 H 
7.75, 7.94 COCH(CH2-p-MeO-C6H4)(CH2)9CH3 H 
7.76, 7.95 COCH((CH2)5CH3)(CH2)15CH3 H 
7.77, 7.96 CO(CH2)5O-p-C6H4-(p-OMe-C6H4) H 
7.77a, 7.96a CO(CH2)5O-p-C6H4-(p-OMe-C6H4) =R1 
7.78, 7.97 CO(CH2)5O-p-C6H4-(1-naphthyl) H 
7.78a, 7.97a CO(CH2)5O-p-C6H4-(1-naphthyl) =R1 
7.79 CO(CH2)5O-p-C6H4-(p-CO2tBu-C6H4) H 
7.80 CO(CH2)5O-p-C6H4-(m-CO2tBu-C6H4) H 
7.80a CO(CH2)5O-p-C6H4-(m-CO2tBu-C6H4) =R1 
7.81, 7.98 CO(CH2)4O(CH2)6CH3 H 
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Table 7.1 (continued) 
7.81a, 7.98a CO(CH2)4O(CH2)6CH3 =R1 
7.82, 7.99 CO(CH2)5O(CH2)5CH3 H 
7.82a, 7.99a CO(CH2)5O(CH2)5CH3 =R1 
7.83, 7.100 CO-p-C6H4O(CH2)9CH3 H 
7.83a, 7.100a CO-p-C6H4O(CH2)9CH3 =R1 
7.84, 7.101 CO(CH2)10CO2H H 
7.85, 7.102 CO(CH2)5O-p-C6H4-(p-CO2H-C6H4) H 
7.86, 7.103 CO(CH2)5O-p-C6H4-(m-CO2H-C6H4) H 
7.86a, 7.103a CO(CH2)5O-p-C6H4-(m-CO2H-C6H4) =R1 
 
Compound 7.106 was synthesized via stepwise acylation of 7.66 and removal of the 
benzyl groups as shown in Scheme 7.11. 
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(CH2)10CH3
O
O
O
OH
i ii
ii
7.104
7.105 7.106  
Scheme 7.11. Synthesis of 7.106. Reagents and conditions: (i) Lauric acid (1 eq), EDAC (1.1 eq), 
DMAP (1.2 eq), DMF, RT overnight; (ii) Monobenzyl malonate (6.33) (1 eq), EDAC (1.1 eq) DMAP (1.2 
eq), DMF, RT overnight; (ii) 10 % Pd/C (cat.), H2, 4 bar, EtOH / EtOAc. 
 
The “bivalent compounds” 7.110-7.112 were accessible from the reaction of the 
pertinent dicarboxylic acids with two equivalents of 7.66 and subsequent deprotection 
according to Scheme 7.12. 
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Scheme 7.12. Synthesis of “bivalent” derivatives 7.110-7.112. Reagents and conditions: (i) 
HO2C(CH2)nCO2H (0.5 eq), EDAC (1.1 eq) DMAP (1.2 eq), DMF, RT overnight; (ii) 10 % Pd/C (cat.), 
H2, 4 bar, EtOH / EtOAc. 
 
With respect to the variation of chain length and the functional groups of the spacer 
in “bivalent enzyme inhibitors”, 11-aminoundecanoic acid was N-boc-protected41 and 
treated with 7.66 to give the ester 7.114 which was N-deprotected and coupled with 
the carboxyalkanoyl-L-ascorbic acid 7.84. Subsequent hydrogenolysis yielded the 
bivalent compound 7.117 (Scheme 7.13). 
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Scheme 7.13. Synthesis of 7.117. Reagents and conditions: (i) Boc2O (1.1 eq), NaOH (2.2 eq) THF / 
MeOH, RT overnight; (ii) 7.66 (1 eq), EDAC (1.1 eq) DMAP (1.2 eq), DMF, RT overnight; (iii) TFA / 
CH2Cl2, RT, 6h (iv) 7.84 (1 eq), EDAC (1.1 eq) DMAP (1.2 eq), DMF, RT overnight; (v) 10 % Pd/C 
(cat.), H2, 4 bar, EtOH / EtOAc. 
 
Ascorbic acid 6-palmitate was 2-O-acylated42-44 with equimolar amounts of cyclic 
anhydrides, which were accessible according to described procedures45, or acid 
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chlorides to yield 7.118-7.121 without using any protecting groups; 7.121a was 
isolated as a byproduct in the monoacylation reaction (Scheme 7.14). 
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C15H33
O
O
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O
O
C15H33
O
i
7.118-7.121, 7.121a
              R1
7.118     CO(CH2)2Ph
7.119     CO(CH2)2CO2H
7.120     CO(CH2)3CO2H
7.121     CO(CH2)4CO2H
7.121a   CO(CH2)4CO2H
R2
H
H
H
H
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Scheme 7.14. Synthesis of 2-O- and 2,3-di-O-acylated ascorbic acid 6-palmitates 7.117-7.120 and 
7.120a. Reagents and conditions: (i) Cyclic anhydride (1 eq), DMAP (cat.), CH2Cl2 / THF, RT 
overnight, or RCOCl (1 eq), DMAP (cat.), NEt3 (1 eq), CH2Cl2 / THF, RT, overnight. 
 
For the 6-O-alkylation of ascorbic acid a modified procedure described by Sanders 
and Dallacker40, 46, 47 was chosen (Scheme 7.15). First 7.66 was selectively 6-O-
tosylated followed by a Finkelstein-like exchange with bromine. Finally 7.123 was 
transformed into the corresponding epoxide which can be opened to form the desired 
6-alkylethers. Neither attempts to substitute the tosylate 7.122 or the bromo-
derivative 7.123 with alcohols in the presence of a base nor ring-opening of the 
epoxide with alcohols under basic conditions were successful. Therefore, alkylation 
of 7.124 was performed under acidic conditions to obtain 7.125 and 7.126 which 
yielded 7.127 and 7.128 after hydrogenolysis. 
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7.122 7.123
7.124 7.125, 7.126 7.127, 7.128
7.66
                     R
7.125, 7.127 (CH2)11CH3
7.126, 7.128 (CH2)17CH3  
Scheme 7.15. Synthesis of 6-O-alkylascorbic acids 7.127 and 7.128. Reagents and conditions: (i) 
TsCl, pyridine, 0 °C – RT overnight; (ii) NaBr, acetone, 120 °C overnight; (iii) KOH, NBu4I (cat.), 
CH2Cl2 / H2O; (iv) ROH, BF3Et2O (cat.), THF, RT overnight; (v) 10 % Pd/C (cat.), H2, 4 bar, EtOH / 
EtOAc, RT overnight. 
 
The synthetic pathway to 2-O-/3-O-alkylascorbic acids is depicted in Scheme 7.16 
(see Table 7.2 for the definition of the residues). Two equivalents of benzyl 
bromoacetate were used to alkylate 7.64 in the presence of K2CO3. Cleavage of the 
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acetal, acylation of O-6 and cleavage of the benzyl esters gave compound 7.132. 
Selective 3-O-alkylation was possible when 7.64 was treated with one equivalent of 
alkyl halide39. Subsequent alkylation of O-248 yielded the precursors 7.135-7.138 
which were then deprotected39 to obtain the 2-O-alkyl ascorbates 7.139 and 7.140. 
Alternatively, only the acetal was cleaved to enable the acylation in position O-6 of 
the vitamin C moiety. After acylation of 7.141 or 7.142 the benzyl groups were 
removed to obtain 7.146-7.148. 
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Scheme 7.16. Synthesis of 2-O-/3-O-alkylated ascorbic acid derivatives 7.132, 7.135, 7.136 and 
7.146-7.148. Reagents and conditions: (i) K2CO3 (1.1 eq), R1Br (2.2 eq), DMF, 40-60 °C; (ii) 2 N HCl, 
MeOH / THF, RT, 6h; (iii) R2CO2H (1 eq), EDAC (1.1 eq) DMAP (1.2 eq), DMF, RT overnight; (iv) 10 
% Pd/C (cat.), H2, 4 bar, EtOH / EtOAc; (v) K2CO3 (1 eq), R1Hal (1 eq), THF / DMF, RT, 4h; (vi) K2CO3 
(1.1 eq), R2Hal (1.1 eq), THF / DMSO, RT, 4h; (vii) 2 N HCl, MeOH / THF, RT, 6h; (viii) 10 % Pd/C 
(cat.), H2, 4 bar, EtOH / EtOAc; (ix) 2 N HCl, MeOH / THF, RT, 6h; (x) R3CO2H (1 eq), EDAC (1.1 eq) 
DMAP (1.2 eq), DMF, RT overnight; (xi) 10 % Pd/C (cat.), H2, 4 bar, EtOH / EtOAc. 
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Table 7.2. Substitution pattern for Scheme 7.16. 
 
No R1 R2 R3 
7.129, 7.130 CH2CO2Bn - - 
7.131 CH2CO2Bn - (CH2)10CH3 
7.132 CH2CO2H - (CH2)10CH3 
7.133 Bn - - 
7.134 CH2CO2Bn - - 
7.135 Bn (CH2)11CH3 - 
7.136 Bn (CH2)15CH3 - 
7.137, 7.141 Bn CH2CO2Bn - 
7.138, 7.142 CH2CO2Bn Bn - 
7.139 H (CH2)11CH3 - 
7.140 H (CH2)15CH3 - 
7.143 Bn CH2CO2Bn (CH2)10CH3 
7.144 Bn CH2CO2Bn (CH2)10O-p-C6H4-Ph 
7.145 CH2CO2Bn Bn (CH2)10CH3 
7.146 H CH2CO2H (CH2)10CH3 
7.147 H CH2CO2H (CH2)10O-p-C6H4-Ph 
7.148 CH2CO2H H (CH2)10CH3 
 
Selective 3-O-alkylation of unprotected ascorbic acid was performed under 
Mitsunobu conditions according to a known procedure49 to obtain 7.149 and 7.150 in 
one step (Scheme 7.17). 
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7.150 (CH2)13CH3
 
Scheme 7.17. Synthesis of 7.149 and 7.150 under Mitsunobu conditions. Reagents and conditions: (i) 
PPh3 (1.14 eq), DIAD (1.12 eq), ROH (1.25 eq), THF / DMF, -78 °C – RT overnight. 
 
Using ascorbic acid 6-palmitate and acrolein as Michael donor and acceptor, 
respectively, resulted in the spirane 7.151 or the bicycyclic compound 7.152 
depending on which solvent was used as described by Witt et al.50 (Scheme 7.18). 
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Scheme 7.18. Synthesis of 7.151 and 7.152. Reagents and conditions: (i) Acrolein (1.2 eq), tBuOH, 70 
°C, 48 h. (ii) (1.2 eq), MeOH, 70 °C, 48 h. 
 
The oxidized compound 7.153 was synthesized from ascorbic acid 6-palmitate as 
described by Okolotowicz et al.51(Scheme 7.19). 
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Scheme 7.19. Oxidation of ascorbic acid 6-palmitate. Reagents and conditions: (i) I2 (1 eq), EtOH, RT, 
30 min. 
 
7.3 Inhibition of hyaluronidases: results and discussion  
 
All synthesized L-ascorbic acid derivatives were investigated for inhibition of 
recombinant human hyaluronidases PH-20 and Hyal-1, the bovine testicular enzyme 
BTH (Neopermease®) and the bacterial hyaluronan lyase SagHyal4755 in a modified 
turbidimetric assay based on the method of Di Ferrante52 as described in chapter 
3.4.3. 
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7.3.1 6-O-Acylated ascorbic acid derivatives 
 
The IC50-values determined for the 6-O-acylated L-ascorbic acid derivatives are 
summarized in Table 7.3.   
Table 7.3. Inhibitory activity of 6-O-acylated ascorbic acid derivatives. 
O
HO
OH
OH
O
O
R
O
 
Hyal-1 PH-20 BTH SagHyal4755 Compd. R1 IC50 [µM]a 
Vitamin C H > 60000 7564 ± 
883 
> 100b 6100 ± 
100b 
Vcpal (CH2)14CH3 > 50 5.0 ± 0.2 57 ± 1b 4.2 ± 0.1b 
7.2a (CH2)6CH3 > 1000 232 ± 46 >2000 772 ± 19 
7.2b (CH2)8CH3 378 ± 12 131 ± 26 1380 ± 49 102 ± 5 
7.2c (CH2)9CH3 143 ± 4 33 ± 2 580 ± 21 72 ± 2 
7.2d (CH2)10CH3 76 ± 3 25 ± 2 208 ± 4 47 ± 2 
7.2e (CH2)11CH3 50 ± 4 14 ± 2 96 ± 5 14 ± 1 
7.2f (CH2)12CH3 > 70 5.8 ± 0.3 71 ± 1 8.4 ± 0.2 
7.2g CH2-p-C6H4-Ph 753 ± 89 156 ± 10 2006 ± 40 358 ± 15 
7.48 (CH2)5SPh 890 ± 42 98 ± 7 > 1500 607 ± 58 
7.49 (CH2)5SCH2Ph 900 ± 100 189 ± 30 > 1000 461 ± 19 
7.50 (CH2)5OPh > 1000 370 ± 53 > 1500 759 ± 45 
7.51 (CH2)5O-p-C6H4-C2H5 895 ± 29 184 ± 38 > 1200 280 ± 9 
7.52 (CH2)5O-p-C6H4-Ph 90 ± 6 20 ± 1 188 ± 3 61 ± 1 
7.53 (CH2)5O-p-C6H4-OCH2Ph > 200 33 ± 1 210 ± 3 76 ± 1 
7.54 (CH2)5OCH2Ph > 800 229 ± 53 > 1000 437 ± 77 
7.55 (CH2)5OCH2-p-C6H4-Ph 124 ± 5 40 ± 2 543 ± 15 102 ± 2 
7.56 (CH2)5O-p-C6H4-2-thienyl ≥ 80 28 ± 1 146 ± 3 54 ± 2 
7.57 (CH2)5O-p-C6H4-(o-OMe-C6H4) 122 ± 16 42 ± 4 > 300 58 ± 6 
7.58 (CH2)5O-p-C6H4-(p-Me-C6H4) > 200 13 ± 1 87 ± 4 24 ± 1 
7.59 (CH2)5O-p-C6H4-(o-Me-C6H4) 63 ± 5 31 ± 2 232 ± 2 67 ± 2 
7.60 (CH2)5O-p-C6H4-(p-OH-C6H4) > 300 53 ± 3 152 ± 1 66 ± 1 
7.61 (CH2)5O-p-C6H4-(m-OH-C6H4) > 300 60 ± 9 > 300 125 ± 3 
7.62 (CH2)10OPh > 200 12 ± 1 105 ± 1 31 ± 1 
7.63 (CH2)10O-p-C6H4-Ph > 150 1.3 ± 0.4 37 ± 1 7.5 ± 0.2 
7.87 o-C6H4O(CH2)9CH3 40 ± 2 6.8 ± 1.1 158 ± 5 21 ± 1 
7.88 m-C6H4O(CH2)9CH3 65 ± 4 6.1 ± 0.5 86 ± 1 5.4 ± 0.2 
7.89 CH((CH2)5CH3)(CH2)7CH3 23 ± 2 5.1 ± 0.5 104 ± 2 9.3 ± 0.7 
7.90 CH((CH2)2CH3)(CH2)9CH3 24 ± 3 8.2 ± 1.3 139 ± 8 13 ± 1 
7.91 CH((CH2)5CH3)(CH2)9CH3 21 ± 1 5.5 ± 0.7 135 ± 6 2.7 ± 0.1 
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Table 7.3 (continued) 
7.92 CH((CH2)9CH3)(CH2)9CH3 28 ± 1 5.0 ± 0.3 135 ± 4 6.4 ± 0.2 
7.93 CH((CH2)2Ph)(CH2)9CH3 24 ± 1 6.9 ± 1.3 197 ± 12 6.8 ± 0.2 
7.94 CH(CH2-p-MeO-C6H4)(CH2)9CH3 22 ± 2 7.8 ± 0.4 176 ± 6 5.3 ± 0.3 
7.95 CH((CH2)5CH3)(CH2)15CH3 17 ± 1 5.5 ± 0.4 99 ± 2 2.2 ± 0.2 
7.96 (CH2)5O-p-C6H4-(p-OMe-C6H4) > 200 11 ± 1 69 ± 1 37 ± 1 
7.97 (CH2)5O-p-C6H4-(1-naphthyl) 17 ± 1 8.9 ± 0.4 316 ± 25 11 ± 1 
7.98 (CH2)4O(CH2)6CH3 390 ± 30 93 ± 9 > 500 257 ± 9 
7.99 (CH2)5O(CH2)5CH3 449 ± 32 74 ± 9 > 500 221 ± 20 
7.100 p-C6H4O(CH2)9CH3 69 ± 2 7.4 ± 1.0 64 ± 2 8.3 ± 0.3 
7.101 (CH2)10CO2H > 400 32 ± 3 > 700 124 ± 6 
7.102 (CH2)5O-p-C6H4-(p-CO2H-C6H4) > 400 18 ± 2 129 ± 4 60 ± 2 
7.103 (CH2)5O-p-C6H4-(m-CO2H-C6H4) > 400 39 ± 2 > 400 94 ± 8 
a inhibition of enzyme expressed as IC50 (µM), mean ± SEM (N = 2, experiments performed in 
duplicate), maximal concentrations of the test compounds were selected with respect to individual 
terminal solubilities in the incubation mixture; IC50 values determined at pH 5.0 (PH-20, BTH, 
SagHyal4755) or 3.5 (Hyal-1) in the turbidimetric assay; bas previously shown53.  
 
In general, lower IC50 values were obtained for human PH-20 and the bacterial 
enzyme compared to Hyal-1 and BTH. When the compounds 7.2a-7.2f are compared 
with ascorbic acid and ascorbic acid 6-palmitate it is obvious that the inhibition of 
human PH-20, the corresponding bovine enzyme and SagHyal4755 increases with the 
length of the aliphatic chain. Vitamin C itself is only a very weak inhibitor of 
SagHyal4755 and human PH-20 with IC50 values of 6.1 mM and 7.6 mM, respectively, 
and does not inhibit Hyal-1 and BTH in the investigated concentration range. By 
contrast, the potency of the synthesized derivatives increased by several orders of 
magnitude, for instance IC50 values of 5.0 µM, 58 µM and 4.2 µM on human PH-20, 
BTH and SagHyal4755, respectively, were determined for Vcpal. The situation is 
different for the inhibition of Hyal-1 by the alkyl derivatives of vitamic C: ascorbic acid 
lacking a hydrophobic alkyl chain did not inhibit this human enzyme and inhibition 
first increased with the length of the attached alkyl chain, but in this case a maximum 
in potency was found for L-ascorbic acid tridecanoate (7.2e) with an IC50 of 50 µM. 
Further lengthening of the chain (compounds 7.2f and Vcpal) resulted in a significant 
decrease in inhibitory activity. Whereas 7.2f caused 50 % inhibition (determined at a 
concentration of 100 µM, corresponding to terminal solubility), no significant inhibition 
was detectable for Vcpal. Therefore, Vcpal is the compound with the highest 
selectivity for human PH-20, BTH and the bacterial enzyme versus human Hyal-1 in 
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this series of ascorbic acid derivatives. The concentration dependent enzymatic 
activity of Hyal-1 in presence of 7.2b-7.2f is depicted in Figure 7.2.  
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Figure 7.2. Enzymatic activity of Hyal-1 in the presence of 7.2b-7.2f. 
 
The prolongation of the alkyl chain selectively affects the inhibitory potencies on the 
investigated enzymes (see Figure 7.3). In this figure the average shifts of the pIC50 
values per C-atom are presented. These quantities are related to the free energy of 
interaction and calculated by the expression  
(pIC50(n+z) – pIC50(n)) / z 
where pIC50(n) applies to the ascorbic acid derivative esterified with a carboxylic acid 
having n C-atoms (reference), and pIC50(n+z) to the adjacent derivative bearing z more 
carbon atoms. Thus, the term pIC50(n)-pIC50(n+z) is the difference between the two 
pIC50 values of neighboring compounds in Table 7.3. The highest gain in inhibitory 
potency on Hyal-1 is observed around derivative 7.2d referring to ascorbic acid 6-
dodecanoate. Further extension of the chain beyond 13 carbon atoms results in a 
decrease in potency. The other enzymes behave differently: increasing the chain 
length leads to increased potency of the inhibitor. Regarding human PH-20, highest 
increase in potency is observed for the derivatives 7.2c and 7.2f bearing 11- and 14-
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membered alkyl chains. The results suggest that the terminal carbon atoms in both 
compounds are important for the inhibition of PH-20, i. e. there appear to be 
especially favored interactions between those two positions of the alkyl chain and 
amino acids of the enzyme. By contrast, the inhibition of BTH, the bovine homolog of 
human PH-20, constantly rises between ascorbic acid 6-undecanoate (7.2c) and –
tridecanoate (7.2e). The biggest gain in inhibitory potency on the bacterial enzyme is 
found for compound 7.2e.  
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Figure 7.3. Plot of the increase / decrease in inhibition of hyaluronidases versus number of carbon 
atoms used to increase hydrophobicity of the 6-O-acylated ascorbic acid derivatives. 
 
The solubility of the ascorbic acid derivatives under the assay conditions is strongly 
impaired depending on the hydrophobic character of the substituents. As lengthening 
of the alkyl chain beyond 14 carbon atoms resulted only in a weak increase in the 
inhibition of PH-20, BTH and SagHyal4755 and virtual inactivity on Hyal-1, additional 
substances bearing hydrophobic residues with 12-13-membered carbon chain were 
synthesized. This compromise should yield more potent compounds which are 
sufficiently soluble in aqueous medium to enable the determination of IC50 values at 
reasonable inhibitor concentrations. 
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The potencies of derivative 7.2g bearing a biphenyl residue are similar as those of 
the linear alkyl chain derivative 7.2a indicating that the more rigid aromatic residue is 
also tolerated by the enzymes. Encouraged by these results additional derivatives 
with aromatic residues in a certain distance to the ascorbic acid moiety were 
synthesized. The synthetic approach using a (thio-)ether linkage to introduce 
aromatic residues made such compounds easily accessible. Moreover, the ether 
group is capable of forming H-bonds in the active site by analogy with the substrate 
hyaluronan. Compared to the ether derivatives 7.50 and 7.54 the corresponding 
thioethers 7.48 and 7.49 are more potent on Hyal-1 and PH-20, suggesting that the 
6-O-acyl residue covers a highly hydrophobic area of the mammalian enzymes 
similar to the orientation of palmitoyl residue found in the crystal structure of the 
hyaluronidase from S. pneumoniae in complex with ascorbic acid 6-palmitate19. Para-
substitution of the terminal phenyl residue in 7.50 with ethyl or phenyl residues (7.51, 
7.52) leads to significant increases in potency. In the case of the biphenyl derivative 
7.52, the IC50 values on all the investigated hyaluronidases are one order of 
magnitude lower than for the unsubstituted derivative 7.50. Whereas compounds 
7.52 and 7.53 are nearly equipotent inhibitors of PH-20, BTH and SagHyal4755, 
inhibition of Hyal-1 is lost when the terminal phenyl residue of 7.52 is replaced by a 
benzyloxy moiety. When an additional methylene group is introduced between the 
biphenyl moiety and the ether oxygen (7.55), the potency on all enzymes is 
approximately halved.  
The potency profile of 7.52 is most similar to that of the ascorbic acid 6-tridecanoate 
derivative 7.2d. As suitable replacement of flexible alkyl chains, the semirigid 
biphenyl moiety of 7.52 was modified to further investigate the role of this moiety 
(compounds 7.56-7.61, 7.96, 7.97, 7.102 and 7.103 in Table 7.3). The bioisosteric 
replacement of the phenyl with a thiophenyl residue (7.52 vs. 7.56) resulted in nearly 
equipotent activity of the compounds on all four hyaluronidases. Due to the poor 
solubility of 7.56 no IC50 value was calculated for Hyal-1, however, a 50 % inhibition 
at a concentration of 80 µM was determined which is comparable to the IC50 of 90 
µM determined for 7.52. Biphenyl derivatives bearing relatively small para-
substituents did not inhibit human Hyal-1 in the investigated concentration ranges 
regardless of the chemical nature of the substituent: compared to the unsubstituted 
reference compound 7.52 neither rather hydrophobic residues like methyl (7.58) or 
methoxy (7.96) nor polar groups like hydroxy (7.60) or carboxy (7.102) were 
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tolerated. Polar meta-substitution as in the case of 7.61 and 7.103 also led to 
inactivity. By contrast, ortho-substitution of the terminal phenyl residue (7.57 and 
7.59) was tolerated. An additional ortho-methyl residue (7.59) even led to an increase 
in potency. These findings suggest that the biphenyl moiety of derivative 7.52 fits well 
to a hydrophobic pocket of Hyal-1. However, this pocket is not yet fully exploited 
since compound 7.97 bearing an additional 1-naphthyl moiety, additionally aligning 
with the ortho- and meta position of the terminal phenyl group of 7.52, proved to be 
the most potent inhibitor of Hyal-1 among the biaryl-series.    
In contrast to the results for Hyal-1, para-methyl and –methoxy substitution (7.58, 
7.96) increased the inhibition of PH-20, BTH and the bacterial enzyme. In the case of 
the bulky 1-naphthyl residue of 7.97, the inhibition of PH-20 and the bacterial enzyme 
rose by at least a factor of two compared to the biphenyl derivative 7.52, whereas the 
inhibitory activity at BTH decreased. When polar para-hydroxy or -carboxy residues 
were introduced (7.60 and 7.102), the potency of the compounds at the bovine 
enzyme increased slightly. The human homolog behaves somewhat differently: 
whereas 7.60 is a less potent inhibitor of PH-20 than the unsubstituted derivative, the 
inhibition of this enzyme is unchanged when the para-carboxy substituted derivative 
7.102 is compared to 7.52. Para-hydroxy or -carboxy substitution also does not lead 
to remarkable changes in inhibition of BTH and the bacterial hyaluronate lyase. 
Nevertheless, these derivatives are superior to the compounds with hydrophobic 
substituents due to their increased water solubility. Ortho or meta substitution of the 
terminal phenyl ring of 7.52 leads to a certain decrease in inhibition of human and 
bovine PH-20, whereas the inhibition of SagHyal4755 remains unaffected in the case 
of ortho substituents. A significant decrease in potency regarding the latter enzyme is 
observed for the derivatives bearing meta-hydroxy (7.61) or -carboxy substituents 
(7.103). The results obtained for the biaryl series indicate characteristic, but not very 
distinctive differences in the SAR of the investigated hyaluronidases. Relatively small 
modifications of the biaryl moiety caused moderate changes in potency and 
selectivity of the compounds, suggesting slightly different binding modes and/or 
differences in the binding pockets of the enzymes. Figure 7.4 illustrates the different 
SAR of synthesized biaryl derivatives upon inhibition of the investigated 
hyaluronidases. 
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Figure 7.4. Inhibitory activity of investigated biaryl derivatives. Compounds marked with * did not show 
inhibitory activity on the investigated enzyme (arbitrary short bars for illustrative reasons). The bar for 
7.56 Hyal-1 is based on the determined 50 % inhibition of Hyal-1 at a concentration of 80 µM. An IC50 
value could not be determined due to the limited solubility of the compound. 
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The elongation of the spacer between the aromatic residue and the ascorbic acid 
core (compare 7.52 with 7.63) leads to complete loss of the inhibitory activity towards 
Hyal-1 but to enhanced inhibition of the other three enzymes also in the case of 7.50 
vs. 7.62 (see Figure 7.5: concentration-dependent activity of the hyaluronidases in 
the presence of 7.52 and 7.63). Again, the increase in potency correlates with the 
hydrophobicity. The biphenyl derivative 7.63 is about three to nine times more potent 
than the corresponding phenyl derivative 7.62. L-ascorbic acid 11-(p-
biphenylyloxy)undecanoate (7.63) represents the most potent inhibitor of human PH-
20 in this series of ascorbic acid derivatives with an IC50 value of 1.3 µM. Moreover, 
compound 7.63 is the most selective inhibitor of PH-20 versus Hyal-1.  
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Figure 7.5. Concentration dependent activity of Hyal-1, PH-20, BTH and SagHyal4755 in the presence 
of 7.52 and 7.63. 
 
The ω-carboxy substituted derivative 7.101 shows no inhibition of human Hyal-1, 
although the maximum chain length (see above) is not exceeded. Obviously, a 
terminal polar group (carboxy as well as p- and m-OH in 7.60 and 7.61, respectively) 
is not tolerated. This finding suggests that the region of the protein surrounding the 
end of the aliphatic chain of the inhibitor is of strongly hydrophobic nature. By 
contrast, the inhibition of the human PH-20 is not affected by the additional carboxy 
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group in 7.101 compared to the corresponding alkanoyl derivative 7.2c, and the 
activities on BTH and SagHyal4755 are only slightly decreased. Interestingly, when an 
oxygen atom is introduced in the center of the aliphatic chain (7.98 and 7.99), the 
inhibition of all four hyaluronidases decreases by at least a factor of five compared to 
the corresponding compound lacking the additional ether bridge (7.2e), again 
indicating that a continuous hydrophobic chain is essential for high affinity to the 
hyaluronidases. Additionally, higher desolvation enthalpy of the ether chain may play 
a role. Finally, the central oxygen atom may cause a different binding mode. The 
significant role of the hydrophobicity is supported by the finding that an aliphatic ether 
group seems to be more inappropriate than an aromatic one (the oxygen 
contributions to log P differ by ca. 1.2 log P units in favor of the latter).  
The introduction of a phenyl moiety next to the ester group (7.87, 7.88 and 7.100) did 
not significantly affect the potency of the hyaluronidase inhibitors. Comparing the IC50 
values for the human enzymes no clear dependence on the substitution pattern of 
those three compounds was obvious. This is in contrast to the bovine and the 
bacterial hyaluronidase: the phenyl residue is also tolerated by both enzymes, but the 
inhibitory potency is significantly decreased when the position of the alkyl substituent 
at the aromatic ring is changed from para or meta to ortho.  
Additional branching as in compounds 7.89-7.94 results in a considerable increase in 
inhibitory potency compared to the corresponding unbranched analogs 7.2b and 
7.2d. However, only marginal activity differences between the branched derivatives 
were detected. Presumably, there are only weak interactions of the additional 
sidechain with the enzymes. SAR considerations are restricted as the branched 
derivatives were synthesized and investigated as diastereomers. But the separation 
of the stereoisomers was considered dispensable because the branched compounds 
are similarly hydrophobic as the unbranched derivatives (compare 7.89 and Vcpal 
which both have the same number of carbon atoms, i. e. in both compounds the 
hydrophobicity of the parent compound ascorbic acid was increased by adding 16 
carbon atoms). In this series of chain-branched 6-O-acylated ascorbic acid 
derivatives the IC50 value of compound 7.95 on Hyal-1 is in contrast to the results for 
the unbranched compounds: As discussed above, inhibition significantly decreased 
when compounds with hydrophobic residues longer than a thirteen-membered chain 
were investigated. In contrast, the potency of 7.95 bearing a C-18 chain is slightly 
increased. Due to the highly flexible alkyl chains these compounds may easily 
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occupy different hydrophobic regions of the protein. Therefore, the binding mode is 
probably different from that of the other investigated compounds. 
 
7.3.2 “Bivalent” ascorbic acid derivatives 
 
Recently, the crystal structure of the hyaluronate lyase from S. pneumoniae in 
complex with ascorbic acid palmitate was elucidated (PDB code 1w3y)19. 
Interestingly, two cryoprotectant xylitol molecules were bound to SpnHyal nearby the 
inhibitor (Figure 7.6). This position of the bound xylitol molecules suggests that the 
affinity of the inhibitor might be enhanced by adding matching groups at the end of 
the hydrophobic chain19. 
 
Figure 7.6. Crystal structure of SpnHyal (PDB code 1w3y) in complex with ascorbic acid 6-palmitate 
(cyan). The protein surface is represented by a Connolly surface coloured by lipophilicity (the warmer 
the colour, the more lipophilic the amino acids). The two cryoprotectant xylitol molecules (yellow) were 
found to be bound to the enzyme nearby the end of the palmitoyl moiety. 
 
Due to this suggestion, the “bivalent” ascorbic acid derivatives 7.110-7.112 and 7.117 
were synthesized. Characteristic of these compounds is the connection of two 
terminal polar ascorbic acid moieties by an alkyl spacer, thus, possibly mimicking the 
alternate occurrence of more polar acidic regions and hydrophobic faces of 
hyaluronan. The IC50 values determined for the investigated hyaluronidases are 
summarized in Table 7.4.  
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Table 7.4. Inhibitory activity of bivalent compounds 7.110-7.112 and 7.117. 
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Hyal-1 PH-20 BTH SagHyal4755 Compound n IC50 [µM]a 
7.110 10 107 ± 7 7.7 ± 0.3 > 300 22 ± 2 
7.111 12 101 ± 9 14 ± 3 129 ± 2 22 ± 1 
7.112 14 > 150 5.0 ± 0.3 32 ± 1 7.4 ± 0.2 
7.117 10 > 40 15 ± 1 > 80 55 ± 2 
a Inhibition of enzyme expressed as IC50 (µM), mean values ± SEM (N = 2, experiments performed in 
duplicate), maximal concentrations of the test compounds were selected with respect to individual 
terminal solubilities in the incubation mixture; IC50 values determined at pH 5.0 (PH-20, BTH, 
SagHyal4755) or 3.5 (Hyal-1) in the turbidimetric assay.  
 
The derivatives 7.110 and 7.111 bearing the shorter spacers possess inhibitory 
activity towards Hyal-1 within the investigated concentration ranges, but inhibition 
does not change significantly when the length of the alkyl spacer is varied from 10 to 
12 methylene groups. The potency decreased with a further elongation of the spacer 
(7.112). Compound 7.117 with a spacer consisting of two decamethylene chains 
connected by an amide bond proved to be inactive on Hyal-1. Human PH-20 was 
inhibited by all four bivalent compounds. Maximum inhibition was achieved with the 
derivatives 7.110 and 7.112. Compound 7.111, bearing a twelve-membered spacer, 
was less potent than the corresponding lower and higher homolog. Interestingly 
compound 7.117 is also an inhibitor of human PH-20 but inactive towards the bovine 
homolog BTH. Highest inhibition of BTH was found for 7.112 with an IC50 of 32 µM. A 
significant loss of inhibitory activity is observed with shorter spacers. Figure 7.7 
illustrates the variations in potency of bivalent ligands investigated for inhibition of 
Hyal-1, PH-20, BTH and SagHyal4755. Generally, the “bivalent” compounds did not 
show substantially increased inhibition of the investigated hyaluronidases compared 
to the “monovalent” ascorbic acid derivatives. Nevertheless, the additional ascorbic 
acid moiety was well tolerated and the water solubility was improved which is 
important for most in vivo studies. Due to the significant increase in potency 
comparing 7.111 and 7.112 it is conceivable that the inhibitory potency of Vcpal on 
the bacterial enzyme can be further increased by adding appropriate residues at the 
end of the C-16 chain. Probably another ascorbic acid moiety in this additional 
position is not optimal and should be replaced by other matching residues. 
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Figure 7.7. Hyaluronidase inhibitory potencies of the bivalent ligands 7.110-7.112 and 7.117. 
Compounds marked with * did not show inhibition of the investigated enzyme (arbitrary low bars for 
illustrative reasons).   
 
7.3.3 Mono-, di- and trisubstituted alkyl and acyl derivatives of vitamin C 
with increased hydrophobicity 
 
The IC50 values of the acylated and alkylated ascorbic acid derivatives, of the 
Michael products 7.151, 7.152 and of oxidized Vcpal (7.153) are summarized in 
Table 7.6 (see Table 7.5 for the definition of residues).  
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Table 7.5. Substitution patterns of investigated ascorbic acid derivatives. 
O
R3O
OR4
OR2
OR1
O
O
O
O
O
HO
OR1H
HO
O
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HO
OR1HO
MeO
HO
OH
7.151 7.152
O OH
OR1
O
HO OH
HO
HO
7.153
7.96a-7.100a,
7.103a, 7.106,
7.118-7.121,
7.121a, 7.127,
7.128, 7.132,
7.139, 7.140,
7.146-7.153  
No R1 R2 R3 R4 
7.96a CO(CH2)5O-p-C6H4-(p-OMe-C6H4) =R1 H H 
7.97a CO(CH2)5O-p-C6H4-(1-naphthyl) =R1 H H 
7.98a CO(CH2)4O(CH2)6CH3 =R1 H H 
7.99a CO(CH2)5O(CH2)5CH3 =R1 H H 
7.100a CO-p-C6H4O(CH2)9CH3 =R1 H H 
7.103a CO(CH2)5O-p-C6H4-(m-CO2H-C6H4) =R1 H H 
7.106 CO(CH2)10CH3 COCH2CO2H H H 
7.118 CO(CH2)14CH3 H CO(CH2)2Ph H 
7.119 CO(CH2)14CH3 H CO(CH2)2CO2H H 
7.120 CO(CH2)14CH3 H CO(CH2)3CO2H H 
7.121 CO(CH2)14CH3 H CO(CH2)4CO2H H 
7.121a CO(CH2)14CH3 H CO(CH2)4CO2H =R3 
7.127 (CH2)11CH3 H H H 
7.128 (CH2)17CH3 H H H 
7.132 CO(CH2)10CH3 H CH2CO2H =R3 
7.139 H H (CH2)11CH3 H 
7.140 H H (CH2)15CH3 H 
7.146 CO(CH2)10CH3 H CH2CO2H H 
7.147 CO(CH2)10O-p-C6H4-Ph H CH2CO2H H 
7.148 CO(CH2)10CH3 H H CH2CO2H 
7.149 H H H (CH2)11CH3 
7.150 H H H (CH2)13CH3 
7.151 CO(CH2)14CH3 - - - 
7.152 CO(CH2)14CH3 - - - 
7.153 CO(CH2)14CH3 - - - 
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Table 7.6. Inhibitory activity of investigated ascorbic acid derivatives. 
 
Hyal-1 PH-20 BTH SagHyal4755 Compound IC50 [µM]a 
7.96a > 50 1.7 ± 0.2 35 ± 0.8 8.0 ± 0.6 
7.97a 15 ± 2 1.9 ± 0.1 > 50 9.8 ± 1.0 
7.98a 31 ± 1 15 ± 1 315 ± 5 17 ± 1 
7.99a 28 ± 2 9.0 ± 0.5 300 ± 9 26 ± 3 
7.100a 108 ± 6 2.2 ± 0.1 65 ± 1 15 ± 1 
7.103a > 60 1.5 ± 0.1 17 ± 1 4.7 ± 0.4 
7.106 49 ± 4 4.3 ± 0.5 233 ± 7 14 ± 1 
7.118 > 30 3.3 ± 0.4 > 30 4.9 ± 0.3 
7.119 25 ± 3 8.6 ± 0.4 84 ± 2 1.7 ± 0.1 
7.120 11 ± 1 1.5 ± 0.3 79 ± 2 2.5 ± 0.2 
7.121 8.3 ± 0.4 2.0 ± 0.1 27 ± 1 2.8 ± 0.1 
7.121a 8.7 ± 1.5 3.2 ± 0.2 45 ± 1 4.9 ± 0.2 
7.127 62 ± 4 10 ± 1 141 ± 4 26 ± 1 
7.128 > 40 2.3 ± 0.1 35 ± 1 1.6 ± 0.1 
7.132 30 ± 2 3.9 ± 0.5 343 ± 14 12 ± 1 
7.139 > 400 21 ± 2 564 ± 7 40 ± 2 
7.140 > 50 36 ± 0.3 > 100 4.1 ± 0.2 
7.146 41 ± 1 9.3 ± 0.8 297 ± 5 15 ± 0.6 
7.147 > 100 1.7 ± 0.1 68 ± 2 2.4 ± 0.1 
7.148 85 ± 6 6.9 ± 0.6 328 ± 15 4.8 ± 0.3 
7.149 117 ± 9 4.5 ± 0.3 > 400 26 ± 1 
7.150 > 100 171 ± 21 > 200 6.0 ± 0.2 
7.151 39 ± 10 2.6 ± 0.2 77 ± 1 21 ± 1 
7.152 > 50 33 ± 2 > 60 27 ± 1 
7.153 > 50 12 ± 0.5 > 70 9.6 ± 0.4 
a Inhibition of enzyme expressed as IC50 (µM), mean values ± SEM (N = 2, experiments performed in 
duplicate), maximal concentrations of the test compounds were selected with respect to individual 
terminal solubilities in the incubation mixture; IC50 values determined at pH 5.0 (PH-20, BTH, 
SagHyal4755) or 3.5 (Hyal-1) in the turbidimetric assay.  
 
When 5,6-di-O-acylated ascorbic acid derivatives 7.96a-7.100a and 7.103a are 
compared with the corresponding monoacylated derivatives 7.96-7.100 and 7.103 an 
increase in potency is observed in most cases. If an IC50 value could not be 
determined due to poor water-solubility, at least a percental inhibition at maximal 
concentrations of such compounds was obtained. More than 6-fold increase in 
potency is observed for 7.98a and 7.99a compared to the monoacylated derivatives 
on all enzymes except BTH. A marked increase in inhibitory activity was also 
observed for 7.103a vs. 7.103, bearing a carboxyl group in meta position of the 
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terminal phenyl ring(s), on human PH-20 (factor 26) and SagHyal4755 (factor 20). In 
Figure 7.8 the differences in pIC50 values determined on PH-20 are visualized for the 
diacylated (7.96a-7.100a and 7.103a) versus the corresponding monoacylated 
ascorbic acid derivatives (7.96a-7.100a and 7.103a). 
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Figure 7.8. Comparison of the pIC50 values for human PH-20 determined for monoacylated and 
diacylated ascorbic acid derivatives. 
 
Whereas the monoacylated derivative 7.103 was too weakly active to determine an 
IC50 value on the bovine testicular hyaluronidase, the diacylated compound 7.103a 
with an IC50 of 17 µM was among the most potent inhibitors for BTH in the ascorbic 
acid series. Obviously, the large additional 5-O-substituent contributes to the binding 
affinity. An exception among the 5,6-diacylated derivatives represents 7.100a: 
whereas the inhibitory potency towards PH-20 is significantly higher than that of 
7.100, the activity is similar towards BTH or even weakened towards Hyal-1 and 
SagHyal4755. The two rigid phenyl rings near the ascorbic acid moiety may hinder the 
fit compared to the other diacylated compounds where only flexible alkanoyl chains 
are attached to the vitamin C core of the molecules. Interestingly, the selectivity of 
the hyaluronidase inhibitors is affected by the diacylation (Figure 7.9): 7.100a and 
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7.103a are highly selective for human PH-20 versus Hyal-1, whereas the PH-20 
selectivity of compound 7.98a is only weak (factor 2). The discrimination between the 
two PH-20 homologs, human PH-20 and BTH, remains largely unaffected by the 
different structural modifications, whereas the selectivity for Hyal-1 over BTH is 
clearly enhanced for 7.98a and 7.99a. By contrast, 7.96a, 7.100a and 7.103a 
possess significant selectivity for BTH over human Hyal-1. 
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Figure 7.9. Selectivity of synthesized 5,6-di-O-acylated ascorbic acid derivatives for the isoforms of 
mammalian hyaluronidases, human Hyal-1, human PH-20 and BTH, expressed as difference of pIC50 
values. 
 
The additional carboxyl group in 7.106, resulting from the acylation of O-5 with a 
malonic acid, slightly lowers the inhibitory potency towards BTH compared to the O-5 
nonsubstituted analogue 7.2d, whereas the inhibition of the other mammalian 
hyaluronidases and the bacterial enzyme is significantly increased. For the 2-O-acyl 
derivatives of ascorbic acid palmitate different SAR were observed: a carboxylic 
group linked to O-2 of Vcpal via different spacers (7.119-7.121) first decreased 
inhibition of BTH (7.119, 7.120) but the potency of 7.121 even exceeded that of Vcpal 
(see Figure 7.10for visualization of pIC50 values). Similar SAR are obtained for PH-
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20, the human homologue of BTH. Whereas 7.119 is a slightly weaker inhibitor of this 
enzyme compared to Vcpal, the extension of the spacer to four or five methylene 
groups gave compounds with enhanced potency (7.120, 7.121). With an IC50 value of 
1.5 µM compound 7.120 is among the most potent inhibitors of human PH-20 known 
so far. An increase in inhibitory potency correlating with the length of the spacer was 
found for Hyal-1. The unsubstituted Vcpal was inactive at the investigated 
concentrations, whereas the carboxyalkanoyl substituted derivatives 7.119-7.121 
were rather potent inhibitors of Hyal-1.  
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Figure 7.10. Inhibitory activity of 2-O-acylated ascorbic acid 6-palmitate derivatives 7.119-7.121 
compared to Vcpal. Compounds marked with * did not show inhibition of the investigated enzyme 
(arbitrary low bars for illustrative reasons).   
 
Regarding all enzymes except BTH, the activities of 7.120 and 7.121 do not 
significantly differ. Although the potency is higher than that of the reference 
compound Vcpal, there is no further gain in potency when a certain spacer length is 
exceeded. A second carboxylic acid residue introduced via the additional acylation of 
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O-3 (7.121a) does not increase the inhibition of the investigated hyaluronidases 
compared to 7.121.  
In contrast to the 2-O-carboxyalkanoyl derivatives the potency of the more 
hydrophobic phenylpropanoate 7.118 is not significantly different from that of the 
parent compound Vcpal. Generally, it seems that bulky substituents at O-2 may align 
with the surface of the different hyaluronidases and that a terminal polar carboxy 
group may contribute to the interactions.  
When various 6-O-acylated vitamin C derivatives bearing additional carboxylic acid 
residues (7.132 and 7.146-7.148) are compared to the corresponding 
monosubstituted substances (7.2d and 7.63) a tendency to increased potency is 
observed for Hyal-1, PH-20 and SagHyal4755. An exception is 7.147 where the 
carboxymethylene group did not improve the inhibition of the two human enzymes. In 
the case of BTH, the additional carboxylic groups even decreased the inhibitory 
potency. Thus, these carboxymethylene compounds are among the vitamin C 
derivatives with highest selectivity for human PH-20 compared to the homologous 
bovine enzyme: an 88-fold higher potency in favour of the human enzyme was 
determined for 7.132. Possibly, the carboxymethylene residues mimic the 
carboxylate moiety of glucuronic acid. The selective inhibition of the human enzyme 
compared to its bovine homologue suggests differences in the binding pocket of 
these two hyaluronidases. Significant selectivity between the two PH-20 enzymes is 
a surprising and important finding, as BTH has always been considered a prototypal 
mammalian hyaluronidase and an appropriate model for the development of 
inhibitors for the corresponding human enzymes. 
The ether 7.127 was synthesized to get some information about the importance of 
the ester carbonyl group. The IC50 values were slightly lower than those determined 
for 7.2d. This may be interpreted as a hint that the carbonyl group is not essential. 
However, increased flexibility of the compound could lead to a better fit to the 
enzymes and compensate for the lack of the carbonyl function. A prolonged chain 
(7.128) leads to a loss in activity for Hyal-1, whereas the potency on the other 
hyaluronidases is improved. When the location of the ether function is shifted from O-
6 of the ascorbic acid moiety to position O-2 (7.139 and 7.140) a complete loss of the 
Hyal-1 inhibition is observed whereas the other hyaluronidases are still inhibited 
albeit with higher IC50 values. Interestingly, lengthening of the hydrophobic sidechain 
does not result in increased inhibitory activity towards the human and the bovine PH-
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20, whereas the potency towards the bacterial hyaluronidase is drastically enhanced 
(see 7.140). The 3-O-alkylated derivative 7.149 shows inhibition of Hyal-1, albeit the 
IC50 value is significantly higher than that of the corresponding 6-O-alkylated 
derivative 7.127. Lengthening the alkyl chain by two methylene groups (7.150) 
results in a loss of the Hyal-1 inhibition. These results suggest similar binding modes 
of 7.149 and 7.127. The 3-O-alkylated derivative 7.149 is an even more potent 
inhibitor of PH-20 compared to 7.127 bearing the 6-O-dodecyl residue, but the 
inhibition drastically decreases with lengthening of the chain (7.150). This tendency is 
similar to that of the 2-O-alkylated derivatives discussed above. For the 3-O-alkylated 
derivatives no inhibition of BTH was detectable. The IC50 values determined on the 
bacterial enzyme are comparable to those of the 6-O-alkylated or 6-O-acylated 
analogues. The selectivities (expressed by the difference of pIC50 values) of the 
ascorbic acid dodecyl ethers 7.127, 7.139 and 7.141 are illustrated in Figure 7.11. 
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Figure 7.11. Enzyme selectivities of ascorbic acid dodecyl ethers. 
 
Comparing the two human enzymes, the 2-O- and 3-O-alkylated derivatives 7.139 
and 7.149 are most selective for PH-20 (with about the same selectivity ratio). 
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Considerung the two PH-20 homologs (human PH-20 vs. BTH), the selectivity of the 
inhibitors depending on the position of the substituent increases in the order 6-O-
alkylated < 2-O-alkylated < 3-O-alkylated ascorbic acid. Comparing human Hyal-1 
and BTH, the selectivity of the 3-O- and 6-O-alkylated derivatives for Hyal-1 is in the 
same range, whereas the 2-O-alkylated derivative 7.139 even shows weak selectivity 
for BTH over Hyal-1. 
Regarding the inhibitory activity towards SagHyal4755, generally, structural modifica-
tions at different positions of the ascorbic acid core lead only to minor changes in IC50 
values, whereas changes in the overall hydrophobicity strongly affect the inhibition. 
This may lead to the assumption that interactions of the inhibitors with the bacterial 
enzyme are mainly of hydrophobic nature with major interaction sites accessible for 
the sidechains of the ascorbic acid derivatives, as found in the crystal structure of 
hyaluronate lyase from S. pneumoniae in complex with Vcpal19. This may imply 
slightly different binding modi of the ascorbic acid moiety depending on the position 
and projection of the substituents. By contrast, distinct interactions with the ascorbic 
acid core must be important for the inhibition of the mammalian enzymes as there 
are considerable changes in potency and selectivity when the region of the 
hydrophobic sidechain is varied.  
Regarding the Michael products 7.151 and 7.152 higher inhibitory potency towards 
all investigated enzymes was found for 7.151 with clear differences between the IC50 
values for Hyal-1, human PH-20 and BTH, and minor differences in activities on 
SagHyal4755. Interestingly, the spiro compound 7.151 was superior to Vcpal in 
inhibition of the two human enzymes but was a less potent inhibitor of bovine and 
bacterial hyaluronidase. However, it should be stressed that interpretations of these 
results are ambiguous in terms of SAR due to the fact that a rearrangement of the 
spiro compound 7.151 was observed in aqueous solutions (Scheme 7.20)50, i. e. it 
remains unclear if the increased inhibitory activity compared to 7.152 has to be 
attributed to 7.151 or the respective pyranoside 7.154 or to both. 
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Scheme 7.20. Equilibrium of 7.151 and 7.154 in aqueous solutions according to Witt et al.50 
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Compared to Vcpal the oxidized derivative 7.153 showed decreased inhibitory 
activity towards PH-20, BTH and SagHyal4755. This may be interpreted as a hint that 
the flat heterocyclic ascorbic acid core is more appropriate for stacking with 
hydrophobic amino acids as it was found for an indole-based inhibitor of bacterial 
hyaluronate lyase54 as well as for Vcpal19. Such a stacking, a commonly observed 
phenomenon also in other carbohydrate binding enzymes55 is not optimal in the case 
of the oxidized compound 7.153 thus explaining the loss of potency. 
 
7.4 Potential binding modes of ascorbic acid derivatives at human 
Hyal-1 
 
Whereas various structural data about hyaluronate lyases are available and distinct 
knowledge exists about the degradation of the substrate or the binding modes of 
inhibitors2, 19, 20, 54, 56-60, there is still a lack of information about mammalian 
hyaluronidases. In 2000, the crystal structure of bee venom hyaluronidase in 
complex with a hyaluronan tetrasaccharide was released61 which provided insight 
into substrate binding, and first speculations about substrate degradation were 
made62. For about six years, BVH, which shares 22.9 % to 25.2 % sequence 
identity62 with human hyaluronidases, was the only member of hyaluronate 4-
glycanohydrolases (EC 3.2.1.35) from which extrapolations could be made. In the 
meantime also the structure of Ves v 2, a hyaluronidase from wasp venom has been 
elucidated63. Very recently, the crystal structure of the first human hyaluronidase was 
published by Chao et al.64 It was proven that the catalytically active part (N-terminus) 
of the enzyme shows high homology with BVH, whereas an additional C-terminal 
domain in human Hyal-1 is missing in BVH. This new structural information was used 
to investigate potential binding modes of the developed ascorbic acid based 
hyaluronidase inhibitors.  
The surface of Hyal-1 is shown Figure 7.12. The substrate binding site, dimensioned 
to bind a hyaluronan octasaccharide, is a long groove traversing the catalytic domain. 
The docked tetrasaccharide (taken from the BVH crystal structure PDB-code 1fcv61) 
results after cleavage at the reducing end and release of the product. There is a 
nearly perfect fit into the binding pocket indicating a similar binding mode as it was 
found for the bee venom enzyme. Hydrophobic interactions with the enzyme are 
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known to play a major role in substrate binding as well as in inhibition of the 
hyaluronidases19, 54, 57, 62. Thus, in a first approach hydrophobic pockets in proximity 
of the binding site were identified. Obviously, there are two highly lipophilic areas 
(see Figure 7.12): the first, marked as lipophilic area 1 is composed of residues 
Tyr286, Tyr202, Trp321, Tyr75, and Tyr245 and forms a narrow pocket nearby the 
catalytic site that surrounds the N-acetyl moiety of a glucosamine residue of the 
substrate. The second, marked as lipophilic area 2 is composed of residues Val251, 
Leu252, Leu213, Phe212, Tyr261, Tyr210, Tyr208, Trp141, Phe139 and Ile225 
forming walls of a crevice distal from the catalytic site, but close to the hyaluronan 
binding groove (product moiety). These two highly lipophilic areas were considered 
as possible binding sites for hydrophobic residues of the inhibitors.  
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Figure 7.12. Surface of human Hyal-1 (PDB code 2pe464) showing two main lipophilic areas. The 
protein surface is represented by a Connolly surface colored by lipophilicity (the warmer the color, the 
more lipophilic the amino acids). The hyaluronan tetrasaccharide (C atoms yellow) is taken from the 
crystal structure PDB code 1fcv61. 
 
The tetrasaccharide binding site of the enzyme was defined by the amino acids 
Trp36, Asn37, Asn39, Gln41, Trp42, Glu45, Thr65, Phe66, Arg67, Ile73, Ser74, 
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Tyr75, Tyr202, Ser245, Tyr247, Ile287, Trp321, Val322, Ser323, Trp324, and Glu325 
and the catalytically active Asp129 and Glu131 (Figure 7.13). 
 
 
Figure 7.13. Tetrasaccharide binding site site of Hyal-1. The catalytically active Asp129 and Glu131 
are marked in cyan. The hyaluronan tetramer (C atoms yellow) is taken from the crystal structure PDB 
code 1fcv61. 
 
In a first attempt 6-O-[6-(4-phenylphenoxy)hexanoyl]ascorbic acid (7.52) was chosen 
for docking experiments using the FlexiDock module of Sybyl 7.3. This inhibitor was 
selected since it is more rigid due to the biphenyl residue compared to the flexible 
alkyl chains present in other inhibitors. Additionally, there are several significant 
differences in the SAR compared to the other hyaluronidases when the biphenyl 
scaffold was slightly modified. As inhibition of the enzyme was determined at pH 3.5, 
the ascorbic acid derivative was used in the fully protonated form. Two approaches 
were selected for docking of 7.52: (1) flexible ligand, fixed amino acid side chains; (2) 
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ligand and amino acid side chains adjustable. While the first strategy resulted in 
many solutions, but all with very weak protein-ligand interactions, the second 
approach led to multiple solutions with distinct interactions between protein and 
inhibitor. The resulting docking poses were analyzed by visual inspection. In most 
cases interactions of the biphenyl residue with hydrophobic amino acids of the 
lipophilic area 1 were found (Figure 7.14). 
 
 
Figure 7.14. Representative binding modes of 7.52 near the lipophilic area 1 as calculated by 
Flexidock. The protein surface is represented by a Connolly surface colored by lipophilicity (the 
warmer the color, the more lipophilic the amino acids). 
 
Most of the calculated binding modes differed especially in the binding of the 
biphenyl moiety to the lipophilic pocket: whereas in some poses the biphenyl moiety 
plugs in the narrow lipophilic pocket (binding modes colored in magenta or cyan), in 
others the aromatic system fits outside resulting in weaker interactions with 
hydrophobic residues (binding modes colored in orange and white). In all cases, the 
ascorbic acid moiety was found to interact with amino acids of the tetrasaccharide 
binding site "westwards" from lipophilic area 1. Poses with close fit of the biphenyl 
residue into the lipophilic pocket correspond to the results obtained for the biaryl 
series: para and meta substitution leads to a significant loss of Hyal-1 inhibition 
whereas ortho substitution is tolerated. Additionally, the overall length of the 
tridecanoyl substituted derivative 7.2e is comparable to the dimensions of the 
biphenyl compound 7.52. Lengthening of the alkyl chain leads to a loss of potency. 
Ascorbic acid derivatives bearing longer alkyl chains may also bind to the 
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"tetrasaccharide region" occupied by the generated docking modes, but in this case 
the hydrophobic chains are not able to fill the narrow pocket. No binding mode with 
reasonable interactions of the inhibitor with lipophilic area 2 was generated. 
However, binding to this second lipophilic area around the product binding site of the 
enzyme must also be considered, since especially disubstituted extended and 
flexible structures can align along both sides of the hyaluronan binding groove. 
Compound 7.121, the most potent Hyal-1 inhibitor in the series, was manually 
docked to check if the hexadecanoyl chain may fit to the second hydrophobic pocket. 
Figure 7.15 displays the obtained docking mode together with a refined docking pose 
of 7.52 (small modifications and energy minimization of a Flexidock solution). 
 
Figure 7.15. Suggested binding modes of 7.52 (C atoms yellow) and 7.121 (C atoms cyan). The 
hyaluronic acid tetrasaccharide (C atoms green) is taken from the complex with bee venom 
hyaluronidase (PDB code 1fcv)61. The protein surface is represented by a Connolly surface colored by 
lipophilicity (the warmer the color, the more lipophilic the amino acids). 
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The ascorbic acid core of 7.52 occupies approximately the same space as the 
terminal glucuronic acid moiety of the tetrasaccharide with the acidic 3-OH of vitamin 
C corresponding to the carboxylate of the carbohydrate. There are only weak protein-
inhibitor interactions with the protein in this region indicating degrees of freedom for 
additional modifications. Due to the flexible link to the biphenyl residue, the ascorbic 
acid moiety could fit to Trp42 and Arg328. The alkyl spacer itself aligns with the 
indole moiety of Trp324 leading to additional hydrophobic interactions. This binding 
mode is in agreement with the results described in chapter 7.3.3: Various 
modifications of the vitamin C enediol system were tolerated and led to an increase 
in inhibition of Hyal-1. The position of the biphenyl residue was not modified, as this 
residue fills the lipophilic pocket 1 (surrounding an N-acetyl moiety of the substrate in 
the active site) and thus explains the observed SAR when the biphenyl-part is 
modified as described above. 
Obviously, the diacylated derivative 2-O-(5-carboxypentanoyl)-6-O-hexadecanoyl-L-
ascorbic acid (7.121) nearly fills the whole substrate groove. The flexible 
hexadecanoyl chain occupies the lipophilic area in the "eastern part" of the 
hyaluronan site (product moiety). The ascorbic acid core is allocated in the center of 
the active site in close proximity to the catalytic amino acids Asp129 and Glu131. The 
carboxypentanoyl residue may occupy the same region as the substrate 
tetrasaccharide by projection towards the non-reducing end. Thus, such an extended 
inhibitor conformation could possibly mimic the linear shape of hyaluronic acid. 
Again, modification of the ascorbic acid scaffold is possible because the 3-OH is 
solvent exposed. Therefore, this binding mode is consistent with the high inhibitory 
potency of the triacylated compound 7.121a. The increased inhibitory activity of 
acylated ascorbic acid derivatives with additional branching in α position of the ester 
(7.89-7.95) could also be explained by this docking mode: The additional alkyl or aryl 
residue could occupy additional regions of this lipophilic area in the "eastern part" of 
the substrate binding groove. 
Due to the nature of both the enzyme and the inhibitor, it is impossible to identify an 
explicit binding mode: The large hyaluronan binding groove of Hyal-1 (and the 
hyaluronidases in general) provides several potential binding sites for hydrophobic 
small molecule inhibitors. In addition, the flexible alkyl chains of the inhibitors are 
able to adopt many different conformations and thus may interact with various sites. 
Therefore the exemplary nature of the given binding modes must clearly be 
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emphasized. Nevertheless, the suggested modes could serve as a base for future 
work. It would be especially interesting to further investigate the binding mode of 
biphenyl derivatives, as the observed different selectivities for various hyaluronidases 
are possibly be associated with the narrow hydrophobic cleft (lipophilic area 1) in 
Hyal-1 if the shape of this cleft is different from other (mammalian) hyaluronidases. 
Thus, optimized interactions with the enzyme in this part of the molecule could lead 
to inhibitors with even increased selectivity. Additionally, variation of the spacer 
length between the biphenyl and the ascorbic acid moiety could lead to optimized 
interactions of the ascorbic acid with amino acids in the "western part" of the 
hyaluronan binding groove. Furthermore, the introduction of more rigid spacers could 
help to identify amino acids involved in the binding of the inhibitor.  
 
7.5 Summary 
 
Starting from ascorbic acid, which is only a weak inhibitor of human PH-20 with an 
IC50 value in the millimolar range and does dot inhibit human Hyal-1, the inhibition of 
the recombinantly expressed human hyaluronidases was improved by adding 
hydrophobic substituents in position O-6 of the ascorbic acid moiety as it was 
recently demonstrated for the bacterial hyaluronate lyase and the bovine enzyme23, 
53. Whereas highest inhibition of PH-20 was achieved for ascorbic acid palmitate with 
an IC50 value of 5.8 µM, this compound was inactive on the human homolog Hyal-1. 
Highest potency on this enzyme was achieved by ascorbic acid 6-O-tridecanoate 
(7.2e) with an IC50 of 50 µM21. Further modification of the hydrophobic alkyl chain, 
e.g. introduction of various aromatic residues resulted in similarly active compounds. 
Again, Hyal-1 was inhibited when shorter spacers were used between the ascorbic 
acid core and the aromatic substituents, whereas the compounds with longer spacers 
were highly potent inhibitors of both PH-20 homologs and the bacterial hyaluronate 
lyase, e.g. 6-O-[11-(4-phenylphenoxy)undecanoyl]ascorbic acid (7.63) with IC50 
values of 1.3 µM (human PH-20), 37 µM (BTH) and 7.5 µM (SagHyal4755). This 
compound represents the most potent inhibitor of human PH-20 among the ascorbic 
acid derivatives. Different SAR resulted also from minor changes in the biphenyl part 
of 6-O-[6-(4-phenylphenoxy)hexanoyl]ascorbic acid (7.52), e.g. introduction of 
methyl, methoxy, hydroxy or carboxy residues, In the case of Hyal-1 major potency 
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differences were observed: Inhibition is lost if para- or meta-substituents are 
introduced, whereas hydrophobic ortho substitution is tolerated, thus indicating a 
lipophilic binding pocket of Hyal-1 which is possibly of different shape in the other 
three enzymes as the modifications of the biphenyl part caused only minor changes 
in inhibition of PH-20, BTH and SagHyal4755.  
Whereas the introduction of an aromatic spacer adjacent to the carbonyl group was 
tolerated (7.87, 7.88), a drastic decrease in potency of the compounds was observed 
if the hydrophobic chain was disrupted by an ether oxygen (7.98 and 7.99). 
Branching of the substituent (7.89-7.95) led to inhibitors with increased potency 
especially for Hyal-1, but variation of the side chains resulted only in minor activity 
changes. 
The “bivalent” compounds presented in chapter 7.3.2 are potent inhibitors of the 
bacterial hyaluronate lyase and the two PH-20 isoenzymes with inhibitory activities 
comparable to those of the “monovalent” derivatives, whereas Hyal-1 was rather 
weakly inhibited. 
5,6-di-O-acylated derivatives (7.96a-7.100a and 7.103a) are advantageous 
compared to the 6-O-acylated compounds (7.96-7.100 and 7.103). The greatest IC50 
ratios (up to 26-fold) were observed for human PH-20. Additional introduction of 
carboxylic acid residues via 2-O-acylation of Vcpal led to potent inhibitors of human 
and bacterial hyaluronidases with IC50 values in the lower micromolar range. 2-O-(5-
carboxypentanoyl)-6-O-hexadecanoyl-L-ascorbic acid (7.121) represents the most 
active inhibitor of human Hyal-1 developed in this project with an IC50 value of 8.3 µM 
und is one of the most potent inhibitors of this enzyme known to date.  
Alkylation of O-6 (7.127 and 7.128) led to inhibitors which are equipotent with the 
corresponding acylated derivatives. Additionally, these alkyl ascorbic acids should 
possess increased stability in aqueous solution. When the position of the 
hydrophobic residue was altered from position O-6 to O-2 (7.149 and 7.150) or O-3 
(7.139 and 7.140), drastic activity and selectivity differences between the two human 
enzymes Hyal-1 and PH-20 as well as between the two PH-20 homologs were 
observed. The inhibiton of the bacterial enzyme remained largely unaffected. 
Taken together, the synthesized ascorbic acid based inhibitors are the most potent 
inhibitors of mammalian hyaluronidases known to date. Specific SAR were obtained 
for each hyaluronidase with distinct differences between the human enzymes on the 
one hand and the human and bovine PH-20 enzymes on the other hand. A common 
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selectivity of the synthesized ascorbic acid derivatives for human PH-20 compared to 
the bovine homolog was obvious. 
The recently published64 crystal structure of human Hyal-1 was used as model to 
perform docking experiments and to identify potential interaction sites explaining the 
results from the turbidimetric assay. As binding of the hydrophobic inhibitors to 
hydrophobic patches of the enzyme is most probable, two highly lipophilic areas near 
the catalytically active center of Hyal-1 were first considered. An automated docking 
(FlexiDock) was performed using 6-O-[6-(4-phenylphenoxy)hexanoyl]ascorbic acid 
(7.52) as ligand. The resulting docking poses suggest a close fit of the biphenyl 
residue into one of the identified lipohilic pockets. Manual docking of the most potent 
Hyal-1 inhibitor, 2-O-(5-carboxypentanoyl)-6-O-hexadecanoyl-L-ascorbic acid 
(7.121), indicates alignment of the alkyl chain with the second hydrophobic patch. 
The suggested binding modes are able to explain various characteristics of the SAR 
and thus may serve as basis for the structure-based design of further Hyal-1 
inhibitors. 
 
7.6 Experimental Section 
 
7.6.1 General conditions 
 
Chemicals were purchased from the following suppliers: Acros Organics (Geel, 
Belgium), IRIS Biotech GmbH (Marktredwitz, Germany), Alfa Aesar GmbH & Co. KG 
(Karlsruhe, Germany), Merck KGaA (Darmstadt, Germany), and Sigma-Aldrich 
Chemie GmbH (Munich, Germany). Deuterated solvents for NMR spectroscopy were 
from Deutero GmbH (Kastellaun, Germany). All solvents were of analytical grade or 
distilled prior to use. If moisture-free conditions were required, reactions were 
performed in dried glassware under inert atmosphere (argon or nitrogen); DMF (H2O 
< 0.01 %) was purchased from Sigma-Aldrich Chemie GmbH. Nuclear Magnetic 
Resonance (1H-NMR and 13C-NMR) spectra were recorded on an Avance-300 NMR 
spectrometer from Bruker BioSpin GmbH (Rheinstetten, Germany). 
Tetramethylsilane was added as internal standard (chemical shift δ = 0 ppm) to all 
samples. Multiplicities are specified with the following abbreviations: s (singlet), d 
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(doublet), t (triplet), q (quartet), m (multiplet), bs (for broad singulet), as well as 
combinations thereof. The multiplicity of carbon atoms (13C-NMR) were determined 
by DEPT 135 and DEPT 90 (distortionless enhancement by polarization transfer): “+” 
primary and tertiary carbon atom (positive DEPT 135 signal), “-“ secondary carbon 
atom (negative DEPT 135 signal), “quat” quaternary carbon atom. Mass 
spectrometry analysis (MS) was performed on a Finnigan MAT 95 (PI-EIMS 70 eV, 
HR-MS), Finnigan SSQ 710A (CI-MS (NH3)) and on a Finnigan ThermoQuest TSQ 
7000 (ESI-MS) spectrometer. The peak-intensity in % relative to the strongest signal 
is indicated in parenthesis. Melting points (mp) were measured on a BÜCHI 530 
using open capillaries and are uncorrected. Merck Silica Gel 60 (particle size 0.040–
0.063 mm) was used for flash column chromatography. Reactions were routinely 
monitored by thin layer chromatography (TLC) on Merck silica gel 60 F254 aluminum 
sheets and spots were visualized with UV light at 254 nm, and/or iodine vapor or 
ammonium molybdate/cerium(IV) sulphate solution. 
Preparative HPLC was performed with a pump model K-1800 (Knauer, Berlin, 
Germany), the column was Eurosphere-100 (250 x 32 mm) (Knauer), which was 
attached to a UV-detector model K-2000 (Knauer). UV-detection was done at 254 
and 210 or 220 nm, respectively. The temperature was 25 °C and the flow rate 37 
ml/min. The mobile phase was 0.1 % TFA in millipore water and MeCN. Analytical 
HPLC was performed on a system from Thermo Separation Products equipped with 
a SN 400 controller, P4000 pump, an AS3000 autosampler and a Spectra Focus UV-
VIS detector. Stationary phase was a Eurosphere-100 C-18 (250 x 4.0, 5 μm) column 
(Knauer) thermostated at 30 °C. As mobile phase gradients of MeCN/0.02 or 0.05 % 
TFA/aq were used (flow rate = 0.7 ml/min). Absorbance was detected at 210 nm. 
 
7.6.2 Chemistry 
 
7.6.2.1 General procedure for the preparation of methyl esters 7.1a-7.1g, 14, 
15 and 34 
To a solution of carboxylic acid (1eq) in anhydrous methanol under nitrogen 
atmosphere was added chlortrimethylsilane (2.2 eq). The mixture was stirred at reflux 
overnight, cooled, and evaporated under reduced pressure. The residue was taken 
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up in diethylether and washed twice with 1 N NaOH and water. After drying over 
magnesium sulfate the solvent was removed under reduced pressure. 
Methyl octanoate65 (7.1a): The title compound was prepared from octanoic acid (50 
mmol, 6.56 ml) and TMSCl (110 mmol, 13.9 ml) in 50 ml anhydrous methanol 
according to the general procedure 7.6.2.1 yielding 7.1a as a colorless oil (7.30 g, 
92 %). 1H-NMR (CDCl3) δ 0.87 (t, 3H, 3J = 6.4 Hz, CH2CH3), 1.27 (m, 8H, 
(CH2)4CH3), 1.61 (m, 2H, COCH2CH2CH2), 2.29 (t, 2H, 3J = 7.5 Hz, COCH2CH2), 
3.65 (s, 3H, OCH3). EI-MS (70 eV) m/z (%): 158 (4) [M+·]. C9H18O2 (158.24). 
Methyl decanoate65 (7.1b): The title compound was prepared from decanoic acid 
(50 mmol, 8.61 g) and TMSCl (110 mmol, 13.9 ml) in 50 ml anhydrous methanol 
according to the general procedure 7.6.2.1 yielding 7.1b as a colorless oil (8.60 g, 
92 %). 1H-NMR (CDCl3) δ 0.87 (t, 3H, 3J = 6.7 Hz, CH2CH3), 1.26 (m, 12H, 
(CH2)6CH3), 1.61 (m, 2H, COCH2CH2CH2), 2.30 (t, 2H, 3J = 7.5 Hz, COCH2CH2), 
3.66 (s, 3H, OCH3). EI-MS (70 eV) m/z (%): 186 (5) [M+·]. C11H22O2 (186.29). 
Methyl undecanoate66 (7.1c): The title compound was prepared from undecanoic 
acid (50 mmol, 9.31 g) and TMSCl (110 mmol, 13.9 ml) in 50 ml anhydrous methanol 
according to the general procedure 7.6.2.1 yielding 7.1c as a colorless oil (9.29 g, 
98 %). 1H-NMR (CDCl3) δ 0.86 (t, 3H, 3J = 6.7 Hz, CH3), 1.24 (m, 14H, 
CH2(CH2)7CH3), 1.60 (m, 2H, COCH2CH2), 2.28 (t, 2H, 3J = 7.5 Hz, COCH2), 3.65 (s, 
3H, OCH3). C12H14O2 (190.24). 
Methyl dodecanoate67 (7.1d): The title compound was prepared from dodecanoic 
acid (50 mmol, 10.02 g) and TMSCl (110 mmol, 13.9 ml) in 50 ml anhydrous 
methanol according to the general procedure 7.6.2.1 yielding 7.1d as a colorless oil 
(10.34 g, 96 %). 1H-NMR (CDCl3) δ 0.88 (t, 3H, 3J = 6.7Hz, CH2CH3), 1.27 (m, 16H, 
(CH2)8CH3), 1.62 (m, 2H, COCH2CH2CH2), 2.30 (t, 2H, 3J = 7.5 Hz, COCH2CH2), 
3.67 (s, 3H, OCH3). EI-MS (70 eV) m/z (%): 214 (10) [M+·]. C13H26O2 (214.34). 
Methyl tridecanoate68 (7.1e): The title compound was prepared from tridecanoic 
acid (25 mmol, 5.36 g) and TMSCl (55 mmol, 7.0 ml) in 25 ml anhydrous methanol 
according to the general procedure 7.6.2.1 yielding 7.1e as a colorless oil (5.50 g, 
96 %). 1H-NMR (CDCl3) δ 0.87 (t, 3H, 3J = 6.7 Hz, CH3),1.26 (m, 18H, 
CH2(CH2)9CH3), 1.61 (m, 2H, COCH2CH2-), 2.29 (t, 2H, 3J = 7.5 Hz, COCH2), 3.66 (s, 
3H, OCH3). EI-MS (70 eV) m/z (%): 228 (20) [M+·]. C14H28O2 (228.37) 
Methyl tetradecanoate65 (7.1f): The title compound was prepared from 
tetradecanoic acid (50 mmol, 11.42 g) and TMSCl (110 mmol, 13.9 ml) in 50 ml 
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anhydrous methanol according to the general procedure 7.6.2.1 yielding 7.1f as a 
colorless oil (11.50 g, 95 %). 1H-NMR (CDCl3) δ 0.87 (t, 3H, 3J = 6.7 Hz, CH2CH3), 
1.25 (m, 20H, (CH2)10CH3), 1.61 (m, 2H, COCH2CH2CH2), 2.29 (t, 2H, 3J = 7.5 Hz, 
COCH2CH2), 3.66 (s, 3H, OCH3). EI-MS (70 eV) m/z (%): 242 (39) [M+·]. C15H30O2 
(242.40). 
Methyl p-biphenylylacetate69 (7.1g): The title compound was prepared from p-
biphenylylacetic acid (25 mmol, 5.31 g) and TMSCl (55 mmol, 7.0 ml) in 25 ml 
anhydrous methanol according to the general procedure 7.6.2.1 yielding 7.1g as a 
pale yellow oil (5.24 g, 93 %). 1H-NMR (CDCl3) δ 3.70 (s, 2H, CH2), 3.74 (s, 3H, 
OCH3), 7.37 (m, 3 H, Ar-H), 7.46 (m, 2H, Ar-H), 7.60 (m, 4H, Ar-H). EI-MS (70 eV) 
m/z (%): 226 (36) [M+·]. C15H14O2 (226.27) 
7.6.2.2 General procedure for the enzymatic synthesis of 6-O-acylated 
ascorbic acids 7.2a-7.2g and 48-63 
Vitamin C (1 eq), the pertinent methyl alkanoate (1.5-4 eq) and the immobilized 
lipase from Candida antarctica (Novozyme 435®) (50 mg per mmol ascorbic acid) 
were suspended in tert-amyl alcohol and submitted to rotary evaporation at 60 °C 
bath temperature and 200 mbar vacuum for 14-24 h. After the major part of ascorbic 
acid was consumed, the reaction mixture was cooled to room temperature, solids 
were removed by filtration, the solvent was evaporated under reduced pressure and 
the resulting material was taken up in EtOAc. After washing with brine and water the 
organic phase was dried over MgSO4, the solvent was removed under reduced 
pressure and the crude products were recrystallized from tert-butyl methyl 
ether/hexane. 
6-O-Octanoyl-L-ascorbic acid70 (7.2a): The title compound was prepared from 
ascorbic acid (3.3 mmol, 0.58 g), 7.1a (4 eq, 13.2 mmol, 2.09 g) and Novozyme 435® 
(165 mg) in 15 ml tert-amyl alcohol according to the general procedure 7.6.2.2 
yielding 7.2a as a white solid (0.45 g, 45 %). mp: 78-80 °C; 1H-NMR (DMSO-d6) δ 
0.85 (t, 3H, 3J = 6.7 Hz, CH3), 1.24 (m, 8H, CH2(CH2)4CH3), 1.53 (m, 2H, 
COCH2CH2), 2.32 (t, 2H, 3J = 7.4 Hz, COCH2), 4.03 (m, 3H, CH2O, CHOH), 4.67 (d, 
1H, 3J = 1.7 Hz, H-5), 5.32 (bs, 1H, CHOH), 8.42 (bs, 1H, OH), 11.12 (bs, 1H, OH). 
13C-NMR (DMSO-d6) δ 13.85 (+, CH3), 21.96 (-, CH2), 24.30 (-, CH2), 28.28 (-, CH2), 
28.33 (-, CH2), 31.03 (-, CH2), 33.30 (-, COCH2CH2), 64.36 (-, CH2O), 65.39 (+, 
CHO), 74.92 (+, CH), 118.07 (quat, C-2), 152.13 09 (quat, C-3), 170.27 (quat, 
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lactone CO), 172.65 (quat, CO2CH2). ES-MS (MeCN + TFA) m/z (%): 303 (100) 
[M+H]+. Anal. (C14H22O7) C, H. C14H22O7 (302.32). 
6-O-Decanoyl-L-ascorbic acid70 (7.2b): The title compound was prepared from 
ascorbic acid (3.3 mmol, 0.58 g), 7.1b (4 eq, 13.2 mmol, 2.45 g) and Novozyme 435® 
(165 mg) in 15 ml tert-amyl alcohol according to the general procedure 7.6.2.2 
yielding 7.2b as a white solid (0.50 g, 46 %). mp: 96-97 °C (ref.71: 100-101 °C); 1H-
NMR (DMSO-d6) δ 0.86 (t, 3H, 3J = 6.7 Hz, CH3), 1.24 (m, 12H, CH2(CH2)6CH3), 1.53 
(m, 2H, COCH2CH2), 2.32 (t, 2H, 3J = 7.4 Hz, COCH2CH2), 4.03 (m, 3H, CH2O, 
CHOH), 4.67 (d, 1H, 3J = 1.6 Hz, H-5), 5.30 (bs, 1H, CHOH), 8.39 (bs, 1H, OH), 
11.10 (bs, 1H, OH). 13C-NMR (DMSO-d6) δ 13.88 (+, CH3), 22.01 (-, CH2), 24.30 (-, 
CH2), 28.37 (-, CH2), 28.56 (-, CH2), 28.63 (-, CH2), 28.77 (-, CH2), 31.19 (-, CH2), 
33.31 (-, COCH2CH2), 64.37 (-, CH2O), 65.41 (+, CHO), 74.92 (+, CH), 118.10 (quat, 
C-2), 152.09 (quat, C-3), 170.25 (quat, lactone CO), 172.66 (quat, CO2CH2). ES-MS 
(DCM/MeOH + NH4OAc) m/z (%): 348 (100) [M+NH4]+. Anal. (C16H26O7) C, H. 
C16H26O7 (330.37). 
6-O-Undecanoyl-L-ascorbic acid70, 72 (7.2c): The title compound was prepared 
from ascorbic acid (3.3 mmol, 0.58 g), 7.1c (4 eq, 13.2 mmol, 2.51 g) and Novozyme 
435® (165 mg) in 15 ml tert-amyl alcohol according to the general procedure 7.6.2.2 
yielding 7.2c as a white solid (0.60 g, 53 %). mp: 96-98 °C;  1H-NMR (DMSO-d6) δ 
0.85 (t, 3H, 3J = 6.7 Hz, CH3), 1.24 (m, 14H, CH2(CH2)7CH3), 1.52 (m, 2H, 
COCH2CH2), 2.32 (t, 2H, 3J = 7.4 Hz, COCH2), 4.03 (m, 3H, CH2O, CHOH), 4.68 (d, 
1H, 3J = 1.5 Hz, H-5), 5.32 (bs, 1H, CHOH), 8.42 (s, 1H, OH), 11.14 (s, 1H, OH). 13C-
NMR (DMSO-d6) δ 13.87 (+, CH3), 22.02 (-, CH2), 24.30 (-, CH2), 28.38 (-, CH2), 
28.62 (-, CH2), 28.82 (-, CH2), 28.88 (-, CH2), 31.21 (-, CH2), 33.30 (-, COCH2CH2), 
64.36 (-, CH2O), 65.41 (+, CHO), 74.92 (+, CH), 118.10 (quat, C-2), 152.09 (quat, C-
3), 170.25 (quat, lactone CO), 172.64 (quat, CO2CH2). ES-MS (MeCN + TFA) m/z 
(%): 345 (100) [M+H]+. Anal. (C17H28O7) C, H. C17H28O7 (344.40). 
6-O-Dodecanoyl-L-ascorbic acid70 (7.2d): The title compound was prepared from 
ascorbic acid (3.3 mmol, 0.58 g), 7.1d (4 eq, 13.2 mmol, 2.83 g) and Novozyme 435® 
(165 mg) in 15 ml tert-amyl alcohol according to the general procedure 7.6.2.2 
yielding 7.2d as a white solid (0.63 g, 53 %). mp: 101-103 °C (ref.53: 95-97);  1H-NMR 
(DMSO-d6) δ 0.85 (t, 3H, 3J = 6.7 Hz, CH2CH3), 1.24 (s, 16H, (CH2)8CH3), 1.52 (m, 
2H, COCH2CH2CH2), 2.32 (t, 2H, 3J = 7.4 Hz, COCH2CH2-), 4.01 (m, 3H, CH2O, 
CHOH), 4.67 (d, 1H, 3J = 1.6 Hz, H-5), 5.33 (d, 1H, 3J = 5.7 Hz, CHOH), 8.42 (s, 1H, 
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OH), 11.14 (s, 1H, OH). 13C-NMR (DMSO-d6) δ 13.89 (+, CH3), 22.04 (-, CH2), 24.30 
(-, CH2), 28.38 (-, CH2), 28.65 (-, CH2), 28.83 (-, CH2), 28.94 (-, CH2), 31.23 (-, CH2), 
33.29 (-, COCH2CH2), 64.36 (-, CH2O), 65.37 (+, CHO), 74.91 (+, CH), 118.08 (quat, 
C-2), 152.10 (quat, C-3), 170.27 (quat, lactone CO), 172.65 (quat, CO2CH2). CI-MS 
(NH3) m/z (%): 376 (100) [M+NH4]+. Anal. (C18H30O7) C, H. C18H30O7 (358.43). 
6-O-Tridecanoyl-L-ascorbic acid73 (7.2e): The title compound was prepared from 
ascorbic acid (3.3 mmol, 0.58 g), 7.1e (4 eq, 13.2 mmol, 3.01 g) and Novozyme 435® 
(165 mg) in 15 ml tert-amyl alcohol according to the general procedure 7.6.2.2 
yielding 7.2e as a white solid (0.79 g, 69 %). mp: 103 °C; 1H-NMR (DMSO-d6) δ 0.85 
(t, 3H, 3J = 6.7 Hz, CH3), 1.24 (s, 18H, CH2(CH2)9CH3), 1.53 (m, 2H, COCH2CH2), 
2.31 (t, 2H,  3J =7.5 Hz, COCH2), 4.04 (m, 3H, CH2O, CHOH), 4.67 (d, 1H, 3J = 1.7 
Hz, H-5), 5.31 (d, 1H, 3J = 5.7 Hz, CHOH), 8.39 (s, 1H, OH), 11.10 (s, 1H, OH). 13C-
NMR (DMSO-d6) δ 13.87 (+, CH3), 22.03 (-, CH2), 24.30 (-, CH2), 28.38 (-, CH2), 
28.64 (-, CH2), 28.82 (-, CH2), 28.93 (-, CH2), 31.22 (-, CH2), 33.30 (-, COCH2CH2), 
64.36 (-, CH2O), 65.41 (+, CHO), 74.92 (+, CH), 118.10 (quat, C-2), 152.07 (quat, C-
3), 170.24 (quat, lactone CO), 172.63 (quat, CO2CH2). ES-MS (DCM/MeOH + 
NH4OAc) m/z (%): 371 (100) [M-H]-. Anal. (C19H32O7) C, H. C19H32O7 (372.45). 
6-O-Tetradecanoyl-L-ascorbic acid74 (7.2f): The title compound was prepared from 
ascorbic acid (3.3 mmol, 0.58 g), 7.1f (4 eq, 13.2 mmol, 3.20 g) and Novozyme 435® 
(165 mg) in 15 ml tert-amyl alcohol according to the general procedure 7.6.2.2 
yielding 7.2f as a white solid (0.76 g, 59 %). mp: 104-105 °C; 1H-NMR (DMSO-d6) δ 
0.85 (t, 3H, 3J = 6.7 Hz, CH3), 1.24 (m, 20H, (CH2)10CH3 ), 1.52 (m, 2H, COCH2CH2), 
2.31 (t, 2H, 3J = 7.4 Hz, COCH2CH2), 4.03 (m, 3H, CH2O, CHOH), 4.67 (d, 1H, 3J = 
1.6 Hz, H-5), 5.31 (bs, 1H, CHOH), 8.40 (s, 1H, OH),  11.11 (s, 1H, OH). 13C-NMR 
(DMSO-d6) δ 13.88 (+, CH3), 22.02 (-, CH2), 24.30 (-, CH2), 28.38 (-, CH2), 28.64 (-, 
CH2), 28.82 (-, CH2), 28.95 (-, CH2), 31.23 (-, CH2), 33.30 (-, COCH2CH2), 64.37 (-, 
CH2O), 65.40 (+, CHO), 74.92 (+, CH), 118.10 (quat, C-2), 152.08 (quat, C-3), 
170.25 (quat, lactone CO), 172.64 (quat, CO2CH2). ES-MS (DCM/MeOH + NH4OAc) 
m/z (%): 404 (100) [M+NH4]+. Anal. (C20H34O7) C, H. C20H34O7 (386.48). 
6-O-(p-Biphenylylacetyl)-L-ascorbic acid (7.2g): The title compound was prepared 
from ascorbic acid (3.3 mmol, 0.58 g), 7.1g (4 eq, 13.2 mmol, 3.73 g) and Novozyme 
435® (165 mg) in 15 ml tert-amyl alcohol according to the general procedure 7.6.2.2 
yielding 7.2g as a white solid (0.45 g, 37 %). mp: 138-141 °C; 1H-NMR (DMSO-d6) δ 
3.77 (s, 2H, CH2), 4.08 (m, 3H, CH2O, CHOH) ppm 4.70 (d, 1H, 3J=1.7 Hz, H-5), 5.37 
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(s, 1H, CHOH ), 7.36 (m, 3H, Ar-H), 7.46 (m, 2H, Ar-H), 7.64 (m, 4H, Ar-H), 8.42 (bs, 
1H, OH), 11.14 (s, 1H, OH). 1H-NMR (DMSO-d6) δ 3.77 (s, 2H, CH2), 4.08 (m, 3H, 
CH2O, CHOH) 4.70 (d, 1H, 3J = 1.7 Hz, H-5), 5.37 (s, 1H, CHOH ), 7.36 (m, 3H, Ar-
H), 7.46 (m, 2H, Ar-H), 7.64 (m, 4H, Ar-H), 8.42 (bs, 1H, OH), 11.14 (s, 1H, OH). 13C-
NMR (DMSO-d6) δ 39.62 (-, CH2C6H4), 64.96 (-, CH2O), 65.41 (+, CHO), 74.93 (+, 
CH), 118.12 (quat, C-2), 126.51 (+, Ar-C), 126.56 (+, Ar-C), 127.30 (+, Ar-C), 128.85 
(+, Ar-C), 129.93 (+, Ar-C), 133.43 (quat, Ar-C), 138.67 (quat, Ar-C), 139.78 (quat, 
Ar-C), 152.11 (quat, C-3), 170.26 (quat, lactone CO), 170.94 (quat, CO2CH2). ES-MS 
(DCM/MeOH + NH4OAc) m/z (%): 369 (100) [M-H]-. Anal. (C20H18O7) C, H. C20H18O7 
(370.35). 
Methyl 6-bromohexanoate (7.3)26: A solution of ε-caprolactone (234.5 mmol, 26 ml) 
in 33 % hydrogen bromide in acetic acid (63 ml) was heated for 6 h at 70 °C, cooled 
to room temperature, treated with methanol (100 ml), and stirred overnight. 
Evaporation of the solvent gave a dark oil which was dissolved in EtOAc (150 ml) 
and washed successively with saturated sodium bicarbonate (3 x 150 ml) and 
saturated sodium chloride (150 ml), dried over MgSO4, and evaporated to yield 7.3 
as a colorless oil (41.4 g, 84 %). 1H-NMR (CDCl3) δ 1.45 (m, 2H, CH2), 1.63 (m, 2H, 
CH2), 1.85 (m, 2H CH2), 2.31 (t, 2H, 3J = 7.4 Hz, COCH2CH2), 3.39 (t, 2H, 3J = 6.8 
Hz, CH2Br), 3.65 (s, 3H, OCH3). EI-MS (70 eV) m/z (%): 208 (20) [M+·]. Anal. 
(C7H13BrO2) C, H. C7H13BrO2 (209.08). 
Methyl 6-(phenylthio)hexanoate75 (7.4): To a solution of 7.3 (20 mmol, 4.18 g) and 
thiophenol (22 mmol, 2.27ml) in anhydrous THF (70 ml) was added DIEA (22 mmol, 
3.77ml) and the mixture was stirred at room temperature overnight. After diluting the 
mixture with EtOAc (70 ml), it was washed with saturated NaHCO3 and dried over 
MgSO4. The solvent was removed under reduced pressure and the residue was 
submitted to flash chromatography (CHCl3/PE 20/80 v/v) to obtain 7.4 as a colorless 
oil (2.69 g, 60 %). 1H-NMR (CDCl3) δ 1.46 (m, 2H, COCH2CH2CH2), 1.65 (m, 4H, 
COCH2CH2, CH2CH2SPh), 2.30 (t, 2H, 3J = 7.4 Hz, COCH2), 2.91 (t, 2H, 3J = 7.3 Hz, 
CH2SPh), 3.66 (s, 3H, OCH3), 7.16 (m, 1H, Ph-H), 7.29 (m, 4H, Ph-H). EI-MS (70 eV) 
m/z (%): 238 (100) [M+·]. Anal. (C13H18O2S·0.5H2O) C, H. C13H18O2S (238,35). 
Methyl 6-(benzylthio)hexanoate76 (7.5): Solid K2CO3 (40 mmol, 5.53 g) was added 
to a solution of benzyl mercaptan (20 mmol, 2.35 ml) in 25 ml of anhydrous THF. The 
mixture was vigorously stirred while 7.3 (20 mmol, 4.18 g) was added dropwise. After 
refluxing overnight the mixture was cooled, insoluble material was filtered off and the 
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solution was evaporated to dryness. The residue was taken up with saturated NaCl 
solution, and the mixture was extracted 3 times with diethyl ether. The combined 
organic phases were washed with saturated NaHCO3 and water, dried over MgSO4 
and concentrated. After flash chromatography (PE/EtOAc 90/10 v/v) the title 
compound was obtained as a colorless oil (3.85g, 76 %). 1H-NMR (CDCl3) δ 1.37 (m, 
2H, COCH2CH2CH2), 1.58 (m, 4H, COCH2CH2, CH2CH2SCH2Ph), 2.29 (t, 2H, 3J = 
7.5 Hz, COCH2), 2.41 (t, 2H, 3J = 7.3 Hz, CH2SCH2Ph), 3.66 (s, 3H, OCH3), 3.70 (s, 
2H, SCH2Ph), 7.26 (m, 5H, Ph-H). CI-MS (NH3) m/z (%): 270 (100) [M+NH4]+. Anal. 
(C14H20O2S) C, H. C14H20O2S (252.37). 
7.6.2.3 General procedure for the synthesis of the ethers 6-13, 16, 33 and 36-
38 
Method A: To a solution of alkyl halide (1eq) and the appropriate phenol (1.5 eq) in 
anhydrous acetone was added K2CO3 (3 eq) and the mixture was refluxed overnight. 
After cooling insoluble material was removed by filtration and the solvent was 
evaporated under reduced pressure. The residue was taken up in EtOAc and 
washed successively with saturated K2CO3, water and brine. The organic phase was 
dried over MgSO4, filtered, and evaporated. The crude product was submitted to 
flash chromatography. 
Method B: A solution of the corresponding lactone (1eq), the appropriate alkyl 
halide (2 eq) and KOH (3 eq) in toluene was heated at reflux overnight. The reaction 
was quenched by acidification with 0.5 N HCl solution (pH value <2). The resulting 
mixture was then extracted four times with diethyl ether. The combined ether extracts 
were washed with brine, dried over MgSO4, filtered and concentrated under reduced 
pressure. The residue was flash chromatographed to yield the target compounds. 
Method C: The corresponding phenol (1.1 eq) was dissolved in ethanol and KOH 
(2.2 eq) was added. The pertinent alkyl halide (1 eq) was added and the reaction 
mixture was refluxed 4 h under an argon atmosphere. After dilution with water and 
acidification with concentrated hydrochloric acid, the solvent was evaporated. 
Methyl 6-phenoxyhexanoate77 (7.6): The title compound was prepared from 7.3 (20 
mmol, 4.18 g), phenol (30 mmol, 2.82 g) and K2CO3 (60 mmol, 8.29 g) in 150 ml 
anhydrous acetone according to 7.6.2.3, Method A and isolated by flash 
chromatography (PE/EtOAc 90/10 v/v) as a colorless oil (3.64 g, 87 %). 1H-NMR 
(CDCl3) δ 1.51 (m, 2H, COCH2CH2CH2), 1.76 (m, 4H, COCH2CH2, CH2CH2OPh), 
2.36 (t, 2H, 3J =7.4 Hz, COCH2), 3.68 (s, 3H, OCH3), 3.96 (t, 2H, 3J = 6.4 Hz, 
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CH2OPh), 6.92 (m, 3H, Ph-H), 7.28 (m, 2H, Ph-H). CI-MS (NH3) m/z (%): 240 (20) 
[M+NH4]+. Anal. (C13H18O3·0.4H2O) C, H. C13H18O3 (222,28). 
Methyl 6-(4-ethylphenoxy)hexanoate (7.7): The title compound was prepared from 
7.3 (20 mmol, 4.18 g), p-ethylphenol (30 mmol, 3.67 g) and K2CO3 (60 mmol, 8.29 g) 
in 150 ml anhydrous acetone according to 7.6.2.3, Method A and was obtained after 
flash chromatography (PE/EtOAc 90/10 v/v) as a colorless oil (4.12 g, 87 %). 1H-
NMR (CDCl3) δ 1.21 (t, 3H, 3J = 7.6 Hz, CH2CH3), 1.50 (m, 2H, COCH2CH2CH2), 
1.74 (m, 4H, COCH2CH2, CH2CH2OC6H4), 2.35 (t, 2H, 3J = 7.4 Hz, COCH2), 2.59 (q, 
2H, 3J =7.6Hz, CH2CH3), 3.67 (s, 3H, OCH3), 3.93 (t, 2H, 3J = 6.4 Hz, CH2OC6H4), 
6.81 (m, 2H, Ar-H), 7.10 (m, 2H, Ar-H). PI-EIMS (70 eV) m/z (%): 250 (50) [M+·]. 
Anal. (C15H22O3·0.4H2O) C, H. C15H22O3 (250.33). 
Methyl 6-(p-biphenylyloxy)hexanoate (7.8): The title compound was prepared from 
7.3 (20 mmol, 4.18g), 4-phenylphenol (30 mmol, 5.11 g) and K2CO3 (60 mmol, 8.29 
g) in 150 ml anhydrous acetone according to 7.6.2.3, Method A. Flash 
chromatography (PE/EtOAc 80/20 v/v) and recrystallization from methanol yielded a 
white solid (3.97 g, 67 %). mp: 65-66 °C; 1H-NMR (CDCl3) δ 1.52 (m, 2H, 
COCH2CH2CH2), 1.77 (m, 4H, , COCH2CH2, CH2CH2OC6H4), 2.36 (t, 2H, 3J = 7.4 Hz, 
COCH2), 3.67 (s, 3H, OCH3), 3.99 (t, 2H, 3J = 6.4 Hz, CH2OC6H4), 6.95 (m, 2H, Ar-
H), 7.29 (m, 1H, Ph-H), 7.41 (m, 2H, Ar-H), 7.53 (m, 4H, Ar-H). CI-MS (NH3) m/z (%): 
316 (100) [M+NH4]+. Anal. (C19H22O3) C, H. C19H22O3 (298.38). 
Methyl 6-[4-(benzyloxy)phenoxy]hexanoate78 (7.9): The title compound was 
prepared from 7.3 (20 mmol, 4.18g), 4-benzyloxyphenol (30 mmol, 6.01 g) and 
K2CO3 (60 mmol, 8.29 g) in 150 ml anhydrous acetone according to 7.6.2.3, Method 
A. Flash chromatography (PE/EtOAc 90/10 v/v) yielded a white solid (4.07 g, 62 %). 
mp: 80-81 °C;  1H-NMR (CDCl3) δ 1.49 (m, 2H, COCH2CH2CH2), 1.72 (m, 4H, 
COCH2CH2, CH2CH2OCH2), 2.34 (t, 2H, 3J = 7.5 Hz, COCH2CH2), 3.67 (s, 3H, 
OCH3), 3.90 (t, 2H, 3J = 6.4 Hz, CH2OCH2Ph), 5.01 (s, 2H, CH2Ph), 6.81 (m, 2H, Ar-
H), 6.89 (m, 2H, Ar-H), 7.36 (m, 5H, Ph-H). CI-MS (NH3) m/z (%): 346 (100) 
[M+NH4]+. Anal. (C20H24O4) C, H. C20H24O4 (328.4). 
6-(Benzyloxy)hexanoic acid79 (7.10): The title compound was prepared from ε-
caprolactone (21 mmol, 2.24 ml), benzyl chloride (42 mmol, 4.83 ml) and KOH (84 
mmol, 4.71 g) in 20 ml toluene according to 7.6.2.3, Method B. Flash 
chromatography (PE/EtOAc 80/20 v/v) gave a colorless oil (3.81 g, 82 %). 1H-NMR 
(CDCl3) δ 1.44 (m, 2H, COCH2CH2CH2), 1.65 (m, 4H, COCH2CH2, CH2CH2OBn), 
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2.36 (t, 2H, 3J = 7.5 Hz, COCH2), 3.48 (t, 2H, 3J = 6.5 Hz, CH2OBn), 4.51 (s, 2H, 
OCH2Ph), 7.32 (m, 5H, Ph-H). EI-MS (70 eV) m/z (%): 222 (4) [M+·]. C13H18O3 
(222,28). 
6-(p-Biphenylylmethoxy)hexanoic acid (7.11): The title compound was prepared 
from ε-caprolactone (4 mmol, 0.44 ml), 4-(bromomethyl)biphenyl (8 mmol, 1.98 g) 
and KOH (16 mmol, 0.90 g) in 5 ml toluene according to 7.6.2.3, Method B and was 
obtained after flash chromatography (PE/EtOAc 80/20 + 0.1 % HOAc v/v) as a 
colorless oil (0.85 g, 71 %). 1H-NMR (CDCl3) δ 1.44 (m, 2H, COCH2CH2CH2), 1.65 
(m, 4H, COCH2CH2, CH2CH2OCH2), 2.36 (t, 2H, 3J = 7.4 Hz, COCH2CH2), 3.50 (t, 
2H, 3J = 6.5 Hz, CH2OCH2C6H4), 4.53 (s, 2H, OCH2C6H4), 7.30 – 7.45 (m, 5H, Ph-H), 
7.58 (m, 4H, Ar-H). CI-MS (NH3) m/z (%): 316 (100) [M+NH4]+. Anal. 
(C19H22O3·0.2C6H4CH3) C, H. C19H22O3 (298.38). 
5-(Heptan-1-yloxy)pentanoic acid (7.12): The title compound was prepared from δ - 
valerolactone (42 mmol, 4.20 g), 1-iodoheptane (84 mmol, 9.5 g which was prepared 
from 1-bromoheptane using standard Finkelstein reaction80, 81) and KOH (168 mmol, 
9.43 g) in 40 ml toluene according to 7.6.2.3, Method B. Flash chromatography 
(PE/EtOAc 80/20 + 0.1 % HOAc v/v) yielded a colorless oil (1.10 g, 12 %). 1H-NMR 
(CDCl3) δ 0.88 (t, 3H, 3J = 6.7 Hz, CH2CH3), 1.29 (m, 8H, (CH2)4CH3),1.65 (m, 6H, 
COCH2(CH2)2, OCH2CH2), 2.39 (t, 2H, 3J = 7.2 Hz, COCH2), 3.41 (m, 4H, CH2OCH2). 
CI-MS (NH3) m/z (%): 234 (100) [M+NH4]+. Anal. (C12H24O3·0.1C6H4CH3) C, H. 
C12H24O3 (216.32). 
6-(Hexan-1-yloxy)hexanoic acid (7.13): The title compound was prepared from ε-
caprolactone (21 mmol, 2.24 ml), 1-iodohexane (42 mmol, 6.2 ml) and KOH (84 
mmol, 4.71 g) in 30 ml toluene according to 7.6.2.3, Method B. Flash 
chromatography (PE/EtOAc 80/20 + 0.1 % HOAc v/v) yielded a colorless oil (1.30 g, 
29 %). 1H-NMR (CDCl3) δ 0.88 (t, 3H, 3J = 6.8 Hz, CH3), 1.25 – 1.71 (m, 14H, 
COCH2(CH2)3, (CH2)4CH3), 2.36 (t, 2H, 3J = 7.5 Hz, COCH2), 3.40 (m, 4H, 
CH2OCH2). CI-MS (NH3) m/z (%): 215 (100) [M-H]-. Anal. (C12H24O3) calc C: 66.63, 
H: 11.18, found C: 65.50, H: 11.78. C12H24O3 (216.32). 
Methyl 6-(benzyloxy)hexanoate82 (7.14): The title compound was prepared from 
7.10 (15.3 mmol, 3.40 g) and TMSCl (33.7 mmol, 4.3 ml) in 25 ml anhydrous 
methanol according to the general procedure 7.6.2.1 yielding 7.14 as a colorless oil 
(2.98 g, 82 %). 1H-NMR (CDCl3) δ 1.41 (m, 2H, COCH2CH2CH2), 1.65 (m, 4H, 
COCH2CH2, CH2CH2OBn), 2.32 (t, 2H, 3J = 7.5 Hz, COCH2), 3.47 (t, 2H, 3J = 6.5 Hz, 
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CH2OBn), 3.66 (s, 3H, OCH3), 4.50 (s, 2H, OCH2Ph), 7.31 (m, 5H, Ph-H). EI-MS (70 
eV) m/z (%): 236 (1) [M+·]. Anal. (C14H20O3·0.8H2O) C, H. C14H20O3 (236,31). 
Methyl 6-(p-biphenylylmethoxy)hexanoate (7.15): The title compound was 
prepared from 7.11 (4.4 mmol, 1.30 g) and TMSCl (9.7 mmol, 1.2 ml) in 20 ml 
anhydrous methanol according to the general procedure 7.6.2.1 yielding 7.15 as a 
pale yellow oil (0.87 g, 63 %). 1H-NMR (CDCl3) δ 1.43 (m, 2H, COCH2CH2CH2-), 1.66 
(m, 4H, COCH2CH2, CH2CH2OCH2), 2.32 (t, 2H, 3J = 7.5 Hz, COCH2CH2), 3.50 (t, 
2H, 3J = 6.5 Hz, CH2OCH2C6H4), 3.66 (s, 3H, OCH3), 4.54 (s, 2H, OCH2C6H4), 7.39 
(m, 5H, Ar-H), 7.58 (m, 4H, Ar-H). CI-MS (NH3) m/z (%): 330 (100) [M+NH4]+. Anal. 
(C20H24O3·0.4H2O) C, H.  C20H24O3 (312.4). 
Methyl 6-(4-bromophenoxy)hexanoate (7.16): The title compound was prepared 
from 7.3 (20 mmol, 4.18g), p-bromophenol (30 mmol, 5.19 g) and K2CO3 (60 mmol, 
8.29 g) in 150 ml anhydrous acetone according to 7.6.2.3, Method A. Flash 
chromatography (PE/EtOAc 90/10 v/v) yielded a colorless solid (4.87 g, 81 %). mp: 
30-31 °C;  1H-NMR (CDCl3) δ 1.49 (m, 2H, COCH2CH2CH2), 1.75 (m, 4H, 
COCH2CH2, CH2CH2OC6H4), 2.35 (t, 2H, 3J = 7.4 Hz, COCH2CH2), 3.67 (s, 3H, 
OCH3), 3.92 (t, 2H, 3J = 6.4 Hz, CH2OC6H4), 6.76 (m, 2H, Ar-H), 7.36 (m, 2H, Ar-H). 
EI-MS (70 eV) m/z (%): 300 (15), 302 (15) [M+·]. Anal. (C13H17BrO3) C, H. C13H17BrO3 
(301.18). 
7.6.2.4 General Suzuki cross coupling conditions for the synthesis of biaryl 
intermediates 17-26 
To a solution of 7.16 (1 eq) and the corresponding boronic acid (1.5 eq) in a mixture 
of 15 ml toluene and 15 ml methanol was added 2 N Na2CO3 (1 – 2 eq), and the 
resulting suspension was purged with argon for 5 min followed by addition of 
Pd(PPh3)4 (1.5 mol- %). The reaction mixture was stirred at 80 °C under argon over 
48 h. After cooling the organic solvent was removed under reduced pressure and the 
residue was taken up in water (20 ml) and extracted tree times with EtOAc. The 
organic layers were combined, dried over MgSO4, filtered, and concentrated under 
reduced pressure. The crude product was purified by flash chromatography.  
Methyl 6-[4-(thiophen-3-yl)phenoxy]hexanoate (7.17): The title compound was 
prepared from 7.16 (3 mmol, 0.90 g), thiophene-2-boronic acid (4.5 mmol, 0.58 g), 
2 N Na2CO3 (1.5 ml) and Pd(PPh3)4 (0.45 mmol, 52 mg) according to general 
conditions 7.6.2.1. Flash chromatography (PE/EtOAc 95/5 v/v) gave a white solid 
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(0.60 g, 72 %). mp: 103 °C; 1H-NMR (CDCl3) δ 1.52 (m, 2H, COCH2CH2CH2), 1.76 
(m, 4H, COCH2CH2, CH2CH2OC6H4), 2.36 (t, 2H, 3J = 7.4 Hz, COCH2CH2), 3.68 (s, 
3H, OCH3), 3.98 (t, 2H, 3J = 6.4 Hz, CH2OC6H4), 6.91 (m, 2H, Ar-H), 7.35 (m, 3H, Ar-
H), 7.51 (m, 2H, Ar-H). CI-MS (NH3) m/z (%): 322 (100) [M+NH4]+. Anal. (C17H20O3S) 
C, H. C17H20O3S (304.40). 
Methyl 6-[4-(4-methoxyphenyl)phenoxy]hexanoate (7.18): The title compound 
was prepared from 7.16 (3 mmol, 0.90 g), 4-methoxyphenylboronic acid which was 
prepared according to known procedures33 (4.5 mmol, 0.68 g), 2 N Na2CO3 (1.5 ml) 
and Pd(PPh3)4 (0.45 mmol, 52 mg) according to general conditions 7.6.2.1. Flash 
chromatography (PE/EtOAc 95/5 to 80/20 v/v) yielded a white solid (0.76 g, 77 %). 
mp: 116-117 °C; 1H-NMR (CDCl3) δ 1.52 (m, 2H, COCH2CH2CH2), 1.77 (m, 4H, 
COCH2CH2, CH2CH2OC6H4), 2.35 (t, 2H, 3J = 7.5 Hz, COCH2CH2), 3.68 (s, 3H, 
CO2CH3),  3.84 (s, 3H, C6H4OCH3), 3.99 (t, 2H, 3J = 6.4 Hz, CH2OC6H4), 6.94 (m, 
4H, Ar-H), 7.47 (m, 4H, Ar-H). CI-MS (NH3) m/z (%): 346 (100) [M+NH4]+. Anal. 
(C20H24O4) C, H. C20H24O4 (328.4). 
Methyl 6-[4-(2-methoxyphenyl)phenoxy]hexanoate (7.19): The title compound 
was prepared from 7.16 (3 mmol, 0.90 g), 2-methoxyphenylboronic acid (4.5 mmol, 
0.68 g), 2 N Na2CO3 (1.5 ml) and Pd(PPh3)4 (0.45 mmol, 52 mg) according to general 
conditions 7.6.2.1. Flash chromatography (PE/EtOAc 90/10 v/v) yielded a colorless 
oil (0.74 g, 75 %). 1H-NMR (CDCl3) δ 1.52 (m, 2H, COCH2CH2CH2), 1.77 (m, 4H, 
COCH2CH2, CH2CH2OC6H4), 2.36 (t, 2H, 3J = 7.4 Hz, COCH2CH2), 3.68 (s, 3H, 
CO2CH3), 3.80 (s, 3H, C6H4OCH3), 3.99 (t, 2H, 3J = 6.4 Hz, CH2OC6H4), 6.97 (m, 4H, 
Ar-H), 7.28 (m, 2H, Ar-H), 7.45 (m, 2H, Ar-H). EI-MS (70 eV) m/z (%): 328 (93) [M+·]. 
Anal. (C20H24O4) C, H. C20H24O4 (328.40). 
Methyl 6-[4-(4-methylphenyl)phenoxy]hexanoate (7.20): The title compound was 
prepared from 7.16 (3 mmol, 0.90 g), 4-methylphenylboronic acid (4.5 mmol, 0.61 g), 
2 N Na2CO3 (1.5 ml) and Pd(PPh3)4 (0.45 mmol, 52 mg) according to general 
conditions 7.6.2.1. Flash chromatography (PE/EtOAc 95/5 to 80/20 v/v) yielded a 
white solid (0.88 g, 94 %). 1H-NMR (CDCl3) δ 1.52 (m, 2H, COCH2CH2CH2), 1.76 (m, 
4H, COCH2CH2, CH2CH2OC6H4), 2.36 (m, 5H, COCH2CH2, C6H4CH3), 3.67 (s, 3H, 
OCH3),  3.99 (t, 2H, 3J = 6.4 Hz, CH2OC6H4), 6.94 (m, 2H, Ar-H), 7.22 (m, 2H, Ar-H) 
7.47 (m, 4H, Ar-H). CI-MS (NH3) m/z (%): 330 (100) [M+NH4]+. Anal. (C20H24O3) C, H. 
C20H24O3 (312.4). 
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Methyl 6-[4-(2-methylphenyl)phenoxy]hexanoate (7.21): The title compound was 
prepared from 7.16 (3 mmol, 0.90 g), 2-methylphenylboronic acid (4.5 mmol, 0.61 g), 
2 N Na2CO3 (1.5 ml) and Pd(PPh3)4 (0.45 mmol, 52 mg) according to general 
conditions 7.6.2.1. Flash chromatography (PE/EtOAc 90/10 v/v) yielded a colorless 
oil (0.89 g, 95 %). 1H-NMR (CDCl3) δ 1.53 (m, 2H, COCH2CH2CH2),  1.78 (m, 4H, 
COCH2CH2, CH2CH2OC6H4), 2.28 (s, 3H, C6H4CH3), 2.37 (t, 2H, 3J = 7.4 Hz, 
COCH2CH2), 3.68 (s, 3H, OCH3), 4.00 (t, 2H, 3J = 6.4 Hz, CH2OC6H4), 6.93 (m, 2H, 
Ar-H), 7.24 (m, 7H, Ar-H). EI-MS (70 eV) m/z (%): 312 (35) [M+·]. Anal. 
(C20H24O3·0.1CH2Cl2) C, H. C20H24O3 (312.40). 
Methyl 6-[4-(naphthalen-1-yl)phenoxy]hexanoate (7.22): The title compound was 
prepared from 7.16 (3 mmol, 0.90 g) naphthalene-1-boronic acid (4.5 mmol, 0.77 g), 
2 N Na2CO3 (1.5 ml) and Pd(PPh3)4 (0.45 mmol, 52 mg) according to general 
conditions 7.6.2.1. Flash chromatography (PE/EtOAc 90/10 v/v) yielded a pale yellow 
oil (0.92 g, 88 %). 1H-NMR (CDCl3) δ 1.55 (m, 2H, COCH2CH2CH2), 1.80 (m, 4H, 
COCH2CH2, CH2CH2OC6H4), 2.38 (t, 2H, 3J = 7.4 Hz, COCH2CH2), 3.69 (s, 3H, 
OCH3), 4.04 (t, 2H, 3J = 6.4 Hz, CH2OC6H4), 7.01 (m, 2H, Ar-H), 7.45 (m, 6H, Ar-H), 
7.87 (m, 3H, Ar-H). EI-MS (70 eV) m/z (%): 348 (64) [M+·]. Anal. (C23H24O3) C, H. 
C23H24O3 (348.43). 
Methyl 6-[4-(4-hydroxyphenyl)phenoxy]hexanoate (7.23): The title compound was 
prepared from 7.16 (3 mmol, 0.90 g), 4-hydroxyphenylboronic acid (4.5 mmol, 0.62 
g), 2 N Na2CO3 (1.5 ml) and Pd(PPh3)4 (0.45 mmol, 52 mg) according to general 
conditions 7.6.2.1. Flash chromatography (PE/EtOAc 90/10 to 70/30 v/v) yielded a 
white solid (0.84 g, 89 %). mp: 113 °C; 1H-NMR (DMSO-d6) δ  1.42 (m, 2H, 
COCH2CH2CH2), 1.65 (m, 4H, COCH2CH2, CH2CH2OC6H4), 2.33 (t, 2H, 3J = 7.3 Hz, 
COCH2CH2), 3.59 (s, 3H, OCH3),  3.96 (t, 2H, 3J = 6.4 Hz, CH2OC6H4), 6.81 (m, 2H, 
Ar-H), 6.94 (m, 2H, Ar-H), 7.44 (m, 4H, Ar-H), 9.44 (s, 1H, -OH). EI-MS (70 eV) m/z 
(%): 314 (42) [M+·]. Anal. (C19H22O4) C, H. C19H22O4 (314.38). 
Methyl 6-[4-(3-hydroxyphenyl)phenoxy]hexanoate (7.24): The title compound was 
prepared from 7.16 (3 mmol, 0.90 g), 3-hydroxyphenylboronic acid (4.5 mmol, 0.62 
g), 2 N Na2CO3 (1.5 ml) and Pd(PPh3)4 (0.45 mmol, 52 mg) according to general 
conditions 7.6.2.1. Flash chromatography (PE/EtOAc 90/10 v/v) yielded a white solid 
(0.76 g, 81 %). mp: 110-111 °C; 1H-NMR (CDCl3) δ 1.52 (m, 2H, COCH2CH2CH2), 
1.76 (m, 4H, COCH2CH2, CH2CH2OC6H4), 2.37 (t, 2H, 3J = 7.4 Hz, COCH2CH2), 3.68 
(s, 3H, OCH3), 3.99 (t, 2H, 3J = 6.4 Hz, CH2OC6H4), 5.15 (s, 1H, OH), 6.77 (m, 1H, 
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Ar-H), 6.94 (m, 2H, Ar-H), 7.02 (m, 1H, Ar-H), 7.11 (m, 1H, Ar-H), 7.26 (m, 1H, Ar-H), 
7.48 (m, 2H, Ar-H). CI-MS (NH3) m/z (%): 332 (100) [M+NH4]+. Anal. (C19H22O4) C, H. 
C19H22O4 (314.38). 
4-[4-(6-Methoxy-6-oxohexan-1-yloxy)phenyl]benzoic acid (7.25): The title 
compound was prepared from 7.16 (3 mmol, 0.90 g), 4-carboxyphenylboronic acid 
which was prepared according to known procedures33 (4.5 mmol, 0.75 g), 2 N 
Na2CO3 (3 ml) and Pd(PPh3)4 (0.45 mmol, 52 mg) according to general conditions 
7.6.2.1. The reaction mixture was acidified (pH <2) with 1 N HCl before extraction. 
Flash chromatography (CHCl3/MeOH 95/5 to 90/10 v/v) yielded a white solid (0.83 g, 
81 %). mp: 155-157 °C; 1H-NMR (DMSO-d6) δ 1.43 (m, 2H, COCH2CH2CH2), 1.66 
(m, 4H,  COCH2CH2, CH2CH2OC6H4), 2.34 (t, 2H, 3J = 7.3 Hz, COCH2CH2), 3.59 (s, 
3H, OCH3), 4.00 (t, 2H, 3J = 6.4 Hz, CH2OC6H4), 7.03 (m, 2H, Ar-H), 7.71 (m, 4H, Ar-
H), 7.98 (m, 2H, Ar-H), 12.91 (bs, 1H, CO2H). EI-MS (70 eV) m/z (%): 342 (34) [M+·]. 
Anal. (C20H22O5) C, H. C20H22O5 (342.39). 
3-[4-(6-Methoxy-6-oxohexan-1-yloxy)phenyl]benzoic acid (7.26): The title 
compound was prepared from 7.16 (3 mmol, 0.90 g), 3-arboxyphenylboronic acid 
(4.5 mmol, 0.75 g), 2 N Na2CO3 (3 ml) and Pd(PPh3)4 (0.45 mmol, 52 mg) according 
to general conditions 7.6.2.1 with additional acidification of the reaction mixture to pH 
<2 with 1 N HCl before extraction and was obtained after flash chromatography 
(CHCl3/MeOH 95/5 to 90/10 v/v) as a white solid (0.95 g, 92 %). 1H-NMR (DMSO-d6) 
δ 1.43 (m, 2H, COCH2CH2CH2), 1.66 (m, 4H, COCH2CH2, CH2CH2OC6H4), 2.34 (t, 
2H, 3J = 7.3 Hz, COCH2CH2), 3.59 (s, 3H, OCH3), 4.00 (t, 2H, 3J = 6.4 Hz, 
CH2OC6H4), 7.03 (m, 2H, Ar-H), 7.58 (m, 3H, Ar-H), 7.87 (m, 2H, Ar-H), 8.13 (m, 1H, 
Ar-H), 12.97 (bs, 1H, CO2H). ES-MS (MeOH + NH4OAc) m/z (%): 341 (100) [M-H]-. 
Anal. (C20H22O5·0.2H2O) C, H. C20H22O5 (342.39). 
7.6.2.5 General procedure for the preparation of the tbutyl esters 27 and 28 
using tert-butyl 2,2,2-trichloroacetimidate 
To a solution of the appropriate carboxylic acid (1 eq) in anhydrous THF was added 
TBTA (2 eq, prepared according to known procedures35), dissolved in anhydrous 
cyclohexane (1ml/mmol) and BF3Et2O (20 µl/mmol). After stirring at room 
temperature overnight NaHCO3 was added and the mixture was stirred for 10 min. 
Insoluble material was filtered off, the solvent was evaporated and the remaining 
crude product was subjected to flash chromatography. 
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tert-Butyl 4-[4-(6-methoxy-6-oxohexyloxy)phenyl]benzoate (7.27): The title 
compound was prepared from 7.25 (2.3 mmol, 0.79 g), TBTA (4.6 mmol, 1.01 g) and 
BF3Et2O (46 µl) in anhydrous THF (10 ml) according to general procedure 7.6.2.5 
and was obtained after flash chromatography (PE/EtOAc 95/5 to 90/10 v/v) as a 
white solid (0.58 g, 64 %). 1H-NMR (CDCl3) δ 1.54 (m, 2H, COCH2CH2CH2), 1.61 (s, 
9H, C(CH3)3), 1.78 (m, 4H, COCH2CH2, CH2CH2OC6H4), 2.36 (t, 2H, 3J = 7.4 Hz, 
COCH2CH2), 3.68 (s, 3H, OCH3), 4.01 (t, 2H, 3J = 6.4 Hz, CH2OC6H4), 6.97 (m, 2H, 
Ar-H), 7.57 (m, 4H, Ar-H), 8.02 (m, 2H, Ar-H). EI-MS (70 eV) m/z (%): 398 (66) [M+·]. 
Anal. (C24H30O5) C, H. C24H30O5 (398.49). 
tert-Butyl 3-[4-(6-methoxy-6-oxohexyloxy)phenyl]benzoate (7.28): The title 
compound was prepared from 7.26 (3.4 mmol, 1.16 g), TBTA (4.6 mmol, 1.45 g) and 
BF3Et2O (68 µl) in anhydrous THF (15 ml) according to general procedure 7.6.2.5 
and was obtained after flash chromatography (PE/EtOAc 90/10 to 80/20 v/v) as a 
white solid (0.61 g, 45 %). mp: 66 °C; 1H-NMR (CDCl3) δ 1.54 (m, 11H, 
COCH2CH2CH2, C(CH3)3), 1.78 (m, 4H, COCH2CH2, CH2CH2OC6H4), 2.37 (t, 2H, 3J 
= 7.4 Hz, COCH2CH2), 3.68 (s, 3H, OCH3), 4.01 (t, 2H, 3J = 6.4 Hz, CH2OC6H4), 6.97 
(m, 2H, Ar-H), 7.45 (m, 1H, Ar-H), 7.54 (m, 2H, Ar-H), 7.70 (m, 1H, Ar-H), 7.92 (m, 
1H, Ar-H), 8.18 (m, 1H, Ar-H). EI-MS (70 eV) m/z (%): 398 (42) [M+·]. Anal. 
(C24H30O5) C, H. C24H30O5 (398.49). 
7.6.2.6 General procedure for the preparation of the carboxylic acids 29-32, 
34a and 39-41 by cleavage of the corresponding methyl esters: 
The corresponding methyl ester (1 eq) was dissolved in THF, MeOH and water. LiOH 
(1.5 eq) was added and the mixture was stirred overnight at room temperature. After 
diluting with water, acidification with 1 N HCl to pH <2 and extraction three times with 
EtOAc, the combined organic phases were washed with brine, dried over MgSO4, 
filtered and evaporated under reduced pressure. The resulting free carboxylic acids 
were used in the next step without further purification. 
6-[4-(4-Methoxyphenyl)phenoxy]hexanoic acid83 (7.29): The title compound was 
prepared from 7.19 (1.6 mmol, 0.53 g), LiOH (2.4 mmol, 57 mg) THF (3 ml), MeOH 
(0.2 ml) and water (1ml) according to general procedure 7.6.2.6 and was obtained as 
a white solid (0.46 g, 91 %). mp: 151 °C; 1H-NMR (DMSO-d6) δ 1.42 (m, 2H, 
COCH2CH2CH2), 1.56 (m, 2H, COCH2CH2), 1.72 (m, 2H, CH2CH2OC6H4), 2.24 (t, 
2H, 3J = 7.2 Hz, COCH2CH2), 3.78 (s, 3H, C6H4OCH3), 3.97 (t, 2H, 3J = 6.4 Hz, , 
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CH2OC6H4), 6.97 (m, 4H, Ar-H), 7.52 (m, 4H, Ar-H), 12.03 (s, 1H, CO2H). ES-MS 
(DCM/MeOH + NH4OAc) m/z (%): 332 (100) [M+NH4]+. Anal. (C19H22O4) C, H. 
C19H22O4 (314.38). 
6-[4-(Naphthalen-1-yl)phenoxy]hexanoic acid (7.30): The title compound was 
prepared from 7.22 (0.8 mmol, 0.28 g), LiOH (1.2 mmol, 29 mg) THF (3 ml), MeOH 
(0.2 ml) and water (1ml) according to general procedure 7.6.2.6 and was obtained as 
a white solid (0.25 g, 93 %). mp: 123 °C; 1H-NMR (DMSO-d6) δ 1.41 – 1.81 (m, 6H, 
COCH2(CH2)2), 2.26 (t, 2H, 3J = 7.2 Hz, COCH2CH2), 4.03 (t, 2H, 3J = 6.4 Hz, 
CH2OC6H4), 7.07 (m, 2H, Ar-H), 7.37 – 7.58 (m, 6H, Ar-H), 7.91 (m, 3H, Ar-H). EI-MS 
(70 eV) m/z (%): 334 (61) [M+·]. Anal. (C22H22O3·0.2H2O) C, H. C22H22O3 (334.41). 
6-[4-(4-tert-Butoxycarbonylphenyl)phenoxy]hexanoic acid (7.31): The title 
compound was prepared from 7.27 (1.2 mmol, 0.48 g), LiOH (1.8 mmol, 43 mg) THF 
(3 ml), MeOH (0.2 ml) and water (1ml) according to general procedure 7.6.2.6 and 
was obtained as a pale yellow solid (0.40 g, 95 %). mp: 83 °C; 1H-NMR (CDCl3) δ 
1.44 (m, 2H, COCH2CH2CH2), 1.57 (m, 11H, C(CH3)3, COCH2CH2), 1.74 (m, 2H, 
CH2CH2OC6H4), 2.24 (t, 2H, 3J = 7.2 Hz, COCH2CH2), 4.01 (t, 2H, 3J = 6.4 Hz, 
CH2OC6H4), 7.04 (m, 2H, Ar-H), 7.66 (m, 2H, Ar-H), 7.74 (m, 2H, Ar-H), 7.94 (m, 2H, 
Ar-H), 12.01 (s, 1H, CO2H). EI-MS (70 eV) m/z (%): 384 (6) [M+·]. Anal. (C23H28O5) C, 
H. C23H28O5 (384.47). 
6-[4-(3-tert-Butoxycarbonylphenyl)phenoxy]hexanoic acid (7.32): The title 
compound was prepared from 7.28 (1.4 mmol, 0.56 g), LiOH (2.1 mmol, 57 mg) THF 
(3 ml), MeOH (0.2 ml) and water (1ml) according to general procedure 7.6.2.6 and 
was obtained as a white solid (0.52 g, 97 %). mp: 91 °C; 1H-NMR (DMSO-d6) δ 1.42 
(m, 2H, COCH2CH2CH2), 1.57 (m, 11H, C(CH3)3, COCH2CH2), 1.73 (m, 2H, 
CH2CH2OC6H4), 2.24 (t, 2H, 3J = 7.2 Hz, COCH2CH2), 4.00 (t, 2H, 3J = 6.4 Hz, 
CH2OC6H4), 7.03 (m, 2H, Ar-H), 7.57 (m, 3H, Ar-H), 7.85 (m, 2H, Ar-H), 8.07 (m, 1H, 
Ar-H), 12.03 (bs, 1H, CO2H). EI-MS (70 eV) m/z (%): 384 (31) [M+·]. Anal. (C23H28O5) 
C, H. C23H28O5 (384.47). 
Methyl 11-phenoxyundecanoate84 (7.33): The title compound was prepared from 
phenol (22 mmol, 2.07 g), KOH (44 mmol, 2.47 g) and 11-bromoundecanoic acid (20 
mmol, 5.30 g) in 150 ml EtOH according to general procedure 7.6.2.3, Method C. 
The resulting raw product was then esterified according to the general procedure for 
the synthesis of methyl esters using TMSCl (44 mmol, 5.6 ml) in anhydrous methanol 
(50 ml) and was obtained after flash chromatography (PE/EtOAc 90/10 v/v) as a 
Chapter 7 Ascorbic acid derivatives as potent hyaluronidase inhibitors 
155 
colorless semisolid substance (2.94 g, 50 %). 1H-NMR (CDCl3) δ 1.24 – 1.51 (m, 
12H, COCH2CH2(CH2)6), 1.61 (m, 2H,  COCH2CH2), 1.77 (m, 2H, CH2CH2OPh), 2.30 
(t, 2H, 3J = 7.5 Hz, COCH2CH2), 3.66 (s, 3H, OCH3), 3.95 (t, 2H, 3J = 6.6 Hz, 
CH2OPh), 6.90 (m, 3H, Ph-H), 7.27 (m, 2H, Ph-H). PI-EIMS (70 eV) m/z (%): 292 
(38) [M+·]. Anal. (C18H28O3·0.5H2O) C, H. C18H28O3 (292.41). 
Methyl 11-(4-phenylphenoxy)undecanoate85 (7.34): The title compound was 
prepared from 4-phenylphenol (22 mmol, 3.74 g), KOH (44 mmol, 2.47 g) and 11-
bromoundecanoic acid (20 mmol, 5.30 g) in 150 ml EtOH according to Method C. 
The resulting raw product was then esterified according to general procedure 7.6.2.1 
using TMSCl (44 mmol, 5.6 ml) in anhydrous methanol (50 ml) and was obtained 
after flash chromatography (PE/EtOAc 90/10 v/v) as a white solid (2.82 g, 38 %). mp: 
78-80 °C; 1H-NMR (CDCl3) δ 1.25 - 1,49 (m, 12H, COCH2CH2(CH2)6), 1.62 (m, 2H, 
COCH2CH2), 1.79 (m, 2H, CH2CH2OC6H4), 2.30 (t, 2H, 3J = 7.5 Hz, COCH2CH2), 
3.66 (s, 3H, OCH3), 3.98 (t, 2H, 3J = 6.5 Hz, CH2OC6H4), 6.96 (m, 2H, Ar-H), 7.29 (m, 
1H, Ph-H), 7.40 (m, 2H, Ar-H), 7.53 (m, 4H, Ar-H). EI-MS (70 eV) m/z (%): 368 (8) 
[M+·]. Anal. (C24H32O3) C, H. C24H32O3 (368.51). 
11-(4-Phenylphenoxy)undecanoic acid86 (7.34a): The title compound was 
prepared from 7.34 (2.8 mmol, 1.03 g), LiOH (4.2 mmol, 0.10 g) THF (20 ml), MeOH 
(5 ml) and water (5ml) according to general procedure 7.6.2.6 and was obtained as a 
white solid (0.87 g, 88 %). 1H-NMR (acetone-d6) δ 1.41 (m, 14H, COCH2(CH2)7), 1.80 
(m, 2H, CH2CH2OC6H4), 2.28 (t, 2H, 3J = 7.4 Hz, COCH2CH2), 4.05 (t, 2H, 3J = 6.5 
Hz, CH2OC6H4), 7.02 (m, 2H, Ar-H), 7.29 (m, 1H, Ar-H), 7.42 (m, 2H, Ar-H), 7.59 (m, 
4H, Ar-H),10.45 (bs, 1H, CO2H). EI-MS (70 eV) m/z (%): 354 (34) [M+·]. Anal. 
(C23H30O3·0.5H2O) C, H. C23H30O3 (354.48). 
Dodecanedioic acid mono-tert-butyl ester (7.35)37: To an ice-cold solution of 
dodecanedioic acid (32.5 mmol, 7.48g), tert-butyl alcohol (32.5 mmol, 32 ml) and a 
catalytic amount of DMAP in anhydrous THF (40 ml), a solution of DCC (39 mmol, 
8.04 g) in anhydrous THF (10 ml) was slowly added. Subsequently, the solution was 
warmed to room temperature and stirred overnight. The reaction mixture was filtered, 
concentrated under reduced pressure und subjected to flash chromatography 
(PE/EtOAc 80/20 to 50/50 v/v). The title compound was obtained as a colorless oil 
(3.02 g, 32 %). 1H-NMR (CDCl3) δ 1.26 (m, 12H, COCH2CH2(CH2)6), 1.43 (s, 9H, 
C(CH3)3), 1.58 (m, 4H, COCH2CH2), 2.19 (t, 2H, 3J = 7.5 Hz, CH2CO2H), 2.33 (t, 2H, 
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3J = 7.5 Hz, CH2CO2tBu), 10.50 (bs, 1H, CO2H). CI-MS (NH3) m/z (%): 304 (56) 
[M+NH4]+. C16H30O4 (286,41). 
Methyl 2-(decan-1-yloxy)benzoate87 (7.36): The title compound was prepared from 
1-bromodecane (10 mmol, 2.1 ml), methyl 2-hydroxybenzoate (15 mmol, 2.28 g) and 
K2CO3 (30 mmol, 4.15 g) in 75 ml anhydrous acetone according to general procedure 
7.6.2.3, Method A and was obtained after flash chromatography (PE/EtOAc 90/10 
v/v) as a colorless oil (2.50 g, 85 %). 1H-NMR (CDCl3) δ 0.88 (t, 3H, 3J = 6.7 Hz, 
CH2CH3), 1.27 – 1.53 (m, 12H, (CH2)6CH3), 1.82 (m, 2H, OCH2CH2CH2), 3.88 (s, 3H, 
OCH3), 4.02 (t, 2H, 3J = 6.5 Hz, COCH2CH2), 6.96 (m, 2H, Ar-H), 7.42 (m, 1H, Ar-H), 
7.77 (dd, 1H, 4J =1.8Hz, 3J = 7.9 Hz, Ar-H). EI-MS (70 eV) m/z (%): 292 (4) [M+·]. 
Anal. (C18H28O3·0.2Cl2CH2) C, H. C18H28O3 (292.41). 
Methyl 3-(decan-1-yloxy)benzoate88 (7.37): The title compound was prepared from 
1-bromodecane (10 mmol, 2.1 ml), methyl 3-hydroxybenzoate (15 mmol, 2.28 g) and 
K2CO3 (30 mmol, 4.15 g) in 75 ml anhydrous acetone according to general procedure 
7.6.2.3, Method A and was obtained after flash chromatography (PE/EtOAc 90/10 
v/v) as a white solid (2.67 g, 91 %). mp: 33 °C; 1H-NMR (CDCl3) δ 0.88 (t, 3H, 3J = 
6.7 Hz, CH2CH3), 1.26 – 1.50 (m, 12H, (CH2)6CH3), 1.79 (m, 2H, OCH2CH2CH2), 3.91 
(s, 3H, OCH3), 3.99 (t, 2H, 3J = 6.5 Hz, COCH2CH2), 7.09 (ddd, 1H, 4J = 1.0 Hz, 4J = 
2.6 Hz, 3J = 8.3 Hz, Ar-H), 7.32 (dd, 1H, 3J = 7.9 Hz, 3J = 7.9 Hz, Ar-H), 7.55 (dd, 1H, 
4J = 1.5 Hz, 4J = 2.5 Hz, 1H, Ar-H), 7.61 (m, 1H, Ar-H). EI-MS (70 eV) m/z (%): 292 
(13) [M+·]. Anal. (C18H28O3) C, H. C18H28O3 (292.41). 
Methyl 4-(decan-1-yloxy)benzoate89 (7.38): The title compound was prepared from 
1-bromodecane (10 mmol, 2.1 ml), methyl 4-hydroxybenzoate (15 mmol, 2.28 g) and 
K2CO3 (30 mmol, 4.15 g) in 75 ml anhydrous acetone according to general procedure 
7.6.2.3, Method A and was obtained after flash chromatography (PE/EtOAc 90/10 
v/v) as a white solid (2.70 g, 92 %). mp: 47 °C (ref.90: 47-48 °C); 1H-NMR (CDCl3) δ 
0.88 (t, 3H, 3J = 6.7 Hz, CH2CH3), 1.27 – 1.50 (m, 12H, (CH2)6CH3), 1.79 (m, 2H, 
OCH2CH2CH2), 3.88 (s, 3H, OCH3), 3.99 (t, 2H, 3J = 6.6 Hz, COCH2CH2), 6.90 (m, 
2H, Ar-H), 7.97 (m, 2H, Ar-H). EI-MS (70 eV) m/z (%): 292 (22) [M+·]. Anal. 
(C18H28O3) C, H. C18H28O3 (292.41). 
2-(Decan-1-yloxy)benzoic acid87 (7.39): The title compound was prepared from 
7.36 (4 mmol, 1.17 g), LiOH (6 mmol, 0.14 g) THF (10 ml), MeOH (2 ml) and water (5 
ml) according to general procedure 7.6.2.6 and was obtained as a white semisolid 
substance (0.70 g, 62 %). 1H-NMR (CDCl3) δ 0.88 (t, 2H, 3J = 6.7 Hz, CH2CH3), 1.27 
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– 1.54 (m, 12H, (CH2)6CH3), 1.92 (m, 2H, OCH2CH2CH2), 4.25 (t, 2H, 3J = 6.6Hz, 
COCH2CH2),  7.05 (dd, 1H, 4J = 0.5 Hz, 3J = 8.4 Hz, Ar-H), 7.13 (ddd, 1H, 4J = 1.0 
Hz, 3J = 7.8 Hz, 3J = 7.7 Hz, Ar-H), 7.55 (ddd, 1H, 4J = 1.9 Hz, 3J = 7.4 Hz, 3J = 8.4 
Hz, Ar-H), 8.20 (dd, 1H, 4J = 1.8 Hz, 3J = 7.8 Hz, Ar-H), 10.96 (bs, 1H, CO2H). CI-MS 
(NH3) m/z (%): 296 (100) [M+NH4]+. Anal. (C17H26O3) C, H. C17H26O3 (278.39). 
3-(Decan-1-yloxy)benzoic acid88 (7.40): The title compound was prepared from 
7.37 (4 mmol, 1.17 g), LiOH (6 mmol, 0.14 g) THF (10 ml), MeOH (2 ml) and water (5 
ml) according to general procedure 7.6.2.6 and was obtained as a white solid (1.06 g, 
95 %). mp: 80 °C; 1H-NMR (CDCl3) δ 0.88 (t, 3H, 3J = 6.7 Hz, CH2CH3), 1.28 – 1.52 
(m, 12H, (CH2)6CH3), 1.80 (m, 2H, OCH2CH2CH2), 4.01 (t, 2H, 3J = 6.5 Hz, 
COCH2CH2), 7.15 (ddd, 1H, 4J = 1.0 Hz, 4J = 2.6 Hz, 3J = 8.3 Hz, Ar-H), 7.37 (dd, 1H, 
3J = 7.9 Hz, 3J = 7.9 Hz, Ar-H), 7.62 (dd, 1H, 4J = 1.5 Hz, 4J = 2.5 Hz, Ar-H), 7.70 (m, 
1H, Ar-H), 10.17 (bs, 1H, CO2H). EI-MS (70 eV) m/z (%): 278 (20) [M+·]. Anal. 
(C17H26O3) C, H. C17H26O3 (278.39). 
4-(Decan-1-yloxy)benzoic acid89 (7.41): The title compound was prepared from 
7.38 (4 mmol, 1.17 g), LiOH (6 mmol, 0.14 g) THF (10 ml), MeOH (2 ml) and water (5 
ml) according to general procedure 7.6.2.6 and was obtained as a white solid (1.03 g, 
92 %). mp: 88 °C (ref.90: 96-97 °C); 1H-NMR (CDCl3) δ 0.88 (t, 3H, 3J = 6.7 Hz, 
CH2CH3), 1.27 – 1.51 (m, 12H, (CH2)6CH3), 1.81 (m, 2H, OCH2CH2CH2), 4.02 (t, 2H, 
3J = 6.5 Hz, COCH2CH2),  6.93 (m, 2H, Ar-H), 8.06 (m, 2H, Ar-H), 11.00 (s, 1H, 
CO2H). EI-MS (70 eV) m/z (%): 278 (36) [M+·]. Anal. (C17H26O3) calcd. C: 73.34, H: 
9.41, found C: 73.22, H: 10.00. C17H26O3 (278.39). 
7.6.2.7 General procedure for the synthesis of the α-branched carboxylic 
acids 42-47 
To a solution of diethyl malonate (1 eq) in anhydrous THF was added NaH (60 % 
suspension, 1 eq), and the mixture was stirred for 10 min under an atmosphere of 
argon. The corresponding first alkyl halide (1 eq) was added followed by stirring at 
reflux overnight. After cooling another portion of NaH (60 % suspension, 1 eq) was 
added and the suspension was stirred for 1 h followed by addition of the second alkyl 
halide (1 eq) and stirring at reflux overnight again. After cooling, solids were removed 
by filtration and the solvent was evaporated. The crude product was suspended in 
EtOH (15 ml) and water (15 ml), KOH (10 eq) was added and the mixture was stirred 
at reflux overnight. The EtOH was removed under reduced pressure and the 
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remaining aqueous solution was diluted, washed with n-hexane, acidified with 2 N 
HCl to pH <2 and extracted three times with diethyl ether. The combined organic 
layers were washed with brine, dried over MgSO4, filtered and evaporated. The crude 
dicarboxylic acid was decarboxylated at 170 – 200 °C in a sand bath for 5 h. The α-
branched carboxylic acid was purified by flash chromatography. 
2-Propyldodecanoic acid91 (7.42): The title compound was prepared according to 
general procedure 7.6.2.7 by alkylating diethyl malonate (10 mmol, 1.5 ml) using 
NaH (60 % suspension, 10 mmol, 0.40 g) and 1-bromodecane (10 mmol, 2.1 ml) in 
the first step and using the same amount of NaH together with 1-iodopropane (10 
mmol, 1.0 ml) in the second step. The product was obtained after flash 
chromatography (PE/EtOAc 90/10 v/v) as a pale yellow oil (0.88 g, 36 %). 1H-NMR 
(CDCl3) δ 0.90 (m, 6H, CH3), 1.23 – 1.68 (m, 22H, (CH2)9CH3, (CH2)2CH3), 2.36 (tt, 
1H, 3J = 5.2 Hz, 3J = 8.8 Hz, COCH), 11.23 (bs, CO2H). CI-MS (NH3) m/z (%): 260 
(100) [M+NH4]+. Anal. (C15H30O2) calcd. C: 74.32, H: 12.43, found C: 74.17, H: 13.12. 
C15H30O2 (242.40). 
2-(Hexan-1-yl)dodecanoic acid92 (7.43): The title compound was prepared 
according to general procedure 7.6.2.7 by alkylating diethyl malonate (10 mmol, 1.5 
ml) using NaH (60 % suspension, 10 mmol, 0.40 g) and 1-bromodecane (10 mmol, 
2.1 ml) in the first step and using the same amount of NaH together with 1-
iodohexane (10 mmol, 1.5 ml) in the second step. The product was obtained after 
flash chromatography (PE/EtOAc 90/10 v/v) as a white foam (0.90 g, 32 %). 1H-NMR 
(CDCl3) δ 0.88 (t, 6H, 3J =6.6Hz, CH2CH3), 1.26 – 1.69 (m, 28H, (CH2)9CH3, 
(CH2)5CH3), 2.34 (tt, 1H, 3J =5.4Hz, 3J =8.6Hz, COCH), 11.30 (bs, 1H, CO2H). EI-MS 
(70 eV) m/z (%): 284 (66) [M+·]. Anal. (C18H36O2) C, H. C18H36O2 (284.48). 
2-(Decan-1-yl)dodecanoic acid93 (7.44): The title compound was prepared 
according to general procedure 7.6.2.7 by alkylating diethyl malonate (10 mmol, 1.5 
ml) using NaH (60 % suspension, 10 mmol, 0.40 g) and 1-bromodecane (10 mmol, 
2.1 ml) in the first step and using the same amount of NaH and 1-bromodecane in 
the second step. The product was obtained after flash chromatography (PE/EtOAc 
90/10 v/v) as a white solid (1.33 g, 39 %). mp: 52 °C; 1H-NMR (CDCl3) δ 0.88 (t, 6H, 
3J = 6.7 Hz, CH2CH3), 1.27 – 1.68 (m, 36H, (CH2)9CH3), 2.34 (tt, 1H, 3J = 5.4 Hz, 3J = 
8.6 Hz, COCH), 9.48 (s, 1H, CO2H). CI-MS (NH3) m/z (%): 359 (100) [M+NH4]+. Anal. 
(C22H44O2) C, H. C22H44O2 (340.58). 
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2-(2-Phenethyl)dodecanoic acid (7.45): The title compound was prepared 
according to general procedure 7.6.2.7 by alkylating diethyl malonate (10 mmol, 1.5 
ml) using NaH (60 % suspension, 10 mmol, 0.40 g) and 1-bromodecane (10 mmol, 
2.1 ml) in the first step and using the same amount of NaH together with (2-
bromoethyl)benzene (10 mmol, 1.4 ml) in the second step. The product was obtained 
after flash chromatography (PE/EtOAc 90/10 v/v) as a pale yellow oil (0.74 g, 24 %). 
1H-NMR (CDCl3) δ 0.88 (t, 3H, 3J = 6.7 Hz, CH2CH3), 1.62 (m, 20H, CH2), 2.42 (m, 
1H, COCH), 2.65 (m, 2H, CH2CH2Ph), 7.23 (m, 10H, Ph-H), 11.08 (bs, 1H, CO2H). 
EI-MS (70 eV) m/z (%): 304 (16) [M+·]. C20H32O2 (304.47). 
2-(4-Methoxybenzyl)dodecanoic acid (7.46): The title compound was prepared 
according to general procedure 7.6.2.7 by alkylating diethyl malonate (10 mmol, 1.5 
ml) using NaH (60 % suspension, 10 mmol, 0.40 g) and 1-bromodecane (10 mmol, 
2.1 ml) in the first step and using the same amount of NaH together with 1-
(chloromethyl)-4-methoxybenzene (10 mmol, 1.4 ml) in the second step. The product 
was obtained after flash chromatography (PE/EtOAc 90/10 v/v) as a pale yellow oil 
(0.53 g, 16 %). 1H-NMR (CDCl3) δ 0.89 (t, 3H, 3J = 6.7 Hz, CH2CH3), 1.25 – 1.68 (m, 
16H, (CH2)8CH3), 2.65 (m, 2H, OCH, CHCH2C6H4), 2.91 (dd, 1H, 3J = 7.7 Hz, 2J = 
13.5 Hz, CHCH2C6H4), 3.79 (s, 3H, OCH3), 6.82 (m, 2H, Ar-H), 7.10 (m, 2H, Ar-H), 
10.45 (bs, 1H, CO2H). EI-MS (70 eV) m/z (%): 320 (8) [M+·]. Anal. 
(C20H32O3·0.01C6H4CH3) C, H. C20H32O3 (320.47). 
2-(Hexan-1-yl)octadecanoic acid94 (7.47): The title compound was prepared 
according to general procedure 7.6.2.7 by alkylating diethyl malonate (10 mmol, 1.5 
ml) using NaH (60 % suspension, 10 mmol, 0.40 g) and 1-bromohexadecane (10 
mmol, 3.05 ml) in the first step and using the same amount of NaH together with 1-
iodohexane (10 mmol, 1.5 ml) in the second step. The product was obtained after 
flash chromatography (PE/EtOAc 90/10 v/v) as a pale yellow oil (0.62 g, 17 %). 1H-
NMR (CDCl3) δ 0.88 (t, 6H, 3J = 6.6 Hz, CH2CH3), 1.49 (m, 40H, (CH2)15CH3, 
(CH2)5CH3), 2.34 (tt, 1H, 3J = 5.4 Hz, 3J = 8.6Hz, COCH). ES-MS (DCM/MeOH + 
NH4OAc) m/z (%): 368 (100) [M-H]-. Anal. (C24H48O2·0.3H2O) C, H. C24H48O2 
(368.64). 
6-O-[6-(Phenylthio)hexanoyl]ascorbic acid (7.48): The title compound was 
prepared from ascorbic acid (2 mmol, 0.35 g), 7.4 (4 eq, 8 mmol, 1.79 g) and 
Novozyme 435® (100 mg) in 15 ml tert-amyl alcohol according to general procedure 
7.6.2.2, yielding 7.48 as a white solid (0.40 g, 54 %). mp: 108-110 °C; 1H-NMR 
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(DMSO-d6) δ 1.40 (m, 2H, COCH2CH2CH2), 1.56 (m, 4H, COCH2CH2, CH2CH2SPh), 
2.32 (t, 2H, 3J = 7.3 Hz, COCH2), 2.95 (t, 2H, 3J = 7.2 Hz, CH2SPh), 4.02 (m, 3H, -
CH2O-, CHOH) ppm 4.68 (d, 1H, 3J = 1.7 Hz, H-5), 5.31 (s, 1H, CHOH), 7.18 (m, 1H, 
Ph-H), 7.31 (m, 4H, Ph-H), 8.40 (bs, 1H, OH), 11.11 (bs, 1H, OH). 13C-NMR (DMSO-
d6) δ 23.83 (-, CH2), 27.47 (-, CH2), 28.13 (-, CH2), 31.67 (-, CH2), 33.18 (-, 
COCH2CH2), 64.39 (-, CH2O), 65.35 (+, CHO), 74.92 (+, CH), 118.08 (quat, C-2), 
125.37 (+, Ph-C), 127.81 (+, Ph-C), 128.91 (+, Ph-C), 136.32 (quat, Ph-C), 152.13 
(quat, C-3), 170.22 (quat, lactone CO), 172.55 (quat, CO2CH2). ES-MS (MeCN + 
TFA) m/z (%): 400 (100) [M+NH4]+. Anal. (C18H22O7S·0.5H2O) C, H. C18H22O7S 
(382.43). 
6-O-[6-(Benzylthio)hexanoyl]ascorbic acid (7.49): The title compound was 
prepared from ascorbic acid (3.3 mmol, 0.58 g), 7.5 (4 eq, 13.2 mmol, 3.33 g) and 
Novozyme 435® (165 mg) in 15 ml tert-amyl alcohol according to general procedure 
7.6.2.2, yielding 7.49 as a white amorphous solid (0.53 g, 41 %). 1H-NMR (DMSO-d6) 
δ 1.31 (m, 2H, COCH2CH2CH2), 1.50 (m, 4H, COCH2CH2, CH2CH2SBn), 2.31 (t, 2H, 
3J = 7.4 Hz, COCH2), 2.37 (t, 2H, 3J = 7.3 Hz, CH2SCH2Ph), 3.71 (s, 2H, SCH2Ph), 
4.03 (m, 3H, CH2O, CHOH), 4.68 (d, 1H, 3J = 1.6 Hz, H-5), 5.32 (d, 1H, 3J = 5.8 Hz, 
CHOH), 7.26 (m, 5H, Ph-H), 8.42 (s, 1H, OH), 11.13 (s, 1H, OH). 13C-NMR (DMSO-
d6) δ 23.87 (-, CH2), 27.57 (-, CH2), 28.26 (-, CH2), 30.36 (-, CH2), 33.19 (-
,COCH2CH2), 34.94 (-, SCH2Ph), 64.40 (-, CH2O), 65.40 (+, CHO), 74.93 (+, CH), 
118.09 (quat, C-2), 126.61 (+, Ph-C), 128.22 (+, Ph-C), 128.70 (+, Ph-C), 138.69 
(quat, Ph-C), 152.12 (quat, C-3), 170.27 (quat, lactone CO), 172.57 (quat, CO2CH2). 
ES-MS (DCM/MeOH + NH4OAc) m/z (%): 395 (100) [M-H]-. Anal. 
(C19H24O7S·0.7H2O) C, H. C19H24O7S (396.45). 
6-O-(6-Phenoxyhexanoyl)ascorbic acid (7.50): The title compound was prepared 
from ascorbic acid (3.3 mmol, 0.58 g), 7.6 (4 eq, 13.2 mmol, 2.75 g) and Novozyme 
435® (165 mg) in 15 ml tert-amyl alcohol according to general procedure 7.6.2.2, 
yielding 7.50 as a white solid (0.55 g, 45 %). 1H-NMR (DMSO-d6) δ 1.43 (m, 2H, 
COCH2CH2CH2), 1.60 (m, 2H, CH2CH2CH2), 1.71 (m, 2H, CH2CH2CH2), 2.37 (t, 2H, 
3J = 7.3 Hz, COCH2),4.03 (m, 5H, CH2O, CHOH, CH2OPh), 4.69 (d, 1H, 3J = 1.7 Hz, 
H-5), 5.32 (d, 1H, 3J = 6.0 Hz, CHOH), 6.91 (m, 3H, Ph-H), 7.27 (m, 2H, Ph-H), 8.40 
(s, 1H, OH), 11.12 (s, 1H, OH). 13C-NMR (DMSO-d6) δ 24.08 (-, CH2), 25.01 (-, CH2), 
28.31 (-, CH2), 33.27 (-, COCH2CH2), 64.42 (-, CH2O), 65.43 (+, CHO), 67.02 (-, 
CH2OPh), 74.95 (+, CH), 114.30 (+, Ph-C), 118.12 (quat, C-2), 120.26 (+, Ph-C), 
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129.36 (+, Ph-C), 152.10 (quat, C-3), 158.53 (quat, Ph-C), 170.26 (quat, lactone CO), 
172.61 (quat, CO2CH2). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 365 (100) [M-H]-. 
Anal. (C18H22O8·0.3H2O) C, H. C18H22O8 (366.36). 
6-O-[6-(4-Ethylphenoxy)hexanoyl]ascorbic acid (7.51): The title compound was 
prepared from ascorbic acid (3.3 mmol, 0.58 g), 7.7 (4 eq, 13.2 mmol, 3.30 g) and 
Novozyme 435® (165 mg) in 15 ml tert-amyl alcohol according to general procedure 
7.6.2.2, yielding 7.51 as a white solid (0.65 g, 50 %). mp: 109-111 °C; 1H-NMR 
(DMSO-d6) δ 1.13 (t, 3H, 3J =7.6Hz, CH2CH3), 1.41 (m, 2H, COCH2CH2CH2), 1.65 
(m, 4H, COCH2CH2, CH2CH2OC6H4), 2.36 (t, 2H, 3J = 7.3 Hz, COCH2), 2.52 (q, 2H, 
3J = 7.5 Hz, CH2CH3), 3.90 (t, 2H, 3J = 6.4 Hz, CH2OC6H4), 4.03 (m, 3H, CH2O, 
CHOH), 4.68 (d, 1H, 3J = 1.5 Hz, H-5), 5.33 (s, 1H, CHOH), 6.81 (d, 2H, 3J = 8.5 Hz, 
Ar-H), 7.09 (d, 2H, 3J = 8.5 Hz, Ar-H), 8.42 (bs, 1H, OH), 11.11 (bs, 1H, OH). 13C-
NMR (DMSO-d6) δ 15.87 (+, CH3), 24.08 (-, CH2), 25.02 (-, CH2), 27.21 (-, CH2), 
28.34 (-, CH2), 33.27 (-, COCH2CH2), 64.42 (-, CH2O), 65.42 (+, CHO), 67.10 (-, 
CH2OC6H4), 74.94 (+, CH), 114.16 (+, Ph-C), 118.10 (quat, C-2), 128.51 (+, Ar-C), 
135.44 (quat, Ar-C), 152.11 (quat, C-3), 156.59 (quat, Ar-C), 170.27 (quat, lactone 
CO), 172.61 (quat, CO2CH2). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 393 (100) 
[M-H]-. Anal. (C20H26O8·0.3H2O) C, H. C20H26O8 (394.42). 
6-O-[6-(4-Phenylphenoxy)hexanoyl]ascorbic acid (7.52): The title compound was 
prepared from ascorbic acid (3.3 mmol, 0.58 g), 7.8 (1.5 eq, 5.0 mmol, 1.48 g) and 
Novozyme 435® (165 mg) in 15 ml tert-amyl alcohol according to general procedure 
7.6.2.2, yielding 7.52 as a white solid (0.60 g, 41 %). mp: 125-126 °C; 1H-NMR 
(DMSO-d6) δ 1.45 (m, 2H, COCH2CH2CH2), 1.61 (m, 2H, COCH2CH2), 1.74 (m, 2H, 
CH2CH2OC6H5) 2.38 (t, 2H, 3J = 7.3 Hz, COCH2), 4.06 (m, 5H, CH2O, CHOH, 
CH2OC6H4), 4.70 (d, 1H, 3J = 1.6 Hz, H-5), 5.33 (bs, 1H, CHOH), 7.01 (m, 2H, Ar-H), 
7.30 (m, 1H, Ph-H), 7.43 (m, 2H, Ar-H), 7.59 (m, 4H, Ar-H), 8.42 (s, 1H, OH), 11.14 
(s, 1H, OH). 13C-NMR (DMSO-d6) δ 24.08 (-, CH2), 25.01 (-, CH2), 28.30 (-, CH2), 
33.28 (-, COCH2CH2), 64.43 (-, CH2O), 65.42 (+, CHO), 67.27 (-, CH2OC6H4), 74.95 
(+, CH), 114.77 (+, Ar-C), 118.11 (quat, C-2), 126.06 (+, Ar-C), 126.58 (+, Ar-C), 
127.64 (+, Ar-C), 128.77 (+, Ar-C), 132.31 (quat, Ar-C), 139.76 (quat, Ar-C), 152.12 
(quat, C-3), 158.20 (quat, Ar-C), 170.28 (quat, lactone CO), 172.62 (quat, CO2CH2). 
ES-MS (MeCN + TFA) m/z (%): 443 (100) [M+H]+. Anal. (C24H26O8) C, H. C24H26O8 
(442.46). 
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6-O-[6-(4-Benzyloxyphenoxy)hexanoyl]ascorbic acid (7.53): The title compound 
was prepared from ascorbic acid (3.3 mmol, 0.58 g), 7.9 (1.5 eq, 5.0 mmol, 1.63 g) 
and Novozyme 435® (165 mg) in 15 ml tert-amyl alcohol according to general 
procedure 7.6.2.2, yielding 7.53 as a white solid (0.51 g, 33 %). mp: 147-148 °C; 1H-
NMR (DMSO-d6) δ 1.41 (m, 2H, COCH2CH2CH2), 1.63 (m, 4H, COCH2CH2, 
CH2CH2OCH2), 2.36 (t, 2H, 3J = 7.3 Hz, COCH2CH2), 3.87 (t, 2H, 3J = 6.4 Hz, 
CH2OCH2Ph), 4.03 (m, 3H, -CH2O-, CHOH), 4.69 (d, 1H, 3J = 1.4 Hz, H-5), 5.02 (s, 
2H, CH2Ph), 5.34 (bs, 1H, CHOH), 6.84 (m, 2H, Ar-H), 6.92 (m, 2H, Ar-H), 7.36 (m, 
5H, Ph-H), 8.43 (s, 1H, OH), 11.14 (s, 1H, OH). 13C-NMR (DMSO-d6) δ 24.09 (-, 
CH2), 25.02 (-, CH2), 28.39 (-, CH2), 33.27 (-, CH2), 64.42 (-, CH2O), 65.40 (+, CHO), 
67.57 CH2O), 69.52 (-, CH2Ph), 74.94 (+, CH), 115.15 (+, Ar-C), 115.57 (+, Ar-C), 
118.09 (quat, C-2), 127.52 (+, Ar-C), 127.62 (+, Ar-C), 128.29 (+, Ar-C), 137.29 
(quat, Ar-C), 152.12 (quat, C-3), 152.16 (quat, Ar-C), 152.72 (quat, Ar-C), 170.28 
(quat, lactone CO), 172.62 (quat, CO2CH2). ES-MS (DCM/MeOH + NH4OAc) m/z 
(%): 471 (100) [M-H]-. Anal. (C25H28O9) C, H. C25H28O9 (472.48). 
6-O-(6-Benzyloxyhexanoyl)ascorbic acid (7.54): The title compound was prepared 
from ascorbic acid (2.5 mmol, 0.44 g), 7.14 (4 eq, 10 mmol, 2.26 g) and Novozyme 
435® (125 mg) in 15 ml tert-amyl alcohol according to general procedure 7.6.2.2, 
yielding 7.54 as a colorless semisolid substance (0.35 g, 37 %). 1H-NMR (DMSO-d6) 
δ 1.33 (m, 2H, -COCH2CH2CH2-), 1.54 (m, 4H, -COCH2CH2-, -CH2CH2OBn), 2.33 (t, 
2H, 3J = 7.4 Hz, -COCH2-), 3.41 (t, 2H, 3J = 6.4 Hz, -CH2OBn), 4.04 (m, 3H, -CH2O-, 
-CHOH), 4.44 (s, 2H, -OCH2Ph), 4.68 (d, 1H, 3J = 1.6 Hz, H-5), 5.33 (s, 1H, -CHOH), 
7.32 (m, 5H, Ph-H), 8.42 (s, 1H, -OH), 11.14 (bs, 1H, -OH). 13C-NMR (DMSO-d6) δ 
24.14 (-, CH2), 25.17(-, CH2), 28.80 (-, CH2), 33.28 (-, COCH2CH2), 64.40 (-, CH2O), 
65.40 (+, CHO), 69.35 (-, CH2OCH2Ph), 71.71 (-, CH2Ph), 74.93 (+, CH), 118.10 
(quat, C-2), 127.22 (+, Ph-C), 127.32 (+, Ph-C), 128.13 (+, Ph-C), 138.61 (quat, Ph-
C), 152.11 (quat, C-3), 170.27 (quat, lactone CO), 172.63 (quat, CO2CH2). ES-MS 
(MeCN + TFA) m/z (%): 381 (100) [M+H]+. Anal. (C19H24O8) C, H. C19H24O8 (380.39). 
6-O-[6-(4-Phenylphenoxy)hexanoyl]ascorbic acid (7.55): The title compound was 
prepared from ascorbic acid (1.7 mmol, 0.30 g), 7.15 (1.5 eq, 2.6 mmol, 0.80 g) and 
Novozyme 435® (85 mg) in 15 ml tert-amyl alcohol according to general procedure 
7.6.2.2, yielding 7.55 as a white solid (0.40 g, 51 %). mp: 104 °C; 1H-NMR (DMSO-
d6) δ 1.35 (m, 2H, COCH2CH2CH2), 1.56 (m, 4H, COCH2CH2, CH2CH2OCH2), 2.34 (t, 
2H, 3J = 7.3 Hz, COCH2CH2) ppm 3.44 (t, 2H, 3J = 6.4 Hz, CH2OCH2C6H4), 4.03 (m, 
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3H, CH2O, CHOH), 4.49 (s, 2H, OCH2C6H4), 4.69 (d, 1H, 3J = 1.6 Hz, H-5), 5.33 (bs, 
1H, CHOH), 7.41 (m, 5H, Ar-H), 7.65 (m, 4H, Ar-H), 8.43 (s, 1H, OH), 11.14 (s, 1H, 
OH). 13C-NMR (DMSO-d6) δ 24.16 (-, CH2), 25.19 (-, CH2), 28.84 (-, CH2), 33.28 (-, 
COCH2), 64.41 (-, CH2O), 65.39 (+, CHO), 69.41 (-, CH2O), 71.39 (-, CH2C6H4), 
74.94 (+, CH), 118.09 (quat, C-2), 126.47 (+, Ar-C), 126.53 (+, Ar-C), 127.30 (+,  Ar-
C), 127.94 (+, Ar-C), 128.85 (+, Ar-C), 137.85 (quat, Ar-C), 139.11 (quat, Ar-C), 
139.84 (quat, Ar-C), 152.13 (quat, C-3), 170.29 (quat, lactone CO), 172.64 (quat, 
CO2CH2). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 455 (100) [M-H]-. Anal. 
(C25H28O8) C, H. C25H28O8 (456.49). 
6-O-{6-[4-(Thiophen-3-yl)phenoxy]hexanoyl}ascorbic acid (7.56): The title 
compound was prepared from ascorbic acid (1.7 mmol, 0.30 g), 7.17 (1.5 eq, 2.6 
mmol, 0.78 g) and Novozyme 435® (85 mg) in 15 ml tert-amyl alcohol according to 
general procedure 7.6.2.2, yielding 7.56 as a white solid (0.40 g, 26 %). mp: 118-120 
°C; 1H-NMR (DMSO-d6) δ 1.44 (m, 2H, COCH2CH2CH2), 1.67 (m, 4H, COCH2CH2, 
CH2CH2OC6H4), 2.37 (t, 2H, 3J = 7.3 Hz, COCH2CH2), 4.03 (m, 5H, CH2O, CHOH, 
CH2OC6H4), 4.70 (d, 1H, 3J = 1.5 Hz, H-5), 5.34 (d, 1H, 3J = 4.6 Hz, CHOH), 6.95 (m, 
2H, Ar-H), 7.50 (m, 1H, Ar-H), 7.62 (m, 3H, Ar-H), 7.72 (m, 1H, Ar-H), 8.43 (s, 1H, 
OH), 11.15 (s, 1H, OH). 13C-NMR (DMSO-d6) δ 24.09 (-, CH2), 25.01 (-, CH2), 28.31 
(-, CH2), 33.26 (-, COCH2CH2), 64.43 (-, CH2O), 65.39 (+, CHO), 67.22 (-, 
CH2OC6H4), 74.94 (+, CH), 114.62 (+, Ar-C), 118.09 (quat, C-2), 119.11 (+, Ar-C), 
125.94 (+, Ar-C), 126.74 (+, Ar-C), 127.14 (+, Ar-C), 127.68 (quat, Ar-C), 141.10 
(quat, Ar-C), 152.14 (quat, C-3), 157.76 (quat, Ar-C), 170.30 (quat, lactone CO), 
172.63 (quat, CO2CH2). ES-MS (MeCN + TFA) m/z (%): 449 (100) [M+H]+. Anal. 
(C22H24O8S ·0.3H2O) C, H. C22H24O8S (448.49). 
6-O-{6-[4-(2-Methoxyphenyl)phenyloxy]hexanoyl}ascorbic acid (7.57): The title 
compound was prepared from ascorbic acid (1.6 mmol, 0.28 g), 7.19 (1.5 eq, 2.4 
mmol, 0.79 g) and Novozyme 435® (80 mg) in 15 ml tert-amyl alcohol according to 
general procedure 7.6.2.2, yielding 7.57 after preparative HPLC (MeCN/0.1 % TFA 
(aq) 55/45 v/v), as a white solid (30 mg, 4 %). mp: 84-85 °C; 1H-NMR (CD3OD) δ 
1.53 (m, 2H, COCH2CH2CH2-), 1.76 (m, 4H, COCH2CH2, CH2CH2OC6H4), 2.42 (t, 
2H, 3J = 7.3 Hz, COCH2CH2), 3.76 (s, 3H, OCH3), 3.99 (t, 2H, 3J = 6.3 Hz, 
CH2OC6H4), 4.07 – 4.30 (m, 3H, CH2O, CHOH), 4.73 (d, 1H, 3J = 2.0 Hz, H-5), 6.96 
(m, 4H, Ar-H), 7.24 (m, 2H, Ar-H), 7.38 (m, 2H, Ar-H). 13C-NMR (CD3OD) δ 25.83 (-, 
CH2), 26.82 (-, CH2), 30.18 (-, CH2), 34.90 (-, COCH2CH2), 56.06 (+, OCH3), 65.95 (-, 
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CH2O), 68.14 (+, CHO), 68.85 (-, CH2OC6H4), 77.29 (+, CH), 112.65 (+, Ar-C), 
115.01 (+, Ar-C), 120.16 (quat, C-2), 121.96 (+, Ar-C), 129.29 (+, Ar-C), 131.54 (+, 
Ar-C), 131.63 (+, Ar-C), 131.82 (quat, Ar-C), 132.40 (quat, Ar-C), 154.08 (quat, C-3), 
157.95 (quat, Ar-C), 159.53 (quat, Ar-C), 173.22 (quat, lactone CO), 175.11 (quat, 
CO2CH2). PI-EIMS (70 eV) m/z (%): 472 (3) [M+·]. HRMS (PI-EIMS) calcd for 
C26H28O9 [M+·], 472.1733; found, 472.1746. Anal. (C25H28O9) C, H. C25H28O9 (472.48). 
6-O-{6-[4-(4-Methylphenyl)phenyloxy]hexanoyl}ascorbic acid (7.58): The title 
compound was prepared from ascorbic acid (1.7 mmol, 0.30 g), 7.20 (1.5 eq, 2.6 
mmol, 0.81 g) and Novozyme 435® (85 mg) in 15 ml tert-amyl alcohol according to 
general procedure 7.6.2.2, yielding 7.58 as a white solid (0.39 g, 50 %). mp: 147-
159 °C;  1H-NMR (DMSO-d6) δ 1.44 (m, 2H, COCH2CH2CH2), 1.68 (m, 4H, 
COCH2CH2, CH2CH2OC6H4), 2.32 (s, 3H, CH3), 2.37 (t, 2H, 3J = 7.3 Hz, COCH2CH2), 
4.04 (m, 5H, CH2O, CHOH, CH2OC6H4), 4.70 (d, 1H, 3J = 1.6 Hz, H-5), 5.34 (d, 1H, 
3J = 2.8 Hz, CHOH), 6.98 (m, 2H, Ar-H), 7.23 (m, 2H, Ar-H), 7.52 (m, 4H, Ar-H), 8.42 
(s, 1H, OH), 11.14 (s, 1H, OH). 13C-NMR (DMSO-d6) δ 20.55 (+, CH3), 24.08 (-, CH2), 
25.01 (-, CH2), 28.30 (-, CH2), 33.27 (-, COCH2CH2), 64.42 (-, CH2O), 65.40 (+, 
CHO), 67.24 (-, CH2OC6H4), 74.94 (+, CH), 114.72 (+, Ar-C), 118.09 (quat, C-2), 
125.88 (+, Ar-C), 127.36 (+,  Ar-C), 129.36 (+, Ar-C), 132.25 (quat, Ar-C), 135.74 
(quat, Ar-C), 136.89 (quat, Ar-C), 152.13 (quat, C-3), 157.95 (quat, Ar-C), 170.29 
(quat, lactone CO), 172.63 (quat, CO2CH2). ES-MS (DCM/MeOH + NH4OAc) m/z 
(%): 455 (100) [M-H]-. Anal. (C25H28O8) C, H. C25H28O8 (456.49).  
6-O-{6-[4-(2-Methylphenyl)phenyloxy]hexanoyl}ascorbic acid (7.59): The title 
compound was prepared from ascorbic acid (1.5 mmol, 0.26 g), 7.21 (1.5 eq, 2.3 
mmol, 0.71 g) and Novozyme 435® (75 mg) in 15 ml tert-amyl alcohol according to 
general procedure 7.6.2.2, yielding 7.59 as a white solid (0.30 g, 44 %). mp: 97-
99 °C;   1H-NMR (DMSO-d6) δ 1.45 (m, 2H, COCH2CH2CH2), 1.68 (m, 4H, 
COCH2CH2, CH2CH2OC6H4), 2.22 (s, 3H, C6H4CH3), 2.38 (t, 2H, 3J = 7.3 Hz, 
COCH2CH2), 4.03 (m, 5H, CH2O, CHOH, CH2OC6H4-), 4.70 (d, 1H, 3J = 1.5 Hz, H-5), 
5.35 (bs, 1H, CHOH), 6.97 (m, 2H, Ar-H),  7.21 (m, 6H, Ar-H), 8.43 (s, 1H, OH), 
11.15 (s, 1H, OH). 13C-NMR (DMSO-d6) δ 20.21 (+, CH3), 24.09 (-, CH2), 25.04 (-, 
CH2), 28.35 (-, CH2), 33.28 (-, CH2OC6H4), 64.43 (-, CH2O), 65.41 (+, CHO), 67.18 (-, 
CH2OC6H4), 74.94 (+, CH), 114.01 (+, Ar-C), 118.09 (quat, C-2), 125.81 (+, Ar-C), 
126.82 (+, Ar-C), 129.46 (+, Ar-C), 129.96(+, Ar-C), 130.20 (+, Ar-C), 133.28 (quat, 
Ar-C), 134.64 (quat, Ar-C), 140.88 (quat, Ar-C), 152.13 (quat, C-3), 157.53 (quat, Ar-
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C), 170.29 (quat, lactone CO), 172.63 (quat, CO2CH2). ES-MS (DCM/MeOH + 
NH4OAc) m/z (%): 455 (100) [M-H]-. Anal. (C25H28O8) C, H. C25H28O8 (456.49). 
6-O-{6-[4-(4-Hydroxyphenyl)phenyloxy]hexanoyl}ascorbic acid (7.60): The title 
compound was prepared from ascorbic acid (1.6 mmol, 0.28 g), 7.22 (1.5 eq, 2.4 
mmol, 0.75 g) and Novozyme 435® (80 mg) in 15 ml tert-amyl alcohol according to 
general procedure 7.6.2.2, yielding 7.60 as a white solid (0.40 g, 55 %). mp: 158-
161 °C; 1H-NMR (DMSO-d6) δ 1.44 (m, 2H, COCH2CH2CH2), 1.67 (m, 4H, 
COCH2CH2, CH2CH2OC6H4), 2.37 (t, 2H, 3J = 7.3 Hz, COCH2CH2), 4.03 (m, 5H, 
CH2O, CHOH, CH2OC6H4), 4.70 (d, 1H, 3J = 1.5 Hz, H-5), 5.35 (bs, 1H, CHOH), 6.81 
(m, 2H, Ar-H), 6.95 (m, 2H, Ar-H), 7.44 (m, 4H, Ar-H), 8.44 (bs, 1H, OH), 9.45 (s, 1H, 
C6H4OH), 11.15 (s, 1H, -OH). 13C-NMR (DMSO-d6) δ 24.08 (-, CH2), 25.01 (-, CH2), 
28.32 (-, CH2), 33.27 (-, COCH2CH2), 64.42 (-, CH2O), 65.40 (+, CHO), 67.20 (-, 
CH2OC6H4), 74.94 (+, CH), 114.64 (+, Ar-C), 115.53 (+, Ar-C), 118.09 (quat, C-2), 
126.89 (+, Ar-C), 127.10 (+, Ar-C), 130.65 (quat, Ar-C), 132.52 (quat, Ar-C), 152.13 
(quat, C-3), 156.38 (quat, Ar-C), 157.39 (quat, Ar-C), 170.29 (quat, lactone CO), 
172.63 (quat, CO2CH2). ES-MS (MeCN + TFA) m/z (%): 459 (100) [M+H]+. Anal. 
(C24H26O9) C, H. C24H26O9 (458.46). 
6-O-{6-[4-(3-Hydroxyphenyl)phenyloxy]hexanoyl}ascorbic acid (7.61): The title 
compound was prepared from ascorbic acid (1.5 mmol, 0.26 g), 7.23 (1.5 eq, 2.3 
mmol, 0.71 g) and Novozyme 435® (75 mg) in 15 ml tert-amyl alcohol according to 
general procedure 7.6.2.2, yielding 7.61 as a white solid (0.30 g, 44 %). mp: 143-
144 °C; 1H-NMR (DMSO-d6) δ 1.45 (m, 2H, COCH2CH2CH2), 1.68 (m, 4H, 
COCH2CH2, CH2CH2OC6H4), 2.37 (t, 2H, 3J = 7.3 Hz, COCH2CH2),  4.04 (m, 5H, 
CH2O, CHOH, CH2OC6H4), 4.70 (d, 1H, 3J = 1.6 Hz, H-5), 5.33 (bs, 1H, CHOH), 6.70 
(m, 1H, Ar-H), 6.98 (m, 4H, Ar-H), 7.21 (m, 1H, Ar-H), 7.50 (m, 2H, Ar-H), 8.42 (s, 
1H, OH), 9.45 (s, 1H, C6H4OH), 11.13 (s, 1H, OH). 13C-NMR (DMSO-d6) δ 24.08 (-, 
CH2), 25.01 (-, CH2), 26.76 (-, CH2), 28.30 (-, CH2), 33.28 COCH2CH2), 64.43 (-, 
CH2O), 65.42 (+, CHO), 67.26 (-, CH2OC6H4), 74.95 (+, CH), 112.88 (+, Ar-C), 
113.60 (+, Ar-C), 114.69 (+, Ar-C), 116.87 (+, Ar-C), 118.11 (quat, C-2), 127.52 (+, 
Ar-C), 129.73 (+, Ar-C), 132.46 (quat, Ar-C), 141.20 (quat, Ar-C), 152.12 (quat, C-3), 
157.66 (quat, Ar-C), 158.14 (quat, Ar-C), 170.28 (quat, lactone CO), 172.62 (quat, 
CO2CH2). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 457 (100) [M-H]-. Anal. 
(C24H26O9) C, H. C24H26O9 (458.46). 
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6-O-(11-Phenoxyundecanoyl)ascorbic acid (7.62): The title compound was 
prepared from ascorbic acid (3.3 mmol, 0.58 g), 7.33 (1.5 eq, 5.0 mmol, 1.45 g) and 
Novozyme 435® (165 mg) in 15 ml tert-amyl alcohol according to general procedure 
7.6.2.2, yielding 7.62 as a white solid (0.69 g, 50 %). mp: 100-103 °C; 1H-NMR 
(DMSO-d6) δ 1.19 – 1.58 (m, 14H, COCH2(CH2)7), 1.69 (m, 2H, CH2CH2OPh), 2.32 
(t, 2H, 3J = 7.4Hz, COCH2CH2), 3.91 – 4.11 (m, 5H, CH2O, CHOH, CH2OPh), 4.68 (d, 
1H, 3J = 1.6 Hz, H-5), 5.32 (d, 1H, 3J = 6.4 Hz, CHOH), 6.90 (m, 3H, Ph-H), 7.27 (m, 
2H, Ph-H), 8.42 (s, 1H, OH), 11.13 (s, 1H, OH). 13C-NMR (DMSO-d6) δ 24.30 (-, 
CH2), 25.45 (-, CH2), 28.38 (-, CH2), 28.62 (-, CH2), 28.68 (-, CH2), 28.77 (-, CH2), 
28.87 (-, CH2), 33.30 (-, COCH2CH2), 64.37 (-, CH2O), 65.39 (+, CHO), 67.12 (-, 
CH2OC6H4), 74.92 (+, CH), 114.27 (+, Ph-C), 118.09 (quat, C-2), 120.22 (+, Ph-C), 
129.35 (+, Ph-C), 152.10 (quat, C-3), 158.55 (quat, Ph-C), 170.27 (quat, lactone CO), 
172.66 (quat, CO2CH2). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 437 (100) [M+H]+. 
Anal. (C23H32O8) C, H. C23H32O8 (436,50). 
6-O-[11-(4-Phenylphenoxy)undecanoyl]ascorbic acid (7.63): The title compound 
was prepared from ascorbic acid (3.0 mmol, 0.53 g), 7.34 (1.5 eq, 4.5 mmol, 1.66 g) 
and Novozyme 435® (150 mg) in 15 ml tert-amyl alcohol according to general 
procedure 7.6.2.2, yielding 7.63 as a white solid (0.40 g, 26 %). mp: 148-149 °C;  1H-
NMR (DMSO-d6) δ 1.26 – 1.55 (m, 14H, COCH2(CH2)7), 1.72 (m, 2H, 
CH2CH2OC6H4), 2.32 (t, 2H, 3J = 7.4 Hz, COCH2CH2), 4.03 (m, 5H, CH2O, CHOH, 
CH2OC6H4), 4.68 (d, 1H, 3J = 1.6 Hz, H-5), 5.33 (bs, 1H, CHOH), 7.00 (m, 2H, Ar-H), 
7.30 (m, 1H, Ph-H), 7.42 (m, 2H, Ar-H), 7.59 (m, 4H, Ar-H), 8.43 (s, 1H, OH), 11.14 
(s, 1H, OH). 13C-NMR (DMSO-d6) δ 24.31 (-, CH2), 25.45 (-, CH2), 28.39 (-, CH2), 
28.63 (-, CH2), 28.70 (-, CH2), 28.78 (-, CH2), 28.89 (-, CH2), 33.30 (-, COCH2CH2), 
64.37 (-, CH2O), 65.39 (+, CHO), 67.38 (-, CH2OC6H4), 74.93 (+, CH), 114.75 (+, Ar-
C), 118.08 (quat, C-2), 126.04 (+, Ar-C), 126.57 (+, Ar-C), 127.63 (+, Ar-C), 128.76 
(+, Ar-C), 132.26 (quat, Ar-C), 139.76 (quat, Ar-C), 152.11 (quat, C-3), 158.23 (quat, 
Ar-C), 170.28 (quat, lactone CO), 172.67 (quat, CO2CH2). ES-MS (DCM/MeOH + 
NH4OAc) m/z (%): 513 (30) [M+H]+. Anal. (C29H36O8) C, H. C29H36O8 (512,59). 
5,6-O-Isopropylidene-L-ascorbic acid (7.64)39: To L-ascorbic acid (100 g, 568 
mmol), suspended in absolute acetone (1 l), was added acetyl chloride (8.0 ml, 
113 mmol) under vigorous stirring. After stirring overnight at room temperature, the 
solid was collected by filtration, washed with EtOAc and dried over potassium 
carbonate to yield the title compound as white solid (89,85 g, 73 %). mp: 193-194 °C 
Chapter 7 Ascorbic acid derivatives as potent hyaluronidase inhibitors 
167 
(ref.95: 201-203 °C); 1H-NMR (DMSO-d6) δ 1.26 (s, 6H, C(CH3)2), 3.88 (dd, 1H, 3J = 
6.3 Hz, 2J = 8.4 Hz, CH2O), 4.10 (dd, 1H, 3J = 7.1 Hz, 2J = 8.3 Hz, CH2O), 4.26 (ddd, 
1H, 3J = 7.1 Hz, 3J = 5.6 Hz, 3J = 2.5 Hz, CHO), 4.71 (d, 1H, 3J = 2.9 Hz, H-5), 8.48 
(bs, 1H, OH), 11.30 (s, 1H, OH). C9H12O6 (216.19). 
7.6.2.8 General procedure for the synthesis of 2,3-di-O-alkylated 5,6-O-
isopropylidene-L-ascorbic acid derivatives 65 and 129 
A solution of 5,6-O-isopropylidene-L-ascorbic acid (7.64) (1 eq), potassium carbonate 
(1.1 eq) and the pertinent alkyl halide (2.2 eq) in anhydrous DMF was heated under 
stirring at 40 °C for 4 h. The solvent was removed under reduced pressure, the oily 
residue was taken up in water and extracted tree times with dichloromethane. The 
combined organic phases were dried over magnesium sulfate and evaporated in 
vacuo. The remaining raw product was recrystallized or subjected to flash 
chromatography. 
2,3-Di-O-benzyl-5,6-O-isopropylidene-L-ascorbic acid96 (7.65): The title 
compound was prepared from 7.64 (100 mmol, 21.60 g), potassium carbonate (110 
mmol, 15.20 g) and benzylbromide (220 mmol, 37.6 g) in anhydrous DMF (300 ml) 
according to general procedure 7.6.2.8. Recrystallization from methanol yielded a 
white solid (29.10 g, 73 %). mp: 116-118 °C (ref.40: 123-125 °C); 1H-NMR (DMSO-
d6): δ 1.28 (s, 3H, C(CH3)2), 1.29 (s, 3H, C(CH3)2), 3.87 (dd, 1H, 2J = 8.5 Hz, 3J = 5.9 
Hz, CH2O), 4.08 (dd, 1H, 2J = 8.5 Hz, 3J = 7.1 Hz, CH2O), 4.27 (ddd, 1H, 3J = 7.1 Hz, 
3J = 5.9 Hz, 3J = 2.5 Hz, CHO), 4.94 (d, 1H, 2J = 11.2 Hz, CH2Ph), 4.95 (d, 1H, 3J = 
2.5 Hz, H-5), 5.01 (d, 1H, 2J =11.2 Hz, CH2Ph), 5.16 (d, 1H, 2J = 11.8 Hz, CH2Ph), 
5.25 (d, 1H, 2J = 11.8 Hz, CH2Ph), 7.27-7.43 (m, 10H, Ph-H). CI-MS (NH3) m/z (%): 
414 (100) [M+NH4]+. C23H24O6 (396.43). 
2,3-Di-O-benzyl-L-ascorbic acid96 (7.66): A solution of 7.65 (50 mmol, 19.8 g), 
methanol (200 ml) and aqueous acetic acid (50 %, 500 ml) was stirred at 90 °C for 5 
h. The solvent was evaporated and the oily yellow residue was dissolved in ethyl 
acetate (400 ml). After washing three times with a saturated solution of sodium 
carbonate, the organic layer was washed with water, dried over magnesium sulfate 
and evaporated under reduced pressure to obtain the title compound as a colorless 
oil which solidified over time (15.1 g, 85 %). mp: 65 °C (ref.40: 67-69 °C); 1H-NMR 
(DMSO-d6) δ 3.36-3.51 (m, 2H, CH2OH), 3.66-3.73 (m, 1H, CHOH), 4.88 (dd, 1H, 3J 
= 6.1 Hz, 3J = 4.8 Hz, CH2OH), 4.90 (d, 1H, 3J = 1.4 Hz, H-5), 4.94 (d, 1H, 2J = 11.3 
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Hz, CH2Ph), 4.98 (d, 1H, 2J = 11.3 Hz, CH2Ph), 5.15 (d, 1H, 3J = 6.3 Hz, CHOH), 
5.20 (d, 1H, 2J = 11.5 Hz, CH2Ph), 5.26 (d, 1H, 2J = 11.5 Hz, CH2Ph), 7.29-7.45 (m, 
10H, Ph-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 374 (100) [M+NH4]+. C20H20O6 
(356.37). 
7.6.2.9 General procedure for the synthesis of 6-O-acylated 2,3-di-O-
protected ascorbic acids 67-83, 77a, 78a, 80a-83a, 104, 107-109, 114, 
131 and 143-145 
To a solution of the corresponding 2,3-di-O-protected ascorbic acid (1 eq), the 
pertinent carboxylic acid (1 eq) and DMAP (1.2 eq) in anhydrous DMF was added 
EDAC (1.1 eq) portion wise under an atmosphere of argon at 0 °C. The mixture was 
stirred overnight at room temperature and the solvent was removed under reduced 
pressure. The remaining raw product was taken up in water and extracted tree times 
with EtOAc. The combined organic layers were washed with 1 N HCl and brine, dried 
over MgSO4, filtered, and the solvent was removed under reduced pressure. The 
acylated products were purified by flash chromatography. 
2,3-Di-O-benzyl-6-O-(12-tert-butoxy-12-oxododecanoyl)-L-ascorbic acid (7.67): 
The title compound was prepared from 7.66 (4.0 mmol, 1.42 g), 7.35 (4.0 mmol, 1.14 
g), DMAP (4.4 mmol, 0.54 g) and EDAC (4.2 mmol, 0.80 g) in anhydrous DMF (15 
ml) according to general procedure 7.6.2.9. Compound 7.67 was obtained after flash 
chromatography (PE/EtOAc 90/10 to 80/20 v/v) as a pale yellow oil (0.63 g, 25 %). 
1H-NMR (CDCl3) δ 1.22 (m, 12H, COCH2CH2(CH2)6), 1.39 (s, 9H, C(CH3)3), 1.53 (m, 
4H, COCH2CH2), 2.15 (t, 2H, 3J = 7.5 Hz, COCH2), 2.28 (t, 2H, 3J = 7.6 Hz, COCH2), 
4.01 (ddd, 1H, 3J = 1.9 Hz, 3J = 5.1 Hz, 3J = 6.7 Hz, CHOH), 4.15 (dd, 1H, 3J = 5.0 
Hz, 2J = 11.6 Hz, CH2O), 4.27 (dd, 1H, 3J = 6.8 Hz, 2J = 11.6 Hz, CH2O), 4.62 (d, 1H, 
3J = 2.1 Hz, H-5), 5.04 (d, 2H, 2J = 11.5 Hz, CH2Ph), 5.08 (d, 1H, 2J = 11.6 Hz, 
CH2Ph), 5.17 (d, 1H, 2J = 11.7 Hz, CH2Ph), 7.17 (m, 2H, Ph-H), 7.32 (m, 8H, Ph-H). 
ES-MS (DCM/MeOH + NH4OAc) m/z (%): 642 (100) [M+NH4]+. C36H48O9 (624.76). 
2,3-Di-O-benzyl-6-O-[2-(decan-1-yloxy)benzoyl]-L-ascorbic acid (7.68): The title 
compound was prepared from 7.66 (2.0 mmol, 0.71 g), 7.39 (2.0 mmol, 0.56 g), 
DMAP (2.4 mmol, 0.29 g) and EDAC (2.2 mmol, 0.42 g) in anhydrous DMF (10 ml) 
according to general procedure 7.6.2.9. Compound 7.68 was obtained after flash 
chromatography (PE/EtOAc 90/10 to 70/30 v/v) as colorless oil (0.43 g, 35 %). 1H-
NMR (CDCl3) δ 0.87 (t, 3H, 3J = 6.7 Hz, CH2CH3), 1.31 (m, 12H, (CH2)6CH3), 1.78 (m, 
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2H, OCH2CH2CH2), 4.00 (t, 1H, 3J = 6.8 Hz, COCH2CH2), 4.20 (m, 1H, CHOH), 4.42 
(dd, 1H, 3J = 5.4 Hz, 2J = 11.4 Hz, CH2O), 4.52 (dd, 1H, 3J = 6.8 Hz, 2J = 11.4 Hz, 
CH2O), 4.79 (d, 1H, 3J = 2.1 Hz, H-5), 5.10 (s, 2H, CH2Ph), 5.13 (d, 1H, 2J = 11.9 Hz, 
CH2Ph), 5.22 (d, 1H, 2J = 11.7 Hz, CH2Ph), 6.95 (m, 2H, Ar-H) 7.20 (m, 2H, Ar-H), 
7.39 (m, 9H, Ar-H), 7.79 (dd, 1H, 4J =1.8Hz, 3J =8.0Hz, Ar-H). ES-MS (DCM/MeOH + 
NH4OAc) m/z (%): 617 (100) [M+H]+. Anal. (C37H44O8) C, H. C37H44O8 (616.74). 
2,3-Di-O-benzyl-6-O-[3-(decan-1-yl)benzoyl]-L-ascorbic acid (7.69): The title 
compound was prepared from 7.66 (2.0 mmol, 0.71 g), 7.40 (2.0 mmol, 0.56 g), 
DMAP (2.4 mmol, 0.29 g) and EDAC (2.2 mmol, 0.42 g) in anhydrous DMF (10 ml) 
according to to general procedure 7.6.2.9. The title compound was obtained after 
flash chromatography (PE/EtOAc 90/10 to 70/30 v/v) as a colorless oil (0.39 g, 
32 %). 1H-NMR (CDCl3) δ 0.88 (t, 3H, 3J = 6.7 Hz, CH2CH3), 1.26 – 1.50 (m, 12H, 
(CH2)6CH3), 1.78 (m, 2H, OCH2CH2CH2), 3.98 (t, 2H, 3J = 6.5 Hz, COCH2CH2), 4.21 
(m, 1H, CHOH), 4.45 (dd, 1H, 3J = 5.2 Hz, 2J = 11.6 Hz, CH2O), 4.55 (dd, 1H, 3J = 
6.7 Hz, 2J = 11.6 Hz, CH2O), 4.76 (d, 1H, 3J = 2.1 Hz, H-5), 5.11 (s, 2H, CH2Ph), 5.13 
(d, 1H, 2J = 12.7 Hz, CH2Ph), 5.22 (d, 1H, 2J = 11.7 Hz, CH2Ph), 7.21 (m, 1H, Ar-H), 
7.35 (m, 9H, Ar-H), 7.53 (dd, 1H, 4J = 1.5 Hz, 4J = 2.4 Hz, Ar-H), 7.60 (m, 1H, Ar-H). 
ES-MS (DCM/MeOH + NH4OAc) m/z (%): 634 (100) [M+NH4]+. Anal. (C37H44O8) C, 
H. C37H44O8 (616.74). 
2,3-Di-O-benzyl-6-O-[2-(hexan-1-yl)decanoyl]-L-ascorbic acid (7.70): The title 
compound was prepared from 7.66 (2.0 mmol, 0.71 g), commercially available 2-
hexyldecanoic acid (2.0 mmol, 0.59 ml), DMAP (2.4 mmol, 0.29 g) and EDAC (2.2 
mmol, 0.42 g) in anhydrous DMF (10 ml) according to general procedure 7.6.2.9. 
Compound 7.70 was obtained after flash chromatography (PE/EtOAc 90/10 v/v) as a 
white solid (0.6 g, 50 %). mp: 43 °C; 1H-NMR (CDCl3) δ 0.87 (m, 6H, CH2CH3), 1.23 
(m, 20H, (CH2)4CH3, (CH2)6CH3), 1.51 (m, 4H, COCHCH2), 2.35 (tt, 1H, 3J = 5.5 Hz, 
3J = 8.7 Hz, COCH), 4.02 – 4.36 (m, 3H, CH2O, CHOH), 4.66 (d, 1H, 3J = 2.0 Hz, H-
5), 5.10 (s, 2H, CH2Ph), 5.14 (d, 1H, 2J = 11.7 Hz, CH2Ph), 5.22 (d, 1H, 3J = 11.7 Hz, 
CH2Ph), 7.22 (m, 2H, Ph-H), 7.36 (m, 8H, Ph-H). ES-MS (DCM/MeOH + NH4OAc) 
m/z (%): 613 (100) [M+NH4]+. Anal. (C36H50O7) C, H. C36H50O7 (594.78). 
2,3-Di-O-benzyl-6-O-[2-(propan-1-yl)dodecanoyl]-L-ascorbic acid (7.71): The title 
compound was prepared from 7.66 (2.0 mmol, 0.71 g), 7.42 (2.0 mmol, 0.49 mg), 
DMAP (2.4 mmol, 0.29 g) and EDAC (2.2 mmol, 0.42 g) in anhydrous DMF (10 ml) 
according to general procedure 7.6.2.9. After flash chromatography (PE/EtOAc 80/20 
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v/v) compound 7.71 was obtained as a colorless oil (0.49 g, 42 %). 1H-NMR (CDCl3) 
δ 0.89 (m, 6H, CH2CH3), 1.18 – 1.68 (m, 22H, (CH2)9CH3, (CH2)2CH3), 2.37 (m, 1H, 
COCH), 4.05 (ddd, 1H, 3J = 1.6 Hz, 3J = 4.8 Hz, 3J = 6.6 Hz, CHOH), 4.17 (ddd, 1H, 
3J = 2.9 Hz, 3J = 5.1 Hz, 2J = 11.6 Hz, CH2O), 4.32 (ddd, 1H, 3J = 3.4 Hz, 3J = 6.9 Hz, 
2J = 11.4 Hz, CH2O), 4.65 (d, 1H, 3J = 2.1 Hz, H-5), 5.07 – 5.25 (m, 4H, CH2Ph), 7.22 
(m, 2H, Ph-H), 7.36 (m, 8H, Ph-H).ES-MS (DCM/MeOH + NH4OAc) m/z (%): 598 
(100) [M+NH4]+. Anal. (C35H48O7) C, H. C35H48O7 (580.75). 
2,3-Di-O-benzyl-6-O-[2-(hexan-1-yl)dodecanoyl]-L-ascorbic acid (7.72): The title 
compound was prepared from 7.66 (2.0 mmol, 0.71 g), 7.43 (2.0 mmol, 0.49 mg), 
DMAP (2.4 mmol, 0.29 g) and EDAC (2.2 mmol, 0.42 g) in anhydrous DMF (10 ml) 
according to general procedure 7.6.2.9. Flash chromatography (PE/EtOAc 80/20 v/v) 
yielded compound 7.72 as a colorless oil (0.52 g, 42 %). 1H-NMR (CDCl3) δ 0.86 (m, 
6H, CH2CH3), 1.24 – 1.65 (m, 28H, (CH2)9CH3, (CH2)5CH3), 2.35 (m, 1H, COCH), 
4.06 (ddd, 1H, 3J = 1.9 Hz, 3J = 4.5 Hz, 3J = 7.1 Hz, CHOH), 4.18 (ddd, 1H, 3J = 1.3 
Hz, 3J = 5.3 Hz, 2J = 11.5 Hz, CH2O), 4.33 (ddd, 1H, 3J = 1.5 Hz, 3J = 6.9 Hz, 2J = 
11.5 Hz, CH2O), 4.66 (d, 1H, 3J = 2.1 Hz, H-5), 5.10 (s, 2H, CH2Ph), 5.14 (d, 1H, 2J = 
11.7 Hz, CH2Ph), 5.22 (d, 1H, 2J = 11.7 Hz, CH2Ph), 7.21 (m, 2H, Ph-H), 7.36 (m, 
8H, Ph-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 640 (100) [M+NH4]+. Anal. 
(C38H54O7) C, H. C38H54O7 (622.83). 
2,3-Di-O-benzyl-6-O-[2-(decan-1-yl)dodecanoyl]-L-ascorbic acid (7.73): The title 
compound was prepared from 7.66 (2.0 mmol, 0.71 g), 7.44 (2.0 mmol, 0.68 mg), 
DMAP (2.4 mmol, 0.29 g) and EDAC (2.2 mmol, 0.42 g) in anhydrous DMF (10 ml) 
according to general procedure 7.6.2.9. Flash chromatography (PE/EtOAc 90/10 v/v) 
gave compound 7.73 as a pale yellow oil (0.45 g, 33 %). 1H-NMR (CDCl3) δ 0.88 (t, 
6H, 3J = 6.7 Hz, CH2CH3), 1.24 – 1.65 (m, 36H, (CH2)9CH3),  2.35 (m, 1H, COCH), 
4.06 (ddd, 1H, 3J = 2.0 Hz, 3J = 5.3 Hz, 3J = 7.1 Hz, CHOH),  4.18 (dd, 1H, 3J = 5.3 
Hz, 2J = 11.5 Hz, CH2O), 4.32 (dd, 1H, 3J = 7.0 Hz, 2J = 11.5 Hz, CH2O), 4.66 (d, 1H, 
3J = 2.0 Hz, H-5), 5.10 (s, 2H, CH2Ph), 5.14 (d, 1H, 2J = 11.7 Hz, CH2Ph), 5.22 (d, 
1H, 2J = 11.7 Hz, CH2Ph), 7.22 (m, 2H, Ar-H), 7.36 (m, 8H, Ar-H). ES-MS 
(DCM/MeOH + NH4OAc) m/z (%): 697 (100) [M+NH4]+. C42H62O7 (678.94). 
2,3-Di-O-benzyl-6-O-[2-(2-phenylethyl)dodecanoyl]-L-ascorbic acid (7.74): The 
title compound was prepared from 7.66 (2.0 mmol, 0.71 g), 7.45 (2.0 mmol, 0.61 mg), 
DMAP (2.4 mmol, 0.29 g) and EDAC (2.2 mmol, 0.42 g) in anhydrous DMF (10 ml) 
according to general procedure 7.6.2.9. Flash chromatography (PE/EtOAc 90/10 to 
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80/20 v/v) yielded 7.74 as a colorless oil (0.30 g, 23 %). 1H-NMR (CDCl3) δ 0.87 (t, 
3H, 3J = 6.7 Hz, CH2CH3), 1.23 – 2.02 (m, 20H, CH2), 2.40 (m, 1H, COCH), 2.58 (m, 
2H, CH2CH2Ph), 4.02 – 4.36 (m, CH2O, CHOH),  4.65 (m, 1H, H-5), 5.09 (d, 1H, 2J = 
11.4 Hz, OCH2Ph), 5.13 (d, 1H, 2J = 11.5 Hz, OCH2Ph), 5.15 (d, 1H, 2J = 11.7 Hz, 
OCH2Ph), 5.22 (d, 1H, 2J = 11.7 Hz, OCH2Ph), 7.26 (m, 15H, Ph-H). ES-MS 
(DCM/MeOH + NH4OAc) m/z (%): 661 (100) [M+NH4]+. Anal. (C40H50O7) C, H. 
C40H50O7 (642.82). 
2,3-Di-O-benzyl-6-O-[2-(4-methoxybenzyl)dodecanoyl]-L-ascorbic acid (7.75): 
The title compound was prepared from 7.66 (1.0 mmol, 0.36 g), 7.46 (1.0 mmol, 0.32 
mg), DMAP (1.2 mmol, 0.15 g) and EDAC (1.1 mmol, 0.21 g) in anhydrous DMF (5 
ml) according to general procedure 7.6.2.9. Flash chromatography (PE/EtOAc 85/15 
to 75/35 v/v) yielded 7.75 as a colorless oil (0.26 g, 39 %). 1H-NMR (CDCl3) δ 0.88 (t, 
3H, 3J = 6.7 Hz, CH2CH3), 1.20 – 1.69 (m, 18H, (CH2)9CH3), 2.73 (m, 3H, 
COCHCH2C6H4), 3.73 – 4.68 (m, 7H, OCH3, CH2O, CHOH, H-5), 5.16 (m, 4H, 
CH2Ph), 6.77 (m, 2H, Ar-H), 7.05 (m, 2H, Ar-H), 7.22 (m, 2H, Ph-H), 7.36 (m, 8H, Ph-
H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 676 (100) [M+NH4]+. Anal. 
(C40H50O8·0.3H2O) C, H. C40H50O8 (658.82). 
2,3-Di-O-benzyl-6-O-[2-(hexan-1-yl)octadecanoyl]-L-ascorbic acid (7.76): The 
title compound was prepared from 7.66 (1.5 mmol, 0.54 g), 7.47 (1.5 mmol, 0.55 mg), 
DMAP (1.8 mmol, 0.22 g) and EDAC (1.65 mmol, 0.32 g) in anhydrous DMF (8 ml) 
according to general procedure 7.6.2.9. Compound 7.76 was obtained after flash 
chromatography (PE/EtOAc 90/10 to 80/20 v/v) as a white solid (0.29 g, 27 %). mp: 
53-54 °C; 1H-NMR (CDCl3) δ 0.87 (m, 6H, CH2CH3), 1.24 – 1.65 (m, 40H, 
(CH2)15CH3, (CH2)5CH3), 2.35 (tt, 1H, 3J = 5.5 Hz, 3J = 8.6 Hz, COCH), 4.05 (ddd, 1H, 
3J = 2.0 Hz, 3J = 5.3 Hz, 3J = 7.1 Hz, CHOH), 4.18 (ddd, 1H, 3J = 1.4 Hz, 3J = 5.3 Hz, 
2J = 11.5 Hz, CH2O), 4.32 (ddd, 1H, 3J = 1.6 Hz, 3J = 7.0 Hz, 2J = 11.5 Hz, CH2O), 
4.66 (d, 1H, 3J = 2.1 Hz, H-5), 5.10 (s, 2H, CH2Ph), 5.15 (d, 1H, 2J = 11.7 Hz, 
CH2Ph), 5.23 (d, 1H, 2J = 11.7 Hz, CH2Ph), 7.22 (m, 2H, Ph-H), 7.36 (m, 8H, Ph-H). 
ES-MS (DCM/MeOH + NH4OAc) m/z (%): 725 (100) [M+NH4]+. Anal. (C44H66O7) C, 
H. C44H66O7 (706.99). 
2,3-Di-O-benzyl-6-O-{6-[4-(4-methoxyphenyl)phenoxy]hexanoyl}-L-ascorbic 
acid (7.77): The title compound was prepared from 7.66 (2.0 mmol, 0.71 g), 7.29 (2.0 
mmol, 0.63 g), DMAP (2.4 mmol, 0.29 g) and EDAC (2.2 mmol, 0.42 g) in anhydrous 
DMF (15 ml) according to general procedure 7.6.2.9. Compound 7.77 was obtained 
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after flash chromatography (PE/EtOAc 80/20 to 60/40 v/v) as a white solid (0.39 g, 
30 %). 1H-NMR (CDCl3) δ 1.51 (m, 2H, COCH2CH2CH2), 1.76 (m, 4H, COCH2CH2, 
CH2CH2OCH2), 2.38 (t, 2H, 3J = 7.4 Hz, COCH2CH2), 3.83 (s, 3H, OCH3), 3.98 (t, 2H, 
3J = 6.3 Hz, CH2OC6H4), 4.14 (m, 2H, CH2O, CHOH), 4.33 (dd, 1H, 3J = 6.7 Hz, 2J = 
11.6 Hz, CH2O), 4.67 (d, 1H, 3J = 2.0 Hz, H-5), 5.09 (s, 2H, CH2Ph), 5.09 (d, 1H, 2J = 
12.8 Hz, CH2Ph), 5.20 (d, 1H, 2J = 11.7 Hz, CH2Ph), 6.94 (m, 4H, Ar-H),  7.21 (m, 
2H, Ar-H),  7.35 (m, 8H, Ar-H) 7.46 (m, 4H, Ar-H). ES-MS (DCM/MeOH + NH4OAc) 
m/z (%): 670 (100) [M+NH4]+. Anal. (C39H40O9) C, H. C39H40O9 (652.73).  
2,3-Di-O-benzyl-5,6-O-bis{6-[4-(4-methoxyphenyl)phenoxy]hexanoyl}-L-
ascorbic acid (7.77a): Compound 7.77a was obtained as a byproduct in the 
synthesis of 7.77 as a colorless oil (0.31 g, 16 %). 1H-NMR (CDCl3) δ 0.88 (t, 6H, 3J = 
6.7 Hz, CH2CH3), 1.27 – 1.49 (m, 24H, (CH2)6CH3), 1.78 (m, 4H, OCH2CH2CH2), 3.99 
(m, 4H, COCH2CH2), 4.62 (m, 2H, CH2O), 4.82 (d, 1H, 2J = 11.2 Hz, CH2Ph), 4.99 
(m, 2H, H-5, CH2Ph), 5.08 (d, 1H, 2J = 11.1 Hz, CH2Ph), 5.14 (d, 1H, 2J = 11.4 Hz, 
CH2Ph), 5.77 (ddd, 1H, 3J = 1.8 Hz, 3J = 6.4 Hz, 3J = 6.0 Hz, CHO), 6.88 (m, 4H, Ar-
H), 7.24 (m, 10H, Ar-H), 7.93 (m, 4H, Ar-H). ES-MS (DCM/MeOH + NH4OAc) m/z 
(%): 895 (100) [M+NH4]+. C54H68O10 (877.11).  
2,3-Di-O-benzyl-6-O-{6-[4-(4-naphthalen-1-yl)phenoxy]hexanoyl}-L-ascorbic 
acid (7.78): The title compound was prepared from 7.66 (0.67 mmol, 0.24 g), 7.30 
(0.67 mmol, 0.22 g), DMAP (0.80 mmol, 0.10 g) and EDAC (0.73 mmol, 0.14 g) in 
anhydrous DMF (5 ml) according to general procedure 7.6.2.9. Compound 7.78 was 
obtained after flash chromatography (PE/EtOAc 80/20 to 60/40 v/v) as a pale yellow 
oil (0.16 g, 35 %). 1H-NMR (CDCl3) δ 1.55 (m, 2H, COCH2CH2CH2), 1.80 (m, 4H, 
COCH2CH2, CH2CH2OC6H4), 2.41 (t, 2H, 3J = 7.4 Hz, COCH2CH2), 4.04 (m, 3H, 
CH2OC6H4, CHOH), 4.23 (dd, 1H, 3J = 4.9 Hz, 2J = 11.6 Hz, CH2O), 4.35 (dd, 1H, 3J 
= 6.8 Hz, 2J = 11.6 Hz, CH2O), 4.68 (d, 1H, 3J = 2.1 Hz, H-5), 5.12 (m, 3H, CH2Ph), 
5.22 (d, 1H, 2J = 11.6 Hz, CH2Ph), 7.01 (m, 2H, Ar-H), 7.22 (m, 2H, Ar-H), 7.32 – 
7.53 (m, 14H, Ar-H), 7.88 (m, 3H, Ar-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 
690 (100) [M+NH4]+. Anal. (C42H40O8·0.2H2O) C, H. C42H40O8 (672.76).  
2,3-Di-O-benzyl-5,6-O-bis{6-[4-(4-napthalen-1-yl)phenoxy]hexanoyl}-L-ascorbic 
acid (7.78a): Compound 7.78a was obtained as byproduct in the synthesis of 7.78 as 
a pale yellow oil (0.11 g, 17 %). 1H-NMR (CDCl3) δ 1.49 – 2.40 (m, 16H), 4.02 (m, 
4H), 4.28 (dd, 1H, 3J = 7.0 Hz, 2J = 11.6 Hz, CH2O), 4.39 (dd, 1H, 3J = 5.5 Hz, 2J = 
11.6 Hz, CH2O), 4.83 (d, 1H, 3J = 2.1 Hz, H-5), 5.14 (m, 4H, CH2Ph), 5.42 (ddd, 1H, 
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3J = 2.1 Hz, 3J = 5.6 Hz, 3J = 7.5 Hz, CHO), 6.99 (m, 4H, Ar-H), 7.24 (m, 2H, Ar-H), 
7.44 (m, 22H, Ar-H), 7.88 (m, 4H, Ar-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 
1007 (100) [M+NH4]+. Anal. (C64H60O10) calc C:77.81, H:6.11 found C:77.29 H:6.67. 
C64H60O10 (989.16). 
2,3-Di-O-benzyl-6-O-{6-[4-(4-tert-butoxycarbonylphenyl)phenoxy]hexanoyl}-L-
ascorbic acid (7.79): The title compound was prepared from 7.66 (0.94 mmol, 0.33 
g), 7.31 (0.94 mmol, 0.36 g), DMAP (1.12 mmol, 0.14 g) and EDAC (1.03 mmol, 0.20 
g) in anhydrous DMF (5 ml) according to general procedure 7.6.2.9. Compound 7.79 
was obtained after flash chromatography (PE/EtOAc 80/20 to 70/30 v/v) as a white 
solid (0.21 g, 31 %). mp: 81-83 °C; 1H-NMR (CDCl3) δ 1.55 (m, 11H, COCH2CH2CH2, 
C(CH3)3), 1.77 (m, 4H, COCH2CH2, CH2CH2OC6H4), 2.39 (t, 2H, 3J = 7.4 Hz, 
COCH2CH2), 4.00 (t, 2H, 3J = 6.3 Hz, CH2OC6H4), 4.06 (ddd, 1H, 3J = 2.0 Hz, 3J = 
5.0 Hz, 3J = 6.8 Hz, CHOH), 4.21 (dd, 1H, 3J = 5.0 Hz, 2J = 11.6 Hz, CH2O), 4.34 (dd, 
1H, 3J = 6.7 Hz, 2J = 11.6 Hz, CH2O), 4.67 (d, 1H, 3J = 2.1 Hz, H-5), 5.10 (s, 2H, 
CH2Ph), 5.12 (d, 1H, 2J = 11.9 Hz, CH2Ph), 5.20 (d, 1H, 2J = 11.7 Hz, CH2Ph), 6.97 
(m, 2H, Ar-H), 7.21 (m, 2H, Ar-H), 7.36 (m, 8H, Ar-H), 7.56 (m, 4H, Ar-H), 8.02 (m, 
2H, Ar-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 740 (100) [M+NH4]+. Anal. 
(C43H46O10) C, H. C43H46O10 (722.82). 
2,3-Di-O-benzyl-6-O-{6-[4-(3-tert-butoxycarbonylphenyl)phenoxy]hexanoyl}-L-
ascorbic acid (7.80): The title compound was prepared from 7.66 (1.20 mmol, 0.43 
g), 7.32 (1.20 mmol, 0.46 g), DMAP (1.44 mmol, 0.18 g) and EDAC (1.32 mmol, 0.25 
g) in anhydrous DMF (5 ml) according to general procedure 7.6.2.9. Compound 7.80 
was obtained after flash chromatography (PE/EtOAc 80/20 to 70/30 v/v) as a 
colorless oil (0.27 g, 31 %). 1H-NMR (CDCl3) δ 1.53 (m, 2H, COCH2CH2CH2), 1.61 (s, 
9H, C(CH3)3), 1.77 (m, 4H, COCH2CH2, CH2CH2OC6H4), 2.39 (t, 2H, 3J = 7.4 Hz, 
COCH2CH2), 4.00 (t, 2H, 3J = 6.3 Hz, CH2OC6H4), 4.07 (ddd, 1H, 3J = 2.0 Hz, 3J = 
5.0 Hz, 3J = 6.8 Hz, CHOH), 4.21 (dd, 1H, 3J = 4.9 Hz, 2J = 11.6 Hz, CH2O), 4.34 (dd, 
1H, 3J = 6.7 Hz, 2J = 11.6 Hz, CH2O), 4.67 (d, 1H, 3J = 2.1 Hz, H-5), 5.10 (s, 2H, 
CH2Ph), 5.12 (d, 1H, 2J = 12.0 Hz, CH2Ph), 5.21 (d, 1H, 2J = 11.7 Hz, CH2Ph) 6.96 
(m, 2H, Ar-H), 7.21 (m, 2H, Ar-H), 7.43 (m, 11H, Ar-H), 7.70 (m, 1H, Ar-H), 7.92 (m, 
1H, Ar-H), 8.17 (m, 1H, Ar-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 740 (100) 
[M+NH4]+. Anal. (C43H46O10) C, H. C43H46O10 (722.82).  
2,3-Di-O-benzyl-5,6-O-bis{6-[4-(3-tert-butoxycarbonylphenyl)phenoxy]-
hexanoyl}-L-ascorbic acid (7.80a): Compound 7.80a was obtained as a byproduct 
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in the synthesis of 7.80 as a pale yellow oil (0.23 g, 18 %). 1H-NMR (CDCl3) δ 1.45 – 
1.85 (m, 30H, C(CH3)3, COCH2(CH2)3), 2.29 (m, 4H, COCH2CH2), 3.97 (m, 4H, 
CH2OC6H4), 4.26 (dd, 1H, 3J = 7.0 Hz, 2J = 11.5 Hz, CH2O), 4.36 (dd, 1H, 3J = 5.6 
Hz, 3J = 11.5 Hz, CH2O), 4.81 (d, 1H, 3J = 2.1 Hz, H-5), 5.05 – 5.18 (m, 4H, CH2Ph), 
5.40 (ddd, 1H, 3J = 2.1 Hz, 3J = 5.6 Hz, 3J = 7.4 Hz, CHO), 6.94 (m, 4H, Ar-H), 7.22 
(m, 2H, Ar-H), 7.32 – 7.54 (m, 14H, Ar-H), 7.69 (m, 2H, Ar-H), 7.91 (m, 2H, Ar-H), 
8.17 (m, 2H, Ar-H). ES-MS (MeOH + NH4OAc) m/z (%): 909 (100) [M+NH4]+. Anal. 
(C66H72O14·0.2H2O) C, H. C66H72O14 (1089.27). 
2,3-Di-O-benzyl-6-O-[6-(hexan-1-yloxy)hexanoyl]-L-ascorbic acid (7.81): The title 
compound was prepared from 7.66 (1.5 mmol, 0.53 g), 7.13 (1.5 mmol, 0.32 g), 
DMAP (1.8 mmol, 0.22 g) and EDAC (1.68 mmol, 0.32 g) in anhydrous DMF (10 ml) 
according to general procedure 7.6.2.9. Flash chromatography (PE/EtOAc 80/20 to 
70/30 v/v) yielded compound 7.81 as a colorless oil (0.21 g, 25 %). 1H-NMR (CDCl3) 
δ 0.88 (t, 3H, 3J = 6.8 Hz, CH2CH3), 1.32 (m, 8H, (CH2)3CH3, COCH2CH2CH2), 1.60 
(m, 6H, COCH2CH2, CH2CH2OCH2CH2), 2.34 (t, 2H, 3J = 7.5 Hz, COCH2CH2), 3.38 
(m, 4H, CH2OCH2), 4.05 (ddd, 1H, 3J = 2.0 Hz, 3J = 5.0 Hz, 3J = 6.8 Hz, CHOH), 4.20 
(dd, 1H, 3J = 4.9 Hz, 2J = 11.6 Hz, CH2O), 4.31 (dd, 1H, 3J = 6.9 Hz, 2J = 11.6 Hz, 
CH2O), 4.66 (d, 1H, 3J = 2.1 Hz, H-5), 5.11 (s, 2H, CH2Ph), 5.13 (d, 1H, 2J = 11.7 Hz, 
CH2Ph), 5.21 (d, 1H, 2J = 11.7 Hz, CH2Ph), 7.21 (m, 2H, Ph-H), 7.36 (m, 8H, Ph-H). 
ES-MS (DCM/MeOH + NH4OAc) m/z (%): 555 (100) [M+H]+. Anal. (C32H42O8) C, H. 
C32H42O8 (554.67).  
2,3-Di-O-benzyl-5,6-O-bis[6-(hexan-1-yloxy)hexanoyl]-L-ascorbic acid (7.81a): 
The title compound was obtained as byproduct in the synthesis of 7.81 as a colorless 
oil (0.17 g, 15 %). 1H-NMR (CDCl3) δ 0.88 (t, 6H, 3J = 6.7 Hz, CH2CH3), 1.32 (m, 
16H, (CH2)3CH3, COCH2CH2CH2), 1.57 (m, 12H, COCH2CH2, CH2CH2OCH2CH2), 
2.24 (m, 4H, COCH2CH2), 3.37 (m, 8H, CH2OCH2), 4.22 (dd, 1H, 3J = 7.1 Hz, 2J = 
11.6 Hz, CH2O), 4.32 (dd, 1H, 3J = 5.7 Hz, 2J = 11.5 Hz, CH2O), 4.80 (d, 1H, 3J = 2.1 
Hz, H-5), 5.07 – 5.18 (m, 4H, CH2Ph), 5.36 (ddd, 1H, 3J = 2.1 Hz, 3J = 5.7 Hz, 3J = 
7.1 Hz, CHO), 7.23 (m, 2H, Ph-H), 7.36 (m, 8H, Ph-H). ES-MS (DCM/MeOH + 
NH4OAc) m/z (%): 771 (100) [M+NH4]+. C44H64O10 (752.97). 
2,3-Di-O-benzyl-6-O-[5-(heptan-1-yloxy)pentanoyl]-L-ascorbic acid (7.82): The 
title compound was prepared from 7.66 (1.5 mmol, 0.53 g), 7.14 (1.5 mmol, 0.32 g), 
DMAP (1.8 mmol, 0.22 g) and EDAC (1.68 mmol, 0.32 g) in anhydrous DMF (10 ml) 
according to general procedure 7.6.2.9. Flash chromatography (PE/EtOAc 80/20 to 
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70/30 v/v) yielded compound 7.82 as a colorless oil (0.22 g, 26 %). 1H-NMR (CDCl3) 
δ 0.87 (t, 3H, 3J = 6.7 Hz, CH2CH3), 1.27 (m, 8H, (CH2)4CH3), 1.61 (m, 4H, 
CH2CH2OCH2CH2), 2.37 (t, 2H, 3J = 7.3 Hz, COCH2CH2), 3.39 (m, 4H, CH2OCH2), 
4.05 (ddd, 1H, 3J = 1.9 Hz, 3J = 4.9 Hz, 3J = 6.8 Hz, CHOH), 4.20 (dd, 1H, 3J =4.9Hz, 
2J =11.6Hz, CH2O), 4.32 (dd, 1H, 3J = 6.9 Hz, 2J = 11.6 Hz, CH2O),  4.67 (d, 1H, 3J = 
2.1 Hz, H-5), 5.10 (s, 2H, CH2Ph), 5.12 (d, 1H, 2J = 11.7 Hz, CH2Ph), 5.21 (d, 1H, 2J 
= 11.7 Hz, CH2Ph), 7.21 (m, 2H, Ph-H), 7.36 (m, 8H, Ph-H). ES-MS (DCM/MeOH + 
NH4OAc) m/z (%): 572 (100) [M+NH4]+. Anal. (C32H42O8) C, H. C32H42O8 (554.67).  
2,3-Di-O-benzyl-5,6-O-bis[5-(heptan-1-yloxy)pentanoyl]-L-ascorbic acid (7.82a): 
The title compound was obtained as byproduct in the synthesis of 7.82 as a colorless 
oil (0.16 g, 12 %). 1H-NMR (CDCl3) δ 0.87 (t, 6H, 3J = 6.2 Hz, CH2CH3), 1.28 (m, 
16H, (CH2)4CH3), 1.60 (m, 8H, CH2CH2OCH2CH2), 2.28 (m, 4H, COCH2CH2), 3.38 
(m, 8H, CH2OCH2), 4.22 (dd, 1H, 3J = 7.0 Hz, 2J = 11.5 Hz, CH2O), 4.33 (dd, 1H, 3J = 
5.7 Hz, 2J = 11.5 Hz, CH2O), 4.80 (d, 1H, 3J = 2.1 Hz, H-5), 5.07 – 5.22 (m, 4H, 
CH2Ph), 5.36 (ddd, 1H, 3J = 2.1 Hz, 3J = 5.9 Hz, 3J = 7.7 Hz, CHO), 7.23 (m, 4H, Ph-
H), 7.36 (m, 8H, Ph-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 771 (100) 
[M+NH4]+. Anal. (C44H64O10) C, H. C44H64O10 (752.97). 
2,3-Di-O-benzyl-6-O-[4-(decan-1-yloxy)benzoyl]-L-ascorbic acid (7.83): The title 
compound was prepared from 7.66 (2.0 mmol, 0.71 g), 7.41 (2.0 mmol, 0.56 g), 
DMAP (2.4 mmol, 0.29 g) and EDAC (2.2 mmol, 0.42 g) in anhydrous DMF (10 ml) 
according to general procedure 7.6.2.9. Compound 7.83 was obtained after flash 
chromatography (PE/EtOAc 90/10 to 70/30 v/v) as a white solid (0.34 g, 28 %). mp: 
78 °C; 1H-NMR (CDCl3) δ 0.88 (t, 3H, 3J = 6.7 Hz, CH2CH3), 1.26 – 1.50 (m, 12H, 
(CH2)6CH3), 1.79 (m, 2H, OCH2CH2CH2), 3.99 (t, 2H, 3J = 6.6 Hz, COCH2CH2),  4.20 
(m, 1H, CHOH), 4.42 (dd, 1H, 3J = 5.2 Hz, 2J = 11.6 Hz, CH2O), 4.53 (dd, 1H, 3J = 
6.7 Hz, 2J = 11.6 Hz, CH2O), 4.75 (d, 1H, 3J = 2.1 Hz, H-5), 5.11 (s, 2H, CH2Ph), 5.13 
(d, 1H, 2J = 12.3 Hz, CH2Ph), 5.22 (d, 1H, 2J = 11.7 Hz, CH2Ph), 6.89 (m, 2H, Ar-H), 
7.21 (m, 2H, Ar-H), 7.35 (m, 8H, Ar-H), 7.96 (m, 2H, Ar-H). ES-MS (DCM/MeOH + 
NH4OAc) m/z (%): 618 (100) [M+H]+. Anal. (C37H44O8) C, H. C37H44O8 (616.74).  
2,3-Di-O-benzyl-5,6-O-bis[4-(decan-1-yloxy)benzoyl]-L-ascorbic acid (7.83a): 
The title compound was obtained as byproduct in the synthesis of 7.83 as a colorless 
oil (0.18 g, 10 %). 1H-NMR (CDCl3) δ 0.88 (t, 6H, 3J = 6.7 Hz, CH2CH3), 1.27 – 1.49 
(m, 24H, (CH2)6CH3), 1.78 (m, 4H, OCH2CH2CH2), 3.99 (m, 4H, COCH2CH2), 4.62 
(m, 2H, CH2O), 4.82 (d, 1H, 2J = 11.2 Hz, CH2Ph), 4.99 (m, 2H, H-5, CH2Ph), 5.08 (d, 
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1H, 2J = 11.1 Hz, CH2Ph), 5.14 (d, 1H, 2J = 11.4 Hz, CH2Ph), 5.77 (ddd, 1H, 3J = 1.8 
Hz, 3J = 6.4 Hz, 3J = 6.0 Hz, CHO), 6.88 (m, 4H, Ar-H), 7.24 (m, 10H, Ar-H), 7.93 (m, 
4H, Ar-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 895 (100) [M+NH4]+. C54H68O10 
(877.11). 
7.6.2.10 General procedure for the synthesis of carboxylic acids 84-86, 86a 
and 115 via cleavage of the corresponding tert-butyl esters 
The pertinent tert-butyl ester was dissolved in CH2Cl2/TFA (80/20 v/v) at 0 °C. After 
stirring for 6 h at room temperature the solvent was evaporated to obtain the free 
carboxylic acid derivative. 
2,3-Di-O-benzyl-6-O-(11-carboxyundecanoyl)-L-ascorbic acid (7.84): The title 
compound was prepared from 7.67 (0.85mmol, 0.52 g), in CH2Cl2/TFA (80/20 v/v, 8 
ml) according to general procedure 7.6.2.10. Compound 7.84 was obtained as a 
yellow oil (0.48 g, 100 %). 1H-NMR (CDCl3) δ 1.22 (m, 12H, COCH2CH2(CH2)6), 1.57 
(m, 4H, COCH2CH2, CH2CH2CO2H), 2.30 (m, 4H, COCH2CH2, CH2CO2H), 4.02 (ddd, 
1H, 3J = 2.0 Hz, 3J = 4.9 Hz, 3J = 6.8 Hz, CHOH), 4.15 (dd, 1H, 3J =4.9Hz, 2J = 11.6 
Hz, CH2O), 4.27 (dd, 1H, 3J = 6.9 Hz, 2J = 11.6 Hz, CH2O), 4.63 (d, 1H, 3J = 2.0 Hz, 
H-5), 5.02 – 5.19 (m, 4H, CH2Ph), 7.09 – 7.26 (m, 10H, Ph-H). C32H40O9 (568.65). 
2,3-Di-O-benzyl-6-O-{6-[4-(4-carboxyphenyl)phenoxy]hexanoyl}-L-ascorbic acid 
(7.85): The title compound was prepared from 7.79, (0.24 mmol, 0.18 g), in 
CH2Cl2/TFA (80/20 v/v, 4 ml) according to general procedure 7.6.2.10. Compound 
7.85 was obtained as a white solid (0.16 g, 100 %). mp: 132-135 °C; 1H-NMR 
(DMSO-d6) δ 1.43 (m, 2H, COCH2CH2CH2), 1.66 (m, 4H, COCH2CH2, 
CH2CH2OC6H4), 2.37 (t, 2H, 3J = 7.3 Hz, COCH2CH2), 3.92 – 4.12 (m, 6H, 
CH2OC6H4, CH2O, CHOH), 4.94 (m, 3H, H-5, CH2Ph), 5.19 (d, 1H, 3J = 11.8 Hz, 
CH2Ph), 5.24 (d, 1H, 2J = 11.8 Hz, CH2Ph), 7.03 (m, 2H, Ar-H), 7.36 (m, 10H, Ar-H), 
7.67 (m, 2H, Ar-H), 7.74 (m, 2H, Ar-H), 7.98 (m, 2H, Ar-H), 12.85 (bs, 1H, CO2H). 
ES-MS (MeOH + NH4OAc) m/z (%): 684 (100) [M+NH4]+. Anal. (C39H38O10·0.3H2O) 
C, H. C39H38O10 (666,71).  
2,3-Di-O-benzyl-6-O-{6-[4-(3-carboxyphenyl)phenoxy]hexanoyl}-L-ascorbic acid 
(7.86): The title compound was prepared from 7.80 (0.37 mmol, 0.27 g), in 
CH2Cl2/TFA (80/20 v/v, 4 ml) according to general procedure 7.6.2.10. Compound 
7.86 was obtained as a pale yellow solid (0.24 g, 100 %). mp: 77-80 °C; 1H-NMR 
(acetone-d6) δ 1.53 (m, 2H, COCH2CH2CH2), 1.76 (m, 4H, COCH2CH2, 
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CH2CH2OC6H4), 2.40 (t, 2H, 3J = 7.3 Hz, COCH2CH2), 4.05 (t, 2H, 3J =6.4Hz, 
CH2OC6H4), 4.13 – 4.32 (m, 3H, CH2O, CHOH), 4.88 (d, 1H, 3J = 1.4 Hz, H-5), 5.05 
(s, 2H, CH2Ph), 5.25 (d, 1H, 2J = 11.8 Hz, CH2Ph), 5.31 (d, 1H, 3J = 11.8 Hz, CH2Ph), 
7.05 (m, 2H, Ar-H), 7.40 (m, 10H, Ar-H), 7.60 (m, 3H, Ar-H), 7.87 (m, 1H, Ar-H), 7.98 
(m, 1H, Ar-H), 8.26 (m, 1H, Ar-H). ES-MS (MeOH + NH4OAc) m/z (%): 684 (100) [M-
H]-. Anal. (C39H38O10·H2O) C, H. C39H38O10 (666.71). 
2,3-Di-O-benzyl-5,6-O-bis{6-[4-(3-carboxyphenyl)phenoxy]hexanoyl}-L-ascorbic 
acid (7.86a): The title compound was prepared from 7.80a (0.21 mmol, 0.23 g), in 
CH2Cl2/TFA (80/20 v/v, 4 ml) according to general procedure 7.6.2.10. Compound 
7.86a was obtained as a white solid (0.20 g, 100 %). mp: 117-119 °C; 1H-NMR 
(acetone-d6) δ 1.51 (m, 4H, COCH2CH2CH2), 1.72 (m, 8H, COCH2CH2, 
CH2CH2OC6H4), 2.36 (m, 4H, COCH2CH2), 4.01 (m, 4H, CH2OC6H4), 4.31 (dd, 1H, 3J 
= 7.8 Hz, 2J = 11.6 Hz, CH2O), 4.44 (dd, 1H, 3J = 4.7 Hz, 2J = 11.6 Hz, CH2O), 5.11 
(m, 3H, CH2Ph, H-5), 5.25 (d, 1H, 2J = 11.6 Hz, CH2Ph), 5.32 (d, 1H, 2J = 11.7 Hz, 
CH2Ph), 5.49 (ddd, 1H, 3J = 1.9 Hz, 3J = 4.7 Hz, 3J = 7.6 Hz, CHO), 7.02 (m, 4H, Ar-
H), 7.39 (m, 10H, Ar-H), 7.60 (m, 6H, Ar-H), 7.85 (m, 2H, Ar-H), 7.98 (m, 2H, Ar-H), 
8.25 (m, 2H, Ar-H). ES-MS (MeOH + NH4OAc) m/z (%): 976 (100) [M-H]-. Anal. 
(C58H56O14) C, H. C58H56O14 (977.06).  
7.6.2.11 General procedure for the synthesis of deprotected ascorbic acid 
derivatives 87-103, 96a-100a, 103a, 106, 110-112, 117, 127, 128, 132, 
139, 140 and 146-148 via hydrogenolytic removal of benzyl groups 
The pertinent benzyl ether or benzyl ester was dissolved in EtOH and EtOAc and a 
catalytic amount of palladium on activated charcoal (10 % Pd) was added. 
Hydrogenolysis was performed in an autoclave under a pressure of 3 bar at room 
temperature for 24 h. Insoluble material was filtered off, and the solvent was 
evaporated to yield the target compound. 
6-O-[2-(Decan-1-yloxy)benzoyl]-L-ascorbic acid (7.87): The title compound was 
prepared from 7.68 (0.54 mmol, 0.33 g), 10 % Pd/C (30 mg) in EtOH (5 ml) and 
EtOAc (5 ml) according to general procedure 7.6.2.11 and was obtained as a white 
solid (0.23 g, 98 %). mp: 53-54 °C; 1H-NMR (DMSO-d6) δ 0.85 (t, 3H, 3J = 6.7Hz, 
CH2CH3), 1.25 – 1.45 (m, 12H, (CH2)6CH3),1.69 (m, 2H, OCH2CH2CH2), 4.05 (m, 3H, 
COCH2CH2, CHOH), 4.20 (dd, 1H, 3J = 6.9 Hz, 2J = 10.7 Hz, CH2O), 4.30 (dd, 1H, 3J 
= 6.7 Hz, 2J = 10.7 Hz, CH2O), 4.79 (d, 1H, 3J = 1.5 Hz, H-5), 5.40 (d, 1H, 3J = 6.2 
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Hz, CHOH), 7.00 (dd, 1H, 3J = 7.5 Hz, 3J = 7.5 Hz, Ar-H), 7.13 (d, 1H, 3J = 8.3 Hz, 
Ar-H), 7.52 (ddd, 1H, 4J = 1.8 Hz, 3J = 7.5 Hz, 3J = 9.0 Hz, Ar-H), 7.71 (dd, 1H, 4J = 
1.7 Hz, 3J = 7.7 Hz, Ar-H), 8.41 (s, 1H, OH), 11.12 (s, 1H, OH). 13C-NMR (DMSO-d6) 
δ 13.88 (+, CH3), 22.02 (-, CH2), 25.36 (-, CH2), 28.51 (-, CH2), 28.62 (-, CH2), 28.88 
(-, CH2), 28.95 (-, CH2), 31.24 (-, CH2), 64.59 (+, CHO), 65.35 (+, CHO), 68.24 (-, 
CH2O), 74.86 (+, CH), 113.37 (+, Ar-C), 118.16 (quat, C-2), 119.86 (+, Ar-C), 130.93 
(+, Ar-C), 133.54 (+, Ar-C), 151.98 (quat, C-3), 157.71 (quat, Ar-H), 165.41 (lactone 
CO), 170.25 (quat, CO2C6H4). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 435 (100) 
[M-H]-. Anal. (C23H32O8·0.2H2O) C, H. C23H32O8 (436.50). 
6-O-[3-(Decan-1-yloxy)benzoyl]-L-ascorbic acid (7.88): The title compound was 
prepared from 7.69 (0.50 mmol, 0.31 g), 10 % Pd/C (30 mg) in EtOH (5 ml) and 
EtOAc (5 ml) according to general procedure 7.6.2.11 and was obtained as a white 
solid (0.21 g, 96 %). mp: 93-95 °C; 1H-NMR (DMSO-d6) δ 0.85 (t, 3H, 3J = 6.7 Hz, 
CH2CH3), 1.25 – 1.45 (m, 12H, (CH2)6CH3), 1.72 (m, 2H, OCH2CH2CH2), 4.02 (t, 2H, 
3J = 6.4 Hz, COCH2CH2), 4.13 (m, 1H, CHOH), 4.32 (m, 2H, CH2O), 4.81 (d, 1H, 3J = 
1.7Hz, H-5), 5.46 (bs, 1H, CHOH),  7.22 (ddd, 1H, 4J = 0.7 Hz, 4J = 2.5 Hz, 3J = 8.2 
Hz, Ar-H), 7.45 (m, 2H, Ar-H), 7.59 (m, 1H, Ar-H), 8.41 (bs, 1H, OH), 11.10 (bs, 1H, 
OH). 13C-NMR (DMSO-d6) δ 13.87 (+, CH3), 22.01 (-, CH2), 25.39 (-, CH2), 28.51 (-, 
CH2), 28.60 (-, CH2), 28.67 (-, CH2), 28.86 (-, CH2), 28.90 (-, CH2), 31.21 (-, CH2), 
65.56 (+, CHO), 67.66 (-, CH2O), 75.12 (+, CH), 114.67 (+, Ar-C), 118.17 (quat, C-2), 
119.60 (+, Ar-C), 121.41 (+, Ar-C), 129.78 (+, Ar-C), 130.81 (quat, Ar-C), 152.08 
(quat, C-3), 158.64 (quat, Ar-C), 165.32 (lactone CO), 170.26 (quat, CO2C6H4). ES-
MS (DCM/MeOH + NH4OAc) m/z (%): 435 (100) [M-H]-. Anal. (C23H32O8·0.4H2O) C, 
H. C23H32O8 (436.50). 
6-O-[2-(Hexan-1-yl)decanoyl]-L-ascorbic acid (7.89): The title compound was 
prepared from 7.70 (0.84 mmol, 0.50 g), 10 % Pd/C (50 mg) in EtOH (10 ml) and 
EtOAc (10 ml) according to general procedure 7.6.2.11 and was obtained as a white 
solid (0.33 g, 95 %). mp: 73 °C; 1H-NMR (DMSO-d6) δ 0.85 (m, 6H, CH2CH3), 1.22 
(m, 10H, (CH2)4CH3, (CH2)6CH3), 1.46 (m, 4H, COCH(CH2-)CH2), 2.33 (m, 1H, 
COCH), 4.01 (m, 3H, CH2O, CHOH), 4.63 (d, 1H, 3J = 1.6 Hz, H-5), 5.33 (s, 1H, 
CHOH) 8.42 (s, 1H, OH), 11.15 (s, 1H, OH). 13C-NMR (DMSO-d6) δ 13.85 (+, CH3), 
13.89 (+, CH3), 21.94 (-, CH2), 22.01 (-, CH2), 26.66 (-, CH2), 28.55 (-, CH2), 28.74 (-, 
CH2), 28.84 (-, CH2), 31.18 (-, CH2), 31.74 (-, CH2), 31.01 (-, CH2), 31.79 (-, CH2), 
44.71 (+, COCH), 64.14 (-, CH2O), 65.42 (+, CHO), 74.90 (+, CH), 118.10 (quat, C-
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2), 151.99 (quat, C-3), 170.23 (quat, lactone CO), 175.15 (quat, CO2CH). CI-MS 
(NH3) m/z (%): 432 (100) [M+NH4]+. Anal. (C22H38O7·0.4H2O) C, H. C22H38O7 
(414.53). 
6-O-[2-(Propan-1-yl)dodecanoyl]-L-ascorbic acid (7.90): The title compound was 
prepared from 7.71 (0.67 mmol, 0.39 g), 10 % Pd/C (30 mg) in EtOH (3 ml) and 
EtOAc (3 ml) according to general procedure 7.6.2.11. Purification by preparative 
HPLC (0 min: MeCN/0.1 % TFA (aq) 80/20, 15 min: 90/10 v/v) yielded 7.90 as a 
white semisolid substance (0.16 g, 60 %). 1H-NMR (CD3OD) δ 0.85 (m, 6H, CH2CH3), 
1.23 - 1.59 (m, 22H, CH(CH2)2CH3, CH(CH2)8CH3), 2.38 (m, 1H, COCH), 4.13 (m, 
3H, CH2O, CHOH), 4.67 (d, 1H, 3J = 2.1 Hz, H-5). 13C-NMR (CD3OD) δ 14.41 (+, 
CH3), 14.54 (+, CH3), 21.75 (-, CH2) ,23.83 (-, CH2), 26.58 (-, CH2), 28.61 (-, CH2), 
30.55 (-, CH2), 30.67 (-, CH2), 30.73 (-, CH2), 30.81 (-, CH2), 33.16 (-, CH2), 33.72 (-, 
CH2), 35.94 (-, CH2), 46.81 (+, COCH), 65.65 (-, CH2O), 68.13 (+, CHO), 77.21 (+, 
CH), 120.17 (quat, C-2), 153.96 (quat, C-3), 173.17, (lactone CO), 177.86 (quat, 
CO2CH). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 418 (100) [M+NH4]+. HRMS (PI-
EIMS) calcd for C21H36O7 [M+·], 400.2461; found, 400.2456.  Anal. (C21H36O7) calc C: 
62.98, H: 9.06, found C: 62.41, H: 9.61. C21H36O7 (400.51). 
6-O-[2-(Hexan-1-yl)dodecanoyl]-L-ascorbic acid (7.91): The title compound was 
prepared from 7.72 (0.69 mmol, 0.43 g), 10 % Pd/C (30 mg) in EtOH (3 ml) and 
EtOAc (3 ml) according to general procedure 7.6.2.11. Purification by preparative 
HPLC (0 min: MeCN/0.1 % TFA (aq) 85/15, 15 min: 95/5 v/v) yielded 7.91 as a white 
semisolid (0.17 g, 56 %). 1H-NMR (CD3OD) δ 0.89 (t, 6H, 3J = 6.3 Hz, CH2CH3), 1.28 
– 1.67 (m, 28H, CH(CH2)5CH3, CH(CH2)9CH3), 2.41 (m, 1H, COCH), 4.08 (ddd, 1H, 
3J = 2.0 Hz, 3J = 6.6 Hz, 3J = 6.7 Hz, CHOH), 4.21 (m, 2H, CH2O), 4.71 (d, 1H, 3J = 
2.1 Hz, H-5). 13C-NMR (CD3OD) δ 14.49 (+, CH3), 14.54 (+, CH3), 23.74 (-, CH2), 
23.83 (-, CH2), 28.58 (-, CH2), 30.41 (-, CH2), 30.55 (-, CH2), 30.65 (-, CH2), 30.70 (-, 
CH2), 30.80 (-, CH2), 32.93 (-, CH2), 33.16 (-, CH2), 33.73 (-, CH2), 46.99 (+, COCH), 
65.56 (-, CH2O), 68.08 (+, CHO), 77.16 (+, CH), 120.16 (quat, C-2), 153.97 (quat, C-
3), 173.17 (lactone CO), 177.86 (quat, CO2CH). ES-MS (DCM/MeOH + NH4OAc) m/z 
(%): 441 (100) [M-H]-. HRMS (PI-EIMS) calcd for C24H42O7 [M+·], 442.2931; found, 
442.2929. Anal. (C24H42O7·0.7H2O) C, H. C24H42O7 (442.59). 
6-O-[2-(Decan-1-yl)dodecanoyl]-L-ascorbic acid (7.92): The title compound was 
prepared from 7.73 (0.62 mmol, 0.42 g), 10 % Pd/C (30 mg) in EtOH (5 ml) and 
EtOAc (5 ml) according to general procedure 7.6.2.11and was recrystallized from 
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IPE/n-hexane to give a white solid (0.20 g, 64 %). 1H-NMR (CD3OD) δ 0.89 (t, 3H, 3J 
= 6.6 Hz, CH2CH3),1.28 – 1.67 (m, 36H, (CH2)9CH3), 2.41 (m, 1H, COCH), 4.08 (ddd, 
1H, 3J = 1.8 Hz, 3J = 6.6 Hz, 3J = 6.6 Hz, CHOH), 4.21 (m, 2H, CH2O), 4.71 (d, 1H, 3J 
= 2.0 Hz, H-5). 13C-NMR (CD3OD) δ 14.57 (+, CH3), 23.84 (-, CH2), 28.58 (-, CH2), 
30.57 (-, CH2), 30.67 (-, CH2), 30.71 (-, CH2), 30.82 (-, CH2), 33.17 (-, CH2), 33.66 (-, 
CH2), 33.70 (-, CH2), 46.95 (+, COCH), 65.57 (-, CH2O), 68.09 (+, CHO), 77.17 (+, 
CH), 120.16 (quat, C-2), 154.00 (quat, C-3), 173.19 (lactone CO), 177.84 (quat, 
CO2CH). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 617 (100) [M+NH4]+. Anal. 
(C28H50O7) C, H. C28H50O7 (498.69). 
6-O-[2-(2-Phenylethyl)dodecanoyl]-L-ascorbic acid (7.93): The title compound 
was prepared from 7.74 (0.35 mmol, 0.23 g), 10 % Pd/C (30 mg) in EtOH (3 ml) and 
EtOAc (3 ml) according to general procedure 7.6.2.11. Purification by preparative 
HPLC (0 min: MeCN/0.1 % TFA (aq) 80/20, 15 min: 90/10 v/v) yielded 7.93 as a 
white semisolid substance (0.12 g, 75 %). 1H-NMR (CD3OD) δ 0.89 (t, 3H, 3J = 6.6 
Hz, CH2CH3), 1.27 – 2.00 (m, 20H, CH2), 2.43 (m, 1H, COCH), 2.59 (m, 2H, 
CH2CH2Ph), 4.22 (m, 3H, -CH2O-, CHOH), 4.72 (m, 1H, H-5), 7.19 (m, 5H, Ph-H). 
13C-NMR (CD3OD) δ 14.55 (+, CH3), 23.83 (-, CH2), 28.47 (-, CH2), 30.55 (-, CH2), 
30.64 (-, CH2), 30.80 (-, CH2), 33.16 (-, CH2), 33.66 (-, CH2), 34.73 (-, CH2), 35.47 (-, 
CH2), 46.35 (+, COCH), 65.75 (-, CH2O), 68.19 (+, CHO), 77.25, (+, CH), 120.20 
(quat, C-2), 127.02 (+, Ar-H),129.46 (+, 2 Ar-H),129.57 (+, 2 Ar-H),143.01 (quat, Ar-
H), 153.97 (quat, C-3),173.18 (lactone CO), 177.58 (quat, CO2CH). ES-MS 
(DCM/MeOH + NH4OAc) m/z (%): 462 (100) [M-H]-. HRMS (PI-LSIMS) calcd for 
C26H39O7 [M+H]+, 463.2696; found, 463.2709. Anal. (C26H38O7·0.3H2O) C, H. 
C26H38O7 (462.58). 
6-O-[2-(4-Methoxybenzyl)dodecanoyl]-L-ascorbic acid (7.94): The title compound 
was prepared from 7.75 (0.29 mmol, 0.19 g), 10 % Pd/C (30 mg) in EtOH (3 ml) and 
EtOAc (3 ml) according to general procedure 7.6.2.11 and was obtained after 
preparative HPLC (MeCN/0.1 % TFA (aq) 65/35 v/v) as a white semisolid (80 mg, 57 
%). mp: 85-87 °C;  1H-NMR (CD3OD) δ 0.89 (t, 3H, 3J = 6.6 Hz, CH2CH3), 1.21 – 1.70 
(m, 18H, (CH2)2CH3), 2.74 (m, 3H, COCHCH2C6H4), 3.72 – 4.38 (m, 7H, OCH3, 
CH2O, CHOH, H-5), 6.80 (m, 2H, Ar-H), 7.07 (m, 2H, Ar-H). 13C-NMR (CD3OD) δ 
14.47 (+, CH3), 23.76 (-, CH2), 28.49 (-, CH2), 30.48 (-, CH2), 30.54 (-, CH2), 30.71 (-, 
CH2), 33.10 (-, CH2), 33.35 (-, CH2), 33.49 (-, CH2), 38.90 (-, CH2), 39.16 (-, CH2), 
49.36 (+, COCH), 49.61 (+, COCH), 55.64 (+, OCH3), 55.67 (+,OCH3), 65.07 (-, 
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CH2O), 65.30 (-, CH2O), 67.65 (+, CHO), 76.57 (+, CH), 76.87 (+, CH), 114.86 (+, Ar-
H), 114.92 (+, Ar-H), 120.06 (quat, C-2), 130.88 (+, Ar-H), 132.57 (quat, Ar-H), 
154.04 (quat, C-3), 154.21 (quat, Ar-H), 159.81 (quat, Ar-H), 173.19 (lactone CO), 
177.12 (quat, CO2CH), 177.19 (quat, CO2CH). ES-MS (DCM/MeOH + NH4OAc) m/z 
(%): 477 (100) [M-H]-. HRMS (PI-LSIMS) calcd for C26H39O8 [M+H]+, 479.2645; 
found, 479.2636.  Anal. (C26H38O8·0.3H2O) C, H. C26H38O8 (478.58). 
6-O-[2-(Hexan-1-yl)octadecanoyl]-L-ascorbic acid (7.95): The title compound was 
prepared from 7.76 (0.31 mmol, 0.22 g), 10 % Pd/C (30 mg) in EtOH (3 ml) and 
EtOAc (3 ml) according to general procedure 7.6.2.11. Purification by preparative 
HPLC (MeCN/0.1 % TFA (aq) 98/2 v/v) yielded compound 7.95 as a white semisolid 
substance (0.10 g, 61 %). 1H-NMR (CD3OD) δ 0.89 (t, 1H, 3J = 5.8 Hz, CH2CH3), 
1.28 – 1.67 (m, 40H, (CH2)15CH3, (CH2)5CH3), 2.41 (m, 1H, COCH), 4.14 (m, 3H, 
CH2O, CHOH), 4.71 (d, 1H, 3J = 1.9 Hz, H-5). 13C-NMR (CD3OD) δ 14.51 (+, CH3), 
14.56 (+, CH3), 23.75 (-, CH2), 23.84 (-, CH2), 28.58 (-, CH2), 30.43 (-, CH2), 30.59 (-, 
CH2), 30.65 (-, CH2), 30.71 (-, CH2), 30.78 (-, CH2), 30.88 (-, CH2), 32.94 (-, CH2), 
33.18 (-, CH2), 33.72 (-, CH2), 46.99 (+, COCH), 65.57 (-, CH2O), 68.09 (+, CHO), 
77.17 (+, CH), 120.16 (quat, C-2), 153.99 (quat, C-3), 173.18 (lactone CO), 177.84 
(quat, CO2CH). HRMS (PI-EIMS) calcd for C30H52O6 [M+·-H2O], 508.3764; found, 
508.3789.  C30H54O7 (526.75). 
6-O-{6-[4-(4-Methoxyphenyl)phenoxy]hexanoyl}-L-ascorbic acid (7.96): The title 
compound was prepared from 7.57 (0.49 mmol, 0.32 g), 10 % Pd/C (20 mg) in EtOH 
(5 ml) and EtOAc (5 ml) according to general procedure 7.6.2.11. Compound 7.96 
was obtained as a white solid (0.22 g, 95 %). mp: 148-150 °C; 1H-NMR (DMSO-d6) δ 
1.44 (m, 2H, COCH2CH2CH2), 1.68 (m, 4H, COCH2CH2, CH2CH2OC6H4), 2.38 (t, 2H, 
3J = 7.3 Hz, COCH2CH2), 3.78 (s, 3H, OCH3), 4.04 (m, 5H, CH2O, CHOH, 
CH2OC6H4), 4.70 (d, 1H, 3J = 1.6 Hz, H-5), 5.34 (bs, 1H, CHOH), 6.98 (m, 4H, Ar-H), 
7.52 (m, 4H, Ar-H), 8.43 (s, 1H, OH) 11.14 (s, 1H, OH). 13C-NMR (DMSO-d6) δ 24.08 
(-, CH2), 25.01 (-, CH2), 28.32 (-, CH2), 33.28 (-, COCH2CH2), 55.04 (+, OCH3), 64.43 
(-, CH2O), 65.42 (+, CHO), 67.24 (-, CH2OC6H4), 74.95 (+, CH), 114.18 (+, Ar-C), 
114.71 (+, Ar-C), 118.11 (quat, C-2), 127.11 (+, Ar-C), 132.10 (quat, Ar-C), 132.25 
(quat, Ar-C), 152.11 (quat, C-3), 157.65 (quat, Ar-C), 158.23 (quat, Ar-C), 170.27 
(quat, lactone CO), 172.62 (quat, CO2CH2). ES-MS (DCM/MeOH + NH4OAc) m/z 
(%): 490 (100) [M+NH4]+. Anal. (C25H28O9) C, H. C25H28O9 (472.48). 
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5-O-,6-O-Bis{6-[4-(4-methoxyphenyl)phenoxy]hexanoyl}-L-ascorbic acid 
(7.96a): The title compound was prepared from 7.77a (0.28 mmol, 0.26 g), 10 % 
Pd/C (20 mg) in EtOH (5 ml) and EtOAc (5 ml) according to general procedure 
7.6.2.11. Compound 7.96a was obtained as a white solid (0.18 g, 84 %). mp: 119-
120 °C; 1H-NMR (DMSO-d6) δ 1.34 – 1.72 (m, 12H, COCH2(CH2)3), 2.29 (m, 4H, 
COCH2CH2), 3.77 (s, 6H, OCH3), 3.93 (t, 4H, 3J = 6.3 Hz, CH2OC6H4), 4.19 (dd, 1H, 
3J = 8.5 Hz, 2J = 11.6 Hz, CH2O), 4.40 (dd, 1H, 3J = 4.0 Hz, 2J = 11.7 Hz, CH2O), 
5.02 (d, 1H, 3J = 2.1 Hz, H-5), 5.42 (ddd, 1H, 3J = 2.3 Hz, 3J = 3.9 Hz, 3J = 8.3 Hz, 
CHO), 6.95 (m, 8H, Ar-H), 7.50 (m, 8H, Ar-H), 8.68 (bs, 1H, OH), 11.39 (bs, 1H, OH). 
13C-NMR (DMSO-d6) δ 24.00 (-, CH2), 24.27 (-, CH2), 24.82 (-, CH2), 24.92 (-, CH2), 
28.29 (-, CH2), 33.18 (-, COCH2CH2), 33.28 (-, COCH2CH2), 55.01 (+, OCH3), 62.19 
(-, CH2O), 67.09 (-, CH2OC6H4), 67.19 (-, CH2OC6H4), 73.25 (+, CHO), 114.16 (+, Ar-
C), 114.66 (+, Ar-C), 118.31 (quat, C-2), 127.07 (+, Ar-C), 132.05 (quat,  Ar-C), 
132.20 (quat,  Ar-C), 150.68 (quat, C-3), 157.63 (quat,  Ar-C), 158.22 (quat,  Ar-C), 
169.54 (quat, lactone CO), 171.55 (quat, CO2CH2), 172.38 (quat, CO2CH2). ES-MS 
(DCM/MeOH + NH4OAc) m/z (%): 767 (100) [M-H]-. Anal. (C44H48O12) C, H. 
C44H48O12 (768.84). 
6-O-{6-[4-(Naphthalen-1-yl)phenoxy]hexanoyl}-L-ascorbic acid (7.97): The title 
compound was prepared from 7.78 (0.21 mmol, 0.14 g), 10 % Pd/C (20 mg) in EtOH 
(3 ml) and EtOAc (3 ml) according to general procedure 7.6.2.11. Compound 7.97 
was obtained as a white foam (0.10 g, 97 %). mp: 80-81 °C; 1H-NMR (CD3OD+ 
CDCl3) δ 1.46 – 1.87 (m, 6H, COCH2(CH2)3), 2.42 (t, 2H, 3J = 7.3 Hz, COCH2CH2), 
4.00 – 4.31 (m, 5H, CH2OC6H4, CH2O, CHOH), 4.70 (d, 1H, 3J = 2.2 Hz, H-5), 6.99 
(m, 2H, Ar-H), 7.31 – 7.49 (m, 6H, Ar-H), 7.82 (m, 3H, Ar-H). 13C-NMR (CD3OD+ 
CDCl3) δ 25.85 (-, CH2), 26.88 (-, CH2), 30.20 (-, CH2), 35.03 (-, COCH2CH2), 65.96 (-
, CH2O), 68.26 (+, CHO), 68.98 (-, CH2OC6H4), 77.42 (+, CH), 115.51 (+, Ar-C), 
126.52 (+, Ar-C), 126.81 (+, Ar-C), 127.01 (+, Ar-C), 127.08 (+, Ar-C), 127.98 (+, Ar-
C), 128.43 (+, Ar-C), 129.41 (+, Ar-C), 132.20 (+, Ar-C), 133.19 (quat, Ar-C), 134.38 
(quat, Ar-C), 135.41 (quat, Ar-C), 141.34 (quat, Ar-C), 155.06 (quat, C-3), 159.91 
(quat, Ar-C), 173.47 (quat, lactone CO), 175.19 (quat, CO2CH2). ES-MS 
(DCM/MeOH + NH4OAc) m/z (%): 493 (100) [M+NH4]+. Anal. (C28H28O8·1.3H2O) C, 
H. C28H28O8 (492.52). 
5,6-O-Bis{6-[4-(naphthalen-1-yl)phenoxy]hexanoyl}-L-ascorbic acid (7.97a): The 
title compound was prepared from 7.78a (0.10 mmol, 0.10 g), 10 % Pd/C (20 mg) in 
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EtOH (3 ml) and EtOAc (3 ml) according to general procedure 7.6.2.11 and was 
obtained as a white foam (0.07 g, 87 %). mp: 63-65 °C; 1H-NMR (CDCl3) δ 1.46 – 
1.87 (m, 12H, COCH2(CH2)3), 2.39 (m, 4H, COCH2CH2), 4.00 (m, 4H, CH2OC6H4), 
4.34 (dd, 1H, 3J = 6.8 Hz, 2J = 11.4 Hz, CH2O), 4.49 (dd, 1H, 3J = 4.0 Hz, 2J = 11.5 
Hz, CH2O), 4.94 (d, 1H, 3J = 3.1 Hz, H-5), 5.50 (m, 1H, CHO), 6.99 (m, 4H, Ar-H), 
7.41 (m, 12H, Ar-H), 7.87 (m, 6H, Ar-H). 13C-NMR (CDCl3) δ 24.55 (-, CH2), 24.79 (-, 
CH2), 25.51 (-, CH2), 25.69 (-, CH2),  28.91 (-, CH2), 29.01 (-, CH2), 29.73 (-, CH2), 
33.93 (-, CH2), 62.29 (-, CH2O), 67.70 (-, CH2OC6H4), 68.15 (-, CH2OC6H4), 68.35 (+, 
CHO), 74.84 (+, CH), 114.28 (+, Ar-C), 114.46 (+, Ar-C), 119.07 (quat, C-2), 125.41 
(+, Ar-C), 125.70 (+, Ar-C), 125.92 (+, Ar-C), 126.02 (+, Ar-C), 126.07 (+, Ar-C), 
126.91 (+, Ar-C), 127.31 (+, Ar-C), 127.37 (+, Ar-C), 128.27 (+, Ar-C), 131.11 (+, Ar-
C), 131.16 (+, Ar-C), 131.78 (quat, Ar-C), 131.82 (quat, Ar-C), 133.04 (quat, Ar-C), 
133.37 (quat, Ar-C), 133.85 (quat, Ar-C), 139.81 (quat, Ar-C), 139.93 (quat, Ar-C), 
150.75 (quat, C-3), 158.11 (quat, Ar-C), 158.36 (quat, Ar-C), 171.28 (quat, lactone 
CO), 172.75 (quat, CO2CH2), 173.46 (quat, CO2CH2). ES-MS (DCM/MeOH + 
NH4OAc) m/z (%): 810 (60) [M+NH4]+. Anal. (C50H48O10·1.5EtOH) C, H. C50H48O10 
(808.91). 
6-O-[5-(Heptan-1-yloxy)pentanoyl]-L-ascorbic acid (7.98): The title compound 
was prepared from 7.81 (0.34 mmol, 0.19 g), 10 % Pd/C (20 mg) in EtOH (3 ml) and 
EtOAc (3 ml) according to general procedure 7.6.2.11 and was obtained as a 
colorless oil (0.13 g, quantitative). 1H-NMR (CD3OD) δ 0.90 (t, 3H, 3J = 6.0 Hz, 
CH2CH3), 1.32 (m, 8H, (CH2)4CH3), 1.62 (m, 4H, CH2CH2OCH2CH2), 2.41 (t, 2H, 3J = 
7.2 Hz, COCH2CH2), 3.42 (m, 4H, CH2OCH2) ppm 4.06 – 4.29 (m, 3H, CH2O, 
CHOH), 4.71 (d, 1H, 3J = 2.1 Hz, H-5). 13C-NMR (CD3OD) δ 14.51 (+, CH3), 22.88 (-, 
CH2), 23.77 (-, CH2), 27.33 (-, CH2), 30.14 (-, CH2), 30.36 (-, CH2), 30.85 (-, CH2), 
33.10 (-, CH2), 34.65 (-, COCH2CH2), 65.92 (-, CH2O), 68.15 (+, CHO), 71.45 (-, 
CH2O), 72.04 (-, CH2O), 77.39 (+, CH), 119.89 (quat, C-2), 155.20 (quat, C-3), 
173.49 (quat, lactone CO), 174.99 (quat, CO2CH2). ES-MS (MeCN + TFA) m/z (%): 
375 (100) [M+H]+. Anal. (C18H30O8) C, H. C18H30O8 (374.43). 
5,6-O-Bis[5-(heptan-1-yloxy)pentanoyl]-L-ascorbic acid (7.98a): The title 
compound was prepared from 7.81a (0.25 mmol, 0.19 g), 10 % Pd/C (20 mg) in 
EtOH (3 ml) and EtOAc (3 ml) according to general procedure 7.6.2.11 and was 
obtained after preparative HPLC (0 min: MeCN/0.1 % TFA (aq) 80/20, 30 min: 95/5 
v/v) as a colorless oil (0.5 g, 35 %). 1H-NMR (CDCl3) δ 0.87 (t, 6H, 3J = 6.7 Hz, 
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CH2CH3), 1.28 (m, 16H, (CH2)4CH3), 1.62 (m, 8H, CH2CH2OCH2CH2), 2.35 (m, 4H, 
COCH2CH2), 3.40 (m, 8H, CH2OCH2), 4.26 (dd, 1H, 3J = 6.9 Hz, 2J = 11.7 Hz, 
CH2O), 4.42 (dd, 1H, 3J = 5.1 Hz, 2J = 11.7 Hz, CH2O), 4.89 (d, 1H, 3J = 2.7 Hz, H-5), 
5.42 (m, 1H, CHO). 13C-NMR (CD3OD) δ 14.54 (+, CH3), 22.80 (-, CH2), 22.97 (-, 
CH2), 23.78 (-, CH2), 27.35 (-, CH2), 29.99 (-, CH2), 30.14 (-, CH2), 30.38 (-, CH2), 
30.88 (-, CH2), 33.11 (-, CH2), 34.60 (-, COCH2CH2), 34.64 (-, COCH2CH2), 63.79 (-, 
CH2O), 69.16 (+, CHO), 71.37 (-, CH2O), 71.43 (-, CH2O), 72.06 (-, CH2O), 75.67 (+, 
CH), 120.37 (quat, C-2), 152.59 (quat, C-3), 172.37 (quat, lactone CO), 173.72 (quat, 
CO2CH2), 174.66 (quat, CO2CH2). ES-MS (MeCN + TFA) m/z (%): 574 (100) [M+H]+. 
HRMS (EI-PIMS) calcd for C30H52O10 [M+·], 572.3560; found, 572.3551. Anal. 
(C30H52O10) C, H. C30H52O10 (572.73).  
6-O-[6-(Hexan-1-yloxy)hexanoyl]-L-ascorbic acid (7.99): The title compound was 
prepared from 7.82 (0.36 mmol, 0.20 g), 10 % Pd/C (20 mg) in EtOH (3 ml) and 
EtOAc (3 ml) according to general procedure 7.6.2.11 and was obtained as a pale 
yellow oil (0.13 g, 96 %). 1H-NMR (CD3OD) δ 0.90 (t, 3H, 3J = 6.8 Hz, CH2CH3), 1.34 
(m, 8H, (CH2)3CH3, COCH2CH2CH2), 1.60 (m, 6H, COCH2CH2, CH2CH2OCH2CH2), 
2.38 (t, 2H, 3J = 7.4 Hz, COCH2CH2), 3.42 (m, 4H, CH2OCH2), 4.09 (ddd, 1H, 3J = 
2.0 Hz, 3J = 5.7 Hz, 3J = 7.4 Hz, CHOH), 4.22 (m, 2H, CH2O-), 4.71 (d, 1H, 3J = 2.1 
Hz, H-5). 13C-NMR (CD3OD) δ 14.47 (+, CH3), 23.79 (-, CH2), 25.86 (-, CH2), 26.89 (-
, CH2), 27.04 (-, CH2), 30.46 (-, CH2), 30.80 (-, CH2), 32.93 (-, CH2), 34.90 (-, 
COCH2CH2), 65.93 (-, CH2O), 68.15 (+, CHO), 71.73 (-, CH2O), 72.05 (-, CH2O), 
77.38 (+, CH), 119.92 (quat, C-2), 155.07 (quat, C-3), 173.45 (quat, lactone CO), 
175.08 (quat, CO2CH2). ES-MS (MeCN + TFA) m/z (%): 375 (100) [M+H]+. Anal. 
(C18H30O8) C, H. C18H30O8 (374.43). 
5,6-O-Bis[6-(hexan-1-yloxy)hexanoyl]-L-ascorbic acid (7.99a): The title 
compound was prepared from 7.82a (0.21 mmol, 0.16 g), 10 % Pd/C (20 mg) in 
EtOH (3 ml) and EtOAc (3 ml) according to general procedure 7.6.2.11 and was 
obtained as a pale yellow oil (0.11 g, 90 %). 1H-NMR (CD3OD + CDCl3) δ 0.89 (t, 6H, 
3J = 6.8 Hz, CH2CH3), 1.33 (m, 16H, (CH2)3CH3, COCH2CH2CH2), 1.58 (m, 12H, 
COCH2CH2, CH2CH2OCH2CH2), 2.31 (m, 4H, COCH2CH2), 3.41 (m, 8H, CH2OCH2), 
4.26 (dd, 1H, 3J = 7.6 Hz, 2J = 11.7 Hz, CH2O), 4.43 (dd, 1H, 3J = 4.5 Hz, 2J = 11.7 
Hz, CH2O), 4.86 (d, 1H, 3J = 2.6 Hz, H-5), 5.44 (ddd, 1H, 3J = 2.6 Hz, 3J = 4.5 Hz, 3J 
= 7.3 Hz, CHO). 13C-NMR (CD3OD + CDCl3) δ 14.75 (+, CH3), 23.86 (-, CH2), 25.84 
(-, CH2), 26.06 (-, CH2), 26.81 (-, CH2), 26.91 (-, CH2), 27.09 (-, CH2), 30.44 (-, CH2), 
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30.52 (-, CH2), 30.85 (-, CH2), 32.99 (-, CH2), 35.01(-, COCH2CH2), 35.08 (-, 
COCH2CH2), 63.83 (-, CH2O), 69.28 (+, CHO), 71.83 (-, CH2O), 72.22 (-, CH2O), 
75.81 (+, CH), 120.15 (quat, C-2), 153.61 (quat, C-3), 172.71 (quat, lactone CO), 
173.93 (quat, CO2CH2), 174.83 (quat, CO2CH2). ES-MS (MeCN + TFA) m/z (%): 573 
(100) [M+H]+. Anal. (C30H52O10·0.4H2O) C, H. C30H52O10 (572.73). 
6-O-[4-(Decan-1-yloxy)benzoyl]-L-ascorbic acid (7.100): The title compound was 
prepared from 7.83 (0.42 mmol, 0.26 g), 10 % Pd/C (30 mg) in EtOH (5 ml) and 
EtOAc (5 ml) according to general procedure 7.6.2.11 and was obtained as a white 
semisolid substance (0.18 g, 98 %). mp: 118-120 °C; 1H-NMR (DMSO-d6) δ 0.85 (t, 
3H, 3J = 6.7 Hz, CH2CH3), 1.34 (m, 12H, (CH2)6CH3), 1.72 (m, 2H, OCH2CH2CH2), 
4.04 (t, 2H, 3J = 6.5 Hz, COCH2CH2), 4.19 (m, 3H, CHOH, CH2O), 4.80 (d, 1H, 3J = 
1.6 Hz, H-5), 5.43 (d, 1H, 3J = 4.7 Hz, CHOH), 7.03 (m, 2H, Ar-H), 7.95 (m, 2H, Ar-
H), 8.41 (s, 1H, OH), 11.11 (s, 1H, OH). 13C-NMR (DMSO-d6) δ 13.85 (+, CH3), 22.00 
(-, CH2), 25.34 (-, CH2), 28.42 (-, CH2), 28.59 (-, CH2), 28.64 (-, CH2), 28.85 (-, CH2), 
28.89 (-, CH2), 31.20 (-, CH2), 65.00 (-, CH2O), 65.64 (+, CHO), 67.79 (-, CH2O), 
75.09 (+, CH), 114.29 (+, Ar-C), 118.18 (quat, C-2), 121.51 (quat, Ar-C), 131.38 (+, 
Ar-C), 152.08 (quat, C-3), 162.62 (quat, Ar-C), 165.13 (lactone CO), 170.26 (quat, 
CO2C6H4). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 499 (100) [M+H]+. Anal. 
(C23H32O8) C, H. C23H32O8 (436.50).  
5,6-O-Bis[4-(decan-1-yloxy)benzoyl]-L-ascorbic acid (7.100a): The title compound 
was prepared from 7.83a (0.15 mmol, 0.13 g), 10 % Pd/C (30 mg) in EtOH (5 ml) and 
EtOAc (5 ml) according to general procedure 7.6.2.11 and was obtained as a white 
semisolid substance (0.10 g, 97 %). 1H-NMR (DMSO-d6) δ 0.84 (t, 6H, 3J = 6.6 Hz, 
CH2CH3), 1.23 – 1.40 (m, 24H, (CH2)6CH3), 1.70 (m, 4H, OCH2CH2CH2), 4.01 (t, 4H, 
3J = 6.0 Hz, COCH2CH2), 4.52 (dd, 1H, 3J = 8.3 Hz, 2J = 11.6 Hz, CH2O), 4.67 (dd, 
1H, 3J = 4.1 Hz, 2J = 11.6 Hz, CH2O), 5.21 (d, 1H, 3J = 2.0 Hz, H-5), 5.73 (ddd, 1H, 3J 
= 2.1 Hz, 3J = 4.2 Hz, 3J = 8.1 Hz, CHO), 6.99 (m, 4H, Ar-H), 7.80 (m, 4H, Ar-H), 8.61 
(bs, 1H, OH), 11.40 (bs, 1H, OH). 13C-NMR (DMSO-d6) δ 13.84 (+, CH3), 22.00 (-, 
CH2), 25.32 (-, CH2), 28.38 (-, CH2), 28.59 (-, CH2), 28.85 (-, CH2), 28.89 (-, CH2), 
31.20 (-, CH2), 62.82 (-, CH2O), 67.77 (-, CH2O), 67.81 (+, CHO), 73.49 (+, CH), 
114.32 (+, Ar-C), 114.46 (+, Ar-C), 118.31 (quat, C-2), 120.77 (quat, Ar-C), 121.06 
(quat, Ar-C), 131.25 (+, Ar-C), 150.82 (quat, C-3), 162.69 (quat, Ar-C), 162.84 (quat, 
Ar-C), 164.11 (quat, CO), 164.87 (quat, CO), 169.61 (quat, CO). ES-MS 
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(DCM/MeOH + NH4OAc) m/z (%): 696 (100) [M-H]-. Anal. (C40H56O10·0.5H2O) C, H. 
C40H56O10 (696.87). 
6-O-(11-Carboxyundecanoyl)-L-ascorbic acid (7.101): The title compound was 
prepared from 7.84 (0.23 mmol, 0.13 g), 10 % Pd/C (20 mg) in EtOH (3 ml) and 
EtOAc (3 ml) according to general procedure 7.6.2.11 and was obtained as a white 
solid (0.08 g, 89 %). mp: 114-115 °C; 1H-NMR (CD3OD) δ 1.31 (m, 12H, 
COCH2CH2(CH2)6), 1.60 (m, 4H, COCH2CH2, CH2CH2CO2H), 2.32 (m, 4H, 
COCH2CH2, CH2CO2H), 4.06 – 4.28 (m, 3H, CH2O, CHOH), 4.73 (d, 1H, 3J = 2.3 Hz, 
H-5). 13C-NMR (CD3OD) δ 26.05 (-, CH2), 26.17 (-, CH2), 30.24 (-, CH2), 30.30 (-, 
CH2), 30.45 (-, CH2), 30.48 (-, CH2), 30.60 (-, CH2), 34.95 (-, CH2CO2), 35.02 (-, 
CH2CO2), 65.88 (-, CH2O), 68.12 (+, CHO), 77.26 (+, CH), 120.15 (quat, C-2), 154.05 
(quat, C-3), 173.21 (quat, lactone CO), 175.22 (quat, CO2CH2), 177.80 (quat, CO2H). 
ES-MS (DCM/MeOH + NH4OAc) m/z (%): 385 (100) [M-H]-. Anal. (C18H28O9) C, H. 
C18H28O9 (388.41).  
6-O-{6-[4-(4-Carboxyphenyl)phenoxy]hexanoyl}-L-ascorbic acid (7.102): The title 
compound was prepared from 7.85 (0.21 mmol, 0.14 g), 10 % Pd/C (20 mg) in EtOH 
(10 ml) and EtOAc (5 ml) according to general procedure 7.6.2.11 and was obtained 
as a white solid (0.10 g, 98 %). mp: 149-151 °C;  1H-NMR (DMSO-d6) δ 1.65 (m, 6H, 
COCH2(CH2)6), 2.37 (t, 2H, 3J = 7.0 Hz, COCH2CH2), 4.04 (m, 5H, CH2OC6H4, CH2O, 
CHOH), 4.69 (d, 1H, 3J = 1.5 Hz, H-5), 5.34 (bs, 1H, CHOH), 7.04 (m, 2H, Ar-H), 
7.71 (m, 4H, Ar-H), 7.98 (m, 2H, Ar-H), 8.49 (bs, 1H, OH), 11.18 (bs, 1H, OH), 12.82 
(bs, 1H, CO2H). 13C-NMR (DMSO-d6) δ 24.07 (-, CH2), 24.98 (-, CH2), 28.26 (-, CH2), 
33.27 (-, COCH2CH2), 64.42 (-, CH2O), 65.41 (+, CHO), 67.33 (-, CH2OC6H4), 74.94 
(+, CH), 114.90 (+, Ar-C), 118.09 (quat, C-2), 126.00 (+, Ar-C), 128.03 (+, Ar-C), 
128.68 (quat, Ar-C), 129.85 (+, Ar-C), 130.98 (quat, Ar-C), 143.88 (quat, Ar-C), 
152.08 (quat, C-3), 158.87 (quat, Ar-C), 167.10 (quat, CO2H), 170.26 (quat, lactone 
CO), 172.62 (quat, CO2CH2). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 485 (100) 
[M-H]-. Anal. (C25H26O10·0.3H2O) C, H. C25H26O10 (486.47).  
6-O-{6-[4-(3-Carboxyphenyl)phenoxy]hexanoyl}-L-ascorbic acid (7.103): The title 
compound was prepared from 7.86 (0.33 mmol, 0.22 g), 10 % Pd/C (20 mg) in EtOH 
(3 ml) and EtOAc (3 ml) according to general procedure 7.6.2.11 and was obtained 
as a white solid (0.16 g, 99 %). mp: 145-148 °C;  1H-NMR (DMSO-d6) δ 1.45 (m, 2H, 
COCH2CH2CH2), 1.68 (m, 4H, COCH2CH2, CH2CH2OC6H4), 2.38 (t, 2H, 3J = 7.2 Hz, 
COCH2CH2), 4.04 (m, 5H, CH2OC6H4, CH2O, CHOH), 4.70 (d, 1H, 3J = 1.4 Hz, H-5), 
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5.32 (bs, 1H, CHOH), 7.03 (m, 2H, Ar-H), 7.58 (m, 3H, Ar-H), 7.87 (m, 2H, Ar-H), 
8.13 (m, 1H, Ar-H), 8.42 (bs, 1H, OH), 11.15 (s, 1H, OH), 13.00 (bs, 1H, CO2H). 13C-
NMR (DMSO-d6) δ 24.08 (-, CH2), 25.00 (-, CH2), 28.29 (-, CH2), 33.27 (-, 
COCH2CH2), 64.43 (-, CH2O), 65.41 (+, CHO), 67.31 (-, CH2OC6H4), 74.94 (+, CH), 
114.91 (+, Ar-C), 118.10 (quat, C-2), 126.64 (+, Ar-C), 127.42 (+, Ar-C), 127.80 (+, 
Ar-C), 129.15 (+, Ar-C), 130.46 (+, Ar-C), 131.29 (quat, Ar-C), 131.32 (quat, Ar-C), 
140.08 (quat, Ar-C), 152.11 (quat, C-3), 158.53 (quat, Ar-C), 167.21 (quat, CO2H), 
170.28 (quat, lactone CO), 172.62 (quat, CO2CH2). ES-MS (DCM/MeOH + NH4OAc) 
m/z (%): 485 (100) [M-H]-. Anal. (C25H26O10) C, H. C25H26O10 (486.47). 
5,6-O-Bis{6-[4-(3-carboxyphenyl)phenoxy]hexanoyl}-L-ascorbic acid (7.103a): 
The title compound was prepared from 7.86a (0.14 mmol, 0.14 g), 10 % Pd/C (20 
mg) in EtOH (10 ml) and EtOAc (5 ml) according to general procedure 7.6.2.11 and 
was obtained as a white solid (0.11 g, 88 %). 1H-NMR (DMSO-d6) δ 1.35 – 1.74 (m, 
12H, COCH2(CH2)3), 2.30 (m, 4H, COCH2CH2), 3.96 (t, 4H, 3J = 6.1 Hz, CH2OC6H4), 
4.19 (dd, 1H, 3J = 8.4 Hz, 2J = 11.6 Hz, CH2O), 4.40 (dd, 1H, 3J = 4.0 Hz, 2J = 11.7 
Hz, CH2O), 5.02 (d, 1H, 3J = 2.1 Hz, H-5), 5.42 (ddd, 1H, 3J = 2.3 Hz, 3J = 3.9 Hz, 3J 
= 8.2 Hz, CHO), 7.00 (m, 4H, Ar-H), 7.57 (m, 6H, Ar-H), 7.86 (m, 4H, Ar-H), 8.12 (m, 
2H, Ar-H), 8.69 (bs, 1H, OH), 11.39 (bs, 1H, OH), 13.00 (bs, 2H, CO2H). Anal. 
(C44H44O14·1.4H2O) C, H. C44H44O14 (796.81). 
2,3-Di-O-benzyl-6-O-dodecanoyl-L-ascorbic acid (7.104): The title compound was 
prepared from 7.66 (8.0 mmol, 4.29 g), lauric acid (8.0 mmol, 1.60 g), DMAP (9.6 
mmol, 1.17 g) and EDAC (8.8 mmol, 1.68 g) in anhydrous DMF (20 ml) according to 
general procedure 7.6.2.9 and was obtained after flash chromatography (PE/EtOAc 
90/10) as a white solid (1.80 g, 43 %). mp: 42 °C (ref.53: 49-50 °C); 1H-NMR (CDCl3) 
δ 0.88 (t, 2H, 3J = 6.7 Hz, CH2CH3), 1.25 (s, 16H, (CH2)8CH3), 1.61 (m, 2H, 
COCH2CH2CH2), 2.33 (t, 2H, 3J = 7.6 Hz, COCH2CH2-), 4.06 (ddd, 1H, 3J = 1.8 Hz, 
3J = 5.1 Hz, 3J = 6.7 Hz, CHOH), 4.20 (dd, 1H, 3J = 5.1 Hz, 2J = 11.6 Hz, CH2O), 4.32 
(dd, 1H, 3J = 6.8 Hz, 2J = 11.6 Hz, CH2O), 4.67 (d, 1H, 3J = 2.0 Hz, H-5), 5.10 (s, 2H, 
CH2Ph), 5.14 (d, 1H, 2J = 11.9 Hz, CH2Ph), 5.21 (d, 1H, 2J = 11.7 Hz, CH2Ph),  7.22 
(m, 2H, Ph-H), 7.36 (m, 8H, Ph-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 556 
(100) [M+NH4]+. Anal. (C32H42O7) C, H. C32H42O7 (538.67). 
Benzyl 3-{(1S)-1-[(5R)-3,4-bis(benzyloxy)-2-oxo-2,5-dihydrofuran-5-yl]-2-
(dodecanoyloxy)ethyloxy}-3-oxopropanoate (7.105): The title compound was 
prepared from 7.104 (1.0 mmol, 0.54 g), 6.33 (1.0 mmol, 0.194 g), DMAP (1.2 mmol, 
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0.15 g) and EDAC (1.1 mmol, 0.11 g) in anhydrous DMF (10 ml) by analogy with 
general procedure 7.6.2.9 and was obtained after flash chromatography (PE/EtOAc 
90/10 v/v) as a colorless oil (0.65 g, 91 %). 1H-NMR (CDCl3) δ 0.88 (t, 3H, 3J =6.7Hz, 
CH2CH3), 1.25 (m, 16H, (CH2)8CH3), 1.57 (m, 2H, COCH2CH2CH2), 2.26 (t, 2H, 3J = 
7.7 Hz, -COCH2CH2), 3.34 (s, 2H, COCH2CO2), 4.24 (dd, 1H, 3J = 7.2 Hz, 2J = 11.6 
Hz, CH2O), 4.34 (dd, 1H, 3J = 5.6 Hz, 2J =11.6Hz, CH2O), 4.80 (d, 1H, 3J = 2.0 Hz, H-
5), 5.17 (m, 6H, CH2Ph), 5.44 (ddd, 1H, 3J = 2.0 Hz, 3J = 5.6 Hz, 3J = 7.4 Hz, CHO), 
7.32 (m, 15H, Ph-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 732 (100) [M+NH4]+. 
Anal. (C42H50O10·1.5H2O) C, H. C42H50O10 (714.84). 
3-{(1S)-1-[(5R)-3,4-Dihydroxy-2-oxo-2,5-dihydrofuran-5-yl]-2-(dodecanoyloxy)-
ethyloxy}-3-oxopropanoic acid (7.106): The title compound was prepared from 
7.105 (0.74 mmol, 0.53 g), 10 % Pd/C (30 mg) in EtOH (3 ml) and EtOAc (3 ml) 
according to general procedure 7.6.2.11 and was obtained after preparative HPLC 
(MeCN/0.1 % TFA (aq) 70/30 v/v) as a white semisolid substance (0.20 g, 61 %). 1H-
NMR (DMSO-d6) δ 0.85 (t, 3H, 3J = 6.7 Hz, CH3), 1.24 (m, 16H, (CH2)8CH3), 1.50 (m, 
2H, COCH2CH2), 2.28 (t, 2H, 3J = 7.4 Hz, COCH2CH2), 3.31 (s, 2H COCH2CO2H), 
4.19 (dd, 1H, 3J = 8.1 Hz, 2J = 11.7 Hz, CH2O), 4.32 (dd, 1H, 3J = 4.5 Hz, 2J = 11.7 
Hz, CH2O), 5.00 (d, 1H, 3J = 2.5 Hz, H-5), 5.39 (ddd, 1H, 3J = 2.5 Hz, 3J = 4.4 Hz, 3J 
= 7.2 Hz, CHO), 8.61 (s, 1H, OH), 11.54 (s, 1H, OH), 12.72 (s, 1H, CO2H). 13C-NMR 
(DMSO-d6) δ 13.88 (+, CH3), 22.02 (-, CH2), 24.11 (-, CH2), 28.35 (-, CH2), 28.61 (-, 
CH2), 28.63 (-, CH2), 28.81 (-, CH2), 28.93 (-, CH2), 31.22 (-, CH2), 33.12 (-, 
COCH2CH2), 40.99 (-, COCH2CO2), 61.62 (-, CH2O), 68.08 (+, CHO), 72.91 (+, CH), 
118.28 (quat, C-2), 150.67 (quat, C-3), 165.72 (quat, COCH2CO2H), 167.22 (quat, 
COCH2CO2H), 169.40 (quat, lactone CO), 172.46 (quat, CO2CH2). ES-MS 
(DCM/MeOH + NH4OAc) m/z (%): 443 (100) [M-H]-. HRMS (PI-LSIMS) calcd for 
C21H33O10 [M+H]+, 445.2074; found, 445.2082.  Anal. (C21H32O10·1.2H2O) C, H. 
C21H32O10 (444.47). 
Bis{(2S)-2-[(5R)-3,4-bis(benzyloxy)-2-oxo-2,5-dihydrofuran-5-yl]-2-hydroxyethyl} 
dodecanedioate (7.107): The title compound was prepared by analogy with general 
method 7.6.2.9 using 7.66 (2.0 mmol, 0.71 g), dodecanedioic acid (1.0 mmol, 0.23 g), 
DMAP (2.6 mmol, 0.32 g) and EDAC (2.4 mmol, 0.46 g) in anhydrous DMF (10 ml). 
Compound 7.107 was obtained after flash chromatography (PE/EtOAc 80/20 v/v) as 
a pale yellow oil (0.13 g, 14 %). 1H-NMR (CDCl3) δ 1.26 (m, 12H, COCH2CH2(CH2)6), 
1.57 (m, 4H, COCH2CH2), 2.32 (t, 4H, 3J = 7.5 Hz, COCH2CH2), 4.06 (m, 2H, 
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CHOH), 4.20 (dd, 2H, 3J = 5.2 Hz, 2J = 11.5 Hz, CH2O), 4.32 (dd, 2H, 3J = 6.8 Hz, 2J 
= 11.5 Hz, CH2O), 4.68 (d, 2H, 3J = 2.0 Hz, H-5), 5.04 – 5.23 (m, 8H, CH2Ph), 7.22 
(m, 4H, Ph-H), 7.36 (m, 16H, Ph-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 925 
(100) [M+NH4]+. Anal. (C52H58O14·1.2H2O) C, H. C52H58O14 (907.01). 
Bis{(2S)-2-[(5R)-3,4-bis(benzyloxy)-2-oxo-2,5-dihydrofuran-5-yl]-2-hydroxyethyl} 
tetradecanedioate (7.108): The title compound was prepared by analogy with 
general method 7.6.2.9 using 7.66 (2.0 mmol, 0.71 g), tetradecanedioic acid (1.0 
mmol, 0.26 g), DMAP (2.6 mmol, 0.32 g) and EDAC (2.4 mmol, 0.46 g) in anhydrous 
DMF (10 ml). Compound 7.108 was obtained after flash chromatography (PE/EtOAc 
70/30 v/v) as a colorless oil (0.3 g, 16 %). 1H-NMR (CDCl3) δ 1.25 (m, 16H, 
COCH2CH2(CH2)8), 1.60 (m, 4H, COCH2CH2), 2.32 (t, 4H, 3J = 7.6 Hz, COCH2CH2), 
4.14 (m, 4H, CH2O, CHOH), 4.33 (dd, 2H, 3J = 6.8 Hz, 2J = 11.5 Hz, CH2O), 4.68 (d, 
2H, 3J = 2.0 Hz, H-5), 5.08 – 5.23 (m, 8H, CH2Ph), 7.22 (m, 4H, Ph-H), 7.36 (m, 16H, 
Ph-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 952 (100) [M+NH4]+. C54H62O14 
(935.06). 
Bis{(2S)-2-[(5R)-3,4-bis(benzyloxy)-2-oxo-2,5-dihydrofuran-5-yl]-2-hydroxyethyl} 
hexadecanedioate (7.109): The title compound was prepared by analogy with 
general method 7.6.2.9 using 7.66 (2.0 mmol, 0.71 g), hexadecanedioic acid (1.0 
mmol, 0.29 g), DMAP (2.6 mmol, 0.32 g) and EDAC (2.4 mmol, 0.46 g) in anhydrous 
DMF (10 ml). Compound 7.109 was obtained after flash chromatography (PE/EtOAc 
95/5 to 60/40 v/v) as a colorless oil (0.12 g, 12 %). 1H-NMR (CDCl3) δ 1.26 (m, 20H, 
COCH2CH2(CH2)10), 1.60 (m, 4H, COCH2CH2), 2.32 (t, 4H, 3J = 7.6 Hz, COCH2CH2), 
4.05 – 4.35 (m, 6H, CH2O, CHOH), 4.68 (d, 2H, 3J = 2.0 Hz, H-5), 5.09 – 5.32 (m, 
8H, CH2Ph), 7.21 (m, 4H, Ph-H), 7.36 (m, 16H, Ph-H). ES-MS (DCM/MeOH + 
NH4OAc) m/z (%): 981 (100) [M+NH4]+. C56H66O14 (963.11). 
Bis{(2S)-2-[(5R)-3,4-dihydroxy-2-oxo-2,5-dihydrofuran-5-yl]-2-hydroxyethyl} 
dodecanedioate (7.110): The title compound was prepared from 7.107 (0.14 mmol, 
0.13 g), 10 % Pd/C (30 mg) in EtOH (4 ml) and EtOAc (4 ml) according to general 
procedure 7.6.2.11 and was obtained as a pale yellow oil (65 mg, 85 %). 1H-NMR 
(CD3OD + CDCl3) δ 1.21 (m, 12H, COCH2CH2(CH2)6), 1.53 (m, 4H, COCH2CH2), 
2.28 (t, 4H, 3J = 7.5 Hz, COCH2CH2), 4.02 (ddd, 1H, 3J = 2.2 Hz, 3J = 6.3 Hz, 3J = 6.4 
Hz, CHOH), 4.12 (dd, 1H, 3J = 5.9 Hz, 2J = 11.1 Hz, CH2O), 4.21 (dd, 1H, 3J = 6.7 
Hz, 2J = 11.2 Hz, CH2O), 4.63 (d, 1H, 3J = 2.2 Hz, H-5). 13C-NMR (CD3OD + CDCl3) 
δ 26.21 (-, CH2), 30.42 (-, CH2), 30.56 (-, CH2), 30.73 (-, CH2), 31.04 (-, CH2), 35.44 
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(-, CH2), 35.55 (-, CH2), 65.83 (-, CH2O), 68.51 (+, CHO), 120.22 (quat, C-2), 153.86 
(quat, C-3), 173.20 (quat, lactone CO), 175.58 (quat, CO2CH2). ES-MS (MeCN + 
TFA) m/z (%): 547 (5) [M+H]+. Anal. (C24H34O14·3H2O) C, H. C24H34O14 (546.52). 
Bis{(2S)-2-[(5R)-3,4-dihydroxy-2-oxo-2,5-dihydrofuran-5-yl]-2-hydroxyethyl} 
tetradecanedioate (7.111): The title compound was prepared from 7.108 (0.32 
mmol, 0.30 g), 10 % Pd/C (30 mg) in EtOH (4 ml) and EtOAc (4 ml) according to 
general procedure 7.6.2.11 and was obtained as a white solid (0.17 g, 95 %). 1H-
NMR (DMSO-d6) δ 1.23 (m, 16H, COCH2CH2(CH2)8), 1.52 (m, 4H, COCH2CH2), 2.32 
(t, 4H, 3J = 7.4 Hz, COCH2CH2), 4.01 (m, 6H, CH2O, CHOH), 4.68 (d, 2H, 3J = 1.5 
Hz, H-5), 5.33 (bs, 2H, CHOH), 8.43 (s, 2H, OH), 11.14 (s, 2H, OH). 13C-NMR 
(DMSO-d6) δ 24.31 (-, CH2), 28.39 (-, CH2), 28.66 (-, CH2), 28.84 (-, CH2), 28.93 (-, 
CH2), 33.29 (-, COCH2), 64.37 (-, CH2O), 65.37 (+, CHO), 74.91 (+, CH), 118.07 
(quat, C-2), 152.07 (quat, C-3), 170.26 (quat, lactone CO), 172.67 (quat,  CO2CH2). 
ES-MS (DCM/MeOH + NH4OAc) m/z (%): 573 (100) [M-H]-. Anal. (C26H38O14·H2O) C, 
H. C26H38O14 (574.57). 
Bis{(2S)-2-[(5R)-3,4-dihydroxy-2-oxo-2,5-dihydrofuran-5-yl]-2-hydroxyethyl} 
hexadecanedioate (7.112): The title compound was prepared from 7.109 (0.11 
mmol, 0.11 g), 10 % Pd/C (30 mg) in EtOH (4 ml) and EtOAc (4 ml) according to 
general procedure 7.6.2.11 as a white solid (65 mg, 98 %). 1H-NMR (CD3OD + 
CDCl3) δ 1.27 (m, 20H, COCH2CH2(CH2)10), 1.60 (m, 4H, COCH2CH2), 2.36 (t, 4H, 3J 
= 7.4 Hz, COCH2CH2), 4.08 (ddd, 2H, 3J = 2.2 Hz, 3J = 5.8 Hz, 3J = 7.1 Hz, CHOH), 
4.18 (dd, 2H, 3J = 5.8 Hz, 3J = 11.1 Hz, CH2O), 4.26 (dd, 2H, 3J = 7.1 Hz, 3J = 11.1 
Hz, CH2O), 4.71 (d, 1H, 3J = 2.2 Hz, H-5). 13C-NMR (CD3OD + CDCl3) δ 26.12 (-, 
CH2), 30.34 (-, CH2), 30.53 (-, CH2), 30.72 (-, CH2), 30.87 (-, CH2), 35.14 (-, 
COCH2CH2), 65.88 (-, CH2O), 68.21 (+, CHO), 77.30 (+, CH), 120.20 (quat, C-2), 
154.04 (quat, C-3), 173.24 (quat, lactone CO), 175.37 (quat, CO2CH2). ES-MS 
(DCM/MeOH + NH4OAc) m/z (%): 620 (100) [M+NH4]+. Anal. (C28H42O14·2.5H2O) C, 
H. C28H42O14 (602.62). 
11-(tert-Butoxycarbonylamino)undecanoic acid41 (7.113): To a solution of 11-
aminoundecanoic acid (24.8 mmol, 5.0 g) in THF (130 ml) and water (130 ml) was 
added NaOH (54,5 mmol, 2.2 g) and the mixture was stirred for 10 min at room 
temperature. Di-tert-butyl dicarbonate (27.3 mmol, 5.3 g) was added and stirring was 
continued overnight. After evaporation of the solvent the residue was taken up in 
CHCl3 (150 ml) and washed three times with 1 N HCl. The organic layer was dried 
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over MgSO4, filtered and evaporated under reduced pressure. The raw product was 
recrystallized from n-hexane to yield the title compound as a white solid (6.44 g, 90 
%).  mp: 64 °C (ref.41: 68 °C);  1H-NMR (CDCl3) δ 1.27 (s, 12H, COCH2CH2(CH2)6), 
1.44 (m, 11H, C(CH3)3, NHCH2CH2), 1.62 (m, 2H, COCH2CH2), 2.34 (t, 2H, 3J = 7.5 
Hz, COCH2), 3.09 (t, 2H, 3J = 6.1 Hz, NHCH2), 4.53 (bs, 1H, CONH), 9.57 (s, 1H, 
CO2H). C16H31NO4 (301.42). 
(2S)-2-[(5R)-3,4-Bis(benzyloxy)-2-oxo-2,5-dihydrofuran-5-yl]-2-hydroxyethyl 11-
(tert-butoxycarbonylamino)undecanoate (7.114): The title compound was 
prepared from 7.66 (4.0 mmol, 1.42 g), 7.113 (4.0 mmol, 1.21 g), DMAP (4.8 mmol, 
0.59 g) and EDAC (4.4 mmol, 0.84 g) in anhydrous DMF (15 ml) according to general 
procedure 7.6.2.9 and was obtained after flash chromatography (PE/EtOAc 90/10 to 
80/20 v/v) as a pale yellow oil (0.79 g, 31 %). 1H-NMR (CDCl3) δ 1.26 (m, 12H, 
COCH2CH2(CH2)6), 1.44 (s, 9H, C(CH3)3), 1.60 (m, 4H, COCH2CH2, CH2CH2NH), 
2.32 (t, 2H, 3J = 7.5 Hz, COCH2CH2), 3.09 (m, 2H, CH2NH), 4.05 (ddd, 1H, 3J 
=2.0Hz, 3J =5.0Hz, 3J =6.9Hz, CHOH), 4.19 (dd, 1H, 3J = 5.0 Hz, 2J = 11.6 Hz, 
CH2O), 4.32 (dd, 1H, 3J = 6.8 Hz, 2J = 11.6 Hz, CH2O), 4.67 (d, 1H, 3J = 2.1 Hz, H-5), 
5.10 (s, 2H, CH2Ph), 5.12 (d, 1H, 2J = 10.9 Hz, CH2Ph), 5.21 (d, 1H, 2J = 11.7 Hz, 
CH2Ph), 7.21 (m, 2H, Ph-H), 7.36 (m, 8H, Ph-H). ES-MS (MeCN + TFA) m/z (%): 640 
(100) [M+H]+. C36H49NO9 (639.78). 
(2S)-2-[(5R)-3,4-Bis(benzyloxy)-2-oxo-2,5-dihydrofuran-5-yl]-2-hydroxyethyl 11-
aminoundecanoate trifluoroacetic acid salt (7.115): The title compound was 
prepared from 7.114 (1.16 mmol, 0.73 g), in CH2Cl2/TFA (80/20 v/v, 10 ml) according 
to general procedure 7.6.2.10 and was obtained as pale yellow oil (0.76 g, 100 %). 
1H-NMR (CDCl3) δ 1.25 (s, 12H, COCH2CH2(CH2)6), 1.60 (m, 4H, COCH2CH2, 
CH2CH2NH2), 2.32 (t, 2H, 3J = 7.3 Hz, COCH2CH2), 2.99 (m, 2H, CH2NH2), 4.19 (m, 
3H, CH2O, CHOH), 4.68 (d, 1H, 3J = 1.9 Hz, H-5), 5.04 (s, 2H, CH2Ph), 5.13 (d, 1H, 
2J = 11.5 Hz, CH2Ph), 5.20 (d, 1H, 2J = 11.6 Hz, CH2Ph), 7.20 (m, 2H, Ph-H), 7.35 
(m, 8H, Ph-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 540 (100) [M+H]+. 
C31H41NO7 CF3COOH (653.68). 
Bis{(2S)-2-[(5R)-3,4-bis(benzyloxy)-2-oxo-2,5-dihydrofuran-5-yl]-2-hydroxyethyl} 
13-oxo-12-azatricosanedioate (7.116): A solution of 7.115 (0.21 mmol, 0.14 g), 
7.84 (0.21 mmol, 0.12 g), DIEA (0.46 mmol, 79 µl), HOBt (0.25 mmol, 39 mg) and 
EDAC (0.25 mmol, 48 mg) in DMF (10 ml) was stirred at room temperature overnight. 
After removal of the solvent under reduced pressure the remaining residue was 
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subjected to flash chromatography to yield the title compound as a colorless oil (0.10 
g, 43 %). 1H-NMR (CDCl3), δ 1.23 (m, 26H, COCH2CH2(CH2)6, NHCH2(CH2)7), 1.51 
(m, 6H, COCH2CH2, CH2CH2NH), 2.15 (t, 2H, 3J = 7.6 Hz, CH2CONH), 2.31 (t, 4H, 3J 
= 7.5 Hz, COCH2CH2), 3.20 (m, 2H, NHCH2), 4.08 (m, 2H, CHOH), 4.20 (dd, 2H, 3J = 
5.4 Hz, 2J = 11.5 Hz, CH2O), 4.32 (dd, 2H, 3J = 6.8 Hz, 2J = 11.5 Hz, CH2O), 4.69 (d, 
2H, 3J = 2.0 Hz, H-5), 5.08 (s, 4H, CH2Ph), 5.11 (d, 2H, 2J = 11.8 Hz, CH2Ph), 5.21 
(d, 2H, 2J = 11.7 Hz, CH2Ph) 5.81 (t, 1H, 3J = 5.5 Hz, CONH-), 7.21 (m, 4H, Ar-H), 
7.38 (m, 16H, Ar-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 1091 (100) [M+H]+. 
C63H79NO15 (1090.30). 
Bis{(2S)-2-[(5R)-3,4-dihydroxy-2-oxo-2,5-dihydrofuran-5-yl]-2-hydroxyethyl} 13-
oxo-12-azatricosanedioate (7.117): The title compound was prepared from 7.116 
(0.08 mmol, 90 mg), 10 % Pd/C (20 mg) in EtOH (3 ml) and EtOAc (3 ml) according 
to general procedure 7.6.2.11 and was obtained as a white solid (60 mg, 100 %). 1H-
NMR (CD3OD) δ 1.24 (m, 26H, COCH2CH2(CH2)6, NHCH2(CH2)7), 1.49 (m, 6H, 
COCH2CH2, CH2CH2NH), 2.10 (t, 2H, 3J = 7.4 Hz, CH2CONH), 2.30 (t, 4H, 3J = 7.4 
Hz, COCH2CH2), 3.24 (m, 2H, NHCH2), 4.09 (m, 6H, CHOH, CH2O), 4.67 (d, 2H, 3J = 
1.6 Hz, H-5). ES-MS (MeCN + TFA) m/z (%): 729 (5) [M-H]-. C35H55NO15 (729.81). 
7.6.2.12 General procedure for the synthesis of 2-O-acylated derivatives of 6-
O-palmitoylascorbic acid 118-121 
To a solution of 6-O-palmitoylascorbic acid (1 eq) and a catalytic amount of DMAP in 
a mixture of anhydrous THF and anhydrous CH2Cl2 was added a solution of the 
pertinent anhydride (1 eq) dissolved in anhydrous THF dropwise at 0 °C under an 
atmosphere of argon. After stirring at room temperature overnight the mixture was 
quenched with 1 N HCl and extracted three times with EtOAc. The combined organic 
phases were washed with brine and water, dried over MgSO4, filtered and the solvent 
was evaporated under reduced pressure. The products were purified by preparative 
HPLC. 
6-O-Hexadecanoyl-2-O-(3-phenylpropanoyl)-L-ascorbic acid (7.118): The title 
compound was prepared by analogy with general procedure 7.6.2.12 using 6-O-
palmitoylascorbic acid (0.5 mmol, 0.21 g), a catalytic amount of DMAP and 3-
phenylpropanoyl chloride (0.5 mmol, 74 µl) together with NEt3 (0.5 mmol, 69 µl) 
instead of the anhydride in  anhydrous CH2Cl2 (30 ml) and anhydrous THF (10 ml). 
Compound 7.118 was obtained after preparative HPLC (0 min: MeCN/0.1 % TFA 
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(aq) 90/10, 20 min: 95/5 v/v) as a white semisolid substance (0.10 g, 37 %). mp: 
95 °C; 1H-NMR (CDCl3) δ 0.88 (t, 3H, 3J = 6.7 Hz, CH2CH3), 1.25 (m, 24H, 
(CH2)12CH3), 1.63 (m, 2H, COCH2CH2), 2.36 (t, 2H, 3J = 7.6Hz, COCH2), 2.98 (m, 
4H, CO(CH2)2Ph), 4.23 (m, 2H, -CHOH, CH2O), 4.39 (dd, 1H, 3J = 5.9 Hz, 2J = 11.0 
Hz, CH2O), 4.82 (d, 1H, 3J = 2.0 Hz, H-5), 7.27 (m, 5H, Ph-H). 13C-NMR (CDCl3) δ 
14.19 (+, CH3), 22.75 (-, CH2), 24.88 (-, CH2), 29.16 (-, CH2), 29.30 (-, CH2), 29.42 (-, 
CH2), 29.50 (-, CH2), 29.66 (-, CH2), 29.71 (-, CH2), 29.74 (-, 4 CH2), 30.46 (-, CH2), 
31.98 (-, CH2), 34.12 (-, CH2), 35.39 (-, CH2), 64.65 (-, CH2O), 68.13 (+, CHO), 75.38 
(+, CH), 115.24 (quat, C-2), 126.79 (+, Ph-C), 128.31 (+, 2 Ph-C), 128.78 (+, 2 Ph-
C), 139.12 (quat, Ph-C), 155.71 (quat, C-3), 166.27 (quat, lactone CO), 173.06 (quat, 
CH2CO2), 174.09 (quat, CH2CO2). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 564 
(100) [M+NH4]+. HRMS (PI-EIMS) calcd for C31H46O8 [M+·], 546.3193; found, 
546.3190.  Anal. (C31H46O8) C, H. C31H46O8 (546.69). 
2-O-(3-Carboxypropanoyl)-6-O-hexadecanoyl-L-ascorbic acid (7.119): The title 
compound was prepared according to general method 7.6.2.12 using 6-O-
palmitoylascorbic acid (0.5 mmol, 0.21 g), a catalytic amount of DMAP and succinic 
anhydride (0.5 mmol, 50 mg) in  anhydrous CH2Cl2 (30 ml) and anhydrous THF (10 
ml). Compound 7.119 was obtained after preparative HPLC (0 min: MeCN/0.1 % TFA 
(aq) 80/20, 20 min: 95/5 v/v) as a white solid (0.15 g, 58 %). mp: 117-119 °C; 1H-
NMR (CD3OD) δ 0.89 (t, 3H, 3J = 6.1 Hz CH2CH3), 1.28 (m, 24H, (CH2)12CH3),  1.64 
(m, 2H, COCH2CH2), 2.37 (t, 2H, 3J = 7.4 Hz, COCH2), 2.67 (t, 2H, 3J = 6.7 Hz, 
COCH2), 2.85 (t, 2H, 3J = 6.7 Hz, COCH2), 4.19 (m, 3H, CH2O, CHOH), 4.92 (d, 1 H, 
under solvent peak, H-5). 13C-NMR (CD3OD) δ 14.53 (+, CH3), 23.83 (-, CH2), 26.06 
(-, CH2), 29.34 (-, CH2), 29.48 (-, CH2), 29.56 (-, CH2), 30.27 (-, CH2), 30.50 (-, CH2), 
30.57 (-, CH2), 30.69 (-, CH2), 30.81 (-, CH2), 30.85 (-, CH2), 33.16 (-, CH2), 34.92 (-, 
CH2), 65.58 (-, CH2O), 67.99 (+, CHO), 77.99 (+, CH), 114.50 (quat, C-2), 165.07 
(quat, C-3), 170.73 (quat, lactone CO), 171.36 (quat, CH2CO2), 175.15 (quat, 
CH2CO2), 175.84 (quat, CO2H). ES-MS (MeOH + NH4OAc) m/z (%): 532 (100) 
[M+NH4]+. HRMS (PI-LSIMS) calcd for C26H43O10 [M+H]+, 515.2856; found, 515.2854.  
Anal. (C26H42O10 ·0.8H2O) C, H. C26H42O10 (514.61). 
2-O-(4-Carboxybutanoyl)-6-O-hexadecanoyl-L-ascorbic acid (7.120): The title 
compound was prepared according to general method 7.6.2.12 using 6-O-
palmitoylascorbic acid (0.5 mmol, 0.21 g), a catalytic amount of DMAP and glutaric 
anhydride (0.5 mmol, 57 mg) in  anhydrous CH2Cl2 (30 ml) and anhydrous THF (10 
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ml). Compound 7.120 was obtained after preparative HPLC (0 min: MeCN/0.1 % TFA 
(aq) 85/15, 15 min: 95/5 v/v) as a white semisolid substance (0.2 g, 76 %). mp: 116-
119 °C; 1H-NMR (CD3OD) δ 0.90 (t, 3H, 3J = 6.6 Hz, CH2CH3), 1.28 (m, 24H, 
(CH2)12CH3), 1.63 (m, 2H, COCH2CH2), 1.96 (m, 2H, COCH2CH2CH2CO2H), 2.40 (m, 
4H, COCH2CH2CH2CO2H), 2.64 (t, 2H, 3J = 7.3 Hz, COCH2), 4.22 (m, 3H, CH2O, 
CHOH), 4.93 (d, 1H, 3J = 1.6 Hz, H-5). 13C-NMR (CD3OD) δ 14.54 (+, CH3), 21.05 (-, 
CH2), 23.83 (-, CH2), 26.06 (-, CH2), 30.28 (-, CH2), 30.51 (-, CH2), 30.57 (-, CH2), 
30.70 (-, CH2), 30.82 (-, CH2), 30.86 (-, CH2), 33.17 (-, CH2), 33.20 (-, CH2), 33.64 (-, 
CH2), 34.92 (-, CH2), 65.57 (-, CH2O), 67.99 (+, CHO), 77.99 (+, CH), 114.53 (quat, 
C-2), 164.98 (quat, C-3), 170.83 (quat, lactone CO), 171.75 (quat, CH2CO2), 175.14 
(quat, CH2CO2), 176.76 (quat, CO2H). ES-MS (MeCN + TFA) m/z (%): 546 (100) 
[M+H]+. Anal. (C27H44O10) C, H. C27H44O10 (528.63). 
2-O-(5-Carboxypentanoyl)-6-O-hexadecanoyl-L-ascorbic acid (7.121): The title 
compound was prepared according to general method 7.6.2.12 using 6-O-
palmitoylascorbic acid (0.5 mmol, 0.21 g), a catalytic amount of DMAP and oxepane-
2,7-dione (0.5 mmol, 64 mg) which was prepared according to known procedures45 in 
anhydrous CH2Cl2 (30 ml) and anhydrous THF (10 ml). Compound 7.121 was 
obtained after preparative HPLC (0 min: MeCN/0.1 % TFA (aq) 70/30, 30 min: 90/10 
v/v) as a white semisolid substance (0.08 g, 29 %). mp: 102-104 °C; 1H-NMR 
(CD3OD) δ 0.89 (t, 3H, 3J = 6.9 Hz, CH2CH3), 1.29 (m, 24H, (CH2)12CH3), 1.67 (m, 
4H, (CH2)2CH2CO2H), 2.35 (m, 4H, COCH2, CH2CO2H), 2.58 (t, 2H, 3J = 6.7 Hz, 
COCH2), 4.19 (m, 3H, CHOH, CH2O), 4.91 (d, 1H, 3J = 1.9 Hz, H-5). 13C-NMR 
(CD3OD) δ 14.41 (+, CH3), 23.71 (-, CH2), 25.09 (-, CH2), 25.31 (-, CH2), 25.96 (-, 
CH2), 30.17 (-, CH2), 30.39 (-, CH2), 30.45 (-, CH2), 30.58 (-, CH2), 30.70 (-, CH2), 
30.74 (-, CH2), 33.05 (-, CH2), 33.68 (-, CH2), 34.47 (-, CH2), 34.85 (-, CH2), 65.50 (-, 
CH2O), 67.96 (+, CHO), 77.92 (+, CH), 114.52 (quat, C-2), 164.93 (quat, C-3), 
170.77 (quat, lactone CO), 171.91 (quat, CH2CO2), 175.09 (quat, CH2CO2),  177.17 
(quat, CO2H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 541 (100) [M-H]-. Anal. 
(C28H46O10) C, H. C28H46O10 (542.66). 
2,3-O-Bis(5-carboxypentanoyl)-6-O-hexadecanoyl-L-ascorbic acid (7.121a): The 
title compound was obtained as byproduct in the synthesis of 7.121 as a white solid 
(40 mg, 12 %). mp: 80-81 °C; 1H-NMR (CD3OD) δ 0.90 (t, 3H, 3J = 6.7 Hz, CH2CH3), 
1.30 (m, 24H, (CH2)12CH3), 1.66 (m, 10H, COCH2CH2, COCH2(CH2)2CH2CO2H), 2.35 
(m, 6H, COCH2, CH2CO2H), 2.61 (m, 4H, COCH2), 4.21 (m, 3H, CHOH, CH2O), 5.31 
Chapter 7 Ascorbic acid derivatives as potent hyaluronidase inhibitors 
195 
(d, 1H, 3J = 1.5 Hz, H-5). 13C-NMR (CD3OD) δ 14.51 (+, CH3), 23.80 (-, CH2), 24.97 (-
, CH2), 25.18 (-, CH2), 25.20 (-, CH2), 25.29 (-, CH2), 26.00 (-, CH2), 30.25 (-, CH2), 
30.47 (-, CH2), 30.54 (-, CH2), 30.67 (-, CH2), 30.80 (-, CH2), 30.85 (-, CH2), 33.14 (-, 
CH2), 33.79 (-, CH2), 34.05 (-, CH2), 34.42 (-, CH2), 34.49 (-, CH2), 34.89 (-, CH2), 
65.36 (-, CH2O), 67.50 (+, CHO), 78.08 (+, CH), 123.08 (quat, C-2), 153.14 (quat, C-
3), 168.03 (quat, CO), 168.89 (quat, CO), 170.39 (quat, CH2CO2), 175.06 (quat, 
CH2CO2), 177.07 (quat, CO2H), 177.13 (quat, CO2H). HRMS (PI-LSIMS) calcd. for 
C34H55O13 [M+H]+, 671.3543; found, 671.3656. Anal. (C34H54O13·1.5H2O) C, H. 
C34H54O13 (670.78). 
2,3-O-Dibenzyl-6-O-(4-methylphenylsulfonyl)-L-ascorbic acid40 (7.122): To a 
solution of 7.66 (42 mmol, 15.1 g) in pyridine (40 ml) and CH2Cl2 (130 ml) was added 
a solution of p-toluenesulfonyl chloride (46.2 mmol, 8.81 g) in CH2Cl2 (80 ml) at 0 °C 
dropwise over a period of 2 h. After stirring overnight CH2Cl2 (340 ml) was added and 
the solution was washed twice with water, dried over MgSO4, filtered and evaporated 
under reduced pressure. Recrystallization of the crude product yielded the title 
compound as colorless crystals (13.3 g, 62 %). mp: 122-123 °C (ref.40: 133-134 °C);  
1H-NMR (CDCl3) δ 2.44 (s, 3H, CH3) 4.12 (m, 3H, CH2O, CHOH), 4.65 (s, 1H, H-5), 
5.06 (s, 2H, CH2Ph), 5.11 (d, 1H, 2J = 11.6 Hz, CH2Ph), 5.19 (d, 1H, 2J = 11.6 Hz, 
CH2Ph), 7.21 (m, 2H, Ph-H), 7.34 (m, 10H, Ar-H), 7.77 (m, 2H, Ar-H). ES-MS 
(DCM/MeOH + NH4OAc) m/z (%): 528 (100) [M+NH4]+. C27H26O8S (510.56). 
(5R)-3,4-Bis(benzyloxy)-5-[(1R)-2-bromo-1-hydroxyethyl]-2,5-dihydrofuran-2-
one40 (7.123): A mixture of 7.122 (25 mmol, 12.8 g), NaBr (30 mmol, 3.1 g) in  
anhydrous acetone (300 ml) was stirred at 120 °C in an autoclave for 7 h. After 
cooling to room temperature solids were removed by filtration and the solvent was 
evaporated to yield the title compound as a brown oil (10.3 g, 98 %) which was used 
without further purification in the next step. CI-MS (NH3) m/z (%): 436 (100) 
[M+NH4]+. C20H19BrO5 (419.27). 
(5R)-3,4-Bis(benzyloxy)-5-[(2S)-oxiran-2-]-2,5-dihydrofuran-2-one40 (7.124): A 
mixture of 7.123 (20 mmol, 8.4 g), KOH (25 mmol, 1.4 g) and N(Bu)4I (100 mg) in 
CH2Cl2 (200 ml) and water (30 ml) was vigorously stirred for 1 h. After separation of 
the water from the organic layer, the organic phase was washed twice with brine and 
once with water, dried over K2CO3, filtered and the solvent was removed under 
reduced pressure. The raw product was submitted to flash chromatography to yield 
the title compound as white solid (5.3 g, 78 %). mp: 48-49 °C (ref.40: 86-87 °C); 1H-
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NMR (CDCl3) δ 2.84 (m, 2H, CHCH2O), 3.12 (ddd, 1H, 3J = 2.7 Hz, 3J = 4.0 Hz, 3J = 
4.0 Hz, CHO), 4.56 (d, 1H, 3J = 3.9 Hz, H-5), 5.06 – 5.23 (m, 4H, CH2Ph), 7.20 (m, 
2H, Ph-H), 7.37 (m, 8H, Ph-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 356 (100) 
[M+NH4]+. C20H18O5 (338.35). 
7.6.2.13 General procedure for the synthesis of 6-O-alkylated ascorbic acids 
125 and 126 
A solution of 7.124 (1 eq), the pertinent alcohol (1.5 eq) and BF3Et2O (0.13 eq) in 
anhydrous CH2Cl2 was stirred at room temperature for 48 h. After dilution with CH2Cl2 
the solution was washed with saturated NaHCO3 and water, dried over MgSO4, 
filtered and the solvent was evaporated. The raw product was subjected to flash 
chromatography. 
2,3-Di-O-benzyl-6-O-(dodecan-1-yl)-L-ascorbic acid (7.125): The title compound 
was prepared according to general procedure 7.6.2.13 using 7.124 (1 mmol, 0.34 g), 
1-dodecanol (1.5 mmol, 0.28 g) and BF3Et2O (0.13 mmol, 16 µl) in CH2Cl2 (15 ml). 
After flash chromatography (CHCl3/MeOH 98/2 v/v) compound 7.125 was obtained 
as a colorless oil (0.28 g, 53 %). 1H-NMR (CDCl3) δ 0.88 (t, 3H, 3J = 6.7 Hz, CH3), 
1.25 (m, 18H, (CH2)9CH3), 1.54 (m, 2H, OCH2CH2CH2), 3.44 (t, 1H, 3J = 6.7 Hz, 
OCH2CH2), 3.54 (m, 2H, CH2OCH2CH2), 4.02 (m, 1H, CHOH), 4.72 (d, 1H, 3J = 2.0 
Hz, H-5), 5.09 (s, 2H, CH2Ph), 5.13 (d, 1H, 2J = 11.7 Hz, CH2Ph), 5.21 (d, 1H, 2J = 
11.7 Hz, CH2Ph), 7.22 (m, 2H, Ph-H), 7.36 (m, 10H, Ph-H). ES-MS (DCM/MeOH + 
NH4OAc) m/z (%): 542 (100) [M+NH4]+. C32H44O6 (524.69). 
2,3-Di-O-benzyl-6-O-(octandecan-1-yl)-L-ascorbic acid (7.126): The title 
compound was prepaded according to general procedure 7.6.2.13 using 7.124 (1 
mmol, 0.34 g), 1-octadecanol (1.5 mmol, 0.41 g) and BF3Et2O (0.13 mmol, 16 µl) in 
CH2Cl2 (15 ml). After flash chromatography (CHCl3/MeOH 98/2 v/v) compound 7.126 
was obtained as a colorless oil (0.38 g, 53 %). 1H-NMR (CDCl3) δ 0.88 (t, 3H, 3J = 6.7 
Hz, CH3), 1.25 (m, 30H, (CH2)15CH3), 1.54 (m, 2H, OCH2CH2CH2), 3.44 (t, 2H, 3J = 
6.7 Hz, OCH2CH2), 3.58 (m, 2H, CH2OCH2CH2), 4.02 (ddd, 1H, 3J = 2.1 Hz, 3J = 6.4 
Hz, 3J = 6.4 Hz, CHOH), 4.72 (d, 1H, 3J = 2.1 Hz, H-5), 5.10 (s, 2H, CH2Ph), 5.14 (d, 
1H, 2J = 11.8 Hz, CH2Ph), 5.21 (d, 1H, 2J = 11.7 Hz, CH2Ph), 7.22 (m, 2H, Ph-H), 
7.36 (m, 8H, Ph-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 626 (100) [M+NH4]+. 
C38H56O6 (608.85). 
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6-O-(Dodecan-1-yl)-L-ascorbic acid (7.127): The title compound was prepared from 
7.125 (0.42 mmol, 0.22 g), 10 % Pd/C (30 mg) in EtOH (5 ml) and EtOAc (5 ml) 
according to general procedure 7.6.2.11. After recystallization from TBME/n-hexane 
compound 7.127 was obtained as a white solid (0.10 g, 69 %). mp: 105-106 °C; 1H-
NMR (DMSO-d6) δ 0.85 (t, 3H, 3J = 6.6 Hz, CH3), 1.24 (m, 18H, (CH2)9CH3), 1.49 (m, 
2H, OCH2CH2CH2), 3.40 (m, 4H, CH2OCH2), 3.87 (m, 1H, CHOH), 4.64 (d, 1H, 3J = 
1.3 Hz, H-5), 5.03 (s, 1H, CHOH), 8.35 (s, 1H, OH), 11.03 (s, 1H, OH). 13C-NMR 
(DMSO-d6) δ 13.90 (+, CH3), 22.04 (-, CH2), 25.54 (-, CH2), 28.65 (-, CH2), 28.81 (-, 
CH2), 28.95 (-, CH2), 29.07 (-, CH2), 31.23 (-, CH2), 65.97 (+, CHO), 70.46 (-, OCH2), 
70.84 (-, OCH2), 74.90 (+, CH), 117.93 (quat, C-2), 152.47 (quat, C-3), 170.45 (quat, 
lactone CO). CI-MS (NH3) m/z (%): 362 (100) [M+NH4]+. Anal. (C18H32O6) C, H. 
C18H32O6 (344.44). 
6-O-(Octandecan-1-yl)-L-ascorbic acid (7.128): The title compound was prepared 
from 7.126 (0.57 mmol, 0.35 g), 10 % Pd/C (30 mg) in EtOH (5 ml) and EtOAc (5 ml) 
according to general procedure 7.6.2.11. After recystallization from IPE compound 
7.128 was obtained as a white solid (0.20 g, 81 %). mp: 104-106 °C; 1H-NMR 
(CD3OD + CDCl3), 0.89 (t, 3H, 3J = 6.7 Hz, CH3), 1.28 (s, 30H, (CH2)15CH3), 1.58 (m, 
2H, OCH2CH2CH2), 3.52 (m, 4H, CH2OCH2), 4.01 (ddd, 1H, 3J = 1.8 Hz, 3J = 6.8 Hz, 
3J = 6.8 Hz, CHOH), 4.75 (d, 1H, 3J = 1.9 Hz, H-5). 13C-NMR (DMSO-d6) δ 13.87 (+, 
CH3), 22.03 (-, CH2), 25.55 (-, CH2), 28.64 (-, CH2), 28.82 (-, CH2), 28.96 (-, CH2), 
29.08 (-, CH2), 31.22 (-, CH2), 66.00 (+, CHO), 70.48 (-, OCH2), 70.86 (-, OCH2), 
74.89 (+, CH), 117.95 (quat, C-2), 152.42 (quat, C-3), 170.41 (quat, lactone CO). ES-
MS (MeCN + TFA) m/z (%): 429 (100) [M+H]+. Anal. (C24H44O6) C, H. C24H44O6 
(428.60). 
2,3-O-Bis(benzyloxycarbonylmethyl)-5-O-,6-O-isopropylidene-L-ascorbic acid 
(7.129): The title compound was prepared from 7.64 (25.0 mmol, 4.40 g), potassium 
carbonate (27.5 mmol, 3.80 g) and benzyl bromoacetate (55.0 mmol, 12.60 g) in 
anhydrous DMF (75 ml) according to general 7.6.2.8. Flash chromatography 
(PE/EtOAc 70/30 v/v) yielded compound 7.129 as a white solid (10.9 g, 85 %). mp: 
64 °C;  1H-NMR (CDCl3) δ 1.35 (s, 3H, C(CH3)2), 1.38 (s, 3H, C(CH3)2), 4.03 (dd, 1H, 
3J = 6.4 Hz, 2J = 8.7 Hz, CH2O), 4.13 (dd, 1H, 3J = 6.7 Hz, 2J = 8.6 Hz, CH2O), 4.26 
(ddd, 1H, 3J = 4.2 Hz, 3J = 6.5 Hz, 3J = 6.5 Hz, CHO), 4.62 (d, 1H, 3J = 4.2 Hz, H-5), 
4.71 (d, 1H, 2J = 16.8 Hz, OCH2CO2), 4.80 (d, 1H, 2J = 16.8 Hz, OCH2CO2), 5.10 - 
8.28 (m, 6H, OCH2CO2, CH2Ph), 7.34 (m, 10H, Ph-H). ES-MS (DCM/MeOH + 
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NH4OAc) m/z (%): 530 (100) [M+NH4]+. Anal. (C27H28O10·0.1CH2Cl2) C, H. C27H28O10 
(512.51). 
7.6.2.14 General procedure for the synthesis of 5,6-O-unprotected ascorbic 
acid derivatives 130 and 139-142 by acid catalyzed acetal cleavage  
The pertinent acetal was stirred in a mixture of methanol, THF and 2 N HCl for 6 h. 
After evaporating the solvent the remaining residue was taken up with water and 
extracted tree times with EtOAc. The combined organic layers were washed with 
water, dried over MgSO4, filtered and evaporated under reduced pressure. The raw 
product was purified, if necessary, using flash chromatography 
2,3-O-Bis(benzyloxycarbonylmethyl)-L-ascorbic acid (7.130): The title compound 
was prepared according to general procedure 7.6.2.14 using 7.129 (2.54 mmol, 1.30 
g) in MeOH (4 ml), THF (4 ml) and 2 N HCl (2,5 ml) and was obtained after flash 
chromatography (PE/EtOAc 2/1 v/v) as a colorless oil (0.81 g, 68 %). 1H-NMR 
(CDCl3) δ 2.45 (dd, 1H, 3J = 3.9 Hz, 3J = 7.9 Hz, CH2OH), 3.68 (d, 1H, 3J = 4.7 Hz, 
CHOH), 3.75 (m, 1H), 3.86 (ddd, 1H, 3J = 3.3 Hz, 3J = 6.9 Hz, 2J = 10.4 Hz, CH2OH), 
4.11 (ddd, 1H, 3J = 5.0 Hz, 3J = 6.8 Hz, 2J = 6.8 Hz, CH2OH), 4.63 (d, 1H, 2J = 16.9 
Hz, OCH2), 4.76 (d, 1H, 3J = 2.0 Hz, H-5), 4.85 (d, 2H, 2J = 16.8 Hz, OCH2),  5.14 (s, 
2H, OCH2), 5.20 (s, 2H, OCH2), 5.64 (d, 1H, 2J = 16.6 Hz, OCH2), 7.34 (m, 10H). ES-
MS (DCM/MeOH + NH4OAc) m/z (%): 490 (100) [M+NH4]+. C24H24O10 (472.44). 
2,3-O-Bis(benzyloxycarbonylmethyl)-6-O-dodecanoyl-L-ascorbic acid (7.131): 
The title compound was prepared from 7.130 (1.0 mmol, 0.47 g), lauric acid (1.0 
mmol, 0.20 g), DMAP (1.2 mmol, 0.15 g) and EDAC (1.1 mmol, 0.21 g) in anhydrous 
DMF (10 ml) according to general procedure 7.6.2.9 and was obtained after flash 
chromatography (PE/EtOAc 80/20 to 60/40 v/v) as a white solid (0.20 g, 31 %). mp: 
44 °C; 1H-NMR (CDCl3) δ 0.88 (t, 3H, 3J = 6.6 Hz, CH2CH3) 1.26 (m, 16H, 
(CH2)4CH3), 1.63 (m, 2H, COCH2CH2CH2), 2.34 (t, 2H, 3J = 7.5 Hz, COCH2CH2), 
4.30 (m, 3H, CH2O, CHOH), 4.62 (d, 1H, 2J = 16.9 Hz, OCH2CO2), 4.76 (d, 1H, 3J = 
1.3 Hz, H-5), 4.81 (d, 1H, 2J = 16.7 Hz, OCH2CO2),  4.87 (d, 1H, 2J = 17.0 Hz, 
OCH2CO2), 5.14 (s, 2H, CH2Ph), 5.20 (s, 2H, CH2Ph) ppm 5.69 (d, 1H, 2J = 16.7 Hz, 
OCH2CO2), 7.34 (m, 10H, Ph-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 672 
(100) [M+NH4]+. Anal. (C36H46O11) C, H. C36H46O11 (654.74). 
2,3-O-Bis(carboxymethyl)-6-O-dodecanoyl-L-ascorbic acid (7.132): The title 
compound was prepared from 7.131 (0.18 mmol, 0.12 g), 10 % Pd/C (30 mg) in 
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EtOH (3 ml) and EtOAc (3 ml) according to general procedure 7.6.2.11 and was 
obtained as a white solid (80 mg, 94 %). mp: 89-90 °C;  1H-NMR (CD3OD) δ 0.89 (t, 
3H, 3J = 6.7 Hz, CH2CH3), 1.29 (s, 16H, (CH2)4CH3), 1.62 (m, 2H, COCH2CH2CH2), 
2.37 (t, 2H, 3J = 7.4 Hz, COCH2CH2), 4.21 (m, 3H, CH2O, CHOH), 4.64 (d, 1H, 2J = 
16.5 Hz, OCH2CO2H), 4.71 (d, 1H, 2J = 16.5 Hz, OCH2CO2H), 4.88 (d, 1H, 3J = 1.7 
Hz, H-5), 5.20 (d, 1H, 2J = 16.5 Hz, OCH2CO2H), 5.29 (d, 1H, 2J = 16.5 Hz, 
OCH2CO2H). 13C-NMR (CD3OD) δ 14.53 (+, CH3), 23.82 (-, CH2), 26.05 (-, CH2), 
30.26 (-, CH2), 30.48 (-, CH2), 30.55 (-, CH2), 30.68 (-, CH2), 30.81 (-, CH2), 33.15 (-, 
CH2), 34.93 (-, COCH2CH2), 65.35 (-, CH2), 67.91 (+, CHO), 68.16 (-, CH2), 68.86 (-, 
CH2), 77.21 (+, CH), 122.92 (quat, C-2), 157.19 (quat, C-3), 170.53 (quat, lactone 
CO), 172.33 (quat, CO2CH2), 175.14 (quat, CO2H). ES-MS (MeCN/H2O/MeOH + 
NH4OAc) m/z (%): 492 (100) [M+NH4]+. Anal. (C22H34O11) C, H. C22H34O11 (474.50). 
7.6.2.15 General procedure for the synthesis of 3-O-mono-alkylated 5,6-O-
isopropylidene-L-ascorbic acid derivatives 133 and 134 
K2CO3 (1 eq) was added to a solution of 7.64 (1 eq) in THF/DMF. After stirring for 10 
min at room temperature an alkyl halide was added dropwise. Stirring was continued 
for 3 h and then the reaction was quenched by addition of water. The mixture was 
neutralized with 1 N HCl and extracted twice with EtOAc. The combined organic 
layers were washed with brine, dried over MgSO4, filtered, concentrated and 
subjected to flash chromatography. 
3-O-Benzyl-5,6-O-isopropylidene-L-ascorbic acid39 (7.133): The title compound 
was prepared according to general procedure 7.6.2.15 using 7.64 (50 mmol, 10.81 
g), K2CO3 (50 mmol, 6.91 g) and benzyl bromide (50 mmol, 5.94 ml) in anhydrous 
THF (30 ml) and anhydrous DMF (10 ml). After flash chromatography (PE/EtOAc 
80/20 v/v) and recrystallization from IPE the product was obtained as a white solid 
(7.0 g, 46 %). mp: 89-91 °C (ref.39: 105-106 °C); 1H-NMR (CDCl3) δ 1.36 (s, 3H, 
C(CH3)2), 1.39 (s, 3H, C(CH3)2), 4.02 (dd, 1H, 3J = 6.8 Hz, 2J = 8.6 Hz, CH2O), 4.10 
(dd, 1H, 3J =6.7Hz, 2J =8.6Hz, CH2O), 4.26 (ddd, 1H, 3J = 3.7 Hz, 3J = 6.7 Hz, 3J = 
6.7 Hz, CHO), 4.57 (d, 1H, 3J = 3.7 Hz, H-5), 5.49 (d, 1H, 2J = 11.8 Hz, CH2Ph), 5.53 
(d, 1H, 2J = 11.8 Hz, CH2Ph), 7.39 (m, 5H, Ph-H). CI-MS (NH3) m/z (%): 324 (100) 
[M+NH4]+. C16H18O6 (306.31). 
3-O-(Benzyloxycarbonylethyl)-5,6-O-isopropylidene-L-ascorbic acid (7.134): 
The title compound was prepared according to general procedure 7.6.2.15 using 7.64 
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(15 mmol, 3.24 g), K2CO3 (15 mmol, 2.07 g) and benzyl bromoacetate (15 mmol, 
3.44 ml) in anhydrous THF (10 ml) and anhydrous DMF (3 ml). Flash 
chromatography (PE/EtOAc 70/30 to 60/40 v/v) yielded a colorless oil (1.4 g, 26 %). 
1H-NMR (CDCl3) δ 1.36 (s, 3H, C(CH3)2), 1.39 (s, 3H, C(CH3)2), 4.10 (m, 2H, CH2O), 
4.27 (ddd, 1H, 3J = 4.2 Hz, 3J = 6.6 Hz, 3J = 6.6 Hz, CHO), 4.67 (d, 1H, 3J = 4.2 Hz, 
H-5), 4.95 (d, 1H, 2J = 16.4 Hz, OCH2CO2), 5.06 (d, 1H, 2J = 16.4 Hz, OCH2CO2), 
5.24 (s, 2H, CH2Ph), 5.95 (bs, 1H, OH), 7.36 (m, 5H, Ph-H). ES-MS (DCM/MeOH + 
NH4OAc) m/z (%): 382 (100) [M+NH4]+. Anal. (C18H20O8·0.9CH2Cl2) C, H. C18H20O8 
(364.35). 
7.6.2.16 General procedure for the synthesis of 2-O-alkylated 3-O-alkyl,5,6-O-
isopropylidene-L-ascorbic acid derivatives 135-138 
K2CO3 (1.1 eq) and the pertinent alkyl halide (1.1 eq) were added to a solution of the 
corresponding ascorbic acid derivative (1 eq) in anhydrous THF/DMSO. After stirring 
for 3 h at 50 °C the reaction was quenched by addition of water. The mixture was 
neutralized with 1 N HCl and extracted three times with EtOAc. The combined 
organic layers were washed with brine, dried over MgSO4, filtered and subjected to 
flash chromatography. 
3-O-Benzyl-2-O-(dodecan-1-yl)-5-O-,6-O-isopropylidene-L-ascorbic acid97 
(7.135): The title compound was prepared according to general procedure 7.6.2.16 
using 7.133 (2 mmol, 0.61 g), K2CO3 (2.2 mmol, 0.30 g) and 1-bromododecane (2.2 
mmol, 0.53 ml) in anhydrous THF (2 ml) and DMSO (2 ml). After flash 
chromatography (PE/EtOAc 80/20 v/v) the product was obtained as a colorless oil 
(0.55 g, 58 %). 1H-NMR (CDCl3) δ 0.88 (t, 3H, 3J = 6.7 Hz, CH2CH3), 1.26 (m, 18H, 
CH2(CH2)9CH3), 1.36 (s, 3H, C(CH3)2), 1.39 (s, 3H, C(CH3)2), 1.65 (m, 2H, 
COCH2CH2), 4.06 (m, 4H, CH2O, OCH2CH2), 4.29 (ddd, 1H, 3J = 3.2 Hz, 3J = 6.7 Hz, 
3J = 6.7 Hz, CHO), 4.54 (d, 1H, 3J = 3.2 Hz, H-5), 5.48 (s, 2H, CH2Ph), 7.38 (m, 5H, 
Ph-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 492 (100) [M+NH4]+. C28H42O6 
(474.63). 
3-O-Benzyl-2-O-(hexadecan-1-yl)-5,6-O-isopropylidene-L-ascorbic acid98 
(7.136): The title compound was prepared according to general procedure 7.6.2.16 
using 7.133 (2 mmol, 0.61 g), K2CO3 (2.2 mmol, 0.30 g) and 1-bromohexadecane 
(2.2 mmol, 0.67 ml) in anhydrous THF (2 ml) and DMSO (2 ml). After flash 
chromatography (PE/EtOAc 90/10 to 80/20 v/v) the product was obtained as a pale 
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yellow oil (0.43 g, 41 %). 1H-NMR (CDCl3) δ 0.88 (t, 3H, 3J = 6.7 Hz, CH2CH3), 1.32 
(m, 32H, CH2(CH2)13CH3), 1.65 (m, 2H, OCH2CH2), 4.05 (m, 4H, OCH2CH2, CH2O), 
4.29 (ddd, 1H, 3J = 3.2 Hz, 3J = 6.7 Hz, 3J = 6.7 Hz, CHO), 4.54 (d, 1H, 3J = 3.2 Hz, 
H-5), 5.48 (s, 2H, CH2Ph), 7.38 (m, 5H, Ph-H). ES-MS (DCM/MeOH + NH4OAc) m/z 
(%): 548 (100) [M+NH4]+. Anal. (C32H50O6) C, H. C32H50O6 (530.74). 
2-O-(Benzyloxycarbonylmethyl)-3-O-benzyl-5,6-O-isopropylidene-L-ascorbic 
acid (7.137): The title compound was prepared according to general procedure 
7.6.2.16 using 7.133 (3 mmol, 0.92 g), K2CO3 (3.3 mmol, 0.46 g) and benzyl 
bromoacetate (3.3 mmol, 0.76 g) in anhydrous THF (3 ml) and DMSO (3 ml). After 
flash chromatography (PE/EtOAc 80/20 to 70/30 v/v) the product was obtained as a 
pale yellow oil (1.20 g, 88 %). 1H-NMR (CDCl3) δ 1.35 (s, 3H, C(CH3)2), 1.37 (s, 3H, 
C(CH3)2), 4.01 (dd, 1H, 3J = 6.7 Hz, 2J = 8.6 Hz, CH2O), 4.09 (dd, 1H, 3J = 6.8 Hz, 2J 
= 8.3 Hz, CH2O), 4.28 (ddd, 1H, 3J = 3.4 Hz,  3J = 6.7 Hz, 3J = 6.7 Hz, CHO), 4.54 (d, 
1H, 3J = 3.4 Hz, H-5), 4.72 (d, 1H, 2J = 16.6 Hz, OCH2CO2), 4.86 (d, 1H, 2J = 16.6 
Hz, OCH2CO2), 5.18 (d, 1H, 2J = 12.1 Hz, OCH2Ph), 5.23 (d, 1H, 2J = 12.1 Hz, 
OCH2Ph), 5.58 (d, 1H, 2J = 11.9 Hz, OCH2Ph), 5.66 (d, 1H, 2J = 11.9 Hz, OCH2Ph), 
7.35 (m, 10H, Ph-H). CI-MS (NH3) m/z (%): 472 (100) [M+NH4]+. Anal. 
(C25H26O8·0.3CH2Cl2) C, H. C25H26O8 (454.47). 
2-O-Benzyl-3-O-(benzyloxycarbonylmethyl)-5,6-O-isopropylidene-L-ascorbic 
acid (7.138): The title compound was prepared according to to general procedure 
7.6.2.16 using 7.134 (2.23 mmol, 0.82 g), K2CO3 (2.46 mmol, 0.34 g) and benzyl 
bromide  (2.45 mmol, 0.29 ml) in anhydrous THF (3 ml) and DMSO (3 ml). After flash 
chromatography (PE/EtOAc 70/30 v/v) the product was obtained as a colorless oil 
(0.83 g, 82 %). 1H-NMR (CDCl3) δ 1.36 (s, 3H, C(CH3)2), 1.41 (s, 3H, C(CH3)2),  4.07 
(m, 2H, CH2O), 4.25 (ddd, 1H, 3J = 3.7 Hz, 3J = 6.6 Hz, 3J = 6.6 Hz, CHO), 4.70 (m, 
3H, H-5, OCH2CO2), 5.08 (m, 4H, CH2Ph), 7.32 (m, 10H, Ar-H). ES-MS (DCM/MeOH 
+ NH4OAc) m/z (%): 472 (100) [M+NH4]+. Anal. (C25H26O8·0.3H2O) C, H. C25H26O8 
(454.47). 
2-O-(Dodecan-1-yl)-L-ascorbic acid95 (7.139): The title compound was prepared 
according to general procedure 7.6.2.14 using 7.135 (0.83 mmol, 0.40 g) in MeOH (3 
ml), THF (1 ml) and 2 N HCl (1 ml). The obtained colorless oil was hydrogenated 
according to general procedure 7.6.2.11 in EtOH (3 ml) and EtOAc (3 ml) using 10 % 
Pd/C (50 mg). Recrystallization from EtOAc/IPE yielded a white solid (0.20 g, 70 %). 
mp: 117-119 °C (ref.98: 127-128 °C); 1H-NMR (DMSO-d6) δ 0.85 (t, 3H, 3J = 6.5 Hz, 
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CH2CH3), 1.24 (m, 18H, CH2(CH2)9CH3), 1.57 (m, 2H, COCH2CH2), 3.42 (m, 2H, 
CH2O), 3.83 (m, 3H, OCH2CH2, CHOH), 4.76 (d, 1H, 3J = 1.0 Hz, H-5), 4.93 (s, 1H, 
OH), 11.58 (s, 1H, OH). 13C-NMR (DMSO-d6) δ 13.90 (+, CH3), 22.04 (-, CH2), 25.10 
(-, CH2), 28.66 (-, CH2), 28.74 (-, CH2), 28.96 (-, CH2), 31.24 (-, CH2), 61.74 (-, 
CH2OH), 68.27 (+, CHOH), 70.93 (-, OCH2), 74.45 (+, CH), 119.79 (quat, C-2), 
159.01 (quat, C-3), 169.65 (quat, CO2CH2). ES-MS (DCM/MeOH + NH4OAc) m/z 
(%): 362 (100) [M+NH4]+. C18H32O6 (344.44). 
2-O-(Hexadecan-1-yl)-L-ascorbic acid97 (7.140): The title compound was prepared 
according to general procedure 7.6.2.14 using 7.136 (0.64 mmol, 0.34 g) in MeOH (3 
ml), THF (1 ml) and 2 N HCl (1 ml). The obtained pale yellow oil was hydrogenated 
according to general procedure 7.6.2.11 in EtOH (3 ml) and EtOAc (3 ml) using 10 % 
Pd/C (50 mg). Recrystallization from EtOAc/IPE yielded a white solid (0.13 g, 51 %). 
mp: 118-120 °C (ref.98: 128-129 °C); 1H-NMR (DMSO-d6) δ 0.85 (t, 3H, 3J = 6.4 Hz, 
CH2CH3), 1.24 (m, 26H, CH2(CH2)13CH3), 1.57 (m,  2H, COCH2CH2), 3.43 (dd, 2H, 3J 
= 6.8 Hz, 2J = 12.6 Hz, CH2O), 3.83 (m, 3H, OCH2CH2, CHOH), 4.75 (d, 1H, 3J = 0.8 
Hz, H-5), 4.93 (bs, 1H, OH), 11.51 (bs, 1H, OH). 13C-NMR (DMSO-d6) δ 13.89 (+, 
CH3), 22.03 (-, CH2), 25.11 (-, CH2), 28.65 (-, CH2), 28.76 (-, CH2), 28.99 (-, CH2), 
31.23 (-, CH2), 61.73 (-, CH2OH), 68.28 (+, CHOH), 70.92 (-, OCH2), 74.48 (+, CH), 
119.74 (quat, C-2), 159.14 (quat, C-3), 169.67 (quat, CO2CH2). ES-MS (DCM/MeOH 
+ NH4OAc) m/z (%): 401 (100) [M+NH4]+. Anal. (C22H40O6) C, H. C22H40O6 (400.55). 
2-O-(Benzyloxycarbonylmethyl)-3-O-benzylascorbic acid (7.141): The title 
compound was prepared according to general procedure 7.6.2.14 using 7.137 (2.3 
mmol, 1.1 g) in MeOH (3 ml), THF (3 ml) and 2 N HCl (2 ml). Flash chromatography 
(PE/EtOAc 3/1 v/v) yielded a white solid (0.64 g, 67 %). mp: 93 °C; 1H-NMR (DMSO-
d6) δ 3.43 (m, 2H, CH2O), 3.72 (ddd, 1H, 3J = 1.0 Hz, 3J = 7.5 Hz, 3J = 7.3 Hz, 
CHOH), 4.71 (d, 1H, 2J = 16.2 Hz, OCH2CO2), 4.77 (d, 1H, 2J = 16.2Hz, OCH2CO2), 
4.89 (m, 2H, H-5, OH), 5.17 (m, 3H, OCH2Ph, OH), 5.50 (d, 1H, 2J = 11.8 Hz, 
OCH2Ph), 5.61 (d, 1H, 2J = 11.8 Hz, OCH2Ph), 7.38 (m, 10H, Ph-H). ES-MS 
(DCM/MeOH + NH4OAc) m/z (%): 415 (100) [M+H]+. Anal. (C22H22O8) C, H. C22H22O8 
(414.41). 
2-O-Benzyl-3-O-(benzyloxycarbonylmethyl)ascorbic acid (7.142): The title 
compound was prepared according to general procedure 7.6.2.14 using 7.138 (1.67 
mmol, 0.76 g) in MeOH (3 ml), THF (3 ml) and 2 N HCl (2 ml). Flash chromatography 
(PE/EtOAc 2/1 v/v) yielded a white solid (0.50 g, 72 %). mp: 77 °C; 1H-NMR (CDCl3) 
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δ 2.33 (bs, 1H, CH2OH), 3.51 (d, 1H, 3J = 3.8 Hz, CHOH), 3.90 (m, 3H, CH2OH, 
CHOH), 4.61 (d, 1H, 2J = 16.5 Hz, OCH2CO2), 4.75 (d, 1H, 3J = 2.0 Hz, H-5), 5.09 
(m, 5H, OCH2CO2, CH2Ph), 7.31 (m, 10H, Ph-H). ES-MS (DCM/MeOH + NH4OAc) 
m/z (%): 432 (100) [M+NH4]+. Anal. (C22H22O8) C, H. C22H22O8 (414.41). 
2-O-(2-Benzyloxycarbonylmethyl)-3-O-benzyl-6-O-dodecanoylascorbic acid 
(7.143): The title compound was prepared from 7.141 (1.0 mmol, 0.41 g), lauric acid 
(1.0 mmol, 0.20 g), DMAP (1.2 mmol, 0.15 g) and EDAC (1.1 mmol, 0.21 g) in 
anhydrous DMF (6 ml) according to general procedure 7.6.2.9 and was obtained 
after flash chromatography (PE/EtOAc 80/20 v/v) as a colorless oil (0.21 g, 35 %). 
1H-NMR (CDCl3) δ 0.88 (t, 3H, 3J = 6.6Hz, CH2CH3), 1.26 (m, 16H, (CH2)8CH3), 1.62 
(m, 2H, COCH2CH2CH2), 2.33 (t, 2H, 3J = 7.6Hz, COCH2CH2), 4.09 – 4.36 (m, 3H, 
CH2O-, CHOH), 4.69 (d, 1H, 3J = 2.0 Hz, H-5), 4.77 (d, 1H, 2J = 16.8 Hz, OCH2CO2), 
4.83 (d, 1H, 2J = 16.8 Hz, OCH2CO2), 5.20 (s, 2H, CH2Ph), 5.60 (d, 1H, 2J = 11.8 Hz, 
CH2Ph), 5.66 (d, 1H, 2J = 11.8 Hz, CH2Ph), 7.36 (m, 10H, Ph-H). CI-MS (NH3) m/z 
(%): 614 (100) [M+NH4]+. Anal. (C34H44O9) C, H. C34H44O9 (596.71). 
2-O-(Benzyloxycarbonylmethyl)-3-O-benzyl-6-O-[11-(4-phenylphenoxy)-
undecanoyl]ascorbic acid (7.144): The title compound was prepared from 7.142 
(1.5 mmol, 0.62 g), 7.34a (1.5 mmol, 0.53 g), DMAP (1.8 mmol, 0.22 g) and EDAC 
(1.65 mmol, 0.32 g) in anhydrous DMF (10 ml) according to general procedure 
7.6.2.9 and was obtained after flash chromatography (PE/EtOAc 80/20 to 70/30 v/v) 
as a colorless oil (0.27 g, 24 %). mp: 115 °C;  1H-NMR (CDCl3) δ 1.26 – 1.84 (m, 
16H, COCH2(CH2)8), 2.33 (t, 2H, 3J = 7.5Hz, COCH2CH2), 3.99 (t, 2H, 3J = 6.6 Hz, 
CH2OC6H4), 4.11 (m, 1H, CHOH), 4.19 (dd, 1H, 3J = 4.9 Hz, 2J = 11.6 Hz, CH2O), 
4.33 (dd, 1H, 3J = 6.7 Hz, 2J = 11.5 Hz, CH2O), 4.69 (d, 1H, 3J = 2.0 Hz, H-5), 4.81 
(s, 2H, OCH2CO2), 5.20 (s, 2H, CH2Ph), 5.61 (d, 1H, 2J = 11.8 Hz, CH2Ph), 5.66 (d, 
1H, 2J = 11.8 Hz, CH2Ph), 6.97 (m, 2H, Ar-H), 7.35 (m, 13H, Ar-H), 7.53 (m, 4H, Ar-
H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 769 (100) [M+NH4]+. C45H50O10 
(750.87). 
2-O-Benzyl-3-O-(benzyloxycarbonylmethyl)-6-O-dodecanoylascorbic acid 
(7.145): The title compound was prepared from 7.142 (1.0 mmol, 0.41 g), lauric acid 
(1.0 mmol, 0.20 g), DMAP (1.2 mmol, 0.15 g) and EDAC (1.1 mmol, 0.21 g) in 
anhydrous DMF (10 ml) according to general procedure 7.6.2.9 and was obtained 
after flash chromatography (PE/EtOAc 80/20 v/v) as a white solid (0.21 g, 35 %). mp: 
55-56 °C; 1H-NMR (CDCl3) δ 0.88 (t, 3H, 3J = 6.6 Hz, CH2CH3), 1.26 (s, 16H, 
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(CH2)4CH3), 1.63 (m, 2H, COCH2CH2CH2), 2.34 (t, 2H, 3J = 7.6 Hz, COCH2CH2), 
4.22 (m, 2H, CH2O, CHOH), 4.36 (dd, 1H, 3J =6.8 Hz, 2J =11.1 Hz, CH2O), 4.59 (d, 
1H, 2J = 16.5 Hz, OCH2CO2), 4.75 (d, 1H, 3J = 1.6 Hz, H-5), 5.12 (m, 5H, OCH2CO2, 
CH2Ph), 7.32 (m, 10H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 614 (100) 
[M+NH4]+. Anal. (C34H44O9) C, H. C34H44O9 (596.71). 
2-O-(Carboxymethyl)-6-O-dodecanoyl-L-ascorbic acid (7.146): The title 
compound was prepared from 7.143 (0.30 mmol, 0.18 g), 10 % Pd/C (30 mg) in 
EtOH (3 ml) and EtOAc (3 ml) according to general procedure 7.6.2.11. 
Recrystallization from IPE/n-hexane yielded a white solid (0.90 g, 50 %). mp: 109-
111 °C; 1H-NMR (CD3OD) δ 0.89 (t, 3H, 3J = 6.6 Hz, CH2CH3), 1.29 (s, 16H, 
(CH2)8CH3), 1.62 (m, 2H, COCH2CH2CH2), 2.37 (t, 2H, 3J = 7.4 Hz, COCH2CH2), 
4.18 (m, 3H, CH2O-, CHOH), 4.57 (d, 1H, 2J =15.0 Hz, CH2CO2), 4.63 (d, 1H, 2J = 
16.4 Hz, CH2CO2), 4.79 (d, 1H, 3J = 1.8Hz, H-5). 13C-NMR (CD3OD) δ 14.56 (+, 
CH3), 23.83 (-, CH2), 26.06 (-, CH2), 30.27 (-, CH2), 30.50 (-, CH2), 30.56 (-, CH2), 
30.69 (-, CH2), 30.82 (-, CH2), 33.16 (-, CH2), 34.95 (-, COCH2CH2), 65.65 (-, CH2O), 
68.01 (+, CHO), 68.72 (-, CH2O), 77.30 (+, CH), 121.77 (quat, C-2), 161.08 (quat, C-
3), 171.73 (quat, lactone CO), 173.86 (quat, CH2CO2) 175.18 (quat, CH2CO2). ES-
MS (DCM/MeOH + NH4OAc) m/z (%): 434 (100) [M+NH4]+. Anal. (C20H32O9) C, H. 
C20H32O9 (416.46). 
2-O-(Carboxymethyl)-6-O-[11-(4-phenylphenoxy)undecanoyl]-L-ascorbic acid 
(7.147): The title compound was prepared from 7.144 (0.33 mmol, 0.25 g), 10 % 
Pd/C (30 mg) in EtOH (3 ml) and EtOAc (3 ml) according to general procedure 
7.6.2.11. Compound 7.147 and was obtained as a white solid (0.17 g, 89 %). mp: 
109-112 °C; 1H-NMR (CD3OD + CDCl3) δ 1.27 – 1.83 (m, 16H, COCH2(CH2)8), 2.35 
(t, 2H, 3J = 7.4 Hz, COCH2CH2), 3.99 (t, 2H, 3J = 6.4 Hz, CH2OC6H4), 4.17 (m, 3H, 
CHOH, CH2O), 4.52 (d, 1H, 2J = 16.3 Hz, OCH2CO2H), 4.59 (d, 1H, 2J = 16.4 Hz, 
OCH2CO2H), 4.76 (d, 1H, 3J = 1.9 Hz, H-5). 13C-NMR (CD3OD + CD3OD) δ 26.09 (-, 
CH2), 27.28 (-, CH2), 30.30 (-, CH2), 30.48 (-, CH2), 30.54 (-, CH2), 30.60 (-, CH2), 
30.62 (-, CH2), 30.74 (-, CH2), 35.08 (-, COCH2CH2), 65.66 (-, CH2O), 68.05 (+, 
CHO), 69.21 (-, CH2O), 69.41 (-, CH2O), 77.33 (+, CH), 115.98 (+, Ar-H), 121.95 
(quat, C-2), 127.67 (+, Ar-H), 127.71 (+, Ar-H), 129.11 (+, Ar-H), 129.85 (+, Ar-H), 
134.90 (quat, Ar-C), 142.25 (quat, Ar-C), 160.17 (quat, Ar-C),  161.18 (quat, C-3), 
171.98 (quat, CH2CO2), 175.26 (quat, CH2CO2). ES-MS (DCM/MeOH + NH4OAc) 
m/z (%): 588 (100) [M+NH4]+. Anal. (C31H38O10) C, H. C31H38O10 (570.63). 
Chapter 7 Ascorbic acid derivatives as potent hyaluronidase inhibitors 
205 
3-O-(Carboxymethyl)-6-O-dodecanoyl-L-ascorbic acid (7.148): The title 
compound was prepared from 7.145 (0.23 mmol, 0.14 g), 10 % Pd/C (30 mg) in 
EtOH (3 ml) and EtOAc (3 ml) according to general procedure 7.6.2.11. Preparative 
HPLC (MeCN/0.1 % TFA (aq) 70/30 v/v) yielded 7.148 as a white semisolid 
substance (60 mg, 63 %). 1H-NMR (CD3OD) δ 0.89 (t, 3H, 3J = 6.7 Hz, CH2CH3), 
1.29 (m, 16H, (CH2)4CH3), 1.62 (m, 2H, COCH2CH2CH2), 2.37 (t, 2H, 3J = 7.4 Hz, 
COCH2CH2), 4.20 (m, 3H, CH2O, CHOH), 4.82 (d, 1H, 3J = 1.6 Hz, H-5), 4.98 (d, 1H, 
2J = 16.5 Hz, OCH2CO2), 5.07 (d, 1H, 2J = 16.5 Hz, OCH2CO2). 13C-NMR (CD3OD) δ 
14.52 (+, CH3), 23.82 (-, CH2), 26.06 (-, CH2), 30.25 (-, CH2), 30.48 (-, CH2), 30.55 (-, 
CH2), 30.68 (-, CH2), 30.81 (-, CH2), 33.15 (-, CH2), 34.95 (-, COCH2CH2), 65.53 (-, 
CH2), 67.98 (-, CH2), 68.23 (+, CHO), 77.13 (+, CH), 122.41 (quat, C-2), 149.73 
(quat, C-3), 172.03 (quat, CO2CH2), 175.20 (quat, CO2H). ES-MS (DCM/MeOH + 
NH4OAc) m/z (%): 434 (100) [M+NH4]+. Anal. (C20H32O9) C, H. C20H32O9 (416.46). 
7.6.2.17 General procedure for the synthesis of 3-O-alkylated ascorbic acid 
derivatives 149 and 150 using Mitsunobu conditions 
To a solution of PPh3 (1.14 eq) in anhydrous THF at -78°C was added DIAD (1.12 
eq) under an atmosphere of argon. After a white solid was formed the mixture was 
stirred for 20 min before a solution of L-ascorbic acid (1 eq) in anhydrous DMF was 
added. The cooling bath was removed and after stirring for 5 min the pertinent 
alcohol (1.25 eq) dissolved in anhydrous THF was added and stirring was continued 
at room temperature overnight. After the solvent was evaporated, the remaining 
residue was subjected to flash chromatography. 
3-O-(Dodecan-1-yl)-L-ascorbic acid99 (7.149): The title compound was prepared 
according to general procedure 7.6.2.17 from PPh3 (2.25 mmol, 0.59 g) in anhydrous 
THF (10 ml), DIAD (2.22 mmol, 0.44 ml), L-ascorbic acid (1.98 mmol, 0.35 g) in 
anhydrous DMF (12 ml) and 1-dodecanol (2.49 mmol, 0.46 g) in anhydrous THF (2 
ml). Compound 7.149 was obtained after flash chromatography (CHCl3/MeOH 97/3 
v/v) as a pale yellow solid (0.18 g, 26 %). mp: 87 °C (ref.99: 90-92 °C); 1H-NMR 
(DMSO-d6) δ 0.85 (t, 3H, 3J = 6.7 Hz, CH2CH3) , 1.24 (m, 18H, (CH2)9CH3), 1.64 (m, 
2H, OCH2CH2), 3.41 (m, 2H, CH2OH), 3.63 (m, 1H, CHOH), 4.36 (m, 2H, OCH2CH2), 
4.73 (d, 1H, 3J = 0.9 Hz, H-5), 4.84 (dd, 1H, 3J = 5.3 Hz, 3J = 6.0 Hz, OH), 4.93 (d, 
1H, 3J = 6.3 Hz, OH), 8.67 (s, 1H, OH). 13C-NMR (DMSO-d6) δ 13.88 (+, CH3), 22.03 
(-, CH2), 24.93 (-, CH2), 28.65 (-, CH2), 28.90 (-, CH2), 28.95 (-, CH2), 29.00 (-, CH2), 
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29.13 (-, CH2), 31.23 (-, CH2), 61.71 (-, CH2O), 68.53 (+, CHO), 70.58 (-, CH2O), 
74.35 (+, CH), 118.80 (quat, C-2), 150.64 (quat, C-3), 170.55 (quat, lactone CO). ES-
MS (DCM/MeOH + NH4OAc) m/z (%): 362 (100) [M+NH4]+. C18H32O6 (344.44). 
3-O-(Tetradecan-1-yl)-L-ascorbic acid99 (7.150): The title compound was prepared 
according to general procedure 7.6.2.17 using PPh3 (2.25 mmol, 0.59 g) in 
anhydrous THF (10 ml), DIAD (2.22 mmol, 0.44 ml), L-ascorbic acid (1.98 mmol, 0.35 
g) in anhydrous DMF (12 ml) and 1-dodecanol (2.49 mmol, 0.53 g) in anhydrous THF 
(10 ml). Compound 7.150 was obtained after flash chromatography (CHCl3/MeOH 
97/3 v/v) as a white solid (0.51 g, 26 %). mp: 85-86 °C (ref.99: 86-88 °C); 1H-NMR 
(DMSO-d6) δ 0.85 (t, 3H, 3J = 6.7 Hz, CH2CH3), 1.24 (m, 22H, (CH2)11CH3), 1.64 (m, 
2H, OCH2CH2), 3.42 (m, 2H, CH2OH), 3.64 (m, 1H, CHOH), 4.35 (m, 2H, OCH2CH2), 
4.73 (d, 1H, 3J = 1.1 Hz, H-5), 4.84 (dd, 1H, 3J = 5.6 Hz, 3J = 5.6 Hz, OH), 4.93 (d, 
1H, 3J = 6.3 Hz, OH), 8.67 (s, 1H, OH). 13C-NMR (DMSO-d6) δ 13.87 (+, CH3), 22.02 
(-, CH2), 24.93 (-, CH2), 28.64 (-, CH2), 26.67 (-, CH2), 28.91 (-, CH2), 28.94 (-, CH2), 
28.99 (-, CH2), 29.14 (-, CH2), 31.23 (-, CH2), 61.72 (-, CH2O), 68.55 (+, CHO), 70.58 
(-, CH2O), 74.36 (+, CH), 118.82 (quat, C-2), 150.64 (quat, C-3), 170.54 (quat, 
lactone CO). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 390 (100) [M+NH4]+.  
C20H36O6 (372.50). 
 
7.6.3 Molecular modeling 
All calculations were done using Sybyl 7.3 (Tripos Inc., St. Louis, USA). The crystal 
structure of Hyal-1 (PDB code 2pe464) was prepared using the Biopolymer structure 
preparation tool. Hydrogens and Amber FF99 charges were added and the additional 
carbohydrates found in the crystal structure were deleted. The structure was 
minimized first with the steepest descent and then with the Powell method using the 
Amber FF99 force field. The dielectric constant was set to 4, one four scaling to 1, 
NB cutoff to 12 Å. The backbone of the protein was initially fixed and freed after the 
first 100 cycles. The termination criterion was set to a gradient norm of 0.1 
kcal/mol*Å. All other variables were set to standard values. 
The inhibitors used for docking were generated with the sketch module of Sybyl and 
energetically minimized using the Tripos Force Field with Gasteiger-Hückel charges 
and a termination gradient norm of 0.05 kcal/mol*Å. The docking calculations with 
compound 7.51 were performed with the FlexiDock module of Sybyl. The binding 
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pocket was either defined by a sphere of 5 Å surrounding the set of amino acids of 
the tetrasaccharide site (Trp36, Asn37, Asn39, Gln41, Trp42, Glu45, Thr65, Phe66, 
Arg67, Ile73, Ser74, Tyr75, Asp129, Glu131, Tyr202, Ser245, Tyr247, Ile287, 
Trp321, Val322, Ser323, Trp324, and Glu325) or a sphere of 15 Å surrounding 
Trp321 and Tyr202 in the active site of Hyal-1. Freely rotatable bonds were: in the 
first approach all bonds of the ligand, in a second approach additionally all bonds of 
the binding site. The ligand was pre-positioned in the binding pocket using various 
starting positions in the different FlexiDock runs. The total number of generations 
was set according to the suggestions made in the Tripos Bookshelf (at least 500 
iterations per rotatable bond). Compound 7.121 was manually docked to check if the 
hexadecanoyl chain may fit to the second hydrophobic pocket. Visualizations of 
protein surfaces were made using the Molcad tool. 
The final docking poses presented for 7.51 and 7.121 were a result of an iterative 
minimization process: After docking, the complex was minimized (steepest descent, 
then Powell) in the Amber99 force field fixing the ligands as aggregates. In a second 
step, the inhibitor together with a sphere of the enzyme 6 Å around the ligand was 
minimized (Tripos force field, Powell method) using the Minimize Subset option of 
Sybyl 7.3. The two steps were repeated in succession until both approached a 
termination gradient norm of 0.05 kcal/mol*Å. 
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8.1 Introduction 
 
Recently, a structure-based strategy for the design of inhibitors of the bacterial 
hyaluronate lyase SagHyal4755 was successfully pursued in our workgroup1, 2. Based 
on two crystal structures from homologous bacterial enzymes (PDB code 1c82 and 
1egu)3, 4 a de novo approach using the program LUDI5, 6 resulted in the identification 
of indole-2-carboxylic acid as a lead structure for the development of hyaluronidase 
inhibitors. Further modifications of the indole scaffold led to the identification of 
indole-based inhibitors of bacterial hyaluronidases with IC50 values in the lower 
micromolar range. Moreover, the crystal structure of bacterial hyaluronidase from 
Streptococcus pneumoniae in complex with 1-decyl-2-(4-sulfamoyloxyphenyl)-1H-
indol-6-yl sulfamate (Figure 8.1) was elucidated (PDB code 2brp)7.  
 
N
(CH2)9CH3
OSO2NH2
H2NO2SO
 
Figure 8.1. Structure of 1-decyl-2-(4-sulfamoyloxyphenyl)-1H-indol-6-yl sulfamate. 
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The indole moiety of the co-crystallized compound was bound to the active site 
explaining the inhibitory activity of the indole derivatives. Figure 8.2 shows the 
binding mode of the indole-type inhibitor within the bacterial enzyme. 
 
 
Figure 8.2. Comparison of binding modes of hylSpn inhibitor sulfamic acid 1-decyl-2-(4-
sulfamoyloxyphenyl)-1H-indol-6-yl ester (carbon atoms orange) and a HA hexasaccharide (carbon 
atoms purple, taken from the X-ray structure PDB code 1loh8, for clarity only a trisaccharide moiety is 
shown). Modified from Botzki, 20049. 
 
Interestingly, the indole derivatives synthesized by Salmen2 and Braun1 did not or 
only very weakly inhibit the bovine testicular hyaluronidase. Due to the fact that 
indomethacin, a non-steroidal anti-inflammatory drug, is described as a 
hyaluronidase inhibitor10 and also does inhibit the recombinantly expressed human 
hyaluronidases Hyal-1 and PH-20 in the used turbidimetric assay (see chapter 5), a 
small collection of commercially available indole derivatives was tested for inhibition 
of Hyal-1 and PH-20, namely indole, indole-2-carboxylic acid, indole-3-carboxylic 
acid, indole-3-acetic acid, indole-3-propionic acid, indole-3-butanoic acid and indole-
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5-carboxylic acid (data not shown). Highest potency among these small molecules 
was found for indole-3-butanoic acid with an IC50 value in the lower millimolar range 
for human PH-20 (Table 8.3, chapter 8.3.2). This result is in agreement with previous 
studies where indole-3-butanoic acid was identified as the most potent inhibitor of the 
bacterial enzyme in this series of compounds2. Due to these promising results 
additional indole derivatives were synthesized. The synthesis and structure-activity 
relationships of substituted indole derivatives are reported in this chapter. 
 
8.2 Chemistry 
 
The N-acylated indole-3-butanoic acid derivatives 8.7-8.12 and 8.18-8.22 were 
synthesized according to Scheme 8.1 using phenol esters as acylation reagents11 
which were prepared from the pertinent carboxylic acids and phenol in the presence 
of standard coupling reagents12. The synthesis of 8.10-8.12 and 8.18 as well as the 
preparation of the required phenol esters (8.4-8.6 and 8.13) was already described 
elsewhere13. 
R O
O
N
OH
O
R
O
R(CO2H)n
i ii
n=1
iii n=2
R O
O
O
O
N
OH
O
R
O
N
OHO
O
8.1-8.6
8.7-8.12
8.13-8.17
8.18-8.22
                R
8.1, 8.7    (CH2)2Ph
8.2, 8.8    (CH2)8CH3
8.3, 8.9    p-Cl-C6H4
8.4, 8.10  p-MeO-C6H4
8.5, 8.11  p-C6H4-Ph
8.6, 8.12  CH2-p-MeO-C6H4
                 R
8.13, 8.18  -p-C6H4-
8.14, 8.19  -CH2-p-C6H4CH2-
8.15, 8.20  -(CH2)6-
8.16, 8.21  -(CH2)10-
8.17, 8.22  -(CH2)14-
iv
 
Scheme 8.1. Synthesis of N-acylated indole-3-butanoic acid derivatives 8.7-8.12 and 8.18-8.22. 
Reagents and conditions: (i) DCC (1.1 eq), phenol (1.2 eq), DMAP (cat.), CH2Cl2 / THF, RT overnight; 
(ii) indole-3-butanoic acid (1.02 eq), NaH (3 eq), DMF, -41 to -20 °C, 30 min; (iii) DCC (2.2 eq), phenol 
(2.4 eq), DMAP (cat.), CH2Cl2 / THF, RT overnight; (iv) indole-3-butanoic acid (2.04 eq), NaH (6 eq), 
DMF, -41 to -20 °C, 30 min. 
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The glycosylamide 8.8a was synthesized from 8.8 and D-glucosamine in the 
presence of EDAC according to Scheme 8.2. 
N
OH
O
H3C(H2C)8
O
N
GlcNH
O
H3C(H2C)8
O
GlcNH =
O
HO
HO
NH
OH
OH
8.8 8.8a
i
 
Scheme 8.2. Synthesis of 8.8a. Reagents and conditions: (i) Glucosamine hydrochloride (2 eq), HOBt 
(1.2 eq), EDAC (1.2 eq), NEt3 (3.2 eq), DMF / H2O, RT overnight. 
 
The methyl ether in 8.10 was cleaved (Scheme 8.3) to yield the corresponding 
hydroxyl derivative 8.23 as described13. 
N
OH
O
O
MeO
N
OH
O
O
HO
i,ii
8.238.10  
Scheme 8.3. Synthesis of 8.23 by cleavage of the methyl ether in 8.23. Reagents and conditions: (i) 
BBr3SMe3, reflux, 24 h; (ii) H2O, RT, 20 min. 
 
Alkyl spacer containing derivatives 8.32, 8.33 and 8.42-8.49 were synthesized 
according to Scheme 8.4. ω-Bromo alkanoic acids were used to alkylate the carboxy-
protected indole. Hence 11-bromoundecanoic acid was esterified with benzyl alcohol 
in the presence of DCC and DMAP and used to N-alkylate tert-butyl indole-3-
butanoate (8.27) which was prepared from the pertinent indolylalkanoic acid14. 16-
Bromohexadecanoic acid (8.24) was prepared from hexadecano-16-lactone by 
saponification to 16-hydroxyhexadecanoic acid (8.24a) and subsequent halogenation 
according to known procedures15 and then treated as in the case of the shorter 
bromoalkanoic acid. After hydrogenolytic cleavage of the benzyl ester, amines or 
alcohols in the presence of standard coupling reagents were used to form amides or 
esters of 8.30 and 8.31. In a last step the tert-butyl ester was cleaved using TFA to 
yield the pertinent N-alkylated indole-3-butanoic acid derivatives. 
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8.41                                                 15   2,3-di-O-benzyl-6-ascorbyl
8.44                                                 10   piperazin-1-yl
8.46                                                 10   6-ascorbyl
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Scheme 8.4. Synthesis of the N-alkylated indole-3-butanoic acid derivatives 8.42-8.49 and the 
corresponding intermediates. Reagents and conditions: (i) 50 % NaOH, NBu4HSO4 (0.01 eq), toluene, 
80-90 °C overnight; (ii) HCl (conc.); (iii) HBr/HOAc, H2SO4 (conc.), RT overnight, 6 h reflux; (iv) BnOH 
(1.1 eq), DCC (1.1 eq), DMAP (0.1 eq), CH2Cl2, RT overnight; (v) TBTA (2 eq), BF3Et2O (cat), THF, 
RT overnight; (vi) NaH (1.2 eq), BnO2C(CH2)nBr (1.2 eq), DMF 60-80 °C; (vii) 10 % Pd/C (cat.), H2 (1 
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atm), EtOH/EtOAc, RT, 30 min; (viii) TFA, CH2Cl2, RT, 6 h; (ix) NHR (2 eq), HOBt (1.2 eq), DIEA (1.2 
eq), EDAC (1.2 eq), DMF, RT overnight; (x) 7.66 (1 eq), EDAC (1.1 eq), DMAP (1.1 eq), DMF, RT 
overnight; (xi) TFA, CH2Cl2, RT, 6 h; (xii) 10 % Pd/C (cat.), H2, 4 bar, EtOH/EtOAc, RT overnight. 
 
To be able to introduce various residues at position C-5 of the indole ring, building 
block 8.52 was prepared from 4-benzyloxyaniline and ethyl 2-oxocyclohexane-
carboxylate using the Japp-Klingemann variant16 of the Fischer indole synthesis 
(Scheme 8.5)17. 8.52 was deprotected and decarboxylated to obtain 8.53-8.55, or the 
benzyl ether of 8.52 was cleaved followed by alkylation of the 5-OH under Mitsunobu 
conditions (compounds 8.57-8.61)18. Subsequent saponification of the ester groups 
led to 8.62-8.66 or N-alkylation of 8.60 was performed before ester cleavage to 
obtain 8.70-8.72. 
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Scheme 8.5. Synthesis of N-alkylated indolylalkanoic acids derivatives 8.53-8.55, 8.62-8.66, 8.70-8.72 
and the pertinent intermediates. Reagents and conditions: (i) NaNO2 (1.05 eq), HCl (conc.) / H2O, 0 
°C, (ii) NaBF4 (1 eq), RT, 20 min; (iii) NaH (1.14 eq), Ethyl 2-oxocyclohexanecarboxylate (1.02 eq), 
THF, reflux, 30 min, then RT, 1 h; (iv) H2SO4, EtOH, reflux overnight; (v) KOH (3 eq), EtOH, reflux 30 
min; (vi) 2 N HCl; (vii) 200-230 °C; (viii) 10 % Pd/C (cat.), H2 (1 atm), EtOH, RT, 30 min; (ix) 10 % 
Pd/C (cat.), H2 (1 atm), EtOH/EtOAc, RT, 30 min; (x) R1OH (1 eq), DIAD (1 eq), PPh3 (1 eq), THF, RT 
overnight; (xi) LiOH (3 eq), THF/MeOH/H2O, RT overnight; (xii) 2 N HCl; (xiii) NaH (1.2 eq), R2Hal (1.2 
eq), DMF, 40-60 °C, 3 h; (xiv) LiOH (3 eq), THF/MeOH/H2O, RT overnight; (xv) 2 N HCl. 
 
N-Alkylation of 8.52 yielded the diester 8.73 which then was saponified to give the 
carboxylic acid (Scheme 8.6). When a slight excess of LiOH was used at room 
temperature the monoester 8.74 was obtained whereas saponification with excess 
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NaOH at reflux resulted in complete conversion to 8.75. Both N-alkylindoles were 
subjected to hydrogenolysis to obtain 8.76 and 8.77. 
N
CO2Et
CO2Et
BnO
(CH2)9CH3
N
H
CO2Et
CO2Et
BnO
8.52
N
CO2H
CO2R
HO
(CH2)9CH3
ii,iii for 8.73
iv,v for 8.74
8.76, 8.778.74, 8.75
                  R
8.74, 8.76  Et
8.75, 8.77  HN
CO2H
CO2R
BnO
(CH2)9CH3
8.73
i
vi
 
Scheme 8.6. Synthesis of 8.73-8.77. Reagents and conditions: (i) NaH (1.2 eq), Br(CH2)9CH3 (1.2 eq), 
DMF, 40-60 °C, 3 h; (ii) LiOH (3 eq), THF/H2O, RT overnight; (iii) 2 N HCl; (iv) NaOH (10 eq), reflux, 
30 min; (v) 2 N HCl; (vi) 10 % Pd/C (cat.), H2 (1 atm), EtOH/EtOAc, RT, 30 min. 
 
The glycosylamide of indomethacin (8.78) was synthesized from indomethacin and 
D-glucosamine according to known procedures19, 20 (Scheme 8.7). 
N
CO2H
MeO
O
Cl
N
MeO
O
Cl
NHGlc =
O
HO
HO
NH
OH
OH
NHGlc
O
i,ii
8.78  
Scheme 8.7. Synthesis of 8.78. Reagents and conditions: (i) SOCl2 (1.05 eq), DMF (1.05 eq), CH2Cl2, 
RT; (ii) Glucosamine hydrochloride (1 eq), NEt3 (2 eq), MeOH / CH2Cl2, RT, 20 min. 
 
8.3 Inhibition of hyaluronidases: results and discussion  
 
All synthesized indole derivatives were investigated for inhibition of recombinant 
human hyaluronidases PH-20 and Hyal-1, the bovine testicular enzyme BTH 
(Neopermease®) and the bacterial hyaluronan lyase SagHyal4755 in a modified 
turbidimetric assay according to the method of Di Ferrante21 as described in chapter 
3. 
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8.3.1 N-Substituted indole-3-butanoic acid derivatives 
 
The IC50 values of the investigated indole-3-butanoic acid derivatives are 
summarized in Table 8.1. 
 
Table 8.1. Inhibitory activity of N-substituted indole-3-butanoic acid derivatives, determined on the 
hyaluronidases Hyal-1, PH-20, BTH and SagHyal4755. 
 
N
R2
O
N
OH
O
R1
O
N
OHO
O
8.7-8.12, 8.23, 8.32,
8.33, 8.42-8.49
8.18-8.22
R1
 
Hyal-1 PH-20 BTH SagHyal4755 No R1 R2 IC50 [µM]a 
8.7 CO(CH2)2Ph OH > 500 83 ± 6 > 500 72 ± 4 
8.8 CO(CH2)8CH3 OH > 100 36 ± 6 > 100 > 100 
8.8a CO(CH2)8CH3 NHGlcb > 150 ≥ 200 > 200 > 200 
8.9 CO-p-Cl-C6H4 OH > 300 41 ± 6 > 1000 125 ± 5 
8.10 CO-p-OMe-C6H4 OH > 400 105 ± 7 > 400 > 400 
8.11 CO-p-C6H4-Ph OH > 100 9.1 ± 0.7 > 100 ≥ 60 
8.12 COCH2-p-OMe-C6H4 OH > 250 113 ± 7 >250 > 250 
8.23 COCH2- p-OH-C6H4 OH 575 ± 25 89 ± 12 1670 ± 20 490 ± 30 
8.18 -p-C6H4- - > 100 6.7 ± 0.6 > 100 > 100 
8.19 -CH2-p-C6H4CH2- - >100 16 ± 2 >100 17 ± 3 
8.20 -(CH2)6- - > 70 23 ± 2 > 70  > 70 
8.21 -(CH2)10- - > 50 8.3 ± 3.2 > 50 18 ± 1 
8.22 -(CH2)14- - > 30 4.4 ± 0.3 > 30 13 ± 1 
8.32 (CH2)10CO2H OH > 150 6.9 ± 0.7 > 150 12 ± 1 
8.33 (CH2)15CO2H OH > 100 3.0 ± 0.5 > 100 16.5 ± 0.4 
8.42 (CH2)10CONH(thiazole-2-yl) OH > 100 6.9 ± 0.7 > 100 > 100 
8.43 
(CH2)10CO(4-
phenylpiperazin-1-yl) 
OH 
> 50 20 ± 2 > 50 > 50 
8.44 (CH2)10CO(piperazin-1-yl) OH > 100 > 100 > 100 61 ± 1 
8.45 (CH2)10CONH-3-OH-C6H4 OH > 100 20 ± 3 > 100 7.4 ± 3 
8.46 (CH2)10CO(6-ascorbyl) OH 29 ± 1 17 ± 1 284 ± 10 7.7 ± 0.5 
8.47 
(CH2)15CO(4-
phenylpiperazin-1-yl) 
OH 
> 30 > 30 > 30 > 30 
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Table 8.1 (continued) 
8.48 (CH2)15CONH-3-OH-C6H4 OH > 30 3.9 ± 0.8 > 30 > 30 
8.49 (CH2)15CO(6-ascorbyl) OH 35 ± 3 3.1 ± 0.5 171 ± 7 8.1 ± 0.3 
a inhibition of enzyme expressed as IC50 (µM), mean values ± SEM (N = 2, experiments performed in 
duplicate), maximal concentrations of the test compounds were selected with respect to individual 
terminal solubilities in the incubation mixture; IC50 values determined at pH 5.0 (PH-20, BTH, 
SagHyal4755) or 3.5 (Hyal-1) in the turbidimetric assay; bGlc: 2-Deoxy-D-glucopyranose-2-yl.  
 
Compared to indole-3-butanoic acid (see Table 8.3, chapter 8.3.2 for IC50 values) a 
dramatic increase in the inhibition of PH-20 and the bacterial enzyme is observed 
when hydrophobic residues are introduced by N-acylation of the indole moiety (8.7-
8.12), e.g. potency increases by over 150-fold to an IC50 of 9.1 µM for the biphenylyl 
derivative 8.11 determined for the human PH-20. Figure 8.3 illustrates the inhibitory 
potencies of 8.7-8.12 and 8.23 on human PH-20. In some cases IC50 values could 
not be calculated for the inhibition of the bacterial enzyme due to poor solubilities of 
the compounds. Nevertheless, a certain percentage of inhibition was observed in all 
cases at micromolar concentrations (data not shown). Some noticeable differences in 
the SAR are observed when bacterial hyaluronate lyase and the human 
hyaluronidase PH-20 are compared: whereas inhibition of the human hyaluronidase 
is significantly increased when the phenylpropanoyl residue of 8.7 is replaced by a 
decanoyl chain (8.8), inhibition of SagHyal4755 is decreased. This is in agreement with 
earlier results, where phenylpropanoyl substitution of the structurally related 
benzoxazole-2-thione scaffold led to increased inhibition of the bacterial 
hyaluronidase, probably by an energetically favored interaction of the phenyl residue 
with a hydrophobic patch which is assumed to interact with the hydrophobic sugar 
ring of N-acetylglucosamine of the substrate hyaluronan1, 7. This result could indicate 
similar binding modes of the presented indole-3-butanoic acids and the earlier 
described benzoxazole-2-thiones when the bacterial enzyme is regarded. An 
additional carbohydrate residue (8.8a) which replaces the carboxyl moiety in 8, leads 
to complete loss of inhibitory activity. When 8.7 is compared with 8.9 bearing a para-
chlorophenyl residue, again differences in SAR of both enzymes are obvious: 
inhibition of PH-20 is increased, whereas inhibition of the bacterial enzyme is 
significantly decreased. Hyal-1 and BTH are not inhibited by 8.7-8.12 and 8.8a. 
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Figure 8.3. PH-20 inhibitory potencies of N-acylated indole-3-butanoic acid derivatives 8.7-8.12 and 
8.23. 
 
An additional methylene group between methoxyphenyl and indole residue (compare 
8.10 with 8.12) does not lead to significant changes of the IC50 values. When the 
hydroxy derivative 8.23 is compared with the methoxy substituted compound 8.12 an 
increase in potency is obvious. Interestingly, 8.23 also inhibits human Hyal-1 and 
bovine PH-20 suggesting a contribution of the OH-group to binding by forming a 
hydrogen bond. Possibly the interaction site of the indole moiety at both human 
enzymes is different from that of the ascorbic acid derivatives described in chapter 7, 
because no increase in potency is achieved by adding hydrophobic sidechains 
(compound 8.8, also see Table 8.3, compounds 8.63-8.66). 
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Interesting results were obtained for the “bivalent” derivatives 8.18-8.22 (see Figure 
8.4 for visualization of the potencies). 
pIC50 [M]
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Figure 8.4. Inhibitory activities of bivalent indole-3-butanoic acid derivatives on human PH-20 and 
SagHyal4755. Compounds marked with * did not show inhibitory activity on the investigated enzyme 
(arbitrary short bars for illustrative reasons). 
 
Again, Hyal-1 and BTH are not inhibited while human PH-20 and bacterial 
hyaluronidases show a concentration dependent decrease in activity in the presence 
of those compounds. Compound 8.18 consisting of two indole-3-butanoic acid 
moieties connected via terephthalic acid possesses remarkable selectivity for the 
human PH-20 compared to the bacterial enzyme. Exceedingly strong inhibition of 
human PH-20 with an IC50 value of 6.7 µM was found for this derivative, whereas 
SagHyal4755 was only slightly inhibited up to a concentration of 100 µM (data not 
shown); an exact IC50 value could not be determined due to insufficient terminal 
solubility. Possibly this relatively rigid molecule does not fit into the narrow crevice 
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which is present in the active site of the bacterial enzyme. A wider cleft as probably 
present in human PH-2022 could accept such a rigid molecule more easily, and thus 
explain the higher inhibitory potency. The elongated aromatic spacer of 8.19 leads to 
a two-fold decrease in inhibition of PH-20, whereas the inhibition of SagHyal4755 is 
drastically increased. Therefore, these two molecules are indicative of the different 
SAR for the human hyaluronidase PH-20 and the bacterial hyaluronate lyase from 
Streptococcus agalactiae, suggesting interactions with different amino acids in the 
binding site of those proteins. When the derivatives 8.20-8.22 which contain alkyl 
spacers are compared, an increase in potency which correlates with the length of the 
aliphatic chain is obvious. By adding four methylene groups to the alkyl spacer 
(compare 8.20 with 8.21 and 8.21 with 8.22) the IC50 value for the human PH-20 
decreases approximately by a factor of two. Regarding the bacterial enzyme, the IC50 
also increases (compare 8.20 and 8.21) but by adding additional four C-atoms the 
gain in inhibitory activity is only marginal (8.22). The bivalent ligands were inactive on 
both human Hyal-1 and BTH within the investigated concentration ranges. 
A striking increase in potency is achieved by adding a terminal carboxyl group (8.32 
and 8.33). The enzymatic activity of PH-20 and the bacterial hyaluronidase in the 
presence of 8.8, 8.32 and 8.33 is depicted in Figure 8.5. Compound 8.32 is about 12-
fold more potent as an inhibitor of human PH-20 compared to the analog lacking the 
additional carboxyl group (8.8). An at least 8-fold increase in potency is observed for 
the bacterial enzyme, too. Lengthening the connecting chain between the indole and 
carboxyl group by five carbon atoms leads to increased inhibition of PH-20, whereas 
a slight decreased inhibition was observed for the hyaluronate lyase. Regarding the 
synthesized esters or amides 8.42-8.49 again distinct differences between PH-20 
and SagHyal4755 are observed: whereas an additional 2-thiazolyl residue does not 
significantly affect the potency at the human enzyme (compare 8.42 and 8.32), the 
inhibition of the bacterial enzyme is lost. Introduction of a basic piperazine ring as in 
8.43 and 8.44 leads to lower inhibitory potency compared to the carboxyl derivative 
8.32 in both cases, however, on PH-20 the piperazinyl derivative 8.44 was less 
potent than the derivative with an additional N-phenyl residue (8.43), and in the case 
of SagHyal4755 the SAR is inverted. The introduction of structural motives bearing 
hydroxyl subtituents (8.45 and 8.46) leads to decreased inhibition of PH 20 
(compared to 8.32), whereas the inhibition of the bacterial enzyme is increased. 
Elongation of the alkyl spacer (compare 8.47-8.49 with 8.44-8.46) does not result in 
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increased potency in the case of the piperazine containing compound, but leads to 
distinct increase in potency against PH-20 when hydroxyl substituted derivatives 8.48 
and 8.49 are regarded. 
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Figure 8.5. Enzymatic activity of human PH-20 (black symbols) and SagHyal4755 (open symbols) in the 
presence of 8.8, 8.32 and 3.33. The different shape of the inhibition curve in the presence of high 
concentrations of 8.8 most probably results from the limited water solubility of this compound. 
 
In contrast, the inhibition of the bacterial enzyme was reduced for the compounds 
with longer chains, 8.48 and 8.49. Nevertheless, the compounds bearing hydroxyl 
moieties are potent inhibitors of bacterial hyaluronidase and PH-20. Under the 
assumption that the hydrophobic chain covers the same space of the protein as the 
substrate hyaluronan, the additional OH-groups may confer additional binding by 
mimicking functional groups of hyaluronic acid. Interestingly 8.46 and 8.49 also inhibit 
human Hyal-1 and the bovine hyaluronidase with IC50 values of 29 µM and 284 µM 
(8.46) and 35 µM and 171 µM (8.49), respectively. Certainly, the additional ascorbic 
acid residue accounts for the binding and inhibition of these enzymes, as no effect of 
other investigated alkyl-indoles lacking the vitamin C moiety was noticed. This may 
be attributed to a change in the binding mode of the compounds when the bacterial 
enzyme is regarded. X-ray analyses of hyaluronate lyase in complex with inhibitors 
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having either an indole or a vitamin C moiety support the working hypothesis that the 
indole occupies the same binding site of SagHyal4755 as the ascorbic acid portion7, 23. 
Whereas the IC50 values of 8.46 and 8.49 are similar for the bacterial enzyme, an 
increase in potency towards human PH-20 is noticed for 8.49, the compound bearing 
the longer alkyl spacer at the indole nitrogen, compared to 8.46. 
 
8.3.2 N-Acylated and N-alkylated indole-3-alkanoic acid derivatives with 
increased lipophilicity 
 
The IC50 values of the investigated indoles, determined on Hyal-1, PH-20, BTH and 
SagHyal4755, are summarized in Table 8.3, the substitution patterns are given in 
Table 8.2. 
 
Table 8.2. Structures of investigated indole derivatives. 
N
R3
R2
R4
R1
8.53-8.55, 8.62-8.66,
8.70-8.72, 8.74-8.78  
Compound R1 R2 R3 R4 
Indole-3-butanoic acid H H (CH2)3CO2H H 
Indomethacin CO-p-Cl-C6H4 Me CH2CO2H OMe 
8.53 H CO2H (CH2)3CO2H OCH2Ph 
8.54 H H (CH2)3CO2H OCH2Ph 
8.55 H H (CH2)3CO2H OH 
8.62 H CO2H (CH2)3CO2H O(CH2)3Ph 
8.63 H CO2H (CH2)3CO2H O(CH2)5CH3 
8.64 H CO2H (CH2)3CO2H O(CH2)11CH3 
8.65 H CO2H (CH2)3CO2H O(CH2)15CH3 
8.66 H CO2H (CH2)3CO2H O(CH2)17CH3 
8.70 (CH2)2CH3 CO2H (CH2)3CO2H O(CH2)15CH3 
8.71 CH2-pyridin-3-yl CO2H (CH2)3CO2H O(CH2)15CH3 
8.72 CH2-p-Br-C6H4 CO2H (CH2)3CO2H O(CH2)15CH3 
8.74 (CH2)9CH3 CO2Et (CH2)3CO2H OCH2Ph 
8.75 (CH2)9CH3 CO2H (CH2)3CO2H OCH2Ph 
8.76 (CH2)9CH3 CO2Et (CH2)3CO2H OH 
8.77 (CH2)9CH3 CO2H (CH2)3CO2H OH 
8.78 CO-p-Cl-C6H4 Me CH2CONHGlc* OMe 
*Glc: 2-Deoxy-D-glucopyranose-2-yl 
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Table 8.3. Inhibitory activity of indole derivatives on Hyal-1, PH-20, BTH and SagHyal4755. 
Hyal-1 PH-20 BTH SagHyal4755 Compound IC50 [µM]a 
Indole-3-butanoic acid > 5000 1425 ± 170 > 5000b 2200b 
Indomethacin 390 ± 30 82 ± 9 540c 350b 
8.53 ≥ 600 141 ± 16 > 1200 164 ± 1 
8.54 > 350 84 ± 8 > 350 318 ± 9 
8.55 > 1000 1082 ± 57 > 1000 n.d. 
8.62 > 600 35 ± 2 > 600 53 ± 2 
8.63 > 700 60 ± 5 > 900 44 ± 3 
8.64 > 80 3.6 ± 0.4 > 90 3.0 ± 0.1 
8.65 > 40 1.3 ± 0.1 > 50 2.4 ± 0.1 
8.66 > 30 5.0 ± 0.9 > 40 6.3 ± 0.2 
8.70 > 30 > 30 > 30 > 50 
8.71 > 50 2.3 ± 0.7 > 50 15 ± 1 
8.72 > 50 11 ± 2 > 50 108 ± 10 
8.74 > 40 11 ± 2 > 40 > 40 
8.75 > 100 4.7 ± 0.3 > 130 20 ± 2 
8.76 > 70 7.5 ± 0.2 > 70 7.5 ± 0.6 
8.77 > 100 4.6 ± 0.2 > 150 9.3 ± 0.3 
8.78 > 1000 604 ± 18 > 1000 189 ± 33 
a inhibition of enzyme expressed as IC50 (µM), mean values ± SEM (N = 2, experiments performed in 
duplicate), maximal concentrations of the test compounds were selected with respect to individual 
terminal solubilities in the incubation mixture; IC50 values determined at pH 5.0 (PH-20, BTH, 
SagHyal4755) or 3.5 (Hyal-1) in the turbidimetric assay; bas determined by Salmen2; cas determined by 
Salmen2 at pH 3.6. 
 
Most of the synthesized indole derivatives described in this chapter were inactive at 
the tested concentrations on human Hyal-1 and BTH, but turned out to be inhibitors 
of human PH-20 and the bacterial enzyme SagHyal4755. Therefore, these indole 
based inhibitors must be clearly differentiated from the ascorbic acid derivatives 
described in chapter 7. Whereas the selectivity of the ascorbic acid type inhibitors is 
generally low, the indole derivatives show distinct selectivity for the bacterial enzyme 
and the human PH-20. Surprisingly, the bovine enzyme and the human Hyal-1 
remained unaffected or were only very weakly inhibited in the presence of the indole 
derivatives, and it was not possible to determine IC50 values. 
Indole-3-butanoic acid which was previously identified as an inhibitor of SagHyal47552 
turned out to be also an inhibitor of the recombinantly expressed human PH-20 with 
comparable inhibitory potency in the millimolar range. 5-Hydroxyindole-3-butanoic 
acid (8.55) was only slightly more potent than indole-3-butanoic acid PH-20, thus, 
there appears to be no relevant interaction of the additional 5-hydroxy group with the 
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enzyme. By contrast, an additional benzyloxy residue (8.54) leads to a drastic 
increase in potency, especially, when human PH-20 is regarded: 8.54 (IC50 84 µM) is 
17 times and 12 times more potent than indole-3-butanoic acid and 8.55, repectively. 
An additional carboxyl residue (8.53) has only minor influence on the IC50 values: the 
inhibitory activities of 8.53 and 8.54 against PH-20 and SagHyal4755 are in the same 
concentration ranges. However, the solubility of the compound in aqueous medium is 
considerably improved. Therefore, compound 8.53 was considered a promising lead 
for further structural variations in 5-position. The pIC50 values of such indole 
derivatives characterized by two carboxyl groups and different hydrophobic 
substituent in 5-position are visualized in Figure 8.6.  
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Figure 8.6. Inhibitory activity of dicarboxylic acids bearing hydrophobic substituents in position 5 of the 
indole scaffold, investigated on human PH-20 and the bacterial hyaluronate lyase. 
 
The extension of the chainlength of hydrophobic substituents in position 5 of the 
indole scaffold (8.62-8.66) resulted in increased potency compared to 8.53. The 
contribution of the hydrophobic residue to the affinity of the compounds is most 
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obvious from the drastic gain in potency found after extension of the alkyl chain from 
6 (8.63) to 12 carbon atoms (8.64): IC50 values of 3.6 µM and 3.0 µM were 
determined for human PH-20 and SagHyal4755 respectively. A further increase in 
chainlength to 16 carbon atoms leads only to a weak increase in potency, and 
extension to a 18-membered carbon chain (8.66) even leads to a decrease in 
inhibitory potency on both enzymes, indicating that there is an optimum size of the 
hydrophobic group around 16 carbon atoms. Thus, in this series of compounds the 
hexadecyloxy substituted indole 8.65 with IC50 values of 1.3 µM and 2.4 µM is the 
most potent inhibitor of human PH-20 and the bacterial enzyme, respectively. The 
compound is characterized by high selectivity for PH-20 and SagHyal4755 compared 
to human Hyal-1 and BTH. 
The introduction of additional residues at the indole nitrogen (8.70-8.72) does not 
lead to increased potency. This may suggest a possible role of the indole-nitrogen as 
H-donor, however, it should be stressed that N-substituents are generally tolerated. 
Interestingly, for compound 8.71 bearing a pyridyl-substituent an IC50 value of 2.3 µM 
was determined on human PH-20, i. e. the potency of this hyaluronidase inhibitor is 
in the same range as that of the N-unsubstituted analog 8.65. It is tempting to 
speculate that the weakly basic pyridine nitrogen is involved in the binding mode 
because the the two N-substituted derivatives 8.70 and 8.72 bearing a propyl- or 
para-bromobenzyl-moiety are much less potent. Therefore, functionalized N-
substituents might be useful with respect to further structural optimization. 
The indole derivatives 8.74-8.77 contain an N-decyl chain. The potency of the 
dicarboxylic acids 8.75 and 8.77 is clearly enhanced when compared to the indole-3-
butanoic acid derivative 8.8 which is bearing a decanoyl sidechain and is lacking the 
2-carboxylic acid and the 5-benzyloxy residue. The ethyl esters 8.74 and 8.76, are 
slightly superior to their corresponding carboxylic acids 8.75 and 8.77, when 
investigated for inhibition of PH-20. On the bacterial enzyme 8.76 and 8.77 are in the 
same range of potency, whereas the inhibitory activity of 8.75 is lost upon 
esterification of 2-carboxyl group (compare 8.75 and 8.74). The only structural 
difference between compounds 8.74/8.75 and 8.76/8.77 is the substitution in position 
5 of the indole ring. Therefore, it cannot be ruled out that the additional hydroxyl or 
benzyloxy moiety causes changes in the binding mode. Concerning the bacterial 
hyaluronidase, the significantly lower IC50 values of 8.76 and 8.77 may be explained 
by additional hydrogen bonds of the free hydroxyl group with amino acids in the 
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binding site. In contrast to the observation made for the bacterial hyaluronate lyase, 
no major changes in potency on human PH-20 are noticed when benzyloxy and the 
hydroxy derivatives are compared (IC50 values:  4.7 µM determined for 8.75 and 4.6 
µM for 8.77). Thus, the hydroxyl or the benzyloxy group in 5-position are presumably 
not essentially involved in binding to the human enzyme. This is in clear contrast with 
the results obtained for the small indole derivatives 8.53-8.55 and indole-3-butanoic 
acid as discussed above, where the additional benzyl residue causes a clear 
increase in potency. This fact is probably the result of a change in binding mode 
again. It is conceivable that the benzyloxy residues of 8.53 and 8.54 occupy the 
same hydrophobic area of the enzymes as the decyl chains of 8.74-8.77, resulting in 
a different orientation of the indole scaffold relative to the enzyme. 
Indomethacin, a known hyaluronidase inhibitor10 inhibits both human enzymes, Hyal-
1 and PH-20, with IC50 values of 390 µM and 82 µM, respectively. The inhibition of 
Hyal-1 and BTH is lost and the activity against human PH-20 is drastically weakened 
when a carbohydrate scaffold is introduced (8.78) to replace the carboxylate in 
indomethacin. Interestingly, this modification yields an inhibitor of SagHyal4755 which 
is more potent than the parent compound, indomethacin. These observations again 
underline the differences in SAR between mammalian hyaluronidases and bacterial 
hyaluronate lyases. 
 
8.4 Summary 
 
Starting from the lead compound, indole-3-butanoic acid, the hydrophobicity of the 
derivatives was increased by N-acylation resulting in an increase in inhibition of 
human PH-20 and the bacterial hyaluronate lyase SagHyal4755. Among the 
synthesized derivatives, the compound bearing a p-biphenylylcarbonyl residue (8.11) 
is a surprisingly potent inhibitor of PH-20 with an IC50 value of 9.1 µM, whereas 
SagHyal4755 is only weakly inhibited. As most of the indoles described in this chapter 
are inactive on human Hyal-1 and bovine testicular hyaluronidase, N-(p-
hydroxybenzoyl)indole-3-butanoic acid (8.23) represents an exception: these two 
enzymes are weakly inhibited by 8.23. Strong inhibition of both human PH-20 and the 
bacterial enzyme is achieved by “bivalent” ligands which are composed of two indole-
3-butanoic acids connected via hydrophobic aromatic or aliphatic spacers attached to 
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the indole-N. Additionally, the derivative containing a phenyl spacer between the two 
indole scaffolds (8.18) was found to possess increased selectivity for PH-20 versus 
SagHyal4755. Whereas additional carboxyl groups at the end of hydrophobic 
undecanoyl or hexadecanoyl spacers are very well tolerated by PH-20 and 
SagHyal4755 and can even enhance the inhibitory activity, additional basic piperazinyl 
moieties drastically decrease potency. When ascorbic acid moieties are attached at 
the end of the hydrophobic chain, inhibition of Hyal-1 and BTH is observed. Possibly, 
the vitamin C scaffold acts as an anchor allowing a switch in the binding mode. The 
ascorbic acid moiety might bind to regions of the enzymes which are different from 
the indole binding site(s). 
Interestingly, the introduction of hydrophobic motives in position 5 of the indole 
scaffold also led to drastic increase in inhibitory activity against human PH-20 and 
the bacterial hyaluronat lyase. A second carboxyl residue, introduced in position 2 of 
indole-3-butanoic acid, retains the potency and considerably improves the solubility 
in water. Lengthening the aliphatic 5-alkyloxy chain results in increased inhibition of 
the two enzymes: IC50 values of 1.3 µM and 2.4 µM were determined for the 5-
hexadecyloxy derivative 8.65 on human PH-20 and SagHyal4755, respectively. A 
further extension of the chainlength leads to a significant decrease in potency. This 
may be interpreted a hint to the dimension of the hydrophobic patch in the binding 
site of those two enzymes. Additional substitution of the indole nitrogen in 5-alkyloxy-
indoledicarboxylic acids does not increase the inhibitory effect. Differences in the 
SAR between human PH-20 and the bacterial enzyme are obvious, especially when 
minor modifications in position 2 and 5 of the indole moiety (compounds 8.74-8.77) 
are considered. 
The presented indole-3-butanoic acid derivatives presented in this chapter must be 
clearly differentiated from the derivatives of glucurono-3,6-lactone (chapter 6) and  
ascorbic acid (chapter 7) in terms of selectivity. Whereas those compounds possess 
more or less pronounced inhibitory activity against all four investigated enzymes, the 
synthesized indole derivatives show distinct selectivity for the human PH-20 and the 
bacterial hyaluronate lyase, whereas human Hyal-1 and bovine testicular 
hyaluronidase are generally not inhibited in the investigated concentration ranges. 
Thus, the synthesized derivatives are the most potent indole-based inhibitors of 
SagHyal4755 and human PH-20 and they are characterized by distinct selectivity for 
PH-20 compared to the other investigated mammalian hyaluronidases. This 
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selectivity is proven by testing at equiactive enzyme concentrations as described for 
selected compounds in chapter 10.3.5. BTH, the prototype of class I hyaluronidases 
(E.C. 3.2.1.35), has been broadly accepted as a model enzyme for the design of 
inhibitors for human hyaluronidases. This working hypothesis is challenged by 
striking results of this thesis: recombinant human PH-20 is strongly inhibited by some 
indoles and the bovine homolog is not. Moreover, the phenomenon that in terms of 
SAR the human PH-20 is more similar to the bacterial hyaluronate lyase than to its 
human homolog Hyal-1 is highly surprising, as there are distinct differences between 
PH-20 and SagHyal4755 in terms of structure and mechanism of action. Both enzymes 
are representatives of different classes of hyaluronidases: whereas the bacterial 
enzyme utilizes a β-elimination mechanism, the human PH-20 is a hydrolase. Thus, a 
comparable behavior of human hyaluronidases Hyal-1 and PH-20 was expected 
rather than similarities between PH-20 and SagHyal4755.   
 
8.5 Experimental Section 
 
8.5.1 General conditions 
 
Chemicals were purchased from the following suppliers: Acros Organics (Geel, 
Belgium), IRIS Biotech GmbH (Marktredwitz, Germany), Alfa Aesar GmbH & Co. KG 
(Karlsruhe, Germany), Merck KGaA (Darmstadt, Germany), and Sigma-Aldrich 
Chemie GmbH (Munich, Germany). Deuterated solvents for NMR spectroscopy were 
from Deutero GmbH (Kastellaun, Germany). All solvents were of analytical grade or 
distilled prior to use. If moisture-free conditions were required, reactions were 
performed in dried glassware under inert atmosphere (argon or nitrogen); DMF (H2O 
< 0.01 %) was purchased from Sigma-Aldrich Chemie GmbH. Nuclear Magnetic 
Resonance (1H-NMR and 13C-NMR) spectra were recorded on an Avance-300 NMR 
spectrometer from Bruker BioSpin GmbH (Rheinstetten, Germany). Tetramethyl-
silane was added as internal standard (chemical shift δ = 0 ppm) to all samples. 
Multiplicities are specified with the following abbreviations: s (singlet), d (doublet), t 
(triplet), q (quartet), m (multiplet), bs (for broad singulet), as well as combinations 
thereof. The multiplicity of carbon atoms (13C-NMR) were determined by DEPT 135 
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and DEPT 90 (distortionless enhancement by polarization transfer): “+” primary and 
tertiary carbon atom (positive DEPT 135 signal), “-“ secondary carbon atom (negative 
DEPT 135 signal), “quat” quaternary carbon atom. Mass spectrometry analysis (MS) 
was performed on a Finnigan MAT 95 (PI-EIMS 70 eV, HR-MS), Finnigan SSQ 710A 
(CI-MS (NH3)) and on a Finnigan ThermoQuest TSQ 7000 (ESI-MS) spectrometer. 
The peak-intensity in parenthesis is indicated relatively to the strongest signal in %. 
Melting points (mp) were measured on a BÜCHI 530 using open capillaries and are 
uncorrected. Merck Silica Gel 60 (particle size 0.040–0.063 mm) was used for flash 
column chromatography. Reactions were routinely monitored by thin layer 
chromatography (TLC) on Merck silica gel 60 F254 aluminum sheets and spots were 
visualized with UV light at 254 nm, and/or iodine vapor or ammonium 
molybdate/cerium(IV) sulfate solution. 
 
8.5.2 Chemistry 
 
8.5.2.1 General procedure for the synthesis of phenyl esters 8.1-8.3, 8.14-8.17 
To a stirred solution of the pertinent carboxylic acid (1 eq) in CH2Cl2/THF was added 
DMAP (0.2 eq / carboxylic acid moiety) and DCC (1.1 eq / carboxylic acid moiety). A 
solution of phenol (1.2 eq / carboxylic acid moiety) in CH2Cl2 was added dropwise 
and the mixture was stirred at room temperature overnight. After removal of the 
solvent under reduced pressure, the residue was taken up in EtOAc, filtered and 
evaporated again. The raw product was submitted to flash chromatography. 
Phenyl 3-phenylpropanoate24 (8.1): The title compound was prepared according to 
general procedure 8.5.2.1 using hydrocinnamic acid (3 mmol, 0.45 g), DMAP (0.6 
mmol, 73 mg), DCC (3.3 mmol, 0.68 g) and phenol (3.6 mmol, 0.34 g) in anhydrous 
CH2Cl2 (10 ml) and was obtained after flash chromatography (PE/CHCl3 2/1 to 1/1 
v/v) as colorless oil (0.64 g, 92 %). 1H-NMR (CDCl3) δ 2.88 (m, 2H, CH2Ph), 3.08 (t, 
2H, 3J = 7.6 Hz, COCH2), 7.01 (m, 2H, Ph-H), 7.18 – 7.39 (m, 8H, Ph-H). EI-MS (70 
eV) m/z (%): 226 (24) [M+·]. C15H14O2 (226.27). 
Phenyl decanoate25 (8.2): The title compound was prepared according to general 
procedure 8.5.2.1 using decanoic acid (3 mmol, 0.52 g), DMAP (0.6 mmol, 73 mg), 
DCC (3.3 mmol, 0.68 g) and phenol (3.6 mmol, 0.34 g) in anhydrous CH2Cl2 (10 ml) 
and was obtained after flash chromatography (PE/CHCl3 2/1 v/v) as colorless oil 
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(0.71 g, 96 %). 1H-NMR (CDCl3) δ 0.88 (t, 3H, 3J = 6.7 Hz, CH3), 1.36 (m, 12H, 
(CH2)6CH3), 1.75 (m, 2H, COCH2CH2), 2.54 (t, 2H, 3J = 8.0 Hz, COCH2), 7.07 (m, 2H, 
Ph-H), 7.21 (m, 1H, Ph-H), 7.36 (m, 2H, Ph-H). EI-MS (70 eV) m/z (%): 248 (28) 
[M+·]. C16H24O2 (248.36). 
Phenyl 4-chlorobenzoate26 (8.3): The title compound was prepared according to 
general procedure 8.5.2.1 using 4-chlorobenzoic acid (3 mmol, 0.47 g), DMAP (0.6 
mmol, 73 mg), DCC (3.3 mmol, 0.68 g) and phenol (3.6 mmol, 0.34 g) in anhydrous 
CH2Cl2 (10 ml) and was obtained after flash chromatography (PE/CHCl3 1/1 v/v) as a 
white solid (0.64 g, 92 %). mp: 95 °C (ref.26: 103-104 °C); 1H-NMR (CDCl3) δ 7.25 (m, 
3H, Ar-H), 7.47 (m, 4H, Ar-H), 8.15 (m, 2H, Ar-H). C13H9ClO2 (232.66). 
8.5.2.2 General procedure for the synthesis of N-acylated indole-3-butanoic 
acids 8.7-8.9 and 8.19-8.22  
A solution of indole-3-butanoic acid (1.02 eq) in anhydrous DMF (3 ml) was added to 
a suspension of NaH (60 % suspension in mineral oil, 3.2 eq) in anhydrous DMF (4 
ml) under an atmosphere of argon at -41 °C. The cooling bath was removed and the 
mixture was stirred at 0 °C for 15 min. After cooling to -20 °C a solution of the 
pertinent phenol ester (1 eq) in anhydrous DMF (3 ml) was added dropwise and the 
mixture was stirred for additional 30 min. The reaction mixture was quenched by 
adding icecold 1 N HCl. The organic compounds were extracted three times with 
EtOAc. After washing the combined organic layers with water and brine, the organic 
phase was dried over MgSO4, filtered and evaporated to dryness. Flash 
chromatography or recrystallization yielded the target compounds. 
1-(3-Phenylpropanoyl)-1H-indole-3-butanoic acid (8.7): The title compound was 
prepared according to general procedure 8.5.2.2 using indole-3-butanoic acid (1.02 
mmol, 0.21 g), NaH (60 % suspension in mineral oil, 3.3 mmol, 0.12 g) and 8.1 (1 
mmol, 0.23 g) and was obtained after flash chromatography (CHCl3/MeOH 93/7 v/v) 
as a pale yellow solid (0.21 g, 63 %). mp: 128-129 °C; 1H-NMR (DMSO-d6) δ 1.90 
(m, 2H, CH2CH2CO2H), 2.31 (t, 2H, 3J = 7.3 Hz, CH2CO2H), 2.67 (t, 2H, 3J = 7.5 Hz, 
CH2(CH2)2CO2H), 3.02 (t, 2H, 3J = 7.6 Hz, COCH2), 3.36 (t, 2H, 3J = 7.6 Hz, CH2Ph), 
7.25 (m, 8H, Ar-H), 7.59 (m, 1H, Ar-H),  7.72 (s, 1H, H-2), 8.35 (m, 1H, Ar-H), 12.08 
(m, 1H, CO2H). 13C-NMR (DMSO-d6) δ 23.61 (-, CH2), 24.03 (-, CH2), 29.76 (-, CH2), 
33.25 (-, CH2), 36.22 (-, CH2), 115.93 (+, indole-C), 118.89 (+, indole-C), 121.00 
(quat, indole-C), 122.85 (+, indole-C), 123.07 (+, indole-C), 124.60 (+, indole-C), 
125.93 (+, Ph-C), 128.20 (+, Ph-C), 128.41 (+, Ph-C), 130.20 (quat, C-8), 135.23 
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(quat, C-7), 140.62 (quat, Ph-C), 170.92 (quat, NCO), 174.27 (quat, CO2H). CI-MS 
(NH3) m/z (%): 353 (100) [M+NH4]+. Anal. (C21H21NO3) C, H, N. C21H21NO3 (335.40). 
1-Decanoyl-1H-indole-3-butanoic acid (8.8): The title compound was prepared 
according to general procedure 8.5.2.2 using indole-3-butanoic acid (1.02 mmol, 0.21 
g), NaH (60 % suspension in mineral oil, 3.3 mmol, 0.12 g) and 8.2 (1 mmol, 0.25 g) 
and was obtained after flash chromatography (CHCl3/MeOH 93/7 v/v) and 
recrystallization from EtOAc/hexane as a white solid (0.19 g, 53 %). mp: 94 °C; 1H-
NMR (DMSO-d6) δ 0.85 (t, 3H, 3J = 6.7 Hz, CH3), 1.30 (m, 12H, (CH2)6CH3), 1.67 (m, 
2H, COCH2CH2), 1.91 (m, 2H, CH2CH2CO2H), 2.32 (t, 2H, 3J = 7.3 Hz, CH2CO2H), 
2.69 (t, 2H, 3J = 7.5 Hz, CH2(CH2)2CO2H), 2.98 (t, 2H, 3J = 7.3 Hz, COCH2), 7.29 (m, 
2H, H-5, indole-H), 7.59 (dd, 1H, 4J = 1.4 Hz, 3J = 6.9 Hz, indole-H), 7.68 (s, 1H, H-
2), 8.34 (dd, 1H, 4J = 1.0 Hz, 3J = 7.3 Hz, indole-H), 12.09 (bs, 1H, CO2H). 13C-NMR 
(DMSO-d6) δ 13.87 (+, CH3), 22.03 (-, CH2), 23.63 (+, CH2), 24.11 (+, CH2), 28.42 (+, 
CH2), 28.60 (+, CH2), 28.76 (+, CH2), 28.85 (+, CH2), 31.21 (+, CH2), 33.26 (+, CH2), 
34.75 (+, CH2), 115.93 (+, indole-C), 118.85 (+, indole-C), 120.91 (quat, C-3), 122.81 
(+, indole-C), 122.99 (+, indole-C), 124.56 (+, indole-C), 130.17 (quat, C-8), 135.22 
(quat, C-7), 171.67 (quat, NCO), 174.26 (quat, CO2H). ES-MS (DCM/MeOH + 
NH4OAc) m/z (%): 358 (100) [M+H]+. Anal. (C22H31NO3) C: 73.91, H: 8.74, N: 3.92, 
found C: 73.37, H: 9.30, N: 3.79. C22H31NO3 (357.49).  
N-[2-Deoxy-D-glucopyranose-2-yl]-1-decanoyl-1H-indole-3-butanoic acid amide 
(8.8a): To a solution of 8.8 (0.20 mmol 71 mg), HOBt (0.24 mmol, 32 mg), NEt3 (0.24 
mmol, 33 µl) and EDAC (0.24 mmol, 46 mg) in  DMF (2 ml) was added a solution of 
D-glucosamine hydrochloride (0.40 mmol, 86 mg) and NEt3 (0.40 mmol, 55 µl) in 
DMF (1 ml) and water (0.5 ml). After stirring overnight the solvent was removed 
under reduced pressure and the remaining raw product was subjected to flash 
chromatography (CHCl3/MeOH 95/5 to 85/15 v/v) to yield the title compound as white 
solid (85 mg, 82 %). mp: 157 °C;  1H-NMR (CD3OD) δ 0.89 (t, 3H, 3J = 6.2 Hz, CH3), 
1.36 (m, 12H, (CH2)6CH3), 1.78 (m, 2H, COCH2CH2), 2.03 (m, 2H, CH2CH2CO2H), 
2.34 (t, 2H, 3J = 7.2 Hz, CH2CO2H), 2.75 (t, 2H, 3J = 7.2 Hz, CH2(CH2)2CO2H), 2.96 
(t, 2H, 3J = 7.3 Hz, COCH2), 3.35 – 3.91 (m, 6H, CH2OH, H-2, H-3, H-4, H-5), 5.14 (d, 
1H, 3J = 3.4 Hz, H-1), 7.26 (m, 2H, indole-H), 7.55 (m, 2H, indole-H), 8.37 (d, 1H, 3J 
= 7.8 Hz, indole-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 519 (100) [M+H]+. 
Anal. (C28H42N2O7) C, H, N. C28H42N2O7 (518.64). 
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1-(4-Chlorobenzoyl)-1H-indole-3-butanoic acid (8.9)27: The title compound was 
prepared according to general procedure 8.5.2.2 using indole-3-butanoic acid (1.02 
mmol, 0.21 g), NaH (60 % suspension in mineral oil, 3.3 mmol, 0.12 g) and 8.3 (1 
mmol, 0.23 g) and was obtained after flash chromatography (CHCl3/MeOH 93/7 v/v) 
and recrystallization from EtOAc/hexane as a white solid (0.20 g, 59 %). mp: 144 °C; 
1H-NMR (DMSO-d6) δ 1.84 (m, 2H, CH2CH2CO2H), 2.27 (t, 2H, 3J = 7.3 Hz, 
CH2CO2H), 2.67 (t, 2H, 3J = 7.5 Hz, CH2(CH2)2CO2H), 7.19 (s, 1H, H-2), 7.37 (m, 2H, 
Ar-H), 7.67 (m, 3H, Ar-H), 7.78 (m, 2H, Ar-H), 8.27 (dd, 1H, 3J = 1.2 Hz, 3J = 7.1 Hz, 
indole-H), 12.08 (s, 1H, CO2H). 13C-NMR (DMSO-d6) δ 23.41 (-, CH2), 24.03 (-, CH2), 
33.11 (-, CH2), 115.86 (+, indole-C), 119.18 (+, indole-C), 121.43 (quat, C-3), 123.69 
(+, indole-C), 124.36 (+, indole-C), 124.76 (+, indole-C), 128.71 (+, Ar-C), 130.61 
(quat, C-8), 130.75 (+, Ar-C), 132.98 (quat, Ar-C), 135.62 (quat, C-7), 136.53 (quat, 
Ar-C), 166.83 (quat, NCO), 174.22 (quat, CO2H). Anal. (C19H16ClNO3) C, H, N. 
C19H16ClNO3 (341.79). 
Diphenyl 2,2'-(1,4-phenylene)diacetate28 (8.14): The title compound was prepared 
according to general procedure 8.5.2.1 using 1,4-phenylenediacetic acid (5 mmol, 
0.97 g), DMAP (2 mmol, 0.24 g), DCC (11 mmol, 2.27 g) and phenol (12 mmol, 1.13 
g) in anhydrous CH2Cl2 (20 ml) and was obtained after flash chromatography 
(PE/CHCl3 1/2 v/v) as a white solid (1.47 g, 85 %). mp: 96-97 °C;  1H-NMR (CDCl3) δ 
3.86 (s, 4H, CH2), 7.06 (m, 4H, Ar-H), 7.21 (m, 2H, Ar-H), 7.35 (m, 8H, Ar-H). EI-MS 
(70 eV) m/z (%): 346 (4) [M+·]. Anal. (C22H18O4) C, H. C22H18O4 (346.38). 
Diphenyl octanedioate29 (8.15): The title compound was prepared according to 
general procedure 8.5.2.1 using octanedioic acid (5 mmol, 0.97 g), DMAP (2 mmol, 
0.24 g), DCC (11 mmol, 2.27 g) and phenol (12 mmol, 1.13 g) in anhydrous CH2Cl2 
(20 ml) and was obtained after flash chromatography (PE/CHCl3 1/2 v/v) as a white 
solid (1.30 g, 80 %). mp: 68 °C (ref.30: 70-71 °C); 1H-NMR (CDCl3) δ 1.49 (m, 4H, 
COCH2CH2(CH2)2), 1.79 (m, 4H, COCH2CH2), 2.57 (t, 4H, 3J = 7.4 Hz COCH2), 7.07 
(m, 4H, Ph-H), 7.22 (m, 2H, Ph-H), 7.37 (m, 4H, Ph-H). EI-MS (70 eV) m/z (%): 326 
(3) [M+·]. Anal. (C20H22O4) C, H. C20H22O4 (326.39). 
Diphenyl dodecanedioate31 (8.16): The title compound was prepared according to 
general procedure 8.5.2.1 using dodecanedioic acid (5 mmol, 1.15 g), DMAP (2 
mmol, 0.24 g), DCC (11 mmol, 2.27 g) and phenol (12 mmol, 1.13 g) in anhydrous 
CH2Cl2 (20 ml) and was obtained after flash chromatography (PE/CHCl3 1/2 v/v) as a 
white solid (1.80 g, 94 %). mp: 64 °C (ref.30: 70-71 °C); 1H-NMR (CDCl3) δ 1.34 (m, 
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12H, COCH2CH2(CH2)6), 1.75 (m, 4H, COCH2CH2), 2.55 (t, 4H, 3J = 7.5 Hz, COCH2), 
7.07 (m, 4H, Ph-H), 7.21 (m, 2H, Ph-H), 7.36 (m, 4H, Ph-H). EI-MS (70 eV) m/z (%): 
382 (10) [M+·]. Anal. (C24H30O4) C, H. C24H30O4 (382.49). 
Diphenyl hexadecanedioate32 (8.17): The title compound was prepared according 
to general procedure 8.5.2.1 using hexadecanedioic acid (5 mmol, 1.43 g), DMAP (2 
mmol, 0.24 g), DCC (11 mmol, 2.27 g) and phenol (12 mmol, 1.13 g) in anhydrous 
CH2Cl2 (20 ml) and was obtained after flash chromatography (PE/CHCl3 1/2 v/v) as a 
white solid (1.91 g, 87 %). mp: 74 °C (ref.32: 86-87 °C); 1H-NMR (CDCl3) δ 1.34 (m, 
20H, COCH2CH2(CH2)10), 1.75 (m, 2H, COCH2CH2), 2.55 (t, 4H, 3J = 7.5 Hz, 
COCH2), 7.07 (m, 4H, Ph-H), 7.21 (m, 2H, Ph-H), 7.37 (m, 4H, Ph-H). EI-MS (70 eV) 
m/z (%): 345 (100) [M-C6H5O+·]. Anal. (C28H38O4) C, H. C28H38O4 (438.60). 
1,1'-(p-Phenylendiacetyl)diindol-3,3'-dibutanoic acid (8.19): The title compound 
was prepared according to general procedure 8.5.2.2 using indole-3-butanoic acid 
(1.02 mmol, 0.21 g), NaH (60 % suspension in mineral oil, 3.3 mmol, 0.12 g) and 
8.14 (0.5 mmol, 0.17 g). After quenching the reaction with 1 N HCl, the resulting 
white solid was collected by filtration and recrystallized from methanol to yield 8.19 
as a white solid (0.15 g, 53 %). 1H-NMR (DMSO-d6) δ 1.92 (m, 4H, CH2CH2CO2H), 
2.34 (t, 4H, 3J = 7.3 Hz, CH2CO2H), 2.71 (t, 4H, 3J = 7.4 Hz, CH2(CH2)2CO2H), 4.39 
(s, 4H, CH2C6H4), 7.30 (m, 8H, indole-H, Ph-H), 7.61 (dd, 2H, 4J = 1.2 Hz, 3J = 6.6 
Hz, indole-H), 7.85 (s, 2H, H-2), 8.33 (dd, 2H, 4J = 1.2 Hz, 3J = 7.4 Hz, indole-H), 
12.11 (s, 2H, CO2H). 13C-NMR (DMSO-d6) δ 23.63 (-, CH2), 24.09 (-, CH2), 33.25 (-, 
CH2), 41.18 (-, CH2C6H4), 115.98 (+, indole-C), 118.94 (+, indole-C), 121.26 (quat, 
indole-C), 123.03 (+, indole-C), 123.23 (+, indole-C), 124.70 (+, indole-C), 129.61 (+, 
Ar-C), 130.29 (quat, C-8), 132.91 (quat, Ar-H), 135.40 (quat, C-7), 169.80 (quat, 
NCO), 174.26 (quat, CO2H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 563 (100) [M-
H]-. Anal. (C34H32N2O6·0.5H2O) C, H, N. C34H32N2O6 (564.63). 
1,1'-Octanedioyldiindol-3,3'-dibutanoic acid (8.20): The title compound was 
prepared according to general procedure 8.5.2.2 using indole-3-butanoic acid (1.02 
mmol, 0.21 g), NaH (60 % suspension in mineral oil, 3.3 mmol, 0.12 g) and 8.15 (0.5 
mmol, 0.16 g). After quenching the reaction with 1 N HCl, the resulting white solid 
was collected by filtration and recrystallized from methanol to yield 8.20 as a white 
solid (0.18 g, 66 %). 1H-NMR (DMSO-d6) δ 1.45 (m, 4H, COCH2CH2(CH2)2), 1.71 (m, 
4H, COCH2CH2), 1.91 (m, 4H, CH2CH2CO2H), 2.32 (t, 4H, 3J = 7.3 Hz, CH2CO2H), 
2.69 (t, 4H, 3J = 7.5 Hz, CH2(CH2)2CO2H), 3.01 (t, 4H, 3J = 7.2 Hz, COCH2), 7.29 (m, 
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4H, H-5, indole-H), 7.60 (m, 2H, indole-H),  7.69 (s, 2H, H-2), 8.35 (m, 2H, indole-H), 
12.09 (s, 2H, CO2H). 13C-NMR (DMSO-d6) δ 23.63 (-, CH2), 23.94 (-, CH2), 24.11 (-, 
CH2), 28.19 (-, CH2), 33.26 (-, CH2), 34.70 (-, CH2), 115.95 (+, indole-C), 118.87 (+, 
indole-C), 120.94 (quat, indole-C), 122.78 (+, indole-C), 123.00 (+, indole-C), 124.57 
(+, indole-C), 130.18 (quat, C-8), 135.23 (quat, C-7), 171.64 (quat, NCO), 174.26 
(quat, CO2H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 546 (100) [M+H]+. Anal. 
(C32H36N2O6·0.25H2O) C, H, N. C32H36N2O6 (544.64). 
1,1'-Dodecanedioyldiindol-3,3'-dibutanoic acid (8.21): The title compound was 
prepared according to general procedure 8.5.2.2 using indole-3-butanoic acid (1.02 
mmol, 0.21 g), NaH (60 % suspension in mineral oil, 3.3 mmol, 0.12 g) and 8.16 (0.5 
mmol, 0.19 g). After quenching the reaction with 1 N HCl, the resulting white solid 
was collected by filtration and recrystallized from methanol to yield 8.21 as a white 
solid (0.15 g, 50 %). 1H-NMR (DMSO-d6) δ 1.32 (m, 12H, COCH2CH2(CH2)6), 1.67 
(m, 4H, COCH2CH2),  1.90 (m, 4H, CH2CH2CO2H), 2.32 (t, 4H, 3J = 6.8 Hz, 
CH2CO2H), 2.68 (t, 4H, 3J = 6.8 Hz, CH2(CH2)2CO2H), 2.98 (t, 4H, 3J = 6.4 Hz, 
COCH2), 7.28 (m, 4H, H-5, indole-H), 7.59 (d, 2H, 3J = 7.0 Hz, indole-H), 7.68 (s, 2H, 
H-2), 8.34 (d, 2H, 3J = 7.6 Hz, indole-H), 12.10 (s, 2H, CO2H). 13C-NMR (DMSO-d6) δ 
23.62 (-, CH2), 24.10 (-, CH2), 28.43 (-, CH2), 28.76 (-, CH2), 28.85 (-, CH2), 33.25 (-, 
CH2), 34.75 (-, CH2), 115.93 (+, indole-C), 118.85 (+, indole-C), 120.90 (quat, indole-
C), 122.80 (+, indole-C), 122.99 (+, indole-C), 124.56 (+, indole-C), 130.16 (quat, C-
8), 135.21 (quat, C-7), 171.67 (quat, NCO), 174.27 (quat, CO2H). ES-MS 
(DCM/MeOH + NH4OAc) m/z (%): 618 (100) [M+NH4]+. Anal. (C36H44N2O6·0.5H2O) C, 
H, N. C36H44N2O6 (600.74). 
1,1'-Hexadecanedioyldiindol-3,3'-dibutanoic acid (8.22): The title compound was 
prepared according to general procedure 8.5.2.2 using indole-3-butanoic acid (1.02 
mmol, 0.21 g), NaH (60 % suspension in mineral oil, 3.3 mmol, 0.12 g) and 8.17 (0.5 
mmol, 0.22 g). The obtained raw product was recrystallized from methanol to yield 
8.22 as a white solid (0.10 g, 30 %). mp: 156-158 °C; 1H-NMR (DMSO-d6) δ 1.28 (m, 
20H, COCH2CH2(CH2)10), 1.68 (m, 4H, COCH2CH2), 1.91 (m, 4H, CH2CH2CO2H), 
2.32 (t, 4H, 3J = 7.3 Hz, CH2CO2H), 2.69 (t, 4H, 3J = 7.5 Hz, CH2(CH2)2CO2H), 2.98 
(t, 4H, 3J = 7.3 Hz, COCH2), 7.28 (m, 4H, H-5, indole-H), 7.59 (dd, 2H, 4J = 1.1 Hz, 3J 
= 6.8 Hz, indole-H), 7.68 (s, 2H, H-2), 8.34 (dd, 2H, 4J = 1.0 Hz, 3J = 7.4 Hz, indole-
H), 12.03 (s, 2H, CO2H). 13C-NMR (DMSO-d6) δ 23.59 (-, CH2), 24.08 (-, CH2), 28.36 
(-, CH2), 28.68 (-, CH2), 28.82 (-, CH2), 28.86 (-, CH2), 28.91 (-, CH2), 33.23 (-, CH2), 
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34.72 (-, CH2), 115.91 (+, indole-C), 118.83 (+, indole-C), 120.89 (quat, indole-C), 
122.79 (+, indole-C), 122.97 (+, indole-C), 124.53 (+, indole-C), 130.16 (quat, C-8), 
135.21 (quat, C-7), 171.66 (quat, NCO), 174.22 (quat, CO2H). ES-MS (DCM/MeOH + 
NH4OAc) m/z (%): 656 (100) [M-H]-. Anal. (C40H52N2O6·0.25H2O) C, H, N. 
C40H52N2O6 (656.85). 
16-Hydroxyhexadecanoic acid (8.24a)15: A mixture of hexadecano-16-lactone (30 
mmol, 7.63 g) and NBu4HSO4 (0.3 mmol, 0.10 g) in toluene (30 ml) and 50 % 
aqueous NaOH (25 ml) was stirred at 80-90 °C overnight. After cooing the resulting 
solid was isolated by filtration, washed with ether and dissolved in water. Acidification 
with concentrated HCl to pH <2 led to precipitation of the product which was isolated 
by filtration, washed with water and dried under reduced pressure to yield the title 
compound as white solid (7.76 g, 95 %). mp: 89-90 °C (Lit.15: 94-95 °C); 1H-NMR 
(DMSO-d6) δ 1.24 (s, 22H, COCH2CH2(CH2)11), 1.43 (m, 4H, COCH2CH2, 
CH2CH2OH), 2.18 (t, 2H, 3J = 7.3 Hz, COCH2), 3.37 (m, 2H, 3J = 5.6 Hz, CH2OH), 
4.32 (t, 2H, 3J = 5.0 Hz, CH2OH), 11.96 (s, 1H, CO2H). CI-MS (NH3) m/z (%): 271 
(100) [M-H]-. C16H32O3 (272.42). 
16-Bromohexadecanoic acid (8.24)15: A mixture of 8.24a (26.8 mmol, 7.29 g) in 42 
ml HBr (33 % solution in acetic acid) and concentrated H2SO4 (13 ml) was stirred 
overnight under an atmosphere of nitrogen. Subsequently the solution was stirred at 
reflux for 6 h. The reaction was quenched by adding icewater and the resulting solid 
was sucked off, washed with water and dried under reduced pressure to yield the title 
compound as white solid (8.57 g, 95 %). mp: 64-66 °C (Lit.15: 67-69 °C); 1H-NMR 
(CDCl3) δ 1.30 (m, 22H, COCH2CH2(CH2)11), 1.63 (m, 2H, COCH2CH2), 1.85 (m, 2H, 
CH2CH2OH), 2.35 (t, 2H, 3J = 7.5 Hz, COCH2), 3.41 (t, 2H, 3J = 6.9 Hz, CH2OH). EI-
MS (70 eV) m/z (%): 334 (13) [M+·]. C16H31BrO2 (335.32). 
8.5.2.3 General procedure for the synthesis of benzyl esters 8.25 and 8.26 
A mixture of the pertinent carboxylic acid (1 eq), benzyl alcohol (1.1 eq), DMAP (0.1 
eq) and DCC (1.1 eq) in anhydrous CH2Cl2 was stirred overnight at room 
temperature under an atmosphere of argon. After filtration the solvent was removed 
under reduced pressure and the resulting raw product was subjected to flash 
chromatography.  
Benzyl 11-bromoundecanoate33 (8.25): The title compound was prepared 
according to general procedure 8.5.2.3 using 11-bromoundecanoic acid (10 mmol, 
2.56 g), DMAP (1 mmol, 0.12 g), DCC (11 mmol, 2.27 g) and benzyl alcohol (11 
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mmol, 1.13 ml) in anhydrous CH2Cl2 (40 ml) and was obtained after flash 
chromatography (PE/EtOAc 90/10 v/v) as a colorless oil (3.27 g, 92 %). 1H-NMR 
(CDCl3) δ 1.29 – 1.89 (m, 16H, COCH2(CH2)8), 2.35 (t, 2H, 3J = 7.5 Hz, COCH2), 
3.39 (t, 2H, 3J = 6.9 Hz, CH2Br), 5.11 (s, 2H, CH2Ph), 7.35 (m, 5H, Ph-H). CI-MS 
(NH3) m/z (%): 355 (100) [M+H]+. C18H27BrO2 (355.31). 
Benzyl 16-bromohexadecanoate (8.26): The title compound was prepared 
according to general procedure 8.5.2.3 using 8.24 (15 mmol, 5.03 g), DMAP (1.5 
mmol, 0.18 g), DCC (16.5 mmol, 3.40 g) and benzyl alcohol (16.5 mmol, 1.70 ml) in 
anhydrous CH2Cl2 (50 ml) and was obtained after flash chromatography (PE/EtOAc 
95/5 to 90/10 v/v) as a pale yellow solid (5.34 g, 84 %). 1H-NMR (CDCl3) δ 1.35 (m, 
22H, COCH2CH2(CH2)11), 1.64 (m, 2H, COCH2CH2), 1.85 (m, 2H, CH2CH2OH), 2.35 
(t, 2H, 3J = 7.5 Hz, COCH2), 3.41 (t, 2H, 3J = 6.9 Hz, CH2OH), 5.12 (s, 2H, CH2Ph), 
7.36 (m, 5H, Ph-H). EI-MS (70 eV) m/z (%): 424 (2) [M+·]. C23H37BrO2 (425.44). 
tert-Butyl 1H-indole-3-butanoate34 (8.27):To a solution of indole-3-butanoic acid 
(10 mmol) in anhydrous THF (10 ml) was added TBTA (20 mmol, 4.38 g) dissolved in 
anhydrous cyclohexane (20 ml) and BF3Et2O (0.2 ml). After stirring at room 
temperature overnight NaHCO3 was added and the mixture was stirred for 10 min. 
Solids were removed by filtration, the solvent was evaporated and the remaining 
crude product was subjected to flash chromatography (PE/EtOAc 90/10 v/v) to yield 
the title compound as a white solid (1.53 g, 59 %). mp: 62-64 °C (ref.34: 69-61 °C); 
1H-NMR (CDCl3) δ 1.45 (s, 9H, C(CH3)3), 2.00 (m, 2H, CH2CH2CO2), 2.30 (t, 2H, 3J = 
7.4 Hz, CH2CO2), 2.79 (t, 2H, 3J = 7.4 Hz, CH2(CH2)2CO2), 6.97 (s, 1H, H-2), 7.15 (m, 
2H, indole-H), 7.34 (m, 1H, indole-H), 7.61 (d, 1H, 3J = 8.0 Hz, indole-H), 8.00 (s, 
1H). PI-EIMS (70 eV) m/z (%): 259 (47) [M+·]. C16H21NO2 (259.34). 
8.5.2.4 General procedure for the synthesis of N-alkylated indoles 8.28, 8.29, 
8.67-8.69 and 8.73 
To a solution of indole derivative (1 eq) in anhydrous DMF was added NaH (60 % 
suspension in mineral oil, 1.2 eq) under an atmosphere of argon. After stirring at 
room temperature for 30 min the pertinent alkyl halide (1.2 eq) was added and 
stirring was continued for 3 h at 40-60 °C. The reaction was quenched by adding 
water and the mixture was extracted tree times with EtOAc. The combined organic 
phases were washed with brine, dried over MgSO4, filtered and evaporated to 
dryness. The crude product was subjected to flash chromatography to yield the target 
compound. 
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Benzyl 11-[3-(4-tert-butoxy-4-oxobutyl)-1H-indol-1-yl]undecanoate (8.28): The 
title compound was prepared according to general method 8.5.2.4 using 8.27 (1 
mmol, 0.26 g), NaH (1.2 mmol, 48 mg) and 8.25 (1.2 mmol, 0.43 g) in anhydrous 
DMF (5 ml) and was obtained after flash chromatography (PE/EtOAc 95/5 to 90/10 
v/v) as a colorless oil (0.31 g, 58 %). 1H-NMR (CDCl3) δ 1.26 (m, 12H, 
NCH2CH2(CH2)6), 1.44 (s, 9H, C(CH3)3), 1.63 (m, 2H, CH2CH2CO), 1.79 (m, 2H, 
NCH2CH2), 1.98 (m, 2H, CH2CH2CO2), 2.28 (t, 2H, 3J = 7.5 Hz, CH2CO2), 2.34 (t, 2H, 
3J = 7.5 Hz, CH2CO2), 2.77 (t, 2H, 3J = 7.4 Hz,  CH2(CH2)2CO2), 4.04 (t, 2H, 3J = 7.2 
Hz, NCH2), 5.11 (s, 2H, CH2Ph), 6.88 (s, 1H, H-2), 7.07 (ddd, 1H, 4J = 1.0 Hz, 3J = 
7.1 Hz, 3J = 7.9 Hz, indole-H), 7.18 (ddd, 1H, 4J = 1.1 Hz, 3J = 6.9 Hz, 3J = 8.2 Hz, 
indole-H), 7.31 (m, 6H, Ph-H, indole-H), 7.58 (m, 1H, indole-H). CI-MS (NH3) m/z 
(%): 534 (32) [M+H]+. C34H47NO4 (533.74). 
Benzyl 16-[3-(4-tert-butoxy-4-oxobutyl)-1H-indol-1-yl]hexadecanoate (8.29): The 
title compound was prepared according to general method 8.5.2.4 using 8.27 (10 
mmol, 2.59 g), NaH (1.2 mmol, 0.48 g) and 8.26 (12 mmol, 5.11 g) in anhydrous 
DMF (25 ml) and was obtained after flash chromatography (PE/EtOAc 95/5 to 90/10 
v/v) as yellow oil (2.06 g, 34 %). 1H-NMR (CDCl3) δ 1.28 (m, 22H, NCH2CH2(CH2)11), 
1.46 (s, 9H, C(CH3)3), 1.65 (m, 2H, CH2CH2CO), 1.81 (m, 2H, NCH2CH2), 2.00 (m, 
2H, CH2CH2CO2), 2.30 (t, 2H, 3J = 7.5 Hz, CH2CO2), 2.36 (t, 2H, 3J = 7.5 Hz, 
CH2CO2), 2.79 (t, 2H, 3J = 7.4 Hz, CH2(CH2)2CO2), 4.06 (t, 2H, 3J = 7.2 Hz, NCH2), 
5.13 (s, 2H, CH2Ph), 6.90 (s, 1H, H-2), 7.09 (ddd, 1H, 4J = 1.0 Hz, 3J = 7.0 Hz, 3J = 
7.9 Hz, indole-H), 7.20 (ddd, 1H, 4J = 1.1 Hz, 3J = 7.0 Hz, 3J = 8.2 Hz, indole-H), 7.34 
(m, 6H, indole-H, Ph-H), 7.60 (m, 1H, indole-H). CI-MS (NH3) m/z (%): 604 (100) 
[M+H]+. C39H57NO4 (603.87). 
8.5.2.5 General procedure for the synthesis of alcohols or carboxylic acids 
8.30, 8.46, 8.49, 8.55, 8.56, 8.76 and 8.77 via cleavage of benzyl 
ether/ester precursors: 
The pertinent benzyl ester/ether was dissolved in EtOH and EtOAc and a catalytic 
amount of palladium on activated charcoal (10 % Pd) was added. A slow stream of 
hydrogen was then bubbled through the suspension for 30 min. Insoluble material 
was filtered off, and the solvent was evaporated to yield the target compound. 
11-[3-(4-tert-Butoxy-4-oxobutyl)-1H-indol-1-yl]undecanoic acid (8.30): The title 
compound was prepared according to general procedure 8.5.2.5 using 8.27 (0.54 
mmol, 0.29 g) and 10 % Pd/C (50 mg) in EtOH (2 ml) and EtOAc (5 ml) and was 
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obtained as a colorless oil (0.23 g, 96 %). 1H-NMR (CDCl3) δ 1.27 (m, 12H, 
NCH2CH2(CH2)6), 1.45 (s, 9H, C(CH3)3), 1.61 (m, 2H, CH2CH2CO2H), 1.80 (m, 2H, 
NCH2CH2), 1.98 (m, 2H, CH2CH2CO2), 2.31 (m, 4H, CH2CO2, CH2CO2H), 2.77 (t, 2H, 
3J = 7.4 Hz, CH2(CH2)2CO2), 4.04 (t, 2H, 3J = 7.1 Hz, NCH2), 6.88 (s, 1H, H-2), 7.08 
(ddd, 1H, 4J = 1.0 Hz, 3J = 7.1 Hz, 3J = 7.9 Hz, indole-H), 7.18 (ddd, 1H, 2J = 1.1 Hz, 
3J = 6.9 Hz, 3J = 8.2 Hz, indole-H), 7.29 (m, 1H, indole-H), 7.59 (m, 1H, indole-H). EI-
MS (70 eV) m/z (%): 443 (27) [M+·]. C27H41NO4 (443.62). 
16-[3-(4-tert-Butoxy-4-oxobutyl)-1H-indol-1-yl]hexadecanoic acid (8.31): The title 
compound was prepared according to the general procedure for cleavage of benzyl 
esters using 8.28 (3.20 mmol, 1.93 g) and 10 % Pd/C (0.30 g) in EtOH (15 ml) and 
EtOAc (15 ml) and was obtained as a pale yellow oil (1.64 g, 99 %). 1H-NMR (CDCl3) 
δ 1.29 (m, 22H, NCH2CH2(CH2)11), 1.46 (s, 9H, C(CH3)3), 1.64 (m, 2H, 
CH2CH2CO2H), 1.81 (m, 2H, NCH2CH2), 2.00 (m, 2H, CH2CH2CO2), 2.32 (m, 4H, 
CH2CO2, CH2CO2H), 2.79 (t, 2H, 3J = 7.4 Hz, CH2(CH2)2CO2), 4.05 (t, 2H, 3J = 7.2 
Hz, NCH2), 6.89 (s, 1H, H-2), 7.09 (ddd, 1H, 4J = 1.0 Hz, 3J = 7.1 Hz, 3J = 7.9 Hz, 
indole-H), 7.20 (ddd, 1H, 3J = 1.1 Hz, 3J = 7.0 Hz, 3J = 8.2 Hz, indole-H), 7.31 (m, 1H, 
indole-H), 7.60 (m, 1H, indole-H), 9.95 (bs, 1H, CO2H). EI-MS (70 eV) m/z (%): 514 
(78) [M+·]. C32H51NO4 (513.75). 
8.5.2.6 General procedure for the synthesis of carboxylic acids 8.32, 8.33, 
8.42-8.45, 8.47 and 8.48 via cleavage of tert-butyl ester precursors: 
The pertinent tert-butyl ester was dissolved in CH2Cl2/TFA (80/20 v/v) at 0 °C. After 
stirring for 6 h at room temperature the solvent was evaporated to yield the free 
carboxylic acid derivative. 
11-[3-(3-Carboxypropyl)-1H-indol-1-yl]undecanoic acid (8.32): The title 
compound was prepared according to general procedure 8.5.2.6 using 8.30 (0.5 
mmol, 0.22 g) in 4 ml of CH2Cl2/TFA (80/20 v/v) and was obtained after flash 
chromatography (PE/EtOAc 1/1 + 0.1 % HOAc v/v) as a white solid (0.16 g, 83 %). 
1H-NMR (CD3OD) δ 1.25 (s, 12H, NCH2CH2(CH2)6), 1.56 (m, 2H, CH2CH2COH), 1.78 
(m, 2H, NCH2CH2), 1.97 (m, 2H, CH2CH2CO2), 2.25 (t, 2H, 3J = 7.4 Hz, CH2CO2H), 
2.33 (t, 2H, 3J = 7.4 Hz, CH2CO2H), 2.77 (t, 2H, 3J = 7.4 Hz, CH2(CH2)2CO2H), 4.09 
(t, 2H, 3J = 6.9 Hz, NCH2), 6.99 (m, 2H, H-2, indole-H), 7.11 (ddd, 1H, 4J = 1.1 Hz, 3J 
= 7.0 Hz, 3J = 7.9 Hz, indole-H), 7.30 (d, 1H, 3J = 8.2 Hz, indole-H), 7.52 (m, 1H, 
indole-H). 13C-NMR (CD3OD) δ 25.47 (-, CH2), 26.15 (-, CH2), 27.03 (-, CH2), 27.99 (-
, CH2), 30.28 (-, CH2), 30.34 (-, CH2), 30.41 (-, CH2), 30.50 (-, CH2), 30.60 (-, CH2), 
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31.43 (-, CH2), 34.57 (-, CH2), 35.03 (-, CH2), 46.87 (-, NCH2), 110.42 (+, indole-C), 
115.08 (quat, C-3), 119.45 (+, indole-C), 119.84 (+, indole-C), 122.26 (+, indole-C), 
126.66 (+, indole-C), 129.40 (quat, C-9), 138.00 (quat, C-8), 177.79 (quat, CO2H). EI-
MS (70 eV) m/z (%): 387 (15) [M+·]. Anal. (C23H33NO4) C, H, N. C23H33NO4 (387.51). 
16-[3-(3-Carboxypropyl)-1H-indol-1-yl]hexadecanoic acid (8.33): The title 
compound was prepared according to general procedure 8.5.2.5 esters using 8.31 
(0.33 mmol, 0.20 g) in 4 ml of CH2Cl2/TFA (80/20 v/v) and was obtained after flash 
chromatography (PE/EtOAc 60/40 + 0.1 % HOAc v/v) as a white solid (0.13 g, 86 %). 
mp: 85-86 °C; 1H-NMR (CD3OD+CDCl3) δ 1.27 (m, 22H, NCH2CH2(CH2)11), 1.58 (m, 
2H CH2CH2CO2H), 1.78 (m, 2H, NCH2CH2), 1.98 (m, 2H, CH2CH2CO2H), 2.26 (t, 2H, 
3J = 7.4 Hz, CH2CO2H), 2.33 (t, 2H, 3J = 7.4 Hz, CH2CO2), 2.77 (t, 2H, 3J = 7.4 Hz, 
CH2(CH2)2CO2H), 4.07 (t, 2H, 3J = 7.0 Hz, NCH2), 6.94 (s, 1H, H-2), 6.99 (ddd, 1H, 4J 
= 0.9 Hz, 3J = 7.1 Hz, 3J = 7.9 Hz, indole-H), 7.11 (ddd, 1H, 4J = 1.1 Hz, 3J = 7.0 Hz, 
3J = 8.2 Hz, indole-H), 7.29 (d, 1H, 3J = 8.2 Hz, indole-H), 7.52 (m, 1H, indole-H). 
13C-NMR (CD3OD+CDCl3) δ 25.54 (-, CH2), 26.19 (-, CH2), 26.98 (-, CH2), 28.07 (-, 
CH2), 30.34 (-, CH2), 30.40 (-, CH2), 30.51 (-, CH2), 30.68 (-, CH2), 30.80 (-, CH2), 
31.47 (-, CH2), 34.71 (-, CH2), 35.16 (-, CH2), 47.02 (-, NCH2), 110.46 (+, indole-C), 
115.13 (quat, C-3), 119.52 (+, indole-C), 119.94 (+, indole-C), 122.33 (+, indole-C), 
126.65 (+, indole-C), 129.37 (quat, C-9), 137.94 (quat, C-8), 177.90 (quat, CO2H). 
ES-MS (DCM/MeOH + NH4OAc) m/z (%): 458 (100) [M+H]+. C28H43NO4 (457.65). 
8.5.2.7 General procedure for the synthesis of amides 8.34-8.37, 8.39 and 
8.40 
A mixture of the pertinent carboxylic acid (1 eq), HOBt (1.2 eq), DIEA (1.2 eq), EDAC 
(1.2 eq) and the pertinent amine (2 eq) in DMF was stirred at room temperature 
overnight. After removal of the solvent the remaining residue was subjected to flash 
chromatography to yield the target compound. 
tert-Butyl {1-[11-oxo-11-(thiazol-2-ylamino)undecan-1-yl]-1H-indole-3-butanoate 
(8.34): The title compound was prepared according to general procedure 8.5.2.7 
using 8.30 (0.5 mmol, 0.22 g), HOBt (0.6 mmol, 81 mg), DIEA (0.6 mmol, 0.10 ml), 
EDAC (0.6 mmol, 115 mg) and 2-aminothiazole (1 mmol, 0.10 g) in DMF (5 ml) and 
was obtained after flash chromatography (CHCl3/MeOH 98/2 v/v) as a pale yellow oil 
(0.20 g, 76 %). 1H-NMR (CDCl3) δ 1.32 (m, 12H, NCH2CH2(CH2)6), 1.44 (s, 9H, 
C(CH3)3), 1.77 (m, 2H, NCH2CH2), 1.98 (m, 2H, CH2CH2CO2), 2.29 (t, 2H, 3J = 7.4 
Hz, CH2CO2), 2.54 (t, 2H, 3J = 7.5 Hz, CH2CONH), 2.77 (t, 2H, 3J =7.4Hz, 
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CH2(CH2)2CO2), 4.04 (t, 2H, 3J = 7.1 Hz, NCH2), 6.88 (s, 1H, H-2), 6.98 (d, 1H, 3J = 
2.9 Hz, thiazole-H), 7.07 (ddd, 1H, 4J = 1.0 Hz, 3J = 7.0 Hz, 3J = 7.9 Hz, indole-H), 
7.18 (ddd, 1H, 4J = 1.0 Hz, 3J = 6.9 Hz, 3J = 7.9 Hz, indole-H), 7.29 (m, 1H, indole-H), 
7.42 (d, 1H, 3J = 2.9 Hz, thiazole-H), 7.59 (m, 1H, indole-H), 8.03 (s, 1H). CI-MS 
(NH3) m/z (%): 526 (100) [M+H]+. Anal. (C30H43N3O3S·0.4H2O) C, H, N. C30H43N3O3S 
(525.75). 
tert-Butyl 1-[11-oxo-11-(4-phenylpiperazin-1-yl)undecan-1-yl]-1H-indole-3-
butanoate (8.35): The title compound was prepared according to general procedure 
8.5.2.7 using 8.30 (0.5 mmol, 0.22 g), HOBt (0.6 mmol, 81 mg), DIEA (0.6 mmol, 
0.10 ml), EDAC (0.6 mmol, 115 mg) and N-phenylpiperazine (1 mmol, 0.15 ml) in 
DMF (5 ml) and was obtained after flash chromatography (PE/EE 60/40 + 0.1 % NEt3 
v/v) as a colorless oil (0.17 g, 98 %). 1H-NMR (CDCl3) δ 1.29 (m, 12H, 
NCH2CH2(CH2)6), 1.45 (s, 9H, C(CH3)3), 1.64 (m, 2H, CH2CH2CO), 1.80 (m, 2H, 
NCH2CH2), 1.99 (m, 2H, CH2CH2CO2), 2.29 (t, 2H, 3J = 7.5 Hz, CH2CO2), 2.36 (t, 2H, 
3J = 7.7 Hz, CH2CON), 2.78 (t, 2H, 3J = 7.4 Hz, CH2(CH2)2CO2), 3.16 (m, 4H, 
piperazine-H), 3.63 (m, 2H, piperazine-H), 3.78 (m, 2H, piperazine-H), 4.05 (t, 2H, 3J 
= 7.1 Hz, NCH2), 6.89 (s, 1H, H-2), 6.93 (m, 4H, Ar-H), 7.08 (ddd, 1H, 4J = 0.9 Hz, 3J 
= 7.1 Hz, 3J = 7.8 Hz, indole-H), 7.19 (ddd, 1H, 4J = 1.1 Hz, 3J = 7.0 Hz, 3J = 8.2 Hz, 
indole-H), 7.29 (m, 2H, Ar-H), 7.60 (m, 1H, indole-H). ES-MS (EtOAc/MeOH + 
NH4OAc) m/z (%): 589 (100) [M+H]+. C37H53N3O3 (587.84). 
tert-Butyl 4-{11-[3-(4-tert-butoxy-4-oxobutyl)-1H-indol-1-yl]undecanoyl}-
piperazine-1-carboxylate (8.36): The title compound was prepared according to 
general procedure 8.5.2.7 using 8.30 (0.5 mmol, 0.22 g), HOBt (0.6 mmol, 81 mg), 
DIEA (0.6 mmol, 0.10 ml), EDAC (0.6 mmol, 115 mg) and N-boc-piperazine (1 mmol, 
0.19 g) in DMF (5 ml) and was obtained after flash chromatography (PE/EE 60/40 + 
0.1 % NEt3 v/v) as a colorless oil (0.26 g, 85 %). 1H-NMR (CDCl3) δ 1.27 (m, 12H, 
NCH2CH2(CH2)6), 1.45 (s, 9H, C(CH3)3), 1.47 (s, 9H, C(CH3)3), 1.61 (m, 2H, 
CH2CH2CO), 1.79 (m, 2H, NCH2CH2), 1.98 (m, 2H, CH2CH2CO2), 2.30 (m, 4H, 
CH2CO2, CH2CON), 2.77 (t, 2H, 3J = 7.4 Hz, CH2(CH2)2CO2), 3.43 (m, 6H, 
piperazine-H), 3.58 (m, 2H, piperazine-H), 4.04 (t, 2H, 3J = 7.1 Hz, NCH2), 6.88 (s, 
1H, H-2), 7.08 (ddd, 1H, 2J = 1.0 Hz, 3J = 7.0 Hz, 3J = 7.9 Hz, indole-H), 7.18 (ddd, 
1H, 2J = 1.0 Hz, 3J = 6.9 Hz, 3J = 8.1 Hz, indole-H), 7.29 (m, 1H, indole-H), 7.59 (m, 
1H, indole-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 613 (100) [M+H]+. 
C36H57N3O5 (611.85). 
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tert-Butyl 1-[11-(3-hydroxyphenylamino)-11-oxoundecan-1-yl]-1H-indole-3-
butanoate (8.37): The title compound was prepared according to general procedure 
8.5.2.7 using 8.30 (0.5 mmol, 0.22 g), HOBt (0.6 mmol, 81 mg), DIEA (0.6 mmol, 
0.10 ml), EDAC (0.6 mmol, 115 mg) and 3-hydroxyphenol (1 mmol, 0.11 g) in DMF (5 
ml) and was obtained after flash chromatography (PE/EE 60/40 + 0.1 % NEt3 v/v) as 
a colorless oil (0.22 g, 82 %). 1H-NMR (CDCl3) δ 1.29 (m, 12H, NCH2CH2(CH2)6), 
1.45 (s, 9H, C(CH3)3), 1.72 (m, 4H, CH2CH2CO, NCH2CH2), 1.98 (m, 2H, 
CH2CH2CO2), 2.29 (t, 2H, 3J = 7.5 Hz, CH2CO), 2.36 (t, 2H, 3J = 7.6 Hz, CH2CO), 
2.77 (t, 2H, 3J = 7.4 Hz, CH2(CH2)2CO2), 4.03 (t, 2H, 3J = 7.1 Hz, NCH2), 6.53 (dd, 
1H, 4J = 0.9 Hz, 3J = 7.9 Hz, Ph-H), 6.64 (dd, 1H, 4J = 1.9 Hz, 3J = 8.1 Hz, Ph-H), 
6.87 (s, 1H, H-2), 7.13 (m, 3H, indole-H, Ph-H), 7.29 (d, 1H, 3J = 8.2 Hz, indole-H), 
7.38 (s, 1H, Ph-H), 7.58 (d, 1H, 3J = 7.8 Hz, indole-H), 7.93 (t, 1H, 3J = 2.0 Hz, 
CONH), 8.19 (bs, 1H, OH). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 552 (100) 
[M+NH4]+. C33H46N2O4 (534.73).  
8.5.2.8 General procedure for the synthesis of esters 8.38 and 8.41 
To a solution of the corresponding carboxylic acid (1eq), the pertinent alcohol (1eq) 
and DMAP (1.2 eq) in anhydrous DMF was added EDAC (1.1 eq) portionwise under 
an atmosphere of argon at 0 °C. The mixture was stirred overnight at room 
temperature and the solvent was removed under reduced pressure. The remaining 
raw product was taken up in water and extracted tree times with EtOAc. The 
combined organic layers were washed with 1 N HCl and brine, dried over MgSO4, 
filtered, and the solvent was removed under reduced pressure. The product was 
obtained after flash chromatography. 
(S)-2-[(R)-3,4-Bis(benzyloxy)-2-oxo-2,5-dihydrofuran-5-yl]-2-hydroxyethyl 11-[3-
(4-tert-butoxy-4-oxobutyl)-1H-indol-1-yl]undecanoate (8.38): The title compound 
was prepared according to general procedure 8.5.2.8 using 8.30 (0.5 mmol, 0.22 g), 
7.66 (0.5 mmol, 0.18 g), DMAP (0.6 mmol, 73 mg) and EDAC (0.55 mmol, 105 mg) in 
anhydrous DMF (5 ml) and was obtained after flash chromatography (PE/EE 90/10 
v/v) as a pale yellow oil (0.13 g, 33 %). 1H-NMR (CDCl3) δ 1.26 (m, 12H, 
NCH2CH2(CH2)6), 1.45 (s, 9H, C(CH3)3), 1.60 (m, 2H, CH2CH2CO), 1.80 (m, 2H, 
NCH2CH2), 1.98 (m, 2H, CH2CH2CO2), 2.30 (m, 4H, CH2CO2, CH2CO2), 2.78 (t, 2H, 
3J = 7.4 Hz, CH2(CH2)2CO2), 4.05 (m, 3H, NCH2, CHOH), 4.19 (dd, 1H, 3J = 5.0 Hz, 
2J = 11.6 Hz, CH2O), 4.32 (dd, 1H, 3J = 6.8 Hz, 2J = 11.6 Hz, CH2O), 4.67 (d, 1H, 3J = 
2.0 Hz, ascorbic acid H-5), 5.11 (s, 2H, CH2Ph), 5.12 (d, 1H, 2J = 10.6 Hz, CH2Ph), 
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5.21 (d, 1H, 2J = 11.7 Hz, CH2Ph), 6.88 (s, 1H, indole H-2), 7.08 (ddd, 1H, 4J = 0.9 
Hz, 3J = 7.0 Hz, 3J = 7.8 Hz, indole-H), 7.16 – 7.40 (m, 12H, indole-H, Ph-H), 7.59 (d, 
1H, 3J = 7.9 Hz, indole-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 800 (100) 
[M+NH4]+. C47H59NO9 (781.97). 
tert-Butyl 1-[16-oxo-16-(4-phenylpiperazin-1-yl)hexadecan-1-yl]-1H-indole-3-
butanoate (8.39): The title compound was prepared according to general procedure 
8.5.2.7 using 8.31 (0.4 mmol, 0.24 g), HOBt (0.48 mmol, 65 mg), DIEA (0.48 mmol,  
82 μl), EDAC (0.48 mmol, 92 mg) and N-phenylpiperazine (0.8 mmol, 0.12 ml) in 
DMF (5 ml) and was obtained after flash chromatography (PE/EE 80/20 + 0.1 % NEt3 
v/v) as a colorless oil (0.14 g, 53 %). 1H-NMR (CDCl3) δ 1.29 (m, 22H, 
NCH2CH2(CH2)11), 1.45 (s, 9H, C(CH3)3), 1.65 (m, 2H, CH2CH2CO), 1.80 (m, 2H, 
NCH2CH2), 1.99 (m, 2H, CH2CH2CO2), 2.29 (t, 2H, 3J = 7.4 Hz, CH2CO2), 2.36 (t, 2H, 
3J = 7.7 Hz, CH2CON), 2.78 (t, 2H, 3J = 7.4 Hz, CH2(CH2)2CO2), 3.16 (m, 4H, 
piperazine-H), 3.63 (m, 2H, piperazine-H), 3.78 (m, 2H, piperazine-H), 4.05 (t, 2H, 3J 
= 7.2 Hz, NCH2), 6.89 (s, 1H, H-2), 6.93 (m, 4H, Ar-H), 7.08 (ddd, 1H, 2J = 1.0 Hz, 3J 
= 7.0 Hz, 3J = 7.9 Hz, indole-H), 7.19 (ddd, 1H, 2J = 1.1 Hz, 3J = 7.0 Hz, 3J = 8.2 Hz, 
indole-H), 7.30 (m, 2H, Ar-H), 7.59 (m, 1H, indole-H). ES-MS (DCM/MeOH + 
NH4OAc) m/z (%): 658 (100) [M+H]+. C42H63N3O3 (657.97). 
tert-Butyl 1-[16-(3-hydroxyphenylamino)-16-oxo(hexadecan-1yl)]-1H-indole-3-
butanoate (8.40): The title compound was prepared according to general procedure 
8.5.2.7 using 8.31 (0.4 mmol, 0.24 g), HOBt (0.48 mmol, 65 mg), DIEA (0.48 mmol,  
82 μl), EDAC (0.48 mmol, 92 mg) and 3-aminophenol (0.8 mmol, 87 mg) in DMF (5 
ml) and was obtained after flash chromatography (PE/EE 80/20 v/v) as a white 
semisolid substance (0.21 g, 87 %). 1H-NMR (CDCl3) δ 1.26 (m, 22H, 
NCH2CH2(CH2)11), 1.45 (s, 9H, C(CH3)3), 1.74 (m, 4H, CH2CH2CO, NCH2CH2), 1.98 
(m, 2H, CH2CH2CO2), 2.29 (t, 2H, 3J = 7.5 Hz, CH2CO2), 2.37 (t, 2H, 3J = 7.6 Hz, 
CH2CON), 2.77 (t, 2H, 3J = 7.4 Hz, CH2(CH2)2CO2), 4.04 (t, 2H, 3J = 7.2 Hz, NCH2), 
6.55 (m, 1H, Ar-H), 6.64 (m, 1H, Ar-H), 6.88 (s, 1H, H-2), 7.05 – 7.31 (m, 4H, indole-
H, Ar-H), 7.59 (m, 1H, indole-H), 7.88 (m, 1H, Ar-H). ES-MS (DCM/MeOH + 
NH4OAc) m/z (%): 604 (100) [M-H]-. Anal. (C38H56N2O4·0.4H2O) C, H, N. C38H56N2O4 
(604.86). 
(S)-2-[(R)-3,4-Bis(benzyloxy)-2-oxo-2,5-dihydrofuran-5-yl]-2-hydroxyethyl 16-[3-
(4-tert-butoxy-4-oxobutyl)-1H-indol-1-yl]hexadecanoate (8.41): The title 
compound was prepared according to general procedure 8.5.2.8 using 8.31 (0.5 
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mmol, 0.22 g), 7.66 (0.5 mmol, 0.18 g), DMAP (0.6 mmol, 73 mg) and EDAC (0.55 
mmol, 105 mg) in anhydrous DMF (5 ml) and was obtained after flash 
chromatography (PE/EE 90/10 v/v) as a pale yellow oil (90 mg, 21 %). 1H-NMR 
(CDCl3) δ 1.26 (m, 22H, NCH2CH2(CH2)11), 1.45 (s, 9H, C(CH3)3), 1.61 (m, 2H 
CH2CH2CO), 1.80 (m, 2H, NCH2CH2), 1.98 (m, 2H, CH2CH2CO2), 2.31 (m, 4H, 
CH2CO2, CH2CO2), 2.78 (t, 2H, 3J = 7.4 Hz, CH2(CH2)2CO2), 4.05 (m, 3H, NCH2, 
CHOH), 4.19 (dd, 1H, 3J = 5.0 Hz, 2J = 11.6 Hz, CH2O), 4.32 (dd, 1H, 3J = 6.8 Hz, 2J 
= 11.6 Hz, CH2O), 4.67 (d, 1H, 3J = 2.1 Hz, ascorbic acid H-5), 5.11 (s, 2H, CH2Ph), 
5.13 (d, 1H, 2J = 10.7 Hz, CH2Ph), 5.21 (d, 1H, 2J = 11.7 Hz, CH2Ph), 6.89 (s, 1H, 
indole H-2), 7.08 (ddd, 1H, 3J = 1.0 Hz, 3J = 7.0 Hz, 3J = 7.9 Hz, indole-H), 7.16 – 
7.40 (m, 12H, indole-H, Ph-H), 7.59 (m, 1H, indole-H). C52H69NO9 (852.11). 
1-[11-Oxo-11-(thiazol-2-ylamino)undecan-1yl]-1H-indole-3-butanoic acid (8.42): 
The title compound was prepared according to general procedure 8.5.2.6 using 8.34 
(0.36 mmol, 0.19 g) in 4 ml of CH2Cl2/TFA (80/20 v/v) and was obtained as a 
colorless oil (0.17 g, 100 %). 1H-NMR (DMSO-d6) δ 1.21 (m, 12H, NCH2CH2(CH2)6), 
1.50 – 1.90 (m, 6H, NCH2CH2, CH2CH2CON, CH2CH2CO2H), 2.25 (t, 2H, 3J = 7.4 Hz, 
CH2CO2H), 2.40 (t, 2H, 3J = 7.4 Hz, CH2CONH), 2.68 (t, 2H, 3J = 7.4 Hz, 
CH2(CH2)2CO2H), 4.08 (t, 2H, 3J = 6.9 Hz, NCH2), 6.95 – 7.28 (m, 4H, indole-H, 
thiazole-H), 7.38 (d, 1H, 3J = 8.2 Hz, indole-H), 7.44 (d, 1H, 3J = 3.6 Hz, thiazole-H), 
7.50 (m, 1H, indole-H), 12.01 (bs, 2H, CO2H, CONH). ES-MS (MeOH + NH4OAc) m/z 
(%): 470 (100) [M+H]+. C26H35N3O3S (469.64). 
1-[11-Oxo-11-(4-phenylpiperazin-1-yl)undecan-1yl]-1H-indole-3-butanoic acid 
ammonium salt (8.43): The title compound was prepared according to general 
procedure 8.5.2.6 using 8.35 (0.29 mmol, 0.17 g) in 4 ml of CH2Cl2/TFA (80/20 v/v) 
and was obtained after flash chromatography (CHCl3/MeOH 80/20 + NH3 v/v) as a 
colorless oil (0.12 g, 75 %). 1H-NMR (CD3OD) δ 1.28 (m, 12H, NCH2CH2(CH2)6), 1.57 
(m, 2H, CH2CH2CO), 1.76 (m, 2H, NCH2CH2), 1.97 (m, 2H, CH2CH2CO2H), 2.32 (t, 
2H, 3J = 7.4 Hz, CH2CO2H), 2.39 (t, 2H, 3J = 7.6 Hz, CH2CON), 2.77 (t, 2H, 3J = 7.4 
Hz, CH2(CH2)2CO2H), 3.10 (m, 4H, piperazine-H), 3.67 (m, 4H, piperazine-H), 4.07 (t, 
2H, 3J = 6.9 Hz, NCH2), 6.85 (m, 1H, indole-H), 6.97 (m, 4H, Ar-H), 7.11 (ddd, 1H, 2J 
= 1.0 Hz, 3J = 7.0 Hz, 3J = 8.2 Hz, indole-H), 7.25 (m, 3H, Ar-H), 7.52 (m, 1H, indole-
H). 13C-NMR (CD3OD) δ 25.53 (-, CH2), 26.66 (-, CH2), 27.11 (-, CH2), 27.99 (-, CH2), 
30.33 (-, CH2), 30.43 (-, CH2), 30.48 (-, CH2), 30.56 (-, CH2), 31.42 (-, CH2), 34.09 (-, 
CH2), 34.80 (-, CH2), 42.87 (-, piperazine-C), 46.88 (-, NCH2), 46.98 (-, piperazine-C), 
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50.73 (-, piperazine-C), 51.25 (-, piperazine-C), 110.44 (+, indole-C), 115.13 (quat, C-
3), 117.98 (+, Ph-C), 119.46 (+, indole-C), 119.87 (+, indole-C), 121.63 (+, Ph-C), 
122.27 (+, indole-C), 126.67 (+, indole-C), 129.42 (quat, C-9), 130.20 (+, Ph-C), 
138.00 (quat, C-8), 152.59 (quat, Ph-C), 174.27 (quat, CH2CON), 177.97 (quat, 
CO2H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 532 (100) [M+H]+. C33H48N4O3 
(548.76).  
1-[11-Oxo-11-(piperazin-1-yl)undecan-1-yl]-1H-indole-3-butanoic acid 
ammonium salt (8.44): The title compound was prepared according to general 
procedure 8.5.2.6 using 8.36 (0.40 mmol, 0.24 g) in 4 ml of CH2Cl2/TFA (80/20 v/v) 
and was obtained after flash chromatography (CHCl3/MeOH 80/20 + NH3 v/v) as a 
pale yellow oil (0.20 g, 95 %). 1H-NMR (CD3OD) δ 1.27 (m, 12H, NCH2CH2(CH2)6), 
1.55 (m, 2H, CH2CH2CO), 1.78 (m, 2H, NCH2CH2), 1.97 (m, 2H, CH2CH2CO2H), 2.30 
(t, 2H, 3J = 7.5 Hz, CH2CO2H), 2.38 (t, 2H, 3J = 7.5 Hz, CH2CON), 2.77 (t, 2H, 3J = 
7.4 Hz, CH2(CH2)2CO2H), 3.12 (m, 4H, piperazine-H), 3.73 (m, 4H, piperazine-H), 
4.09 (t, 2H, 3J = 6.9 Hz, NCH2), 6.98 (m, 2H, indole-H), 7.10 (ddd, 1H, 2J = 1.0 Hz, 3J 
= 6.9 Hz, 3J = 8.2 Hz, indole-H), 7.30 (m, 1H, indole-H), 7.52 (m, 1H, indole-H). 13C-
NMR (CD3OD) δ 25.68 (-, CH2), 26.27 (-, CH2), 27.61 (-, CH2), 27.91 (-, CH2), 30.26 
(-, CH2), 30.30 (-, CH2), 30.41 (-, CH2), 30.48 (-, CH2), 31.36 (-, CH2), 33.69 (-, CH2), 
36.17 (-, CH2), 40.11 (-, piperazine-C), 44.26 (-, piperazine-C), 44.68 (-, piperazine-
C), 44.89 (-, piperazine-C), 46.82 (-, NCH2), 110.38 (+, indole-C), 115.33 (quat, C-3), 
119.38 (+, indole-C), 119.86 (+, indole-C), 122.19 (+, indole-C), 126.60 (+, indole-C), 
129.43 (quat, C-9), 137.97 (quat, C-8), 174.37 (quat, CH2CON), 179.70 (quat, 
CO2H). ES-MS (DCM/MeCN + TFA) m/z (%): 456 (100) [M+H]+. Anal. (C27H44N4O3) 
C: 70.87, H: 9.39, N: 6.87, found C: 70.43, H: 8.83, N: 6.36. C27H44N4O3 (472.66). 
1-[11-(3-Hydroxyphenylamino)-11-oxoundecan-1yl]-1H-indole-3-butanoic acid 
(8.45): The title compound was prepared according to general procedure 8.5.2.6 
using 8.37 (0.36 mmol, 0.19 g) in 4 ml of CH2Cl2/TFA (80/20 v/v) and was obtained 
after flash chromatography (CHCl3/MeOH 80/20 + NH3 v/v) as a brown solid (0.14 g, 
81 %). mp: 65-66 °C; 1H-NMR (CD3OD) δ 1.25 (m, 12H, NCH2CH2(CH2)6), 1.64 (m, 
2H, CH2CH2CO), 1.76 (m, 2H, NCH2CH2), 1.97 (m, 2H, CH2CH2CO2H), 2.31 (m, 4H, 
CH2CO2H, CH2CON), 2.77 (t, 2H, 3J = 7.4 Hz, CH2(CH2)2CO2H), 4.07 (t, 2H, 3J = 6.9 
Hz, NCH2),  6.51 (m, 1H, Ar-H), 6.90 – 7.23 (m, 6H, Ar-H), 7.29 (m, 1H, indole-H), 
7.51 (m, 1H, indole-H). 13C-NMR (CD3OD) δ 25.47 (-, CH2), 27.02 (-, CH2), 27.99 (-, 
CH2), 30.34 (-, CH2), 30.43 (-, CH2), 30.59 (-, CH2), 31.43 (-, CH2), 30.48 (-, CH2), 
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34.56 (-, CH2), 38.13 (-, CH2), 46.87 (-, NCH2), 108.46 (+, Ph-C), 110.43 (+, indole-
C), 112.13 (+, Ph-C), 112.39 (+, Ph-C), 115.06 (quat, C-3), 119.45 (+, indole-C), 
119.84 (+, indole-C), 122.26 (+, indole-C), 126.67 (+, indole-C), 129.39 (quat, C-9), 
130.53 (+, Ph-C), 138.00 (quat, C-8), 141.06 (quat, Ph-C), 158.94 (quat, Ph-C), 
174.77 (quat, CH2CON), 177.80 (quat, CO2H). ES-MS (DCM/MeOH + NH4OAc) m/z 
(%): 496 (100) [M+NH4]+. C29H38N2O4 (478.62). 
1-{11-[(S)-2-((R)-3,4-Dihydroxy-2-oxo-2,5-dihydrofuran-5-yl)-2-hydroxyethoxy]-
11-oxoundecan-1-yl}-1H-indole-3-butanoic acid (8.46): The title compound was 
prepared from 8.38 (0.15 mmol, 0.12 g) by removing the tert-butyl moiety according 
to general method 8.5.2.6 in 4 ml of CH2Cl2/TFA (80/20 v/v) and subsequent 
hydrogenolysis according to general procedure 8.5.2.5 using 10 % Pd/C (20 mg) in 
EtOH (2 ml) and EtOAc (2 ml) to yield 8.46 as a pale yellow semisolid substance (60 
mg, 73 %). 1H-NMR (acetone-d6) δ 1.29 (m, 12H, NCH2CH2(CH2)6), 1.58 (m, 2H, 
CH2CH2CO), 1.79 (m, 2H, NCH2CH2), 1.98 (m, 2H, CH2CH2CO2H), 2.35 (m, 4H, 
CH2CO2, CH2CO2H), 2.80 (t, 2H, 3J = 7.5 Hz, CH2(CH2)2CO2H), 4.22 (m, 5H, NCH2, 
CHOH, CH2O), 4.78 (d, 1H, 3J = 1.5 Hz, ascorbic acid H-5), 7.00 (ddd, 1H, 2J = 0.8 
Hz, 3J = 7.1 Hz, 3J = 7.9 Hz, indole-H), 7.12 (m, 2H, indole-H), 7.38 (m, 1H, indole-
H), 7.57 (m, 1H, indole-H). 13C-NMR (acetone-d6) δ 25.13 (-, CH2), 25.64 (-, CH2), 
26.22 (-, CH2), 26.59 (-, CH2), 27.64 (-, CH2), 29.77 (-, CH2), 29.98 (-, CH2), 30.22 (-, 
CH2), 31.12 (-, CH2), 33.87 (-, CH2), 34.52 (-, CH2), 46.52 (-, CH2), 65.42 (-, CH2), 
67.66 (+, CHOH), 68.12 (-, CH2), 76.14 (+, CH), 110.35 (+, indole-C), 114.77 (quat, 
indole C-3), 119.16 (+, indole-C), 119.68 (+, indole-C), 120.10 (quat, ascorbic acid C-
3), 121.94 (+, indole-C), 126.50 (+, indole-C), 129.02 (quat, indole C-9), 137.51 
(quat, indole C-8), 151.05 (quat, ascorbic acid C-4), 170.39 (quat, lactone CO), 
173.64 (quat, CO2CH2), 174.79 (quat, CO2H). ES-MS (MeCN + TFA) m/z (%): 546 
(100) [M+H]+. C29H39NO9 (545.62). 
1-[16-Oxo-16-(4-phenylpiperazin-1-yl)hexadecan-1-yl)]-1H-indole-3-butanoic 
acid trifluoroacetic acid salt (8.47): The title compound was prepared according to 
general procedure 8.5.2.6 using 8.39 (0.20 mmol, 0.13 g) in 4 ml of CH2Cl2/TFA 
(80/20 v/v) and was obtained after flash chromatography (CHCl3/MeOH 80/20 + NH3 
v/v) as a yellow oil (0.14 g, quantitative). 1H-NMR (CD3OD) δ 1.29 (m, 1H, 
NCH2CH2(CH2)11), 1.61 (m, 2H, CH2CH2CO), 1.77 (m, 2H, NCH2CH2), 1.97 (m, 2H, 
CH2CH2CO2H), 2.32 (t, 2H, 3J = 7.4 Hz, CH2CO2H), 2.44 (t, 2H, 3J = 7.6 Hz, 
CH2CON), 2.77 (t, 2H, 3J = 7.4 Hz, CH2(CH2)2CO2H), 3.41 (m, 4H, piperazine-H), 
Chapter 8 Indolylalkanoic acids: potent inhibitors of human PH-20 and SagHyal4755 
253 
3.85 (m, 4H, piperazine-H), 4.08 (t, 2H, 3J = 6.9 Hz, NCH2), 6.99 (m, 2H, H-2, Ar-H), 
7.11 (m, 1H, indole-H), 7.22 (m, 1H, indole-H), 7.31 (m, 3H, Ar-H), 7.46 (m, 3H, Ar-
H). 13C-NMR (CD3OD) δ 25.46 (-, CH2), 26.44 (-, CH2), 26.99 (-, CH2), 27.95 (-, CH2), 
30.31 (-, CH2), 30.46 (-, CH2), 30.57 (-, CH2), 30.61 (-, CH2), 30.75 (-, CH2), 31.40 (-, 
CH2), 33.89 (-, CH2), 34.55 (-, CH2), 41.59 (-, piperazine-C), 45.63 (-, piperazine-C), 
46.85 (-, NCH2), 53.35 (-, piperazine-C), 53.66 (-, piperazine-C), 110.41 (+, indole-C), 
115.08 (quat, C-3), 119.45 (+, indole-C), 119.84 (+, indole-C), 119.98 (+, Ph-C), 
122.25 (+, indole-C), 126.44 (+, Ph-C), 126.64 (+, indole-C), 129.39 (quat, C-9), 
130.99 (+, Ph-C), 137.98 (quat, C-8), 147.95 (quat, Ph-C), 174.27 (quat, CH2CON), 
177.72 (quat, CO2H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 602 (100) [M+H]+. 
C40H56F3N3O5 (715.88). 
1-[16-(3-Hydroxyphenylamino)-16-oxohexadecan-1-yl]-1H-indole-3-butanoic 
acid (8.48): The title compound was prepared according to general procedure 
8.5.2.6 using 8.40 (0.31 mmol, 0.19 g) in 4 ml of CH2Cl2/TFA (80/20 v/v) and was 
obtained after flash chromatography (CHCl3/MeOH 80/20 + NH3 v/v) as a white 
semisolid (0.17 g, quantitative). 1H-NMR (CD3OD) δ 1.29 (m, 22H, NCH2CH2(CH2)11), 
1.72 (m, 4H, CH2CH2CO, NCH2CH2), 1.97 (m, 2H, CH2CH2CO2H), 2.32 (m, 4H, 
CH2CO2H, CH2CON), 2.77 (t, 2H, 3J = 7.4 Hz, CH2(CH2)2CO2H), 4.07 (t, 2H, 3J = 6.9 
Hz, NCH2), 6.51 (m, 1H, Ar-H), 7.11 (m, 7H), 7.51 (d, 1H, 3J = 7.6 Hz, Ar-H). 13C-
NMR (CD3OD) δ 24.36 (-, CH2), 25.92 (-, CH2), 26.88 (-, CH2), 29.29 (-, CH2), 29.42 
(-, CH2), 29.56 (-, CH2), 29.66 (-, CH2), 30.32 (-, CH2), 33.45 (-, CH2), 37.02 (-, CH2), 
45.76 (-, NCH2), 107.36 (+, Ph-C), 109.31 (+, indole-C), 111.02 (+, Ph-C), 111.29 (+, 
Ph-C), 113.96 (quat, C-3), 118.34 (+, indole-C), 118.73 (+, indole-C), 121.15 (+, 
indole-C), 125.27 (+, indole-C), 125.53 (quat, C-9), 129.41 (+, Ph-C), 136.89 (quat, 
C-8), 139.95 (quat, Ph-C), 157.84 (quat, Ph-C), 173.65 (quat, CH2CON), 176.67 
(quat, CO2H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 549 (100) [M+H]+. 
C34H48N2O4 (548.76). 
1-{16-[(S)-2-((R)-3,4-Dihydroxy-2-oxo-2,5-dihydrofuran-5-yl)-2-hydroxyethoxy]-
16-oxohexadecan-1-yl}-1H-indole-3-butanoic acid (8.49): The title compound was 
prepared from 8.41 (0.09 mmol, 80 mg) by removing the tert-butyl moiety according 
to general method 8.5.2.6 in 4 ml of CH2Cl2/TFA (80/20 v/v) and subsequent 
hydrogenolysis according to general procedure 8.5.2.5 using 10 % Pd/C (20 mg) in 
EtOH (2 ml) and EtOAc (2 ml) to yield 8.49 as a pale yellow semisolid substance (50 
mg, 86 %). 1H-NMR (CD3OD+CDCl3) δ 1.28 (m, 22H, NCH2CH2(CH2)6), 1.61 (m, 2H, 
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CH2CH2CO), 1.78 (m, 2H, NCH2CH2), 1.98 (m, 2H, CH2CH2CO2H), 2.31 (m, 4H, 
CH2CO2, CH2CO2H), 2.77 (t, 2H, 3J = 7.3 Hz, CH2(CH2)2CO2H), 4.03 – 4.29 (m, 5H, 
NCH2, CHOH, CH2O), 4.68 (d, 1H, 3J = 2.1 Hz, ascorbic acid H-5), 6.97 (m, 2H, 
indole-H), 7.12 (ddd, 1H, 4J = 1.1 Hz, 3J = 5.0 Hz, 3J = 8.3 Hz, indole-H), 7.29 (m, 1H, 
indole-H), 7.52 (m, 1H, indole-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 614 
(100) [M-H]-. C34H49NO9 (615.75).  
4-Benzyloxybenzenediazonium tetrafluoroborate35 (8.50): To a suspension of 4-
benzyloxyaniline hydrochloride (33.0 mmol, 7.78) in water (24 ml) and concentrated 
HCl (24 ml) was added dropwise a solution of sodium nitrite (34.65 mmol, 2.39 g) in 
water (10 ml) at 0 °C. After stirring for 10 min a solution of NaBF4 (33 mmol, 3.62 g) 
in water (8 ml) was added and the cooling bath was removed. Stirring was continued 
for additional 20 min at room temperature. The resulting grey solid was isolated by 
filtration and washed tree times with water, methanol and ether. After drying under 
reduced pressure the title compound was obtained as a pale grey solid which was 
used without further purification in the next step (7.90 g, 80 %). mp: 136 °C (ref.35: 
137 °C); C13H11BF4N2O (298.04). 
Ethyl 1-(4-benzyloxyphenyldiazenyl)-2-oxocyclohexanecarboxylate (8.51): To a 
suspension of NaH (60 % suspension in mineral oil, 20.8 mmol, 0.83g) in anhydrous 
THF (25 ml) was added dropwise a solution of  ethyl 2-oxocyclohexanecarboxylate 
(18.3 mmol, 2.91 ml) and the mixture was refluxed for 30 min. After cooling to -5 °C, 
8.50 (18.0 mmol, 5.36) was added in portions and the resulting dark red solution was 
stirred for 1 h at room temperature. The mixture was then poured into water (200 ml) 
and extracted with ether (3 x 100 ml). The combined organic layers were washed 
with water (100 ml) dried over MgSO4, filtered and evaporated to afford the title 
compound as dark red oil which was used without further purification in the next step 
(6.5 g, 95 %). C22H24N2O4 (380.44). 
Ethyl 5-benzyloxy-2-ethoxycarbonyl-1H-indole-3-butanoate (8.52): A solution of 
8.51 (21.6 mmol, 8.2 g) and concentrated H2SO4 (2 ml) in anhydrous EtOH (50 ml) 
was refluxed overnight. After cooling the solution was diluted with water (250 ml) and 
extracted tree times with CHCl3. The combined organic phases were washed with 
water, dried over MgSO4, filtered and evaporated to dryness. The raw product was 
subjected to flash chromatography (PE/EtOAc 80/20 v/v) to obtain the title compound 
as pale brown solid (3.8 g, 42 %). 1H-NMR (CDCl3) δ 1.24 (t, 3H, 3J = 7.1 Hz, 
CH2CH3), 1.41 (t, 3H, 3J = 7.1 Hz, CH2CH3), 1.96 (m, 2H, CH2CH2CO2), 2.33 (t, 1H, 
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3J = 7.5 Hz, CH2CO2), 3.06 (t, 2H, 3J = 7.4 Hz, CH2(CH2)2CO2), 4.11 (q, 2H, 3J = 7.1 
Hz, CH2CH3), 4.38 (q, 2H, 3J = 7.1 Hz, CH2CH3), 5.11 (s, 2H, CH2Ph), 7.07 (dd, 1H, 
4J = 2.4 Hz, 3J = 9.0 Hz, H-6), 7.14 (d, 1H, 4J = 2.2 Hz, H-4), 7.22 (d, 1H, 3J = 9.0 Hz, 
H-7), 7.37 (m, 3H, Ph-H), 7.49 (m, 2H, Ph-H), 8.02 (s, 1H, NH). CI-MS (NH3) m/z (%): 
427 (53) [M+NH4]+. Anal. (C24H27NO5·0.75H2O) C, H, N. C24H27NO5 (409.47). 
5-Benzyloxy-2-carboxy-1H-indole-3-butanoic acid36 (8.53): A solution of 8.52 
(13.1 mmol, 5.37 g) and KOH (39.3 mmol, 2.21 g) in ethanol (50 ml) was refluxed for 
30 min. After cooling, the diacid which precipitated was isolated by filtration and 
resuspended in 2 N HCl (30 ml). The mixture was stirred for 2 h, solids were isolated 
by filtration, washed with water and dried under reduced pressure to obtain the title 
compound as a pale brown solid (2.3 g, 49 %). mp: 185-187 °C (ref.36: 185 °C); 1H-
NMR (DMSO-d6) δ 1.83 (m, 2H, CH2CH2CO2H), 2.22 (t, 2H, 3J = 7.4 Hz, CH2CO2H), 
3.04 (t, 2H, 3J = 7.1 Hz, CH2(CH2)2CO2H), 5.11 (s, 2H, CH2Ph), 6.97 (dd, 1H, 4J = 2.3 
Hz, 3J = 8.9 Hz, H-6), 7.23 (d, 1H, 3J = 2.0 Hz, H-4), 7.35 (m, 4H, H-7, Ph-H), 7.50 
(m, 2H, Ph-H), 11.28 (s, 1H, NH), 12.45 (s, 2H, CO2H). 13C-NMR (DMSO-d6) δ 23.25 
(-, CH2), 33.24 (-, CH2), 25.80 (-, CH2CO2H), 69.62 (-, CH2Ph), 102.07 (+, C-4), 
113.21 (+, indole-C), 116.24 (+, indole-C), 121.33 (quat, C-3), 124.54 (quat, C-2), 
127.52 (quat, indole-C), 127.62 (+, Ph-C), 127.78 (+, Ph-C), 128.26 (+, Ph-C), 131.39 
(quat, indole-C), 137.40 (quat, Ph-C), 152.30 (quat, C-5), 163.26 (quat, CO2H), 
174.49 (quat, CO2H). ES-MS (MeOH + NH4OAc) m/z (%): 371 (100) [M+NH4]+. Anal. 
(C20H19NO5·0.2H2O) C, H, N. C20H19NO5 (353.37). 
5-Benzyloxy-1H-indole-3-butanoic acid36 (8.54): 8.53 (2.83 mmol, 1.00 g) was 
heated for 2 h at 200-230 °C. After cooling, the raw product was subjected to flash 
chromatography (CHCl3/MeOH 98/2 v/v) to obtain the title compound as brown solid 
(0,79 g, 90 %). mp: 100 °C (ref.36: 86-95 °C); 1H-NMR (DMSO-d6) δ 1.85 (m, 2H, 
CH2CH2CO2H), 2.27 (t, 2H, 3J = 7.3 Hz, CH2CO2H), 2.66 (t, 2H, 3J = 7.4 Hz, 
CH2(CH2)2CO2H), 5.09 (s, 2H, CH2Ph), 6.79 (dd, 1H, 4J = 2.4 Hz, 3J = 8.7 Hz, H-6), 
7.07 (d, 1H, 4J = 2.1 Hz, H-4), 7.11 (d, 1H, 3J = 2.3 Hz, H-2), 7.32 (m, 4H, H-7, Ph-H), 
7.48 (m, 2H, Ph-H), 10.63 (d, 1H, 3J = 1.5 Hz, NH), 12.04 (s, 1H, CO2H). 13C-NMR 
(DMSO-d6) δ 24.01 (-, CH2CH2CO2H), 25.23 (-, CH2(CH2)2CO2H), 33.33 (-, 
CH2CO2H), 69.75 (-, CH2Ph), 101.76 (+, C-4), 111.49 (+, indole-C), 111.87 (+, indole-
C), 113.62 (quat, C-3), 123.01 (+, C-2), 127.37 (quat, indole-C), 127.50 (+, Ph-C), 
127.61 (+, Ph-C), 128.23 (+, Ph-C), 131.53 (quat, indole-C), 137.76 (quat, Ph-C), 
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151.80 (quat, C-5), 174.48 (quat, CO2H). CI-MS (NH3) m/z (%): 327 (100) [M+NH4]+. 
C19H19NO3 (309.36). 
5-Hydroxy-1H-indole-3-butanoic acid (8.55): The title compound was prepared 
according to general procedure 8.5.2.5 using 8.54 (0.32 mmol, 0.10 g) and 10 % 
Pd/C (50 mg) in EtOH (5 ml) and was obtained as a pale brown solid (0.23 g, 96 %). 
mp: 143 °C; 1H-NMR (CD3OD) δ 1.96 (m, 2H, CH2CH2CO2H), 2.33 (t, 2H, 3J = 7.4 
Hz, CH2CO2H), 2.71 (t, 2H, 3J = 7.4 Hz, CH2(CH2)2CO2H), 6.65 (dd, 1H, 4J = 2.3 Hz, 
3J = 8.6 Hz, H-6), 6.90 (d, 1H, 3J = 2.3 Hz, H-4), 6.95 (s, 1H, H-2), 7.14 (d, 1H, 3J = 
8.5 Hz, H-7). EI-MS (70 eV) m/z (%): 219 (29) [M+·]. C12H13NO3 (219.24). 
Ethyl 3-(4-ethoxy-4-oxobutyl)-5-hydroxy-1H-indole-2-carboxylate37 (8.56): The 
title compound was prepared according to general procedure 8.5.2.5 using 8.52 (1.0 
mmol, 0.41 g) and 10 % Pd/C (50 mg) in EtOH (10 ml) and was obtained as a pale 
yellow solid (0.30 g, 95 %). mp: 125-127 °C; 1H-NMR (DMSO-d6) δ 1.15 (t, 3H, 3J = 
7.1Hz, CH2CH3), 1.33 (t, 3H, 3J = 7.1 Hz, CH2CH3), 1.83 (m, 2H, CH2CH2CO2), 2.27 
(t, 2H, 3J = 7.4 Hz, CH2CO2), 2.97 (t, 2H, 3J = 7.3 Hz, CH2(CH2)2CO2), 4.02 (q, 2H, 3J 
= 7.1 Hz, CH2CH3), 4.31 (q, 2H, 3J = 7.1 Hz, CH2CH3), 6.81 (dd, 1H, 4J = 2.3 Hz, 3J = 
8.8 Hz, H-6), 6.89 (d, 1H, 4J = 2.2 Hz, H-4), 7.23 (d, 1H, 3J = 8.8 Hz, H-7), 8.92 (s, 
1H, NH),  11.23 (s, 1H, OH). CI-MS (NH3) m/z (%): 320 (100) [M+H]+. C17H21NO5 
(319.35). CD3OD 
8.5.2.9 General procedure for the synthesis of 5-O-alkylated indoles 8.57-8.61 
using Mitsunobu conditions 
To a solution of 8.56 (1 eq) in anhydrous THF was added the pertinent alcohol (1 eq), 
PPh3 (1 eq) and DIAD (1 eq) at 0 °C under an atmosphere of argon. After stirring for 
10 min the cooling bath was removed and stirring was continued at room 
temperature overnight. The mixture was poured into water (20 ml) and extracted 
three times with EtOAc. The combined organic layers were washed with brine, dried 
over MgSO4, filtered and evaporated to dryness. The 5-O-alkylated indoles were then 
obtained after flash chromatography. 
Ethyl 3-(4-ethoxy-4-oxobutyl)-5-(3-phenylpropoxy)-1H-indole-2-carboxylate 
(8.57): The title compound was prepared according to general procedure 8.5.2.9 
from 8.56 (1.0 mmol, 0.32 g), 3-phenylpropan-1-ol (1.0 mmol, 0,14 g), PPh3 (1.0 
mmol, 0.26 g) and DIAD (1.0 mmol, 0.20 ml) in anhydrous THF (10 ml) and was 
obtained after flash chromatography (PE/EtOAc 80/20 v/v) as a pale yellow semisolid 
(0.27 g, 62 %). 1H-NMR (DMSO-d6) δ 1.14 (t, 3H, 3J = 7.1 Hz, CH2CH3), 1.34 (t, 3H, 
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3J = 7.1 Hz, CH2CH3), 1.84 (m, 2H, CH2CH2CO2), 2.03 (m, 2H, OCH2CH2), 2.28 (t, 
2H, 3J = 7.4 Hz, CH2CO2), 2.77 (m, 2H, CH2Ph), 3.02 (t, 2H, 3J = 7.2 Hz, 
CH2(CH2)2CO2),  4.01 (m, 4H, CH2CH3, OCH2), 4.32 (q, 2H, 3J = 7.1 Hz, CH2CH3), 
6.94 (dd, 1H, 4J = 2.3 Hz, 3J = 8.9 Hz, H-6), 7.08 (d, 1H, 3J = 2.1 Hz, H-4), 7.25 (m, 
6H, H-7, Ph-H), 11.38 (s, 1H, NH). CI-MS (NH3) m/z (%): 455 (100) [M+NH4]+. Anal. 
(C26H31NO5·0.4H2O) C, H, N. C26H31NO5 (437.53). 
Ethyl 3-(4-ethoxy-4-oxobutyl)-5-hexyloxy-1H-indole-2-carboxylate (8.58): The 
title compound was prepared according to general procedure 8.5.2.9 from 8.56 (1.0 
mmol, 0.32 g), hexan-1-ol (1.0 mmol, 0,13 ml), PPh3 (1.0 mmol, 0.26 g) and DIAD 
(1.0 mmol, 0.20 ml) in anhydrous THF (10 ml) and was obtained after flash 
chromatography (PE/EtOAc 90/10 to 80/20 v/v) as pale yellow semisolid substance 
(0.21 g, 52 %). 1H-NMR (DMSO-d6) δ 0.88 (t, 3H, 3J = 7.0 Hz, (CH2)5CH3), 1.15 (t, 
3H, 3J = 7.1 Hz, CH2CH3), 1.37 (m, 9H, CH2CH3, (CH2)3CH3), 1.72 (m, 2H, 
OCH2CH2), 1.85 (m, 2H, CH2CH2CO2), 2.29 (t, 2H, 3J = 7.4 Hz, CH2CO2), 3.02 (t, 2H, 
3J = 7.2 Hz, CH2(CH2)2CO2), 3.99 (m, 4H, CH2CH3, OCH2), 4.32 (q, 2H, 3J = 7.1 Hz, 
CH2CH3), 6.91 (dd, 1H, 4J = 2.3 Hz, 3J = 8.9 Hz, H-6), 7.08 (d, 1H, 4J = 2.2 Hz, H-4), 
7.30 (d, 1H, 3J = 8.9 Hz, H-7), 11.36 (s, 1H, NH). CI-MS (NH3) m/z (%): 421 (100) 
[M+NH4]+. Anal. (C23H33NO5) C, H, N. C23H33NO5 (403.51). 
Ethyl 3-(4-ethoxy-4-oxobutyl)-5-(dodecan-1-yl)-oxy-1H-indole-2-carboxylate 
(8.59): The title compound was prepared according to general procedure 8.5.2.9 
from 8.56 (1.0 mmol, 0.32 g), dodecan-1-ol (1.0 mmol, 0,19 g), PPh3 (1.0 mmol, 0.26 
g) and DIAD (1.0 mmol, 0.20 ml) in anhydrous THF (10 ml) and was obtained after 
flash chromatography (PE/EtOAc 90/10 to 80/20 v/v) as a pale yellow solid (0.30 g, 
62 %). 1H-NMR (DMSO-d6) δ 0.84 (t, 6H, 3J = 6.5 Hz, (CH2)11CH3), 1.12 – 1.45 (m, 
24H,  (CH2)9CH3, CH2CH3), 1.71 (m, 2H, OCH2CH2), 1.85 (m, 2H, CH2CH2CO2), 2.29 
(t, 2H, 3J = 7.4 Hz, CH2CO2), 3.02 (t, 2H, 3J = 7.2 Hz, CH2(CH2)2CO2), 3.99 (m, 4H, 
CH2CH3, OCH2), 4.32 (q, 2H, 3J = 7.2 Hz, CH2CH3), 6.90 (dd, 1H, 4J = 2.3 Hz, 3J = 
8.9 Hz, H-6), 7.07 (d, 1H, 4J = 2.1 Hz, H-4), 7.30 (d, 1H, 3J = 8.9 Hz, H-7), 11.36 (s, 
1H, NH). CI-MS (NH3) m/z (%): 505 (100) [M+NH4]+. C29H45NO5 (487.67). 
Ethyl 3-(4-ethoxy-4-oxobutyl)-5-(hexadecan-1-yl)-oxy-1H-indole-2-carboxylate 
(8.60): The title compound was prepared according to general procedure 8.5.2.9 
from 8.56 (1.0 mmol, 0.32 g), hexadecan-1-ol (1.0 mmol, 0,24 g), PPh3 (1.0 mmol, 
0.26 g) and DIAD (1.0 mmol, 0.20 ml) in anhydrous THF (10 ml) and was obtained 
after flash chromatography (PE/EtOAc 95/5 to 80/20 v/v) as a white solid (0.36 g, 64 
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%). mp: 50 °C; 1H-NMR (CDCl3) δ 0.88 (t, 3H, 3J = 6.7 Hz, (CH2)15CH3), 1.21 – 1.60 
(m, 32H, (CH2)13CH3, CH2CH3), 1.81 (m, 2H, OCH2CH2), 2.02 (m, 2H, CH2CH2CO2), 
2.36 (t, 2H, 3J = 7.6 Hz, CH2CO2), 3.12 (t, 2H, 3J = 7.4 Hz, CH2(CH2)2CO2), 4.00 (t, 
2H, 3J = 6.6 Hz, OCH2), 4.10 (q, 2H, 3J = 7.1 Hz, CH2CH3), 4.40 (q, 2H, 3J = 7.1 Hz, 
CH2CH3), 6.99 (dd, 1H, 4J = 2.4 Hz, 3J = 8.8 Hz, H-6), 7.05 (d, 1H, 4J = 2.2 Hz, H-4), 
7.26 (d, 1H, 3J = 8.8 Hz, H-7), 8.66 (s, 1H, NH). CI-MS (NH3) m/z (%): 561 (100) 
[M+NH4]+. C33H53NO5 (543.78). 
Ethyl 3-(4-ethoxy-4-oxobutyl)-5-(octadecan-1-yl)-oxy-1H-indole-2-carboxylate 
(8.61): The title compound was prepared according to general procedure 8.5.2.9 
from 8.56 (1.0 mmol, 0.32 g), octadecan-1-ol (1.0 mmol, 0,27 g), PPh3 (1.0 mmol, 
0.26 g) and DIAD (1.0 mmol, 0.20 ml) in anhydrous THF (10 ml) and was obtained 
after flash chromatography (PE/EtOAc 95/5 to 80/20 v/v) as pale yellow solid (0.35 g, 
61 %). mp: 52 °C; 1H-NMR (CDCl3) δ 0.88 (t, 3H, 3J = 6.7 Hz, (CH2)17CH3), 1.18 – 
1.57 (m, 36H, (CH2)15CH3, CH2CH3), 1.81 (m, 2H, OCH2CH2), 2.02 (m, 2H, 
CH2CH2CO2), 2.36 (t, 2H, 3J = 7.6 Hz, CH2CO2), 3.12 (t, 2H, 3J = 7.4 Hz, 
CH2(CH2)2CO2), 4.00 (t, 2H, 3J = 6.6 Hz, OCH2), 4.11 (q, 2H, 3J = 7.1 Hz, CH2CH3), 
4.40 (q, 2H, 3J = 7.1 Hz, CH2CH3), 6.99 (dd, 1H, 4J = 2.4 Hz, 3J = 8.8 Hz, H-6), 7.04 
(d, 1H, 4J = 2.3 Hz, H-4), 7.26 (d, 1H, 3J = 8.8 Hz, H-7), 8.64 (s, 1H, NH). CI-MS 
(NH3) m/z (%): 589 (100) [M+NH4]+. C35H57NO5 (571.83). 
8.5.2.10 General method for the synthesis of carboxylic acids 8.62-8.66, 8.70-
8.72 and 8.74 via saponification of ethyl ester precursors 
To a solution of the pertinent ethyl ester (1 eq) in THF/MeOH/H2O was added LiOH 
(1.5 eq) and the mixture was stirred at room temperature overnight. After dilution with 
water and acidification with 2 N HCl to pH <2 the mixture was extracted three times 
with EtOAc. The combined organic layers were washed with brine, dried over 
MgSO4, filtered and evaporated to dryness to obtain the pertinent carboxylic acids. 
2-Carboxy-5-(3-phenylpropoxy)-1H-indole-3-butanoic acid (62): The title 
compound was prepared according to general procedure 8.5.2.10 using 8.57 (0.75 
mmol, 0.33 g) and LiOH (2.26 mmol, 54 mg) in THF (5 ml), MeOH (1 ml) and H2O (2 
ml) and was obtained after recrystallization from EtOAc/PE as a white solid (0.20 g, 
70 %). mp: 170-171 °C; 1H-NMR (DMSO-d6) δ 1.81 (m, 2H, CH2CH2CO2H), 2.03 (m, 
2H, OCH2CH2), 2.21 (t, 2H, 3J = 7.4 Hz, CH2CO2H), 2.77 (m, 2H, CH2Ph), 3.01 (t, 2H, 
3J = 7.2 Hz, CH2(CH2)2CO2H), 3.99 (t, 2H, 3J = 6.3 Hz, OCH2), 6.92 (dd, 1H, 4J = 2.3 
Hz, 3J = 8.9 Hz, H-6), 7.09 (d, 1H, 4J = 2.2 Hz, H-4), 7.23 (m, 6H, H-7, Ph-H), 11.27 
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(s, 1H, NH), 12.41 (bs, 1H, CO2H). 13C-NMR (DMSO-d6) δ 23.24 (-, CH2), 25.78 (-, 
CH2), 30.57 (-, CH2), 31.56 (-, CH2), 33.21 (-, CH2), 67.02 (-, OCH2), 101.58 (+, C-4), 
113.19 (+, indole-C), 116.22 (+, indole-C), 121.45 (quat, C-3), 124.23 (quat, C-2), 
125.71 (+, Ph-C), 127.52 (quat, indole-C), 128.24 (+, Ph-C), 128.27 (+, Ph-C), 131.37 
(quat, indole-C), 141.49 (quat, Ph-C), 152.60 (quat, C-5), 163.16 (quat, CO2H), 
174.42 (quat, CO2H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 380 (100) [M-H]-. 
Anal. (C22H23NO5·0.2H2O) C, H, N. C22H23NO5 (381.42). 
2-Carboxy-5-(hexan-1-yloxy)-1H-indole-3-butanoic acid (8.63): The title 
compound was prepared according to general procedure 8.5.2.10 using 8.58 (0.40 
mmol, 0.16 g) and LiOH (1.20 mmol, 29 mg) in THF (5 ml), MeOH (1 ml) and H2O (2 
ml) and was obtained after recrystallization from EtOAc/PE as a white solid (90 mg, 
65 %). mp: 154 °C; 1H-NMR (DMSO-d6) δ 0.88 (t, 3H, 3J = 7.0 Hz, CH2CH3), 1.37 (m, 
6H, (CH2)3CH3), 1.77 (m, 4H, OCH2CH2), 2.21 (t, 2H, 3J = 7.4 Hz, CH2CH2CO2H), 
3.01 (t, 2H, 3J = 7.2 Hz, CH2(CH2)2CO2H), 3.96 (t, 2H, 3J = 6.4 Hz, OCH2), 6.88 (dd, 
2H, 4J = 2.3 Hz, 3J = 8.9 Hz, H-6), 7.08 (d, 1H, 4J = 2.2 Hz, H-4), 7.27 (d, 1H, 3J = 8.9 
Hz, H-7), 11.25 (s, 1H, NH), 12.39 (bs, 2H, CO2H). 13C-NMR (DMSO-d6) δ 13.84 (+, 
CH3), 22.02 (-, CH2), 23.22 (-, CH2), 25.25 (-, CH2), 25.77 (-, CH2), 28.79 (-, CH2), 
31.01 (-, CH2), 33.19 (-, CH2), 67.69 (-, CH2O), 101.36 (+, C-4), 113.15 (+, indole-C), 
116.21 (+, indole-C), 121.45 (quat, C-3), 124.17 (quat, C-2), 127.53 (quat, indole-C), 
131.30 (quat, indole-C), 152.69 (quat, C-5), 163.16 (quat, CO2H), 174.42 (quat, 
CO2H). CI-MS (NH3) m/z (%): 346 (100) [M-H]-. Anal. (C19H25NO5) C, H, N. 
C19H25NO5 (347.41). 
2-Carboxy-5-(dodecan-1-yloxy)-1H-indole-3-butanoic acid (8.64): The title 
compound was prepared according to general procedure 8.5.2.10 using 8.59 (0.45 
mmol, 0.22 g) and LiOH (1.35 mmol, 32 mg) in THF (5 ml), MeOH (0,5 ml) and H2O 
(1 ml) and was obtained after recrystallization from EtOAc/PE as a pale yellow solid 
(130 mg, 67 %). mp: 145 °C; 1H-NMR (DMSO-d6) δ 0.85 (t, 3H, 3J = 6.7 Hz, 
(CH2)11CH3), 1.31 (m, 18H, (CH2)9CH3), 1.71 (m, 2H, OCH2CH2), 1.81 (m, 2H, 
CH2CH2CO2H), 2.21 (t, 2H, 3J = 7.4 Hz, CH2CO2H), 3.01 (t, 2H, 3J = 7.2 Hz, 
CH2(CH2)2CO2H), 3.95 (t, 2H, 3J = 6.4 Hz, OCH2), 6.88 (dd, 1H, 4J = 2.3 Hz, 3J = 8.9 
Hz, H-6), 7.07 (d, 1H, 4J = 2.2 Hz, H-4), 7.27 (d, 1H, 3J = 8.9 Hz, H-7), 11.25 (s, 1H, 
NH), 12.39 (s, 2H, CO2H). 13C-NMR (DMSO-d6) δ 13.87 (+, CH3), 22.02 (-, CH2), 
23.22 (-, CH2), 25.56 (-, CH2), 25.77 (-, CH2), 28.64 (-, CH2), 28.77 (-, CH2), 28.81 (-, 
CH2), 28.94 (-, CH2), 31.22 (-, CH2), 33.19 (-, CH2), 67.66 (-, OCH2), 101.33 (+, C-4), 
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113.13 (+, indole-C), 116.19 (+, indole-C), 121.42 (quat, C-3), 124.18 (quat, C-2), 
127.52 (quat, indole-C), 131.29 (quat, indole-C), 152.68 (quat, C-5), 163.17 (quat, 
CO2H), 174.41 (quat, CO2H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 430 (100) 
[M-H]-. Anal. (C25H37NO5) C, H, N. C25H37NO5 (431.56). 
2-Carboxy-5-(hexadecan-1-yloxy)-1H-indole-3-butanoic acid (8.65): The title 
compound was prepared according to general procedure 8.5.2.10 using 8.60 (0.53 
mmol, 0.29 g) and LiOH (1.60 mmol, 38 mg) in THF (4 ml), MeOH (1 ml) and H2O (2 
ml) and was obtained after recrystallization from EtOAc/PE as a white solid (0.15 g, 
58 %). mp: 143 °C;  1H-NMR (DMSO-d6) δ 0.84 (t, 3H, 3J = 6.7 Hz, (CH2)15CH3), 1.35 
(m, 26H, (CH2)13CH3), 1.71 (m, 2H, OCH2CH2), 1.81 (m, 2H, CH2CH2CO2H), 2.21 (t, 
2H, 3J = 7.4 Hz, CH2CO2H), 3.01 (t, 2H, 3J = 7.1 Hz, CH2(CH2)2CO2H), 3.95 (t, 2H, 3J 
= 6.4 Hz, OCH2), 6.87 (dd, 1H, 4J = 2.3 Hz, 3J = 8.9 Hz, H-6), 7.07 (d, 1H, 4J = 2.2 
Hz, H-4), 7.27 (d, 1H, 3J = 8.9 Hz, H-7), 11.24 (s, 1H, NH), 12.38 (s, 2H, CO2H). 13C-
NMR (DMSO-d6) δ 13.86 (+, CH3), 22.02 (-, CH2), 23.24 (-, CH2), 25.56 (-, CH2), 
25.77 (-, CH2), 28.63 (-, CH2), 28.77 (-, CH2), 28.82 (-, CH2), 28.96 (-, CH2), 31.22 (-, 
CH2), 33.20 (-, CH2), 67.67 (-, OCH2), 101.33 (+, C-4), 113.12 (+, indole-C), 116.17 
(+, indole-C), 121.41 (quat, C-3), 124.18 (quat, C-2), 127.52 (quat, indole-C), 131.31 
(quat, indole-C), 152.68 (quat, C-5), 163.16 (quat, CO2H), 174.39 (quat, CO2H). ES-
MS (DCM/MeOH + NH4OAc) m/z (%): 486 (100) [M-H]-. Anal. (C29H45NO5) C, H, N. 
C29H45NO5 (487.67). 
2-Carboxy-5-(octadecan-1-yloxy)-1H-indole-3-butanoic acid (8.66): The title 
compound was prepared according general procedure 8.5.2.10 using 8.61 (0.48 
mmol, 0.28 g) and LiOH (1.44 mmol, 34 mg) in THF (4 ml), MeOH (1 ml) and H2O (2 
ml) and was obtained after recrystallization from EtOAc/PE as a white solid (0.15 g, 
61 %). mp: 138-139 °C; 1H-NMR (DMSO-d6) δ 0.84 (t, 3H, 3J = 6.6 Hz, (CH2)18CH3), 
1.31 (m, 30H, (CH2)15CH3), 1.77 (m, 4H, CH2CH2CO2H, OCH2CH2), 2.21 (t, 2H, 3J = 
7.4 Hz, CH2CO2H), 3.01 (t, 2H, 3J = 7.1 Hz, CH2(CH2)2CO2H), 3.95 (t, 2H, 3J = 6.3 
Hz, OCH2), 6.87 (dd, 1H, 4J = 2.2 Hz, 3J = 8.9 Hz, H-6), 7.07 (d, 1H, 4J = 2.0 Hz, H-
4), 7.27 (d, 1H, 3J = 8.9 Hz, H-7), 11.24 (s, 1H, NH). 13C-NMR (DMSO-d6) δ 13.86 (+, 
CH3), 22.03 (-, CH2), 23.23 (-, CH2), 25.57 (-, CH2), 25.76 (-, CH2), 28.65 (-, CH2), 
28.78 (-, CH2), 28.83 (-, CH2), 28.96 (-, CH2), 31.23 (-, CH2), 33.18 (-, CH2), 67.63 (-, 
OCH2), 101.27 (+, C-4), 113.12 (+, indole-C), 116.16 (+, indole-C), 121.41 (quat, C-
3), 124.15 (quat, C-2), 127.51 (quat, indole-C), 131.29 (quat, indole-C), 152.67 (quat, 
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C-5), 163.16 (quat, CO2H), 174.41 (quat, CO2H). ES-MS (DCM/MeOH + NH4OAc) 
m/z (%): 514 (100) [M-H]-. Anal. (C31H49NO5) C, H, N. C31H49NO5 (515.72). 
Ethyl 2-ethoxycarbonyl-5-(hexadecan-1-yloxy)-1-propyl-1H-indole-3-butanoate 
(8.67): The title compound was prepared according to general procedure 8.5.2.4 
using 8.60 (0.5 mmol, 0.27 g), NaH (0.6 mmol, 24 mg) and 1-iodopropane (0.6 mmol, 
68 µl) in anhydrous DMF (3 ml) and was obtained after flash chromatography 
(PE/EtOAc 95/5 v/v) as a pale yellow semisolid substance (0.15 g, 51 %). 1H-NMR 
(CDCl3) δ 0.89 (m, 6H, CH2CH3), 1.19 – 1.54 (m, 30H, (CH2)12CH3, CH2CH3), 1.79 
(m, 4H, OCH2CH2, NCH2CH2), 1.99 (m, 2H, CH2CH2CO2), 2.36 (t, 2H, 3J = 7.6 Hz, 
CH2CO2), 3.08 (t, 2H, 3J = 7.5 Hz, CH2(CH2)2CO2), 4.00 (t, 2H, 3J = 6.6 Hz, OCH2), 
4.12 (q, 2H, 3J = 7.1 Hz, CH2CH3), 4.39 (m, 4H, CH2CH3, NCH2), 7.03 (m, 2H, H-4, 
H-6), 7.25 (d, 1H, 3J = 8.7 Hz, H-7). EI-MS (70 eV) m/z (%): 585 (100) [M+·]. Anal. 
(C36H59NO5·0.2H2O) C, H, N. C36H59NO5. (585.86). 
Ethyl 2-ethoxycarbonyl-5-(hexadecan-1-yloxy)-1-(pyridin-3-ylmethyl)-1H-indole-
3-butanoate (8.68): The title compound was prepared according to general 
procedure 8.5.2.4 using 8.60 (0.5 mmol, 0.27 g), NaH (1.2 mmol, 48 mg) and 3-
chloromethylpyridinium chloride (0.6 mmol, 0,10 g) in anhydrous DMF (3 ml) and was 
obtained after flash chromatography (PE/EtOAc 80/20 v/v) as a pale yellow semisolid 
(0.16 g, 50 %). 1H-NMR (CDCl3) δ 0.88 (t, 3H, 3J = 6.7 Hz, (CH2)15CH3), 1.31 (m, 
38H), 1.81 (m, 2H, OCH2CH2), 2.01 (m, 2H, CH2CH2CO2), 2.38 (t, 2H, 3J = 7.5 Hz, 
CH2CO2), 3.12 (t, 2H, 3J = 7.5 Hz, CH2(CH2)2CO2), 4.01 (t, 2H, 3J = 6.5 Hz, OCH2), 
4.12 (q, 2H, 3J = 7.1 Hz, CH2CH3), 4.33 (q, 2H, 3J = 7.1 Hz, CH2CH3), 5.75 (s, 2H, 
NCH2), 7.00 (dd, 1H, 4J = 2.4 Hz, 3J = 9.0 Hz, H-6), 7.09 (d, 1H, 4J = 2.2 Hz, H-4), 
7.19 (m, 2H, H-7, pyridine-H), 7.32 (m, 1H, pyridine-H), 8.45 (m, 2H, pyridine-H). CI-
MS (NH3) m/z (%): 635 (100) [M+H]+. Anal. (C39H58N2O5·0.2H2O) C, H, N. 
C39H58N2O5 (634.89). 
Ethyl 2-ethoxycarbonyl-1-(4-bromobenzyl)-5-(hexadecane-1-yloxy)-1H-indole-3-
butanoate (8.69): The title compound was prepared according to general procedure 
8.5.2.4 using 8.60 (0.5 mmol, 0.27 g), NaH (0.6 mmol, 24 mg) and 4-bromobenzyl 
bromide (0.6 mmol, 0,15 g) in anhydrous DMF (3 ml) and was obtained after flash 
chromatography (PE/EtOAc 90/10 v/v) as a white solid (0.23 g, 64 %). mp: 53 °C;  
1H-NMR (CDCl3) δ 0.88 (t, 3H, 3J = 6.7 Hz, CH2CH3), 1.04 – 1.53 (m, 30H, 
(CH2)12CH3, CH2CH3), 1.81 (m, 2H, OCH2CH2), 2.01 (m, 2H, CH2CH2CO2), 2.37 (t, 
2H, 3J = 7.5 Hz, CH2CO2), 3.11 (t, 2H, 3J = 7.5 Hz, CH2(CH2)2CO2), 4.00 (t, 2H, 3J = 
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6.5 Hz, OCH2), 4.12 (q, 2H, 3J = 7.1 Hz, CH2CH3), 4.32 (q, 2H, 3J = 7.1 Hz, CH2CH3), 
5.66 (s, 2H, CH2C6H4), 6.86 (m, 2H, Ar-H), 6.99 (dd, 1H, 4J =2.4Hz, 3J =9.0Hz, H-6), 
7.08 (d, 1H, 4J = 2.2 Hz, H-4), 7.15 (d, 1H, 3J = 9.0 Hz, H-7), 7.35 (m, 2H, Ar-H). ES-
MS (DCM/MeOH + NH4OAc) m/z (%): 772 (100) [M+CH3COO]-. C40H58BrNO5 
(712.80). 
2-Carboxy-5-(hexadecan-1-yloxy)-1-propyl-1H-indole-3-butanoic acid (8.70): The 
title compound was prepared according to general procedure 8.5.2.10 using 8.67 
(0.18 mmol, 0.11 g) and LiOH (0.54 mmol, 13 mg) in THF (3 ml), MeOH (0.5 ml) and 
H2O (1 ml) and was obtained after recrystallization from EtOAc/PE as a white solid 
(50 mg, 52 %). mp: 61 °C; 1H-NMR (CDCl3) δ 0.89 (m, 6H, CH3), 1.35 (m, 26H, 
(CH2)13CH3), 1.78 (m, 4H, CH2), 2.01 (m, 2H, CH2), 2.43 (t, 2H, 3J = 7.4 Hz, 
CH2CO2H), 3.10 (t, 2H, 3J = 7.4 Hz, CH2(CH2)2CO2H), 4.00 (t, 2H, 3J = 6.5 Hz, 
OCH2), 4.38 (m, 2H, NCH2), 7.03 (m, 2H, indole-H), 7.26 (m, 1H, indole-H). 13C-NMR 
(CDCl3) δ 11.38 (+, CH3), 14.34 (+, CH3), 22.71 (-, CH2), 24.01 (-, CH2), 24.70 (-, 
CH2), 25.78 (-, CH2), 26.18 (-, CH2), 29.38 (-, CH2), 29.50 (-, CH2), 29.65 (-, CH2), 
29.72 (-, CH2), 31.94 (-, CH2), 33.56 (-, CH2), 60.39 (-, NCH2), 68.68 (-, OCH2), 
101.73 (+, indole-C), 111.31 (+, indole-C), 117.15 (+, indole-C), 123.27 (quat, indole-
C), 124.54 (quat, indole-C), 126.77 (quat, indole-C), 133.78 (quat, indole-C), 153.71 
(quat, C-5), 162.56 (quat, CO2H), 179.46 (quat, CO2H). ES-MS (MeOH + NH4OAc) 
m/z (%): 547 (100) [M+NH4]+. Anal. (C32H51NO5) C, H, N. C32H51NO5 (529.75). 
2-Carboxy-5-(hexadecan-1-yloxy)-1-(pyridin-3-ylmethyl)-1H-indole-3-butanoic 
acid hydrochloride (8.71): The title compound was prepared according to general 
procedure 8.5.2.10 using 8.68 (0.22 mmol, 0.14 g) and LiOH (0.55 mmol, 16 mg) in 
THF (4 ml), MeOH (0.5 ml) and H2O (1 ml) and was obtained after recrystallization 
from EtOAc/PE as a white solid (44 mg, 32 %). mp: 114-116 °C; 1H-NMR 
(CDCl3+CD3OD) δ 0.74 (t, 3H, 3J = 6.0 Hz), 1.09 – 1.40 (m, 26H), 1.68 (m, 2H, 
OCH2CH2), 1.88 (m, 2H, CH2CH2CO2H), 2.25 (t, 2H, 3J = 7.3 Hz, CH2CO2H), 3.03 
(m, 2H, CH2(CH2)2CO2H), 3.90 (t, 2H, 3J = 6.4 Hz, OCH2), 5.69 (d, 2H, 2J = 11.2 Hz, 
CH2Ph), 6.89 (m, 1H, H-6), 7.01 (m, 1H, H-4), 7.13 (m, 1H, H-7), 7.34 (m, 1H, Ar-H), 
7.49 (m, 1H, Ar-H), 8.29 (m, 2H, Ar-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 
577 (100) [M-H]-. Anal. (C35H51ClN2O5) C: 68.33, H: 8.36, N: 4.55, found C: 70.94, H: 
8.51, N: 4.32. C35H51ClN2O5 (615.24). 
1-(4-Bromobenzyl)-2-carboxy-5-(hexadecan-1yloxy)-1H-indole-3-butanoic acid 
(8.72): The title compound was prepared according to general procedure 8.5.2.10 
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using 8.69 (0.24 mmol, 0.17 g) and LiOH (0.72 mmol, 17 mg) in THF (4 ml), MeOH 
(0.5 ml) and H2O (1 ml) and was obtained after recrystallization from EtOAc/PE as a 
white solid (64 mg, 41 %). mp: 153-155 °C; 1H-NMR (CDCl3+CD3OD) δ 0.74 (t, 3H, 
3J = 5.7 Hz, CH2CH3), 1.07 – 1.39 (m, 26H, (CH2)13CH3), 1.67 (m, 2H, OCH2CH2), 
1.88 (m, 2H, CH2CH2CO2H), 2.24 (t, 2H, 3J = 7.5 Hz, CH2CO2H), 3.03 (t, 2H, 3J = 7.3 
Hz, CH2(CH2)2CO2H), 3.88 (t, 2H, 3J = 6.4 Hz, OCH2), 5.56 (s, 2H, CH2C6H4), 6.74 
(m, 2H, Ar-H), 6.84 (dd, 1H, 4J = 2.2 Hz, 3J = 9.0 Hz, H-6), 6.97 (d, 1H, 4J = 1.9 Hz, 
H-4), 7.02 (d, 1H, 3J = 9.0 Hz, H-7), 7.20 (m, 2H, Ar-H). 13C-NMR (CDCl3+CD3OD) δ 
17.84 (+, CH3), 26.52 (-, CH2), 28.45 (-, CH2), 29.87 (-, CH2), 29.99 (-, CH2), 33.21 (-, 
CH2), 33.32 (-, CH2), 33.47 (-, CH2), 33.50 (-, CH2), 33.53 (-, CH2), 35.78 (-, CH2), 
37.58 (-, CH2), 51.54 (-, CH2C6H4), 72.74 (-, OCH2), 106.22 (+, indole-C), 115.30 (+, 
indole-C), 121.33 (+, indole-C), 124.49 (quat, C-2), 128.76 (quat, indole-C), 129.01 
(quat, indole-C), 131.09 (+, Ar-C), 131.83 (+, Ar-C), 135.37 (quat, Ar-C), 138.11 
(quat, Ar-C), 141.90 (quat, Ar-C), 157.80 (quat, C-5), 168.17 (quat, CO2H), 180.42 
(quat, CO2H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 656 (100) [M-H]-. Anal. 
(C36H50BrNO5) C, H, N. C36H50BrNO5 (656.69). 
Ethyl 5-benzyloxy-1-(decan-1-yl)-2-ethoxycarbonyl-1H-indole-3-butanoate 
(8.73): The title compound was prepared according to general procedure 8.5.2.4 
using 8.52 (1.5 mmol, 0.61 g), NaH (1.8 mmol, 72 mg) and 1-bromodecane (1.8 
mmol, 0.38 ml) in anhydrous DMF (8 ml) and was obtained after flash 
chromatography (PE/EtOAc 90/10 v/v) as a pale yellow oil (0.55 g, 67 %). 1H-NMR 
(CDCl3) δ 0.88 (t, 3H, 3J = 6.7 Hz, CH2CH3), 1.27 (m, 20H, (CH2)7CH3, CH2CH3), 1.74 
(m, 2H, NCH2CH2), 1.98 (m, 2H, CH2CH2CO2), 2.34 (t, 2H, 3J = 7.6 Hz, CH2CO2), 
3.07 (t, 2H, 3J = 7.4 Hz, CH2(CH2)2CO2), 4.12 (q, 2H, 3J = 7.1 Hz, CH2CH3), 4.40 (q, 
2H, 3J = 7.1 Hz, CH2CH3), 4.44 (t, 2H, 3J = 7.5 Hz, NCH2), 5.12 (s, 2H, CH2Ph), 7.09 
(dd, 1H, 3J = 2.4 Hz, 3J = 9.0 Hz, indole-H), 7.15 (d, 1H, 3J = 2.2 Hz, indole-H), 7.30 – 
7.43 (m, 4H, indole-H, Ph-H), 7.49 (m, 2H, Ph-H). ES-MS (DCM/MeOH + NH4OAc) 
m/z (%): 551 (100) [M+H]+. Anal. (C34H47NO5) C, H, N. C34H47NO5 (549.74). 
5-Benzyloxy-1-(decan-1-yl)-2-ethoxycarbonyl-1H-indole-3-butanoic acid (8.74): 
The title compound was prepared according to general procedure 8.5.2.10 using 8.73 
(0.89 mmol, 0.49 g) and LiOH (2.67 mmol, 64 mg) in THF (8 ml), and H2O (2 ml) and 
was obtained as a pale yellow solid (0.43 g, 93 %). 1H-NMR (CDCl3) δ 0.88 (t, 3H, 3J 
= 6.7 Hz, CH2CH3), 1.27 (m, 14H, (CH2)7CH3), 1.42 (t, 3H, 3J = 7.1 Hz, CH2CH3), 
1.74 (m, 2H, NCH2CH2), 1.98 (m, 2H, CH2CH2CO2H), 2.39 (t, 2H, 3J = 7.3 Hz, 
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CH2CO2H), 3.09 (t, 2H, 3J = 7.4 Hz, CH2(CH2)2CO2H), 4.39 (q, 2H, 3J = 7.2 Hz, 
CH2CH3), 4.44 (m, 2H, 3J = 7.6 Hz, NCH2), 5.10 (s, 2H, CH2Ph), 7.10 (dd, 1H, 4J = 
2.4 Hz, 3J = 9.0 Hz, indole-H), 7.14 (d, 1H, 4J = 2.2 Hz, indole-H), 7.25 – 7.40 (m, 4H, 
indole-H, Ph-H), 7.48 (m, 2H, Ph-H), 10.87 (bs, 1H, CO2H). 13C-NMR (CDCl3) δ 
14.13 (+, CH3), 14.35 (+, CH3), 22.69 (-, CH2), 24.68 (-, CH2), 25.73 (-, CH2), 27.05 (-, 
CH2), 29.31 (-, CH2), 29.41 (-, CH2), 29.58 (-, CH2), 30.81 (-, CH2), 31.89 (-, CH2), 
33.52 (-, CH2), 60.43 (-, OCH2CH3), 70.73 (-, CH2Ph), 102.37 (+, C-4), 111.39 (+, 
indole-C), 117.27 (+, indole-C), 123.34 (quat, C-3), 124.60 (quat, C-2), 126.76 (quat, 
indole-C), 127.69 (+, Ph-C), 127.87 (+, Ph-C), 128.53 (+, Ph-C), 133.83 (quat, indole-
C), 137.37 (quat, Ph-C), 153.35 (quat, C-5), 162.51 (quat, CO2Et), 179.64 (quat, 
CO2H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 522 (100) [M+H]+. Anal. 
(C32H43NO5) C, H, N. C32H43NO5 (521.69). 
5-Benzyloxy-3-(3-carboxypropyl)-1-(decan-1-yl)-1H-indole-2-carboxylic acid 
(8.75): A solution of 8.73 (1 mmol, 0.55 g) and KOH (10 mmol, 0.56 g) in ethanol (10 
ml) was refluxed for 45 min. After cooling, the diacid which precipitated was isolated 
by filtration and resuspended in 2 N HCl (10 ml). The mixture was stirred for 2 hours, 
and then extracted tree times with EtOAc. The combined organic layers were washed 
with brine, dried over MgSO4, filtered and the solvent was evaporated to give the title 
compound as a white solid (0.37 g, 75 %). 1H-NMR (CDCl3) δ 0.86 (t, 3H, 3J = 6.7 
Hz, CH2CH3), 1.28 (m, 14H, (CH2)7CH3), 1.77 (m, 2H, NCH2CH2), 2.04 (m, 2H, 
CH2CH2CO2H), 2.39 (t, 2H, 3J = 7.4 Hz, CH2CO2H), 3.29 (t, 2H, 3J = 7.1 Hz, 
CH2(CH2)2CO2H), 4.47 (t, 2H, 3J = 7.4 Hz, NCH2), 5.13 (s, 2H, CH2Ph), 7.15 (m, 2H, 
indole-H), 7.25 – 7.51 (m, 6H, indole-H, Ph-H), 12.59 (s, 2H, CO2H). ES-MS 
(DCM/MeOH + NH4OAc) m/z (%): 494 (100) [M+H]+. Anal. (C30H39NO5) C, H, N. 
C30H39NO5 (493.63). 
1-(Decan-1-yl)-2-ethoxycarbonyl-5-hydroxy-1H-indole-3-butanoic acid (8.76): 
The title compound was prepared according to general procedure 8.5.2.5 using 8.74 
(0.38 mmol, 0.20 g) and 10 % Pd/C (50 mg) in EtOH (3 ml) and EtOAc (3 ml) and 
was obtained as a pale grey solid (0.30 g, 95 %). 1H-NMR (CDCl3) δ 0.87 (t, 3H, 3J = 
6.6 Hz, CH2CH3), 1.25 (m, 14H, (CH2)7CH3), 1.40 (t, 3H, 3J = 8.3 Hz, CH2CH3), 1.71 
(m, 2H, NCH2CH2), 1.96 (m, 2H, CH2CH2CO2H), 2.39 (t, 2H, 3J = 6.9 Hz, CH2CO2H), 
3.04 (t, 2H, 3J = 7.4 Hz, CH2(CH2)2CO2H), 4.38 (m, 4H, CH2CH3, NCH2), 6.96 (dd, 
1H, 4J = 2.2 Hz, 3J = 8.9 Hz, H-6), 7.08 (d, 1H, 4J = 2.0 Hz, H-4), 7.20 (d, 1H, 3J = 8.9 
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Hz, H-7). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 432 (100) [M+H]+. Anal. 
(C25H37NO5) C, H, N. C25H37NO5 (431.56). 
2-Carboxy-1-(decan-1-yl)-5-hydroxy-1H-indole-3-butanoic acid (77): The title 
compound was prepared according to general procedure 8.5.2.5 using 8.75 (0.13 
mmol, 64 mg) and 10 % Pd/C (20 mg) in EtOH (2 ml) and EtOAc (2 ml) and was 
obtained as a grey semisolid (50 mg, 95 %). 1H-NMR (CDCl3+ CD3OD) δ 0.84 (t, 3H, 
3J = 6.7 Hz, CH2CH3), 1.23 (m, 14H, (CH2)7CH3), 1.69 (m, 2H, NCH2CH2), 1.94 (m, 
2H, CH2CH2CO2H), 2.31 (t, 2H, 3J = 7.5 Hz, CH2CO2H), 3.06 (t, 2H, 3J = 7.5 Hz, 
CH2(CH2)2CO2H), 4.42 (t, 2H, 3J = 7.3 Hz, NCH2), 6.90 (m, 1H, H-6), 7.01 (d, 1H, 4J = 
2.3 Hz, H-4), 7.19 (dd, 1H, 4J = 2.6 Hz, 3J = 8.9 Hz, H-7). ES-MS (DCM/MeOH + 
NH4OAc) m/z (%): 404 (100) [M+H]+. C23H33NO5 (403.51). 
N-[2-Deoxy-D-glucopyranose-2-yl]-1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-
indole-3-acetamide (8.78)20: To a solution of SOCl2 (1.05 mmol, 76 µl) in anhydrous 
CH2Cl2 (5 ml) was added a solution of DMF (1.05 mmol, 77 76 µl) in anhydrous 
CH2Cl2 (1 ml) and the mixture was stirred for 10 min at room temperature. The 
solution then was added to a suspension of indomethacin (1 mmol, 0.36 g) in 
anhydrous CH2Cl2 (2 ml). After evaporation of the solvent, the oily residue was 
treated with ether to get a pale yellow solid which was dried under reduced pressure. 
The crude acid chloride was then dissolved in anhydrous CH2Cl2 (2 ml) and was 
added dropwise to a solution of D-glucosamine hydrochloride (1 mmol, 0.22 g) and 
NEt3 (2 mmol, 0.28 ml) in methanol (10 ml) at 0 °C. After 10 min the resulting solid 
was isolated by filtration and dried under reduced pressure to obtain the title 
compound as pale yellow solid (0.32 g, 61 %). 1H-NMR (DMSO-d6) δ 2.22 (s, 3H, 
CH3), 3.06 (m, 2H, H-3, H-6), 3.48 (m, 1H, H-6),  3.59 (m, 6H, CH2CO, H-2, H-4, H-5, 
H-6), 3.76 (s, 3H, OCH3), 4.44 (t, 1H, 3J = 5.8 Hz, 6-OH), 4.66 (d, 1H, 3J = 5.3 Hz, 4-
OH), 4.94 (m, 2H, H-1, 3-OH), 6.47 (d, 1H, 3J = 4.2 Hz, 1-OH), 6.68 (dd, 1H, 4J = 2.5 
Hz, 3J = 9.0 Hz, Ar-H), 6.93 (d, 1H, 3J = 8.9 Hz, Ar-H), 7.17 (d, 1H, 4J = 2.4 Hz, Ar-H), 
7.66 (m, 4H, Ar-H), 7.99 (d, 1H, 3J = 7.4 Hz, NH). ES-MS (DCM/MeOH + NH4OAc) 
m/z (%): 519 (100) [M+H]+. C25H27ClN2O8 (518.94). 
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9.1 Introduction 
 
Previous studies led to the identification of sulfated carbohydrates as inhibitors of 
bacterial and bovine hyaluronidase1, 2. The sulfated hydroquinone digalactoside 9.1 
(Figure 9.1) was among inhibitors with potencies in the lower micromolar range on 
BTH, BVH and SagHyal4755. A major disadvantage of such sulfated carbohydrates is 
the lack of information on the exact structure. Mixtures of sulfated compounds were 
used with a mean degree of sulfation (DS) of 0.81. For SAR considerations 
information about the position of the sulfate groups is essential. As a starting point for 
the synthesis of sulfated and non-sulfated carbohydrates as potential hyaluronidase 
inhibitors, the synthesis and inhibitory activity of a non-sulfated carbohydrate 
connected via a hydroquinone linker is described in this chapter. 
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Figure 9.1. Structure and inhibitory activity of 9.1 as determined by Salmen1, 2 using the colorimetric 
Morgan Elson assay. IC50 values determined at pH 3.6 (BTH and BVH) or 5.0 (SagHyal4755). 
 
Salmen also demonstrated the inhibitory activity of a sulfated disaccharide (9.2) 
bearing a phenyl residue at the reducing end (Figure 9.2). Following a substrate 
analog approach, the synthesis of a hyaluronan disaccharide fragment bearing a 
hydrophobic methoxyphenyl substituent (9.3) was proposed and is presented here. 
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Figure 9.2. Structure and inhibitory activity of 9.2 as determined by Salmen1, 2 and structure of 9.3. 
IC50 values determined at pH 3.6 (BTH and BVH) or 5.0 (SagHyal4755) in the Morgan Elson Assay. 
 
Based on theoretical considerations Botzki suggested diketopiperazines as potential 
inhibitors of mammalian hyaluronidases3. Diketopiperazines were recently 
investigated as inhibitors of chitinase4, 5 which belong to a class of enzymes related 
to the hyaluronidases6. Thus, compounds like Cl-4 are suggested to mimic a 
hydrolysis intermediate (Figure 9.3). Based on the superposition of Cl-4 and a 
hyaluronic acid disaccharide fragment using a model of BTH3, 9.4 was suggested as 
an inhibitor of mammalian hyaluronidases. The synthesis and inhibitory activity of the 
thio analog 9.5, which was chosen for the synthesis due to economic reasons, is 
presented in this chapter. 
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Figure 9.3. Structures of the chitinase inhibitors Cl-4, the proposed hydrolysis intermediate of N-
acetylglucosamine residue, the derived potential BTH inhibitor 9.4 and the synthesized analog 9.5. 
 
Furthermore, the investigation of several additional compounds for inhibition of 
hyaluronidases is presented in this chapter. Due to structural similarities with the 
synthesized ascorbic acid derivatives described in chapter 8, melophlins, a class of 
N-methyl-3-acyltetramic acids that possess biological effects such as general 
cytotoxic, antiproliferative, antifungal, antibacterial, and antiviral activity7, were 
investigated for hyaluronidase inhibition. Additionally, a selection of 
alkylphosphocholines which were previously broadly studied due to their antitumor 
activities8-12 were included in our screening for hyaluronidase inhibitors as those 
substances contain long hydrophobic structural elements, a common motive of 
several hyaluronidase inhibitors presented in chapters 6-8. 
 
9.2 Synthesis 
 
The glucopyranoside 9.8 was synthesized according to Scheme 9.1 starting from 
glucose, which was peracetylated13 und subsequently treated with hydroquinone in 
the presence of TMSTf14 to obtain the fully acetylated glycoside 9.7 which was 
deprotected using catalytic amounts of NaOMe15. 
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Scheme 9.1. Synthesis of 9.8. 
 
 
For the synthesis of 9.3, which contains a hyaluronic acid disaccharide, two building 
blocks had to be prepared, the glycosyldonor and –acceptor (Scheme 9.2). TMSTf 
catalyzed reaction of a trichloroacetimidate donor was chosen for the formation of the 
glycosidic bond to obtain high β-selectivity. As the neighboring N-acetyl group of the 
glycosyl donor is incompatible with that method16, the N-acetyl moiety had to be 
introduced after the glycosylation reaction. The preparation of the glycosyl donor 9.12 
according to Blattner et al.17 is depicted in Scheme 9.3. 
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Scheme 9.2. Retrosynthetic approach for the synthesis of disaccharide 9.3. 
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Scheme 9.3. Preparation of glycosyl donor 9.11. Reagents and conditions: (i) NaHCO3 (3 eq), 
Cl3COCl (1.5 eq), H2O, RT, 1 h; (ii) Ac2O, pyridine, RT overnight; (iii) Hydrazine acetate (1.5 eq), DMF, 
RT, 20 min; (iv) CCl3CN (10 eq), DBU (0.25 eq), RT, 30 min. 
 
In the first step the nitrogen of D-glucosamine was acylated using trichloroacetyl 
chloride followed by acylation of the hydroxyl residues to form 9.10. Afterwards, 
selective cleavage of the anomeric acetyl group was afforded using hydrazine 
acetate. The crude product was used in the next step without further purification to 
obtain the acetimidate 9.11 via reaction of the carbohydrate with trichloroacetonitrile 
in presence of DBU.  
The glycosyl donor 9.17 was synthesized by analogy with the method described by 
Rye and Withers18 with minor modifications (Scheme 9.4). After alkylation of 9.6 
using p-methoxyphenol and catalytic amounts of trifluorosulfonic acid19 and 
subsequent cleavage of acetyl groups to form 9.12, anisaldehyde dimethyl acetal in 
the presence of p-toluenesulfonic acid was used to protect the 4-OH and 6-OH of the 
carbohydrate scaffold (9.13)18. Acetylation of the free 2-OH and 3-OH followed by 
removal of the acetal under acidic conditions20 yielded 9.15 which was oxidized using 
NaOCl and catalytic amounts of TEMPO under phase transfer conditions18 to get the 
carboxylic acid 9.16. Although no side reactions occurred when this reaction was 
performed on a small scale, the aromatic core was variously halogenated when the 
reaction was performed on a larger scale. As the various halogenated products could 
not be separated and a dehalogenation reaction was already planned in a later step 
to prepare the N-acetyl moiety, the reactions were carried on using the partly purified 
mixture of halogenated derivatives. 
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Scheme 9.4. Synthesis of the glycoside acceptor 9.17. Reagents and conditions: (i) p-Methoxyphenol 
(2 eq), CF3SO3H (0.16 eq), CH2Cl2, 0 °C, 6 h; (ii) NaOMe (cat.), MeOH, RT overnight; (iii) p-
Anisaldehyde dimethyl acetal (1.5 eq), TsOH (0.02 eq), DMF, 50-60 °C, 20 mbar, 4.5 h; (iv) Ac2O, 
pyridine, RT, 1.5 h; (v) HOAc (aq), 70 °C overnight; (vi) TEMPO (cat.) NaOCl, TBAB (cat.), EtOAc, sat. 
NaHCO3, sat NaCl, NaBr, O °C, 1h; (vii) Acidic ion exchanger, MeOH, RT overnight. 
 
To protect the carboxylic acid residue, a methyl ester was introduced utilizing an 
acidic ion exchanger in methanol18 to obtain the glycosyl acceptor 9.17.  
The two building blocks 9.11 and 9.17 were finally coupled to form the protected 
disaccharide 9.17 in the presence of catalytic amounts of TMSTf (Scheme 9.5). 
Hydrogenolytic dehalogenation of 9.18 was successfully performed using palladium 
on activated carbon in the presence of sodium acetate21. Finally, compound 9.3 was 
obtained after removal of the protecting groups under aqueous basic conditions. 
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Scheme 9.5. Synthesis of 9.3 starting from the building blocks 9.11 and 9.17. Reagents and 
conditions: (i) TMSTf (0.2 eq), molsieves, 1,2-dichloroethane, 0 °C, 4.5 h; (ii) 10 % Pd/C (cat.),  
NaOAc (4 eq), H2 (6 atm), THF, RT, 72 h; (iii) 3 N NaOH (30 eq), MeOH / H2O, RT, 6 h, then HOAc. 
 
The synthesis of the diketopiperazine 9.5 is depicted in Scheme 9.6. Starting from 
bromoacetic acid, L-cysteine was used for the alkylation22 to obtain 9.20 which was 
selectively esterified using TMSCl in methanol23. After treating with triphosgene24 the 
obtained N-carboxyanhydride 9.22 was allowed to react with D-proline methyl ester 
(9.23)25 according to the synthetic procedure described by Schöllkopf26. Basic 
hydrolysis of the methyl ester 9.24 yielded too much side products, therefore 9.5 was 
prepared by enzymatic cleavage of the ester moiety using porcine liver esterase (EC 
3.1.1.1) in buffered solution27. 
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Scheme 9.6. Syntesis of diketopiperazine 9.5. Reagents and conditions: (i) L-Cysteine (1.2 eq), H2O, 
7 N NaOH, 1 h, RT; (ii) HOAc; (iii) TMSCl (1.8 eq), MeOH, 6 min, RT; (iv) Triphosgene (0.33 eq), THF, 
50 °C, 3 h; (v) Proline methyl ester hydrochloride (9.23, 1 eq), NEt3 (2.25 eq), CH2Cl2, -78 °C, 30 min; 
(vi) Toluene, reflux; (vii) Porcine liver esterase (EC 3.1.1.1), acetone / phosphate buffer (pH 8.0), RT 
overnight. 
 
9.3 Inhibition of hyaluronidases: results and discussion 
 
9.3.1 Compounds with carbohydrate or peptidic scaffolds 
 
All synthesized L-ascorbic acid derivatives were investigated for inhibition of 
recombinant human hyaluronidases PH-20 and Hyal-1, the bovine testicular enzyme 
BTH (Neopermease®) and the bacterial hyaluronan lyase SagHyal4755 in a modified 
turbidimetric assay based on the method of Di Ferrante28 as described in chapter 3. 
The IC50 values of the synthesized compounds are summarized in Table 9.1. 
Significant inhibition was only found for 9.8 when investigated on human PH-20 and 
the bacterial hyaluronate lyase with IC50 values of 336 µM and 1608 µM, respectively 
(see Figure 9.4 for the dose dependent inhibition). Compared to the sulfated 
glycoside 9.1 which inhibits BTH and SagHyal4755 with IC50 values in the lower 
micromolar range (see chapter 9.1), there is an enormous decrease in potency. 
Similarly, the hyaluronic acid fragment 9.3 turned out to be inactive, whereas the IC50 
values determined for the sulfated disaccharide 9.2 are in the micromolar range. 
These results again underline the importance of the strongly acidic hydrogensulfate 
groups for the inhibition of the hyaluronidases. In chapter 6-8 it was demonstrated for 
different classes of compounds that the hydrophobic aryl or alkyl motive which is 
generally required to achieve reasonable inhibitory potency should have at least the 
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dimension of an octyl residue. Probably, the hydrophobicity of the synthesized 
disaccharide 9.3 bearing a methoxyphenyl residue is too low. Possibly, inhibition 
could also be achieved by extension of the disaccharide to a tetra- or even 
hexasaccharide to improve the binding of the compound to the hyaluronidases. 
Nevertheless, the synthetic effort to obtain such oligosaccharides is very high and not 
appropriate to produce substance libraries for inhibitor screening. Therefore, this 
carbohydrate based approach was discontinued. 
 
Table 9.1. Inhibitory activity of compounds 9.3, 9.5 and 9.8. 
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Hyal-1 PH-20 BTH SagHyal4755 Compound IC50 [µM]a 
9.3 > 3000 > 3000 > 3000 > 3000 
9.5 > 3000 > 3000 > 3000 > 3000 
9.8 > 6000 336 ± 75 > 6000 1608 ± 60 
a Inhibition of enzyme expressed as IC50 (µM), mean values ± SEM (N = 2, experiments performed in 
duplicate); IC50 values determined at pH 5.0 (PH-20, BTH, SagHyal4755) or 3.5 (Hyal-1) in the 
turbidimetric assay. 
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Figure 9.4. Activity of human PH-20 and SagHyal4755 in the presence of 9.8. 
 
In contrast to previous suggestions based on theoretical considerations the 
synthesized diketopiperazine 9.5 does not inhibit the hyaluronidases in the 
turbidimetric assay. It remains unclear, if structural differences between 
hyaluronidases and chitinases or shortcomings of the BTH model account for that 
negative result. As a consequence the peptide based approach was discontinued. 
 
9.3.2 Melophlins and related structures 
 
The melophlins and related compounds were kindly provided by Prof. Dr. R. 
Schobert (Institute of Organic Chemistry, University of Bayreuth). The IC50 values 
determined in the turbidimetric assay (chapter 3) are summarized in Table 9.3, 
substitution patterns are given in Table 9.2. 
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Table 9.2. Substitution patterns of investigated melophlin and agglomerin derivatives. 
N
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N O
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O
OH
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Agglomerin B
 
Compound R1 R2 
Melophlin A H (CH2)14CH3 
Melophlin B (S)-CH3 (CH2)2CHMe(CH2)7CH3 
Melophlin C (S,R)-CH3 (CH2)3CHMe(CH2)6CH3 
Melophlin G H (CH2)12CH3 
Melophlin P (S,R)-CH3 (CH2)14CH3 
Melophlin Q (S,R)-CH3 (CH2)11CH(CH3)2 
Melophlin R (S,R)-CH3 (CH2)10CH(CH3)(CH2CH3) 
Ca(Mel-A)2 - (CH2)14CH3 
Agglomerin B - (CH2)3CH=CH(CH2)5CH3 
 
Table 9.3. Inhibitory activity of melophlin and agglomerin derivatives on hyaluronidases. 
Hyal-1 PH-20 BTH SagHyal4755 Compound IC50 [µM]a 
Melophlin A > 100 2.6 ± 0.2 > 100 6.6 ± 3 
Melophlin B > 200 15 ± 1 > 200 75 ± 7 
Melophlin C > 200 12 ± 1 > 200 33 ± 2 
Melophlin G > 200 6.9 ± 0.2 > 200 14 ± 1 
Melophlin P > 100 2.3 ± 0.1 > 100 9.0 ± 1.0 
Melophlin Q > 200 177 ± 17 > 250 > 250 
Melophlin R > 200 8.2 ± 0.4 > 200 18 ± 1 
Ca(Mel-A)2 > 100 1.9 ± 0.1 > 100 5.0 ± 0.2 
Agglomerin B > 100 > 50 > 100 > 100 
a inhibition of enzyme expressed as IC50 (µM), mean values ± SEM (N = 2, experiments performed in 
duplicate); IC50 values determined at pH 5.0 (PH-20, BTH, SagHyal4755) or 3.5 (Hyal-1) in the 
turbidimetric assay. 
 
Obviously, none of the investigated compounds inhibits human Hyal-1 and BTH, 
whereas several compounds show inhibition of human PH-20 and the bacterial 
hyaluronate lyase. Strongest inhibition of PH-20 was found for monomeric, 
pentadecyl substituted melophlins A and P with IC50 values around 2 µM. The 
additional methyl group in melophlin P does not lead to noteworthy changes in 
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potency. The dimeric calcium complex Ca(Mel-A)2 possesses even increased 
potency, but the stability of this complex under the aqueous assay conditions is 
questionable. Thus, by dissociation, the lower IC50 value could possibly be the result 
of an increased concentration of free monomer in solution. Similar results were 
obtained for SagHyal4755, albeit IC50 values are higher. A drastic drop in potency is 
observed for melophlin Q when compared to melophlin P: a comparable overall 
length but an additional terminal branching leads to 77 times lower potency on PH-20 
and a complete loss of activity against SagHyal4755. However, the inhibitory activity 
against both enzymes is regained, when the branching is moved away from the chain 
terminus (melophlin R). Compounds with shorter alkyl chains are significantly less 
potent hyaluronidase inhibitors (compare melophlins A and G). An additional methyl 
residue situated at different positions of the alkyl chain does contribute to increased 
potency (melophlins B and C), but it should be considered that the alkyl residues in 
these derivatives are shorter than that in melophlin P, and do not fulfill the structural 
requirements to give potent inhibitors as shown in chapters 6-8. The different position 
of the methyl residue causes only minor changes, albeit melophlin C is more potent 
than melophlin B, especially when the bacterial enzyme is regarded. Interestingly, 
none of the four investigated hyaluronidases is inhibited by agglomerin B. This 
cannot be explained on the basis of available data, but might be associated with the 
differences in the heterocyclic part of the molecule, or depend on the double bond. 
 
9.3.3 Alkylphosphocholines 
 
A selection of alkylphosphocholines (Table 9.4) was investigated for hyaluronidase 
inhibition in the turbidimetric assay (chapter 3). The obtained IC50 values are 
presented in Table 9.4. No inhibition of Hyal-1 and BTH was observed for the 
phosphocholines in the investigated concentration range, whereas PH-20 and the 
bacterial hyaluronate lyase were inhibited in a concentration-dependent manner and 
with similar SAR: Comparing miltefosine (9.25) with the derivative bearing the longer 
octadecyl sidechain (9.26) no significant change in potencies is obvious when tested 
upon PH-20 and SagHyal4755 inhibition. This result is in agreement with observations 
made for indole-type hyaluronidase inhibitors (chapter 8) where no further increase in 
inhibition occurs if a certain length of the hydrophobic motive is exceeded. 
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Replacement of the trimethylammonium residue with an N-methyl-piperidinium 
moiety results in a significant increase in potency. 
 
Table 9.4. Structures and inhibitory activity of alkylphosphocholines on hyaluronidases. 
R
O
P
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N
9.25: R=(CH2)15CH3
9.26: R=(CH2)17CH3
H3C(H2C)17
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Hyal-1 PH-20 BTH SagHyal4755 Compound IC50 [µM]a 
9.25 > 200 6.8 ± 0.8 > 200 1.6 ± 0.3 
9.26 > 200 6.5 ± 0.5 > 200 1.9 ± 0.1 
9.27 > 200 4.0 ± 0.3 > 200 0.88 ± 0.1 
9.28 > 200 7.5 ± 1.1 > 200 1.5 ± 0.2 
a inhibition of enzyme expressed as IC50 (µM), mean values ± SEM (N = 2, experiments performed in 
duplicate); IC50 values determined at pH 5.0 (PH-20, BTH, SagHyal4755) or 3.5 (Hyal-1) in the 
turbidimetric assay. 
 
For compound 9.27 IC50 values of 4.0 µM and 0.88 µM were determined for human 
PH-20 and SagHyal4755, thus this derivative represents the most potent inhibitor of 
the bacterial enzyme in this work. Perifosine (9.28) is a weaker hyaluronidase 
inhibitor than 9.27, the IC50 value is comparable to that of 9.26 which has the same 
octadecyl chain but different substitution in the charged ammonium part of the 
molecule. The phosphocholines have a significant preference for the bacterial 
enzyme over the human PH-20. This is in contrast to the melophlines which turned 
out to slightly prefer the human enzyme. 
 
9.4 Summary 
 
In this chapter several approaches for the design and synthesis of hyaluronidase 
inhibitors as well as the investigation of compounds provided by other groups are 
described. In a first effort carbohydrate based molecules were synthesized by 
analogy with the sulfated inhibitors described by Salmen2. Unfortunately, the 
nonsulfated derivatives did not or only very weakly inhibit the investigated 
mammalian and bacterial hyaluronidases, thus confirming the conclusion that the 
sulfate groups of the previously published compounds are key to high affinity. A 
second approach based on a homology model of bovine testicular hyaluronidsase led 
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to the proposal of a peptidic transition state mimic as potential inhibitor of mammalian 
hyaluronidase3. As the synthesized diketopiperazine did not meet the predictions in 
terms of hyaluronidase inhibitory activity this approach was discontinued. 
Some aza-analogs of ascorbic acid, so-called melophlins, which are structurally 
related to the synthesized vitamin C based inhibitors, were investigated for 
hyaluronidase inhibition. These compounds proved to be rather potent inhibitors of 
human PH-20 and bacterial hyaluronate lyase, whereas human Hyal-1 and BTH 
were not affected. Thus, despite structural similarity with vitamin C derivatives these 
compounds must be clearly separated from the ascorbic acid derivatives described in 
chapter 7, but may rather be compared with the PH-20 and SagHyal4755 inhibitors 
presented in the indole chapter (chapter 8). Finally, a set of alkylphosphocholines 
was investigated. Among them, 9.27 was found to be the most potent inhibitor of 
bacterial hyaluronate lyase identified in this work with an IC50 value of 0.88 µM. 
Interestingly, no inhibition of Hyal-1 and the bovine enzyme was observed, but in 
contrast to the melophlins which possess slight selectivity for human PH-20 versus 
SagHyal4755, the alkylphosphocholines have significant preference for the bacterial 
over the human enzyme. 
 
9.5 Experimental Section 
 
9.5.1 General conditions 
 
Chemicals were purchased from the following suppliers: Acros Organics (Geel, 
Belgium), IRIS Biotech GmbH (Marktredwitz, Germany), Alfa Aesar GmbH & Co. KG 
(Karlsruhe, Germany), Merck KGaA (Darmstadt, Germany), and Sigma-Aldrich 
Chemie GmbH (Munich, Germany). Esterase (EC 3.1.1.1) from porcine liver with an 
activity of 20 units/mg was purchased from Sigma-Aldrich Chemie GmbH (Munich, 
Germany). The investigated alkylphosphocholines were kindly provided by Asta 
Medica AG (Frankfurt, Germany). Deuterated solvents for NMR spectroscopy were 
from Deutero GmbH (Kastellaun, Germany). All solvents were of analytical grade or 
distilled prior to use. If moisture-free conditions were required, reactions were 
performed in dried glassware under inert atmosphere (argon or nitrogen); DMF (H2O 
< 0.01 %) was purchased from Sigma-Aldrich Chemie GmbH. Nuclear Magnetic 
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Resonance (1H-NMR and 13C-NMR) spectra were recorded on an Avance-300 NMR 
spectrometer from Bruker BioSpin GmbH (Rheinstetten, Germany). 
Tetramethylsilane was added as internal standard (chemical shift δ = 0 ppm) to all 
samples. Multiplicities are specified with the following abbreviations: s (singlet), d 
(doublet), t (triplet), q (quartet), m (multiplet), bs (for broad singulet), as well as 
combinations thereof. The multiplicity of carbon atoms (13C-NMR) were determined 
by DEPT 135 and DEPT 90 (distortionless enhancement by polarization transfer): “+” 
primary and tertiary carbon atom (positive DEPT 135 signal), “-“ secondary carbon 
atom (negative DEPT 135 signal), “quat” quaternary carbon atom. Mass 
spectrometry analysis (MS) was performed on a Finnigan MAT 95 (PI-EIMS 70 eV, 
HR-MS), Finnigan SSQ 710A (CI-MS (NH3)) and on a Finnigan ThermoQuest TSQ 
7000 (ESI-MS) spectrometer. The peak-intensity in parenthesis is indicated relatively 
to the strongest signal in %. Melting points (mp) were measured on a BÜCHI 530 
using open capillaries and are uncorrected. Merck Silica Gel 60 (particle size 0.040–
0.063 mm) was used for flash column chromatography. Reactions were routinely 
monitored by thin layer chromatography (TLC) on Merck silica gel 60 F254 aluminum 
sheets and spots were visualized with UV light at 254 nm, and/or iodine vapor or 
ammonium molybdate/cerium(IV) sulfate solution. 
 
9.5.2 Chemistry 
 
β-D-Glucose pentaacetate (9.6)13: To a mixture of anhydrous pyridine (50 ml) and 
acetic acid anhydride (0.5 mol, 47.0 ml) was added β-D-glucose (50 mmol, 11.0 g) at 
0 °C and the reaction was stirred overnight at room temperature. After evaporation of 
the solvent and recrystallization of the crude material, the title compound was 
obtained as a white solid (16.3 g, 84 %). EI-MS (70 eV) m/z (%): 390 (1) [M+·]. 
C16H22O11 (390.34). 
1,4-Phenylene-bis(2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside) (9.7): To a 
solution of 9.6 (4.0 mmol, 1.56 g) in anhydrous CH2Cl2 (5 ml) was subsequently 
added freshly activated molecular sieves and TMSTf (4.0 mmol, 0.77 ml). After 
stirring for 30 min at room temperature, hydroquinone (2.0 mmol, 0.22 g) was added 
and stirring was continued overnight. Solids were removed by filtration and after 
dilution with CH2Cl2 and addition of saturated NaHCO3, the mixture was extracted 
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three times with CH2Cl2. The combined organic layers were dried over MgSO4, 
filtered and evaporated. The title compound was obtained after flash chromatography 
(PE/EtOAc 90/10 v/v) as a white foam (0.23 g, 15 %). 1H-NMR (CDCl3) δ 2.04 – 2.09 
(m, 24H, CH3), 4.17 (m, 4H, CH2O), 4.97 – 5.72 (m, 10H, CH), 6.97 (m, 4H, Ar-H). 
PI-EIMS (70 eV) m/z (%): 770 (20) [M+·]. C34H42O20 (770.69). 
1,4-Phenylene-bis(β-D-glucopyranoside) (9.8): To a suspension of 9.7 (0.29 mmol, 
0.22 g) in anhydrous methanol (5 ml) was added 1 N methanolic NaOMe (20 µl) and 
the mixture was stirred at room temperature overnight. The precipitated product was 
dissolved by adding water and the mixture was neutralized with an acidic ionic 
exchanger (Amberlite® CG-120, loaded prior to use). After filtration and evaporation 
to dryness, the title compound was obtained as a pale brown solid (0.12 g, 95 %). 1H-
NMR (DMSO-d6) δ 3.11 – 3.79 (m, 12H, CH, CH2), 4.50 – 5.31 (m, 10H, OH, H-1), 
6.99 (m, 4H, Ar-H). ES-MS (H2O/MeOH + NH4OAc) m/z (%): 452 (100) [M+NH4]+.  
C18H26O12 (434.39). 
2-Deoxy-2-trichloroacetamido-D-glucopyranose (9.9)17: To a vigorously stirred 
solution of D-glucosamine hydrochloride (0.1 mol, 21.6 g) and NaHCO3 (0.3 mol, 
25.2 g) in water (200 ml) was added trichloroacetyl chloride (0.15 mol, 16.8 ml) 
dropwise over a period of 1 h at room temperature. After stirring of the solution for an 
additional hour, the mixture was neutralized by addition of 1 N HCl and the solvent 
was evaporated. The remaining residue was taken up in methanol (200 ml) und 
stirred for 2 h. The precipitated salt was removed by filtration, and after evaporation 
of the solvent the crude material was recrystallized from cold water to obtain the title 
compound as a white solid (19.1 g, 59 %). 1H-NMR (DMSO-d6) δ 2.09 (s, 1H, 1-OH), 
3.49 (m, 6H, CH, OH), 4.65 (d, 1H, 3J = 6.7 Hz, H-1β), 5.05 (s, 1H, H-1α), 8.34 (s, 
1H, NHα), 8.66 (s, 1H, NHβ). mp: 160-163 °C (Lit: 163-165 °C17); ES-MS (MeOH + 
NH4OAc) m/z (%): 322 (100) [M-H]-. C8H12Cl3NO6 (324.54). 
1,3,4,6-Tetra-O-acetyl-2-deoxy-2-trichloroacetamido-α-D-glucopyranose 
(9.10)17: To a solution of 9.9 (6.2 mmol, 2.0 g) in anhydrous pyridine (20 ml) was 
added acetic anhydride (10 ml) and the mixture was stirred at room temperature 
overnight. After addition of toluene (40 ml), the mixture was filtrated and the solvent 
was evaporated under reduced pressure. Recrystallization from EtOAc/Hexane 
yielded the title compound as  a pale yellow solid (2.0 g, 65 %). mp: 153-155 °C (ref. 
17: 156-157 °C); 1H-NMR (CDCl3) δ 2.07 (s, 6H, CH3), 2.11 (s, 3H, CH3), 2.20 (s, 3H, 
CH3), 4.02 – 4.11 (m, 2H, H-5, H-6b), 4.28 – 4.39 (m, 2H, H-6a, H-2), 5.26 (t, 1H, 3J = 
Chapter 9 Miscellaneous compounds as potential hyaluronidase inhibitors 
285 
9.8 Hz, H-4), 5.35 (dd, 1H, 3J = 10.8 Hz, 3J = 9.6 Hz, H-3), 6.31 (d, 1H, 3J = 3.7 Hz, 
H-1), 6.83 (d, 1H, 3J = 8.3 Hz, NH). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 509 
(100) [M+NH4]+. C16H20Cl3NO10 (492.69). 
3,4,6-Tri-O-acetyl-2-deoxy-2-trichloroacetamido-α-D-glucopyranosyl 
trichloroacetimidate (9.11)17: To a solution of 9.10 (4.0 mmol, 1.96 g) in anhydrous 
DMF (20 ml) was added hydrazine acetate (6 mmol, 0.55 g) and the mixture was 
stirred for 20 min at room temperature. After addition of EtOAc (80 ml), the mixture 
was washed subsequently with water, saturated NaHCO3 and water again. The 
organic phase was dried over MgSO4, filtered and evaporated to dryness. The 
remaining residue was dissolved in anhydrous CH2Cl2 (12 ml) and 
trichloroacetonitrile (30 mmol, 4.0 ml) and DBU (1 mmol, 0.15 ml) were added. After 
stirring for 30 min at room temperature, the solvent was distilled off and the crude 
product was purified by flash chromatography (PE/EtOAc 2/1 v/v + 0.1 % NEt3) to 
obtain the title compound as a white solid (1.5 g, 42 %). mp: 150-153 °C (ref.17: 160-
161 °C); 1H-NMR (CDCl3) δ 2.07 (s, 3H, CH3), 2.08 (s, 3H, CH3), 2.10 (s, 3H, CH3), 
4.15 (m, 2H, H-6b, H-5), 4.30 (dd, 1H, 3J = 4.1 Hz, 3J = 12.5 Hz, H-6a), 4.46 (ddd, 
1H, 3J = 3.6 Hz, 3J = 8.5 Hz, 3J = 10.7 Hz, H-2), 5.31 (t, 1H, 3J = 9.9 Hz, H-4), 5.45 
(dd, 1H, 3J = 9.8 Hz, 3J = 10.6 Hz, H-3), 6.50 (d, 1H, 3J = 3.6 Hz, H-1), 7.01 (d, 1H, 3J 
= 8.5 Hz, NH), 8.85 (s, 1H, C=NH). C16H18Cl6N2O9 (595.04). 
p-Methoxyphenyl-β-D-glucopyranoside (9.12)29: To a solution of 9.6 (46.3 mmol, 
18.1 g) and p-methoxyphenol (92.6 mmol, 11.5 g) in anhydrous CH2Cl2 (100 ml) was 
added CF3SO3H (7.4 mmol,  0.65 ml) dropwise at 0 °C. After the solution was stirred 
for 6 h at room temperature, CH2Cl2 (100 ml) was added and the mixture was 
washed twice with 2 N NaOH and water. The organic phase was dried over MgSO4, 
filtered and evaporated to give a colorless oil which was dissolved in anhydrous 
methanol (100 ml). After addition of a catalytic amount of NaOMe (50 mg) and stirring 
overnight at room temperature, the solution was neutralized with an acidic ion 
exchanger (Amberlite® CG-120, loaded prior to use), filtered and evaporated to 
dryness. The title compound was obtained after recrystallization of the crude material 
from ethanol as a white solid (8.6 g, 64 %). mp: 155-156 °C (ref.30: 160 °C); 1H-NMR 
(DMSO-d6) δ 3.09 – 3.68 (m, 6H, CH, CH2), 3.70 (s, 3H, OCH3), 4.56 (t, 1H, 3J = 5.7 
Hz, OH), 4.70 (d, 1H, 3J = 7.3 Hz, OH), 5.00 (d, 1H, 3J = 5.1 Hz, OH), 5.06 (d, 1H, 3J 
= 4.1 Hz, OH), 5.27 (d, 1H, 3J = 4.7 Hz, H-1), 6.85 (m, 2H, Ar-H), 6.98 (m, 2H, Ar-H). 
ES-MS (H2O/MeOH + NH4OAc) m/z (%): 304 (100) [M+NH4]+. C13H18O7 (286.28). 
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p-Methoxyphenyl-4,6-O-(4-methoxybenzylidene)-β-D-glucopyranoside (9.13): 
9.12 (36.3 mmol, 10.3 g), 4-methoxybenzaldehyde dimethyl acetal (54.4 mmol, 9.3 
ml) and p-toluenesulfonic acid monohydrate (0.7 mmol, 0.13 g) were suspended in 
DMF (50 ml) and submitted to rotary evaporation at 50-60 °C bath temperature and 
20 mbar vacuum for 4.5 h. The temperature was raised to 70 °C and the mixture was 
concentrated until a solid began to form. The residue was poured into a mixture of 
saturated NaHCO3 (50 ml), diethyl ether (50 ml) and ice. The resulting white solid 
was sucked off, washed with water and diethyl ether und was dried over P2O5 to 
obtain the title compound as a white solid which was used without further purification 
in the next step (13.20 g, 90 %). C21H24O8 (404.41). 
p-Methoxyphenyl-2,3-di-O-acetyl-4,6-O-(4-methoxybenzylidene)-β-D-
glucopyranoside (9.14): The crude 9.13 (13.2 g, 32.6 mmol) was dissolved in 
anhydrous pyridine (25 ml) and acetic acid anhydride (32 ml) and was stirred for 1.5 
h at room temperature. After dilution with CH2Cl2 (100 ml), the mixture was 
subsequently washed with water, 1 N HCl, saturated NaHCO3 and water. The 
organic layer was dried over MgSO4, filtered and evaporated to dryness. The target 
compound was obtained after recrystallization of the crude product as a white solid 
(12.7 g, 80 %). 1H-NMR (DMSO-d6) δ 2.01 (s, 3H, CH3), 2.03 (s, 3H, CH3), 3.71 (s, 
3H, OCH3), 3.75 (s, 3H, OCH3), 3.79 (m, 1H, CH), 3.89 (m, 2H, CH), 4.27 (m, 1H, 
CH), 5.04 (dd, 1H, 3J = 7.9 Hz, 3J = 9.4 Hz, CH), 5.40 (m, 2H, CH), 5.59 (s, 1H, CH), 
6.91 (m, 8H, Ar-H), 7.30 (m, 2H, Ar-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 
489 (100) [M+H4]+.  C25H28O10 (488.48). 
p-Methoxyphenyl-2,3-di-O-acetyl-β-D-glucopyranoside (9.15): A solution of 9.14 
(20 mmol, 9.8 g) in 80 % aqueous HOAc (300 ml) was stirred at 70 °C overnight. 
After removal of the solvent at reduced pressure, the raw product was subjected to 
flash chromatography (PE/EtOAc 30/70 v/v) to obtain the target compound as a white 
solid (5.6 g, 75 %). 1H-NMR (CD3OD) δ 1.99 (s, 3H, CH3), 2.03 (s, 3H, CH3),  3.58 
(ddd, 1H, 3J = 2.1 Hz, 3J = 5.0 Hz, 2J = 10.0Hz, H-6a), 3.68 (m, 2H, H-6b, CH), 3.69 
(s, 3H, OCH3), 3.83 (dd, 1H, 3J = 2.1 Hz, 3J = 12.5 Hz, CH), 4.95 (dd, 1H, 3J = 8.0 
Hz, 3J = 9.6 Hz, CH), 5.10 (m, 1H, CH), 5.19 (d, 1H, 3J = 7.9 Hz, CH), 6.85 (m, 2H, 
Ar-H), 6.95 (m, 2H, Ar-H). ES-MS (MeOH + NH4OAc) m/z (%): 388 (100) [M+NH4]+.  
C17H22O9 (370.35). 
p-Methoxyphenyl-2,3-di-O-acetyl-β-D-glucopyranosiduronic acid (9.16): To a 
solution of 9.15 (14 mmol, 5.2 g), TEMPO (0.35 mmol, 55 mg), TBAB (1 mmol, 0.34 
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g) and NaBr (1.7 mmol, 0.17 g) in EtOAc (60 ml) and saturated NaHCO3 (40 ml) was 
added a solution of 12 % NaOCl (52 mmol, 32 ml), saturated NaHCO3 (30 ml) and 
saturated NaCl (60 ml) dropwise at 0 °C. After stirring for 1 h at 0 °C, 6 N HCl was 
added to adjust the pH value <2, and the mixture was extracted three times with 
EtOAc. The product was obtained after partial purification using flash chromato-
graphy (CH2Cl2/acetone 80/20 v/v + 0.1 % HOAc) together with halogenated 
byproducts as a pale yellow foam (4.39 g, 82 %) and was used in the next step 
without further purification. ES-MS (DCM/MeOH + NH4OAc) m/z (%): 383 (100) [M-
H]-, 417 (85) [M+Cl-H]-, 461 (40) [M+2Cl-H]-. C17H20O10 (384.33). 
Methyl p-methoxyphenyl-2,3-di-O-acetyl-β-D-glucopyranosiduronate (9.17): A 
solution of 9.16 (3.9 mmol, 1.5 g) and Amberlite® CG-120 (1 g, loaded prior to use) in 
absolute methanol (50 ml) was stirred at room temperature overnight. After filtration 
and evaporation of the solvent, the crude product was partly purified using flash 
chromatography (PE/EtOAc 40/60 v/v) to obtain the title compound with halogenated 
impurities as a colorless amorphous substance (0.98 g, 63 %). ES-MS (DCM/MeOH 
+ NH4OAc) m/z (%): 416 (20) [M+NH4]+, 450 (100) [M+Cl+NH4]+, 494 (35) 
[M+2Cl+NH4]+. C18H22O10 (398.36). 
Methyl p-methoxyphenyl-O-(3,4,6-tri-O-acetyl-2-deoxy-2-trichloroacetamido-β-
D-glucopyranosyl)-(1→4)-2,3-di-O-acetyl-β-D-glucopyranosiduronate (9.18): A 
solution of 9.11 (0.65 mmol, 0.39 g) and 9.17 (0.5 mmol, 0.20 g) in anhydrous 1,2-
dichloroethane was stirred with molecular sieves under an atmosphere of argon for 
1.h at room temperature. After cooling to 0 °C, TMSTf (0.1 mmol, 20 µl) was added 
and stirring was continued for additional 3 h. The mixture was quenched by adding 
NEt3 and solids were removed by filtration. After evaporation of the solvent the crude 
mixture was subjected to flash chromatography (PE/EtOAc 70/30 v/v) to obtain the 
title compound with halogenated impurities as a white solid (0.21 g, 51 %). ES-MS 
(DCM/MeOH + NH4OAc) m/z (%): 849 (20) [M+NH4]+, 883 (100) [M+Cl+NH4]+, 927 
(45) [M+2Cl+NH4]+. C32H38Cl3NO18 (831.00). 
Methyl (p-methoxyphenyl-O-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-gluco-
pyranosyl)-(1→4)-2,3-di-O-acetyl-β-D-glucopyranosid)uronate (9.19): A mixture 
of 9.18 (0.59 mmol, 0.49 g), sodium acetate (2.36 mmol, 0.19 g), palladium on 
activated charcoal (10 % Pd, 0.49 g) in THF (20 ml) was hydrogenated in an 
autoclave under a pressure of 6 bar at room temperature for 72 h. Insoluble material 
was filtered off, and the remaining solution was diluted with EtOAc. After washing 
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successively with 1 N NaOH, water and brine, the organic layer was dried over 
MgSO4, filtered and concentrated to dryness. The title compound was obtained after 
flash chromatography (EtOAc) as a white solid (0.25 g, 58 %). 1H-NMR (CDCl3) δ 
1.89 (s, 3H, CH3), 1.99 (s, 3H, CH3), 1.99 (s, 3H, CH3), 2.03 (s, 3H, CH3), 2.05 (s, 3H, 
CH3), 2.08 (s, 3H, CH3), 3.66 – 4.39 (m, 11H, CH, CH2, CO2CH3, OCH3), 4.73 (d, 1H, 
3J = 8.4 Hz, CH), 5.02 (m, 2H, CH), 5.20 (m, 3H, CH), 5.70 (d, 1H, 3J = 8.7 Hz, CH), 
6.80 (m, 2H, Ar-H), 6.91 (m, 2H, Ar-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 
728 (100) [M+H]+. C32H41NO18 (727.66). 
p-Methoxyphenyl-O-(2-acetamido-2-deoxy-β-D-glucopyranosyl)-(1→4)-β-D-
glucopyranosiduronic acid (9.3): To a suspension of 9.19 (0.32 mmol, 0.22 g) in 
methanol (5 ml) and water (1 ml) was slowly added 3 N NaOH (9.6 mmol, 3.2 ml) 
dropwise. After stirring for 6 h, HOAc was added and the solvent was evaporated. 
Flash chromatography (EtOAc/MeOH/H2O 10/6/2 v/v/v + 0.5 % HOAc) yielded the 
target compound with salt impurities which were removed by passing an ion 
exchanger (Bio Rad, AG 50W-X8, loaded with NH4+, mobile phase: H2O). After drying 
under reduced pressure the target compound was obtained as a white hygroscopic 
solid (50 mg, 31 %). 1H-NMR (600 MHz, DMSO-d6) δ 1.89 (s, 3H, CH3), 3.27 (m, 8H, 
CH), 3.58 (d, 1H, 3J = 9.4 Hz, CH), 3.69 (m, 1H, CH), 3.70 (s, 3H, OCH3), 4.42 (d, 
1H, 3J = 8.4 Hz, CH), 4.75 (d, 1H, 3J = 7.6 Hz, CH), 6.84 (m, 2H, Ar-H), 6.95 (m, 2H, 
Ar-H), 8.53 (d, 1H, 3J = 5.9 Hz, NH). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 504 
(100) [M+H]+. C21H29NO13 (503.45). 
S-Carboxymethyl-L-cysteine (9.20)22: To a solution of bromoacetic acid (56 mmol, 
7.8 g) and L-cysteine hydrochloride monohydrate (67 mmol, 11.8 g) in water (60 ml) 
was added 7 N NaOH (0.34 mol, 49 ml) at 0 °C over a period of 30 min. After stirring 
for additional 60 min, acetic acid (200 ml) was added and the mixture was kept in the 
refrigerator overnight. The precipitated product was sucked off, recrystallized from 
water and dried under reduced pressure to obtain a white solid (5.6 g, 52 %). mp: 
187-189 °C (ref.22: 191 °C). ES-MS (H2O/MeOH + NH4OAc) m/z (%): 180 (100) 
[M+H]+. C5H9NO4S (179.19). 
S-Methoxycarbonylmethyl-L-cysteine hydrochloride (9.21)23: To a suspension of 
9.20 (8.0 mmol, 1.55 g) in anhydrous methanol (50 ml) was added TMSCl (17.6 
mmol, 2.2 ml) dropwise. After stirring for 6 min at room temperature, the solution was 
concentrated and poured into a mixture of EtOAc (100 ml) and Et2O (100 ml). 
Crystals obtained after storage in the refrigerator overnight and were collected by 
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filtration to yield the title compound as a white solid (1.7 g, 93 %). 1H-NMR (D2O) δ 
3.05 (dd, 1H, 3J = 7.8 Hz, 2J = 15.1 Hz, SCH2CH), 3.20 (dd, 1H, 3J = 4.5 Hz, 2J = 
15.2 Hz, SCH2CH), 3.41 (s, 2H, SCH2CO), 3.66 (s, 3H, OCH3), 4.16 (dd, 1H, 3J = 4.4 
Hz, 3J = 7.8 Hz, CH). C6H12ClNO4S (229.68). 
Methyl (R)-2-(2,5-dioxooxazolidin-4-ylmethylthio)acetate (9.22): To a suspension 
of 9.21 (3.0 mmol, 0.66 g) in anhydrous THF (10 ml) was added triphosgene (1.0 
mmol, 0.30 g) at 50 °C under an atmosphere of argon. After stirring for 3 h at 50 °C, 
the solution was purred into hexane (50 ml) and stored in the refrigerator overnight. 
The crystals were sucked off to yield the target compound as a white solid (0.57 g, 
87 %). 1H-NMR (CDCl3) δ 2.98 (dd, 1H, 3J = 7.7 Hz, 2J = 14.8 Hz, SCH2CH), 3.27 
(dd, 1H, 3J = 3.6 Hz, 2J = 14.7 Hz, SCH2CH), 3.36 (s, 2H, SCH2CH), 3.78 (s, 3H, 
OCH3), 4.59 (ddd, 1H, 3J = 0.9 Hz, 3J = 3.6 Hz, 3J = 7.7 Hz, CH), 7.05 (bs, 1H, NH). 
C7H9NO5S (219.22). 
D-Proline methyl ester hydrochloride (9.23)31: To a suspension of D-proline (20 
mmol, 2.3 g) in anhydrous methanol (20 ml) was added thionyl chloride (22 mmol, 
1.6 ml) at 0 °C and the mixture was stirred for 2 h at room temperature. After stirring 
for additional 1.5 h at reflux, volatiles were removed to obtain the title compound as a 
very hygroscopic semisolid substance (3.3 g, 100 %). 1H-NMR (D2O) δ 1.92 – 2.41 
(m, 4H, CH2), 3.33 (m, 2H, CH2NH), 3.75 (s, 3H, CO2CH3), 4.40 (dd, 1H, 3J = 7.4 Hz, 
3J = 8.5 Hz, CH). EI-MS (70 eV) m/z (%): 129 (4) [M+·]. C6H12ClNO2 (165.62). 
Methyl 2-[((3R,8aR)-1,4-dioxooctahydropyrrolo[1,2-a]pyrazin-3-yl)methylthio]-
acetate (9.24): To a solution of 9.21 (1.5 mmol, 0.33 g) in anhydrous THF (5 ml) was 
added a solution of 9.23 (1.5 mmol, 0.25 g) and NEt3 (3.38 mmol, 0.47 ml) in 
anhydrous CH2Cl2 (10 ml) dropwise at -70 °C under an atmosphere of argon. After 
stirring for 3 h at -70 °C, the cooling bath was removed and stirring was continued for 
additional 30 min at room temperature. The mixture was filtered, the solvent was 
evaporated and the crude residue was dissolved in anhydrous toluene (20 ml) and 
stirred at reflux overnight. After removal of the solvent under reduced pressure, the 
raw product was subjected to flash chromatography (CHCl3/MeOH 97/3 v/v) to obtain 
the title compound as a pale yellow oil (0.35 g, 68 %). 1H-NMR (DMSO-d6) δ 1.69 – 
2.63 (m, 4H, CH2), 2.93 (dd, 1H, 3J = 4.9 Hz, 2J = 13.8 Hz, SCH2CH), 3.02 (dd, 1H, 3J 
= 6.7 Hz, 2J = 13.8 Hz, SCH2CH), 3.40 (m, 4H, SCH2, NCH2), 3.65 (s, 3H, CO2CH3), 
3.93 (ddd, 1H, 3J = 4.5 Hz, 3J = 4.5 Hz, 3J = 6.5 Hz, CH), 4.24 (dd, 1H, 3J = 6.9 Hz, 3J 
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= 9.3 Hz, CH), 8.29 (d, 1H, 3J = 3.8 Hz, NH). EI-MS (70 eV) m/z (%): 272 (21) [M+·]. 
C11H16N2O4S (272.32). 
Sodium 2-[((3R,8aR)-1,4-dioxooctahydropyrrolo[1,2-a]pyrazin-3-yl)methylthio]-
acetate (9.5): To a solution of 9.23 (0.59 mmol, 0.16 g) in acetone (1ml) and 0.1 N 
phosphate buffer (13 ml, pH 8.0) was added porcine liver esterase (30 mg) and the 
mixture was stirred at room temperature overnight. The mixture was concentrated 
under reduced pressure and the remaining suspension was subjected to flash 
chromatography (CHCl3/MeOH 80/20) to obtain the title compound as a white solid 
(0.10 g, 66 %). 1H-NMR (DMSO-d6) δ 1.67 – 2.21 (m, 4H, CH2), 2.90 (d, 2H, 3J = 6.2 
Hz, SCH2CH), 3.07 (s, 2H, SCH2), 3.38 (m, 2H, NCH2), 3.88 (m, 1H, CH), 4.26 (dd, 
1H, 3J = 6.9 Hz, 3J = 9.1 Hz, H), 8.56 (d, 1H, 3J = 3.6 Hz, NH). ES-MS (H2O/MeOH + 
NH4OAc) m/z (%): 257 (100) [M-H]-. C10H13N2NaO4S (280.28). 
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10.1 Introduction 
 
Many hyaluronidase inhibitors synthesized in this work comprise on one hand a large 
lipophilic fragment (alkyl, aryl residues) and on the other hand a polar, acidic motive 
(e.g. polyhydroxy compounds such as ascorbic acid and carbohydrate(-like) 
structures, indole carboxylic acids). Thereby, these molecules mimic respective 
amphiphilic repetitive motives of the substrate hyaluronan. Due to the 
aforementioned structural features these hyaluronidase inhibitors possess detergent-
like properties which may compromise their hyaluronidase inhibitory activity in vitro 
and in vivo. Therefore, selected hyaluronidase inhibitors were investigated with 
respect to micelle formation and the induction of hemolysis, both characteristic for 
detergent-like molecules. Due to observed inconsistencies, when the compounds 
were investigated for hyaluronidase inhibition on crude hyaluronidase preparations, 
protein binding of the compounds was studied, too. Furthermore, selectivity of 
representative inhibitors from various compound classes against different 
mammalian hyaluronidases was determined using equiactive enzyme con-
centrations. In addition, the toxicity of selected substances was investigated in a 
standard chemosensitivity assay.  
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10.2 Materials and methods 
 
10.2.1 Determination of critical micelle concentrations (CMCs) 
 
The determination of CMC values based upon measurement of the surface tension 
was performed according to literature procedures1-3.  
Stock solutions of the investigated hyaluronidase inhibitors were prepared in DMSO. 
For CMC determination solutions were prepared, which contained 0.6 ml of each 
inhibitor solution, 6.2 ml of McIlvaine’s buffer (solution A: 0.2 M Na2HPO4, 0.1 M 
NaCl, solution B: 0.1 M citric acid, 0.1 M NaCl; solution A and B were mixed in the 
appropriate proportions to reach pH 5.0), 3.62 ml of BSA solution (0.2 mg/ml in 
water), 2.56 ml of water and 1.62 ml of HA solution (2 mg/ml in water). The surface 
tension of the resulting samples was determined using a ring tensiometer (Lecompte 
du Noüy) K8600 equipped with a platinum-iridium ring from Kruss, Optisch-
mechanische Werkstätten (Hamburg, Germany). Measurements were performed in 
duplicate. 
 
10.2.2 Determination of hemolytic properties using human erythrocytes 
 
The determination of hemolytic properties of the compounds was performed as 
previously described4, 5.  
 
10.2.2.1 Isolation and purification of erythrocytes 
 
Isotonic NaCl solution (4 ml) was added to fresh human heparinized blood (8 ml) and 
the suspension was centrifuged at 4 °C (2000 g, 10 min). After removal of the 
supernatant plasma and the thin colorless leukocyte-layer using a Pasteur pipette, 
the erythrocytes were re-suspended in isotonic NaCl solution (8 ml) and centrifuged 
again (2000 g, 10 min, 4 °C). After removal of the supernatant, the washing 
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procedure was repeated twice. Finally, the supernatant was discarded and the 
erythrocytes were stored on ice before use on the same day. 
 
10.2.2.2 Determination of hemolysis 
 
Stock solutions (20 mM) of inhibitor dissolved in DMSO were prepared and diluted to 
concentrations of 0.2, 2 and 10 mM with DMSO.  
To a suspension of freshly prepared erythrocytes (50 µl) and isotonic NaCl solution 
(0.945 µl) appropriate volumes of the solutions of the inhibitors were added to an 
Eppendorf reaction vessel to obtain the final concentrations of the test compounds 
(1, 10, 50 and 100 µM). To achieve 100 % hemolysis, a solution of digitonin in DMSO 
(2 %, w/v) was used as reference. For the 0 % value DMSO without any inhibitor was 
added. After careful mixing, the reaction vessels were incubated for 1 h at 37 °C and 
vortexed periodically every 15 min. The suspensions were centrifuged at 4 °C (2000 
g, 10 min), and 50 µl of the supernatant were transferred to acryl cuvettes and diluted 
with water (950 µl). Absorbance of the samples was measured at 585 nm. The 
hemolytic activity (percentage) was calculated according to the following equation: 
% Hemolysis = 100 · (A – A0%) / A100% 
whereas A is the measured absorbance of the sample, A0% is the absorbance of the 
references with DMSO only and A100% is the absorption of the sample with digitonin. 
 
10.2.3 Chemosensitivity assay 
 
The assay was performed as previously described by Bernhardt et al.6: Tumor cell 
suspensions (100 µl/well) were seeded into 96-well flat-bottomed microtitration plates 
(Greiner, Frickenhausen, Germany) at a density of ca 15 cells/microscopic field 
(magnification 320x). After 2 days of incubation, the culture medium was removed by 
suction and replaced by fresh medium (200 µl/well) containing varying hyaluronidase 
inhibitor concentrations. On every plate 16 wells served as controls and 16 wells 
were used per compound concentration. After various periods of incubation the cells 
were fixed with glutaraldehyde (Merck, Darmstadt, Germany) and stored at 4 °C. At 
the end of the experiment all plates were stained with crystal violet (Serva, 
Heidelberg, Germany) simultaneously. Absorbance was measured at 578 nm using a 
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Biotek 309 Autoreader (Tecnomara, Fernwald, Germany). Growth curves were 
constructed using SigmaPlot analysis software (Systat Software GmBH, Erkrath, 
Germany). 
10.2.4 Determination of hyaluronidase activitiy 
 
10.2.4.1 Morgan-Elson assay 
 
The Morgan-Elson assay was carried out as described in chapter 3.4.2 at pH 3.5 
using murine serum (50 µl) instead of enzyme solution and an incubation period of 48 
h. For experiments with BTH in the presence of murine serum, 50 µl of a solution of 
Neopermease® (400 IE/ml* in BSA (0.2 mg/ml)) were used, and 50 µl of water were 
replaced with murine serum. In this case the samples were incubated for 1 h. 50 µl of 
Neopermease® (400 IE/ml* in BSA (0.2 mg/ml)) and an incubation period of 1 h were 
also chosen to perform the assay in the presence of various concentrations of (heat-
denatured) BSA. In the latter case the standard BSA solution (0.2 mg/ml) was 
replaced by a solution containing 40 mg/ml of BSA. 
 
10.2.4.2 Turbidimetric assay using equiactive hyaluronidase concentrations 
 
To determine the selectivity of hyaluronidase inhibitors the turbidimetric assay was 
performed as described in chapter 3.4.3 using equiactive enzyme concentrations: A 
final enzymatic activity of 0.01 mU of each enzyme and incubation times of 4.5 h 
were used in the assay. 
 
10.2.5 Investigations on serum protein binding using HPLC 
 
A mixture of 240 µl of phosphate buffer (pH 5.0 as described in chapter 3), 200 µl of 
water, 60 µl of human plasma, 20 µl of DMSO and 20 µl of inhibitor (0.93 mg 7.52 
dissolved in 400 µl DMSO) were incubated for 30 min at 37 °C. 400 µl of the 
incubation mixture were filtered using Microcon centrifugal filter devices (Microcon 
                                            
* according to the declaration of the supplier 
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YM-10, 10000 MWCO from Micon® Bioseparations, Millipore, Eschborn, Germany). 
After approximately half of the solution was filtered (13000 rpm, 13000 g), 100 µl 
samples of the filtrate, the supernatant and the unfiltered sample were taken and 
diluted with ice-cold acetonitrile. To complete deproteinisation, the solutions were 
stored on ice for 30 min and centrifuged again (13000 rpm, 13000 g, 4°C, 15 min). 
200 µl of the supernatants were diluted with aqueous TFA (0.1 %). The solutions 
were used for HPLC analysis immediately. As a reference, the same procedure was 
repeated without human serum (replaced by water). 
Analytical HPLC was performed on a Kontron system consisting of an HPLC Pump 
430, a gradient mixer M491, an autosampler 460, and a 430 UV/VIS detector 
(Kontron, Neufahrn, Germany). The stationary phase was a Eurosphere-100 C-18 
(250 x 4.0, 5 μm) column (Knauer) thermostatted at 30 °C with a Shimadzu CTO-2A 
column oven. 50 µl of each sample were injected. As mobile phase a mixture (65/45 
(v/v)) of MeCN/TFAaq (0.1 %) was used at a flow rate of 0.7 ml/min. Absorbance was 
detected at 210 nm. 
 
10.3 Results and discussion 
 
10.3.1 Determination of the CMCs of selected compounds 
 
Vcpal is known to form micelles in aqueous solutions. CMC values of 120-260 µM 
were determined at pH 7.007. Due to the fact that micelle formation depends on 
various conditions like temperature, pH-value, ionic strength or concentration of co-
solutes, CMC values vary over o broad range. It is known that hyaluronan can 
influence surfactant properties in aqueous media8. To investigate, if the synthesized 
hyaluronidase inhibitors form micelles under the conditions of the enzymatic assays 
performed in this work, the concentration dependent surface tension of solutions 
containing selected hyaluronidase inhibitors, namely the ascorbic acid derivatives 
Vcpal and 7.112 and the indole-3-butyric acid derivative 8.32 (see Figure 10.1 for 
structures) was determined using a ring tensiometer.  
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Figure 10.1. Chemical structures of investigated hyaluronidase inhibitors. 
 
Solutions were prepared by analogy with the incubation mixture of the turbidimetric 
hyaluronidase activity assay. Figure 10.2 shows the surface tension in the presence 
of varying concentrations of the investigated compounds under assay conditions. 
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Figure 10.2. Suface tension in the presence of varying concentrations of selected hyaluronidase 
inhibitors. CMC values were determined by analogy of the conditions of the turbidimetric 
hyaluronidase assay at pH 5.0, 20 °C. 
 
In the case of Vcpal it is obvious from Figure 10.2 that an increase in the 
concentration of the compound (0.1 µM-20 µM) initially leads to a steep decrease in 
surface tension. This behavior is typical for surfactants, and a critical micelle 
concentration of 13 µM can be calculated from the two linear regression graphs (0.1 
µM -10 µM and 20 µM-70 µM). The determined CMC value is much lower compared 
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to literature values which probably results from different conditions such as pH value, 
ionic strength and compounds like BSA and HA which are also present in the 
incubation mixture.  
The indole-3-butyric acid derivative (8.32) is also surface-active and forms micelles 
with a CMC of 22 µM, although this compound bears a carboxylic acid at the end of 
the lipophilic alkyl chain. Thus, micelle formation or better the formation of bilayers, 
ellipsoids, cylinders or other aggregates cannot be prevented by the simple 
introduction of polar residues at the end of the alkyl chain. As long as there are large 
lipophilic fragments in the inhibitor, aggregation will always be a problem. In contrast 
to Vcpal, no CMC was measured for the “bivalent” ascorbic acid 7.112 up to a 
concentration of 80 µM. Therefore, this compound may be a candidate for further 
investigations due to its improved physicochemical properties compared to the other 
hyaluronidase inhibitors with a highly lipophilic residue facilitating micelle formation. 
There are also consequences for the determination of the hyaluronidase inhibitory 
potency of the compounds: as soon as micelles begin to form, the concentration of 
“inhibitor monomers” decreases in solution, which affects the determined IC50 values. 
It is known that micelle formation often leads to a flattening of the SAR. This may 
also be the case in the SAR presented in this work, especially when only weak 
inhibition of the enzymes is observed as it is often the case with bovine testicular 
hyaluronidase. 
 
10.3.2 Hemolytic properties of selected hyaluronidase inhibitors 
 
Ionic and non-ionic detergents often induce hemolysis9, that means the abnormal 
breakdown of red blood cells, which leads to the release of hemoglobin into the 
surrounding fluid. As proven in chapter 10.3.1 at least some hyaluronidase inhibitors 
show surface activity like formation of micelles, thus the hemolytic properties were 
investigated as a prerequisite for in vivo investigations. Figure 10.4 shows the 
percentage of hemolysis compared to the reference compound digitonin, which is 
known to be strongly hemolytic10 (see Figure 10.3 for structures of investigated 
hyaluronidase inhibitors). The detergent sodium dodecyl sulfate (SDS) was also 
investigated for comparative reasons. 
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Figure 10.4. Hemolysis induced by hyaluronidase inhibitors and SDS in % values at various 
concentrations compared to digitonin. 
 
All investigated hyaluronidase inhibitors induced weak hemolysis at the highest 
concentrations tested (100 µM). Nevertheless, compared to SDS the hemolytic effect 
was significantly lower at every concentration. At concentrations below 50 µM the 
hemolytic effect of the inhibitors is marginal. Negligible hemolysis was also observed 
for 7.52, a compound where the alkyl chain present in all the other inhibitors is 
replaced by a biphenyl containing residue. On the contrary, distinct hemolysis was 
observed for 7.149, where additional carboxy substituents were introduced. The 
indole derivative 8.32 possesses no significant hemolytic activity below 100 µM. 
Taken together, with respect to in vivo experiments, inhibitor concentrations higher 
than 50-100 µM should be avoided.  
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10.3.3 Cytotoxicity of representative hyaluronidase inhibitors 
 
As a prerequisite for application as pharmacological tools in vivo, several 
hyaluronidase inhibitors were tested with respect to cytotoxicity in the crystal violet 
based chemosensitivity assay6. The human glioblastoma cell variant U-373 MG and 
the colon carcinoma cells HT-29 were used for these investigations. Paclitaxel was 
taken as reference compound. Structures of investigated compounds are shown in 
Figure 10.5. 
N
H
CO2H
CO2H
H3C(H2C)17O
8.65
O
HO
OH
OH
O
O
(CH2)14CH3
O
O
HO
OH
OH
O
O
(CH2)5O
O
O
O
O
OH
O
O
(CH2)10CH3
O
HO2C
CO2H
Vcpal
7.132
7.52
O
HO
O(CH2)11CH3
OH
OH
O
7.149
O
HO
OH
OH
O
O
O (CH2)5CH3
(CH2)7CH3
7.89
OC16H33
O
O
OO
O
O
CO2H
O
HO2C
6.51
O
O
O
O
OH
OO
O
HO
NH
OH
OO
O
O
Paclitaxel
 
Figure 10.5. Chemical structures of the compounds investigated in the cytotoxicity assay. 
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 Exemplary data is depicted in Figure 10.6. 
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Figure 10.6.  Incubation of a) HT-29 cells with various concentrations of paclitaxel b) HT-29 cells with 
various concentrations of 7.52 c) HT-29 cells with various concentrations of 8.65 and d) U-272 MG 
cells with various concentrations of 8.65. 
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The reference compound paclitaxel clearly caused a cytostatic effect at the 
investigated concentrations (Figure 10.6a), whereas cell proliferation was not 
affected by all but one of the investigated hyaluronidase inhibitors up to a 
concentration of 30 µM (see Figure 10.6b for the representative ascorbic acid 
derivative 7.52). The only exception was the indole based inhibitor 8.65 when tested 
against HT-29 cells (Figure10.6c). At the highest concentration of 30 µM cell growth 
was significantly reduced. Due to the fact that the compound was barely soluble in 
the cell suspension at this concentration and precipitation of the compound was 
observed after adding the stock solution to the cell medium, this observation might be 
the result of mechanical processes rather than of toxic properties of the compound. 
As shown in Figure 10.6d, the U-373 MG cells were not affected by the highest 
concentration of 8.65.  
 
10.3.4 Effect of murine serum and BSA on the inhibitory activity of 
representative compounds 
 
During investigations with mouse serum using the colorimetric Morgan Elson assay 
(see chapter 3), we encountered problems when serum was taken as a source of 
hyaluronidase (see Figur 10.7 for the results of the Morgan Elson assay). None of the 
previously identified inhibitors was able to inhibit the murine hyaluronidase at 
concentration of 1 mM (Figure 10.7a), although mouse Hyal-1, which is present in the 
serum, is closely related to the human enzyme (the degree of homology between the 
pairs of orthologs of human and mouse is much higher than that between human 
paralogs11). To verify if the compounds are active in presence of mouse serum, we 
added bovine testicular hyaluronidase, which is definitely inhibited by these 
compounds (see chapter 6-8): No inhibitory activity was found for 7.127, although 
BTH was clearly inhibited without serum (Figur 10.7b). The activity of BTH in 
presence of murine serum was proven previously12. In a next step we replaced the 
mouse serum by a physiological concentration of BSA (solutions of 40 mg/ml were 
used for the incubation mixture instead of the 0.2 mg/ml BSA solution, which was 
routinely used in this work). Again, no inhibition of the hyaluronidase was observed. 
Boiling of the BSA-solution for 5 min prior to use led to a significant increase in the 
inhibition of BTH by 7.127 and 6.42, an indication for specific binding of the 
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compounds to native BSA. These results suggest that the hyaluronidase inhibitors 
possess high affinity to serum albumin. 
enzymatic activity [%]
0 20 40 60 80 100
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Mouse serum + Indomethacin
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Mouse serum + Vcpal
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a)
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BTH + BSA, denatured by heat
(40 mg/ml) + 6.42
 
Figure 10.7. Effect of mouse serum and BSA on the inhibitory activity of selected compounds. 
Enzymatic activity determined at pH 3.5 using the Morgan Elson assay under different assay 
conditions: a) in the presence of murine serum (incubation time: 48 h), b) in the presence of BTH 
(incubation time: 1h).  Final inhibitor concentration in the assay was 1 mM. 
 
Extensive investigations on the binding properties of low molecular weight 
compounds to serum albumin led to the identification of two main high affinity binding 
sites. The existence of several additional binding sites has been proposed13-18. 
Especially anionic and lipophilic drugs are known to show high binding to serum 
albumin15. As the investigated hyaluronidase inhibitors possess both, anionic and 
lipophilic motives, the protein binding was further investigated. 
Thus, ascorbic acid 6-palmitate was tested in the turbidimetric assay (see chapter 3) 
with respect to the inhibition of the bacterial hyaluronate lyase in the presence of 
various concentrations of BSA. The results are summarized in Table 10.1. 
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Table 10.1.  IC50 values of Vcpal against HylB4755 at pH 5.0 from the turbidimetric assay in the 
presence of varying  concentrations of BSA in the incubation mixture. 
c(BSA) 
[µM]* 
IC50 
[µM] 
Δc(BSA) 
[µM] 
ΔIC50 
[µM] 
ΔIC50 / 
Δc(BSA) 
0 3.6    
  0.3 1.6 5.3 
0.3 5.2    
  0.3 1.5 5.0 
0.6 6.7    
  0.8 3.5 4.4 
1.4 10.2    
  1.2 7.2 6.0 
2.6 17.4    
  2.4 2.5 1.0 
5.0 19.9    
  11.8 47.9 4.1 
16.8 67.8    
  165 666 4.0 
182 734    
*a molar weight of 66.0 kDa was used to calculate the BSA concentrations. 
 
Obviously an increase in protein concentration leads to an increase in the IC50 values 
from 3.6 µM in the absence of BSA to 734 µM determined at a BSA concentration of 
182 µM. In the last column the difference of the IC50 values divided by the differences 
in BSA-concentration were calculated. This quotient is approximately 5 at lower BSA 
concentrations, i.e. 5 molecules of the inhibitor are bound to one molecule of BSA. At 
concentrations around 20 µM the number of molecules bound to BSA drops to one. 
Interestingly, this is exactly the concentration range where micelle formation occurs 
(see chapter 10.3.1). Thus, via micelle formation the concentration of free monomer 
is lowered in solution and a smaller number of inhibitor monomers are bound to BSA. 
An increase in the BSA concentration to 16.8 µM leads to an increase in the number 
of molecules bound to BSA. The protein concentration (c(BSA)=182 µM = 12 mg/ml) 
in last row of Table 10.1 amounts approx. to the serum albumin concentration in 
human blood (c(HSA) ≥ 30 mg/ml).  
To investigate, if, beside Vcpal, other inhibitors also bind to BSA, the IC50 values of 
selected compounds were determined (see Figure 10.8 for chemical structures of 
investigated compounds) in the presence of elevated BSA concentrations. The IC50 
values determined at different BSA concentrations are summarized in Table 10.2. 
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Figure 10.8. Investigated hyaluronidase inhibitors. 
 
Table 10.2. IC50 values of selected inhibitors in the presence of 0.3 µM BSA and 16.8 µM BSA. 
Compound 
IC50 [µM]a 
c(BSA)=0.3 µM 
IC50 [µM]a 
c(BSA)=16.8 µM 
ΔIC50 / Δc(BSA) 
7.52 61 127 4.0 
7.63 7.5 225 13.2 
7.102 60 137 4.7 
7.111 22 138 7.0 
8.21 18 73 3.3 
Glycyrrhizic acid 46 129 5.0 
Lauryl gallate 13 155 8.6 
Indomethacin 350b 590 14.5 
aSEM values < 5 %.bdetermined by Salmen. 
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In every case, a significant drop of the IC50 value was observed when a high 
concentration of BSA was used in the turbidimetric assay. Around five molecules of 
each inhibitor were calculated to be bound per molecule of BSA as in the case of 
Vcpal. An exceptional loss of potency was observed for the ascorbic acid derivative 
7.63 bearing an elongated alkyl spacer, when compared to 7.52. The lowest protein 
binding was found for the bivalent indole moiety 8.21 with around three molecules 
bound per molecule of serum albumin. Glycyrrhizic acid, which is known to be among 
the most potent inhibitors for human hyaluronidases also seems to bind to BSA with 
a ratio of 5.0. By contrast, the decrease in the inhibitory activity of lauryl gallate is 
more pronounced: The IC50 value drops to 155 µM in the presence of higher protein 
concentration, which corresponds to 8.6 molecules bound per molecule of BSA. For 
indomethacin an exceedingly high number of molecules bound to BSA was 
determined. The value of 14.5 determined via the turbidimetric assay is in good 
agreement with previous investigations, where 15 molecules of indomethacin were 
found to bind so serum albumin by different techniques13. Generally, the obtained 
results are indications for a specific binding to serum albumin rather than unspecific 
binding. 
To further investigate the protein binding, an HPLC based approach was carried out: 
a mixture containing phosphate buffer, human plasma (which contains human serum 
albumin as major protein component) and inhibitor (7.52) was incubated at 37 °C and 
then filtered using a cutoff of 10 kDa to remove serum albumin. The concentration of 
serum proteins was approximately 100 µM in the incubation mixture; the inhibitor 
concentration was 200 µM. As a control experiment, the same procedure was carried 
out with solutions containing water instead of plasma. After preparation for analytical 
HPLC, samples before filtration, and samples from the filtrate as well from the 
supernatant were analyzed. 
In the control experiment without serum, the inhibitor was able to pass the 
membrane. The obtained HPLC-traces for the plasma samples are depicted in Figure 
10.9. 
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Figure 10.9. HPLC traces of samples containing 7.51 in presence of human plasma taken a) before 
filtration, b) from the supernatant and c) from the filtrate. The area under the curve (A) is given for the 
inhibitor peak. 
 
As shown in Figure 10.9 a higher concentration of 7.51 was found in the supernatant 
when compared to the sample without filtration. In the filtrate only a very small 
amount of the inhibitor was detectable, indicating that the inhibitor was nearly 
completely bound to serum proteins and therefore did not pass the membrane in the 
filtration step. Due to the fact that the inhibitor versus protein ratio in this experiment 
was 2:1 it can be concluded that at least two inhibitor molecules are bound to one 
molecule of protein. These results are in agreement with the data obtained before. 
Taken together, both experiments show that the synthesized inhibitors share the fate 
of many other drugs and bind to serum proteins. This protein binding will be a 
general problem of hyaluronidase inhibitors as long as lipophilic fatty acid-like 
moieties on the one hand and negatively charged groups on the other hand are 
required to achieve inhibition of the enzymes, as these characteristics also promote 
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the protein binding capabilities. A literature example is the NSAID indomethacin, 
which is known to inhibit hyaluronidases in vivo: The protein binding of indomethacin 
in human plasma was calculated to be 90% and the number of binding sites on 
albumin was determined to be around 1513. Due to the high potency of many drugs 
(IC50 values in the nanomolar range), protein binding may not be a serious problem 
as the amount of unbound drug is still sufficient to generate the desired effect. 
However, in the case of the investigated hyaluronidase inhibitors, the IC50 values are 
in the (lower) micromolar range and therefore probably concentrations in the 
millimolar range would be necessary to achieve inhibition in presence of 
physiological amounts of plasma proteins. Surely, these results must be considered, 
when the inhibitors are used in in vivo experiments. 
 
10.3.5 Determination of the selectivity of representative hyaluronidase 
inhibitors under “equiactive conditions” 
 
Routinely, slightly different amounts of hyaluronidase were used in the turbidimetric 
assay to determine the inhibitory activities of investigated compounds: whereas 
comparable amounts of Hyal-1 and BTH were used in this thesis, a lower PH-20 
concentration was used in the assays due to economic reasons. The incubation 
times were adjusted to obtain comparable substrate degradation. In chapters 6-9 a 
distinct selectivity of the inhibitors for human PH-20 versus the bovine homolog was 
derived from the IC50 values. As IC50 values are dependent on the assay conditions, 
this could possibly be the result of the different enzyme concentrations used in the 
turbidimetric assay. Due to that reason selected compounds were investigated using 
the turbidimetric assay under “equiactive conditions”, that means the concentrations 
of Hyal-1 and BTH were reduced to adjust the enzymatic activities to that of PH-20 
used in routine. Furthermore, incubation periods were adjusted to exclude changes in 
the IC50 values which could result from degradation of the inhibitors due to limited 
stability in aqueous solution. The results are summarized in Table 10.3. IC50 values 
obtained using the standard assay conditions as in chapters 5-9 are added for 
comparative reasons.  
 
Chapter 10 Biopharmaceutical and toxicological investigations  
311 
Table 10.3. Inhibitory activities (selectivities) of representative compounds determined under standard 
assay conditions used in chapters 5-9 compared to the values determined under “equiactive 
conditions”.  
Hyal-1 PH-20 BTH Hyal-1 PH-20 BTH 
Compound IC50 [µM]a 
(as determined in chapters 6-9) 
IC50 [µM]a 
(as determined under equiactive 
conditions) 
6.6 > 30 > 30 > 30 > 30 > 30 > 30 
6.51 33 ± 1 2.3 ± 0.1 49 ± 1 10 ± 2 2.3 ± 0.1 42 ± 3 
6.55 14 ± 2 1.4 ± 0.1 31 ± 1 n.d. 1.4 ± 0.1 26 ± 1 
7.121 8.3 ± 0.4 2.0 ± 0.1 27 ± 1 8.8 ± 0.7 2.0 ± 0.1 23 ± 1 
7.127 62 ± 4 10 ± 1 141 ± 4 40 ± 2 10 ± 1 164 ± 10 
7.149 117 ± 9 4.5 ± 0.3 > 400 n.d. 4.5 ± 0.3 > 400 
8.18 > 100 6.7 ± 0.6 > 100 > 100 6.7 ± 0.6 > 100 
8.19 > 100 16 ± 2 > 100 n.d. 16 ± 2 ≥ 100 
8.64 > 80 3.6 ± 0.4 > 90 > 100 3.6 ± 0.4 > 100 
Glycyrrhizin 26 ± 1 17 ± 1 737 ± 30 n.d. 17 ± 1 587 ± 11 
Melophlin P > 100 2.3 ± 0.1 > 100 > 100 2.3 ± 0.1 > 100 
a inhibition of enzyme expressed as IC50 (µM), mean values ± SEM; IC50 values determined at pH 5.0 
(PH-20, BTH) or 3.5 (Hyal-1) in the turbidimetric assay. 
 
The trends in selectivity are comparable with those described in the previous 
chapters. All compounds, except 6.6, for which no inhibition of the investigated 
enzymes was obtained, possess distinct selectivity for the human PH-20 versus the 
bovine homolog. IC50 values determined under “equiactive conditions” for Hyal-1 and 
BTH are significantly lower for the glucurono-6,3-lactones 6.51 and 6.55. This was 
expected due to the reduced amount of Hyal-1 and BTH in the assay compared to 
the standard conditions. The enzyme selectivity of compound 6.51 and 6.55 for PH-
20 versus the human isoenzyme drops marginally in both cases. When the ascorbic 
acid derivative 7.127 is regarded, even a decrease in inhibition at equiactive 
concentrations is observed for BTH. This surely is a result of the longer period of 
incubation: whereas the ester moiety of acylated vitamin C is stable under aqueous 
conditions for hours to days, and the alkyl ether in 7.127 should be stable in slightly 
acidic aqueous solution, the ascorbic acid core is known to be slowly degraded under 
these conditions19, 20. This effect is much more pronounced in neutral to basic 
solutions where the 3-OH of ascorbic acid is deprotonated compared to acidic 
conditions around pH 3.0, where this hydroxyl is protonated20. This pH-dependency 
of stability explains the results obtained at equiactive enzyme concentrations: the 
decrease in inhibitory potency against BTH (tested at pH 5.0) is significantly higher 
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compared to Hyal-1 (tested at pH 3.5). In the case of 7.121 lower IC50 values were 
determined, indicating that the degradation of the acylated ascorbic acid plays only a 
minor role. This is in agreement with investigations of 2-O-modified ascorbic acids 
which are known to possess increased stability19. Thus, the selectivity of 7.121 for 
the human PH-20 drops slightly, but the IC50 value for inhibition of BTH is still more 
than an order of magnitude higher when compared to the human homolog. The 
selectivity of the 3-O-alkylated ascorbic acid 7.149 for human PH-20 versus the 
bovine enzyme was proven, too. When the results for the investigated indoles (8.18, 
8.19 and 8.64) are regarded, still no significant inhibition of Hyal-1 and BTH is 
observable in the investigated concentration ranges with the exception of 8.19, where 
the enzymatic activity of BTH was reduced to 60 % in presence of 100 µM of this 
“bivalent” compound (data not shown). Thus, the remarkable selectivity of those 
compounds for human PH-20 compared to the other mammalian hyaluronidases is 
confirmed. The same observations were made for the melophlin derivative tested 
under “equiactive conditions”. Glycyrrhizin follows the trend found for the glucurono-
6,3-lactones, that is the inhibitory potency against BTH increased under “equiactive 
conditions”. Nevertheless, this compound is still 35 times more potent when the 
human PH-20 is investigated under those assay conditions. 
 
10.4 Summary and conclusions 
 
In a fist attempt, selected inhibitors were characterized according to their surfactant 
properties. By measuring the surface tension, it was proven that ascorbic acid 
palmitate probably forms micelles under the conditions applied in the enzymatic 
assay used in this work. A CMC of 13 µM was determined. Thus, it cannot be ruled 
out that at least in some of the cases of lower inhibitory activity, the IC50 values are 
influenced by micelle formation, a phenomenon which reduces the concentration of 
free inhibitor monomer in solution. Considering these circumstances, the “bivalent” 
inhibitors are clearly advantageous, as no CMC was found for 7.112, a 
representative compound of this class of inhibitors. 
In preparation for in vivo experiments using the synthesized inhibitors, the hemolytic 
properties and the toxicity of selected compounds were determined: although weak 
hemolytic effects were induced by the investigated inhibitors at higher 
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concentrations, which are certainly due to the lipophilic alkyl chains, the compounds 
were generally inconspicuous at concentrations below 50-100 µM. In the 
chemosensitivity assay using U-373 MG and HT-29 cells the investigated inhibitors 
did not show any cytotoxic effects. Only one indole-based inhibitor significantly 
reduced cell growth at the highest concentration tested, but this effect is supposed to 
result from physical processes due to the limited solubility of this compound rather 
than from chemical reasons. Thus, the presented inhibitors should be applicable in 
vivo. 
The investigation of protein binding revealed that the synthesized hyaluronidase 
inhibitiors as well as reference compounds known from the literature tend to bind to 
plasma proteins and thus share the fate of well known drugs with high affinity to 
various proteins. It was shown that in most cases roughly five molecules bind to one 
molecule serum albumin. This is not an exceptionally high value when it is compared 
to 15 molecules of the NSAID (and hyaluronidase inhibitor) indomethacin binding to 
one molecule of albumin13. Additionally, these results suggest a distinct interaction 
between protein and the hyaluronidase inhibitor rather than unspecific binding as 
supposed for strong detergents. These findings must be considered, when the 
inhibitors are used in the presence of high amounts of protein especially in vivo. 
In the last part of this chapter, investigations on the selectivity of enzyme inhibition 
were performed. Testing at equiactive enzyme concentrations revealed selectivity of 
indole based inhibitors, melophlins, glucurono-6,3-lactone and ascorbic acid based 
inhibitors for human PH-20 over the bovine homolog.  
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There is a need for hyaluronidase inhibitors as pharmacological tools to study the 
(patho)physiological role of these enzymes. As such compounds could also be useful 
as drugs, e.g. in the treatment of (bacterial) infections, arthroses and cancer or as 
contraceptives, the goal of this thesis was the synthesis, identification and structural 
optimization of low molecular weight inhibitors. 
 
The synthesized compounds were tested in a turbidimetric assay for inhibition of the 
recombinantly expressed human hyaluronidases Hyal-1 and PH-20, bovine testicular 
hyaluronidase (BTH) and a bacterial hyaluronate lyase (SagHyal4755). 
 
In a first attempt derivatives of the glucurono-6,3-lactone were synthesized and 
investigated for their inhibitory activity. Whereas 1-O-alkyl derivatives were inactive 
or only weakly active on human Hyal-1 and BTH, these compounds exhibited 
pronounced inhibition of human PH-20 and SagHyal4755. The inhibitory potency 
against all investigated hyaluronidases was increased by adding polar substituents 
(IC50 values in the lower micromolar range). Furthermore, 1-O-alkyl-β-D-gluco-
furanosiduronic acids and -uronamides were prepared which proved to be preferably 
inhibitors of PH-20 and SagHyal4755. 
 
In a second attempt various ascorbic acid derivatives with increased hydrophobicity 
were prepared, since the inhibitors ascorbic acid and its 6-O-palmitoyl derivative 
were proven to bind to the active center of a bacterial hyaluronate lyase by X-ray 
crystallography. A clear correlation between chain length of the 6-alkanoyl residue 
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and inhibitory potency was found. Whereas BTH, PH-20 and SagHyal4755 were most 
potently inhibited by ascorbic acid 6-O-palmitate, strongest inhibition of Hyal-1 was 
achieved with the 6-O-tridecanoate. The differences in inhibitory activity became 
even more prominent when compounds bearing biaryl residues were investigated: 
rather small modifications of the terminal phenyl residue led to different SAR for all 
investigated hyaluronidases. Among the ascorbic acid derivatives 6-O-[11-(4-
phenylphenoxy)undecanoyl]ascorbic acid was identified as one of the most potent 
low molecular weight inhibitors of human PH-20 known so far with an IC50 value of 
1.3 µM. “Bivalent” inhibitors, characterized by two vitamin C moieties connected by 
alkanedioyl spacer groups, proved to be roughly equipotent with the corresponding 
“monovalent” ligands. By contrast, 5,6-di-O-acylation of ascorbic acid led to 
significantly enhanced inhibition compared to monoacyl derivatives. The differences 
in IC50 values due to diacylation were most evident for human PH-20 where up to 26-
fold higher potency was obtained. Introduction of carboxylic acid residues led to 
potent inhibitors of the hyaluronidases, e.g. 2-O-(5-carboxypentanoyl)-6-O-
hexadecanoyl-L-ascorbic acid (IC50 values: 8.3 µM (Hyal-1), 2.0 µM (PH-20), 27 µM 
(BTH), 2.8 µM (SagHyal4755)) represents the most potent inhibitor of human Hyal-1 
developed in this work and thus is one of the most potent inhibitors of Hyal-1 known 
to date. Additionally, 2-, 3- and 6-O-alkylated ascorbic acid derivatives were prepared 
with respect to higher stability under physiological conditions compared to carboxylic 
esters. Strikingly, distinct differences in the SAR for the mammalian and bacterial 
hyaluronidases are obvious in this series again. 
 
The recently published crystal structure of human Hyal-1 was used as a 3-D model to 
perform an automated (FlexiDock) as well as a manual docking using potent ascorbic 
acid based inhibitors as ligands. The suggested binding modes are appropriate to 
explain several characteristics of the SAR and thus could provide the basis for further 
structure-based development of Hyal-1 inhibitors. 
 
In a third synthetic approach indole based inhibitors were synthesized. Especially 
“bivalent” indole-3-butanoic acids, derivatives containing large hydrophobic 
fragments and manifold substituted indoles proved to be potent inhibitors of human 
PH-20 and bacterial hyaluronidase with selectivity over human Hyal-1 and BTH (e.g. 
2-carboxy-5-(hexadecan-1-yl)oxy-1H-indole-3-butanoic acid, IC50 values: 1.3 µM 
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(PH-20) and 3.4 µM (SagHyal4755)). These compounds are characterized by distinct 
selectivity for human PH-20 compared to the other investigated mammalian 
hyaluronidases. Previously, BTH has been broadly accepted as a model enzyme for 
human hyaluronidases. This working hypothesis is challenged by the results of this 
thesis as human PH-20 is strongly inhibited by some indoles and the bovine homolog 
is not. 
 
Whereas additional approaches to develop carbohydrate- or peptide-based inhibitors 
failed, rather potent inhibitors of human PH-20 and SagHyal4755 were identified 
among small series of melophlins and alkylphosphocholines. 
With respect to planned in vivo investigations selected hyaluronidase inhibitors were 
investigated in more detail. Whereas cytotoxicity was not detected and micelle 
formation and hemolytic activity, respectively, became prominent at irrelevantly high 
concentrations the detected plasma protein binding must be considered in further 
investigations. 
 
In summary, the compounds described in this thesis are among the most potent low 
molecular weight inhibitors of human and bacterial hyaluronidases known to date. 
Structure-activity relationships were studied in detail using purified human 
hyaluronidases for the first time. The SAR, which are surprisingly unique for the 
investigated hyaluronidases, in combination with molecular modeling and structural 
information could provide the basis for the rational design of more potent and 
selective inhibitors. 
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12.1 Appendix 1: Elemental analysis data 
 
Calculated Found 
No Formula 
C H N C H N 
6.2 C15H18O6·0.8H2O 58.36 6.40  58.12 6.16  
6.3 C14H24O6 58.32 8.39  58.14 8.39  
6.4 C14H25NaO7·0.6H2O 49.58 7.79  49.44 7.99  
6.6 C22H40O6 65.97 10.07  65.97 10.25  
6.9 C18H33NaO7·0.6H2O 54.70 8.72  54.52 8.66  
6.12 C18H35NO6 59.81 9.76 3.87 59.53 9.34 3.45 
6.13 C29H49NO6 68.61 9.73 2.76 68.45 9.83 2.46 
6.14 C30H51NO6 69.06 9.86 2.68 68.94 9.95 2.24 
6.15 C26H51NO6 65.93 10.85 2.96 65.79 10.85 2.60 
6.16 C32H63NO6 68.9 11.38 2.51 68.55 11.53 2.14 
6.17 C24H47NO7 62.44 10.26 3.03 62.24 10.35 2.55 
6.20 C26H49NO8 62.00 9.81 2.78 61.92 9.92 2.44 
6.21 C27H51NO8 62.64 9.93 2.71 62.76 10.17 2.44 
6.22 C31H57NO8 65.12 10.05 2.45 64.91 10.41 2.09 
6.23 C25H47NO8·0.2H2O 60.88 9.69 2.84 60.59 9.77 2.56 
6.25 C30H55NO8·0.8H2O 62.97 9.97 2.45 62.72 9.72 2.07 
6.27 C27H48O7 66.91 9.98  66.77 10.18  
6.29 C25H41NO7 64.22 8.84 3.00 64.07 9.19 2.61 
6.30 C23H39F3O8S 51.87 7.38  51.81 7.32  
6.32 C29H46O6 70.99 9.45  70.79 9.56  
6.36 C30H46O8 67.39 8.67  67.13 8.41  
6.41 C21H34O9·0.3H2O 57.86 8.00  57.99 8.23  
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Elemental analysis data (continued) 
6.42 C25H42O9 61.71 8.70  61.71 8.66  
6.43 C26H44O9 62.38 8.86  62.67 8.60  
6.47 C25H42O9 61.71 8.70  62.03 8.76  
6.48 C26H44O9 62.38 8.86  62.44 8.91  
6.51 C28H44O12·1.8H2O 55.58 7.93  55.58 7.71  
6.52 C30H48O12·H2O 58.24 8.15  58.01 8.09  
7.2a C14H22O7 55.62 7.33  55.50 7.54  
7.2b C16H26O7 58.17 7.93  57.80 8.18  
7.2c C17H28O7 59.29 8.19  58.91 8.32  
7.2d C18H30O7 60.32 8.44  60.30 8.79  
7.2e C19H32O7 61.27 8.66  61.14 9.00  
7.2f C20H34O7 62.15 8.87  61.90 9.06  
7.2g C20H18O7 65.86 4.90  64.73 5.17  
7.3 C7H13BrO2 40.21 6.27  40.00 6.05  
7.4 C13H18O2S·0.5H2O 63.12 7.74  63.48 7.63  
7.5 C14H20O2S 66.63 7.99  66.44 8.22  
7.6 C13H18O3·0.4H2O 68.04 8.26  67.91 8.28  
7.7 C15H22O3·0.4H2O 69.95 8.92  69.95 8.74  
7.8 C19H22O3 76.13 7.09  76.24 7.35  
7.9 C20H24O4 73.15 7.37  73.11 7.49  
7.11 C19H22O3·0.2C6H4CH3 77.54 7.53  77.20 7.43  
7.12 C12H24O3·0.1C6H4CH3 67.63 11.08  67.54 11.46  
7.13 C12H24O3 66.63 11.18  65.50 11.78  
7.14 C14H20O3·0.8H2O 67.07 8.68  67.19 8.57  
7.15 C20H24O3·0.4H2O 75.16 7.82  74.98 7.51  
7.16 C13H17BrO3 51.84 5.69  51.98 5.67  
7.17 C17H20O3S 67.08 6.62  67.01 6.72  
7.18 C20H24O4 73.15 7.37  73.34 7.56  
7.19 C20H24O4 79.28 6.94  78.92 6.87  
7.20 C20H24O3 76.86 7.74  76.62 7.59  
7.21 C20H24O3·0.1CH2Cl2 75.23 7.60  75.41 7.36  
7.22 C23H24O3 79.28 6.94  78.92 6.87  
7.23 C19H22O4 72.59 7.05  72.51 6.89  
7.24 C19H22O4 72.59 7.05  72.77 7.16  
7.25 C20H22O5 70.16 6.48  69.88 6.26  
7.26 C20H22O5·0.2H2O 69.43 5.53  69.55 6.30  
7.27 C24H30O5 72.34 7.59  72.26 7.96  
7.28 C24H30O5 72.34 7.59  72.24 7.46  
7.29 C19H22O4 72.59 7.05  72.39 6.95  
7.30 C22H22O3·0.2H2O 78.17 6.68  78.37 7.06  
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Elemental analysis (continued) 
7.31 C23H28O5 71.85 7.34  71.88 7.47  
7.32 C23H28O5 71.85 7.34  71.54 7.47  
7.33 C18H28O3·0.5H2O 71.72 9.70  71.68 9.64  
7.34 C24H32O3 78.22 8.75  77.82 8.65  
7.34a C23H30O3·0.5H2O 76.00 8.60  76.16 8.94  
7.36 C18H28O3·0.2Cl2CH2 70.65 9.25  70.45 8.90  
7.37 C18H28O3 73.93 9.65  73.88 9.59  
7.38 C18H28O3 73.93 9.65  73.92 9.78  
7.39 C17H26O3 73.34 9.41  73.13 9.79  
7.40 C17H26O3 73.34 9.41  73.24 9.48  
7.41 C17H26O3 73.34 9.41  73.22 10.00  
7.42 C15H30O2 74.32 12.47  74.17 13.12  
7.43 C18H36O2 62.88 5.72  62.81 6.04  
7.44 C22H44O2 77.58 13.02  77.33 13.33  
7.46 C20H32O3·0.01C6H4CH3 75.00 10.06  74.69 10.09  
7.47 C24H48O2·0.3H2O 77.07 13.10  77.09 13.16  
7.48 C18H22O7S·0.5H2O 53.99 6.04  54.32 5.83  
7.49 C19H24O7S·0.7H2O 55.79 6.26  55.86 6.59  
7.50 C18H22O8·0.3H2O 58.15 6.13  58.06 6.14  
7.51 C20H26O8·0.3H2O 60.08 6.71  59.85 6.38  
7.52 C24H26O8 60.32 8.44  60.30 8.79  
7.53 C25H28O9 63.55 5.97  63.88 6.05  
7.54 C19H24O8 59.99 6.36  59.65 6.68  
7.55 C25H28O8 65.78 6.18  65.90 6.27  
7.56 C22H24O8S ·0.3H2O 58.22 5.46  57.95 5.57  
7.57 C25H28O9 63.55 5.97  63.84 5.91  
7.58 C25H28O8 65.78 6.18  60.97 5.89  
7.59 C25H28O8 65.78 6.18  65.96 6.56  
7.60 C24H26O9 62.88 5.72  62.81 6.04  
7.61 C24H26O9 62.88 5.72  62.91 5.93  
7.62 C23H32O8 63.29 7.39  63.24 7.38  
7.63 C29H36O8 67.95 7.18  68.17 7.08  
7.68 C37H44O8 72.06 70.19  72.12 7.38  
7.69 C37H44O8 72.06 7.19  71.83 6.99  
7.70 C36H50O7 72.70 8.47  72.48 8.64  
7.71 C35H48O7 72.38 8.33  72.58 8.15  
7.72 C38H54O7 73.28 8.74  73.31 8.78  
7.74 C40H50O7 74.74 7.84  74.98 7.66  
7.75 C40H50O8·0.3H2O 72.33 7.68  72.35 7.86  
7.76 C44H66O7 74.75 9.41  74.12 9.49  
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Elemental analysis (continued) 
7.77 C39H40O9 71.76 6.18  71.76 6.24  
7.78 C42H40O8·0.2H2O 74.58 6.02  74.45 6.39  
7.78a C64H60O10 77.71 6.11  77.26 6.67  
7.79 C43H46O10 71.45 6.41  71.57 6.63  
7.80 C43H46O10 71.45 6.41  71.23 6.43  
7.80a C66H72O14·0.2H2O 72.53 6.68  72.31 6.87  
7.81 C32H42O8 62.29 7.63  69.11 7.83  
7.82 C32H42O8 62.29 7.63  69.01 7.68  
7.82a C44H64O10 70.18 8.57  70.39 8.86  
7.83 C37H44O8 72.16 7.19  72.18 7.40  
7.85 C39H38O10·0.3H2O 69.63 5.79  69.64 5.85  
7.86 C39H38O10·H2O 68.41 5.89  68.78 5.91  
7.86a C58H56O14 71.30 5.78  71.19 5.89  
7.87 C23H32O8·0.2H2O 62.77 7.42  62.87 7.77  
7.88 C23H32O8·0.4H2O 62.26 7.45  62.41 7.05  
7.89 C22H38O7·0.4H2O 62.65 9.27  62.66 9.04  
7.90 C21H36O7 62.98 9.06  62.41 9.61  
7.91 C24H42O7·0.7H2O 63.33 9.61  63.32 9.30  
7.92 C28H50O7 67.44 10.11  67.09 9.98  
7.93 C26H38O7·0.3H2O 66.73 8.31  66.88 8.57  
7.94 C26H38O8·0.3H2O 64.52 8.04  64.58 7.94  
7.96 C25H28O9 63.55 5.97  63.86 6.07  
7.96a C44H48O12 68.74 6.29  68.43 5.91  
7.97 C28H28O8·1.3H2O 65.18 5.98  65.13 5.68  
7.97a C50H48O10·1.5EtOH 72.5 6.54  72.45 6.56  
7.98 C18H30O8 57.74 8.08  57.75 7.89  
7.98a C30H52O10 62.15 9.15  62.53 8.80  
7.99 C18H30O8 57.74 8.08  57.95 8.44  
7.99a C30H52O10·0.4H2O 62.13 9.18  61.96 9.44  
7.100 C23H32O8 63.29 7.39  63.55 7.34  
7.100a C40H56O10·0.5H2O 68.08 8.14  68.06 8.29  
7.101 C18H28O9 55.66 7.27  55.55 7.60  
7.102 C25H26O10·0.3H2O 62.05 5.45  60.40 5.06  
7.103 C25H26O10 61.72 5.39  61.54 5.30  
7.103a C44H44O14·1.4H2O 64.29 5.74  64.19 5.58  
7.104 C32H42O7 71.35 7.86  71.36 7.90  
7.105 C42H50O10·1.5H2O 68.00 7.20  67.93 6.84  
7.106 C21H32O10·1.2H2O 54.11 7.44  54.17 7.83  
7.107 C52H58O14·1.2H2O 67.26 6.56  67.10 6.44  
7.110 C24H34O14·3H2O 48.00 6.71  48.05 6.41  
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Elemental analysis (continued) 
7.111 C26H38O14·H2O 52.70 8.80  52.58 7.10  
7.112 C28H42O14·2.5H2O 51.93 7.31  51.83 7.30  
7.118 C31H46O8 68.11 8.48  68.06 8.78  
7.118 C26H42O10 ·0.8H2O 59.03 8.31  58.76 7.92  
7.120 C27H44O10 61.34 8.39  61.01 8.40  
7.121 C28H46O10 61.97 8.54  61.73 8.64  
7.121a C34H54O13·1.5H2O 58.52 8.23  58.62 8.35  
7.127 C18H32O6 62.77 9.36  62.84 9.56  
7.128 C24H44O6 67.26 10.35  67.31 10.21  
7.129 C27H28O10·0.1CH2Cl2 62.47 5.45  62.74 5.32  
7.131 C36H46O11 66.04 7.08  66.42 7.42  
7.132 C22H34O11 55.69 7.22  55.52 7.53  
7.134 C18H20O8·0.9CH2Cl2 51.50 4.98  51.19 5.17  
7.136 C32H50O6 72.42 9.50  72.28 9.83  
7.137 C25H26O8·0.3CH2Cl2 63.31 5.59  62.91 5.43  
7.138 C25H26O8·0.3H2O 65.29 5.83  65.20 5.74  
7.140 C22H40O6 65.97 10.07  65.92 10.19  
7.141 C22H22O8 63.76 5.35  63.77 5.48  
7.142 C22H22O8 63.76 5.35  63.67 5.59  
7.143 C34H44O9 68.44 7.43  77.37 7.49  
7.145 C34H44O9 68.44 7.43  68.38 7.57  
7.146 C20H32O9 57.68 7.74  57.74 8.03  
7.147 C31H38O10 65.25 6.71  64.91 6.24  
7.148 C20H32O9 57.68 7.74  57.65 8.03  
7.150 C20H36O6·0.3H2O 63.57 9.56  63.52 9.66  
8.7 C21H21NO3 75.20 6.31 4.18 74.80 6.36 3.92 
8.8 C22H31NO3 73.91 8.74 3.92 73.37 9.30 3.79 
8.8a C28H42N2O7 64.84 8.16 5.40 63.15 8.54 5.08 
8.9 C19H16ClNO3 66.77 4.72 4.10 66.60 4.71 4.06 
8.14 C22H18O4 76.29 5.24  76.42 5.33  
8.15 C20H22O4 73.60 6.79  73.73 7.01  
8.16 C24H30O4 72.36 7.91  75.21 7.83  
8.17 C28H38O4 76.68 8.73  76.48 8.54  
8.19 C34H32N2O6·0.5H2O 71.19 5.80 4.88 71.31 5.63 4.83 
8.20 C32H36N2O6·0.25H2O 69.99 6.17 5.10 69.86 6.77 5.04 
8.21 C36H44N2O6·0.5H2O 70.91 7.44 4.59 70.81 7.23 4.33 
8.22 C40H52N2O6·0.25H2O 72.64 8.00 4.24 72.37 8.18 4.03 
8.32 C23H33NO4·0.1H2O 70.96 8.60 3.60 70.83 8.88 3.36 
8.34 C30H43N3O3S·0.4H2O 67.61 8.28 7.88 67.65 8.37 8.01 
8.40 C38H56N2O4·0.4H2O 74.57 9.35 4.58 74.85 9.73 4.50 
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Elemental analysis (continued) 
8.44 C27H44N4O3 70.87 9.39 6.87 70.43 9.83 6.36 
8.52 C24H27NO5·0.75H2O 68.15 6.79 3.31 68.29 7.02 3.51 
8.53 C20H19NO5·0.2H2O 67.29 5.28 3.92 67.00 5.46 3.82 
8.57 C26H31NO5·0.4H2O 70.22 7.21 3.15 70.23 7.44 3.41 
8.58 C23H33NO5 68.46 8.24 3.47 68.74 8.19 3.30 
8.62 C22H23NO5·0.2H2O 68.63 6.13 3.64 68.50 6.09 3.33 
8.63 C19H25NO5 65.69 7.25 4.03 65.81 7.53 3.96 
8.64 C25H37NO5 69.58 8.64 3.25 69.47 8.48 3.01 
8.65 C29H45NO5 71.42 9.30 2.87 71.37 9.37 2.56 
8.66 C31H49NO5 71.69 9.59 2.70 71.68 9.40 2.54 
8.67 C36H59NO5·0.2H2O 73.35 10.16 2.38 73.32 10.37 2.44 
8.68 C39H58N2O5·0.2H2O 73.36 9.22 4.39 73.12 9.32 4.32 
8.70 C32H51NO5 72.55 9.70 2.64 72.61 9.78 2.32 
8.71 C35H50N2O5·HCl 68.33 8.36 4.55 70.94 8.51 4.32 
8.72 C36H50BrNO5 65.84 7.67 2.13 65.80 7.64 1.94 
8.73 C34H47NO5 74.28 8.62 2.55 74.25 8.69 2.31 
8.74 C32H43NO5 73.67 8.31 2.68 73.47 8.20 2.47 
8.75 C30H39NO5 72.99 7.96 2.84 73.16 8.09 2.62 
8.76 C25H37NO5 69.58 8.64 3.25 69.23 8.44 2.97 
 
12.2 Appendix 2: Abbreviations 
 
Ac    Acetyl 
Bn    Benzyl 
BSA    Bovine serum albumin 
BSE    Bovine spongiform encephalopathy 
BTH    Bovine testicular hyaluronidase 
BVH    Bee venom hyaluronidase 
CDI    N,N’-Carbonyldiimidazole 
CAZY    Carbohydrate active enzyme database 
CD44    Cluster determinant 44 
CMC    Critical micelle concentration 
Cmpd    Compound 
CTAB    Cetyltrimethylammonium bromide 
cy    Cyclohexyl 
DBU    1,8-Diazabicyclo[5.4.0]undec-7-ene 
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DCC    N,N′-Dicyclohexylcarbodiimide 
DEPT    Distortionless enhancement by polarization transfer 
DIAD    Diisopropyl azodicarboxylate 
DIEA    N,N-Diisopropylethylamine 
DMAP   4-(Dimethylamino)pyridine 
DMF    N,N-Dimethylformamide 
DSCG   Disodium cromoglycate 
DMSO   Dimethylsulfoxide 
ECM    Extracellular matrix 
EDAC N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride 
ENTV    Enzootic nasal tumor virus 
EtOAc   Ethyl acetate 
GAG    Glucosaminoglycane 
GlcNAc   N-Acetylglucosamine 
GlcUA    Glucuronic acid 
GPI    Glycosylphosphatidylinositol 
h    Hours 
HA    Hyaluronic acid 
HARE    Hyaluronan receptor for endocytosis 
HAS    Hyaluronan synthase 
HOAc    Acetic acid 
HOBT    1-Hydroxybenzotriazole 
HPLC    High-pressure liquid chromatography 
HR-MS   High resolution mass spectroscopy 
HSA    Human serum albumin 
hylSpn   S. pneumoniae hyaluronidase 
IC50    concentration of an inhibitor required to give 50% inhibition 
of enzyme activity 
IPE    Diisopropylether 
JSRV    Jaagsiekte sheep retrovirus 
LUCA-1   Lung cancer gene 1 
LYVE-1   Lymphatic vessel endothelial HA receptor 
LEC    Liver endothelial cell clearance 
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mp    Melting point 
MS    Mass spectrometry 
Mw    Molecular weight 
n.d.    Not determined 
NMR    Nuclear magnetic resonance 
NSAID   Non-steroidal anti-inflammatory drug 
OD    Optical density 
pH    Negative logarithm of the hydrogen ion concentration 
ppm    Parts per million 
RT    Room temperature 
SagHyal3502   Hyaluronate lyase of S. agalactiae strain 3502 
SagHyal4755   Hyaluronate lyase of S. agalactiae strain 4755 
SAR    Structure-activity relationships 
SEM    Standard error of the mean 
SPAM1   Sperm adhesion molecule 
TBAB    Tetrabutylammonium bromide 
TBME    tert-Butyl methyl ether 
TBTA    tert-Butyl 2,2,2-trichloroacetimidate 
TEMPO   2,2,6,6-Tetramethylpiperidine 1-oxyl 
TFA    Trifluoroacetic acid 
THF    Tetrahydrofuran 
TIM    Triose phosphate isomerase 
TLC    Thin layer chromatography 
TLR-4    Toll like receptor 4 
TMSCl   Chlortrimethylsilane 
PE    Petrol ether 
PG    Protecting group    
RHAMM   Receptor for hyaluronate-mediated motility 
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